

## Scientific Programme

### Saturday, 29 August 2020

---

General

12:30 - 13:15

Auditorium 1

#### **GS1, Opening Ceremony**

**Welcome and introduction**

Nicolaus Kröger (Germany)

**12:30 - 12:35**

**Welcome and introduction to the conference**

Rafael Duarte (Spain)

**12:35 - 12:40**

**Welcome from the Nurses Group**

John Murray (United Kingdom)

**12:40 - 12:44**

**EBMT Patient Advocacy Committee: Welcome note**

Bregje Verhoeven (Netherlands)

**12:44 - 12:48**

**Introduction of the Keynote speaker**

Rafael Duarte (Spain)

**12:48 - 12:50**

**Keynote Lecture: How the treatment is evolving in transplant-eligible newly diagnosed Multiple Myeloma?**

María-Victoria Mateos (Spain)

**12:50 - 13:15**

Industrial Theatre

12:30 - 18:30

Industry Theatre

#### **IT1, TLS in the context of new treatments in hematology - Sanofi Genzyme Industry Theatre Session**

Industrial Theatre

12:30 - 18:30

Industry Theatre

#### **IT3, Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite Industry Theatre Session**

Industrial Theatre

12:30 - 18:30

Industry Theatre

#### **IT4, KYMRIA in the Real World - Novartis Industry Theatre Session**

## Scientific Programme

Industrial Theatre  
12:30 - 18:30

Industry Theatre

### **IT5, How I manage CMV in HSCT patients - MSD Industry Theatre Session**

Industrial Theatre  
12:30 - 18:30

Industry Theatre

### **IT6, Gene therapy: From clinical trials to clinical practice - Bluebirdbio Industry Theatre Session**

#### **Chairs:**

Franco Locatelli (Italy)

Industrial Theatre  
12:30 - 18:30

Industry Theatre

### **IT2, Clinical Data on Treosulfan-based Conditioning Treatment (Trecondi®) in Paediatric Patients - Medac Industry Theatre Session**

e-Posters  
12:30 - 18:30

ePoster Area

## **Lymphoma**

**LONG TERM SURVIVAL AFTER 2 YEARS EVENT FREE SURVIVAL IN RELAPSED DLBCL AFTER AUTOLOGOUS TRANSPLANTATION IN THE TWO RANDOMIZED TRIALS LY.12 AND CORAL**

**EXPLORATORY ANALYSIS OF BRENTUXIMAB VEDOTIN PLUS CHP (A+CHP) AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS (ECHELON-2): IMPACT OF CONSOLIDATIVE STEM CELL TRANSPLANT**

**BRENTUXIMAB VEDOTIN FOR RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN LYMPHOMA: A STUDY OF THE LWP-EBMT**

**ALLOGENEIC STEM CELL TRANSPLANTATION AS A CURATIVE OPTION IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH/GELTAMO STUDY**

**ADAM17 INHIBITOR INCB7839 WITH RITUXIMAB AS CONSOLIDATION AFTER AUTOLOGOUS HCT FOR DIFFUSE LARGE B CELL LYMPHOMA: A NOVEL RELAPSE PREVENTION STRATEGY**

**COMPARISON OF REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A CIBMTR ANALYSIS**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH NON-HODGKIN LYMPHOMA: THE SPANISH EXPERIENCE**

**EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS AFFECTED BY ADVANCED LYMPHOID MALIGNANCIES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY**

## Scientific Programme

**BRENTUXIMAB-VEDOTIN IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY PRIOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HODGKIN LYMPHOMA: REAL-WORLD DATA FROM A TWO CENTERS STUDY**

**NON-MYELOABLATIVE CONDITIONING REGIMEN BEFORE T-CELL REplete HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ADVANCED LYMPHOMA**

**IMPACT OF KIR LIGAND MISMATCH AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY IN 383 PATIENTS FROM THE SFGM-TC**

**THE IMPACT AND CHALLENGES OF PERFORMING BEAM CONDITIONED AUTOLOGOUS TRANSPLANTS IN 'OLDER' PATIENTS WITH LYMPHOMA**

**ACCESSIBILITY AND IMPACT ON LONG-TERM OVERALL SURVIVAL OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS: A SINGLE INSTITUTION INTENTION-TO-TREAT ANALYSIS**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TRANSFORMED FOLLICULAR LYMPHOMA (FL): RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY FROM GELTH/GELTAMO GROUP**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSE AFTER AUTOLOGOUS TRANSPLANTATION**

**SIGNIFICANT ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA**

**HIGH DOSE CHEMOTHERAPY TEAM FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA: RESULTS OF A PROSPECTIVE STUDY**

**AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIV+ AND HIV- LYMPHOMA PATIENTS: A PROPENSITY SCORE MATCHED ANALYSIS**

**AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR DOUBLE HIT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS**

**ALLOGENEIC STEM CELL TRANSPLANTATION CAN BE SUCCESSFULLY DELIVERED FOLLOWING BTKI THERAPY FAILURE FOLLOWING R-BAC RE-INDUCTION CHEMOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA**

**CLINICAL OUTCOMES OF EBV+ PTLD PATIENTS FOLLOWING HCT WHO FAIL RITUXIMAB: A RETROSPECTIVE CHART REVIEW STUDY FROM FRANCE**

**THE IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) ON THE OUTCOME OF POOR-RISK NON-HODGKIN LYMPHOMA (NHL): UPDATE OF A RETROSPECTIVE INTENT-TO-TRANSPLANT (ITT) ANALYSIS**

**REDUCING THE COST OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMAS AT LIMITED-RESOURCE CENTERS IN DEVELOPING COUNTRIES**

**COMPARISON OF MITOXANTRONE - MELPHALAN AND BEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS**

**NIVOLUMAB RE-CHALLENGE IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: WHERE IS THE PLACE FOR ALLOHSCT?**

**OUTCOME OF TRANSPLANT ELIGIBLE MANTLE CELL LYMPHOMA PATIENTS WITH FIRST-LINE REGIMENS IN A REAL-WORLD SETTING: A PORTUGUESE MULTICENTER RETROSPECTIVE ANALYSIS**

## **Scientific Programme**

**EVALUATION OF FRACTIONATED ICE AS AN ALTERNATIVE OUTPATIENT OPTION FOR RELAPSED/REFRACTORY LYMPHOMAS**

**EFFICACY OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA**

**RISK FACTORS FOR INTENSIVE CARE UNIT ADMISSION IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

**AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA**

**DIFFERENT OUTCOMES WITH DIFFERENT DONORS IN ALLOGENEIC STEM CELL TRANSPLANTATIONS IN MALIGNANT LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE**

**THE IRISH EXPERIENCE OF THIOTEPA, CARMUSTINE AND ETOPOSIDE CONDITIONING PRIOR TO ASCT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS**

**TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA**

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS TREATMENT OPTION FOR RARE TRANSDIFFERENTIATION OF LYMPHOID NEOPLASMS INTO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS TO ACHIEVE LONG-TERM SURVIVAL**

**OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH PERIPHERAL T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)**

**TREATMENT OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. A STUDY OF THE POLISH LYMPHOMA RESEARCH GROUP**

**PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH T-CELL LYMPHOMAS: PAVLOV UNIVERSITY EXPERIENCE**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA: TOXICITY AND SURVIVAL STUDY**

**AUTOIMMUNE COMPLICATIONS IN CHILDREN WITH HODGKIN DISEASE (HD) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT)**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIV-RELATED LYMPHOMA**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS OF 23 PATIENTS**

**NIVOLUMAB BASED RESPONSE ADAPTED TREATMENT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS**

**AUTOLOGOUS STEM CELL TRANSPLANT IN A SEROPOSITIVE A PATIENT WITH PLASMABLASTIC LYMPHOMA (PBL)**

**COMPARING THE EFFICACY AND TOXICITY BETWEEN TWO CONDITIONING REGIMEN IN LYMPHOMA PATIENTS IN WEST OF IRAN (BENDAMUSTIN) OR (CCNU) WITH (ETOPOSIDE, CITARABINE, MELPHALANE)**

## Scientific Programme

e-Posters  
12:30 - 18:30

ePoster Area

### Acute leukaemia

**ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HIV-INFECTION: AN UPDATED PAIR-MATCHED COHORT STUDY BY THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION**

**COMPARABLE OUTCOMES OF AML PATIENTS RECEIVING HAPLO-HCT WITH THIOTEPA/BUSULFAN/FLUDARABINE CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS A MATCHED UNRELATED DONOR WITH FLUDARABINE/BUSULFAN CONDITIONING, REGARDLESS OF DISEASE STATUS**

**TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT: IMPROVED SURVIVAL FOR YOUNG PATIENTS IN RECENT YEARS**

**ANTI-CD3/CD33 BISPECIFIC ANTIBODIES EFFICIENTLY REDIRECT DONOR T CELLS AGAINST HLA LOSS LEUKEMIA RELAPSES**

**POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) EMERGES AS A KEY DRIVER OF HLA CLASS II NEGATIVE POST-TRANSPLANTATION RELAPSE**

**ALLOGENEIC HCT FOR ADULTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA HARBORING *IKZF1* GENE MUTATIONS: A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**

**ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN CHILDREN AND ADULTS WITH RELAPSED/REFRACTORY B-ALL: FOCUS ON ANTI-CD19, ANTI-CD22 MONOCLONAL ANTIBODIES**

**THE VALUE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH AND WITHOUT *ASXL1*, *RUNX1* AND *TP53* MUTATIONS**

**ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT**

**RIC COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE PROVIDES HIGHER GVHD-FREE/RELAPSE FREE SURVIVAL IN FIT YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA**

**LOW-DOSE MEMORY DONOR LYMPHOCYTE INFUSION AFTER  $\alpha\beta$  T CELL-DEPLETED HSCT AMONG CHILDREN WITH HIGH-RISK LEUKEMIA: RESULTS OF A PROSPECTIVE RANDOMIZED SINGLE-CENTER TRIAL**

**DEVELOPMENT OF A CORD BLOOD STEM CELL-DERIVED DENDRITIC CELL VACCINE TO PREVENT RELAPSE AFTER CORD BLOOD TRANSPLANTATION IN AML**

**THE BRAZILIAN EXPERIENCE WITH HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTS (HAPLO-HCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**BETTER LEUKEMIA-FREE SURVIVAL WITH ALLOGENEIC THAN WITH AUTOLOGOUS HCT IN AML PATIENTS WITH ISOLATED TRISOMY 8: A STUDY FROM THE ALWP OF THE EBMT**

**ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML PATIENTS WITH RUNX1 MUTATION IN FIRST COMPLETE REMISSION: A STUDY ON BEHALF OF THE ALWP OF THE EBMT**

**GRAFT FAILURE AFTER UNMANIPULATED HAPLO-HSCT WITH PT-CY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION, ON BEHALF OF THE ALWP-EBMT**

## Scientific Programme

### **IMPLICATIONS OF NOVEL RISKS SCORES (AML-DRG AND AML-HCT-CR) IN ALLOGENEIC CD34+ SELECTED GRAFT TRANSPLANT OUTCOMES**

Rosalía Alonso Trillo, Marta Garcia Recio, Martina Pennisi, Christina Cho, Sean M. Devlin, Josel D. Ruiz, Molly A. Maloy, Ana Alarcon Tomas, Nerea Castillo, Richard J. Lin, Ioannis Politikos, Miriam Sanchez Escamilla, Michael Scordo, Gunjan L. Shah, Juliet N. Barker, Hugo Castro-Malaspina, Boglarka Gyurkocza, Parastoo B. Dahi, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Craig S. Sauter, Brian C. Shaffer, Roni Shouval, Roni Tamari, Marcel R. M. van den Brink, James W. Young, Sergio A. Giralt, Miguel Perales (Spain)

### **DOWNREGULATION OF HLA-DR IN BLASTS OF PATIENTS WITH ACUTE LEUKAEMIA RELAPSING AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **ESTABLISHMENT OF A NATIONAL STEM CELL TRANSPLANT CLINICAL TRIALS NETWORK: THE UK IMPACT PARTNERSHIP FOR ACCELERATED CELLULAR THERAPIES**

### **DIFFERENTIAL IMPACT OF NPM1 MUTATION ON THE POST-TRANSPLANT OUTCOME OF ADULT FLT3ITD MUTATED AML RECEIVING ALLOGENEIC TRANSPLANT IN CR1 AND AFTER CR1**

### **A REGION-WIDE RETROSPECTIVE ANALYSIS OF OUTCOME FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA**

### **PRE-HARVEST HIGHER DONOR FOXP3 MRNA AND LOWER CD4+ T CELL CONCENTRATION PREDICT INCREASED RISK OF ALL RELAPSE AFTER MYELOABLATIVE HCT WITH T-REPLETE BONE MARROW GRAFTS**

### **EPIDEMIOLOGY, MANAGEMENT AND ECONOMIC IMPACT OF ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME IN SPAIN: A CLAIMS DATABASE ANALYSIS**

### **PRE-TRANSPLANT BONE MARROW CELLULARITY AND BLOOD COUNT RECOVERY ARE NOT ASSOCIATED WITH RELAPSE OR SURVIVAL RISK FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT FOR AML IN CR1**

### **IMMUNOTHERAPY SALVAGE FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS BY THE ALWP OF THE EBMT**

### **COMPARISON OF PRE-TRANSPLANT COMORBIDITY INDICES IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **SALVAGE USE OF VENETOCLAX-BASED THERAPY FOR RELAPSED AML POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT**

### **FACTORS PREDICTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA**

### **ROLE OF CHIMERISM AND FLOW-CYTOMETRIC MONITORING OF MEASURABLE RESIDUAL DISEASE (MRD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN PREDICTING RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)**

### **SORAFENIB PROLONGED MAINTENANCE IN FLT3-MUTATED AML POST TRANSPLANTATION**

### **PULMONARY COMPLICATIONS (PC) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN CHILDREN WITH HIGH-RISK ACUTE LEUKEMIA (AL)**

### **MORE THAN TWO CYCLES OF CONSOLIDATION THERAPY PRE-TRANSPLANTATION BENEFITS AML PATIENTS IN CR1 WHO UNDERWENT HLA-MATCHED SIBLING ALLOGRAFTS: A MULTICENTER STUDY**

### **WHAT CAN CNV ANALYSIS ADD TO THE ROUTINE GENETIC DESCRIPTION OF AML CASES?**

### **COMPARISON OF THE PROGNOSTIC ABILITY OF THE HCT-CI THE MODIFIED EBMT AND THE EBMT-ADT PRE-TRANSPLANT RISK SCORES FOR ACUTE LEUKEMIA**

## **Scientific Programme**

**GO-FLAG REGIMEN AS A BRIDGE THERAPY TO ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS**

**THE IMPACT OF ALLOGENEIC TRANSPLANTATION IN AML AND MDS WITH CHROMOSOME 3 ABNORMALITIES**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY-ALONE IN THE TREATMENT OF PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS WITH MIXED LINEAGE LEUKEMIA (MLL) REARRANGEMENTS: SINGLE CENTER EXPERIENCE**

**POSTTRANSPLANTATION BENDAMUSTINE FOR GVHD PROPHYLAXIS IN REFRACTORY ACUTE LEUKEMIA PATIENTS**

**IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE**

**FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS**

**TYROSINE KINASE INHIBITOR TREATMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA**

**OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR CYTOGENETIC INTERMEDIATE-RISK AML ACCORDING TO THE MOLECULAR RISK BASED ON ELN 2017 RISK STRATIFICATION SYSTEM; SINGLE CENTER EXPERIENCE IN KOREA**

**THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY WT1 GENE EXPRESSION IN PERIPHERAL BLOOD BEFORE AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS**

**IMPACT OF POSTTRANSPLANT TYROSINE KINASE INHIBITORS ADMINISTRATION ON LONG TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**

**THE INFLUENCE OF ANTI-THYMOCYTE GLOBULIN (ATG) ON THE OUTCOMES OF PATIENTS WITH AML W/O MEASURABLE RESIDUAL DISEASE (MRD) AT THE TIME OF UNRELATED DONOR TRANSPLANTATION**

**MLL-AF6 FUSION GENE POSITIVE AML TREATED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS EXCELLENT OVERALL SURVIVAL**

**BENEFICIAL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM**

**INDUCTION OF SYNERGISTIC APOPTOSIS AND OVERCOMING OF DRUG RESISTANCE BY COTARGETING OF BCL-2 AND NA/H EXCHANGER 1 PATHWAY IN ACUTE MYELOID LEUKEMIA CELLS**

**GEMTUZUMAB-OZOGAMICIN FOR BRIDGING TO TRANSPLANT IN REFRACTORY/RELAPSED CD33 POSITIVE ACUTE LEUKEMIA - IS IT WORTHWHILE?**

**THE EFFECTS OF CYTOMEGALOVIRUS INFECTION ON TRANSPLANT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**AZACYTIDINE AND DONOR LYMPHOCYTES INFUSIONS IN RELAPSED AML AFTER ALLOGENEIC HSCT: RESULTS IN 40 PATIENTS**

**THE RESULTS OF AML RELAPSE AFTER ALLOGENEIC TRANSPLANTATION TREATMENT, SINGLE CENTRE APPROACH EVALUATION**

## Scientific Programme

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE CENTER ANALYSIS**

**THE OPTIMAL TIME FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA**

**IMPACT OF ABO MISMATCH ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTRE EXPERIENCE**

**DONOR SOURCE IMPACTS ON LONG TERM SURVIVAL FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN AML PATIENTS AGED 60 AND ABOVE**

**EXTRA-MEDULLARY RECURRENCE OF ACUTE MYELOID LEUKEMIA AS MYELOID SARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE SERIES**

**SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA: SINGLE CENTER EXPERIENCE**

**ALLOGENEIC STEM CELL TRANSPLANTS IN ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE EXPERIENCE**

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA NOT RESPONDING TO FIRST INDUCTION THERAPY**

e-Posters  
12:30 - 18:30

ePoster Area

## Aplastic anaemia

**LNP023 - A NEW ORAL COMPLEMENT FACTOR-B INHIBITOR NORMALIZES HEMOGLOBIN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH POOR RESPONSE TO ECULIZUMAB, BOTH AS ADD-ON AND MONOTHERAPY**

**EPIGENETIC AGING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH SEVERE APLASTIC ANEMIA: RESULTS FROM DNA-METHYLATION GRIMAGE**

**GVHD AND RELAPSE FREE SURVIVAL (GRFS) AFTER ALLOGENEIC TRANSPLANTATION FOR IDIOPATHIC SEVERE APLASTIC ANEMIA: AN ANALYSIS FROM THE SAAWP DATA QUALITY INITIATIVE PROGRAM OF EBMT**

**OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP**

**REDUCED INTENSITY CONDITIONING IS EFFECTIVE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND-BLACKFAN ANEMIA**

**PROSPECTIVE STUDY OF ECULIZUMAB BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA / APLASTIC ANEMIA**

**OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT FOR FANCONI ANEMIA IN INDIA**

**ALTERNATE DONOR HSCT FOR 109 CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA: A SINGLE CENTER RETROSPECTIVE ANALYSIS**

**SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH REFRACTORY ACTIVE INFECTION: A PROSPECTIVE MULTICENTER CLINICAL STUDY IN CHINA**

## Scientific Programme

**INCIDENCE AND MANAGEMENT OF APLASTIC ANEMIA IN SPAIN (IMAS). AN AMBISPECTIVE STUDY OF BIODONOSTIA / PETHEMA**

**ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS FOR CHILDREN WITH APLASTIC ANEMIA**

**OUTCOME OF PEDIATRIC ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE**

**OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR SEVERE APLASTIC ANEMIA IN PAKISTAN: DATA FROM A DEVELOPING COUNTRY**

**IMPACT OF CD34+-STEM CELL BOOST ON OUTCOME AND HEMATOLOGICAL RECONSTITUTION IN PATIENTS WITH SEVERE APLASTIC ANEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY**

**HEMATOPOIETIC STEM CELL TRANSPLANT IN ADULTS WITH ACQUIRED SEVERE APLASTIC ANEMIA**

**HEMATOPOIETIC STEM CELL TRANSPLANT IN FANCONI ANEMIA USING MATCHED RELATED AND HAPLOIDENTICAL DONORS- A SINGLE CENTRE EXPERIENCE**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC SEVERE APLASTIC ANEMIA: RESULTS OF A SINGLE CENTER**

**EFFECT OF SINGLE UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION ON APLASTIC ANEMIA IN CHILDREN**

**IMMUNOSUPPRESSIVE THERAPY IN PEDIATRIC APLASTIC ANEMIA, SINGLE CENTRE EXPERIENCE**

**CYCLOSPORINE, DANAZOL AND ROMIPLOSTIM IN SEVERE APLASTIC ANEMIA IN PRETRANSPLANT PERIOD: RETROSPECTIVE ANALYSIS OF FIVE CASES**

e-Posters  
12:30 - 18:30

ePoster Area

## Autoimmune diseases

**AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR STIFF PERSON SYNDROME**

**BEAM VS CYCLOPHOSPHAMIDE-BASED CONDITIONING REGIMEN IN AGGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE ANALYSIS OF EUROPEAN BLOOD AND MARROW TRANSPLANTATION SOCIETY**

**A NOVEL TARGETED APPROACH TO ACHIEVE IMMUNE SYSTEM RESET: CD45-TARGETED ANTIBODY DRUG CONJUGATES AMELIORATE DISEASE IN PRECLINICAL AUTOIMMUNE DISEASE MODELS AND ENABLE AUTOHSCT**

**LONG TERM FOLLOW UP OF SYSTEMIC SCLEROSIS FRENCH PATIENTS INCLUDED IN THE ASTIS TRIAL USING SCOT TRIAL GLOBAL RANK COMPOSITE SCORE (GRCS)**

**ADVANCES IN MULTIPLE SCLEROSIS (MS) TREATMENT: CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION**

## Scientific Programme

**POST TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES OUTCOME AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ANIMAL MODEL OF MULTIPLE SCLEROSIS**

**THE LONG-TERM SAFETY AND EFFICACY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS INDIRECTLY COMPARED TO ALEMTUZUMAB: A SYSTEMATIC REVIEW**

**RECONSTITUTION OF NATURAL OR VACCINATION-DRIVEN IMMUNITY AFTER AHSCT IN MULTIPLE SCLEROSIS**

**HIGH-DOSE IMMUNODEPLETION WITH AUTOLOGOUS STEM CELL RESCUE FOR TREATMENT OF AGGRESSIVE MULTIPLE SCLEROSIS**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT CHANGE THE EXPRESSION OF ENDOTHELIAL MARKERS IN SKIN BIOPSIES OF SYSTEMIC SCLEROSIS PATIENTS**

**AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NON HEMATOLOGICAL DISEASES. THE DUTCH EXPERIENCE OF MS PATIENTS GOING ABROAD**

**ANALYSIS OF COST AND CHARGES FOR NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES**

**AUTOLOGOUS STEM CELL TRANSPLANTATION IN BEHÇET'S DISEASE: A RETROSPECTIVE STUDY**

**SAFETY AND TOLERABILITY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE SCLEROSIS: A SINGLE CENTER EXPERIENCE**

**OUTCOME OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY TAKAYASU ARTERITIS, A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS IN NORWAY**

**THE USE OF AUTOLOGOUS HAEMOPOETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS AFTER ALEMTUZUMAB TREATMENT FAILURE: A CASE SERIES**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF SYSTEMIC SCLEROSIS, AN OPTION FOR REFRACTORY PATIENTS**

**A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE**

e-Posters  
12:30 - 18:30

ePoster Area

## CAR-based Cellular Therapy - clinical

**KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS FROM PHASE 2 OF ZUMA-2**

**SAFETY AND EFFICACY RESULTS FROM TRANSCEND NHL 001, A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA**

**CD19/CD22 DUAL TARGETED (CHIMERIC ANTIGEN RECEPTOR) CAR-T THERAPY FOR RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)**

## Scientific Programme

**AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE. ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP)**

**THIRD-GENERATION CAR T CELLS WITHIN THE HEIDELBERG CAR TRIAL 1 (HD-CAR-1) DISPLAY AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS**

**OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL IN 3 CLINICAL STUDIES OF RELAPSED/REFRACTORY LARGE B-CELL NHL, INCLUDING SECOND-LINE TRANSPLANT NONELIGIBLE PATIENTS: TRANSCEND NHL 001, OUTREACH, AND PILOT**

**CORRELATIVE ANALYSES OF PATIENT AND CLINICAL CHARACTERISTICS ASSOCIATED WITH EFFICACY IN TISAGENLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE JULIET TRIAL**

**CAR T CELLS (CART) OR ALLOGENEIC TRANSPLANTATION (ALLOHCT) FOR MULTIPLY RELAPSED DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)? A RETROSPECTIVE INTENT-TO-TREAT (ITT) COMPARISON**

**HIGH ACTIVATION OF BCMA CAR-T CELLS CONTRIBUTES TO INCREASED RESPONSE RATE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**

**A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL; AXI-CEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL)**

**CD19-TARGETED CAR-T CELL THERAPY FOR 32 B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)**

**INTERNATIONAL PROGNOSTIC INDEX PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACTORY LARGE DIFFUSE B CELL LYMPHOMA TREATED WITH COMMERCIAL CAR T CELLS**

**THE PHASE 1B PORTIA STUDY: SAFETY AND EFFICACY OF TISAGENLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA**

**REAL-WORLD EVIDENCE OF THE USE OF TISAGENLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS. THE SPANISH EXPERIENCE**

**NATIONAL IMPLEMENTATION OF THE USE OF TISAGENLEUCEL IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN NATIONAL HEALTH SERVICE ENGLAND (NHSE)**

**REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA**

**CORRELATIVE MARKERS OF TOXICITY IN PATIENTS WITH DLBCL TREATED WITH CD19 CAR T CELL THERAPY**

**EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)**

**ASSOCIATION OF AXI-CEL CAR-T CELL CONCENTRATION WITH TREATMENT RESPONSE AND SIDE EFFECTS AND IMPACT OF DEXAMETHASONE TREATMENT ON KINETICS**

**SIMPLIFIED-EASIX (SEASIX) IS AN EARLY PREDICTOR OF SEVERE CYTOKINE RELEASE SYNDROME AND IMMUNE-EFFECTOR-CELLS-ASSOCIATED NEUROTOXICITY SYNDROME IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T CELLS**

**NIVOLUMAB AS SALVAGE THERAPY IN PATIENTS WHO FAILED TO ACHIEVE COMPLETE REMISSION AFTER ANTI-CD19 CAR T-CELL THERAPY FOR DLBCL**

## Scientific Programme

**SURVEILLANCE OF MINIMAL RESIDUAL DISEASE (MRD) IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY CIRCULATING TUMOR DNA (CTDNA) PROFILING AFTER CHIMERIC ANTIGEN RECEPTOR T (CAR-T)**

**A DIGITAL-PCR ASSAY FOR PRECISE IN-VIVO QUANTIFICATION OF ADOPTIVELY TRANSFERRED CD19-CAR T CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**

**FEASIBILITY OF MANUFACTURING TISAGENLECLEUCEL IN PATIENTS LESS THAN 3 YEARS OF AGE WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA**

**AXICABTAGENE CILOLEUCEL CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: REAL-WORLD OUTCOMES, TOXICITY AND PREDICTORS OF RESPONSE FROM A PROSPECTIVE UK COHORT**

**MARKERS OF INITIAL AND LONG-TERM RESPONSES TO IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) IN THE CRB-401 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA**

**SINUSOIDAL OBSTRUCTION SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) TREATED WITH ARI-0001 CELLS**

**HUMORAL IMMUNE RESPONSE IN PATIENTS WITH CD19-POSITIVE RELAPSED/REFRACTORY B-CELL MALIGNANCIES RECRUITED INTO THE CART19-BE-01 CLINICAL TRIAL, AN ACADEMIC CAR19**

**REAL-WORLD DATA FROM KINGS COLLEGE HOSPITAL: INFECTION COMPLICATIONS POST CAR-T TREATMENT IN HIGH-GRADE B CELL NON-HODGKIN LYMPHOMA**

**SENESCENT/EXHAUSTED PHENOTYPE OF CD19-TARGETED CAR-T CELLS AND IMMUNOREGULATORY ENVIRONMENT CORRELATE WITH REDUCED RESPONSE TO CAR-T CELL THERAPY IN RELAPSED/REFRACTORY B CELL MALIGNANCIES**

**CHARACTERISATION OF EARLY AND LATE CYTOPENIAS IN LYMPHOMA PATIENTS FOLLOWING TREATMENT WITH ANTI-CD19 CAR-T THERAPY**

**CD4+ CAR-T CELLS MAINTAIN MEMORY PHENOTYPES AND MEDIATE LONGER-TERM ANTITUMOR ACTIVITY IN VIVO**

**IMPACT OF ETHNICITY IN R/R DLBCL AND B-CELL ALL PATIENTS TREATED WITH TISAGENLECLEUCEL**

**IMPACT OF DIFFERENT CHEMOTHERAPY REGIMENS AND DURATION OF DLBCL ON LYMPHOPHERESIS AND CAR-T T-CELL IMMUNOPHENOTYPING**

**CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA**

**CHALLENGES IN PROVIDING GOOD LEUKAPHERESIS PRODUCTS FOR THE PRODUCTION OF CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY NHL OR ALL**

**NKG2D CAR T CELLS ARE NOT AFFECTED BY SOLUBLE NKG2D LIGANDS**

**EMERGING CYTOKINE RELEASE SYNDROME IS ASSOCIATED WITH REDUCTION OF CD4+CD25HIGH127DIM T REGULATORY CELLS IN PATIENTS AFTER CAR T CELL THERAPY**

**EXCELLENT PROLIFERATION AND PERSISTENCE OF ALLOGENEIC CAR-T CELLS DESPITE IMMUNOSUPPRESSION WITH CYCLOSPORINE A**

**A FRENCH BIOBANKING NETWORK TO CREATE A UNIQUE COLLECTION OF SAMPLES OF PATIENTS TREATED WITH CAR-T CELLS**

## Scientific Programme

**CAR T CELL THERAPY DIRECTED AGAINST CD19 IN PATIENTS WITH B-CELL LYMPHOMA AFTER AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IS FEASIBLE AND SAFE**

**LYMPHOCYTE COLLECTION FOR GENERATION OF CAR T-CELLS IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE**

**BASELINE HYPOALBUMINEMIA DOES NOT APPEAR TO BE AN ADVERSE PROGNOSTIC FACTOR IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMAS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**

**FACTORS PREDICTING CD3+ COLLECTION FOR THE PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS**

**CYTOPENIAS AFTER TISAGENLECLEUCEL IN PAEDIATRIC/YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSE B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): A REAL-LIFE SINGLE-CENTRE EXPERIENCE**

**THE RISK OF HEPATITIS B REACTIVATION IS CONTROLLABLE IN B-CELL MALIGNANCIES PATIENTS WITH CONCOMITANT HEPATITIS B VIRUS INFECTION AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY**

**CUMULATIVE RITUXIMAB EXPOSURE PRIOR TO AXICABTAGENE CILOLEUCEL IS NOT ASSOCIATED WITH PERSISTENT LEUKOPENIA AND THROMBOCYTOPENIA AT DAY +90 POST INFUSION**

**COMPREHENSIVE IMMUNE CELL MONITORING REVEALS AN ALTERED LYMPHOCYTE SUBSET PHENOTYPE IN PATIENTS NOT RESPONDING TO TISAGENLECLEUCEL ONE MONTH POST INFUSION**

**NEUROTOXICITY ASSOCIATED WITH CAR T CELL THERAPY: NEUROLOGICAL MANAGEMENT AND WORK-UP OF 11 ADULT PATIENTS**

**NUTRITIONAL ASSESSMENT OF PATIENTS UNDERGOING CD19-TARGETED CAR-T THERAPY FOR NON-HODGKIN'S LYMPHOMA AND THE SHORT TERM EFFECT OF TREATMENT ON NUTRITIONAL STATUS**

**EFFECTIVENESS OF AUTOLOGOUS LEUKAPHERESIS COLLECTIONS FOR CAR T-CELL MANUFACTURING IN PATIENTS WITH B-CELL MALIGNANCIES**

**DEFINITION AND IMPLEMENTATION OF CLINICAL AND QUALITY ENDPOINTS IN CENTERS ADMINISTERING A COMMERCIAL CAR-T PRODUCT**

**CAR-T IN BREAST AND OTHER EXTRA-MEDULLARY RELAPSED/REFRACTORY ALL**

**PREDICTING CAR T-CELL INFUSION AFTER SUCCESSFUL MANUFACTURING: REAL-WORLD DATA**

**EVALUATION OF THE INTEREST OF A DRUG RECONCILIATION ACTIVITY IN PATIENTS TREATED WITH CAR T-CELLS: A DESCRIPTIVE STUDY**

e-Posters  
12:30 - 18:30

ePoster Area

## CAR-based Cellular Therapy - preclinical

**MODULATION OF CYTOSOLIC CA<sup>2+</sup> REGULATES CAR-T CELL DIFFERENTIATION AND THERAPEUTIC POTENCY**

## Scientific Programme

**BREAKING PD-L1-MEDIATED RESISTANCE IN ANTI-CD19 AND ANTI-CD22 CAR T CELLS WITH PD-1/CD28 FUSION RECEPTORS**

**ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR-INVARIANT NATURAL KILLER T CELLS EXERT BOTH DIRECT AND INDIRECT ANTITUMOR EFFECTS THROUGH HOST CD8 T CELL CROSS-PRIMING**

**DUVELISIB GENERATES CAR T CELLS WITH ENHANCED MITOCHONDRIAL BIOGENESIS AND REDUCED EXPRESSION OF PD-1, TIM-3, AND LAG-3, ENABLING GREATER ANTI-LEUKEMIA CYTOTOXICITY AGAINST CLL**

**NKG2D CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS**

**CLINICAL-GRADE MANUFACTURING OF ROR1 CAR T-CELLS USING A NOVEL VIRUS-FREE PROTOCOL**

**LENTIVIRALLY AND ALPHARETROVIRALLY ENGINEERED CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS ARE HIGHLY CYTOTOXIC AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA**

**NOVEL STRATEGIES TO ENHANCE THE SAFETY OF CAR T-CELL IMMUNOTHERAPY: THE IMSAVAR PROJECT**

**ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIC CELLS**

**ENHANCEMENT OF CYTOTOXICITY, EXPANSION AND PERSISTENCE OF CD19 CAR-T CELLS VIA PRE-SENSITIZATION OF B CELL MALIGNANCIES BY BCL-2 SELECTIVE INHIBITORS**

**TYROSINE KINASE INHIBITOR FOLLOWED BY CART THERAPY FOR THE TREATMENT OF RELAPSED PHILADELPHIA CHROMOSOME-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

e-Posters  
12:30 - 18:30

ePoster Area

## Cellular Therapies other than CARs

**CTLA4IG PRIMED SEQUENTIAL DLI IMPROVES GVHD AND RELAPSE-FREE SURVIVAL COMPARED TO UNPRIMED DLI IN PATIENTS UNDERGOING PTCY-BASED HAPLOIDENTICAL HCT FOR ADVANCED HEMATOLOGICAL MALIGNANCIES**

**HLA-MISMATCHED MOBILIZED CELLULAR THERAPY (MICROTRANSPLANT, MST) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES**

**DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PTCY: A STUDY ON BEHALF OF THE CTIWP OF THE EBMT**

**SAFETY, EFFECTIVENESS AND PERSISTENCE OF LOW-DOSE DONOR MEMORY T CELL INFUSIONS AFTER AB T CELL-DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER T-CELL-REPLETE ALLOGENEIC HSCT PREVENTS DISEASE RELAPSE AND PROLONGS SURVIVAL IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIA**

**BASELINE IMMUNE STATUS PREDICTS RESPONSE TO ADOPTIVE THERAPY WITH CMV CTLs FOR REFRACTORY CMV**

## Scientific Programme

**EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY ON BEHALF OF GETH (GRUPO ESPAÑOL TRASPLANTE HEMATOPOYÉTICO)**

**PHASE I STUDY OF ADOPTIVE TRANSFER OF HAPLOIDENTICAL EXPANDED NK CELLS**

**OFF-TARGET HLA CROSS-REACTIVITY BY (THIRD PARTY) VIRUS-SPECIFIC T CELLS IS SURPRISINGLY AFFECTED BY HLA RESTRICTION AND HLA BACKGROUND BUT NOT BY VIRUS SPECIFICITY**

**ADOPTIVE IMMUNOTHERAPY OF REFRACTORY VIRAL INFECTIONS AFTER ALLOGENEIC HSCT: AN ACADEMIC NETWORK FRAMING THE USE OF AN ATMP UNDER HOSPITAL EXEMPTION**

**HOW TO BENEFIT FROM EXHAUSTION: PATIENT-DERIVED INHIBITED T CELLS AS A NOVEL SOURCE OF TUMOR-REACTIVE T CELL CLONES**

**EFFICIENT CRISPR/CAS9-MEDIATED INACTIVATION OF THE GLUCOCORTICOID RECEPTOR FOR ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY**

**COMPARISON OF OUTCOME POST-SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION VERSUS DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS**

**AUTOMATED APPLICATION FOR DEPLETION OF TCRAB+, CD19+ AND CD45RA+ CELLS FROM APHERESIS PRODUCTS USING THE CLINIMACS PRODIGY (R)**

**THE FIRST FUNCTIONAL HLA-A\*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES**

**GOOD RESPONSE RATES OF WJ-MSC, COMPARABLE TO BM-MSC, IN THE TREATMENT OF REFRACTORY GVHD**

**AN 'ALL IN ONE' T-CELL PRODUCT FROM NON-TRANSPLANTABLE CORD BLOOD UNITS FOR VIRUS- AND LEUKEMIA-SPECIFIC T-CELL IMMUNOTHERAPY**

**CLINICAL SUCCESS OF GRANULOCYTE TRANSFUSIONS IN ADULT NEUTROPENIC PATIENTS AFTER CHEMOTHERAPY AND/OR ALLOGENEIC TRANSPLANTATION - TIME MATTERS!**

**IMPACT OF LONG-TERM CRYOPRESERVATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS PRODUCTS**

**OPTIMIZING LENTIVIRAL VECTOR TRANSDUCTION TO GENE MODIFY CORD BLOOD CD8+ T CELLS FOR OFF-THE-SHELF ADOPTIVE CELL THERAPY TO TREAT CANCER**

**DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTRE EXPERIENCE**

**CASE REPORT: CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION (CAEBV) CONTROLLED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) AND TRANSFUSION OF EBV-SPECIFIC T-CELLS**

e-Posters  
12:30 - 18:30

ePoster Area

## Chronic leukaemia and other myeloproliferative disorders

**TIMING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A JOINT STUDY FROM THE INTERNATIONAL MDS/MPN WORKING GROUP AND EBMT**

## Scientific Programme

**RELAPSE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IN THE PATHWAY INHIBITOR (PI) ERA: NO LONGER A DEAD-END STREET**

**THE 10-YEARS EBMT LANDSCAPE OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) FOR CHRONIC LYMPHOCYTIC LEUKEMIA**

**DETERMINANTS OF SURVIVAL IN MYELOFIBROSIS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT**

**SPLENECTOMY DOESN'T PRECLUDE SUBSEQUENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELOFIBROSIS PATIENTS: A FRENCH NATIONWIDE STUDY USING A MULTISTATE MODEL**

**INCIDENCE OF LATE RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: THE EXPERIENCE OF THREE UNIVERSITY TRANSPLANT CENTRES IN ROME**

**AUSTRALASIAN TRENDS IN ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS IN MOLECULAR ERA**

**CML RELAPSE AFTER ALLOGENEIC HSCT: SURVIVAL, TREATMENT EFFICACY AND PROGNOSTIC FACTORS FOR OUTCOME**

**CHRONIC MYELOID LEUKEMIA: ALLOGENEIC HEMOPOIETIC STEM CELLS TRANSPLANTATION IN THE ERA OF TYROSINE KINASE INHIBITORS**

**REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT WITH CAMPATH T-CELL DEPLETION FOR MYELOFIBROSIS IN THE ERA OF JAK INHIBITORS- A SINGLE CENTRE EXPERIENCE**

**ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS**

**ALLOGENEIC STEM CELL TRANSPLANTATION FOR IDIOPATIC MYELOFIBROSIS: A SINGLE CENTRE EXPERIENCE**

**A CASE OF SUCCESSFUL SECOND HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AFTER SECONDARY GRAFT FAILURE IN A PATIENT WITH REFRACTORY CHRONIC MYELOID LEUKEMIA**

e-Posters  
12:30 - 18:30

ePoster Area

## Conditioning regimens

**THE IMPACT OF CONDITIONING IN CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY "FORUM" ON BEHALF OF AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP**

**POPULATION PHARMACOKINETIC ESTIMATION OF ATG EXPOSURE PREDICTS IMMUNE RECONSTITUTION AND SURVIVAL IN ADULTS UNDERGOING EX VIVO CD34-SELECTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

## **Scientific Programme**

**FLAMSA-BASED REDUCED INTENSITY CONDITIONING VERSUS MYELOABLATIVE CONDITIONING IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH ACTIVE DISEASE AT THE TIME OF TRANSPLANTATION: AN ALWP/EBMT ANALYSIS**

**TOTAL BODY IRRADIATION/FLUDARABINE VERSUS THIOTEPA/BUSULFAN/FLUDARABINE FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH HAPLOIDENTICAL HCT. A STUDY BY ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**

**BUSULFAN-CYCLOPHOSPHAMIDE VERSUS CYCLOPHOSPHAMIDE-BUSULFAN AS CONDITIONING REGIMEN BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A PROSPECTIVE RANDOMIZED TRIAL**

**RABBIT ANTI-THYMOCYTE GLOBULIN (ATG) EXPOSURE AFTER EX VIVO T-CELL-DEPLETED HEMATOPOIETIC CELL TRANSPLANTATION IS VARIABLE AND IMPACTS IMMUNE RECONSTITUTION AND SURVIVAL IN CHILDREN AND YOUNG ADULTS**

**A RETROSPECTIVE COMPARATIVE STUDY OF BEAM VS FEAM VS TEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT**

**REDUCED INTENSITY VERSUS MYELOABLATIVE CONDITIONING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS < 60 WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTI-CENTER CANADIAN EXPERIENCE**

**COMBINING CLOFARABINE AND FLUDARABINE WITH EXPOSURE TARGETED BUSULFAN FOR PEDIATRIC LEUKEMIA: AN EFFECTIVE, LOW TOXIC, TBI-FREE CONDITIONING REGIMEN**

**BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II STUDY**

**REDUCED-TOXICITY CONDITIONING WITH FLUDARABINE, THIOTEPA AND MELPHALAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH IMPAIRED LUNG FUNCTION**

**ALLOGENEIC STEM CELL TRANSPLANT WITH MINIMAL-INTENSITY CONDITIONING IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA: A SINGLE CENTRE RETROSPECTIVE REVIEW**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%.A STUDY FROM THE ALWP-EBMT**

**A PROSPECTIVE COHORT STUDY COMPARING LONG-TERM OUTCOMES WITH AND WITHOUT PALIFERMIN IN PATIENTS RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES**

**PHARMACOKINETICS OF MELPHALAN IN LYMPHOMA PATIENTS UNDERGOING BEAM AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT**

**MELPHALAN IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION: DOES ONE SIZE FIT ALL?**

**COMPARISON OF TOTAL BODY IRRADIATION- VS CHEMOTHERAPY-BASED CONDITIONINGS FOR EARLY COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ALL**

**DIFFERENTIAL ALEMTUZUMAB DOSAGES IN T-CELL DEplete ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTS FOR MYELOID MALIGNANCIES**

**THE INFLUENCE OF TDM ON ACHIEVING BUSULFAN TARGET EXPOSURE AND RELATED DETERMINANTS, IN BOTH CHILDREN AND ADULTS WHO UNDERWENT AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

## Scientific Programme

**NOVEL REDUCED INTENSITY CONDITIONING (RIC) APPROACH TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH BENIGN AND MALIGNANT DISORDERS OF T CELL PROLIFERATION OR DYSREGULATION**

**PROFOUND LYMPHOPENIA AT THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION IS NOT PREDICTIVE OF SURVIVALS AFTER ALLO-TRANSPLANTATION**

**LIPID CORE NANOPARTICLES AS VEHICLE FOR ETOPOSIDE IN THE CONDITIONING REGIMEN OF MARROW TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA NOT RESPONDING TO INDUCTION THERAPY: A PILOT STUDY**

**A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF SHORT-TERM EVEROLIMUS IN ADDITION TO POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-EVER)**

**ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS  $\geq$  65 YEARS WITH HEMATOLOGICAL MALIGNANCIES AFTER MYELOABLATIVE TREOSULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS**

**BUTYRYLCHOLINESTERASE ACTIVITY AFTER CYCLOPHOSPHAMIDE CONDITIONING AS A PREDICTIVE MARKER OF LIVER TRANSPLANT-RELATED COMPLICATIONS AND ITS CORRELATION WITH TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS**

**FLUDARABINE-MELPHALAN CONDITIONING RESULTS IN FAVORABLE LEUKEMIA-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH ACTIVE OR MEASURABLE RESIDUAL AML**

**SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS)**

**INCREASED NON-RELAPSE MORTALITY AND POOR OVERALL SURVIVAL IN ELDERLY PATIENTS TREATED WITH FLUDARABINE AND MYELOABLATIVE DOSE OF BUSULFAN: TRANSPLANT COMPLICATIONS WORKING GROUP OF THE JSHCT**

**TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA**

**A CD45-TARGETED ANTIBODY DRUG CONJUGATE ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS A SINGLE AGENT IN MICE**

**INFLUENCE OF THE CELL SOURCE TYPE AND CONDITIONING TYPE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME**

**PRECONDITIONING INTENSITY IMPACTS ON IMMUNE RECONSTITUTION AND OUTCOMES FOLLOWING CORD BLOOD TRANSPLANTATION**

**FINAL RESULTS OF A PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY ON THIOTEPA-BASED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (ASCT) FOR CNS OR NON-CNS LYMPHOMA**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY), CYCLOSPORIN (CSA) AND MYCOPHENOLATE (MMF) FOR PATIENTS GRAFTED FROM HLA IDENTICAL SIBLINGS OR MATCHED UNRELATED DONORS**

**COMPARISON OF FLUDARABINE + BUSULFAN AND FLUDARABINE+BUSUFAN+ LOW-DOSE ATG CONDITIONING REGIMENS IN PATIENTS WITH MYELOID MALIGNANCIES WHO HAD ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

## **Scientific Programme**

**CONDITIONING REGIMEN COMPARISON FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA**

**PK-GUIDED BUSULFAN CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) WITH PTCY AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**A THIOTEPA BASED INTENSIFIED REDUCED INTENSITY CONDITIONING REGIME IN ADULT CORD BLOOD TRANSPLANT IS A PROMISING ALTERNATIVE IN PATIENTS UNABLE TO RECEIVE MYELOABLATIVE CONDITIONING**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE USING AS CONDITIONING FLUDARABINE MELPHALAN PLUS LOW DOSES OF TOTAL BODY IRRADIATION. LONG TERM FOLLOW-UP OF 60 PATIENTS**

**TREOSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE**

**COMPARISON OF BEAM AND TEAM AS CONDITIONING REGIMEN FOR LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

**ASSESSMENT OF THE SAFETY AND EFFICACY OF THE CONDITIONING REGIMEN BEEAC BEFORE AUTO-HSCT FOR THE TREATMENT OF PRIMARY-REFRACTORY AND RELAPSED FORMS OF MALIGNANT LYMPHOMAS**

**ALLOGENEIC STEM CELL TRANSPLANTATION AFTER TOTAL-BODY IRRADIATION USING HELICAL TOMOTHERAPY: A SINGLE CENTER EXPERIENCE**

**FEASIBILITY OF CLAMSA-RIC AS AN ALTERNATIVE CONDITIONING REGIMEN COMPARED TO FLAMSA-RIC IN HEAVILY PRETREATED REFRACTORY AML PATIENTS - A RETROSPECTIVE SINGLE CENTER ANALYSIS**

**THIOTEPA, BUSULPHAN AND FLUDARABINE CONDITIONING IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA**

**FLAMSA-BASED HIGH-DOSE SEQUENTIAL CONDITIONING REGIMEN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): IS IT EFFECTIVE IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE LEUKEMIA?**

**INCREASING IN SERUM TOTAL AMYLASE LEVELS AFTER TOTAL BODY IRRADIATION CONDITIONING REGIMEN AS A PREDICTIVE MARKER OF TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS**

**EVOLUTION OF DONOR CHIMERISM AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT - CLINICAL CORRELATIONS**

**THIOTEPA-BUSULFAN-FLUDARABINE AS CONDITIONING REGIMEN FOR PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA-HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE REGIMEN IN CHILDREN**

**ANALYSIS OF DIFFERENCES IN PREVENTIVE MEASURES AFTER HIGH-DOSE CYCLOPHOSPHAMIDE AMONG BELGIAN STEM CELL TRANSPLANT CENTRES**

**IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION**

**LOW GRAFT CD4 CELL DOSE PREDICTS RELAPSE IN THE ATG-BASED MYELOABLATIVE CONDITIONING REGIMEN**

## Scientific Programme

**CLINICAL EFFICACY OF HAPLOID TRANSPLANTATION WITH BU/CY/MEL PRETREATMENT SCHEME TO IMPROVE 68 CASES OF UNICENTRIC REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA**

**REDUCING INTENSITY CONDITIONING (RIC) PROTOCOL HARMONISATION IN THE UK**

**HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN HIGH-RISK HEMATOLOGICAL MALIGNANCIES, ALGERIAN EXPERIENCE**

**INTERRUPTION OF CONDITIONING FOR ALLO-HCT DOES NOT AFFECT CLINICAL OUTCOMES OTHER THAN CHRONIC GVHD**

**THERAPEUTIC DRUG MONITORING OF BUSULFAN IN PEDIATRIC POPULATION**

**REDUCED INTENSITY CONDITIONING FOLLOWED BY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (RIC-HAPLOHCT) AND POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS, FOR HEMATOLOGICAL DISORDERS: SINGLE CENTRE EXPERIENCE**

**HIGH DOSE TREATMENT WITH LEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION DURING THE SHORTAGE OF MOSTLY USED AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA**

**REDUCED DOSE ALEMTUZUMAB IN REDUCED INTENSITY CONDITIONING VOLUNTEER DONOR UNRELATED TRANSPLANT FOR MYELOID MALIGNANCIES IS SAFE AND EFFICACIOUS. A SINGLE CENTRE EXPERIENCE**

**DESCRIBE AND EXPLORE A PATIENTS' OUTLOOK ON DENTAL CARE IN THE CONTEXT OF THEIR MEDICAL DIAGNOSIS AND TREATMENT PRIOR TO AND FOLLOWING ALLOGENEIC HSCT**

**SAFETY AND EFFICACY OF LOW-DOSE BENDA-EAM AS COMPARED TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION OF REFRACTORY/RELAPSED LYMPHOMA PATIENTS**

**CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS**

**OUTCOMES OF UNRELATED DONOR STEM CELL TRANSPLANTATION WITH OR WITHOUT ANTI-THYMOCYTE GLOBULIN USED AS GRAFT-VERSUS HOST DISEASE (GVHD) PROPHYLAXIS: A SINGLE CENTER EXPERIENCE**

**BUSULFAN-FLUDARABINE CONDITIONING REGIMEN FOR CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE TWO-CENTER STUDY**

**ATG IN CONDITIONING FOR SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

e-Posters  
12:30 - 18:30

ePoster Area

## Data Management

**SUPPORTING TOOLS FOR ACCURATE DATA COLLECTION - DO WE GET THE BENEFIT?**

**ARE TRANSPLANTS TRULY AVAILABLE TO ALL, REGARDLESS OF GEOGRAPHY, SOCIOECONOMIC STATUS AND ETHNIC GROUP? A BSBMTCT REPORT**

**MISMATCHED DONOR AND GRADE 2 TO 4 ACUTE GVHD AS TWO-RISK MODEL FOR CYTOMEGALOVIRUS VIREMIA AND DISEASE AFTER ALLOGENEIC TRANSPLANTATION - SINGLE INSTITUTE ANALYSIS OF 1180 PATIENTS**

## Scientific Programme

e-Posters  
12:30 - 18:30

ePoster Area

### Experimental stem cell transplantation

**LOW-DOSE DECITABINE IMPROVES REFRACTORY PROLONGED ISOLATED THROMBOCYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A RANDOMIZED MULTICENTER CLINICAL TRIAL**

**AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY**

**2ND ALLO-HSCT FOR PATIENTS WHO DIAGNOSED RECURRENCE ALL AFTER THE 1ST ALLO-HSCT**

**ESTABLISHING A TRANSPLANT SHARING PROGRAM**

e-Posters  
12:30 - 18:30

ePoster Area

### Experimental transplantation

**SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTICS**

**IMPACT OF GUT FUNGAL COMPOSITION ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**MONITORING HEMATOPOIETIC CELL MICROPARTICLES IN ALLOGRAFTS AND TRANSPLANT RECIPIENTS**

**EARLY HEPATIC COMPLICATIONS DURING THE FIRST YEAR AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITH LEUKEMIA**

**PERFORMANCE OF BONE MARROW TRANSPLANTATION CENTER IN IMAM REZA HOSPITAL, KERMANSHAH, IRAN**

e-Posters  
12:30 - 18:30

ePoster Area

### Gene Therapy

**CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT  $\beta$ -THALASSEMIA**

**LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY (HSPC-GT) FOR METACHROMATIC LEUKODYSTROPHY (MLD): CLINICAL OUTCOMES FROM 33 PATIENTS**

**A SINGLE DOSE OF SHORT HALF-LIFE CD117 ANTIBODY DRUG CONJUGATE ENABLES HEMATOPOIETIC STEM CELL BASED GENE THERAPY IN NONHUMAN PRIMATES**

**LENTI-D HEMATOPOIETIC STEM CELL GENE THERAPY STABILIZES NEUROLOGIC FUNCTION IN BOYS WITH CEREBRAL ADRENOLEUKODYSTROPHY**

**SAFETY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH GENE ADDITION THERAPY FOR TRANSFUSION-DEPENDENT  $\beta$ -THALASSEMIA, SICKLE CELL DISEASE, AND CEREBRAL ADRENOLEUKODYSTROPHY**

## Scientific Programme

### EX-VIVO AUTOLOGOUS HAEMATOPOIETIC STEM CELL GENE THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE IIIA

e-Posters  
12:30 - 18:30

ePoster Area

## Graft-versus-host disease - clinical

**KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) - LONG-TERM FOLLOW-UP OF A PHASE 2A STUDY (KD025-208)**

**A PHASE 2 STUDY OF F-652, A NOVEL TISSUE-TARGETED RECOMBINANT HUMAN INTERLEUKIN-22 (IL-22) DIMER, FOR TREATMENT OF NEWLY DIAGNOSED ACUTE LOWER GI GVHD**

**THE MAGIC BIOMARKER ALGORITHM PREDICTS OUTCOMES FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE**

**A NOVEL TREATMENT IN CHRONIC OCULAR GRAFT-VS-HOST DISEASE (OGVHD): A PHASE II CLINIC TRIAL WITH TRANSDERMAL PROGESTERONE**

**EARLY CD4+ T-CELL RECONSTITUTION IS AN EXCELLENT PREDICTOR OF OUTCOMES IN PEDIATRIC PATIENTS WHO DEVELOP MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST-DISEASE: A DUAL CENTER VALIDATION**

**EFFECT OF SINGLE OR DOUBLE MISMATCHES AT EACH HLA LOCUS ON THE OUTCOMES AFTER SINGLE CORD BLOOD TRANSPLANTATION: THE JSHCT HLA WG STUDY**

**INTERIM ANALYSIS OF KD025-213: A PHASE 2, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KD025 IN SUBJECTS WITH CGVHD (THE ROCKSTAR STUDY)**

**ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) AND RITUXIMAB FOR IMMUNOMODULATION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT FAILURE IN PATIENTS WITH NON-MALIGNANT DISORDERS: RESULTS OF A MULTICENTRE, RANDOMIZED, OPEN-LABEL STUDY**

**EXPERIENCE USING DUAL T-CELL DEPLETION WITH ATG AND PTCY FOR GVHD PROPHYLAXIS IN RIC ALLOHCT USING IN 10/10 MATCHED RELATED AND UNRELATED DONORS**

**MACHINE LEARNING APPLIED TO THE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE IMPROVES SURVIVAL ESTIMATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**SINGLE-CELL MOLECULAR ANALYSIS DEFINES CHARACTERIZATION OF SPECIFIC T CELL SUBSETS CORRELATE WITH HUMAN CHRONIC GVHD AND BRONCHIOLITIS OBLITERANS**

**A PHASE II TRIAL EVALUATING THE USE OF THE HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PREVENTION**

**REDUCED CALCIUM SIGNALING IS ASSOCIATED WITH GVHD: RESULTS FROM PRECLINICAL ALLOST MODELS AND FROM A PROSPECTIVE MULTICENTER STUDY**

**IDENTIFICATION OF PREDICTIVE MODELS INCLUDING POLYMORPHISMS IN CYTOKINES GENES ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND OVERALL SURVIVAL AFTER IDENTICAL HLA-ALLOGENEIC STEM-CELL TRANSPLANTATION**

**SEARCH FOR CIRCULATING ENDOTHELIAL CELLS OF DONOR ORIGIN AFTER ALLO-HSCT: POTENTIAL CLINICALLY RELEVANT IMPLICATIONS IN THE CONTEXT OF GRAFT-VERSUS-HOST DISEASE**

## **Scientific Programme**

**DOUBLE LUNG TRANSPLANTATION IN ADULTS FOR CHRONIC PULMONARY GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**REDUCED INFLAMMATORY TISSUE INFILTRATION DURING INTESTINAL STEROID-REFRACTORY GVHD**

**IMPACT OF ANTITHYMOCYTE GLOBULIN DOSE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN STEM CELL TRANSPLANTATION FROM UNRELATED DONORS**

**DECREASED SOLUBLE HLA-E LEVELS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH SEVERE ACUTE AND EXTENDED CHRONIC GRAFT-VERSUS-HOST DISEASE AND INFERIOR OVERALL SURVIVAL**

**EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON PRODUCTION OF SERUM SOLUBLE CD163: RELATIONSHIP TO IMMUNOSUPPRESSION AND DISEASE ACTIVITY IN CHRONIC GRAFT VERSUS HOST DISEASE**

**POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE OVERCOMES THE DETRIMENTAL EFFECT OF A SINGLE-LOCUS HLA MISMATCHED IN UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: 'SIR-PTCY' RESULTS IN 249 PATIENTS**

**A NEW HOPE IN THE TREATMENT OF STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE (SR-GVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT): RUXOLITINIB**

**AZACITIDINE IS SAFE AND ACTIVE IN THE TREATMENT OF STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST-DISEASE - INTERIM RESULTS OF THE PHASE II AZTEC TRIAL**

**BASILIXIMAB AS TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EFFICACY AND TOLERANCE OF NILOTINIB IN PATIENTS WITH REFRACTORY CHRONIC GVHD WHO ARE REFRACTORY/INTOLERANT TO IMATINIB: A PROSPECTIVE MULTICENTER PHASE II STUDY OF THE SFGM-TC**

**EVALUATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC ASSESSMENT OF ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE UPPER GASTROINTESTINAL TRACT ACCORDING TO LERNER EARLY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**CYCLOSPORINE A ALONE VERSUS MYCOPHENOLATE MOFETIL PLUS CYCLOSPORINE A BASED GVHD PROPHYLAXIS FOR PATIENTS WITH AML UNDERGOING MUD TRANSPLANTATION. A STUDY FROM THE ALWP**

**TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE**

**DIAGNOSTIC SIGNIFICANCE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD)**

**LONG TERM OUTCOMES OF RUXOLITINIB THERAPY IN STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN AND ADULTS**

**INVESTIGATING ANTIBIOTIC EXPOSURE AND RISK OF SEVERE ACUTE GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## **Scientific Programme**

**EFFICACY AND TOXICITY OF RUXOLITINIB IN PATIENTS WITH STEROID-RESISTANT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION**

**PATIENT CHARACTERIZATION AND SURVIVAL OUTCOMES IN PAEDIATRIC CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS: A POPULATION-BASED STUDY IN SWEDEN**

**CYTOKINE LEVELS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A MATCH-PAIR ANALYSIS OF HOME CARE VERSUS HOSPITAL CARE**

**FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH STEROID-RESISTANT GRAFT VERSUS HOST DISEASE COLONIZED BY ANTIBIOTIC-RESISTANT BACTERIA - SINGLE-CENTER ANALYSIS OF 15 PROCEDURES**

**INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE: RESULTS FROM A PROSPECTIVE MULTICENTRE ANALYSIS OF 2 COHORTS**

**THE CXCL9 POLYMORPHISM RS884304 COUNTERACTS CALCINEURIN-INHIBITOR REPRESSION OF EARLY CXCL9 RECONSTITUTION AND ASSOCIATES WITH SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE**

**EARLY INTRODUCTION OF RUXOLITINIB FOR CHILDREN WITH GRAFT VERSUS HOST DISEASE - A STITCH IN TIME SAVES NINE**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE AS AN EFFECTIVE STRATEGY FOR GVHD PREVENTION IN BOTH HLA-MATCHED AND MISMATCHED ALLOGENEIC TRANSPLANTS**

**SERUM AUTOANTIBODIES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY**

**OPTIMIZED STARTING DOSE OF CYCLOSPORINE REDUCES RISK OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**SUCCESS OF IMMUNOSUPPRESSION IN PATIENTS WITH CHRONIC GVHD: ANALYSIS ON 108 ADULT LONG-TERM SURVIVORS AFTER MATCHED AND HAPLO HSCT**

**INCIDENCE AND OUTCOME OF LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE DURING TAPERING OR AFTER STOPPING CALCINEURIN INHIBITORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING AND MATCHED UNRELATED COMPARED TO HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, A STUDY ON BEHALF OF GETH**

**MESENCHYMAL STROMAL CELLS (MSC) FOR STEROID-REFRACTORY ACUTE GVHD, A SINGLE CENTER PHASE I/II TRIAL**

**T-LYMPHOCYTE TRANSCRIPTIONAL SIGNATURE IN ECP-TREATED PAEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE**

**EFFICACY OF LOW-DOSE RUXOLITINIB AS SAVAGE THERAPY IN HEAVILY PRETREATED PATIENTS WITH MODERATE/SEVERE STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE**

**RESTRICTIVE USE OF INTRAVENOUS ANTIBIOTICS IN ALLOGENEIC SCT PTS WITH FEVER DUE TO CYTOKINE RELEASE SYNDROME ALLOWS MICROBIOTA PROTECTION WITHOUT INCREASE OF INFECTIONS AND TRM**

**EXTRACORPOREAL PHOTOPHERESIS (ECP) AS FIRST-LINE TREATMENT FOR ACUTE GVHD (AGVHD) IN PEDIATRIC PATIENTS WHO UNDERWENT T-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (APLO-HSCT)**

## Scientific Programme

**EFFICACY OF METHOXSALEN STERILE SOLUTION IN CONJUNCTION WITH THE THERAKOS (R) CELLEX (R) PHOTOPHERESIS SYSTEM IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: INTERIM ANALYSIS**

**MICRO RNA PROFILING OF ACOUSTICALLY-ISOLATED EXTRACELLULAR VESICLES IDENTIFIES POTENTIAL BIOMARKERS FOR POST-ALLO-HSCT COMPLICATIONS**

**COLONIZATION PLAYS AN IMPORTANT ROLE IN THE OUTCOME OF ALLOGENEIC TRANSPLANTATION**

**ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) SCORE AT THE ONSET OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PREDICTING OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION-A RETROSPECTIVE ANALYSIS**

**CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS**

**COMPARISON OF EXCLUSIVE POSTTRANSPLANT CYCLOPHOSPHAMIDE VERSUS A CALCINEURIN INHIBITOR BASED REGIMEN AS GVHD PROPHYLAXIS IN ALLOGENEIC BONE MARROW TRANSPLANTATION FROM HLA IDENTICAL SIBLING**

**SIROLIMUS VERSUS CYCLOSPORINE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND MYCOPHENOLATE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL TRANSPLANTS: A RETROSPECTIVE ANALYSIS OF ONE SINGLE INSTITUTION**

Mario Andres Sanchez Salinas, Rafael Hernani Morales, Ana Benzaquen Vallejos, Juan Carlos Hernandez Boluda, Ariadna Perez Martinez, Paula Amat Martinez, Montserrat Gomez Calafat, Rosa Goterris Vicedo, Carlos Solano Vercet (Spain)

**TARGETED SEQUENCE CAPTURE METAGENOMICS (VIROCAP) TO DETECT VIRUS IN STOOL SAMPLES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS**

**EXTRACORPOREAL PHOTOPHERESIS AND PRODUCTION OF SERUM IL-34 AND ELAFIN IN CHRONIC GRAFT VERSUS HOST DISEASE**

**IMPACT OF UPPER AND LOWER ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE ON GRADING AND OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS IN 122 CONSECUTIVE PATIENTS**

Monica Poiani, Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Marianna Mariani, Giorgia Micucci, Chiara Montagna, Giuseppina Urbano, Federica Monaco, Giuseppe Tarantino, Irene Federici, Attilio Olivieri (Italy)

**PRELIMINARY EXPERIENCE WITH THE USE OF RUXOLITINIB, IBRUTINIB OR IMATINIB FOR THE TREATMENT OF ACUTE OR CHRONIC GVHD**

**RUXOLITINIB WITH OR WITHOUT IBRUTINIB AS AN ALTERNATIVE FIRST LINE THERAPY FREE OF CORTICOSTEROIDS OR CALCINEURIN INHIBITORS IN TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE**

**CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS**

**IMPACT OF KIR/HLA INCOMPATIBILITIES AFTER POSTTRANSPLANT CYCLOPHOSPHAMIDE BASED T CELL-REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ELEVATED PTH LEVELS AMONG CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS AND OTHER LONG TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION**

## **Scientific Programme**

**ACUTE GVHD INCIDENCE IN MISMATCHED UNRELATED DONOR HSCT IN PAEDIATRIC AD  
ADULT PATIENTS: A STUDY FROM THE TURIN METROPOLITAN TRANSPLANT CENTER**

**PRACTICAL IMPLEMENTATION OF THE NIH DIAGNOSTIC CRITERIA FOR ORAL CHRONIC GVHD  
IN A MULTIDISCIPLINARY TEAM IN THE LATE FOLLOW UP OF ALLOGENEIC HSCT PATIENTS**

**THE IMPACT OF ANTIBIOTIC-MEDIATED MODIFICATION OF THE INTESTINAL MICROBIOME ON  
OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SYSTEMATIC REVIEW  
AND META-ANALYSIS**

**CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON'S JELLY IN  
PATIENTS WITH GRAFT-VERSUS-HOST DISEASE**

**PREDICTIVE ROLE OF ENDOSCOPIC/HISTOLOGICAL EXAMINATIONS FOR GASTRO-INTESTINAL  
ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELLS TRANSPLANT: 'A  
POSTERIORI' ANALYSIS IN A SINGLE CENTER**

**THE INCIDENCE, RISK FACTORS, AND OUTCOMES OF ACUTE GRAFT-VERSUS-HOST DISEASE  
IN PEDIATRIC HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROGNOSTIC CT FINDINGS AROUND THE ONSET OF ACUTE GASTROINTESTINAL GRAFT-  
VERSUS-HOST DISEASE**

**THYMOGLOBULIN AND GRAFALON EFFECT ON ALLOGENEIC STEM CELL TRANSPLANT -  
POOLED DATA FROM WROCLAW MEDICAL UNIVERSITY, POLAND AND UNIVERSITY MEDICAL  
CENTER LJUBLJANA, SLOVENIA**

**THE ROLE OF LOW-DOSE ANTI-THYMOCYTE GLOBULIN IN MATCHED SIBLING DONOR  
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES**

**NEPHROTIC SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AS A FORM OF  
CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE**

**CORRELATION AMONG TOTAL NUCLEATED CELLS (TNC), CD34+, CD3+ CELL CONTENT IN G-  
CSF-PRIMED BONE MARROW COLLECTIONS AND THEIR RELATIVE INFLUENCE ON  
DEVELOPMENT OF ACUTE GVHD**

**PREDICTION FOR LETHAL ACUTE GRAFT VERSUS HOST DISEASE AND NON-RELAPSE  
MORTALITY BY EARLY PLASMA BIOMARKERS: A SINGLE CENTER RETROSPECTIVE STUDY IN  
JAPAN**

**RUXOLITINIB IN THE TREATMENT OF CORTICOSTEROID-REFRACTORY GRAFT-VERSUS-HOST  
DISEASE (GVHD): ONE SINGLE CENTER EXPERIENCE**

**OUTCOME OF PATIENTS ALIVE AT 1-YEAR POST ALLOGENEIC STEM CELL TRANSPLANTATION:  
A RETROSPECTIVE ANALYSIS FROM A SINGLE INSTITUTION**

**RUXOLITINIB IN STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE:  
EXPERIENCE IN OUR CENTRE**

**LOW-DOSE OF RUXOLITINIB: AN EFFECTIVE THERAPY FOR REFRACTORY BOS PATIENTS**

**SIROLIMUS BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PAEDIATRIC PATIENTS  
UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR BENIGN  
DISEASE**

**DETECTION OF BIOMARKERS PREDICTIVE OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC  
HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY**

**OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)  
AFTER PD-1 BLOCKADE IN RELAPSED/REFRACTORY (R/R) LYMPHOMAS: A SINGLE CENTER  
EXPERIENCE**

## Scientific Programme

**CD3+ DOSE IN PERIPHERAL BLOOD PROGENITOR CELLS PRODUCTS FOR ALLOTRANSPLANT FROM MATCHED UNRELATED DONORS FOR AML: IMPACT ON CHRONIC GRAFT VERSUS HOST DISEASE AND SURVIVAL**

**CYCLOPHOSPHAMIDE FOR SALVAGE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE ANALYSIS**

**A ROLE OF METHOTREXATE IN THE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE - A MULTICENTER OBSERVATIONAL STUDY ON BEHALF OF POLISH ADULT LEUKEMIA GROUP (PALG)**

**EVALUATION OF EXTRACORPOREAL PHOTOPHERESIS USED AS SECOND-LINE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HSCT IN A BRAZILIAN CENTER**

**THE OPTIMAL GVHD PROPHYLAXIS IN UNRELATED TRANSPLANTATIONS OF NON-MANIPULATED HEMATOPOIETIC STEM CELLS IN CHILDREN**

**ANALYSIS OF HISTOLOGY'S IMPACT IN PATIENTS WITH ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE**

**IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT). UNICENTRIC EXPERIENCE**

**FECAL MICROBIOTA TRANSPLANTATION FOR TREATING STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE OF THE GUT: A PILOT STUDY**

**EARLY RECOVERY OF LYMPHOCYTES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS RISK FACTOR OF CGVHD**

**FAVORABLE OUTCOME USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN HAPLOIDENTICAL (HAPLO-SCT) AND MATCHED RELATED DONORS (MRD): SINGLE CENTER EXPERIENCE IN CHILE**

**COMBINED THERAPY WITH MSC INFUSIONS TO OVERCOME STEROID-DEPENDENCY IN A CASE OF SEVERE PULMONARY CGVHD**

**MULTIPLE STRICTURES OF THE SMALL INTESTINE DEMANDING SURGICAL INTERVENTION AS A COMPLICATION OF GRAFT VERSUS HOST DISEASE: A CASE REPORT**

**A REMARKABLY LONG REMISSION ACHIEVED WITH IBRUTINIB MONOTHERAPY IN A PATIENT WHO WAS DIAGNOSED WITH STEROID REFRACTORY SCLEROSING CHRONIC GVHD**

**INCREASED RISK OF ACUTE GVHD IN PATIENTS WITH MYELOFIBROSIS AFTER ALLO TRANSPLANT IN THE ABSENCE OF JAK-STAT INHIBITION**

**AUTOIMMUNE MYOSITIS AS PARANEOPLASTIC COMPLICATION OF A SQUAMOUS CELL CARCINOMA OF THE TONGUE AFTER SEVERE CHRONIC GRAFT VERSUS HOST DISEASE**

**UNUSUAL CAUSE OF DYSPNEA IN POST-TRANSPLANT PATIENT**

e-Posters  
12:30 - 18:30

ePoster Area

## Graft-versus-host disease - preclinical and animal models

**DIETARY STEARIC ACID LEADS TO A SEVERE AGVHD BY MODULATING THE GUT MICROBIOTA AND GLUCOSE METABOLISM**

## Scientific Programme

**GRANULOCYTE COLONY-STIMULATING FACTOR-PRIMED DONOR T CELLS ATTENUATE MURINE ACUTE GVHD THROUGH REGULATING T CELL DIFFERENTIATION IN TARGET ORGANS**

**MTOR REGULATE GENERATION AND FUNCTION OF PMN-MDSCS AND PLAY PROTECTION ROLE IN ACUTE GRAFT-VERSUS-HOST DISEASE**

**FULL REGULATORY T CELL RECONSTITUTION BEFORE T CELL TRANSFER PREVENTS GRAFT-VERSUS-HOST DISEASE BY SUPPRESSING COSTIMULATION AND T CELL ACTIVATION IN A HAPLOIDENTICAL MODEL**

**TARGETING OF CHEMOKINE RECEPTOR 7 PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE**

**ENHANCING REGULATORY T CELL FUNCTION AND HOMING TO THE GUT TO IMPROVE GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER ADOPTIVE TRANSFER IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION**

**LYG1-DEFICIENT DONOR SPLENOCYTES ATTENUATED THE SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE VIA SKEWING CD4+ T CELL POLARIZATION TOWARDS TREG CELLS**

**ATTENUATION OF MURINE CHRONIC GRAFT VERSUS HOST DISEASE BY THE NRF2 ACTIVATOR MANGIFERIN**

**CHEMOTHERAPY AND INFLAMMATION INDUCED DAMAGE OF INTESTINAL EPITHELIUM IS ASSOCIATED WITH INCREASED T CELL CHEMOTAXIS**

**INKT CELLS PROMOTE IMMUNE TOLERANCE BY SELECTIVE DENDRITIC CELL APOPTOSIS**

**ACTIVE PARTICIPATION OF CXCR4+ T LYMPHOCYTES IN ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC TRANSPLANTATION**

**A MURINE MODEL REVEALS A CRITICAL ROLE FOR REACTIVE OXYGEN SPECIES IN HYPERACUTE GRAFT-VERSUS-HOST DISEASE**

**MAPPING THE ROAD OF GVHD AND GVT. A LONGITUDINAL STUDY OF IMMUNE-TRANSCRIPTOME SIGNATURES AS NOVEL APPROACH TO SOLVE POST-ALLOGENEIC TRANSPLANTATION DILEMMAS**

**CELL-FREE DNA LEVELS ARE INCREASED IN ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS AND MICE**

**DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION**

**ENDOTHELIAL MICROPARTICLES DELIVERING LNCRNA NEAT1 ARE INVOLVED IN THE PATHOPHYSIOLOGY OF AGVHD FOLLOWING ALLO-HSCT**

**B-T CELL INTERACTIONS IN GRAFT-VERSUS-HOST DISEASE**

**IDENTIFICATION OF POTENTIAL MICROBIOME MARKERS FOR AGVHD EARLY DIAGNOSIS**

e-Posters  
12:30 - 18:30

ePoster Area

## Granulocyte and osteoclast disorders

**HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR OSTEOPETROSIS**

## Scientific Programme

e-Posters  
12:30 - 18:30

ePoster Area

### Haematopoietic stem cells

**HAPLOIDENTICAL DONOR BEATS MATCHED SIBLING DONOR FOR PRE-TRANSPLANTATION MRD POSITIVE ALL: A PHASE 3 BIOLOGICALLY RANDOMIZED STUDY**

**RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED RELATED DONOR WITH TCR $\alpha\beta$ +/-CD19+-DEPLETION AND A FIXED DOSE MEMORY T CELL (CD45RA-DEPLETED) ADD-BACK**

**CLONAL DYNAMICS AND GENOMIC INTEGRITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN HUMAN ALLOGENEIC TRANSPLANTATION RECIPIENTS**

**ALLOGENEIC TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELL GRAFTS RESULTS IN A MASSIVE DECREASE OF PRIMITIVE HEMATOPOIETIC PROGENITOR FREQUENCIES IN RECONSTITUTED BONE MARROWS**

**TREATMENT OF PURE RED CELL APLASIA AFTER MAJOR ABO INCOMPATIBLE ALLOGENIC STEM CELL TRANSPLANTATION: A FRENCH RETROSPECTIVE STUDY**

**FEASIBILITY AND OUTCOMES OF A THIRD ALLOGENEIC HAEMATOPETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM THE ALWP OF EBMT**

**CHANGES IN VIABILITY MARKERS OF HAEMATOPETIC STEM CELLS FOLLOWING LONG-TERM CRYOPRESERVATION**

**HIGH PRE-TRANSPLANT INTERLEUKIN-18 IS ASSOCIATED WITH POOR HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND PREDICTS INCREASED NON-RELAPSE MORTALITY**

**MICROBIAL DIVERSITY, SURVIVAL, AND ACUTE GVHD IN ADULT RECIPIENTS OF ALLO-HSCT AFTER MYELOABLATIVE CONDITIONING: RESULTS OF A NUTRITIONAL INTERVENTION TRIAL**

**UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS**

**RECONSTRUCTION OF THE DONOR-RECIPIENT HAEMATOPETIC CELL PHYLOGENY USING SOMATIC MUTATIONS TO ESTABLISH NUMBERS OF ENGRAFTING LONG-TERM HSCS IN REAL-WORLD TRANSPLANTATION**

**SUCCESSFUL CLEARANCE OF DONOR SPECIFIC ANTI-HLA ANTIBODIES AFTER DESENSITIZATION WITH RITUXIMAB, VELCADE AND PLASMA-EXCHANGE FOLLOWED BY A HAPLOIDENTICAL STEM CELL TRANSPLANTION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

**IMPACT OF PRE-TRANSPLANTATION MINIMAL RESIDUAL DISEASE DETERMINED BY FLOW CYTOMETRY ON OUTCOME OF ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**ECONOMIC BURDEN OF CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SPANISH MULTICENTER, RETROSPECTIVE STUDY**

**INCIDENCE AND OUTCOME OF CLONAL AND MALIGNANT TRANSFORMATION (CMT) AMONG PEDIATRIC PATIENTS WITH INHERITED BONE MARROW FAILURE SYNDROMES (IBMFSS)**

**IMPACT OF POST-TRANSPLANT IMMUNOSUPPRESSION WEAN VS. BOOST IN EARLY MIXED CHIMERISM FOLLOWING G-CSF-PRIMED MARROW TRANSPLANT IN THALASSEMIC PATIENTS**

**COMPARISON OF THE CONDITIONING REGIMENS WITH TMLI, NON-RADIATION AND TBI FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

## **Scientific Programme**

**VALIDATION OF DISEASE RISK COMORBIDITY INDEX (DRCI) FOR OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) WITH PARTIALLY T-CELL DEPLETED GRAFT**

**ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PRETREATED WITH JAK1/JAK2 INHIBITORS**

**THE DETERMINATIVE ROLE OF PATIENT-CONTROLLED-ANALGESIA (PCA) IN THE EARLY COURSE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HIGH SURVIVAL RATE AND LOW INCIDENCE OF AGVHD AFTER CD34+ STEM CELLS SELECTION AND CD3+ T CELLS ADDBACK IN PEDIATRIC MUD HSCT**

**IMPACT OF ABO INCOMPATIBILITY ON OUTCOMES AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA**

**COMPARISON OF OUTCOMES AFTER HAPLOIDENTICAL VERSUS UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER REVIEW**

**EFFECT OF DIFFERENT TIMINGS OF UMBILICAL CORD CLAMPING ON THE LEVEL OF CD34+ CELLS IN FULL-TERM NEONATES**

**SEQUENTIAL CONDITIONING REGIMEN (FLAMSA-BU-MEL) IN HLA-MATCHED OR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY MYELOID DISEASE**

**SEQUENCE CYTOREDUCTIVE CHEMOTHERAPY FOLLOWED BY MA CONDITIONING REGIMEN HSCT WITH INTERMEDIATE - OR ADVERSE RISK AML IN CR: A SINGLE CENTER STUDY**

**INVESTIGATION OF VIROLOGICAL FEATURES AND CLINICAL OUTCOMES ASSOCIATED WITH PRE-ENGRAFTMENT CYTOMEGALOVIRUS DNAEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS**

**CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE AS A PREDICTOR OF ENGRAFTMENT AND SURVIVAL IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

**USE OF PLERIXAFOR IN POOR MOBILIZER PATIENTS WITH MYELOMA AND LYMPHOMA: CLONOGENIC CAPACITY AND ENGRAFTMENT DATA**

**OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRICS: A SINGLE CENTER EXPERIENCE FROM INDIA**

**RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: LONG TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA**

**PRE-EMPTIVE USE OF SORAFENIB COMBINED WITH DLI POST HSCT IN AML FLT3+: A SINGLE CENTER EXPERIENCE**

**USE OF ELTROMBOPAG FOR THE MANAGEMENT OF POOR GRAFT FUNCTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN**

**TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH ELTROMBOPAG**

**EFFICACY OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED TO CHEMOTHERAPY AS POST-REMISSION TREATMENT FOR CHILDREN WITH INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION**

**THE TREATMENT OF BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE**

## **Scientific Programme**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA  
IRREVERSIBLY DEPLETES NAÏVE T LYMPHOCYTES**

**DESENSITIZATION PROTOCOL IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL  
TRANSPLANT RECIPIENTS WITH ANTI-HLA DONOR-SPECIFIC ANTIBODIES (DSA): A SINGLE-  
CENTER EXPERIENCE**

**ASSOCIATION BETWEEN METABOLIC ALTERATION WITH TYPE AND INDICATION OF  
HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR PATIENTS RECEIVING UMBILICAL  
CORD BLOOD TRANSPLANTS AT THE ROYAL MARSDEN HOSPITAL BETWEEN 2007 AND 2017**

**HIGHER COST AND NO SURVIVAL BENEFIT WITH ADDITION OF RITUXIMAB TO BEAM  
CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH  
RELAPSED/REFRACTORY DLBCL**

**ASSOCIATION BETWEEN METABOLIC ALTERATIONS WITH AGE AND GENDER OF PATIENTS  
WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HAPLOIDENTICAL HSCT IN CHILDREN WITH VERY HIGH-RISK HAEMATOLOGIC MALIGNANCIES:  
A SINGLE-CENTRE EXPERIENCE**

**COMPARATIVE STUDY OF THE HEMATOPOIETIC RECONSTITUTION**

**INFUSED TOTAL NUCLEATED CELL DOSE IS NOT ASSOCIATED WITH ENGRAFTMENT IN  
AUTOLOGOUS STEM CELL TRANSPLANTATION**

**A COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND BFM 95  
CHEMOTHERAPY PROTOCOL IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA**

**THE IMPACT OF CD34+ CELL AND IMMUNEFFECTOR CELL DOSE ON TRANSPLANT OUTCOMES**

**TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC  
STEM CELL TRANSPLANTATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL  
WITH LOW RELATED TOXICITY**

**OUTCOME OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS  
POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**MOTIVATION FOR ANTIFUNGAL USE IN PEDIATRIC HSCT PATIENTS IN AN INSTITUTION IN  
SOUTHERN BRAZIL**

**IMPACT OF THE USE OF GRANULOCYTIC COLONY-STIMULATING FACTOR AFTER ALLOGENEIC  
HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RARE FORMS OF  
PRIMARY IMMUNODEFICIENCIES (PIDS) IN ARGENTINA**

**PHASE II STUDY OF PLERIXAFLOX AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE  
AUTOLOGOUS TRANSPLANTATION PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B  
CELL, PET POSITIVE AFTER TWO R-DHAP**

**THE EFFECT OF CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE ON THE HEMATOPOIETIC  
RECOVERY AND SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS  
UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION**

**THE EVENTUAL ROLE OF DONOR AND RECIPIENT VITAMIN D LEVELS IN ALLOGENEIC  
HEMATOPOIETIC STEM CELL TRANSPLANT SETTING**

**AVERAGE LENGTH OF HOSPITAL STAY FOR PEDIATRIC BLOOD AND MARROW TRANSPLANTS  
IN THE BACKDROP OF CELL SOURCE, TRANSPLANT TYPE AND OUTCOME**

## **Scientific Programme**

**ONE CENTER EXPERIENCE IN OFFLINE TECHNIQUE VALIDATION WITH BIOLOGICAL QUALITY TESTS**

**A MONOCENTRIC CLINICAL OBSERVATION OF ALLOGENEIC TRANSPLANTATION IN 22 PATIENTS WITH ACUTE MEGAKARYOCYTIC LEUKEMIA**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN SCIENTIFIC CENTRE OF PEDIATRICS AND CHILD SURGERY**

**THE OUTCOME OF ALLOTRANSPLANT USING TBF CONDITIONING FROM MATCHED SIBLING RELATED DONORS IN HIGH RISK MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE SINGLE CENTER EXPERIENCE**

**EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA: RETROSPECTIVE ANALYSIS IN OUR CENTER**

**CARDIOVASCULAR RISK IN PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**INFECTIONS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS IN PERU: EXPERIENCE OF A REFERRAL CENTER**

**HAEMATOPOIETIC STEM CELL PRODUCT VIABILITY: A COMPARATIVE STUDY BETWEEN BAGS AND VIALS**

**TRANSFUSION SUPPORT IN THE FIRST 30 AND 100 DAYS AFTER HAPLOIDENTICAL VERSUS HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MACS IN A PERUVIAN HEALTH CHILDRENS INSTITUTE: THREE-YEAR EXPERIENCE**

**COLLECTION, CRYOPRESERVATION AND AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELLS IN KAUNAS, LITHUANIA 2015-2019**

**EVALUATION OF OVERALL SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT): UNICENTRIC EXPERIENCE**

**MONITORING OF THE EXPRESSION OF THE VEGF-A GENE (VASCULAR ENDOTHELIAL GROWTH FACTOR) DURING THE EVOLUTION OF PEDIATRIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION. A PILOT STUDY**

**REFRACTORY T-CELL CUTANEOUS LYMPHOMA TREATED WITH ALLOGENEIC HAPLOIDENTIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT**

**VITAMIN D DEFICIENCY AND OUTCOMES IN ADULT ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE OVER LAST YEARS**

**CAUSES OF COMPLICATIONS IN ADULTS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

e-Posters  
12:30 - 18:30

ePoster Area

**Haemoglobinopathy and inborn errors**

## Scientific Programme

**SUCCESSFUL HLA-MISMATCHED HSCT IN PAEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES USING ATG SEROTHERAPY AND POSTTRANSPLANT CYCLOPHOSPHAMIDE**

**OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH CEREBRAL ADRENOLEUKODYSTROPHY VARY BY DONOR CELL SOURCE, CONDITIONING REGIMEN, AND STAGE OF CEREBRAL DISEASE STATUS**

**OUTCOME OF NON MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE: A 100 PATIENT EXPERIENCE FROM SAUDI ARABIA**

**HIGH DOSE STEM CELL THERAPIES, LIKE MGTA-456, ENABLE COMPLETE NEURAL AND PERIPHERAL DISEASE CROSS-CORRECTION THROUGH RAPID AND ROBUST HEMATOPOIETIC ENGRAFTMENT**

**HLA SET-UP IS A MAJOR PREDICTOR OF ENGRAFTMENT IN HAPLO-IDENTICAL TRANSPLANT FOR SEVERE THALASSEMIA (ST) USING POST-CYCLOPHOSPHAMIDE (PTCY)**

**CTLA4IG-BASED T CELL COSTIMULATION BLOCKADE IN PTCY BASED HAPLOIDENTICAL HCT FOR THALASSEMIA MAJOR [TM] AND SICKLE CELL DISEASE [SCD] RESULTS IN IMPROVED DISEASE-FREE SURVIVAL WITHOUT GVHD**

**LENTIGLOBIN GENE THERAPY TREATMENT OF TWO PATIENTS WITH TRANSFUSION-DEPENDENT  $\beta$ -THALASSEMIA**

**BONE MARROW TRANSPLANT IN PATIENTS WITH SICKLE CELL ANAEMIA. EXPERIENCE IN ONE CENTRE**

Marina García Morín, Laura Escobar Fernández, Eduardo Bardón Cancho, Cristina Beléndez Bieler, Jorge Huerta Aragón, Carmen Garrido Colino, Cristina Mata Fernández, Elena Cela de Julián (Spain)

**OUTCOMES IN CEREBRAL ADRENOLEUKODYSTROPHY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

**NEURODEVELOPMENTAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MUCOPOLYSACCHARIDOSIS TYPE II: A PROSPECTIVE, LONGITUDINAL STUDY**

**HEMATOPOIETIC RECOVERY AND TRANSFUSION NEED AFTER HAPLOIDENTICAL TRANSPLANTATION IN BETA THALASSEMIA PATIENTS**

**PRE- AND POST-TRANSPLANT RITUXIMAB REDUCES THE HIGH INCIDENCE OF PRIMARY GRAFT FAILURE AND IMMUNE-MEDIATED CYTOPENIA FOLLOWING CORD BLOOD TRANSPLANT FOR LYSOSOMAL STORAGE DISEASE IN CHILDREN**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: THE SPANISH EXPERIENCE**

**LONG-TERM QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD**

**HIGH INCIDENCE OF AUTOIMMUNE CYTOPENIAS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE: THE IMPACT OF MATCHED UNRELATED DONOR**

**ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI MAY REDUCE RISK OF GRAFT FAILURE IN MATCHED SIBLING DONOR ALLOGENEIC HSCT IN ADULT SICKLE CELL PATIENTS**

**A PHASE II STRATIFIED TRIAL TO ASSESS HAPLOIDENTICAL T-DEPLETED STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE WITH NO AVAILABLE SIBLING DONOR**

## Scientific Programme

**COMBINED UMBILICAL CORD BLOOD AND BONE MARROW FROM HLA-IDENTICAL SIBLING DONORS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA MAJOR**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF METABOLISM USING ALTERNATE DONORS: A PROSPECTIVE SINGLE STUDY**

**UMBILICAL CORD BLOOD TRANSPLANTATION IN CHILDREN WITH LEUKODYSTROPHIES: SINGLE CENTER EXPERIENCE IN CHINA**

**PEARSON SYNDROME IN A PATIENT TRANSPLANTED FOR DIAMOND-BLACKFAN ANEMIA**

**CHALLENGES AND SUCCESSES WITH PRE-TRANSPLANT IMMUNE SUPPRESSION IN ALTERNATIVE DONOR TRANSPLANTS**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CLASS 3 THALASSEMIA MAJOR USING POST-TRANSPLANT CYCLOPHOSPHAMIDE**

e-Posters  
12:30 - 18:30

ePoster Area

## Immunodeficiency diseases and macrophages

**IMPACT OF DIFFERENT *EX VIVO* T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY**

**OUTCOMES AND IMMUNE RECONSTITUTION AFTER T-CELL REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FOR PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCIES**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY IN JAPAN: OVERVIEW OF A NATIONWIDE RETROSPECTIVE ANALYSIS**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY IN JAPAN: A NATIONWIDE RETROSPECTIVE ANALYSIS**

**UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY: SINGLE-INSTITUTION EXPERIENCE IN CHINA**

**IMMUNODEFICIENCY - CENTROMERIC INSTABILITY - FACIAL DYSMORPHISM (ICF) SYNDROME: EVALUATION OF CHARACTERISTICS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THIOTEPA VERSUS MELPHALAN CONTAINING CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATIONS WITH TCR $\alpha\beta$ /CD19 GRAFT DEPLETION FOR PRIMARY IMMUNODEFICIENCIES**

**IMPROVED TRANSPLANT SURVIVAL AND LONG-TERM DISEASE OUTCOME FOR CHILDREN WITH CD40 LIGAND DEFICIENCY**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES INCLUDING IMMUNE RECONSTITUTION IN PRIMARY IMMUNODEFICIENCIES: 5 YEARS OF SINGLE CENTRE EXPERIENCE**

**OUTCOMES OF STEM CELL TRANSPLANT FOR RIPK1 DEFICIENCY: A SINGLE CENTRE EXPERIENCE**

## Scientific Programme

**IMPROVING THE RESULT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY WITH SERIOUS INFECTION IN DEVELOPING COUNTRIES USING RIC REGIMENT**

**SINGLE-CENTER EXPERIENCE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCR  $\alpha\beta$  DEPLETION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY SYNDROMES**

**HAPLO-IDENTICAL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY - A TERTIARY CARE CENTRE EXPERIENCE FROM SOUTH INDIA**

**NECROTIZING ENTEROCOLITIS IN A TWO-MONTH-OLD SCID PATIENT AFTER BONE MARROW TRANSFUSION - SURGICAL INTERVENTION AT DAY +1: YES OR NO?**

**UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH TWO DIFFERENT CONDITIONING REGIMEN FOR CHRONIC GRANULOMATOUS DISEASE: SINGLE-INSTITUTION EXPERIENCE IN CHINA**

**THE OUTCOMES OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE IN CHILDREN WITH RAG GENE MUTATION**

**LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) IN ADA-SCID PATIENTS: THE SHADOW OF MALIGNANCIES**

**HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR X-LINKED AGAMMAGLOBULINAEMIA COMPLICATED BY CHRONIC NOROVIRUS ENTEROPATHY**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CD40 LIGAND DEFICIENCY**

**DIAGNOSTIC MARKERS FOR AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR CHRONIC GRANULOMATOUS DISEASE (CGD) IN CHILDHOOD**

e-Posters  
12:30 - 18:30

ePoster Area

## Infectious complications

**PNEUMOCYSTIS PNEUMONIA AFTER ALLOGENEIC HCT: A CASE-CONTROL STUDY ON RISK FACTORS, TIMING, AND PCR USE, FROM THE IDWP OF EBMT**

**UPPER AND/OR LOWER RESPIRATORY TRACT INFECTION CAUSED BY HUMAN CORONAVIRUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**SUCCESSFUL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH JC- TARGETED T-CELL THERAPY**

**EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAs) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY**

**TUBERCULOSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT**

**FAECAL MICROBIOTA TRANSPLANT (FMT) CAN REDUCE THE HIGH NRM ASSOCIATED WITH MULTI-DRUG RESISTANT ORGANISM (MDRO) COLONISATION PRIOR TO ALLOGENEIC HCT**

## **Scientific Programme**

**EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY**

**USE OF LETERMOVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY**

**RISK OF INFECTIOUS COMPLICATIONS IN ADULT PATIENTS AFTER ALLOGENEIC HSCT DEPENDING ON THE SITE OF CENTRAL VENOUS CATHETER INSERTION - MULTICENTRE PROSPECTIVE STUDY**

**INFECTION PREVENTION PRACTICES AMONG EBMT HEMATOPOIETIC CELL TRANSPLANT CENTERS: A SURVEY OF THE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT**

**PRIMARY LETERMOVIR PROPHYLAXIS IN CMV SEROPOSITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE**

**HEV INFECTION IN HCT RECIPIENTS - RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) OF EBMT**

**THE ROLE OF COMBINATION PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTION AFTER EX VIVO AB T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT (HHCT) IN CHILDREN**

**IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY**

**COMPARISON OF IMMUNE CELL RESPONSE TO CYTOMEGALOVIRUS PROTEINS VERSUS PEPTIDES USING AN IFN- $\gamma$  ELISPOT ASSAY TO MONITOR CYTOMEGALOVIRUS-SPECIFIC IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HUMAN HERPESVIRUS TYPE 6 REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION: RISK FACTORS AND CLINICAL IMPACT**

**INCREMENTAL INPATIENT HEALTHCARE RESOURCE USE AND COSTS AMONG CMV SEROPOSITIVE ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS MANAGED THROUGH PREEMPTIVE APPROACH**

**POOR RECOVERY AND IMPAIRED FUNCTION OF V $\beta$ 1+ T CELLS IN REFRACTORY/RECURRENT CMV REACTIVATION AFTER HEMATOPOIETIC TRANSPLANTATION**

**SAFETY AND EFFICACY OF BRINCIDOFOVIR FOR REFRACTORY ADENOVIRUS INFECTION IN CHILDREN RECEIVING ALLOGENEIC SCT: A RETROSPECTIVE ANALYSES FROM THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION (AIEOP)**

**ALLOPLUS: RESULTS OF THE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS -POSITIVE PATIENTS, A RETROSPECTIVE STUDY OF THE SFGM-TC**

**SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A PROSPECTIVE STUDY TO MEASURE FEASIBILITY, SAFETY AND HEALTH CARE RESOURCE USE**

**FREQUENCY, RISK FACTORS AND OUTCOME OF ACTIVE TUBERCULOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**INFECTIOUS COMPLICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA AFTER NEW AGENTS' THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION**

**SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION**

## **Scientific Programme**

**CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION**

**FECAL MICROBIOTA TRANSPLANTATION IN CHILDREN TO TREAT ACUTE GVHD OR MULTI-DRUG RESISTANT BACTERIA COLONIZATION**

**VACCINATION AGAINST TICK-BORNE ENCEPHALITIS (TBE) AFTER AUTOLOGOUS AND ALLOGENEIC BONE MARROW TRANSPLANTATION**

**RIFAXIMIN USE FAVOURED MICAFUNGIN RESISTANT CANDIDA SPP INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT**

**IMPACT OF HHV-6 REACTIVATION AFTER T-REG/T-CON IMMUNOTHERAPY IN ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY**

**ADENOVIRUS INFECTIONS AFTER HCT: INFECTIOUS DISEASES WORKING PARTY RETROSPECTIVE EBMT REGISTRY STUDY**

**CLINICAL IMPACT OF COLONIZATION BY MULTIDRUG-RESISTANT ENTEROBACTERIACEAE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**POST-ALLOGENEIC TRANSPLANTATION PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, CLINICAL AND BIOLOGICAL FEATURES, TREATMENT AND OUTCOMES: A RETROSPECTIVE STUDY FROM THE SFGM-TC**

**RESPIRATORY VIRAL INFECTIONS IN ADULT PATIENTS UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION FROM UNRELATED DONORS AFTER MYELOABLATIVE CONDITIONING REGIMEN**

**EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS**

**RISK FACTORS AND CLINICAL OUTCOMES OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL AND MATCHED-SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**STANDARDIZED MONITORING OF CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY CAN IMPROVE RISK STRATIFICATION OF RECURRENT CYTOMEGALOVIRUS REACTIVATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**IMPACT OF LEVOFLOXACIN FOR PROPHYLAXIS OF PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTER ALLOGENEIC HSCT: A SINGLE-CENTER MATCHED ANALYSIS IN AN ENDEMIC COUNTRY FOR CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA**

**PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) AFTER HCT - A RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT**

**ORAL RIBAVIRIN IS A HIGHLY EFFICACIOUS TREATMENT FOR LOWER RESPIRATORY TRACT INFECTION DUE TO RESPIRATORY SYNCYTIAL OR PARAINFLUENZA VIRUS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS**

**TIMING OF INDUCTION TREATMENT FOR REACTIVATION OF CYTOMEGALOVIRUS IMPACTS OVERALL SURVIVAL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT**

**PREDICTION OF BLOODSTREAM INFECTION RISK USING CITRULLINE AS BIOMARKER OF INTESTINAL MUCOSITIS IN HEMATO-ONCOLOGY PATIENTS**

## **Scientific Programme**

**PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT**

**COMPARISON OF INFECTIOUS COMPLICATIONS AMONG PATIENTS RECEIVING UNMANIPULATED HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETED HAPLOIDENTICAL TRANSPLANT**

**THE CUMULATIVE INCIDENCE OF MULTIPLE DNA VIRUS REACTIVATION IS NOT DIFFERENT IN NON-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION AND UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION**

**NEUTROPHILS RESPONSE TO HUMAN CMV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

**CLINICAL EFFICACY OF LETERMIVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**AT-HOME FOSCARNET ADMINISTRATION IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION PATIENTS WITH CYTOMEGALOVIRUS INFECTION: A SAFETY FEASIBLE MODEL**

**EFFECTS OF THE ANTIBIOTICS CHANGE OR THE ADDITION OF ANTI-MRSA DRUGS FOR PERSISTENT FEBRILE NEUTROPENIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION**

**THERAPEUTIC DRUG MONITORING OF POSACONAZOLE AND SUBSEQUENT DOSING IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

**IS PREEMPTIVE STRATEGY ENOUGH? RELATIONSHIP BETWEEN CMV REACTIVATION AND STEROID THERAPY FOR GHVD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: 97 PATIENTS FROM TURKEY**

**PROPHYLAXIS WITH AZITHROMYCIN IN ALLOGENEIC CORD BLOOD TRANSPLANT AND ASSOCIATION WITH RELAPSE RATE AND TRANSPLANT OUTCOMES**

**REACTIVATED VARICELLA ZOSTER (VZV) INFECTION (SHINGLES), AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT) FOR HAEMATOLOGICAL DISEASE IN CHILDREN: A SIGNIFICANT PROBLEM AND PROPOSAL FOR FUTURE MANAGEMENT**

**LETERMIVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE**

**ANALYSIS OF CMV REACTIVATION RISK AFTER T CELL REplete HAPLOIDENTICAL AND MATCHED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ASPERGILLUS NON-FUMIGATUS INVASIVE ASPERGILLOSIS IN CHILDREN AND ADULTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) & CHEMOTHERAPY**

**INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS JIROVECI PROPHYLAXIS IN HEMATOLOGICAL PATIENTS TREATED WITH CHEMOTHERAPY, HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) AND CAR-T CELL THERAPY**

**INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS**

**LOW RELAPSE RISK FOR REDUCED INTENSITY CONDITIONED ALEMTUZUMAB-BASED ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMAS IS OFFSET BY CYTOMEGALOVIRUS RISK: DATA FROM SINGLE CENTRE STUDY**

## **Scientific Programme**

**PROPHYLACTIC DOSE TRIMETHOPRIM/SULFAMETHOXAZOLE DOES NOT LEAD TO DELAYED NEUTROPHIL AND PLATELET ENGRAFTMENT IN ALLOGENEIC HAEMATOPOETIC STEM CELL TRANSPLANT RECIPIENTS**

**HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EPIDEMIOLOGICAL SCREENING FOR BACTERIAL RESISTANCE BY DIFFERENT TECHNIQUES IN ALLO-HSCT PATIENTS**

**INVASIVE MOLD DISEASE IN A REAL-WORLD HEMATO-ONCOLOGY SETTING: VALUE OF A DIAGNOSTIC-DRIVEN CARE PATHWAY**

**SINGLE CENTER ANALYSIS ON THE MANAGEMENT OF ACYCLOVIR RESISTANT HERPES SIMPLEX VIRUS STOMATITIS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**EARLY BACTEREMIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION WITHOUT THE USE OF PROPHYLACTIC ANTIBIOTIC: CHANGING EPIDEMIOLOGY AND ANTIMICROBIAL RESISTANCE (2016-2018)**

**DIAGNOSTIC YIELD OF BRONCHOALVEOLAR LAVAGE (BAL) IN HAEMATOLOGICAL PATIENTS AFTER ALLOGENEIC/ AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) - COMPARISON WITH BAL PERFORMANCE IN NON-TRANSPLANTED PATIENTS**

**A NOVEL EFFICIENCY STRATEGY TO PREVENT HBV-RELATED HEPATITIS AFTER ALLOGENEIC HSCT FROM HBSAG- POSITIVE DONORS TO RECIPIENTS**

**BK VIRUS EFFECT ON DEVELOPING LATE HEMORRHAGIC CYSTITIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS: SINGLE CENTER EXPERIENCE**

**VERSATILE EFFECTS OF LETERMIVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS**

**IMPACT OF A CHANGE IN ANTIBACTERIAL PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION IN ONE SINGLE CENTER**

**INTRAVESICAL INSTILLATION OF CIDOVIFIR IS EFFICIENT FOR THE TREATMENT OF BK VIRUS HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC TRANSPLANTATION**

**MANAGEMENT OF BK POLYOMA VIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE**

**RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RISK FACTORS FOR CYTOMEGALOVIRUS INFECTION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**IMPACT OF HYPOGAMMAGLOBULINEMIA ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**

**THE USE OF RIFAXIMINE IN ANTI-BACTERIAL PROPHYLAXIS IN PATIENT UNDERGOING HSCT**

**BKV VIRUS - HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: INCIDENCE, SEVERITY AND RISK FACTORS**

**RUXOLITINIB FOR STEROID-REFRACTORY GVHD ABOLISHES ANTIVIRAL IMMUNE RESPONSE FOLLOWING T-CELL TRANSFER FOR REFRACTORY ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

## **Scientific Programme**

**RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMOVIR PROPHYLAXIS**

**ISAVUCONAZOLE (ISA) USE IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) RECIPIENTS: A SINGLE-CENTER EXPERIENCE**

**TIME- AND THERAPY-DEPENDENT BACTERIURIA IN CHILDREN AND YOUNG ADULTS FOLLOWING ALLOGENEIC HSCT**

**PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF MARIBAVIR COMPARED WITH VALGANCICLOVIR FOR TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS (STUDY DESIGN)**

**INCIDENCE AND RISK FACTORS OF VIRAL COMPLICATIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM HUNGARY**

**CONTRIBUTING FACTORS TO PRE ENGRAFTMENT BACTEREMIA AND PNEUMONIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A LEBANESE SINGLE CENTER EXPERIENCE**

**UNICENTRIC STUDY: PROPHYLAXIS STRATEGY AGAINST GVHD WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (CPYT) AND ITS RELATIONSHIP WITH CYTOMEGALOVIRUS**

**EPIDEMIOLOGY AND CLINICAL FEATURES OF FEBRILE NEUTROPENIC EPISODES: THREE YEARS EXPERIENCE AT HEMATOLOGY WARDS**

**USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS**

**TOXOPLASMOSIS DISEASE AFTER ALLO-HSCT. WHAT HAVE WE LEARNT?**

**TUBERCULOSIS IN PATIENTS WHO RECEIVE AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. TWO CASE REPORT**

**POLYOMAVIRUS BK INFECTION IN BONE MARROW TRANSPLANTATION RECIPIENTS. A COMPARATIVE ANALYSIS ON CHILDREN AND ADULTS**

**LEFLUNOMIDE, SUCCESSFUL PRE-EMPTIVE THERAPY IN RESISTANT CYTOMEGALOVIRUS REACTIVATION IN A HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT**

**LETERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**INFECTIOUS COMPLICATIONS IN HEMATOLOGIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EARLY MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA - A SINGLE CENTER EXPERIENCE**

**CMV RETINITIS IN A STEM CELL TRANSPLANT RECIPIENT TREATED WITH FOSCARNET INTRAVITREAL INJECTION AND CMV SPECIFIC IMMUNOGLOBULIN**

e-Posters  
12:30 - 18:30

ePoster Area

### **Minimal residual disease, tolerance, chimerism and immune reconstitution**

**T CELL CHIMERISM AFTER HCT DOES NOT PREDICT FOR GRAFT LOSS IN NON-MALIGNANT DISEASES, AND IS A FAILURE OF MYELOSUPPRESSION RATHER GRAFT REJECTION**

## Scientific Programme

**FASTER ENGRAFTMENT AND RECONSTITUTION OF INNATE-IMMUNITY AFTER ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) THAN POST-TRANSPLANT-CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS AFTER MYELOABLATIVE CONDITIONING (MAC) PERIPHERAL-BLOOD-STEM-CELL (PBSC) ALLOGENEIC-TRANSPLANTATION (ALLO-SCT)**

**CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENEIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMIVIR**

**COMPARING OUTCOMES OF PATIENTS HAVING MIXED T CHIMERISM AND UNRELATED DONOR ALLOGRAFTS FOR ACUTE LEUKAEMIA/MDS TO PATIENTS WITH COMPLETE CHIMERISM - SINGLE CENTRE RETROSPECTIVE STUDY**

**CMV INFECTION IS ASSOCIATED WITH REDUCED THYMIC FUNCTION AND LESS REGULATORY T CELLS AFTER PEDIATRIC ALLOGENEIC HSCT**

**IMPACT OF PRE-TRANSPLANT MRD BURDEN MEASURED BY MULTICOLOR FLOW CYTOMETRY ON RELAPSE AND SURVIVAL IN AML PATIENTS UNDERGOING ALLO-SCT IN CR**

**FLOW-BASED PRE-TRANSPLANT MRD DETECTION STRONGLY IMPACTS ON THE OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION WITH AB T CELL DEPLETION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA**

**CMV-SPECIFIC T CELL COUNTS EARLY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION STRATIFY THE RISK OF SUBSEQUENT CMV REACTIVATIONS: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY**

**IMPROVED RELAPSE-FREE-SURVIVAL IN PATIENTS WITH HIGH NATURAL KILLER CELL DOSES IN GRAFTS AND DURING EARLY IMMUNE RECONSTITUTION AFTER ALLOGENEIC TRANSPLANTATION WITH PERIPHERAL BLOOD STEM CELLS**

**POTENTIAL INFLUENCE OF IMMUNODEFICIENCY-RELATED HEREDITARY PREDISPOSITION GENE VARIANTS ON RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**COMPARABLE RESULTS OF PREEMPTIVE RECOMBINANT IL-2 AND DONOR LYMPHOCYTE INFUSION IN HEMATOLOGICAL MALIGNANCY PATIENTS WITH LATE-ONSET MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**SURVIVAL ANALYSIS ACCORDING TO MINIMAL RESIDUAL DISEASE BY FLOW CYTOMETRY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA**

**IMPACT OF RESIDUAL CIRCULATING TUMOR DNA STATUS POST ALLOGENEIC SCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: INTERIM RESULTS OF A PROSPECTIVE STUDY**

**EARLY CD4+ T CELL RECONSTRUCTION AS PREDICTOR FOR OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS: A VALIDATION COHORT ANALYSIS**

**PATTERN OF RECONSTITUTION OF RECENT THYMIC EMIGRANTS AFTER REDUCED INTENSITY CONDITIONING BASED ON TARGETED BUSULFAN IN PAEDIATRIC RECIPIENTS OF ALLOGENEIC HAEMATOPOETIC STEM CELL TRANSPLANTATION**

**A RISK SCORE SYSTEM BASED ON POST-TRANSPLANTATION MINIMAL RESIDUAL DISEASE FOR STRATIFICATION OF RELAPSE IN B-ALL PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION**

**OUTCOME OF CHILDREN WITH HEMATOLOGICAL MALIGNANCIES WHO DEVELOP MIXED DONOR CHIMERISM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROPHYLACTIC HIGH-DOSE DONOR CD45RO+ MEMORY T-CELLS INFUSION AFTER ALLOGENEIC TRANSPLANTATION: SAFETY AND OUTCOME**

## Scientific Programme

**MULTICOLOR FLOW CYTOMETRY PANEL WITH CCD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT**

**NON-INVASIVE MONITORING OF MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE BY CIRCULATING CELL-FREE NUCLEIC ACIDS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**TORQUE TENO VIRUS AS BIOMARKER TO PREDICT COMPLICATIONS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PREEMPTIVE INTERFERON- $\alpha$  TREATMENT COULD PROTECT AGAINST RELAPSE AND IMPROVE SURVIVAL OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THE ADDITION OF BUSULFAN REDUCES THE INCIDENCE OF MIXED CHIMERISM FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA**

**A NEW MULTIVARIATE MODEL TO DESCRIBE IMPACT OF IMMUNE RECONSTITUTION ON THE DEVELOPMENT OF RELAPSE IN CHILDREN UNDERGOING ALLO-HSCT FOR HEMATOLOGIC MALIGNANCIES AT DAY +100**

**ACQUISITION OF COMPLETE CHIMERISM IN BONE MARROW, PERIPHERAL BLOOD AND LEUKOCYTE SUBSETS DEPENDS ON THE TRANSPLANT SETTING AND CORRELATES WITH THE CLINICAL OUTCOME**

**EARLY LYMPHOID SUBSETS RECONSTITUTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AS PREDICTOR OF RELAPSE AND SURVIVAL IN ACUTE LEUKEMIAS**

**COMPARISON OF IMMUNE RECONSTITUTION BETWEEN 30MG/KG AND 60MG/KG ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANSPLANTATION**

**FUNCTIONAL IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COMPARISON OF PRE- AND POST-TRANSPLANTATION CYTOKINE RESPONSES IN STIMULATED WHOLE-BLOOD**

**MEASURABLE RESIDUAL DISEASE (MRD) TESTING FOR ACUTE LEUKEMIA IN EBMT TRANSPLANT CENTERS: A SURVEY ON BEHALF OF THE ALWP OF THE EBMT**

**TBF REGIMEN INDUCES FULL DONOR CHIMERISM AFTER ALLOGRAFTS IN MYELOFIBROSIS**

**REAL WORLD UTILITY OF TREATING MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA**

**COMPARISON OF IMMUNE RECOVERY IN CORD BLOOD AND T AND B DEPLETED HAPLOIDENTICAL GRAFTS RECIPIENTS**

**THE BCR-ABL P210 CHIMERIC TRANSCRIPT IN VITRO TRANSFER INTO BONE MARROW MESENCHYMAL STROMAL CELLS VIA EXOSOMES**

**PROGNOSTIC SIGNIFICANCE OF DONOR-SPECIFIC ISOAGGLUTININ RE-APPEARANCE IN ABO-MISMATCHED STEM CELL TRANSPLANT RECIPIENTS**

Maryam Pourabdollah, Christine Cserti, [Dennis Dong Hwan Kim](#), Eshetu Atenafu, Ivan Pasic, Zeyad Al-Shaibani, Aijun Law, Wilson Lam, Armin Gerbitz, Jeffery Lipton, Auro Viswabandya, Rajat Kumar, Jonas Mattson, Fotios Michelis, Nayana Soni, Jacob Pendergrast (Canada)

**IMMUNE-RECONSTITUTION OF LYMPHOCYTE SUBPOPULATIONS WITH RESPECT TO MSC-TREATMENT FOR STEROID REFRACTORY GVHD FOLLOWING HSCT**

## Scientific Programme

**DAY+100 FULL DONOR CHIMERISM IN THE BONE MARROW CONFERS BETTER OVERALL SURVIVAL IN REDUCED INTENSITY CONDITIONED WITH ALEMTUZUMAB ALLOGENEIC STEM CELL TRANSPLANTATION FOR LYMPHOMAS**

**DONOR FACTORS INFLUENCE OUTCOMES OF PATIENTS RECEIVING DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION**

**DETERMINE PATIENTS AT RISK OF RELAPSE AND DEATH IN ACUTE LEUKEMIA AND MYELOYDYSPLASIC SYNDROME USING CHIMERISM ON BONE MARROW SAMPLES AT DAY 28 AFTER HSCT**

**CONCURRENT- SYNERGISTIC ASSESSMENT OF TWO TECHNIQUES IN MONITORING MINIMAL RESIDUAL DISEASE FOR PH(-) ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANTATION LEADS TO FAVORABLE CLINICAL OUTCOMES**

**DONOR CHIMERISM EVALUATION OF MRD-SUSPECTED CELLS ISOLATED BY FLOW CELL SORTING IS AN ACCESSIBLE TOOL FOR MRD VERIFICATION IN PATIENTS AFTER ALLOGENEIC HSCT**

**ONE-STEP CHECK PURITY OF CD3+ SORTED CELLS ALONG MONITORING HEMATOPOIETIC CHIMERISM AFTER HSCT**

**DONOR LYMPHOCYTE INFUSIONS AUGMENT GRAFT VERSUS MALIGNANCY EFFECT FOLLOWING ALEMTUZUMAB-BASED REDUCED INTENSITY ALLOGRAFTS: REFLECTIONS ON A SINGLE CENTRE STUDY**

**MYELOID-DERIVED SUPPRESSOR CELLS RECOVER QUICKLY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS**

**PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY**

e-Posters  
12:30 - 18:30

ePoster Area

## Multiple myeloma

**DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF HIGH-RISK PATIENTS IN CASSIOPEIA**

**EVALUATION OF PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (PET/CT) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PHASE 3 CASSIOPEIA STUDY PATIENTS: CASSIOPET STUDY RESULTS**

**CONCORDANCE OF POSTCONSOLIDATION MINIMAL RESIDUAL DISEASE RATES BY MULTIPARAMETRIC FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING IN CASSIOPEIA**

**LONG-TERM FOLLOW-UP OF THE RANDOMIZED PHASE 3 PETHEMA/GEM 2005MENOS65 STUDY SUPPORTS THE USE OF VTD (BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE) AS PRETRANSPLANT INDUCTION REGIMEN FOR MULTIPLE MYELOMA (MM)**

**DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE**

**HOW TO ASSESS RISK OF PROGRESSION IN MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE REMISSION AFTER AUTOLOGOUS TRANSPLANT: SUB ANALYSIS FROM THE GEM2012MENOS65 PHASE III CLINICAL TRIAL**

## Scientific Programme

**OUTCOMES OF ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS**

**25 YEARS OF AUTOLOGOUS TRANSPLANTATION FOR MYELOMA IN EBMT CENTRES - CHANGING PRACTICE PATTERNS**

**PROGNOSIS IN DIFFERENT RISK-GROUPS OF MULTIPLE MYELOMA WITH MINIMAL RESIDUAL DISEASE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BORTEZOMIB-INTEGRATED CONDITIONING: A SINGLE-CENTER EXPERIENCE**

**UNINTERRUPTED MOBILIZATION AND TRANSPLANTATION PROCEDURE WITH NON-CRYOPRESERVED YIELD IS FEASIBLE WITHOUT INCREASEMENT OF COMPLICATION RISK IN MULTIPLE MYELOMA PATIENTS**

**CONDITIONING WITH BORTEZOMIB-MEL200 IN COMPARISON TO MEL200 IMPROVES SURVIVAL AMONG MYELOMA PATIENTS IN  $\leq$ PR PRIOR TO AUTO-HCT: A STUDY FROM THE CMWP OF THE EBMT**

**RESULTS OF DEFERRED AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED STAGES OF SYSTEMIC AL AMYLOIDOSIS**

**IN VITRO STIMULATION WITH CD40L/IL-21 CAN RETRIEVE B-CELL DYSFUNCTION IN MULTIPLE MYELOMA PATIENTS SUFFERING FROM SECONDARY IMMUNODEFICIENCY**

**ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA; EXCELLENT OUTCOMES FOR EARLY TRANSPLANTATION**

**SEQUENTIAL HEART TRANSPLANTATION FOLLOWED BY HIGH DOSE CHEMOTHERAPY PLUS AUTOLOGOUS STEM CELL REINFUSION IN CARDIAC AL AMYLOIDOSIS**

**AUTOGRAFT CELLULAR COMPOSITION AND OUTCOME IN MYELOMA PATIENTS: RESULTS OF THE PROSPECTIVE MULTICENTER GOA STUDY**

**RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE**

**PHASE 3, OPEN-LABEL, NONINFERIORITY STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): BODY WEIGHT SUBGROUP ANALYSIS OF COLUMBA**

**ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) IS A RELIABLE PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION**

**ABERRANT PHENOTYPE PLASMA CELL MULTIPARAMETRIC FLOW CYTOMETRY (MFC) DETECTION IN AUTOGRAFT PRODUCTS OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)**

**RETROSPECTIVE MULTI-CENTER STUDY OF ADOLESCENT AND YOUNG ADULT (AYA) MULTIPLE MYELOMA IN KANSAI MYELOMA FORUM REGISTRY**

**MAINTENANCE THERAPY WITH ELOTUZUMAB AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA**

**AUTOLOGOUS STEM CELL TRANSPLANTATION CANDIDACY IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS**

**NOVEL PROTOCOL FOR AUTOLOGOUS HSCT IN MULTIPLE MYELOMA ACHIEVES 'ZERO' CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS (CLABSI)**

**OUTCOMES OF NON-CRYOPRESERVED VERSUS CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA**

## Scientific Programme

**DOWN REGULATION OF AUTOPHAGY ENHANCES BORTEZOMIB-INDUCED APOPTOSIS OF MYELOMA CELL BY UP REGULATION OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES**

**RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE**

**FAVORABLE LONG-TERM OUTCOMES WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HIGH RISK PATIENTS WITH MULTIPLE MYELOMA WHO ARE POSITIVE AT FDG-PET/CT**

**LONG TERM SURVIVAL OF MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELATION TO AVAILABILITY OF NOVEL DRUGS**

**MULTIPLE MYELOMA (MM) IN FIRST RELAPSE PATIENTS. ROLE OF THE SECOND AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT) IN REAL LIFE: EXPERIENCE OF TWO SPANISH CENTERS**

**ROLE OF ANALYSIS OF CHIMERISM IN MULTIPLE MYELOMA PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE**

**USE OF NETUPITRANT/PALONOSETRON IN MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE**

**THE EFFECT OF UCP-2 AND NR3C1 GENES ON TREATMENT EFFICACY AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA**

**SAFETY AND EFFECTIVENESS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA IN FIRST LINE**

**PLASMAPHERESIS ASSISTED THE TREATMENT OF 1 CASE OF HYPERGLOBULINEMIA AFTER CART THERAPY**

e-Posters  
12:30 - 18:30

ePoster Area

## Myelodysplastic syndromes

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OF ADULT PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA: A NORDIC RETROSPECTIVE STUDY**

**DECITABINE MONOTHERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION RESULTED IN SUPERIOR SURVIVAL FOR MYELODYSPLASTIC SYNDROME PATIENTS WITH EXCESS BLASTS**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM: A STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT**

**IMPACT OF MUTATION PROFILE IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**NEW INSIGHTS OF MYELODYSPLASTIC SYNDROME (MDS) WITH ERYTHROID PREDOMINANCE BASED ON THE NEXT-GENERATION SEQUENCING AND SINGLE-CELL RNA SEQUENCING**

**IMPACT OF TREATMENT PRIOR TO ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: RESULTS OF THE LATIN AMERICAN BONE MARROW TRANSPLANT REGISTRY**

## Scientific Programme

**RESULTS OF LATIN AMERICAN RECORD OF BONE MARROW TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME**

**OUTCOME AND MUTATIONAL PROFILE IN MDS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

e-Posters  
12:30 - 18:30

ePoster Area

### New drug- and cell-based immune therapies

**NIVOLUMAB INCREASES ANTIGEN SPECIFIC IMMUNE RESPONSES AGAINST LEUKEMIC PROGENITOR AND STEM CELLS (LSC/LPC)**

**PROPHYLACTIC OR PREEMPTIVE LOW-DOSE AZACITIDINE AND DONOR LYMPHOCYTE INFUSION TO PREVENT DISEASE RELAPSE FOLLOWING ALLOGENEIC TRANSPLANTATION IN 60 PATIENTS WITH HIGH RISK AML OR MDS**

**ELTROMBOPAG FOR THE TREATMENT OF POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTS: A MULTICENTER SURVEY UPDATE**

**DONOR NK CELLS INFUSION AS A STRATEGY OF IMMUNOTHERAPY TO PREVENT HHV6 REACTIVATION IN PEDIATRIC PATIENTS AFTER CD45RA-DEPLETED TRANSPLANTATION**

**DEVELOPMENT OF CELL VACCINE BASED ON AUTOLOGOUS DENDRITIC CELLS LOADED WITH LIPID NANOPARTICLES CONTAINING CMV PP65 MESSENGER RNA**

**SMAC MIMETICS (SM) AND NATURAL KILLER (NK) CELLS - A PROMISING COMBINATION TO OVERCOME CELL DEATH RESISTANCE OF RHABDOMYOSARCOMA (RMS) CELLS**

**'KIT'-MEDIATED BLASTMODULATION TO LEUKEMIA-DERIVED DC SIGNIFICANTLY IMPROVES ANTILEUKEMIC ACTIVITIES IN WHOLE BLOOD INDEPENDENT OF AML-PATIENTS' SUBTYPES**

**ROLE OF EXOSOMES AS PROMOTORS OR BIOMARKERS TO STUDY ACTIVATION OF LEUKEMIA-DERIVED DENDRITIC CELLS (DCLEU)-MEDIATED ANTILEUKEMIC ACTIVATION OF ADAPTIVE AND INNATE IMMUNE-REACTIVE CELLS AGAINST AML-BLASTS**

**HIGHER INCIDENCE OF SEVERE AUTOIMMUNE HEMOLYTIC ANEMIA AFTER TCR $\alpha\beta$ + /CD19+ CELL DEPLETED HAPLOIDENTICAL-HSCT AND POSTGRAFT CELLULAR IMMUNOTHERAPIES: CTLA4-IG VERY EFFECTIVE THERAPEUTIC OPTION FOR THIS LIFE-THREATENING DISEASE**

**BLINATUMOMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM A SINGLE CENTER**

**IMMUNOMODULATION OF BLASTS WITH CLINICALLY APPROVED RESPONSE MODIFIERS TO IMPROVE ANTILEUKEMIC T-CELL REACTIVITY IN AML: AN EX VIVO SIMULATION OF THE CLINICAL SITUATION**

**IFNY SECRETION OF ADAPTIVE AND INNATE IMMUNE CELLS AS A PARAMETER TO DISPLAY LEUKAEMIA DERIVED DENDRITIC CELL (DC<sub>LEU</sub>) MEDIATED IMMUNE RESPONSES IN AML**

**TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721)**

## Scientific Programme

e-Posters  
12:30 - 18:30

ePoster Area

### Non-haematopoietic stem cells

**THE POTENTIAL ROLES OF MUCOSA-ASSOCIATED INVARIANT T CELLS IN THE PATHOGENESIS OF GUT GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**FACTORS INFLUENCING THE PRESENCE OF BONE MARROW MESENCHYMAL STEM CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**ANALYSIS OF THE GENETIC STABILITY OF DONORS' BONE MARROW STROMA MESENCHYMAL CELLS DURING CULTIVATION**

**EFFECT OF MATERNAL AND NEONATAL FACTORS ON THE YIELD OF WHARTON'S JELLY MESENCHYMAL STEM CELLS**

**THE POLISH EXPERIENCE OF WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF PAEDIATRIC PATIENTS**

**THE POLISH EXPERIENCE OF WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF ADULT PATIENTS**

**A RETROSPECTIVE ANALYSIS OF BONE MARROW EXAMINATION RESULTS FROM A SINGLE CENTER INSTITUTION: CAN WE REDUCE THE OCCURRENCE OF UNNECESSARY BONE MARROW EXAMINATIONS?**

e-Posters  
12:30 - 18:30

ePoster Area

### Non-infectious early complications

**IMPACT OF DONOR-DIRECTED HLA ALLO-ANTIBODIES ON PRIMARY GRAFT FAILURE AFTER UNRELATED DONOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION**

**ELTROMBOPAG TREATMENT AIDED IN PLATELET RECOVERY AND REDUCED PLATELET INFUSION FOR PATIENTS WITH POST-TRANSPLANTATION THROMBOCYTOPENIA**

**IMPACT OF FLUID OVERLOAD (FO) IN POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL DISEASES**

**INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS**

**USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT**

**REDUCED POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSES IN T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**ABO ISOAGGLUTININ LEVELS IN GUIDED MANAGEMENT OF ABO INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**METHYLPREDNISOLONE STRATIFIED INTERVENTION BASED ON RISK CLASSIFICATION IN THE TREATMENT OF PRE-ENGRAFTMENT SYNDROME AFTER UNRELATED CORD BLOOD TRANSPLANTATION: A PROSPECTIVE, NON-RANDOMIZED, AND OPEN-LABEL STUDY**

## Scientific Programme

**PRETRANSPLANT NUTRITION MEASURES AND SYSTEMIC INFLAMMATORY RESPONSE PREDICT OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**A MULTI-CENTRE, MULTI-NATIONAL, PROSPECTIVE OBSERVATIONAL REGISTRY STUDY OF DEFIBROTIDE IN PATIENTS DIAGNOSED WITH SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)**

**DEFIBROTIDE TREATMENT FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES BY SEVERITY AND MULTI-ORGAN FAILURE STATUS IN AN OBSERVATIONAL REGISTRY STUDY**

**INTRODUCTION OF NEW PEDIATRIC EBMT CRITERIA FOR VOD <b>Diagnosis: </b> IS IT LIFE- SAVING OR MONEY-WASTING?**

**PROSPECTIVE PILOT STUDY ON FRAILTY AND FUNCTION ASSESSMENT DURING CLINICS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**HISTOLOGIC FEATURES OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY WITH AND WITHOUT CONCOMITANT ACUTE GRAFT- VERSUS-HOST DISEASE**

**HIGH SURVIVAL RATE OF PEDIATRIC PATIENTS WITH PRIMARY GRAFT FAILURE WHO UNDERGO A SECOND PROCEDURE. THE EXPERIENCE OF 3 SPANISH PEDIATRIC TRANSPLANT UNITS**

**CHEMOTHERAPY-INDUCED GUT MUCOSAL INJURY INITIATES MICROBIAL DISRUPTION IN STEM CELL TRANSPLANT RECIPIENTS**

**BACTERIAL AND METABOLIC PROFILING OF THE SALIVA IDENTIFIES UNIQUE PATTERNS OF MICROBIOTA INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT WITH SEVERE ORAL MUCOSITIS**

**DIAGNOSIS AND MANAGEMENT OF SECONDARY HLH/MAS FOLLOWING HSCT AND CAR-T CELL THERAPY IN ADULTS: AN EBMT-WIDE SURVEY ON BEHALF OF THE ADWP AND TCWP**

**IMPACT OF ABO INCOMPATIBILITY ON COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION- RETROSPECTIVE, INTERNATIONAL, MULTICENTER ANALYSIS BY THE TRANSPLANT COMPLICATIONS WORKING PARTY EBMT**

**HYPOALBUMINEMIA PRIOR ALLOHCT IS A RELEVANT NEGATIVE PREDICTOR FOR SURVIVAL**

**INCIDENCE AND CLINICAL IMPACT OF ATRIAL FIBRILLATION DIAGNOSED DURING HOSPITAL STAY FOR ALLOGENEIC STEM CELL TRANSPLANTATION**

**TRANSPLANTATION-ASSOCIATED MICROANGIOPATHY (TAM) IN RECIPIENTS OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS USING PTCY FOR GVHD PROPHYLAXIS: INCIDENCE AND OUTCOME**

**IGF-1 AND IGFBP-3 GENE POLYMORPHISMS PREDICT CIRCULATING IGF LEVELS AND SYSTEMIC INFLAMMATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**LOW RISK OF EARLY TOXICITY AND UNPLANNED 100-DAY READMISSIONS AFTER MATCHED AND MISMATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

**KERATINOCYTE GROWTH FACTOR DECREASES HOSPITAL READMISSION AND REGIMEN- RELATED TOXICITIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA**

**ELTROMBOPAG FOR TREATING THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

## Scientific Programme

**SYSTEMIC CORTICOSTEROID THERAPY IS UNLIKELY TO BE THE PRIMARY CAUSE OF HYPERGLYCEMIA FOLLOWING TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE**

**COST-EFFECTIVENESS ANALYSIS OF DEFIBROTIDE FOR THE TREATMENT OF SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME IN SPAIN**

**NEUROLOGIC COMPLICATIONS IN 169 CONSECUTIVE ALLOGENEIC STEM CELL TRANSPLANTS: ETIOLOGY, CLINICAL SYNDROMES AND OUTCOME**

**VENETOCLAX, HYPOMETHYLATING AGENTS AND DLI FOR SALVAGE TREATMENT OF MYELOID MALIGNANCIES RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EVALUATION OF TGF-BETA LEVEL AFTER SUPPLEMENTATION WITH WHEY PROTEIN CONCENTRATE FOR ORAL MUCOSITIS PROPHYLAXIS**

**TREOSULFAN-INDUCED MYALGIA IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**VALIDATION OF EARLY INCREASE OF SC5B-9 AS A PREDICTIVE MARKER FOR LATER TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY**

**DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**EARLY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION IMPROVES OUTCOME OF VERY SEVERE HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER UNMANIPULATED HAPLOIDENTICAL HSCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

**DOES THE TYPE OF NUTRITIONAL SUPPORT AFFECT THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION? A PEDIATRIC CENTER EXPERIENCE**

**NEUROLOGICAL COMPLICATIONS IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY**

**ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO THE INTENSIVE CARE UNIT - REAPPRAISAL OF PROGNOSIS AND PROGNOSTIC FACTORS: A SINGLE CENTER STUDY**

**ENTERAL VERSUS PARENTERAL NUTRITION IN ADULT HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS SUFFERING FROM GASTROINTESTINAL MUCOSITIS**

**DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS**

**THE USEFULNESS OF LIVER STIFFNESS MEASUREMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT SINUSOIDAL OBSTRUCTION SYNDROME**

**ENDOTHELIAL CELL COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION, A SINGLE CENTRE ANALYSIS ON 99 CONSECUTIVE PATIENTS UNDERGOING ALLO-SCT**

Giorgia Mancini, Matteo Candelora, Giuseppina Urbano, Francesco Saraceni, Monica Poiani, Marianna Mariani, Irene Federici, Giuseppe Tarantino, Ilaria Scortechini, Attilio Olivieri (Italy)

**INFLUENCE OF ABO-INCOMPATIBILITY ON THE OUTCOME OF STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY ON CHILDREN AND YOUNG ADULTS**

**EASIX IS USEFUL FOR PREDICTING THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS**

## Scientific Programme

**SECOND TRANSPLANTATION USING A NOVEL CONDITIONING REGIMEN WITH DIFFERENT DONOR FOR GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**A SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME**

**VENO-OCCLUSIVE DISEASE: ONLINE, INTERPROFESSIONAL, CASE-BASED EDUCATION SIGNIFICANTLY IMPROVES KNOWLEDGE AND SKILLS OF THE ENTIRE CARE TEAM**

**HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME**

**EASIX AS A PREDICTIVE BIOMARKER OF COMPLICATIONS AND OUTCOME IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**SURVIVAL WITH NORMAL PULMONARY FUNCTION IS POSSIBLE DESPITE SIGNIFICANT AND PROLONGED RESPIRATORY SUPPORT, INCLUDING PROLONGED HIGH FREQUENCY OSCILLATORY VENTILATION (HFOV) IN CHILDREN**

**USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION**

**CURRENT PRACTICE IN NUTRITION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AUSTRIA, GERMANY AND SWITZERLAND**

**INCIDENCE AND SEVERITY OF CYTOKINE RELEASE SYNDROME FOLLOWING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL INFUSION**

**ENGRAFTMENT SYNDROME FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY FROM A SINGLE CENTER**

**WERNICKE'S ENCEPHALOPATHY IN A CHILD WITH B LYMPHOBLASTIC LYMPHOMA AFTER HAPLO-HSCT**

**ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE**

**IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN TERMS OF SINUSOIDAL OBSTRUCTION SYNDROME (SOS)**

**ISCHEMIC STROKE IN CHILDREN AND YOUNG ADULTS WITH MALIGNANT HEMATOLOGICAL AND ONCOLOGICAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**MELPHALAN DOSE ADJUSTMENT AND CRYOTHERAPY REDUCE ORAL MUCOSITIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CLINICAL FEATURES AND RISK FACTORS OF ENGRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**REAL-LIFE EXPERIENCE OF TWO ITALIAN HEMATOLOGY CENTRES ON EFFICACY AND SAFETY OF ORAL NEPA (NETUPITANT/PALONOSETRON) IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EARLY TREATMENT WITH DARATUMUMAB FOR REFRACTORY POST-ALLOGENEIC STEM CELL TRANSPLANT PURE RED CELL APLASIA**

**PROGNOSTIC FACTORS FOR EARLY MORTALITY OF HEMATOLOGICAL PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT: PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTER STUDY**

## Scientific Programme

**ACUTE KIDNEY INJURY DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS: INCIDENCE AND RISK FACTORS**

**T-PA/UROKINASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA**

**HEMOPHAGOCYTIC SYNDROME AFTER EX-VIVO LYMPHODEPLETED HEMATOPOIETIC TRANSPLANTATION**

**IMMUNOADSORPTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MAJOR ABO INCOMPATIBILITY**

**IMMUNE-MEDIATED FEVER AFTER T-CELL REPLETE HAPLOIDENTICAL HSCT USING PERIPHERAL BLOOD STEM CELL GRAFTS AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

e-Posters  
12:30 - 18:30

ePoster Area

## Non-infectious late effects, quality of life and fertility

**EASIX-1YEAR- THE FIRST BIOMARKER PREDICTING LATE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**AN UPDATED REPORT ON SECONDARY SOLID CANCER FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMIA MAJOR**

**ALLOGENEIC STEM-CELL TRANSPLANTATION IN AML AND MDS USING CONDITIONING REGIMENS WITH DIFFERENT DOSE-INTENSITIES; 15 YEARS LATER**

**EMPLOYMENT STATUS AND RETURN TO WORK AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A NATIONWIDE SURVEY**

**FUNCTIONAL OUTCOME MEASURES IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): FOCUS ON THE 2-MINUTE WALK TEST**

**FERTILITY IN ADULT FEMALE ALLOGENEIC STEM CELL RECIPIENTS**

**A RISK SCORE MODEL (HAD-TCG) TO EVALUATE THE RISK OF STROKE IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**BRONCHIOLITIS OBLITERANS SYNDROME IN THE CHANGING LANDSCAPE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CURRENT STATUS AND NEEDS OF LONG-TERM FOLLOW-UP CLINICS FOR HEMATOPOIETIC CELL TRANSPLANT SURVIVORS: RESULTS OF A NATIONWIDE SURVEY IN JAPAN**

**SURVIVORSHIP CARE FOR ALLOGENEIC TRANSPLANT PATIENTS IN THE UK: CURRENT SERVICE PROVISION AND BARRIERS TO IMPLEMENTATION**

**CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN EPSTEIN-BARR VIRUS RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (EBV-PTLD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)**

**INCIDENCE, RISK FACTORS AND OUTCOMES OF DIFFUSE ALVEOLAR HEMORRHAGE AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION**

**WHOLE BODY VIBRATION TRAINING DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - THE EFFECTS ON PATIENTS' PHYSICAL CAPACITY, FATIGUE, BODY COMPOSITION AND QUALITY OF LIFE**

**MULTI-MORBIDITY IN ADULT SURVIVORS OF STEM CELL TRANSPLANTATION (SCT)**

## **Scientific Programme**

**GONADOTOXICITY AFTER TREOSULFAN-BASED MYELOABLATIVE CONDITIONING REGIMEN FOR ALLOGENEIC HSCT IN GIRLS WITH LEUKEMIA**

**REDUCED-INTENSITY TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH HIGH-RISK OR ADVANCED HEMATOLOGICAL MALIGNANCIES IN LAST 10 YEARS - SINGLE CENTRE EXPERIENCE**

**FATHERHOOD AFTER A MYELOABLATIVE TREOSULFAN BASED ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS ON 453 PATIENTS**

**COMPARISON OF CENTRAL NERVOUS SYSTEM RELAPSE OUTCOMES FOLLOWING HAPLOIDENTICAL VS IDENTICAL-SIBLING TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA**

**OLDER AGE AND PERIPHERAL BLOOD AS A STEM CELL SOURCE ARE THE MAJOR NEGATIVE PREDICTORS OF SURVIVAL LONG TERM**

**PREVALENCE OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLOHSCT) IN THE US, EUROPE AND JAPAN**

**NETUPITANT-PALONOSETRON (NEPA) TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MULTIPLE MYELOMA (MM) PATIENTS RECEIVING HIGH-DOSE (HD) MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)**

**MOST FREQUENT LATE EFFECTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA DOES NOT SEEM TO WORSEN PERFORMANCE STATUS**

**INVOLVING STEM CELL TRANSPLANT PATIENTS AND THEIR FAMILIES TO IMPROVE THE ANTHONY NOLAN MY TRANSPLANT TRACKER APP**

**EARLY MENOPAUSE AND RISK FACTORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PREMENOPAUSAL ADULT WOMEN**

**MUSCULOSKELETAL COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

**CLINICAL CHARACTERISTICS AND MANAGEMENT OF LATE RELAPSE OF ACUTE MYELOID LEUKAEMIA MORE THAN FIVE YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**FOLLOWING UP WITH ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING 5+ YEARS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**LOW BACK PAIN AND LASER ACUPUNCTURE IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELLS TRANSPLANTATION**

**EFFECTS OF CONTROLLED EXERCISE ON PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANT IN AN ASIAN POPULATION: A SINGLE-CENTER EXPERIENCE**

**DEVELOPMENT OF GUILLAIN-BARRE-LIKE SYNDROME IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELLS TRANSPLANTATION**

## Scientific Programme

e-Posters  
12:30 - 18:30

ePoster Area

### Nurses Posters - Adult

**ROLE OF QUICKSOFA IN PREDICTING SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL PATIENTS**

**<i>BOLUS:</i> TARGETED SPECIALIST HAEMATOLOGY/BMT PODCASTS: AN EFFECTIVE METHOD OF EDUCATION**

**A PATHWAY FOR RECOVERY: D+100 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT) FOLLOW UP PILOT FOR LYMPHOMA**

**REDUCING ACCIDENTAL FALLS CAUSED BY ORTHOSTATIC HYPOTENSION IN BONE MARROW TRANSPLANT RECIPIENTS**

**THE EFFECT OF MOTIVATIONAL INTERVIEW PERFORMED AFTER STEM CELL TRANSPLANTATION ON SEXUAL EXPERIENCE, SEXUAL SELF-AWARENESS AND SEXUAL SELF-EFFICACY**

**STUDY ON COGNITIVE FUNCTION AND RELATED FACTORS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THE EFFECT OF RELAXING BREATHING EXERCISES ON PAIN, FATIGUE AND LEUKOCYTE COUNT IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**UNDERSTANDING OF PROGNOSIS, QUALITY OF LIFE AND PSYCHIATRIC STATUS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY OF 348 PATIENTS**

**AN OUTPATIENT MODEL OF CARE TO SAFELY DELIVER AUTOLOGOUS STEM CELL TRANSPLANTATION**

**EFFECTS OF TREATMENTS FOR HAEMATOLOGICAL MALIGNANCIES ON SEXUALITY AND FERTILITY: WHEN DO PATIENTS NEED IT AND WHOM REALLY WANTS TO KNOW?**

**EFFICACY OF THERAPEUTIC EDUCATION TO REDUCE RISKS AND COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY**

**SELF-EFFICACY AND SELF-CARE PRACTICES OF PATIENTS WHO HAVE BEEN TRANSPLANTED WITH ALLOGENEIC HEMATOPOIETIC STEM CELLS ACCORDING TO THE DEVELOPMENT OF AN INDIVIDUAL EDUCATION PROGRAM**

**DETERMINING THE SYMPTOMS AND COPING METHODS OF PATIENTS AT HOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THE EFFECT OF ORAL CARE PROTOCOL ON ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) WITHIN AN AMBULATORY CARE SETTING; A PATIENTS' PERSPECTIVE**

**REDUCING ANTITHYMOCYTE GLOBULIN ( ATG) INFUSION RELATED REACTION BY INCREASING THE INFUSION DURATION IN ADULT SCT PATIENTS ; A SINGLE INSTITUTION EXPERIENCE FROM SAUDI ARABIA**

**NURSE LED TELEPHONE FOLLOW UP FOR LATE EFFECTS SERVICE**

**NURSING CARE OF 15 PATIENTS WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CHIMERIC ANTIGEN RECEPTOR T CELLS**

## **Scientific Programme**

**NURSING CARE OF A PATIENT WITH HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY COMPLICATED WITH AXONAL DEGENERATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EFFECT OF NURSES EDUCATION PROGRAM ON CATHETER RELATED BLOOD STREAM INFECTIONS**

**THE CURRENT SITUATION AND INFLUENCING FACTORS OF MANAGEMENT OF CENTER VENOUS ACCESS DEVICE-ASSOCIATED SKIN IMPAIRMENT DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EXERCISE SUPPORT FOR PEOPLE POST TREATMENT AS PART OF THEIR RETURN TO WORK JOURNEY: A CASE STUDY EXEMPLAR**

**ONCOSAFETY: A NEW TOOL FOR HEMATOLOGY NURSES TO AVOID CHEMOTHERAPY ERRORS**

**PATIENT INFORMATION SHEET FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: THE IMPACT OF THE DISEASE AND TREATMENT ON SEXUAL FUNCTION AND SEXUALITY**

**CHANGING PRACTICE BY USING CYCLOPRIME 1.5G/M2 PRIMING REGIME UP FRONT FOR LYMPHOMA PATIENTS TO ENSURE GOOD MOBILISATION OF STEM CELLS**

**THE CHALLENGES OF LOOKING AFTER AN INCREASING NUMBER OF SURVIVORS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION**

**VENO-OCCLUSIVE DISEASE (VOD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT NURSING CONSIDERATIONS AND MANAGEMENT: A CASE STUDY**

**RECOGNIZING LOW HEALTH SKILLS AND LOW LITERACY DURING CONSULTATION**

**PRE-HABILITATION PRIOR TO STEM CELL TRANSPLANT - ONE CENTRES EXPERIENCE**

**THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY**

**PLASMAPHERESIS: TAKING THE EDGE OFF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTIBODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

**INCIDENCE & CHARACTERISTICS OF VARICELLA ZOSTER VIRUS INFECTION POST HEMATOPOIETIC STEM CELL TRANSPLANTATION; EXPERIENCE OF A SINGLE CENTER IN SAUDI ARABIA**

**SEMI-STRUCTURED INTERVIEW ASSESSMENT OF THE CLINICAL NURSE EDUCATOR ROLE IN SUPPORTING NEWLY QUALIFIED NURSES DURING TRANSITION TO POST-REGISTRATION PRACTICE INSIDE THE BONE MARROW TRANSPLANT SETTING**

**TRAINING NURSING PROGRAMME IN NEW THERAPIES: CAR T CELLS**

**NURSES' ROLE IN IMPROVING PATIENTS' FOOD INTAKE IN THE ACUTE HSCT PHASE**

**USE THE AVAILABLE KNOWLEDGE - ENSURE THAT THE PATIENT RECEIVES THE BEST CARE IN STEM CELL TRANSPLANTATION**

**THE PSYCHO EMOTIONAL DISAGUE IN ADULT PATIENTS SUBJECT TO MIDOLLO TRANSPLANT: INITIAL STUDY OF A SINGLE CENTER**

**NURSING CARE OF 15 PATIENTS WITH HEMATOLOGICAL MALIGNANT TUMOR COMPLICATED WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CAR-T CELLS**

**RETROSPECTIVE OBSERVATIONAL STUDY ON THE TRANSMISSION OF HEALTCARE ASSOCIATED INFECTIONS AMONG NEUTROPENIC PATIENTS WITHIN THE HEMATOLOGY UNIT OF PIACENZA HOSPITAL**

## Scientific Programme

### **GUIDE FOR PATIENTS AND DONORS BEFORE A PERIPHERAL BLOOD STEM CELL COLLECTION**

Natalia Lorente del Río, Cristina Alberquilla Ramos, Salvadora Aleza Esteras, Isabel María Fernández Morales, M<sup>a</sup> Del Carmen Freire Mourón, Ana García Carulla, Carmen Granado Rodilla, Mercedes Jiménez Meoro, Rosario López López, Marta Vela Garicano, Jesús Zalvide Torrente, Laura Bibiloni Martínez (Spain)

### **IMPACT OF AN IMPROVEMENT PLAN ON THE REDUCTION OF BACTERIEMIA BY CENTRAL CATHETER IN A PATIENT RECEIVER OF A CELLULAR THERAPY**

### **ARE TYMPANIC THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?**

### **RELATIONSHIPS BETWEEN THE HEALTHCARE NEEDS AND QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS**

### **PAIN ASSESSMENT DURING BONE MARROW BIOPSY PROCEDURE AND BONE MARROW ASPIRATE PROCEDURE: A SPECIFIC NURSING ASSESSMENT**

### **AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION IN SYSTEMIC SCLEROSIS: CASE STUDY**

### **LEADERSHIP - LEADING THE TEAM**

### **PAIN ASSESSMENT IN ONCO\_HEMATOLOGICAL PATIENT SUBJECTED TO CENTRAL VENOUS CATHETER POSITIONING (CVC) OR PERIPHERALLY INSERTED CENTRAL CATHETER POSITIONING (PICC)**

### **TOCILIZUMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME**

### **COMPLICATIONS ASSOCIATED WITH THE COLLECTION OF PERIPHERAL BLOOD PROGENITOR CELLS**

### **IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS!**

### **INCIDENCE OF ACUTE GUT GVHD IN PATIENTS WHO HAVE UNDERGONE ALLOGENIC STEM CELL TRANSPLANT: CASE STUDY**

### **COMPLETION TIME TO HLA TYPING**

### **GYNECOLOGICAL TREATMENT EXPERIENCE OF MENOPAUSAL SYNDROME AND SEXUAL DISORDERS IN FEMALE PATIENTS WHO UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION**

e-Posters  
12:30 - 18:30

ePoster Area

## **Nurses Posters - Paediatric**

### **TRANSITION STRATEGY: FROM PEDIATRIC TO ADULT HEALTH CARE AND LONG TERM FOLLOW-UP**

### **CAREGIVER EDUCATION AND TRAINING FOR SELF ADMINISTRATION OF ORAL DRUGS IN A PAEDIATRIC CENTER**

### **EXERCISE THERAPY ON CANCER-RELATED FATIGUE AND QUALITY OF LIFE IN CHILDREN UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION**

### **SEXUAL HEALTH FOR YOUNG PEOPLE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

## **Scientific Programme**

**EVALUATION OF A PREVENTIVE SKIN CARE PROTOCOL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA**

**CAR-T: THE DUTCH PEDIATRIC NURSING EXPERIENCE**

**SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEIPIENTS: A SINGLE CENTER EXPERIENCE**

**PEDIATRIC PHOTOAPHAERESIS: THE DILEMMA OF VASCULAR ACCESSES**

**TOTALLY IMPLANTABLE VASCULAR ACCESS DEVICES RUPTURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: PROPHYLAXIS AND TREATMENT**

**USE OF VOLUMETRIC PUMPS FOR THE INFUSION OF HEMATOPOIETIC STEM CELLS AS A STANDARD METHOD IN PEDIATRIC PATIENTS**

**PEDIATRIC PATIENT TRANSFER FROM A TPH WARD TO ICU: HOW CAN WE IMPROVE OUR COMMUNICATION?**

**CARING FOR MINOR SIBLING DONORS**

**EFFECTIVE MOBILISATION WITH PLERIXAFOR FOLLOWING CRANIA-SACRAL RADIOTHERAPY AND HIGH-DOSE CHEMOTHERAPY: A CASE REPORT OF AN ELEVEN-YEAR OLD BOY WITH GLIOBLASTOMA MULTIFORME**

**EARLY RECOGNITION OF PEDIATRIC GVHD: EDUCATION AND AWARENESS AMONGST NURSES**

**RISK ASSESSING PAEDIATRIC PATIENTS' NUTRITIONAL NEEDS PRIOR TO BONE MARROW TRANSPLANT**

e-Posters  
12:30 - 18:30

ePoster Area

## **Nurses Posters - Research**

**FAMILY CAREGIVERS SUPPORT NEEDS DURING ALLO-HSCT - A LONGITUDINAL STUDY (PRELIMINARY RESULTS)**

**PAIN AND ANXIETY MANAGEMENT DURING BONE MARROW ASPIRATES IN ITALIAN TRANSPLANT PROGRAMS. A NATIONWIDE SURVEY ON BEHALF OF GITMO NG**

**PREVALENCE, PREDICTORS AND OUTCOMES OF CLABSI AMONG HSCT PATIENTS**

**CREATION OF THE LABMT NURSES GROUP**

**SYMPTOMS AND QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY**

**SOCIAL SUPPORT MODERATES THE EFFECTS OF HEALTH STRESSORS ON HEALTH CARE ADHERENCE AND PSYCHOLOGICAL DISTRESS IN LONG-TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS**

**SYMPTOM DISTRESS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY**

**NURSE INVOLVEMENT AND IMPACT OF JACIE ACCREDITATION ON NURSE PRACTICE**

**CONSTRUCTION OF QUALITY INDICATORS SYSTEM OF NUTRITION CARE FOR ADULT PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH AN EVIDENCE-BASED APPROACH**

## Scientific Programme

**ARE CAREGIVERS RECEIVING ENOUGH INFORMATION TO CARE? A PILOT STUDY ON A HAEMATOLOGICAL TRANSPLANT UNIT**

**MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A THREE YEARS FOLLOWING UP**

**VENOUS ACCESS IN AUTOLOGOUS VERSUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONORS: A RETROSPECTIVE STUDY OF AN APHERESIS UNIT**

**A STUDY TO ASSESS THE LEVEL OF BURNOUT AMONG NURSES WORKING IN BONE MARROW TRANSPLANT (BMT) UNIT OF A TERTIARY CARE CANCER HOSPITAL**

**DO WE KNOW ENOUGH ABOUT THE BONE MARROW DONATION?**

**ASSOCIATION OF AIR BORN PARTICLE SIZE AND PARTICLE COUNT WITH INCIDENCE OF INFECTIONS IN HEPA FILTERED ROOMS-A SINGLE CENTRE EXPERIENCE**

**SYSTEMATIC REVIEW OF SIGNS AND SYMPTOMS OF THE HUMAN HERPES VIRUS 6 AND THEIR ASSESSMENT TOOLS**

**A STUDY TO ASSESS PERCEIVED STRESSORS AND COPING STRATEGIES ADOPTED BY PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL INFUSION IN SELECTED CANCER HOSPITAL, INDIA**

**ROLE OF THERAPEUTIC APHERESIS IN ALLOGENEIC TRANSPLANTATION: A CASE REPORT**

**SYMPTOMS OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER INDUCTION CHEMOTHERAPY**

e-Posters  
12:30 - 18:30

ePoster Area

## Paediatric issues

**PROSPECTIVE OPEN-LABEL PHASE II TRIAL OF INDIVIDUALIZED ANTI-THYMOCYTE GLOBULIN SHOWS IMPROVED EARLY CD4+ T-CELL RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE PARACHUTE-TRIAL**

**EBMT LESSONS FROM 40 YEARS OF HIGH DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN NEUROBLASTOMA: A REPORT FROM THE PAEDIATRIC WORKING PARTY**

Ruth Ladenstein, Ulrike Poetschger, Penelope Brock, Roberto Luksch, Victoria Castel, Shifra Ash, Vassilios Papadakis, Geneviève Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz de Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Evgenia Glogova, Dominique Valteau-Couanet, Selim Corbacioglu (Austria)

**INCIDENCE OF SECONDARY MALIGNANCIES AFTER TBI/VP16 CONDITIONING FOR CHILDHOOD ALL: RESULTS OF THE PROSPECTIVE ALL-SCT-BFM-2003 TRIAL**

**OUTCOME AND RISK FACTORS OF AUTOIMMUNE CYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY**

**EBMT SURVEY ON 40 YEARS OF HIGH-DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN EWING TUMOURS (ET). A REPORT FROM THE PAEDIATRIC WORKING PARTY**

Ruth Ladenstein, Evgenia Glogova, Christelle Dufour, Edoardo Lanino, Jean Michon, Paul Veys, Roberto Luksch, Uta Dirksen, Krzysztof Kalwak, Stefan Burdach, Henk van den Berg, Boris Afanasyev, Franco Locatelli, Emmanuelle Nicolas-Virelizier, Shifra Ash, Nathalie Gaspar, Jeremy Whelan, Philippe Brault, Ulrike Poetschger, Selim Corbacioglu (Austria)

## Scientific Programme

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN - RETROSPECTIVE REPORT ON BEHALF OF I-BFM SCT COMMITTEE AND EBMT PEDIATRIC DISEASES WP**

**IS THE EBMT RISK SCORE PREDICTIVE OF OUTCOMES IN PAEDIATRIC ACUTE LEUKEMIA?**

**TCR $\alpha\beta$ + /CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION**

**THE GREAT ORMOND STREET (GOS) PAEDIATRIC CO-MORBIDITY SCORE FOR OUTCOME POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HIGH PREVALENCE OF CAROTID PLAQUES IN YOUNG ADULTS AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD**

**HAPLOIDENTICAL DONOR OR UNRELATED DONOR FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY?**

**A 'RISK-ADJUSTED' CYTOREDUCTION WITHOUT RADIATION FOR PATIENTS WITH FANCONI ANEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT)**

**USE OF RUXOLITINIB IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD)**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN REFRACTORY CYTOPENIA OF CHILDHOOD (RCC): IMPROVED ENGRAFTMENT FOLLOWING A TREOSULFAN BASED CONDITIONING REGIMEN**

**PHARMACOKINETICS OF ACTIVE ATG IMPACTS T-CELL RECOVERY AFTER TCR $\alpha\beta$ /CD19-DEPLETED HSCT IN PAEDIATRIC PATIENTS**

**HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A MULTICENTRE STUDY FROM INDIA**

**IMMUNE RECOVERY AND LONG-TERM SURVIVAL FOLLOWING HAPLOIDENTICAL T AND B CELL DEPLETED STEM CELL TRANSPLANTATION - INFLUENCE OF VARIOUS ATG DOSES**

**OUTCOMES OF HAPLOIDENTICAL VS MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC HIGH-RISK ALL AND AML IN 1ST AND 2ND CR**

**COMBINED TCR ALPHA BETA AND CD45RA DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BENIGN HAEMATOLOGICAL CONDITIONS, SINGLE CENTRE EXPERIENCE**

**GENETIC SUSCEPTIBILITY TO HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC PATIENTS UNDERGOING HSCT**

**HAPLO HSCT WITH IN VIVO T-CELL DEPLETION AFTER REDUCED INTENSITY CONDITIONING REGIMEN AND MYELOABLATIVE MUD AND MMUD DONOR HSCT IN PEDIATRIC PATIENTS AFFECTED BY MALIGNANCIES**

**THINKING BEYOND HLH: CLINICAL FEATURES OF PATIENTS WITH CONCURRENT PRESENTATION OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND THROMBOTIC MICROANGIOPATHY**

**LANDMARK ANALYSIS IN HIGH RISK CHILDHOOD ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE STUDY**

**DEFIBROTIDE IN HEMATOPOIETIC STEM CELL TRANSPLANT: AN STUDY OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH) AND GRUPO ESPAÑOL DE TRASPLANTE DE MEDULA EN NIÑOS (GETMON)**

## Scientific Programme

**NIVOLUMAB-BASED THERAPY PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC HODGKIN'S LYMPHOMA**

**HUMAN LEUKOCYTE ANTIGEN DISPARITIES REDUCE RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA**

**SCHOOL DURING AND AFTER ALLOGENEIC HSCT: A SURVEY OF PRACTICES IN THREE EUROPEAN COUNTRIES**

**HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HURLER SYNDROME: SINGLE CENTER EXPERIENCE**

**HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FANCONI ANAEMIA: EXPERIENCE OF THE SPANISH WORKING GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETMON)**

**IMPACT OF MEMORY T-CELL DOSES INFUSED WITH T-CELL DEPLETED HAPLOIDENTICAL STEM CELL GRAFTS ON TRANSPLANT OUTCOMES**

**THE ROLE OF DONOR KIR GENOTYPING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISORDERS**

**SINGLE-CENTER EXPERIENCE OF TCR $\alpha\beta$ /CD19 DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANEMIA**

**DETECTION OF RECIPIENT-SPECIFIC  $\alpha/\beta$ -T-CELLS DURING THE PRE-ENGRAFTMENT PHASE DOES NOT PREDICT GRAFT REJECTION IN PATIENTS AFTER HAPLOSCT: PRELIMINARY RESULTS OF SINGLE CENTRE PROSPECTIVE TRIAL**

**IMPROVED SURVIVAL AFTER MIBG THERAPY IN COMBINATION WITH MEGACHEMOTHERAPY THAN AFTER STAND-ALONE THERAPY IN CHILDREN WITH NEUROBLASTOMA - POLISH NATION-WIDE RETROSPECTIVE STUDY**

**THE IMPACT OF HOUSEHOLD INCOME ON ACUTE HOSPITALIZATION DAYS IN PEDIATRIC ALLOGENEIC TRANSPLANT RECIPIENTS**

**USE OF RIC REGIMENS COMBINED WITH TCRAB DEPLETION AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC MISMATCHED SCT**

**THE ROLE OF HLA-DP MATCHING IN DONOR SELECTION FOR MUD-HSCT IN CHILDREN WITH HEMATOLOGIC MALIGNANT DISEASES**

**CLINICAL IMPLICATION ON RECOVERY OF  $\gamma\delta$  T CELLS AFTER TCR $\alpha\beta$ -DEPLETED HAPLOIDENTICAL HSCT IN PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE**

**EARLY INITIATION OF CYCLOSPORINE-MYCOPHENOLATE PLUS ANTITHYMOCYTE GLOBULIN IN HAPLO TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: LOW INCIDENCE OF SEVERE ACUTE GVHD WITH ENCOURAGING SURVIVAL**

**FEASIBILITY AND SAFETY OF SURGICAL FERTILITY PRESERVATION TECHNIQUES PROXIMAL TO INITIATION OF CONDITIONING THERAPY IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT**

**VENO-OCCLUSIVE DISEASE WITH EMPHASIS ON RENAL MANIFESTATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: A SINGLE CENTER EXPERIENCE**

**OUTCOME AFTER HSCT IN CHILDREN WITH JMML FROM A HISTORICAL POINT OF VIEW**

**THE IMPACT RECOVERY ABSOLUTE LYMPHOCYTE COUNT AT DAYS +21 ON OUTCOME ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALL**

**T-CELL-RICH HAPLOIDENTICAL STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN CHILDREN WITH ACUTE LEUKEMIA RELAPSED AFTER ALLOGENEIC TRANSPLANTATION**

## **Scientific Programme**

**HIGH PREVALENCE OF VITAMIN C DEFICIENCY IN A LARGE PAEDIATRIC COHORT UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE FROM 2003-2019**

**EX VIVO T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE**

**LONG-TERM ERYTHROPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: HOST DETERMINES RESULT**

**BOOST WITH CD34+ CELLS FOR POOR GRAFT FUNCTION TREATMENT AFTER HSCT IN PAEDIATRIC PATIENTS. A MULTICENTER STUDY**

**NO DIFFERENCE IN SURVIVAL AFTER HLA MISMATCHED VERSUS HLA MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION**

**ALLOGENIC STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE**

**STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-ANAPLASTIC PERIPHERAL T-CELL LYMPHOMA ON BEHALF OF THE EBMT-PEDIATRIC DISEASES WORKING PARTY**

**FIRST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RASGRP1 DEFICIENCY  
SUCCESSFUL HSCT IN IMMUNE DISREGULATORY DISEASES**

**LEVOFLOXACIN BASED PROPHYLAXIS IN CHILDREN RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT AFFECT THE INCIDENCE OF ACUTE GVHD AND BLOODSTREAM INFECTIONS**

**RITUXIMAB-INDUCED SECONDARY HYPOGAMMAGLOBULINEMIA: MEMORIAL SLOAN KETTERING'S 10-YEAR EXPERIENCE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

**'INCURABLE' PAEDIATRIC MYELOID LEUKAEMIA TREATED WITH NOVEL CELL-BASED THERAPEUTICS**

**EFFECT OF SERUM PANEL REACTIVE ANTIBODIES ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE**

**SINGLE CENTRE EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR INHERITED BONE MARROW FAILURE SYNDROMES**

**IS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A GOOD INDICATION FOR PATIENTS WITH SIFD SYNDROME?**

**TIME COURSE AND IMPACT OF BODY WEIGHT CHANGE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HIGH RISK EWING SARCOMA, A SINGLE CENTER EXPERIENCE**

**CONDITIONING FOR RETRANSPLANTATION FROM THE SAME DONOR AFTER PARTIAL AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH PID: IMMUNOSUPPRESSION IS NOT REQUIRED**

**TOCILIZUMAB TREATMENT FOR CRS IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

## Scientific Programme

**IDIOPATHIC PNEUMONIA SYNDROME (IPS) AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM UNRELATED DONOR FOR HURLER SYNDROME (MUCOPOLYSACCHARIDOSIS TYPE 1) SUCCESSFULLY TREATED WITH ETANERCEPT AND STEROIDS**

**EFFECT OF DESENSITIZATION PROTOCOL ON TRANSPLANTATION SUCCESS IN CHILDREN WITH ANTI-HLA ANTIBODIES**

**OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOHSCT) WITH DIFFERENT INTENSITY CONDITIONING REGIMENS IN INFANT AML**

**VENETOCLAX/DECITABINE FOR PEDIATRIC MDR-AML RELAPSED AFTER TWO ALLO HSCTS**

**HIGHER INCIDENCE OF CMV AND BKV REACTIVATION IN HAPLOIDENTICAL TRANSPLANTS COMPARATIVE TO MUD OR MSD TRANSPLANTS - SINGLE CENTRE RETROSPECTIVE ANALYSIS**

**USE OF POLYCLONAL IGM-ENRICHED IMMUNOGLOBULINS FOR THE TREATMENT OF SEPTIC EPISODES IN CHILDREN WITH ONCOHEMATOLOGICAL DISEASES**

**PAEDIATRIC BONE MARROW TRANSPLANT CARE ON BMT VERSUS NON-BMT PAEDIATRIC WARDS**

**CHRONIC HEALTH PROBLEMS IN CHILDREN AFTER ALLOGENEIC HSCT: THE TOP OF THE ICEBERG?**

**HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE-CENTER SERIES OF 14 CASES**

**NON-WHITE HISPANIC ETHNICITY AS A RISK FACTOR FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC TRANSPLANT**

**PNEUMATOSIS INTESTINALIS AS A RARE POST-TRANSPLANT COMPLICATION IN PEDIATRIC PATIENTS**

**THE CHALLENGES AND OUTCOMES SURROUNDING INTRAVESICULAR CIDOFOVIR ADMINISTRATION: A PAEDIATRIC PHARMACY PERSPECTIVE**

**THE EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RARE HEMATOLOGIC DISEASE**

**SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH DNA LIGASE IV DEFICIENCY WITH NONMYELOABLATIVE CONDITIONING REGIMEN**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT-HD-CYCLOPHOSPHAMIDE FOR RELAPSED B-LYMPHOBLASTIC LYMPHOMA (B-LBL) WITH MLL-REARRANGEMENT IN 1 Y.O. CHILD: A CLINICAL CASE**

e-Posters  
12:30 - 18:30

ePoster Area

## Pharmacology

**ELTROMBOPAG THERAPY IN STEM CELL TRANSPLANT RECIPIENTS SHOWS EFFECTIVE IRON MOBILISATION**

**CLINICAL IMPACT OF MODEL PK GUIDED-CYCLOSPORINE DOSE INDIVIDUALIZATION IN CHILDREN UNDERGOING HSCT**

**INFLUENCE OF CYP2D6 METABOLIZER STATUS ON THE CONTROL OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING BY ONDANSETRON ON PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## Scientific Programme

**ESTIMATION OF GLOMERULAR FILTRATION RATE IN ADULTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CYSTATIN C VERSUS CREATININE**

**USE OF SUBLINGUAL TACROLIMUS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH HISTORY OF ANAPHYLAXIS TO INTRAVENOUS CYCLOSPORINE**

**ORAL CLONAZEPAM FOR SEIZURE PROPHYLAXIS IN ADULT PATIENTS TREATED WITH HIGH DOSE BUSULFAN**

**DISSOLUTION TIME FOR CONVENTIONAL AND LYOPHILIZED CYCLOPHOSPHAMIDE: A SINGLE CENTER STUDY**

**OUTCOMES OF EBV VIREMIA AND PTLD AFTER RITUXIMAB: A PHARMACO-COST ANALYSIS**

**PHARMACOLOGICAL INTERACTIONS IN THE POST-TRANSPLANT PHASE OF HEMATOPOIETIC PROGENITORS TRANSPLANTATION**

**EVALUATION OF SIDE EFFECTS AND EFFICACY OF LOMUSTINE (CCNU) AND BANDAMUSTINE IN PATIENTS WITH LYMPHOMA**

e-Posters  
12:30 - 18:30

ePoster Area

## Psychological issues

**INVESTIGATING THE LONG-TERM OUTCOMES OF ADULT PATIENTS WHO UNDERWENT HAEMATOPOIETIC STEM CELL TRANSPLANT FOR PRIMARY IMMUNODEFICIENCY DURING CHILDHOOD**

**THE IMPACT OF MEDICAL AND SOCIAL REHABILITATION ON THE QUALITY OF LIFE IN CHILDREN WITH ONCOLOGIC AND HEMATOLOGIC DISEASES**

**THE IMPACT OF PRE-TRANSPLANT DEPRESSION AND ANXIETY ON THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION, A STUDY OF THE TCWP OF THE EBMT**

**ASSOCIATIONS BETWEEN FAMILY FUNCTION DOMAINS AND COPING STRATEGIES OF ADOLESCENTS UNDERGOING HSCT**

**HOW PATIENTS' VIEWS ARE HELPING SHAPE PLANS FOR A NEW TRANSPLANT PSYCHOLOGY SERVICE**

**CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: TWO DIFFERENT ANALYTICAL APPROACHES**

**ARC CLINIC: APPLYING PSYCHOLOGICAL INSIGHTS TO PROMOTE EARLY REHABILITATION IN MYELOMA POST-TRANSPLANT**

**FROM HOSPITALIZATION TO RETURN HOME: A TRANSITIONAL ACTION RESEARCH IN THE HEMATOLOGY SECTOR**

**1000 IN 10 . 10 YEARS OF CLINICAL PSYCHOLOGY PRACTICE WITH 1000 PATIENTS IN THE SAME BMT UNIT IN MARSEILLE, FRANCE**

**IMPLEMENTATION OF PSYCHOLOGICAL SUPPORT AND DEVELOPMENT OF EDUCATIONAL PROGRAM FOR CHILDREN AND ADOLESCENTS UNDERGOING HSCT AND THEIR PARENTS IN RUSSIA**

## Scientific Programme

e-Posters  
12:30 - 18:30

ePoster Area

### Quality Management

**COMPARING COMPLIANCE FOR COLLECTION FACILITY JACIE STANDARDS 6.1 AND 7TH EDITIONS**

**INTEGRATION OF THEORY AND PRACTICE: SCENARIO-BASED SKILL TRAINING IN ADMINISTERING CAR-T CELLS**

**"TPFMEA", AN INTERNATIONAL MODEL FOR ASSESSING RISKS IN A STEM CELL TRANSPLANT PROGRAM**

**DEFINING PATIENT-IMPORTANT OUTCOMES AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT**

**IMPLEMENTATION OF JACIE ACCREDITATION AT A NOVEL TRANSPLANT PROGRAM: THE IMPACT ON THE CLINICAL PRACTICE**

**HOW ONE PROCESSING CENTRE PREPARED FOR ITS FIRST JACIE INSPECTION?**

**TIPS FOR GENERATING SUCCESSFUL 'TEAMWORKING' IN OUR HEALTHCARE FACILITIES: THE EXPERIENCE OF A HOSPITAL UNIT IN A FRENCH CANCER CENTER**

**IMPLEMENTATION OF A QUALITY SYSTEM FOR RUNNING A CELL AND GENE THERAPY CLINICAL TRIAL WITHIN A JACIE-ACCREDITED TRANSPLANT PROGRAM**

**NEW ONLINE PLATFORMS IN QUALITY MANAGEMENT: COORDINATION AND MULTIDISCIPLINARY CARE**

**RISK MANAGEMENT ASSESSMENT IN IMPLEMENTING CAR-T CELL THERAPY IN A CLINICAL UNIT**

**FEBRILE REACTION AFTER HSC INFUSION IS MORE FREQUENT IF NO STEROID PREMEDICATION IS GIVEN WHICH RESULTS IN MORE FREQUENT USE OF ANTIBIOTICS EARLY POST-TRANSPLANT**

**SEARCHING FOR OTHER TOPICS OF QUALIFICATION PLANS IN THE TRANSPLANT PROGRAM CLINICAL PART - THE ONE CENTER EXPERIENCE**

**PRACTICE PATTERNS IN CHRONIC GVHD PATIENT MANAGEMENT AND PATIENT REPORTED OUTCOME MEASURES ACROSS THE EBMT ALLOGENEIC TRANSPLANTATION NETWORK**

**MAINTAINING DONOR SAFETY AND WELFARE THROUGHOUT CELLULAR THERAPY PRODUCT DONATION**

**DIGITAL JACIE AT THE CHRISTIE**

**INTEGRATION OF CELLULAR THERAPY IN THE JACIE (JOINT ACCREDITATION COMMITTEE ISCT-EBMT) QUALITY MANAGEMENT PLAN. SINGLE CENTER EXPERIENCE**

**AUDIT - A METHOD TO EVALUATE INTERVENTIONS - EXPERIENCES FROM AN ATTEMPT TO IMPROVE NUTRITIONAL STATUS IN PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**QUALITY OF LIFE ASSESSMENT AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RETROSPECTIVE ANALYSIS OF TIME TO ALTERNATIVE DONOR IDENTIFICATION AND HEMATOPOIETIC STEM CELLS PROCUREMENT IN THE ABSENCE OF MATCHED-SIBLING DONORS IN A SINGLE CENTER IN SPAIN**

## Scientific Programme

**GOVERNANCE, RISKS AND REGULATORY ASPECTS OF UNLICENSED LENTIVIRAL VECTOR-MODIFIED AUTOLOGOUS STEM CELL TREATMENT**

**UNIQUE SUPPORTIVE CARE ALGORITHMS FOR CHILDREN UNDERGOING HAPLOIDENTICAL HSCT FOR BENIGN HAEMATOLOGICAL DISORDERS**

**QUALITY OF LIFE IN PARENTS OF TURKISH AND SYRIAN PEDIATRIC BONE MARROW TRANSPLANT AND ONCOLOGY PATIENTS**

**COLLECTION OF AUTOLOGOUS MONONUCLEAR CELLS IN NON-CYTOKINE STIMULATED DONORS: COMPARING TWO APHERESIS METHODS**

**EFFECTIVE CAR-T CELL DELIVERY: A MULTIDISCIPLINARY APPROACH AT MFT**

**HAEMOPOIETIC PROGENITOR CELL PROFICIENCY TESTING**

**VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ALERT (R) 3D (TM) AND VIRTUO (TM) MICROBIAL BIOBURDEN SYSTEMS FOR HAEMATOPOIETIC PROGENITOR CELLS (HPC)**

**START-UP OF AN ADHERENCE RECEPTION FOR ALLOGENIC STEM CELL TRANSPLANTED PATIENTS AT THE HEMATOLOGICAL DEPARTMENT LINKÖPING, SWEDEN**

**ENUMERATION OF RESIDUAL RED BLOOD CELLS IN MIS-MATCHED ALLOGENEIC PBSC COLLECTIONS - TRADITIONAL HAEMATOLOGY ANALYSER VS FLOW CYTOMETRY**

**INVESTIGATION AND ANALYSIS OF FACTORS AFFECTING GASTROINTESTINAL NUTRITION RECOVERY AFTER MULTIPLE MYELOMA AUTOLOGOUS STEM CELL TRANSPLANTATION AND EFFECTS OF NUTRITIONAL INTERVENTION**

**CHARACTERISTICS OF IRON DEFICIENCY ANEMIA IN PRE-MENOPAUSAL WOMEN IN KOREA  
LEUKEMIA AND ITS TYPES**

e-Posters  
12:30 - 18:30

ePoster Area

## Regenerative medicine

**WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL THERAPY IMPROVES THE QUALITY OF LIFE AND SELF-SUFFICIENCY OF CHILDREN WITH AUTISM SPECTRUM DISORDER**

**MARROW DERIVED CELLS BRING A LONG LASTING RELIEF WHEN INJECTED INTRAARTICULARLY TO THE JOINTS WITH DEGENERATIVE ARTHRITIS**

**OSTEOGENIC DIFFERENTIATION CAPACITY OF ADIPOSE-DERIVED STEM CELLS AFFECTED WITH COLD STORAGE**

e-Posters  
12:30 - 18:30

ePoster Area

## Solid tumours

**SUCCESSFUL KIR ALLOREACTIVE HSCT IN A CHILD WITH RESISTANT EWING SARCOMA**

**TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS**

## Scientific Programme

### **VOC PATTERN RECOGNITION OF LUNG CANCER: A COMPARATIVE EVALUATION OF DIFFERENT DOG- AND ENOSE-BASED STRATEGIES USING DIFFERENT SAMPLING MATERIALS**

e-Posters  
12:30 - 18:30

ePoster Area

## Statistics

### **USE OF VARIABLE SELECTION METHODS TO IDENTIFY CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THE CLINICAL OUTCOME OF PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **THE IMPACT OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON WORK AND PRODUCTIVITY LOSS IN PATIENTS WITH ACUTE LEUKAEMIA: RESULTS FROM A RAPID REVIEW**

### **GEOGRAPHIC AND SOCIOECONOMIC IMPACTS ON SURVIVAL AMONG ALLOGENEIC TRANSPLANT RECIPIENTS**

e-Posters  
12:30 - 18:30

ePoster Area

## Stem cell donor

### **DONOR-RECIPIENT HLA MATCHING FOR UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION <b>Outcomes: </b> A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY (CTIWP) OF THE EBMT**

### **PRESENCE OF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN DONOR DOES NOT INCREASE THE RISK OF LATE SECONDARY MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Kyoung Ha Kim, Tae Hyung Kim, Jae-Sook Ahn, Ivan Pasic, Zeyad Al-Shaibani, Arjun Law, Wilson Lam, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Zhaolei Zhang, Tamir Biezuner, Liran Shlush, [Dennis Dong Hwan Kim](#) (Canada)

### **SERIOUS EVENTS AND ADVERSE REACTIONS IN RELATION TO BLOOD STEM CELL DONATION REPORTED TO WMDA IN 2018**

### **THE IMPROVEMENT IN OVERALL SURVIVAL FROM UNRELATED DONOR TRANSPLANT IN AUSTRALIA AND NEW ZEALAND IS DRIVEN BY A REDUCTION IN TRANSPLANT RELATED MORTALITY**

### **POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING, UNRELATED AND HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA, A COMPARATIVE STUDY OF THE ALWP EBMT**

### **ALLOREACTIVITY AGAINST HLA-DPB1 IN HOST-VERSUS-GRAFT DIRECTION IS ASSOCIATED WITH INCREASED RISK OF GRAFT FAILURE AFTER MATCHED UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES**

### **IMPACT OF KIR ON PATIENTS WITH LYMPHOID DISEASES AFTER T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **INDICATIONS AND SAFETY OF MULTIPLE BONE MARROW HARVESTS IN PEDIATRIC DONORS FOR MATCHED SIBLING RECIPIENT TRANSPLANTATION**

### **HEALTHY VOLUNTARY STEM CELL DONORS: FOLLOW UP AFTER HPC APHERESIS DONATION: THE EXPERIENCE OF ITALIAN BONE MARROW DONOR REGISTRY**

## **Scientific Programme**

**ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH INHERITED DISORDERS**

**HAPLOIDENTICAL REDUCED-INTENSITY HEMATOPOIETIC CELL TRANSPLANTATION USING BUSULFAN, FLUDARABINE, AND ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**

**THE RESULTS OF A TELECONFERENCE ABOUT THE EXPERIENCES AND EXPECTATIONS OF RELATED HEMATOPOIETIC STEM CELL DONORS AFTER DONATION**

**IMPACT OF THE ESTABLISHMENT OF THE TURKISH NATIONAL DONOR REGISTRY (TURKOK) ON A SINGLE CENTER'S TRANSPLANT OUTCOME: INTERNATIONAL STEM CELL DONORS VERSUS NATIONAL**

**YOUNG MALE DONORS MAY RESULT IN BETTER OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA WITH PT-CY**

**DONORS OF PERIPHERAL HEMATOPOIETIC STEM CELLS, OUR EXPERIENCE FOR LAST 10 YEARS**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS OVER 70 YEARS :A MONOCENTRIC EXPERIENCE OF 48 PATIENTS**

**COMPARISON OF TRANSPLANT OUTCOMES AND ECONOMIC COSTS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML AND MDS BETWEEN THE DIFFERENT TYPE OF DONORS**

**HIGH DISEASE-FREE SURVIVAL OF THE SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DONOR CHANGE AND MAINLY REDUCED-INTENSITY CONDITIONING IN RELAPSED HEMATOLOGICAL MALIGNANCIES**

**EPIDEMIOLOGICAL STUDY OF RARE ANTIGENS OF THE MAIN HISTOCOMPATIBILITY COMPLEX AMONG HEMATOPOIETIC STEM CELL DONORS IN BELARUS**

**IMPACT OF DONOR-RECIPIENT SEX MISMATCH IN PATIENTS RECEIVING PARTIAL T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE MONOCENTRIC STUDY**

**HAPLOIDENTICAL DONOR SELECTION AND ITS IMPLICATIONS IN TRANSPLANTATION OUTCOME. OUR EXPERIENCE AT HUDGC DR. NEGRIN**

**OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ACCORDING TO DONOR AVAILABILITY, DURATION FROM DIAGNOSIS TO TRANSPLANT AND DONOR-SPECIFIC PARAMETERS - A SINGLE CENTER ANALYSIS**

**THE BENEFITS OF HLA-MATCHED RELATED DONORS FOR PATIENTS LACKING HLA-IDENTICAL SIBLING IN THE ABSENCE OF POWERFUL LOCAL UNRELATED REGISTRY IN COUNTRIES WITH PREVALENT COUSIN MARRIAGES**

**DONOR AGE INFLUENCES THE GRAFT-VERSUS-HOST-DISEASE-FREE AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ELDERLY PATIENTS IN LATIN AMERICA**

**A STUDY OF THE UNCERTAINTY, UNCERTAINTY APPRAISAL AND GROWTH AND THE AFFECTED FACTORS ON HEMATOPOIETIC STEM CELL DONORS**

**WITHDRAWAL OF VOLUNTEER DONORS FROM THE INTERNATIONAL REGISTRIES: A SINGLE CENTRE EXPERIENCE**

**OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION FOR AML AND MYELODYSPLASTIC SYNDROME IN ELDERLY WITH REDUCED-INTENSITY CONDITIONING**

**HAPLOIDENTICAL VS UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS WITH HEMATOLOGIC MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS**

## Scientific Programme

**HEPATITIS E VIRUS (HEV) CONTAMINATED HEMATOPOIETIC STEM CELL GRAFT IN A MATCHED UNRELATED DONOR TRANSPLANTATION**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MATCH RELATED DONORS IN CHILDHOOD: SINGLE CENTER EXPERIENCE**

**FIRST EXPERIENCE WITH UNRELATED STEM CELL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A TRANSPLANT CENTER FROM NORTH MACEDONIA**

e-Posters  
12:30 - 18:30

ePoster Area

### Stem cell mobilization, collection and engineering

**TWO YEAR ANALYSIS OF A PROSPECTIVE PHASE I/II CLINICAL TRIAL IN ADULTS USING TCR ALPHA/BETA DEPLETED STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONORS**

**A NEW BSA-BASED THRESHOLD PREDICTS OPTIMAL PBSC COLLECTION IN T-CELL DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

**PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILIZATION AND COLLECTION OF CD34+ HSCS WITHOUT G-CSF**

**DEPLETION OF  $\alpha\beta$  T-CELLS AND B-CELLS BEFORE HLA-HAPLOIDENTICAL HSCT IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT OF 473 PROCEDURES**

**ACOUSTOPHORESIS ENABLES THE LABEL-FREE SEPARATION OF DISTINCT SUBSETS FROM CULTURED BONE MARROW STROMAL CELLS**

**FEASIBILITY OF MODIFIED CD45RA NEGATIVE DONOR LYMPHOCYTES INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**BEYOND STEM CELLS - DOES IT MATTER WHAT'S IN THE BAG IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA AND LYMPHOMA?**

**EXPRESSIONS OF CO-INHIBITORY MARKERS INCREASE EFFECTOR MEMORY T CELLS IN G-CSF MOBILIZED PERIPHERAL STEM CELLS**

**LIPEGFILGRASTIM COMBINED WITH CHEMOTHERAPY WAS MORE COST-EFFECTIVE THAN PEGFILGRASTIM IN THE MOBILIZATION OF CD34+ CELLS IN NHL PATIENTS**

**MOBILIZATION AND HARVEST OF PERIPHERAL BLOOD STEM CELLS (PBSC) FOR ALLOGENEIC STEM CELL TRANSPLANTATION FROM 335 PEDIATRIC SIBLING HEALTHY DONORS**

**A COMPARISON OF CHEMO-FREE STRATEGY WITH G-CSF PLUS PLERIXAFOR ON DEMAND VERSUS ID-CYCLOPHOSPHAMIDE AND G-CSF AS PBSC MOBILIZATION IN MULTIPLE MYELOMA: AN EXPLORATIVE COST ANALYSIS**

**EVALUATION OF VIA FREEZETM QUAD FOR LIQUID NITROGEN-FREE CGMP-COMPATIBLE CONTROLLED-RATE FREEZING OF HEMATOPOIETIC PROGENITOR CELL GRAFTS**

**CD34 + CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS**

## **Scientific Programme**

**PLERIXAFOR ON DEMAND IN COMBINATION WITH LOW-DOSE CYCLOPHOSPHAMIDE AND G-CSF FOR THE MOBILIZATION OF HSC IN MULTIPLE MYELOMA PATIENTS: HIGH EFFICACY AND LOW TOXICITY**

**PERFORMANCE QUALIFICATION OF LOVOTM MEDICAL DEVICE FOR WASHING AND CONCENTRATING 3 AND MORE HEMATOPOIETIC PROGENITOR CELL CRYOPRESERVED BAGS**

**FROM WORK-UP REQUEST TO DONATION IN THREE WEEKS: A DEDICATED REGISTRY INTEGRATED UNRELATED DONOR STEM CELL COLLECTION CENTER IS SAFE, EFFICIENT AND CONVENIENT FOR DONORS**

**LOW-DOSE CYCLOPHOSPHAMIDE + G-CSF IS NO MORE EFFECTIVE THAN G-CSF ALONE WHEN MOBILIZING AND COLLECTING STEM CELLS FOR AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS**

**FIRST INTERIM RESULTS OF NIS OPTIMOB - NATIONWIDE TRIAL OF MOBILIZATION AND COLLECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS**

**THE IMPACT OF PLERIXAFOR 'ON DEMAND' ON THE HEMATOPOIETIC STEM CELL (HSC) COLLECTION, PRODUCT'S QUALITY AND ENGRAFTMENT**

**ELEVATED SERUM LACTATE DEHYDROGENASE AFTER STEM CELL MOBILISATION PREDICTS SUCCESSFUL STEM CELL COLLECTION IN CHILDREN**

**INFLUENCE OF THE DMSO WASH STRATEGY ON ADVERSE REACTIONS DURING INFUSION OF HEMATOPOIETIC PROGENITORS**

**BONE MARROW DONOR CHARACTERISTICS: INFLUENCE ON HARVEST YIELD AND DONOR RECOVERY**

**PLERIXAFOR SALVAGES AUTOLOGOUS STEM CELL MOBILISATION PROCEDURES IN MYELOMA PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE OR AUTOLOGOUS HSCT: COST-EFFECTIVENESS OF UPFRONT USE SHOULD BE EXPLORED**

**EFFECT OF SHIPPING TIME AND TRANSPORT CONDITIONS ON THE VIABILITY OF CORD BLOOD LEUKOCYTES**

**OPTIMIZATION OF A STEM CELL MOBILIZATION STRATEGY FOR PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA**

**AUTOLOGOUS LYMPHAPHERESIS FOR THE PRODUCTION OF CAR-T CELLS**

**RED BLOOD CELL DEPLETION AND/OR VOLUME REDUCTION IN BONE MARROW PROCESSING: A COMPARISON OF TWO METHODS**

**CORRELATION OF INTRA-OPERATIVE TOTAL NUCLEATED COUNT AND DONOR CHARACTERISTICS WITH FINAL ALLOGENEIC BONE MARROW GRAFT CHARACTERISTICS AND RECIPIENT CLINICAL OUTCOMES**

**MULTICENTRE EVALUATION OF THE HPC MODUS (XN-20) FOR TIMING THE HARVEST OF STEM CELLS FROM PERIPHERAL BLOOD**

**IMPACT OF CHANGE OF MOBILISATION METHOD ON ADEQUACY OF STEM CELL COLLECTION IN MULTIPLE MYELOMA PATIENTS: SINGLE CENTRE EXPERIENCE**

**TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE**

**AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS (PBSCS) MOBILIZATION AND COLLECTION- PRINCESS NOORAH ONCOLOGY CENTER EXPERIENCE, KAMC - JEDDAH - SAUDI ARABIA**

**REVIEW OF PLERIXAFOR USE IN A TERTIARY PAEDIATRIC ONCOLOGY CENTRE**

## Scientific Programme

**UNUSUAL HIGH COUNT OF CD34+ AFTER CHEMO MOBILIZATION WITH MATRIX IN PATIENT WITH PRIMARY CNS LYMPHOMA IS ASSOCIATED WITH PROMPT AND ROBUST ENGRAFTMENT**

**LEUKOCYTAPHERESIS - ONE TECHNIQUE, DIVERSE OPPORTUNITIES IN THE THERAPY OF PATIENTS**

**COMPARISON OF CONTINUOUS MONONUCLEAR CELL COLLECTION (CMNC) AND MONONUCLEAR CELL CELL (MNC) METHODS FOR CELL PROLIFERATION (APHERESIS) IN PATIENTS WITH BONE MARROW TRANSPLANTATION**

e-Posters  
12:30 - 18:30

ePoster Area

### Stem cell source

**OPTIMIZING OUTCOMES OF ACUTE LEUKEMIA AFTER TRANSPLANTS WITH SINGLE UNRELATED CORD BLOOD UNITS SELECTED ACCORDING TO CURRENT INTERNATIONAL RECOMMENDATIONS FOR CELL DOSE AND HLA MATCH**

**IMPACT OF HLA-MISMATCH ON OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE ANALYSIS BY THE JSHCT HLA WORKING GROUP**

**CLINICAL IMPACT OF DONOR EPITOPE-SPECIFIC HLA ANTIBODIES AND THIRD-PARTY HLA ANTIBODIES IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION**

**ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS**

**THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION**

**COMPARATIVE STUDY OF HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETION VS UNRELATED CORD BLOOD TRANSPLANT FOR ADULTS WITH HAEMATOLOGICAL MALIGNANCIES**

**USE OF G-CSF MOBILIZED BONE MARROW GRAFTS IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION (BMT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) DECREASES RISK OF SEVERE ACUTE GVHD**

**CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION**

**REDUCED INTENSITY (RIC) VS MYELOABLATIVE CONDITIONING (MAC) IN CORD BLOOD TRANSPLANTATION FOR AML (40-60 YEARS) ACROSS MISMATCHED HLA BARRIERS - ANALYSIS BY CTIWP/EUROCORD OF EBMT**

**COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL WORLD: AN ANALYSIS USING THE JAPANESE NATIONAL DATABASE**

**ASSOCIATION BETWEEN THE DOSE OF CD3+ AND CD34+ CELLS IN THE GRAFT AND POST-TRANSPLANT OUTCOMES**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A RELATED DONOR WITH HLA-1 ANTIGEN MISMATCH IN THE GRAFT-VERSUS-HOST DIRECTION USING LOW-DOSE ANTI-THYMOCYTE GLOBULIN: MULTICENTER PHASE II TRIAL**

## Scientific Programme

**INTRA-BONE CORD-BLOOD TRANSPLANT OF UNWASHED UNITS WITH ATG-FREE AND SIROLIMUS-BASED GVHD PROPHYLAXIS: FAST IMMUNE-RECONSTITUTION AND LONG-TERM DISEASE CONTROL IN 22 PATIENTS WITH HIGH-RISK DISEASES**

**ANTI-HLA DONOR SPECIFIC ANTIBODIES (DSA) DOES NOT AFFECT GRAFT AND SURVIVAL IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) WITH ORIGINAL POST-TRANSPLANT CYCLOFOSFAMIDE (PT-CY) SCHEDULE**

**MESENCHYMAL STEM/STROMAL CELL PRODUCTION COMPLIANT WITH GOOD MANUFACTURING PRACTICE: COMPARISON BETWEEN BONE MARROW AND WHARTON'S JELLY**

**EFFICIENT DMSO REMOVAL AND HIGH CELL RECOVERY WITH LOVO CELL PROCESSING SYSTEM IN HPC-A CONCENTRATES: A SINGLE CENTRE EXPERIENCE**

Special Session  
13:30 - 14:30

Auditorium 1

### SS1, Impact of COVID-19 in Hematology, Transplantation and Cellular Therapy

**Chairs:**

Rafael Duarte (Spain)

Nicolaus Kröger (Germany)

<b>The challenge of COVID-19 for HSCT: EBMT recommendations and prospective registry study</b>	<b>13:30 - 13:42</b>
Per Ljungman (Sweden)	
<b>The challenge of COVID-19 for HSCT in Italy</b>	<b>13:42 - 13:54</b>
Fabio Ciceri (Italy)	
<b>The challenge of COVID-19 for HSCT in Spain</b>	<b>13:54 - 14:06</b>
Anna Sureda (Spain)	
<b>The challenge of COVID-19 for HSCT in the UK</b>	<b>14:06 - 14:18</b>
Kim Orchard (United Kingdom)	
<b>Q&amp;A</b>	<b>14:18 - 14:30</b>

Nurses Group  
13:30 - 14:30

Auditorium 2

### NG01, Nurses Education Day: Steroids - The haematology bad boys. Love them, loathe them, can't live without them

**Chairs:**

Julia Ruiz Pato (Spain)

<b>Welcome and introduction</b>	<b>13:30 - 13:35</b>
John Murray (United Kingdom)	
<b>Overview: Indications and implications</b>	<b>13:35 - 13:55</b>
Jörg Halter (Switzerland)	
<b>How does it work? Mechanism of action</b>	<b>13:55 - 14:15</b>
Agnès Bonnin (France)	

## Scientific Programme

### Q&A

**14:15 - 14:30**

Educational  
13:30 - 14:30

Auditorium 3

### E1, Autoimmune diseases

#### Chairs:

Tobias Alexander (Germany)  
Raffaella Greco (Italy)

#### **Current indications and scientific correlations of HSCT in autoimmune diseases**

**13:30 - 13:45**

Maria Carolina Oliveira Rodrigues (Brazil)

#### **HSCT in Multiple Sclerosis: State of the art and future questions**

**13:45 - 14:00**

Giovanni Mancardi (Italy)

#### **HSCT in Systemic Sclerosis: State of the art and future questions**

**14:00 - 14:15**

Jacob M. van Laar (Netherlands)

### Q&A

**14:15 - 14:30**

Psy Day  
13:30 - 14:30

Auditorium 4

### Psy1, Workshop I: Survivorship programme

#### Chairs:

Frank Schulz-Kindermann (Germany)

#### **Introduction**

**13:30 - 13:45**

Anna Barata (United States)

#### **Survivorship**

**13:45 - 14:00**

Karen Syrjala (United States)

#### **Working therapeutically with despair: Supporting patients with prolonged hospital admissions post-BMT**

**14:00 - 14:15**

Surabhi Chaturvedi (United Kingdom)

#### **Text chat Q&A**

**14:15 - 14:30**

Pharmacists Day  
13:30 - 14:30

Auditorium 5

### Pharm1, Pharmacotherapy in HSCT

#### Chairs:

Rick Admiraal (Netherlands)

## Scientific Programme

<b>GFR estimation in HSCT patients: Is creatinine enough?</b> Claudia Langebrake (Germany)	<b>13:30 - 13:45</b>
<b>ATG vs. post-cyclophosphamide</b> Eolia Brissot (France)	<b>13:45 - 14:00</b>
<b>EVALUATION OF THE ROBUSTNESS OF THERAPEUTIC DRUG MONITORING COUPLED WITH BAYESIAN FORECASTING OF BUSULFAN WITH REGARD TO INACCURATE DOCUMENTATION</b> <u>Adrin Dadkhah</u> , Dzenefa Alihodzic, Astrid Broeker, Nicolaus Kroeger, Claudia Langebrake, Sebastian Wicha (Germany)	<b>14:00 - 14:15</b>
<b>Text chat Q&amp;A</b>	<b>14:15 - 14:30</b>

Educational  
15:00 - 16:00

Auditorium 1

### E2, Educational forum on microbiota and allogeneic HSCT

#### Chairs:

Ernst Holler (Germany)  
Grzegorz Basak (Poland)

<b>Current understanding of the impact of microbiome on HSCT alloreactive phenomena and outcome</b> Daniela Weber (Germany)	<b>15:00 - 15:15</b>
<b>Gut microbiota and GVHD in children</b> Riccardo Masetti (Italy)	<b>15:15 - 15:30</b>
<b>Preventive and therapeutic interventions in the microbiota</b> Florent Malard (France)	<b>15:30 - 15:45</b>
<b>Q&amp;A</b>	<b>15:45 - 16:00</b>

Nurses Group  
15:00 - 16:00

Auditorium 2

### NG02, Nurses Education Day: Steroids - The haematology bad boys. Love them, loathe them, can't live without them

#### Chairs:

Isabel Salcedo (Spain)

<b>Osteonecrosis</b> Nicola Chesman (United Kingdom)	<b>15:00 - 15:25</b>
<b>Effects on immune system: Infections</b> Lucrecia Yáñez San Segundo (Spain)	<b>15:25 - 15:50</b>
<b>Q&amp;A</b>	<b>15:50 - 16:00</b>

## Scientific Programme

Educational  
15:00 - 16:00

Auditorium 3

### E3, Infectious complications: New therapies and prevention

#### Chairs:

Jan Styczynski (Poland)  
Rafael de la Cámara (Spain)

<b>Multiresistant bacteria in children and adults: Insight on new antibiotics</b>	<b>15:00 - 15:15</b>
Dina Averbuch (Israel)	
<b>Management strategies in the new adenovirus landscape</b>	<b>15:15 - 15:30</b>
Per Ljungman (Sweden)	
<b>How to structure an effective HSCT vaccine programme</b>	<b>15:30 - 15:45</b>
Catherine Cordonnier (France)	
<b>Q&amp;A</b>	<b>15:45 - 16:00</b>

Psy Day  
15:00 - 16:00

Auditorium 4

### Psy2, Workshop II: Donors, caregivers and the transplant team

#### Chairs:

Surabhi Chaturvedi (United Kingdom)

<b>The dynamics of donor commitment</b>	<b>15:00 - 15:15</b>
Suzanna M. van Walraven (Netherlands)	
<b>Supporting transplant caregivers</b>	<b>15:15 - 15:30</b>
Maria Die Trill (Spain)	
<b>Supporting the transplant team</b>	<b>15:30 - 15:45</b>
Alice Polomeni (France)	
<b>Text chat Q&amp;A</b>	<b>15:45 - 16:00</b>

Pharmacists Day  
15:00 - 16:00

Auditorium 5

### Pharm2, Management of adverse events

#### Chairs:

Vera Pires (Portugal)

<b>Management of adverse events of CAR T (tisagenlecleucel) in paediatrics</b>	<b>15:00 - 15:15</b>
Barbara de Moerloose (Belgium)	
<b>CAR T and the clinical pharmacist - Standardisation of toxicity management across the UK</b>	<b>15:15 - 15:30</b>
Jackie Chappell (United Kingdom)	
Sumantha Gabriel (United Kingdom)	

## Scientific Programme

<b>Management of mucositis in HSCT</b>	<b>15:30 - 15:45</b>
Filipa Cosme Silva (Portugal)	
<b>Text chat Q&amp;A</b>	<b>15:45 - 16:00</b>

Educational  
16:30 - 17:30

Auditorium 1

### E4, Therapies to bring resistant acute leukaemia into HSCT

#### Chairs:

Mohamad Mohty (France)

<b>Novel targeted therapy before HSCT for AML/MDS</b>	<b>16:30 - 16:45</b>
Guillermo García-Manero (United States)	
<b>New conditioning regimen for relapsed acute leukaemia</b>	<b>16:45 - 17:00</b>
Ali Bazarbachi (Lebanon)	
<b>Sequential therapy for AML</b>	<b>17:00 - 17:15</b>
Rémy Duléry (France)	
<b>Q&amp;A</b>	<b>17:15 - 17:30</b>

Nurses Group  
16:30 - 17:30

Auditorium 2

### NG03, GVHD

#### Chairs:

John Murray (United Kingdom)

Klara Kabatova Maxova (Czech Republic)

<b>GVHD practical tips</b>	
<b>Eye</b>	<b>16:30 - 16:42</b>
Sandra Schoenfeld (Switzerland)	
<b>Oral</b>	<b>16:42 - 16:54</b>
Nathaniel Simon Triester (United States)	
<b>Genital</b>	<b>16:54 - 17:06</b>
Angela Leather (United Kingdom)	
<b>Scoring system</b>	<b>17:06 - 17:18</b>
John Murray (United Kingdom)	
<b>Q&amp;A</b>	<b>17:18 - 17:30</b>

## Scientific Programme

Joint Session  
16:30 - 17:30

Auditorium 3

### JS1, Joint session LABMT: Towards an EBMT-LABMT confluence - Benefits of a mixed chimera

**Chairs:**

Rafael Duarte (Spain)  
Gregorio Jaimovich (Argentina)

<b>Development opportunities from an EBMT perspective</b>	<b>16:30 - 16:40</b>
Alejandro Madrigal (United Kingdom)	
<b>Development opportunities from an LABMT perspective</b>	<b>16:40 - 16:50</b>
Amado Karduss (Colombia)	
<b>Conditioning regimens: Is less better?</b>	<b>16:50 - 17:00</b>
Manuel Abecasis (Portugal)	
<b>Accreditation: Experience on implementing the "FACT-JACIE International Stepwise Accreditation Programme" in Latin America</b>	<b>17:00 - 17:20</b>
Patricia Abichaín (Argentina) Raquel Espada (Spain)	
<b>Q&amp;A</b>	<b>17:20 - 17:30</b>

Psy Day  
16:30 - 17:30

Auditorium 4

### Psy3, How do I...?

**Chairs:**

Anna Barata (United States)

<b>How do I... Evaluate psychosocial factors and complexities that may influence the HSCT process and outcomes?</b>	<b>16:30 - 16:45</b>
Alex King (United Kingdom)	
<b>How do I... Address the psycho-oncologists well-being?</b>	<b>16:45 - 17:00</b>
Frank Schulz-Kindermann (Germany)	
<b>How do I... Identify unmet needs and plan research?</b>	<b>17:00 - 17:15</b>
Corinna Bergelt (Germany)	
<b>Text chat Q&amp;A</b>	<b>17:15 - 17:30</b>

Pharmacists Day  
16:30 - 17:30

Auditorium 5

### Pharm3, Update infectious diseases in HSCT

**Chairs:**

Agnès Bonnin (France)

## Scientific Programme

<b>What's new in antivirals?</b> Per Ljungman (Sweden)	<b>16:30 - 16:45</b>
<b>What's new in vaccines? The Dutch guidelines for HSCT patients</b> Marjolein Hensgens (Netherlands)	<b>16:45 - 17:00</b>
<b>The effect of antibiotics on the microbiome in HSCT patients: Is it relevant?</b> Florent Malard (France)	<b>17:00 - 17:15</b>
<b>Text chat Q&amp;A</b>	<b>17:15 - 17:30</b>

Meet the Expert  
17:30 - 18:30

Meet the Expert Rooms

### MTE1, Meet the Expert session 1 - Room MTE1

<b>Viral infections in HSCT recipients: The challenges in 2020</b> Francisco Marty (United States)	<b>17:30 - 18:30</b>
---	----------------------

Meet the Expert  
17:30 - 18:30

Meet the Expert Rooms

### MTE2, Meet the Expert session 2 - Room MTE2

<b>Extracorporeal photopheresis in the management of acute and chronic GVHD</b> Daniel Couriel (United States)	<b>17:30 - 18:30</b>
---	----------------------

Meet the Expert  
17:30 - 18:30

Meet the Expert Rooms

### MTE3, Meet the Expert session 3 - Room MTE3

<b>The role of donor registries in the changing landscape of allogeneic HSCT in 2020</b> Juliana Villa (Spain)	<b>17:30 - 18:30</b>
---	----------------------

Meet the Expert  
17:30 - 18:30

Meet the Expert Rooms

### MTE4, Meet the Expert session 4 - Room MTE4

<b>How to manage chronic GVHD in 2020 and beyond</b> Steven Pavletic (United States)	<b>17:30 - 18:30</b>
---	----------------------

## Scientific Programme

Meet the Expert  
17:30 - 18:30

Meet the Expert Rooms

### **MTE5, Meet the Expert session 5 - Room MTE5**

**The role of cord blood banks in the changing landscape of allogeneic HSCT in 2020**

**17:30 - 18:30**

Sergio Querol Giner (Spain)

Meet the Expert  
17:30 - 18:30

Meet the Expert Rooms

### **MTE6, Meet the Expert session 6 - Room MTE6**

**How to establish a CAR T-cell Delivery Centre**

**17:30 - 18:30**

Claire Roddie (United Kingdom)

Meet the Expert  
17:30 - 18:30

Meet the Expert Rooms

### **MTE7, Meet the Expert session 7 - Room MTE7**

**How to manage acute promyelocytic leukaemia in 2020. Current role of haematopoietic cell transplantation**

**17:30 - 18:30**

Miguel Ángel Sanz Alonso (Spain)

Social Events  
17:40 - 18:00

Auditorium 1

### **Yoga session**

## Scientific Programme

### Sunday, 30 August 2020

---

Non-Profit Symposium  
08:30 - 10:00

Auditorium 1

#### **IS2, How does MRD impact outcome of stem cell transplantation in AML, now and in the future? - AML Hub non-profit symposium**

##### **Chairs:**

Gert Ossenkoppele (Netherlands)

<b>Welcome and introduction</b> Gert Ossenkoppele (Netherlands)	<b>08:30 - 08:35</b>
<b>Challenges in MRD measurement by Multiparameter Flow Cytometry (MFC) in AML</b> Jacqueline Cloos (Netherlands)	<b>08:35 - 08:50</b>
<b>New developments in molecular MRD assessment in AML</b> Christian Thiede (Germany)	<b>08:50 - 09:05</b>
<b>Does current evidence support the use of MRD guided treatment before transplant in patients with AML?</b> Adriano Venditti (Italy)	<b>09:05 - 09:20</b>
<b>Why should we use MRD assessment post hematopoietic stem cell transplantation?</b> Charles Craddock (United Kingdom)	<b>09:20 - 09:35</b>
<b>Round table discussion: Use of MRD guided treatment decisions before and after transplantation</b>	<b>09:35 - 09:50</b>
<b>Summary and conclusions: Establishing MRD as surrogate endpoint in AML, and what does the future hold</b> Gert Ossenkoppele (Netherlands)	<b>09:50 - 10:00</b>

Special Session  
08:30 - 10:00

Auditorium 5

#### **SS2, Global Committee Session - The impact of infections on HSCT performance worldwide**

##### **Chairs:**

Norbert-Claude Gorin (France)  
Nicolaus Kröger (Germany)

<b>Introduction</b> Norbert-Claude Gorin (France)	<b>08:30 - 08:33</b>
<b>Impact (known or potential) of community respiratory virus infections on the outcome of recipients of an allogeneic HSCT or CAR T-cell therapy</b> Rodrigo Martino (Spain)	<b>08:33 - 08:48</b>

## Scientific Programme

<b>Tropical diseases and HSCT</b> Francesca Norman (Spain)	<b>08:48 - 09:03</b>
<b>Parasitic infections in HSCT</b> Gregorio Jaimovich (Argentina)	<b>09:03 - 09:18</b>
<b>Impact of infections in Asia</b> Alok Srivastava (India)	<b>09:18 - 09:33</b>
<b>Particularities of infections in limited-resource countries</b> Asma Quessar (Morocco)	<b>09:33 - 09:48</b>
<b>Conclusions and Q&amp;A</b> Nicolaus Kröger (Germany)	<b>09:48 - 09:50</b>

Industrial Theatre  
08:30 - 19:00

Industry Theatre

### **IT1, TLS in the context of new treatments in hematology - Sanofi Genzyme Industry Theatre Session**

Industrial Theatre  
08:30 - 19:00

Industry Theatre

### **IT3, Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite Industry Theatre Session**

Industrial Theatre  
08:30 - 19:00

Industry Theatre

### **IT4, KYMRIA in the Real World - Novartis Industry Theatre Session**

Industrial Theatre  
08:30 - 19:00

Industry Theatre

### **IT2, Clinical Data on Treosulfan-based Conditioning Treatment (Trecondi®) in Paediatric Patients - Medac Industry Theatre Session**

Industrial Theatre  
08:30 - 19:00

Industry Theatre

### **IT5, How I manage CMV in HSCT patients - MSD Industry Theatre Session**

## Scientific Programme

Industrial Theatre  
08:30 - 19:00

Industry Theatre

### IT6, Gene therapy: From clinical trials to clinical practice - Bluebirdbio Industry Theatre Session

**Chairs:**  
Franco Locatelli (Italy)

e-Posters  
08:30 - 19:00

ePoster Area

### Acute leukaemia

**ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HIV-INFECTION: AN UPDATED PAIR-MATCHED COHORT STUDY BY THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION**

**COMPARABLE OUTCOMES OF AML PATIENTS RECEIVING HAPLO-HCT WITH THIOTEPA/BUSULFAN/FLUDARABINE CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS A MATCHED UNRELATED DONOR WITH FLUDARABINE/BUSULFAN CONDITIONING, REGARDLESS OF DISEASE STATUS**

**TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT: IMPROVED SURVIVAL FOR YOUNG PATIENTS IN RECENT YEARS**

**ANTI-CD3/CD33 BISPECIFIC ANTIBODIES EFFICIENTLY REDIRECT DONOR T CELLS AGAINST HLA LOSS LEUKEMIA RELAPSES**

**POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) EMERGES AS A KEY DRIVER OF HLA CLASS II NEGATIVE POST-TRANSPLANTATION RELAPSE**

**ALLOGENEIC HCT FOR ADULTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA HARBORING *IKZF1* GENE MUTATIONS: A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**

**ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN CHILDREN AND ADULTS WITH RELAPSED/REFRACTORY B-ALL: FOCUS ON ANTI-CD19, ANTI-CD22 MONOCLONAL ANTIBODIES**

**THE VALUE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH AND WITHOUT *ASXL1*, *RUNX1* AND *TP53* MUTATIONS**

**ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT**

**RIC COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE PROVIDES HIGHER GVHD-FREE/RELAPSE FREE SURVIVAL IN FIT YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA**

**LOW-DOSE MEMORY DONOR LYMPHOCYTE INFUSION AFTER  $\alpha\beta$  T CELL-DEPLETED HSCT AMONG CHILDREN WITH HIGH-RISK LEUKEMIA: RESULTS OF A PROSPECTIVE RANDOMIZED SINGLE-CENTER TRIAL**

**DEVELOPMENT OF A CORD BLOOD STEM CELL-DERIVED DENDRITIC CELL VACCINE TO PREVENT RELAPSE AFTER CORD BLOOD TRANSPLANTATION IN AML**

## Scientific Programme

**THE BRAZILIAN EXPERIENCE WITH HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTS (HAPLO-HCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**BETTER LEUKEMIA-FREE SURVIVAL WITH ALLOGENEIC THAN WITH AUTOLOGOUS HCT IN AML PATIENTS WITH ISOLATED TRISOMY 8: A STUDY FROM THE ALWP OF THE EBMT**

**ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML PATIENTS WITH RUNX1 MUTATION IN FIRST COMPLETE REMISSION: A STUDY ON BEHALF OF THE ALWP OF THE EBMT**

**GRAFT FAILURE AFTER UNMANIPULATED HAPLO-HSCT WITH PT-CY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION, ON BEHALF OF THE ALWP-EBMT**

**IMPLICATIONS OF NOVEL RISKS SCORES (AML-DRG AND AML-HCT-CR) IN ALLOGENEIC CD34+ SELECTED GRAFT TRANSPLANT OUTCOMES**

Rosalía Alonso Trillo, Marta García Recio, Martina Pennisi, Christina Cho, Sean M. Devlin, Josel D. Ruiz, Molly A. Maloy, Ana Alarcon Tomas, Nerea Castillo, Richard J. Lin, Ioannis Politikos, Miriam Sanchez Escamilla, Michael Scordo, Gunjan L. Shah, Juliet N. Barker, Hugo Castro-Malaspina, Boglarka Gyurkocza, Parastoo B. Dahi, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Craig S. Sauter, Brian C. Shaffer, Roni Shouval, Roni Tamari, Marcel R. M. van den Brink, James W. Young, Sergio A. Giral, Miguel Perales (Spain)

**DOWNREGULATION OF HLA-DR IN BLASTS OF PATIENTS WITH ACUTE LEUKAEMIA RELAPSING AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ESTABLISHMENT OF A NATIONAL STEM CELL TRANSPLANT CLINICAL TRIALS NETWORK: THE UK IMPACT PARTNERSHIP FOR ACCELERATED CELLULAR THERAPIES**

**DIFFERENTIAL IMPACT OF NPM1 MUTATION ON THE POST-TRANSPLANT OUTCOME OF ADULT FLT3ITD MUTATED AML RECEIVING ALLOGENEIC TRANSPLANT IN CR1 AND AFTER CR1**

**A REGION-WIDE RETROSPECTIVE ANALYSIS OF OUTCOME FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA**

**PRE-HARVEST HIGHER DONOR FOXP3 MRNA AND LOWER CD4+ T CELL CONCENTRATION PREDICT INCREASED RISK OF ALL RELAPSE AFTER MYELOABLATIVE HCT WITH T-REPLETE BONE MARROW GRAFTS**

**EPIDEMIOLOGY, MANAGEMENT AND ECONOMIC IMPACT OF ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME IN SPAIN: A CLAIMS DATABASE ANALYSIS**

**PRE-TRANSPLANT BONE MARROW CELLULARITY AND BLOOD COUNT RECOVERY ARE NOT ASSOCIATED WITH RELAPSE OR SURVIVAL RISK FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT FOR AML IN CR1**

**IMMUNOTHERAPY SALVAGE FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS BY THE ALWP OF THE EBMT**

**COMPARISON OF PRE-TRANSPLANT COMORBIDITY INDICES IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**SALVAGE USE OF VENETOCLAX-BASED THERAPY FOR RELAPSED AML POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT**

**FACTORS PREDICTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA**

**ROLE OF CHIMERISM AND FLOW-CYTOMETRIC MONITORING OF MEASURABLE RESIDUAL DISEASE (MRD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN PREDICTING RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)**

**SORAFENIB PROLONGED MAINTENANCE IN FLT3-MUTATED AML POST TRANSPLANTATION**

## Scientific Programme

**PULMONARY COMPLICATIONS (PC) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN CHILDREN WITH HIGH-RISK ACUTE LEUKEMIA (AL)**

**MORE THAN TWO CYCLES OF CONSOLIDATION THERAPY PRE-TRANSPLANTATION BENEFITS AML PATIENTS IN CR1 WHO UNDERWENT HLA-MATCHED SIBLING ALLOGRAFTS: A MULTICENTER STUDY**

**WHAT CAN CNV ANALYSIS ADD TO THE ROUTINE GENETIC DESCRIPTION OF AML CASES?**

**COMPARISON OF THE PROGNOSTIC ABILITY OF THE HCT-CI THE MODIFIED EBMT AND THE EBMT-ADT PRE-TRANSPLANT RISK SCORES FOR ACUTE LEUKEMIA**

**GO-FLAG REGIMEN AS A BRIDGE THERAPY TO ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS**

**THE IMPACT OF ALLOGENEIC TRANSPLANTATION IN AML AND MDS WITH CHROMOSOME 3 ABNORMALITIES**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY-ALONE IN THE TREATMENT OF PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS WITH MIXED LINEAGE LEUKEMIA (MLL) REARRANGEMENTS: SINGLE CENTER EXPERIENCE**

**POSTTRANSPLANTATION BENDAMUSTINE FOR GVHD PROPHYLAXIS IN REFRACTORY ACUTE LEUKEMIA PATIENTS**

**IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE**

**FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS**

**TYROSINE KINASE INHIBITOR TREATMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA**

**OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR CYTOGENETIC INTERMEDIATE-RISK AML ACCORDING TO THE MOLECULAR RISK BASED ON ELN 2017 RISK STRATIFICATION SYSTEM; SINGLE CENTER EXPERIENCE IN KOREA**

**THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY WT1 GENE EXPRESSION IN PERIPHERAL BLOOD BEFORE AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS**

**IMPACT OF POSTTRANSPLANT TYROSINE KINASE INHIBITORS ADMINISTRATION ON LONG TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**

**THE INFLUENCE OF ANTI-THYMOCYTE GLOBULIN (ATG) ON THE OUTCOMES OF PATIENTS WITH AML W/O MEASURABLE RESIDUAL DISEASE (MRD) AT THE TIME OF UNRELATED DONOR TRANSPLANTATION**

**MLL-AF6 FUSION GENE POSITIVE AML TREATED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS EXCELLENT OVERALL SURVIVAL**

**BENEFICIAL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM**

**INDUCTION OF SYNERGISTIC APOPTOSIS AND OVERCOMING OF DRUG RESISTANCE BY COTARGETING OF BCL-2 AND NA/H EXCHANGER 1 PATHWAY IN ACUTE MYELOID LEUKEMIA CELLS**

## Scientific Programme

**GEMTUZUMAB-OZOGAMICIN FOR BRIDGING TO TRANSPLANT IN REFRACTORY/RELAPSED CD33 POSITIVE ACUTE LEUKEMIA - IS IT WORTHWHILE?**

**THE EFFECTS OF CYTOMEGALOVIRUS INFECTION ON TRANSPLANT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**AZACYTIDINE AND DONOR LYMPHOCYTES INFUSIONS IN RELAPSED AML AFTER ALLOGENEIC HSCT: RESULTS IN 40 PATIENTS**

**THE RESULTS OF AML RELAPSE AFTER ALLOGENEIC TRANSPLANTATION TREATMENT, SINGLE CENTRE APPROACH EVALUATION**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE CENTER ANALYSIS**

**THE OPTIMAL TIME FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA**

**IMPACT OF ABO MISMATCH ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTRE EXPERIENCE**

**DONOR SOURCE IMPACTS ON LONG TERM SURVIVAL FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN AML PATIENTS AGED 60 AND ABOVE**

**EXTRA-MEDULLARY RECURRENCE OF ACUTE MYELOID LEUKEMIA AS MYELOID SARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE SERIES**

**SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA: SINGLE CENTER EXPERIENCE**

**ALLOGENEIC STEM CELL TRANSPLANTS IN ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE EXPERIENCE**

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA NOT RESPONDING TO FIRST INDUCTION THERAPY**

e-Posters  
08:30 - 19:00

ePoster Area

## Aplastic anaemia

**LNP023 - A NEW ORAL COMPLEMENT FACTOR-B INHIBITOR NORMALIZES HEMOGLOBIN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH POOR RESPONSE TO ECULIZUMAB, BOTH AS ADD-ON AND MONOTHERAPY**

**EPIGENETIC AGING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH SEVERE APLASTIC ANEMIA: RESULTS FROM DNA-METHYLATION GRIMAGE**

**GVHD AND RELAPSE FREE SURVIVAL (GRFS) AFTER ALLOGENEIC TRANSPLANTATION FOR IDIOPATHIC SEVERE APLASTIC ANEMIA: AN ANALYSIS FROM THE SAAWP DATA QUALITY INITIATIVE PROGRAM OF EBMT**

**OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP**

**REDUCED INTENSITY CONDITIONING IS EFFECTIVE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND-BLACKFAN ANEMIA**

## Scientific Programme

**PROSPECTIVE STUDY OF ECULIZUMAB BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA / APLASTIC ANEMIA**

**OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT FOR FANCONI ANEMIA IN INDIA**

**ALTERNATE DONOR HSCT FOR 109 CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA: A SINGLE CENTER RETROSPECTIVE ANALYSIS**

**SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH REFRACTORY ACTIVE INFECTION: A PROSPECTIVE MULTICENTER CLINICAL STUDY IN CHINA**

**INCIDENCE AND MANAGEMENT OF APLASTIC ANEMIA IN SPAIN (IMAS). AN AMBISPECTIVE STUDY OF BIODONOSTIA / PETHEMA**

**ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS FOR CHILDREN WITH APLASTIC ANEMIA**

**OUTCOME OF PEDIATRIC ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE**

**OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR SEVERE APLASTIC ANEMIA IN PAKISTAN: DATA FROM A DEVELOPING COUNTRY**

**IMPACT OF CD34+-STEM CELL BOOST ON OUTCOME AND HEMATOLOGICAL RECONSTITUTION IN PATIENTS WITH SEVERE APLASTIC ANEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY**

**HEMATOPOIETIC STEM CELL TRANSPLANT IN ADULTS WITH ACQUIRED SEVERE APLASTIC ANEMIA**

**HEMATOPOIETIC STEM CELL TRANSPLANT IN FANCONI ANEMIA USING MATCHED RELATED AND HAPLOIDENTICAL DONORS- A SINGLE CENTRE EXPERIENCE**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC SEVERE APLASTIC ANEMIA: RESULTS OF A SINGLE CENTER**

**EFFECT OF SINGLE UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION ON APLASTIC ANEMIA IN CHILDREN**

**IMMUNOSUPPRESSIVE THERAPY IN PEDIATRIC APLASTIC ANEMIA, SINGLE CENTRE EXPERIENCE**

**CYCLOSPORINE, DANAZOL AND ROMIPLOSTIM IN SEVERE APLASTIC ANEMIA IN PRETRANSPLANT PERIOD: RETROSPECTIVE ANALYSIS OF FIVE CASES**

e-Posters  
08:30 - 19:00

ePoster Area

## Autoimmune diseases

**AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR STIFF PERSON SYNDROME**

**BEAM VS CYCLOPHOSPHAMIDE-BASED CONDITIONING REGIMEN IN AGGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE ANALYSIS OF EUROPEAN BLOOD AND MARROW TRANSPLANTATION SOCIETY**

## **Scientific Programme**

**A NOVEL TARGETED APPROACH TO ACHIEVE IMMUNE SYSTEM RESET: CD45-TARGETED ANTIBODY DRUG CONJUGATES AMELIORATE DISEASE IN PRECLINICAL AUTOIMMUNE DISEASE MODELS AND ENABLE AUTOHSCT**

**LONG TERM FOLLOW UP OF SYSTEMIC SCLEROSIS FRENCH PATIENTS INCLUDED IN THE ASTIS TRIAL USING SCOT TRIAL GLOBAL RANK COMPOSITE SCORE (GRCS)**

**ADVANCES IN MULTIPLE SCLEROSIS (MS) TREATMENT: CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION**

**POST TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES OUTCOME AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ANIMAL MODEL OF MULTIPLE SCLEROSIS**

**THE LONG-TERM SAFETY AND EFFICACY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS INDIRECTLY COMPARED TO ALEMTUZUMAB: A SYSTEMATIC REVIEW**

**RECONSTITUTION OF NATURAL OR VACCINATION-DRIVEN IMMUNITY AFTER AHSCT IN MULTIPLE SCLEROSIS**

**HIGH-DOSE IMMUNODEPLETION WITH AUTOLOGOUS STEM CELL RESCUE FOR TREATMENT OF AGGRESSIVE MULTIPLE SCLEROSIS**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT CHANGE THE EXPRESSION OF ENDOTHELIAL MARKERS IN SKIN BIOPSIES OF SYSTEMIC SCLEROSIS PATIENTS**

**AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NON HEMATOLOGICAL DISEASES. THE DUTCH EXPERIENCE OF MS PATIENTS GOING ABROAD**

**ANALYSIS OF COST AND CHARGES FOR NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES**

**AUTOLOGOUS STEM CELL TRANSPLANTATION IN BEHÇET'S DISEASE: A RETROSPECTIVE STUDY**

**SAFETY AND TOLERABILITY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE SCLEROSIS: A SINGLE CENTER EXPERIENCE**

**OUTCOME OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY TAKAYASU ARTERITIS, A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS IN NORWAY**

**THE USE OF AUTOLOGOUS HAEMOPOETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS AFTER ALEMTUZUMAB TREATMENT FAILURE: A CASE SERIES**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF SYSTEMIC SCLEROSIS, AN OPTION FOR REFRACTORY PATIENTS**

**A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE**

## Scientific Programme

e-Posters  
08:30 - 19:00

ePoster Area

### CAR-based Cellular Therapy - clinical

**KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS FROM PHASE 2 OF ZUMA-2**

**SAFETY AND EFFICACY RESULTS FROM TRANSCEND NHL 001, A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA**

**CD19/CD22 DUAL TARGETED (CHIMERIC ANTIGEN RECEPTOR) CAR-T THERAPY FOR RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)**

**AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE. ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP)**

**THIRD-GENERATION CAR T CELLS WITHIN THE HEIDELBERG CAR TRIAL 1 (HD-CAR-1) DISPLAY AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS**

**OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL IN 3 CLINICAL STUDIES OF RELAPSED/REFRACTORY LARGE B-CELL NHL, INCLUDING SECOND-LINE TRANSPLANT NONELIGIBLE PATIENTS: TRANSCEND NHL 001, OUTREACH, AND PILOT**

**CORRELATIVE ANALYSES OF PATIENT AND CLINICAL CHARACTERISTICS ASSOCIATED WITH EFFICACY IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE JULIET TRIAL**

**CAR T CELLS (CART) OR ALLOGENEIC TRANSPLANTATION (ALLOHCT) FOR MULTIPLE RELAPSED DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)? A RETROSPECTIVE INTENT-TO-TREAT (ITT) COMPARISON**

**HIGH ACTIVATION OF BCMA CAR-T CELLS CONTRIBUTES TO INCREASED RESPONSE RATE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**

**A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL; AXI-CEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL)**

**CD19-TARGETED CAR-T CELL THERAPY FOR 32 B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)**

**INTERNATIONAL PROGNOSTIC INDEX PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACTORY LARGE DIFFUSE B CELL LYMPHOMA TREATED WITH COMMERCIAL CAR T CELLS**

**THE PHASE 1B PORTIA STUDY: SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA**

**REAL-WORLD EVIDENCE OF THE USE OF TISAGENLECLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS. THE SPANISH EXPERIENCE**

**NATIONAL IMPLEMENTATION OF THE USE OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN NATIONAL HEALTH SERVICE ENGLAND (NHSE)**

**REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA**

## **Scientific Programme**

**CORRELATIVE MARKERS OF TOXICITY IN PATIENTS WITH DLBCL TREATED WITH CD19 CAR T CELL THERAPY**

**EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)**

**ASSOCIATION OF AXI-CEL CAR-T CELL CONCENTRATION WITH TREATMENT RESPONSE AND SIDE EFFECTS AND IMPACT OF DEXAMETHASONE TREATMENT ON KINETICS**

**SIMPLIFIED-EASIX (SEASIX) IS AN EARLY PREDICTOR OF SEVERE CYTOKINE RELEASE SYNDROME AND IMMUNE-EFFECTOR-CELLS-ASSOCIATED NEUROTOXICITY SYNDROME IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T CELLS**

**NIVOLUMAB AS SALVAGE THERAPY IN PATIENTS WHO FAILED TO ACHIEVE COMPLETE REMISSION AFTER ANTI-CD19 CAR T-CELL THERAPY FOR DLBCL**

**SURVEILLANCE OF MINIMAL RESIDUAL DISEASE (MRD) IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY CIRCULATING TUMOR DNA (CTDNA) PROFILING AFTER CHIMERIC ANTIGEN RECEPTOR T (CAR-T)**

**A DIGITAL-PCR ASSAY FOR PRECISE IN-VIVO QUANTIFICATION OF ADOPTIVELY TRANSFERRED CD19-CAR T CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**

**FEASIBILITY OF MANUFACTURING TISAGENLECLEUCEL IN PATIENTS LESS THAN 3 YEARS OF AGE WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA**

**AXICABTAGENE CILOLEUCEL CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: REAL-WORLD OUTCOMES, TOXICITY AND PREDICTORS OF RESPONSE FROM A PROSPECTIVE UK COHORT**

**MARKERS OF INITIAL AND LONG-TERM RESPONSES TO IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) IN THE CRB-401 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA**

**SINUSOIDAL OBSTRUCTION SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) TREATED WITH ARI-0001 CELLS**

**HUMORAL IMMUNE RESPONSE IN PATIENTS WITH CD19-POSITIVE RELAPSED/REFRACTORY B-CELL MALIGNANCIES RECRUITED INTO THE CART19-BE-01 CLINICAL TRIAL, AN ACADEMIC CAR19**

**REAL-WORLD DATA FROM KINGS COLLEGE HOSPITAL: INFECTION COMPLICATIONS POST CAR-T TREATMENT IN HIGH-GRADE B CELL NON-HODGKIN LYMPHOMA**

**SENESCENT/EXHAUSTED PHENOTYPE OF CD19-TARGETED CAR-T CELLS AND IMMUNOREGULATORY ENVIRONMENT CORRELATE WITH REDUCED RESPONSE TO CAR-T CELL THERAPY IN RELAPSED/REFRACTORY B CELL MALIGNANCIES**

**CHARACTERISATION OF EARLY AND LATE CYTOPENIAS IN LYMPHOMA PATIENTS FOLLOWING TREATMENT WITH ANTI-CD19 CAR-T THERAPY**

**CD4+ CAR-T CELLS MAINTAIN MEMORY PHENOTYPES AND MEDIATE LONGER-TERM ANTITUMOR ACTIVITY IN VIVO**

**IMPACT OF ETHNICITY IN R/R DLBCL AND B-CELL ALL PATIENTS TREATED WITH TISAGENLECLEUCEL**

**IMPACT OF DIFFERENT CHEMOTHERAPY REGIMENS AND DURATION OF DLBCL ON LYMPHOPHERESIS AND CAR-T T-CELL IMMUNOPHENOTYPING**

**CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA**

## Scientific Programme

**CHALLENGES IN PROVIDING GOOD LEUKAPHERESIS PRODUCTS FOR THE PRODUCTION OF CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY NHL OR ALL**

**NKG2D CAR T CELLS ARE NOT AFFECTED BY SOLUBLE NKG2D LIGANDS**

**EMERGING CYTOKINE RELEASE SYNDROME IS ASSOCIATED WITH REDUCTION OF CD4+CD25HIGH127DIM T REGULATORY CELLS IN PATIENTS AFTER CAR T CELL THERAPY**

**EXCELLENT PROLIFERATION AND PERSISTENCE OF ALLOGENEIC CAR-T CELLS DESPITE IMMUNOSUPPRESSION WITH CYCLOSPORINE A**

**A FRENCH BIOBANKING NETWORK TO CREATE A UNIQUE COLLECTION OF SAMPLES OF PATIENTS TREATED WITH CAR-T CELLS**

**CAR T CELL THERAPY DIRECTED AGAINST CD19 IN PATIENTS WITH B-CELL LYMPHOMA AFTER AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IS FEASIBLE AND SAFE**

**LYMPHOCYTE COLLECTION FOR GENERATION OF CAR T-CELLS IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE**

**BASELINE HYPOALBUMINEMIA DOES NOT APPEAR TO BE AN ADVERSE PROGNOSTIC FACTOR IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMAS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**

**FACTORS PREDICTING CD3+ COLLECTION FOR THE PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS**

**CYTOPENIAS AFTER TISAGENLECLEUCEL IN PAEDIATRIC/YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSE B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): A REAL-LIFE SINGLE-CENTRE EXPERIENCE**

**THE RISK OF HEPATITIS B REACTIVATION IS CONTROLLABLE IN B-CELL MALIGNANCIES PATIENTS WITH CONCOMITANT HEPATITIS B VIRUS INFECTION AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY**

**CUMULATIVE RITUXIMAB EXPOSURE PRIOR TO AXICABTAGENE CILOLEUCEL IS NOT ASSOCIATED WITH PERSISTENT LEUKOPENIA AND THROMBOCYTOPENIA AT DAY +90 POST INFUSION**

**COMPREHENSIVE IMMUNE CELL MONITORING REVEALS AN ALTERED LYMPHOCYTE SUBSET PHENOTYPE IN PATIENTS NOT RESPONDING TO TISAGENLECLEUCEL ONE MONTH POST INFUSION**

**NEUROTOXICITY ASSOCIATED WITH CAR T CELL THERAPY: NEUROLOGICAL MANAGEMENT AND WORK-UP OF 11 ADULT PATIENTS**

**NUTRITIONAL ASSESSMENT OF PATIENTS UNDERGOING CD19-TARGETED CAR-T THERAPY FOR NON-HODGKIN'S LYMPHOMA AND THE SHORT TERM EFFECT OF TREATMENT ON NUTRITIONAL STATUS**

**EFFECTIVENESS OF AUTOLOGOUS LEUKAPHERESIS COLLECTIONS FOR CAR T-CELL MANUFACTURING IN PATIENTS WITH B-CELL MALIGNANCIES**

**DEFINITION AND IMPLEMENTATION OF CLINICAL AND QUALITY ENDPOINTS IN CENTERS ADMINISTERING A COMMERCIAL CAR-T PRODUCT**

**CAR-T IN BREAST AND OTHER EXTRA-MEDULLARY RELAPSED/REFRACTORY ALL**

**PREDICTING CAR T-CELL INFUSION AFTER SUCCESSFUL MANUFACTURING: REAL-WORLD DATA**

## Scientific Programme

### EVALUATION OF THE INTEREST OF A DRUG RECONCILIATION ACTIVITY IN PATIENTS TREATED WITH CAR T-CELLS: A DESCRIPTIVE STUDY

e-Posters  
08:30 - 19:00

ePoster Area

## CAR-based Cellular Therapy - preclinical

**MODULATION OF CYTOSOLIC CA<sup>2+</sup> REGULATES CAR-T CELL DIFFERENTIATION AND THERAPEUTIC POTENCY**

**BREAKING PD-L1-MEDIATED RESISTANCE IN ANTI-CD19 AND ANTI-CD22 CAR T CELLS WITH PD-1/CD28 FUSION RECEPTORS**

**ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR-INVARIANT NATURAL KILLER T CELLS EXERT BOTH DIRECT AND INDIRECT ANTITUMOR EFFECTS THROUGH HOST CD8 T CELL CROSS-PRIMING**

**DUVELISIB GENERATES CAR T CELLS WITH ENHANCED MITOCHONDRIAL BIOGENESIS AND REDUCED EXPRESSION OF PD-1, TIM-3, AND LAG-3, ENABLING GREATER ANTI-LEUKEMIA CYTOTOXICITY AGAINST CLL**

**NKG2D CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS**

**CLINICAL-GRADE MANUFACTURING OF ROR1 CAR T-CELLS USING A NOVEL VIRUS-FREE PROTOCOL**

**LENTIVIRALLY AND ALPHARETROVIRALLY ENGINEERED CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS ARE HIGHLY CYTOTOXIC AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA**

**NOVEL STRATEGIES TO ENHANCE THE SAFETY OF CAR T-CELL IMMUNOTHERAPY: THE IMSAVAR PROJECT**

**ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIC CELLS**

**ENHANCEMENT OF CYTOTOXICITY, EXPANSION AND PERSISTENCE OF CD19 CAR-T CELLS VIA PRE-SENSITIZATION OF B CELL MALIGNANCIES BY BCL-2 SELECTIVE INHIBITORS**

**TYROSINE KINASE INHIBITOR FOLLOWED BY CART THERAPY FOR THE TREATMENT OF RELAPSED PHILADELPHIA CHROMOSOME-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

e-Posters  
08:30 - 19:00

ePoster Area

## Cellular Therapies other than CARs

**CTLA4IG PRIMED SEQUENTIAL DLI IMPROVES GVHD AND RELAPSE-FREE SURVIVAL COMPARED TO UNPRIMED DLI IN PATIENTS UNDERGOING PTCY-BASED HAPLOIDENTICAL HCT FOR ADVANCED HEMATOLOGICAL MALIGNANCIES**

**HLA-MISMATCHED MOBILIZED CELLULAR THERAPY (MICROTRANSPLANT, MST) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES**

## Scientific Programme

**DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PTCY: A STUDY ON BEHALF OF THE CTIWP OF THE EBMT**

**SAFETY, EFFECTIVENESS AND PERSISTENCE OF LOW-DOSE DONOR MEMORY T CELL INFUSIONS AFTER AB T CELL-DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER T-CELL-REPLETE ALLOGENEIC HSCT PREVENTS DISEASE RELAPSE AND PROLONGS SURVIVAL IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIA**

**BASELINE IMMUNE STATUS PREDICTS RESPONSE TO ADOPTIVE THERAPY WITH CMV CTLs FOR REFRACTORY CMV**

**EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY ON BEHALF OF GETH (GRUPO ESPAÑOL TRASPLANTE HEMATOPOYÉTICO)**

**PHASE I STUDY OF ADOPTIVE TRANSFER OF HAPLOIDENTICAL EXPANDED NK CELLS**

**OFF-TARGET HLA CROSS-REACTIVITY BY (THIRD PARTY) VIRUS-SPECIFIC T CELLS IS SURPRISINGLY AFFECTED BY HLA RESTRICTION AND HLA BACKGROUND BUT NOT BY VIRUS SPECIFICITY**

**ADOPTIVE IMMUNOTHERAPY OF REFRACTORY VIRAL INFECTIONS AFTER ALLOGENEIC HSCT: AN ACADEMIC NETWORK FRAMING THE USE OF AN ATMP UNDER HOSPITAL EXEMPTION**

**HOW TO BENEFIT FROM EXHAUSTION: PATIENT-DERIVED INHIBITED T CELLS AS A NOVEL SOURCE OF TUMOR-REACTIVE T CELL CLONES**

**EFFICIENT CRISPR/CAS9-MEDIATED INACTIVATION OF THE GLUCOCORTICOID RECEPTOR FOR ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY**

**COMPARISON OF OUTCOME POST-SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION VERSUS DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS**

**AUTOMATED APPLICATION FOR DEPLETION OF TCRAB+, CD19+ AND CD45RA+ CELLS FROM APHERESIS PRODUCTS USING THE CLINIMACS PRODIGY (R)**

**THE FIRST FUNCTIONAL HLA-A\*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES**

**GOOD RESPONSE RATES OF WJ-MSC, COMPARABLE TO BM-MSC, IN THE TREATMENT OF REFRACTORY GVHD**

**AN 'ALL IN ONE' T-CELL PRODUCT FROM NON-TRANSPLANTABLE CORD BLOOD UNITS FOR VIRUS- AND LEUKEMIA-SPECIFIC T-CELL IMMUNOTHERAPY**

**CLINICAL SUCCESS OF GRANULOCYTE TRANSFUSIONS IN ADULT NEUTROPENIC PATIENTS AFTER CHEMOTHERAPY AND/OR ALLOGENEIC TRANSPLANTATION - TIME MATTERS!**

**IMPACT OF LONG-TERM CRYOPRESERVATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS PRODUCTS**

**OPTIMIZING LENTIVIRAL VECTOR TRANSDUCTION TO GENE MODIFY CORD BLOOD CD8+ T CELLS FOR OFF-THE-SHELF ADOPTIVE CELL THERAPY TO TREAT CANCER**

**DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTRE EXPERIENCE**

**CASE REPORT: CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION (CAEBV) CONTROLLED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) AND TRANSFUSION OF EBV-SPECIFIC T-CELLS**

## Scientific Programme

e-Posters  
08:30 - 19:00

ePoster Area

### Chronic leukaemia and other myeloproliferative disorders

**TIMING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A JOINT STUDY FROM THE INTERNATIONAL MDS/MPN WORKING GROUP AND EBMT**

**RELAPSE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IN THE PATHWAY INHIBITOR (PI) ERA: NO LONGER A DEAD-END STREET**

**THE 10-YEARS <u>E</u>BMT <u>L</u>ANDSCAPE OF <u>A</u>LLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) FOR <u>C</u>HRONIC LYMPHOCYTIC LEUKEMIA**

**DETERMINANTS OF SURVIVAL IN MYELOFIBROSIS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT**

**SPLENECTOMY DOESN'T PRECLUDE SUBSEQUENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELOFIBROSIS PATIENTS: A FRENCH NATIONWIDE STUDY USING A MULTISTATE MODEL**

**INCIDENCE OF LATE RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: THE EXPERIENCE OF THREE UNIVERSITY TRANSPLANT CENTRES IN ROME**

**AUSTRALASIAN TRENDS IN ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS IN MOLECULAR ERA**

**CML RELAPSE AFTER ALLOGENEIC HSCT: SURVIVAL, TREATMENT EFFICACY AND PROGNOSTIC FACTORS FOR OUTCOME**

**CHRONIC MYELOID LEUKEMIA: ALLOGENEIC HEMOPOIETIC STEM CELLS TRANSPLANTATION IN THE ERA OF TYROSINE KINASE INHIBITORS**

**REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT WITH CAMPATH T-CELL DEPLETION FOR MYELOFIBROSIS IN THE ERA OF JAK INHIBITORS- A SINGLE CENTRE EXPERIENCE**

**ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS**

**ALLOGENEIC STEM CELL TRANSPLANTATION FOR IDIOPATIC MYELOFIBROSIS: A SINGLE CENTRE EXPERIENCE**

**A CASE OF SUCCESSFUL SECOND HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AFTER SECONDARY GRAFT FAILURE IN A PATIENT WITH REFRACTORY CHRONIC MYELOID LEUKEMIA**

e-Posters  
08:30 - 19:00

ePoster Area

### Conditioning regimens

## Scientific Programme

**THE IMPACT OF CONDITIONING IN CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY "FORUM" ON BEHALF OF AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP**

**POPULATION PHARMACOKINETIC ESTIMATION OF ATG EXPOSURE PREDICTS IMMUNE RECONSTITUTION AND SURVIVAL IN ADULTS UNDERGOING EX VIVO CD34-SELECTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**FLAMSA-BASED REDUCED INTENSITY CONDITIONING VERSUS MYELOABLATIVE CONDITIONING IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH ACTIVE DISEASE AT THE TIME OF TRANSPLANTATION: AN ALWP/EBMT ANALYSIS**

**TOTAL BODY IRRADIATION/FLUDARABINE VERSUS THIOTEPA/BUSULFAN/FLUDARABINE FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH HAPLOIDENTICAL HCT. A STUDY BY ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**

**BUSULFAN-CYCLOPHOSPHAMIDE VERSUS CYCLOPHOSPHAMIDE-BUSULFAN AS CONDITIONING REGIMEN BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A PROSPECTIVE RANDOMIZED TRIAL**

**RABBIT ANTI-THYMOCYTE GLOBULIN (ATG) EXPOSURE AFTER EX VIVO T-CELL-DEPLETED HEMATOPOIETIC CELL TRANSPLANTATION IS VARIABLE AND IMPACTS IMMUNE RECONSTITUTION AND SURVIVAL IN CHILDREN AND YOUNG ADULTS**

**A RETROSPECTIVE COMPARATIVE STUDY OF BEAM VS FEAM VS TEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT**

**REDUCED INTENSITY VERSUS MYELOABLATIVE CONDITIONING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS < 60 WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTI-CENTER CANADIAN EXPERIENCE**

**COMBINING CLOFARABINE AND FLUDARABINE WITH EXPOSURE TARGETED BUSULFAN FOR PEDIATRIC LEUKEMIA: AN EFFECTIVE, LOW TOXIC, TBI-FREE CONDITIONING REGIMEN**

**BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II STUDY**

**REDUCED-TOXICITY CONDITIONING WITH FLUDARABINE, THIOTEPA AND MELPHALAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH IMPAIRED LUNG FUNCTION**

**ALLOGENEIC STEM CELL TRANSPLANT WITH MINIMAL-INTENSITY CONDITIONING IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA: A SINGLE CENTRE RETROSPECTIVE REVIEW**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%.A STUDY FROM THE ALWP-EBMT**

**A PROSPECTIVE COHORT STUDY COMPARING LONG-TERM OUTCOMES WITH AND WITHOUT PALIFERMIN IN PATIENTS RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES**

**PHARMACOKINETICS OF MELPHALAN IN LYMPHOMA PATIENTS UNDERGOING BEAM AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT**

**MELPHALAN IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION: DOES ONE SIZE FIT ALL?**

**COMPARISON OF TOTAL BODY IRRADIATION- VS CHEMOTHERAPY-BASED CONDITIONINGS FOR EARLY COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ALL**

## Scientific Programme

**DIFFERENTIAL ALEMTUZUMAB DOSAGES IN T-CELL DEplete ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTS FOR MYELOID MALIGNANCIES**

**THE INFLUENCE OF TDM ON ACHIEVING BUSULFAN TARGET EXPOSURE AND RELATED DETERMINANTS, IN BOTH CHILDREN AND ADULTS WHO UNDERWENT AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**NOVEL REDUCED INTENSITY CONDITIONING (RIC) APPROACH TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH BENIGN AND MALIGNANT DISORDERS OF T CELL PROLIFERATION OR DYSREGULATION**

**PROFOUND LYMPHOPENIA AT THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION IS NOT PREDICTIVE OF SURVIVALS AFTER ALLO-TRANSPLANTATION**

**LIPID CORE NANOPARTICLES AS VEHICLE FOR ETOPOSIDE IN THE CONDITIONING REGIMEN OF MARROW TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA NOT RESPONDING TO INDUCTION THERAPY: A PILOT STUDY**

**A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF SHORT-TERM EVEROLIMUS IN ADDITION TO POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-EVER)**

**ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS  $\geq 65$  YEARS WITH HEMATOLOGICAL MALIGNANCIES AFTER MYELOABLATIVE TREOSULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS**

**BUTYRYLCHOLINESTERASE ACTIVITY AFTER CYCLOPHOSPHAMIDE CONDITIONING AS A PREDICTIVE MARKER OF LIVER TRANSPLANT-RELATED COMPLICATIONS AND ITS CORRELATION WITH TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS**

**FLUDARABINE-MELPHALAN CONDITIONING RESULTS IN FAVORABLE LEUKEMIA-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH ACTIVE OR MEASURABLE RESIDUAL AML**

**SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS)**

**INCREASED NON-RELAPSE MORTALITY AND POOR OVERALL SURVIVAL IN ELDERLY PATIENTS TREATED WITH FLUDARABINE AND MYELOABLATIVE DOSE OF BUSULFAN: TRANSPLANT COMPLICATIONS WORKING GROUP OF THE JSHCT**

**TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA**

**A CD45-TARGETED ANTIBODY DRUG CONJUGATE ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS A SINGLE AGENT IN MICE**

**INFLUENCE OF THE CELL SOURCE TYPE AND CONDITIONING TYPE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME**

**PRECONDITIONING INTENSITY IMPACTS ON IMMUNE RECONSTITUTION AND OUTCOMES FOLLOWING CORD BLOOD TRANSPLANTATION**

**FINAL RESULTS OF A PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY ON THIOTEPA-BASED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (ASCT) FOR CNS OR NON-CNS LYMPHOMA**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY), CYCLOSPORIN (CSA) AND MYCOPHENOLATE (MMF) FOR PATIENTS GRAFTED FROM HLA IDENTICAL SIBLINGS OR MATCHED UNRELATED DONORS**

## Scientific Programme

**COMPARISON OF FLUDARABINE + BUSULFAN AND FLUDARABINE+BUSUFAN+ LOW-DOSE ATG CONDITIONING REGIMENS IN PATIENTS WITH MYELOID MALIGNANCIES WHO HAD ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

**CONDITIONING REGIMEN COMPARISON FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA**

**PK-GUIDED BUSULFAN CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) WITH PTCY AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**A THIOTEPA BASED INTENSIFIED REDUCED INTENSITY CONDITIONING REGIME IN ADULT CORD BLOOD TRANSPLANT IS A PROMISING ALTERNATIVE IN PATIENTS UNABLE TO RECEIVE MYELOABLATIVE CONDITIONING**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE USING AS CONDITIONING FLUDARABINE MELPHALAN PLUS LOW DOSES OF TOTAL BODY IRRADIATION. LONG TERM FOLLOW-UP OF 60 PATIENTS**

**TREOSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE**

**COMPARISON OF BEAM AND TEAM AS CONDITIONING REGIMEN FOR LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

**ASSESSMENT OF THE SAFETY AND EFFICACY OF THE CONDITIONING REGIMEN BEEAC BEFORE AUTO-HSCT FOR THE TREATMENT OF PRIMARY-REFRACTORY AND RELAPSED FORMS OF MALIGNANT LYMPHOMAS**

**ALLOGENEIC STEM CELL TRANSPLANTATION AFTER TOTAL-BODY IRRADIATION USING HELICAL TOMOTHERAPY: A SINGLE CENTER EXPERIENCE**

**FEASIBILITY OF CLAMSA-RIC AS AN ALTERNATIVE CONDITIONING REGIMEN COMPARED TO FLAMSA-RIC IN HEAVILY PRETREATED REFRACTORY AML PATIENTS - A RETROSPECTIVE SINGLE CENTER ANALYSIS**

**THIOTEPA, BUSULPHAN AND FLUDARABINE CONDITIONING IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA**

**FLAMSA-BASED HIGH-DOSE SEQUENTIAL CONDITIONING REGIMEN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): IS IT EFFECTIVE IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE LEUKEMIA?**

**INCREASING IN SERUM TOTAL AMYLASE LEVELS AFTER TOTAL BODY IRRADIATION CONDITIONING REGIMEN AS A PREDICTIVE MARKER OF TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS**

**EVOLUTION OF DONOR CHIMERISM AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT - CLINICAL CORRELATIONS**

**THIOTEPA-BUSULFAN-FLUDARABINE AS CONDITIONING REGIMEN FOR PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA-HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE REGIMEN IN CHILDREN**

**ANALYSIS OF DIFFERENCES IN PREVENTIVE MEASURES AFTER HIGH-DOSE CYCLOPHOSPHAMIDE AMONG BELGIAN STEM CELL TRANSPLANT CENTRES**

## Scientific Programme

**IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION**

**LOW GRAFT CD4 CELL DOSE PREDICTS RELAPSE IN THE ATG-BASED MYELOABLATIVE CONDITIONING REGIMEN**

**CLINICAL EFFICACY OF HAPLOID TRANSPLANTATION WITH BU/CY/MEL PRETREATMENT SCHEME TO IMPROVE 68 CASES OF UNICENTRIC REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA**

**REDUCING INTENSITY CONDITIONING (RIC) PROTOCOL HARMONISATION IN THE UK**

**HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN HIGH-RISK HEMATOLOGICAL MALIGNANCIES, ALGERIAN EXPERIENCE**

**INTERRUPTION OF CONDITIONING FOR ALLO-HCT DOES NOT AFFECT CLINICAL OUTCOMES OTHER THAN CHRONIC GVHD**

**THERAPEUTIC DRUG MONITORING OF BUSULFAN IN PEDIATRIC POPULATION**

**REDUCED INTENSITY CONDITIONING FOLLOWED BY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (RIC-HAPLOHCT) AND POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS, FOR HEMATOLOGICAL DISORDERS: SINGLE CENTRE EXPERIENCE**

**HIGH DOSE TREATMENT WITH LEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION DURING THE SHORTAGE OF MOSTLY USED AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA**

**REDUCED DOSE ALEMTUZUMAB IN REDUCED INTENSITY CONDITIONING VOLUNTEER DONOR UNRELATED TRANSPLANT FOR MYELOID MALIGNANCIES IS SAFE AND EFFICACIOUS. A SINGLE CENTRE EXPERIENCE**

**DESCRIBE AND EXPLORE A PATIENTS' OUTLOOK ON DENTAL CARE IN THE CONTEXT OF THEIR MEDICAL DIAGNOSIS AND TREATMENT PRIOR TO AND FOLLOWING ALLOGENEIC HSCT**

**SAFETY AND EFFICACY OF LOW-DOSE BENDA-EAM AS COMPARED TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION OF REFRACTORY/RELAPSED LYMPHOMA PATIENTS**

**CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS**

**OUTCOMES OF UNRELATED DONOR STEM CELL TRANSPLANTATION WITH OR WITHOUT ANTI-THYMOCYTE GLOBULIN USED AS GRAFT-VERSUS HOST DISEASE (GVHD) PROPHYLAXIS: A SINGLE CENTER EXPERIENCE**

**BUSULFAN-FLUDARABINE CONDITIONING REGIMEN FOR CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE TWO-CENTER STUDY**

**ATG IN CONDITIONING FOR SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

e-Posters  
08:30 - 19:00

ePoster Area

## Data Management

**SUPPORTING TOOLS FOR ACCURATE DATA COLLECTION - DO WE GET THE BENEFIT?**

## Scientific Programme

**ARE TRANSPLANTS TRULY AVAILABLE TO ALL, REGARDLESS OF GEOGRAPHY, SOCIOECONOMIC STATUS AND ETHNIC GROUP? A BSBMTCT REPORT**

**MISMATCHED DONOR AND GRADE 2 TO 4 ACUTE GVHD AS TWO-RISK MODEL FOR CYTOMEGALOVIRUS VIREMIA AND DISEASE AFTER ALLOGENEIC TRANSPLANTATION - SINGLE INSTITUTE ANALYSIS OF 1180 PATIENTS**

e-Posters  
08:30 - 19:00

ePoster Area

### Experimental stem cell transplantation

**LOW-DOSE DECITABINE IMPROVES REFRACTORY PROLONGED ISOLATED THROMBOCYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A RANDOMIZED MULTICENTER CLINICAL TRIAL**

**AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY**

**2ND ALLO-HSCT FOR PATIENTS WHO DIAGNOSED RECURRENCE ALL AFTER THE 1ST ALLO-HSCT**

**ESTABLISHING A TRANSPLANT SHARING PROGRAM**

e-Posters  
08:30 - 19:00

ePoster Area

### Experimental transplantation

**SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTICS**

**IMPACT OF GUT FUNGAL COMPOSITION ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**MONITORING HEMATOPOIETIC CELL MICROPARTICLES IN ALLOGRAFTS AND TRANSPLANT RECIPIENTS**

**EARLY HEPATIC COMPLICATIONS DURING THE FIRST YEAR AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITH LEUKEMIA**

**PERFORMANCE OF BONE MARROW TRANSPLANTATION CENTER IN IMAM REZA HOSPITAL, KERMANSHAH, IRAN**

e-Posters  
08:30 - 19:00

ePoster Area

### Gene Therapy

**CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT  $\beta$ -THALASSEMIA**

**LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY (HSPC-GT) FOR METACHROMATIC LEUKODYSTROPHY (MLD): CLINICAL OUTCOMES FROM 33 PATIENTS**

## Scientific Programme

**A SINGLE DOSE OF SHORT HALF-LIFE CD117 ANTIBODY DRUG CONJUGATE ENABLES HEMATOPOIETIC STEM CELL BASED GENE THERAPY IN NONHUMAN PRIMATES**

**LENTI-D HEMATOPOIETIC STEM CELL GENE THERAPY STABILIZES NEUROLOGIC FUNCTION IN BOYS WITH CEREBRAL ADRENOLEUKODYSTROPHY**

**SAFETY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH GENE ADDITION THERAPY FOR TRANSFUSION-DEPENDENT  $\beta$ -THALASSEMIA, SICKLE CELL DISEASE, AND CEREBRAL ADRENOLEUKODYSTROPHY**

**EX-VIVO AUTOLOGOUS HAEMATOPOIETIC STEM CELL GENE THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE IIIA**

e-Posters  
08:30 - 19:00

ePoster Area

### Graft-versus-host disease - clinical

**KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) - LONG-TERM FOLLOW-UP OF A PHASE 2A STUDY (KD025-208)**

**A PHASE 2 STUDY OF F-652, A NOVEL TISSUE-TARGETED RECOMBINANT HUMAN INTERLEUKIN-22 (IL-22) DIMER, FOR TREATMENT OF NEWLY DIAGNOSED ACUTE LOWER GI GVHD**

**THE MAGIC BIOMARKER ALGORITHM PREDICTS OUTCOMES FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE**

**A NOVEL TREATMENT IN CHRONIC OCULAR GRAFT-VS-HOST DISEASE (OGVHD): A PHASE II CLINIC TRIAL WITH TRANSDERMAL PROGESTERONE**

**EARLY CD4+ T-CELL RECONSTITUTION IS AN EXCELLENT PREDICTOR OF OUTCOMES IN PEDIATRIC PATIENTS WHO DEVELOP MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST-DISEASE: A DUAL CENTER VALIDATION**

**EFFECT OF SINGLE OR DOUBLE MISMATCHES AT EACH HLA LOCUS ON THE OUTCOMES AFTER SINGLE CORD BLOOD TRANSPLANTATION: THE JSHCT HLA WG STUDY**

**INTERIM ANALYSIS OF KD025-213: A PHASE 2, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KD025 IN SUBJECTS WITH CGVHD (THE ROCKSTAR STUDY)**

**ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) AND RITUXIMAB FOR IMMUNOMODULATION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT FAILURE IN PATIENTS WITH NON-MALIGNANT DISORDERS: RESULTS OF A MULTICENTRE, RANDOMIZED, OPEN-LABEL STUDY**

**EXPERIENCE USING DUAL T-CELL DEPLETION WITH ATG AND PTCY FOR GVHD PROPHYLAXIS IN RIC ALLOHCT USING IN 10/10 MATCHED RELATED AND UNRELATED DONORS**

**MACHINE LEARNING APPLIED TO THE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE IMPROVES SURVIVAL ESTIMATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**SINGLE-CELL MOLECULAR ANALYSIS DEFINES CHARACTERIZATION OF SPECIFIC T CELL SUBSETS CORRELATE WITH HUMAN CHRONIC GVHD AND BRONCHIOLITIS OBLITERANS**

**A PHASE II TRIAL EVALUATING THE USE OF THE HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PREVENTION**

## Scientific Programme

**REDUCED CALCIUM SIGNALING IS ASSOCIATED WITH GVHD: RESULTS FROM PRECLINICAL ALLOSCT MODELS AND FROM A PROSPECTIVE MULTICENTER STUDY**

**IDENTIFICATION OF PREDICTIVE MODELS INCLUDING POLYMORPHISMS IN CYTOKINES GENES ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND OVERALL SURVIVAL AFTER IDENTICAL HLA-ALLOGENEIC STEM-CELL TRANSPLANTATION**

**SEARCH FOR CIRCULATING ENDOTHELIAL CELLS OF DONOR ORIGIN AFTER ALLO-HSCT: POTENTIAL CLINICALLY RELEVANT IMPLICATIONS IN THE CONTEXT OF GRAFT-VERSUS-HOST DISEASE**

**DOUBLE LUNG TRANSPLANTATION IN ADULTS FOR CHRONIC PULMONARY GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**REDUCED INFLAMMATORY TISSUE INFILTRATION DURING INTESTINAL STEROID-REFRACTORY GVHD**

**IMPACT OF ANTITHYMOCYTE GLOBULIN DOSE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN STEM CELL TRANSPLANTATION FROM UNRELATED DONORS**

**DECREASED SOLUBLE HLA-E LEVELS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH SEVERE ACUTE AND EXTENDED CHRONIC GRAFT-VERSUS-HOST DISEASE AND INFERIOR OVERALL SURVIVAL**

**EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON PRODUCTION OF SERUM SOLUBLE CD163: RELATIONSHIP TO IMMUNOSUPPRESSION AND DISEASE ACTIVITY IN CHRONIC GRAFT VERSUS HOST DISEASE**

**POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE OVERCOMES THE DETRIMENTAL EFFECT OF A SINGLE-LOCUS HLA MISMATCHED IN UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: 'SIR-PTCY' RESULTS IN 249 PATIENTS**

**A NEW HOPE IN THE TREATMENT OF STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE (SR-GVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT): RUXOLITINIB**

**AZACITIDINE IS SAFE AND ACTIVE IN THE TREATMENT OF STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST-DISEASE - INTERIM RESULTS OF THE PHASE II AZTEC TRIAL**

**BASILIXIMAB AS TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EFFICACY AND TOLERANCE OF NILOTINIB IN PATIENTS WITH REFRACTORY CHRONIC GVHD WHO ARE REFRACTORY/INTOLERANT TO IMATINIB: A PROSPECTIVE MULTICENTER PHASE II STUDY OF THE SFGM-TC**

**EVALUATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC ASSESSMENT OF ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE UPPER GASTROINTESTINAL TRACT ACCORDING TO LERNER EARLY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**CYCLOSPORINE A ALONE VERSUS MYCOPHENOLATE MOFETIL PLUS CYCLOSPORINE A BASED GVHD PROPHYLAXIS FOR PATIENTS WITH AML UNDERGOING MUD TRANSPLANTATION. A STUDY FROM THE ALWP**

**TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE**

## Scientific Programme

**DIAGNOSTIC SIGNIFICANCE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD)**

**LONG TERM OUTCOMES OF RUXOLITINIB THERAPY IN STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN AND ADULTS**

**INVESTIGATING ANTIBIOTIC EXPOSURE AND RISK OF SEVERE ACUTE GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EFFICACY AND TOXICITY OF RUXOLITINIB IN PATIENTS WITH STEROID-RESISTANT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION**

**PATIENT CHARACTERIZATION AND SURVIVAL OUTCOMES IN PAEDIATRIC CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS: A POPULATION-BASED STUDY IN SWEDEN**

**CYTOKINE LEVELS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A MATCH-PAIR ANALYSIS OF HOME CARE VERSUS HOSPITAL CARE**

**FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH STEROID-RESISTANT GRAFT VERSUS HOST DISEASE COLONIZED BY ANTIBIOTIC-RESISTANT BACTERIA - SINGLE-CENTER ANALYSIS OF 15 PROCEDURES**

**INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE: RESULTS FROM A PROSPECTIVE MULTICENTRE ANALYSIS OF 2 COHORTS**

**THE CXCL9 POLYMORPHISM RS884304 COUNTERACTS CALCINEURIN-INHIBITOR REPRESSION OF EARLY CXCL9 RECONSTITUTION AND ASSOCIATES WITH SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE**

**EARLY INTRODUCTION OF RUXOLITINIB FOR CHILDREN WITH GRAFT VERSUS HOST DISEASE - A STITCH IN TIME SAVES NINE**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE AS AN EFFECTIVE STRATEGY FOR GVHD PREVENTION IN BOTH HLA-MATCHED AND MISMATCHED ALLOGENEIC TRANSPLANTS**

**SERUM AUTOANTIBODIES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY**

**OPTIMIZED STARTING DOSE OF CYCLOSPORINE REDUCES RISK OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**SUCCESS OF IMMUNOSUPPRESSION IN PATIENTS WITH CHRONIC GVHD: ANALYSIS ON 108 ADULT LONG-TERM SURVIVORS AFTER MATCHED AND HAPLO HSCT**

**INCIDENCE AND OUTCOME OF LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE DURING TAPERING OR AFTER STOPPING CALCINEURIN INHIBITORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING AND MATCHED UNRELATED COMPARED TO HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, A STUDY ON BEHALF OF GETH**

**MESENCHYMAL STROMAL CELLS (MSC) FOR STEROID-REFRACTORY ACUTE GVHD, A SINGLE CENTER PHASE I/II TRIAL**

**T-LYMPHOCYTE TRANSCRIPTIONAL SIGNATURE IN ECP-TREATED PAEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE**

**EFFICACY OF LOW-DOSE RUXOLITINIB AS SAVAGE THERAPY IN HEAVILY PRETREATED PATIENTS WITH MODERATE/SEVERE STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE**

## Scientific Programme

**RESTRICTIVE USE OF INTRAVENOUS ANTIBIOTICS IN ALLOGENEIC SCT PTS WITH FEVER DUE TO CYTOKINE RELEASE SYNDROME ALLOWS MICROBIOTA PROTECTION WITHOUT INCREASE OF INFECTIONS AND TRM**

**EXTRACORPOREAL PHOTOPHERESIS (ECP) AS FIRST-LINE TREATMENT FOR ACUTE GVHD (AGVHD) IN PEDIATRIC PATIENTS WHO UNDERWENT T-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (APLO-HSCT)**

**EFFICACY OF METHOXSALEN STERILE SOLUTION IN CONJUNCTION WITH THE THERAKOS (R) CELLEX (R) PHOTOPHERESIS SYSTEM IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: INTERIM ANALYSIS**

**MICRO RNA PROFILING OF ACOUSTICALLY-ISOLATED EXTRACELLULAR VESICLES IDENTIFIES POTENTIAL BIOMARKERS FOR POST-ALLO-HSCT COMPLICATIONS**

**COLONIZATION PLAYS AN IMPORTANT ROLE IN THE OUTCOME OF ALLOGENEIC TRANSPLANTATION**

**ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) SCORE AT THE ONSET OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PREDICTING OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION-A RETROSPECTIVE ANALYSIS**

**CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS**

**COMPARISON OF EXCLUSIVE POSTTRANSPLANT CYCLOPHOSPHAMIDE VERSUS A CALCINEURIN INHIBITOR BASED REGIMEN AS GVHD PROPHYLAXIS IN ALLOGENEIC BONE MARROW TRANSPLANTATION FROM HLA IDENTICAL SIBLING**

**SIROLIMUS VERSUS CYCLOSPORINE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND MYCOPHENOLATE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL TRANSPLANTS: A RETROSPECTIVE ANALYSIS OF ONE SINGLE INSTITUTION**

Mario Andres Sanchez Salinas, Rafael Hernani Morales, Ana Benzaquen Vallejos, Juan Carlos Hernandez Boluda, Ariadna Perez Martinez, Paula Amat Martinez, Montserrat Gomez Calafat, Rosa Goterris Viciado, Carlos Solano Vercet (Spain)

**TARGETED SEQUENCE CAPTURE METAGENOMICS (VIROCAP) TO DETECT VIRUS IN STOOL SAMPLES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS**

**EXTRACORPOREAL PHOTOPHERESIS AND PRODUCTION OF SERUM IL-34 AND ELAFIN IN CHRONIC GRAFT VERSUS HOST DISEASE**

**IMPACT OF UPPER AND LOWER ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE ON GRADING AND OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS IN 122 CONSECUTIVE PATIENTS**

Monica Poiani, Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Marianna Mariani, Giorgia Micucci, Chiara Montagna, Giuseppina Urbano, Federica Monaco, Giuseppe Tarantino, Irene Federici, Attilio Olivieri (Italy)

**PRELIMINARY EXPERIENCE WITH THE USE OF RUXOLITINIB, IBRUTINIB OR IMATINIB FOR THE TREATMENT OF ACUTE OR CHRONIC GVHD**

**RUXOLITINIB WITH OR WITHOUT IBRUTINIB AS AN ALTERNATIVE FIRST LINE THERAPY FREE OF CORTICOSTEROIDS OR CALCINEURIN INHIBITORS IN TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE**

**CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS**

**IMPACT OF KIR/HLA INCOMPATIBILITIES AFTER POSTTRANSPLANT CYCLOPHOSPHAMIDE BASED T CELL-REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## **Scientific Programme**

**ELEVATED PTH LEVELS AMONG CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS AND OTHER LONG TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION**

**ACUTE GVHD INCIDENCE IN MISMATCHED UNRELATED DONOR HSCT IN PAEDIATRIC ADULT PATIENTS: A STUDY FROM THE TURIN METROPOLITAN TRANSPLANT CENTER**

**PRACTICAL IMPLEMENTATION OF THE NIH DIAGNOSTIC CRITERIA FOR ORAL CHRONIC GVHD IN A MULTIDISCIPLINARY TEAM IN THE LATE FOLLOW UP OF ALLOGENIC HSCT PATIENTS**

**THE IMPACT OF ANTIBIOTIC-MEDIATED MODIFICATION OF THE INTESTINAL MICROBIOME ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SYSTEMATIC REVIEW AND META-ANALYSIS**

**CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON'S JELLY IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE**

**PREDICTIVE ROLE OF ENDOSCOPIC/HISTOLOGICAL EXAMINATIONS FOR GASTRO-INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELLS TRANSPLANT: 'A POSTERIORI' ANALYSIS IN A SINGLE CENTER**

**THE INCIDENCE, RISK FACTORS, AND OUTCOMES OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROGNOSTIC CT FINDINGS AROUND THE ONSET OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE**

**THYMOGLOBULIN AND GRAFALON EFFECT ON ALLOGENEIC STEM CELL TRANSPLANT - POOLED DATA FROM WROCLAW MEDICAL UNIVERSITY, POLAND AND UNIVERSITY MEDICAL CENTER LJUBLJANA, SLOVENIA**

**THE ROLE OF LOW-DOSE ANTI-THYMOCYTE GLOBULIN IN MATCHED SIBLING DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES**

**NEPHROTIC SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AS A FORM OF CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE**

**CORRELATION AMONG TOTAL NUCLEATED CELLS (TNC), CD34+, CD3+ CELL CONTENT IN G-CSF-PRIMED BONE MARROW COLLECTIONS AND THEIR RELATIVE INFLUENCE ON DEVELOPMENT OF ACUTE GVHD**

**PREDICTION FOR LETHAL ACUTE GRAFT VERSUS HOST DISEASE AND NON-RELAPSE MORTALITY BY EARLY PLASMA BIOMARKERS: A SINGLE CENTER RETROSPECTIVE STUDY IN JAPAN**

**RUXOLITINIB IN THE TREATMENT OF CORTICOSTEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD): ONE SINGLE CENTER EXPERIENCE**

**OUTCOME OF PATIENTS ALIVE AT 1-YEAR POST ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM A SINGLE INSTITUTION**

**RUXOLITINIB IN STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: EXPERIENCE IN OUR CENTRE**

**LOW-DOSE OF RUXOLITINIB: AN EFFECTIVE THERAPY FOR REFRACTORY BOS PATIENTS**

**SIROLIMUS BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PAEDIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR BENIGN DISEASE**

## Scientific Programme

**DETECTION OF BIOMARKERS PREDICTIVE OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY**

**OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) AFTER PD-1 BLOCKADE IN RELAPSED/REFRACTORY (R/R) LYMPHOMAS: A SINGLE CENTER EXPERIENCE**

**CD3+ DOSE IN PERIPHERAL BLOOD PROGENITOR CELLS PRODUCTS FOR ALLOTRANSPLANT FROM MATCHED UNRELATED DONORS FOR AML: IMPACT ON CHRONIC GRAFT VERSUS HOST DISEASE AND SURVIVAL**

**CYCLOPHOSPHAMIDE FOR SALVAGE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE ANALYSIS**

**A ROLE OF METHOTREXATE IN THE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE - A MULTICENTER OBSERVATIONAL STUDY ON BEHALF OF POLISH ADULT LEUKEMIA GROUP (PALG)**

**EVALUATION OF EXTRACORPOREAL PHOTOPHERESIS USED AS SECOND-LINE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HSCT IN A BRAZILIAN CENTER**

**THE OPTIMAL GVHD PROPHYLAXIS IN UNRELATED TRANSPLANTATIONS OF NON-MANIPULATED HEMATOPOIETIC STEM CELLS IN CHILDREN**

**ANALYSIS OF HISTOLOGY'S IMPACT IN PATIENTS WITH ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE**

**IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT). UNICENTRIC EXPERIENCE**

**FECAL MICROBIOTA TRANSPLANTATION FOR TREATING STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE OF THE GUT: A PILOT STUDY**

**EARLY RECOVERY OF LYMPHOCYTES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS RISK FACTOR OF CGVHD**

**FAVORABLE OUTCOME USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN HAPLOIDENTICAL (HAPLO-SCT) AND MATCHED RELATED DONORS (MRD): SINGLE CENTER EXPERIENCE IN CHILE**

**COMBINED THERAPY WITH MSC INFUSIONS TO OVERCOME STEROID-DEPENDENCY IN A CASE OF SEVERE PULMONARY CGVHD**

**MULTIPLE STRICTURES OF THE SMALL INTESTINE DEMANDING SURGICAL INTERVENTION AS A COMPLICATION OF GRAFT VERSUS HOST DISEASE: A CASE REPORT**

**A REMARKABLY LONG REMISSION ACHIEVED WITH IBRUTINIB MONOTHERAPY IN A PATIENT WHO WAS DIAGNOSED WITH STEROID REFRACTORY SCLEROSING CHRONIC GVHD**

**INCREASED RISK OF ACUTE GVHD IN PATIENTS WITH MYELOFIBROSIS AFTER ALLO TRANSPLANT IN THE ABSENCE OF JAK-STAT INHIBITION**

**AUTOIMMUNE MYOSITIS AS PARANEOPLASTIC COMPLICATION OF A SQUAMOUS CELL CARCINOMA OF THE TONGUE AFTER SEVERE CHRONIC GRAFT VERSUS HOST DISEASE**

**UNUSUAL CAUSE OF DYSPNEA IN POST-TRANSPLANT PATIENT**

## Scientific Programme

e-Posters  
08:30 - 19:00

ePoster Area

### Graft-versus-host disease - preclinical and animal models

**DIETARY STEARIC ACID LEADS TO A SEVERE AGVHD BY MODULATING THE GUT MICROBIOTA AND GLUCOSE METABOLISM**

**GRANULOCYTE COLONY-STIMULATING FACTOR-PRIMED DONOR T CELLS ATTENUATE MURINE ACUTE GVHD THROUGH REGULATING T CELL DIFFERENTIATION IN TARGET ORGANS**

**MTOR REGULATE GENERATION AND FUNCTION OF PMN-MDSCS AND PLAY PROTECTION ROLE IN ACUTE GRAFT-VERSUS-HOST DISEASE**

**FULL REGULATORY T CELL RECONSTITUTION BEFORE T CELL TRANSFER PREVENTS GRAFT-VERSUS-HOST DISEASE BY SUPPRESSING COSTIMULATION AND T CELL ACTIVATION IN A HAPLOIDENTICAL MODEL**

**TARGETING OF CHEMOKINE RECEPTOR 7 PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE**

**ENHANCING REGULATORY T CELL FUNCTION AND HOMING TO THE GUT TO IMPROVE GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER ADOPTIVE TRANSFER IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION**

**LYG1-DEFICIENT DONOR SPLENOCYTES ATTENUATED THE SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE VIA SKEWING CD4+ T CELL POLARIZATION TOWARDS TREG CELLS**

**ATTENUATION OF MURINE CHRONIC GRAFT VERSUS HOST DISEASE BY THE NRF2 ACTIVATOR MANGIFERIN**

**CHEMOTHERAPY AND INFLAMMATION INDUCED DAMAGE OF INTESTINAL EPITHELIUM IS ASSOCIATED WITH INCREASED T CELL CHEMOTAXIS**

**INKT CELLS PROMOTE IMMUNE TOLERANCE BY SELECTIVE DENDRITIC CELL APOPTOSIS**

**ACTIVE PARTICIPATION OF CXCR4+ T LYMPHOCYTES IN ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC TRANSPLANTATION**

**A MURINE MODEL REVEALS A CRITICAL ROLE FOR REACTIVE OXYGEN SPECIES IN HYPERACUTE GRAFT-VERSUS-HOST DISEASE**

**MAPPING THE ROAD OF GVHD AND GVT. A LONGITUDINAL STUDY OF IMMUNE-TRANSCRIPTOME SIGNATURES AS NOVEL APPROACH TO SOLVE POST-ALLOGENEIC TRANSPLANTATION DILEMMAS**

**CELL-FREE DNA LEVELS ARE INCREASED IN ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS AND MICE**

**DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION**

**ENDOTHELIAL MICROPARTICLES DELIVERING LNCRNA NEAT1 ARE INVOLVED IN THE PATHOPHYSIOLOGY OF AGVHD FOLLOWING ALLO-HSCT**

**B-T CELL INTERACTIONS IN GRAFT-VERSUS-HOST DISEASE**

**IDENTIFICATION OF POTENTIAL MICROBIOME MARKERS FOR AGVHD EARLY DIAGNOSIS**

## Scientific Programme

e-Posters  
08:30 - 19:00

ePoster Area

### Granulocyte and osteoclast disorders

**HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR OSTEOPETROSIS**

e-Posters  
08:30 - 19:00

ePoster Area

### Haematopoietic stem cells

**HAPLOIDENTICAL DONOR BEATS MATCHED SIBLING DONOR FOR PRE-TRANSPLANTATION MRD POSITIVE ALL: A PHASE 3 BIOLOGICALLY RANDOMIZED STUDY**

**RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED RELATED DONOR WITH TCR $\alpha\beta$ + /CD19+-DEPLETION AND A FIXED DOSE MEMORY T CELL (CD45RA-DEPLETED) ADD-BACK**

**CLONAL DYNAMICS AND GENOMIC INTEGRITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN HUMAN ALLOGENEIC TRANSPLANTATION RECIPIENTS**

**ALLOGENEIC TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELL GRAFTS RESULTS IN A MASSIVE DECREASE OF PRIMITIVE HEMATOPOIETIC PROGENITOR FREQUENCIES IN RECONSTITUTED BONE MARROWS**

**TREATMENT OF PURE RED CELL APLASIA AFTER MAJOR ABO INCOMPATIBLE ALLOGENIC STEM CELL TRANSPLANTATION: A FRENCH RETROSPECTIVE STUDY**

**FEASIBILITY AND OUTCOMES OF A THIRD ALLOGENEIC HAEMATOPOETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM THE ALWP OF EBMT**

**CHANGES IN VIABILITY MARKERS OF HAEMATOPOIETIC STEM CELLS FOLLOWING LONG-TERM CRYOPRESERVATION**

**HIGH PRE-TRANSPLANT INTERLEUKIN-18 IS ASSOCIATED WITH POOR HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND PREDICTS INCREASED NON-RELAPSE MORTALITY**

**MICROBIAL DIVERSITY, SURVIVAL, AND ACUTE GVHD IN ADULT RECIPIENTS OF ALLO-HSCT AFTER MYELOABLATIVE CONDITIONING: RESULTS OF A NUTRITIONAL INTERVENTION TRIAL**

**UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS**

**RECONSTRUCTION OF THE DONOR-RECIPIENT HAEMATOPOIETIC CELL PHYLOGENY USING SOMATIC MUTATIONS TO ESTABLISH NUMBERS OF ENGRAFTING LONG-TERM HSCS IN REAL-WORLD TRANSPLANTATION**

**SUCCESSFUL CLEARANCE OF DONOR SPECIFIC ANTI-HLA ANTIBODIES AFTER DESENSITIZATION WITH RITUXIMAB, VELCADE AND PLASMA-EXCHANGE FOLLOWED BY A HAPLOIDENTICAL STEM CELL TRANSPLANTION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

**IMPACT OF PRE-TRANSPLANTATION MINIMAL RESIDUAL DISEASE DETERMINED BY FLOW CYTOMETRY ON OUTCOME OF ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**ECONOMIC BURDEN OF CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SPANISH MULTICENTER, RETROSPECTIVE STUDY**

## **Scientific Programme**

**INCIDENCE AND OUTCOME OF CLONAL AND MALIGNANT TRANSFORMATION (CMT) AMONG PEDIATRIC PATIENTS WITH INHERITED BONE MARROW FAILURE SYNDROMES (IBMFSS)**

**IMPACT OF POST-TRANSPLANT IMMUNOSUPPRESSION WEAN VS. BOOST IN EARLY MIXED CHIMERISM FOLLOWING G-CSF-PRIMED MARROW TRANSPLANT IN THALASSEMIC PATIENTS**

**COMPARISON OF THE CONDITIONING REGIMENS WITH TMLI, NON-RADIATION AND TBI FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**VALIDATION OF DISEASE RISK COMORBIDITY INDEX (DRCI) FOR OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) WITH PARTIALLY T-CELL DEPLETED GRAFT**

**ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PRETREATED WITH JAK1/JAK2 INHIBITORS**

**THE DETERMINATIVE ROLE OF PATIENT-CONTROLLED-ANALGESIA (PCA) IN THE EARLY COURSE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HIGH SURVIVAL RATE AND LOW INCIDENCE OF AGVHD AFTER CD34+ STEM CELLS SELECTION AND CD3+ T CELLS ADDBACK IN PEDIATRIC MUD HSCT**

**IMPACT OF ABO INCOMPATIBILITY ON OUTCOMES AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA**

**COMPARISON OF OUTCOMES AFTER HAPLOIDENTICAL VERSUS UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER REVIEW**

**EFFECT OF DIFFERENT TIMINGS OF UMBILICAL CORD CLAMPING ON THE LEVEL OF CD34+ CELLS IN FULL-TERM NEONATES**

**SEQUENTIAL CONDITIONING REGIMEN (FLAMSA-BU-MEL) IN HLA-MATCHED OR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY MYELOID DISEASE**

**SEQUENCE CYTOREDUCTIVE CHEMOTHERAPY FOLLOWED BY MA CONDITIONING REGIMEN HSCT WITH INTERMEDIATE - OR ADVERSE RISK AML IN CR: A SINGLE CENTER STUDY**

**INVESTIGATION OF VIROLOGICAL FEATURES AND CLINICAL OUTCOMES ASSOCIATED WITH PRE-ENGRAFTMENT CYTOMEGALOVIRUS DNAEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS**

**CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE AS A PREDICTOR OF ENGRAFTMENT AND SURVIVAL IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

**USE OF PLERIXAFOR IN POOR MOBILIZER PATIENTS WITH MYELOMA AND LYMPHOMA: CLONOGENIC CAPACITY AND ENGRAFTMENT DATA**

**OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRICS: A SINGLE CENTER EXPERIENCE FROM INDIA**

**RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: LONG TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA**

**PRE-EMPTIVE USE OF SORAFENIB COMBINED WITH DLI POST HSCT IN AML FLT3+: A SINGLE CENTER EXPERIENCE**

**USE OF ELTROMBOPAG FOR THE MANAGEMENT OF POOR GRAFT FUNCTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN**

## Scientific Programme

**TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH ELTROMBOPAG**

**EFFICACY OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED TO CHEMOTHERAPY AS POST-REMISSION TREATMENT FOR CHILDREN WITH INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION**

**THE TREATMENT OF BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA IRREVERSIBLY DEPLETES NAÏVE T LYMPHOCYTES**

**DESENSITIZATION PROTOCOL IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH ANTI-HLA DONOR-SPECIFIC ANTIBODIES (DSA): A SINGLE-CENTER EXPERIENCE**

**ASSOCIATION BETWEEN METABOLIC ALTERATION WITH TYPE AND INDICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR PATIENTS RECEIVING UMBILICAL CORD BLOOD TRANSPLANTS AT THE ROYAL MARSDEN HOSPITAL BETWEEN 2007 AND 2017**

**HIGHER COST AND NO SURVIVAL BENEFIT WITH ADDITION OF RITUXIMAB TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL**

**ASSOCIATION BETWEEN METABOLIC ALTERATIONS WITH AGE AND GENDER OF PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HAPLOIDENTICAL HSCT IN CHILDREN WITH VERY HIGH-RISK HAEMATOLOGIC MALIGNANCIES: A SINGLE-CENTRE EXPERIENCE**

**COMPARATIVE STUDY OF THE HEMATOPOIETIC RECONSTITUTION**

**INFUSED TOTAL NUCLEATED CELL DOSE IS NOT ASSOCIATED WITH ENGRAFTMENT IN AUTOLOGOUS STEM CELL TRANSPLANTATION**

**A COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND BFM 95 CHEMOTHERAPY PROTOCOL IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA**

**THE IMPACT OF CD34+ CELL AND IMMUNEFFECTOR CELL DOSE ON TRANSPLANT OUTCOMES**

**TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANTATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY**

**OUTCOME OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**MOTIVATION FOR ANTIFUNGAL USE IN PEDIATRIC HSCT PATIENTS IN AN INSTITUTION IN SOUTHERN BRAZIL**

**IMPACT OF THE USE OF GRANULOCYTIC COLONY-STIMULATING FACTOR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RARE FORMS OF PRIMARY IMMUNODEFICIENCIES (PIDS) IN ARGENTINA**

**PHASE II STUDY OF PLERIXAFLOL AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL, PET POSITIVE AFTER TWO R-DHAP**

## **Scientific Programme**

**THE EFFECT OF CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE ON THE HEMATOPOIETIC RECOVERY AND SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION**

**THE EVENTUAL ROLE OF DONOR AND RECIPIENT VITAMIN D LEVELS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SETTING**

**AVERAGE LENGTH OF HOSPITAL STAY FOR PEDIATRIC BLOOD AND MARROW TRANSPLANTS IN THE BACKDROP OF CELL SOURCE, TRANSPLANT TYPE AND OUTCOME**

**ONE CENTER EXPERIENCE IN OFFLINE TECHNIQUE VALIDATION WITH BIOLOGICAL QUALITY TESTS**

**A MONOCENTRIC CLINICAL OBSERVATION OF ALLOGENEIC TRANSPLANTATION IN 22 PATIENTS WITH ACUTE MEGAKARYOCYTIC LEUKEMIA**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN SCIENTIFIC CENTRE OF PEDIATRICS AND CHILD SURGERY**

**THE OUTCOME OF ALLOTRANSPLANT USING TBF CONDITIONING FROM MATCHED SIBLING RELATED DONORS IN HIGH RISK MYELOYDYSPLASIA AND ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE SINGLE CENTER EXPERIENCE**

**EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA: RETROSPECTIVE ANALYSIS IN OUR CENTER**

**CARDIOVASCULAR RISK IN PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**INFECTIONS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS IN PERU: EXPERIENCE OF A REFERRAL CENTER**

**HAEMATOPOIETIC STEM CELL PRODUCT VIABILITY: A COMPARATIVE STUDY BETWEEN BAGS AND VIALS**

**TRANSFUSION SUPPORT IN THE FIRST 30 AND 100 DAYS AFTER HAPLOIDENTICAL VERSUS HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MACS IN A PERUVIAN HEALTH CHILDRENS INSTITUTE: THREE-YEAR EXPERIENCE**

**COLLECTION, CRYOPRESERVATION AND AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELLS IN KAUNAS, LITHUANIA 2015-2019**

**EVALUATION OF OVERALL SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT): UNICENTRIC EXPERIENCE**

**MONITORING OF THE EXPRESSION OF THE VEGF-A GENE (VASCULAR ENDOTHELIAL GROWTH FACTOR) DURING THE EVOLUTION OF PEDIATRIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION. A PILOT STUDY**

**REFRACTORY T-CELL CUTANEOUS LYMPHOMA TREATED WITH ALLOGENEIC HAPLOIDENTIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT**

**VITAMIN D DEFICIENCY AND OUTCOMES IN ADULT ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE OVER LAST YEARS**

## Scientific Programme

### CAUSES OF COMPLICATIONS IN ADULTS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

e-Posters  
08:30 - 19:00

ePoster Area

## Haemoglobinopathy and inborn errors

**SUCCESSFUL HLA-MISMATCHED HSCT IN PAEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES USING ATG SEROTHERAPY AND POSTTRANSPLANT CYCLOPHOSPHAMIDE**

**OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH CEREBRAL ADRENOLEUKODYSTROPHY VARY BY DONOR CELL SOURCE, CONDITIONING REGIMEN, AND STAGE OF CEREBRAL DISEASE STATUS**

**OUTCOME OF NON MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE: A 100 PATIENT EXPERIENCE FROM SAUDI ARABIA**

**HIGH DOSE STEM CELL THERAPIES, LIKE MGTA-456, ENABLE COMPLETE NEURAL AND PERIPHERAL DISEASE CROSS-CORRECTION THROUGH RAPID AND ROBUST HEMATOPOIETIC ENGRAFTMENT**

**HLA SET-UP IS A MAJOR PREDICTOR OF ENGRAFTMENT IN HAPLO-IDENTICAL TRANSPLANT FOR SEVERE THALASSEMIA (ST) USING POST-CYCLOPHOSPHAMIDE (PTCY)**

**CTLA4IG-BASED T CELL COSTIMULATION BLOCKADE IN PTCY BASED HAPLOIDENTICAL HCT FOR THALASSEMIA MAJOR [TM] AND SICKLE CELL DISEASE [SCD] RESULTS IN IMPROVED DISEASE-FREE SURVIVAL WITHOUT GVHD**

**LENTIGLOBIN GENE THERAPY TREATMENT OF TWO PATIENTS WITH TRANSFUSION-DEPENDENT  $\beta$ -THALASSEMIA**

**BONE MARROW TRANSPLANT IN PATIENTS WITH SICKLE CELL ANAEMIA. EXPERIENCE IN ONE CENTRE**

Marina García Morín, Laura Escobar Fernández, Eduardo Bardón Cancho, Cristina Beléndez Bieler, Jorge Huerta Aragonés, Carmen Garrido Colino, Cristina Mata Fernández, Elena Cela de Julián (Spain)

**OUTCOMES IN CEREBRAL ADRENOLEUKODYSTROPHY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

**NEURODEVELOPMENTAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MUCOPOLYSACCHARIDOSIS TYPE II: A PROSPECTIVE, LONGITUDINAL STUDY**

**HEMATOPOIETIC RECOVERY AND TRANSFUSION NEED AFTER HAPLOIDENTICAL TRANSPLANTATION IN BETA THALASSEMIA PATIENTS**

**PRE- AND POST-TRANSPLANT RITUXIMAB REDUCES THE HIGH INCIDENCE OF PRIMARY GRAFT FAILURE AND IMMUNE-MEDIATED CYTOPENIA FOLLOWING CORD BLOOD TRANSPLANT FOR LYSOSOMAL STORAGE DISEASE IN CHILDREN**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: THE SPANISH EXPERIENCE**

**LONG-TERM QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD**

**HIGH INCIDENCE OF AUTOIMMUNE CYTOPENIAS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE: THE IMPACT OF MATCHED UNRELATED DONOR**

## Scientific Programme

**ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI MAY REDUCE RISK OF GRAFT FAILURE IN MATCHED SIBLING DONOR ALLOGENEIC HSCT IN ADULT SICKLE CELL PATIENTS**

**A PHASE II STRATIFIED TRIAL TO ASSESS HAPLOIDENTICAL T-DEPLETED STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE WITH NO AVAILABLE SIBLING DONOR**

**COMBINED UMBILICAL CORD BLOOD AND BONE MARROW FROM HLA-IDENTICAL SIBLING DONORS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA MAJOR**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF METABOLISM USING ALTERNATE DONORS: A PROSPECTIVE SINGLE STUDY**

**UMBILICAL CORD BLOOD TRANSPLANTATION IN CHILDREN WITH LEUKODYSTROPHIES: SINGLE CENTER EXPERIENCE IN CHINA**

**PEARSON SYNDROME IN A PATIENT TRANSPLANTED FOR DIAMOND-BLACKFAN ANEMIA**

**CHALLENGES AND SUCCESSES WITH PRE-TRANSPLANT IMMUNE SUPPRESSION IN ALTERNATIVE DONOR TRANSPLANTS**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CLASS 3 THALASSEMIA MAJOR USING POST-TRANSPLANT CYCLOPHOSPHAMIDE**

e-Posters  
08:30 - 19:00

ePoster Area

### Immunodeficiency diseases and macrophages

**IMPACT OF DIFFERENT *EX VIVO* T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY**

**OUTCOMES AND IMMUNE RECONSTITUTION AFTER T-CELL REplete HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FOR PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCIES**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY IN JAPAN: OVERVIEW OF A NATIONWIDE RETROSPECTIVE ANALYSIS**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY IN JAPAN: A NATIONWIDE RETROSPECTIVE ANALYSIS**

**UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY: SINGLE-INSTITUTION EXPERIENCE IN CHINA**

**IMMUNODEFICIENCY - CENTROMERIC INSTABILITY - FACIAL DYSMORPHISM (ICF) SYNDROME: EVALUATION OF CHARACTERISTICS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THIOTEPA VERSUS MELPHALAN CONTAINING CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATIONS WITH TCR $\alpha\beta$ /CD19 GRAFT DEPLETION FOR PRIMARY IMMUNODEFICIENCIES**

**IMPROVED TRANSPLANT SURVIVAL AND LONG-TERM DISEASE OUTCOME FOR CHILDREN WITH CD40 LIGAND DEFICIENCY**

## Scientific Programme

**HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES INCLUDING IMMUNE RECONSTITUTION IN PRIMARY IMMUNODEFICIENCIES: 5 YEARS OF SINGLE CENTRE EXPERIENCE**

**OUTCOMES OF STEM CELL TRANSPLANT FOR RIPK1 DEFICIENCY: A SINGLE CENTRE EXPERIENCE**

**IMPROVING THE RESULT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY WITH SERIOUS INFECTION IN DEVELOPING COUNTRIES USING RIC REGIMENT**

**SINGLE-CENTER EXPERIENCE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCR  $\alpha\beta$  DEPLETION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY SYNDROMES**

**HAPLO-IDENTICAL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY - A TERTIARY CARE CENTRE EXPERIENCE FROM SOUTH INDIA**

**NECROTIZING ENTEROCOLITIS IN A TWO-MONTH-OLD SCID PATIENT AFTER BONE MARROW TRANSFUSION - SURGICAL INTERVENTION AT DAY +1: YES OR NO?**

**UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH TWO DIFFERENT CONDITIONING REGIMEN FOR CHRONIC GRANULOMATOUS DISEASE: SINGLE-INSTITUTION EXPERIENCE IN CHINA**

**THE OUTCOMES OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE IN CHILDREN WITH RAG GENE MUTATION**

**LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) IN ADA-SCID PATIENTS: THE SHADOW OF MALIGNANCIES**

**HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR X-LINKED AGAMMAGLOBULINAEMIA COMPLICATED BY CHRONIC NOROVIRUS ENTEROPATHY**

**HEMATOPOETIC STEM CELL TRANSPLANTATION IN CD40 LIGAND DEFICIENCY**

**DIAGNOSTIC MARKERS FOR AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME**

**ALLOGENEIC HEMOTOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR CHRONIC GRANULOMATOUS DISEASE (CGD) IN CHILDHOOD**

e-Posters  
08:30 - 19:00

ePoster Area

## Infectious complications

**PNEUMOCYSTIS PNEUMONIA AFTER ALLOGENEIC HCT: A CASE-CONTROL STUDY ON RISK FACTORS, TIMING, AND PCR USE, FROM THE IDWP OF EBMT**

**UPPER AND/OR LOWER RESPIRATORY TRACT INFECTION CAUSED BY HUMAN CORONAVIRUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**SUCCESSFUL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH JCV-TARGETED T-CELL THERAPY**

**EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY**

## **Scientific Programme**

**TUBERCULOSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT**

**FAECAL MICROBIOTA TRANSPLANT (FMT) CAN REDUCE THE HIGH NRM ASSOCIATED WITH MULTI-DRUG RESISTANT ORGANISM (MDRO) COLONISATION PRIOR TO ALLOGENEIC HCT**

**EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY**

**USE OF LETERMIVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY**

**RISK OF INFECTIOUS COMPLICATIONS IN ADULT PATIENTS AFTER ALLOGENEIC HSCT DEPENDING ON THE SITE OF CENTRAL VENOUS CATHETER INSERTION - MULTICENTRE PROSPECTIVE STUDY**

**INFECTION PREVENTION PRACTICES AMONG EBMT HEMATOPOIETIC CELL TRANSPLANT CENTERS: A SURVEY OF THE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT**

**PRIMARY LETERMIVIR PROPHYLAXIS IN CMV SEROPOSITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE**

**HEV INFECTION IN HCT RECIPIENTS - RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) OF EBMT**

**THE ROLE OF COMBINATION PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTION AFTER EX VIVO AB T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT (HHCT) IN CHILDREN**

**IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY**

**COMPARISON OF IMMUNE CELL RESPONSE TO CYTOMEGALOVIRUS PROTEINS VERSUS PEPTIDES USING AN IFN- $\gamma$  ELISPOT ASSAY TO MONITOR CYTOMEGALOVIRUS-SPECIFIC IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HUMAN HERPESVIRUS TYPE 6 REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION: RISK FACTORS AND CLINICAL IMPACT**

**INCREMENTAL INPATIENT HEALTHCARE RESOURCE USE AND COSTS AMONG CMV SEROPOSITIVE ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS MANAGED THROUGH PREEMPTIVE APPROACH**

**POOR RECOVERY AND IMPAIRED FUNCTION OF V $\beta$ 1+ T CELLS IN REFRACTORY/RECURRENT CMV REACTIVATION AFTER HEMATOPOIETIC TRANSPLANTATION**

**SAFETY AND EFFICACY OF BRINCIDOFOVIR FOR REFRACTORY ADENOVIRUS INFECTION IN CHILDREN RECEIVING ALLOGENEIC SCT: A RETROSPECTIVE ANALYSES FROM THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION (AIEOP)**

**ALLOPLUS: RESULTS OF THE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS -POSITIVE PATIENTS, A RETROSPECTIVE STUDY OF THE SFGM-TC**

**SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A PROSPECTIVE STUDY TO MEASURE FEASIBILITY, SAFETY AND HEALTH CARE RESOURCE USE**

**FREQUENCY, RISK FACTORS AND OUTCOME OF ACTIVE TUBERCULOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## **Scientific Programme**

**INFECTIOUS COMPLICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA AFTER NEW AGENTS' THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION**

**SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION**

**CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION**

**FECAL MICROBIOTA TRANSPLANTATION IN CHILDREN TO TREAT ACUTE GVHD OR MULTI-DRUG RESISTANT BACTERIA COLONIZATION**

**VACCINATION AGAINST TICK-BORNE ENCEPHALITIS (TBE) AFTER AUTOLOGOUS AND ALLOGENEIC BONE MARROW TRANSPLANTATION**

**RIFAXIMIN USE FAVOURED MICAFUNGIN RESISTANT CANDIDA SPP INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT**

**IMPACT OF HHV-6 REACTIVATION AFTER T-REG/T-CON IMMUNOTHERAPY IN ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY**

**ADENOVIRUS INFECTIONS AFTER HCT: INFECTIOUS DISEASES WORKING PARTY RETROSPECTIVE EBMT REGISTRY STUDY**

**CLINICAL IMPACT OF COLONIZATION BY MULTIDRUG-RESISTANT ENTEROBACTERIACEAE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**POST-ALLOGENEIC TRANSPLANTATION PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, CLINICAL AND BIOLOGICAL FEATURES, TREATMENT AND OUTCOMES: A RETROSPECTIVE STUDY FROM THE SFGM-TC**

**RESPIRATORY VIRAL INFECTIONS IN ADULT PATIENTS UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION FROM UNRELATED DONORS AFTER MYELOABLATIVE CONDITIONING REGIMEN**

**EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS**

**RISK FACTORS AND CLINICAL OUTCOMES OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL AND MATCHED-SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**STANDARDIZED MONITORING OF CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY CAN IMPROVE RISK STRATIFICATION OF RECURRENT CYTOMEGALOVIRUS REACTIVATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**IMPACT OF LEVOFLOXACIN FOR PROPHYLAXIS OF PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTER ALLOGENEIC HSCT: A SINGLE-CENTER MATCHED ANALYSIS IN AN ENDEMIC COUNTRY FOR CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA**

**PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) AFTER HCT - A RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT**

**ORAL RIBAVIRIN IS A HIGHLY EFFICACIOUS TREATMENT FOR LOWER RESPIRATORY TRACT INFECTION DUE TO RESPIRATORY SYNCYTIAL OR PARAINFLUENZA VIRUS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS**

## **Scientific Programme**

**TIMING OF INDUCTION TREATMENT FOR REACTIVATION OF CYTOMEGALOVIRUS IMPACTS OVERALL SURVIVAL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT**

**PREDICTION OF BLOODSTREAM INFECTION RISK USING CITRULLINE AS BIOMARKER OF INTESTINAL MUCOSITIS IN HEMATO-ONCOLOGY PATIENTS**

**PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT**

**COMPARISON OF INFECTIOUS COMPLICATIONS AMONG PATIENTS RECEIVING UNMANIPULATED HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETED HAPLOIDENTICAL TRANSPLANT**

**THE CUMULATIVE INCIDENCE OF MULTIPLE DNA VIRUS REACTIVATION IS NOT DIFFERENT IN NON-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION AND UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION**

**NEUTROPHILS RESPONSE TO HUMAN CMV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

**CLINICAL EFFICACY OF LETERMIVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**AT-HOME FOSCARNET ADMINISTRATION IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION PATIENTS WITH CYTOMEGALOVIRUS INFECTION: A SAFETY FEASIBLE MODEL**

**EFFECTS OF THE ANTIBIOTICS CHANGE OR THE ADDITION OF ANTI-MRSA DRUGS FOR PERSISTENT FEBRILE NEUTROPENIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION**

**THERAPEUTIC DRUG MONITORING OF POSACONAZOLE AND SUBSEQUENT DOSING IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

**IS PREEMPTIVE STRATEGY ENOUGH? RELATIONSHIP BETWEEN CMV REACTIVATION AND STEROID THERAPY FOR GHVD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: 97 PATIENTS FROM TURKEY**

**PROPHYLAXIS WITH AZITHROMYCIN IN ALLOGENEIC CORD BLOOD TRANSPLANT AND ASSOCIATION WITH RELAPSE RATE AND TRANSPLANT OUTCOMES**

**REACTIVATED VARICELLA ZOSTER (VZV) INFECTION (SHINGLES), AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT) FOR HAEMATOLOGICAL DISEASE IN CHILDREN: A SIGNIFICANT PROBLEM AND PROPOSAL FOR FUTURE MANAGEMENT**

**LETERMIVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE**

**ANALYSIS OF CMV REACTIVATION RISK AFTER T CELL REPLETE HAPLOIDENTICAL AND MATCHED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ASPERGILLUS NON-FUMIGATUS INVASIVE ASPERGILLOSIS IN CHILDREN AND ADULTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) & CHEMOTHERAPY**

**INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS JIROVECI PROPHYLAXIS IN HEMATOLOGICAL PATIENTS TREATED WITH CHEMOTHERAPY, HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) AND CAR-T CELL THERAPY**

## **Scientific Programme**

**INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS**

**LOW RELAPSE RISK FOR REDUCED INTENSITY CONDITIONED ALEMTUZUMAB-BASED ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMAS IS OFFSET BY CYTOMEGALOVIRUS RISK: DATA FROM SINGLE CENTRE STUDY**

**PROPHYLACTIC DOSE TRIMETHOPRIM/SULFAMETHOXAZOLE DOES NOT LEAD TO DELAYED NEUTROPHIL AND PLATELET ENGRAFTMENT IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

**HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EPIDEMIOLOGICAL SCREENING FOR BACTERIAL RESISTANCE BY DIFFERENT TECHNIQUES IN ALLO-HSCT PATIENTS**

**INVASIVE MOLD DISEASE IN A REAL-WORLD HEMATO-ONCOLOGY SETTING: VALUE OF A DIAGNOSTIC-DRIVEN CARE PATHWAY**

**SINGLE CENTER ANALYSIS ON THE MANAGEMENT OF ACYCLOVIR RESISTANT HERPES SIMPLEX VIRUS STOMATITIS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**EARLY BACTEREMIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION WITHOUT THE USE OF PROPHYLACTIC ANTIBIOTIC: CHANGING EPIDEMIOLOGY AND ANTIMICROBIAL RESISTANCE (2016-2018)**

**DIAGNOSTIC YIELD OF BRONCHOALVEOLAR LAVAGE (BAL) IN HAEMATOLOGICAL PATIENTS AFTER ALLOGENEIC/ AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) - COMPARISON WITH BAL PERFORMANCE IN NON-TRANSPLANTED PATIENTS**

**A NOVEL EFFICIENCY STRATEGY TO PREVENT HBV-RELATED HEPATITIS AFTER ALLOGENEIC HSCT FROM HBSAG- POSITIVE DONORS TO RECIPIENTS**

**BK VIRUS EFFECT ON DEVELOPING LATE HEMORRHAGIC CYSTITIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS: SINGLE CENTER EXPERIENCE**

**VERSATILE EFFECTS OF LETERMIVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS**

**IMPACT OF A CHANGE IN ANTIBACTERIAL PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION IN ONE SINGLE CENTER**

**INTRAVESICAL INSTILLATION OF CIDOVIFIR IS EFFICIENT FOR THE TREATMENT OF BK VIRUS HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC TRANSPLANTATION**

**MANAGEMENT OF BK POLYOMA VIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE**

**RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RISK FACTORS FOR CYTOMEGALOVIRUS INFECTION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**IMPACT OF HYPOGAMMAGLOBULINEMIA ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**

**THE USE OF RIFAXIMINE IN ANTI-BACTERIAL PROPHYLAXIS IN PATIENT UNDERGOING HSCT**

## **Scientific Programme**

**BKV VIRUS - HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: INCIDENCE, SEVERITY AND RISK FACTORS**

**RUXOLITINIB FOR STEROID-REFRACTORY GVHD ABOLISHES ANTIVIRAL IMMUNE RESPONSE FOLLOWING T-CELL TRANSFER FOR REFRACTORY ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

**RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMOVIR PROPHYLAXIS**

**ISAVUCONAZOLE (ISA) USE IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) RECIPIENTS: A SINGLE-CENTER EXPERIENCE**

**TIME- AND THERAPY-DEPENDENT BACTERIURIA IN CHILDREN AND YOUNG ADULTS FOLLOWING ALLOGENEIC HSCT**

**PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF MARIBAVIR COMPARED WITH VALGANCICLOVIR FOR TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS (STUDY DESIGN)**

**INCIDENCE AND RISK FACTORS OF VIRAL COMPLICATIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM HUNGARY**

**CONTRIBUTING FACTORS TO PRE ENGRAFTMENT BACTEREMIA AND PNEUMONIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A LEBANESE SINGLE CENTER EXPERIENCE**

**UNICENTRIC STUDY: PROPHYLAXIS STRATEGY AGAINST GVHD WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (CPYT) AND ITS RELATIONSHIP WITH CYTOMEGALOVIRUS**

**EPIDEMIOLOGY AND CLINICAL FEATURES OF FEBRILE NEUTROPENIC EPISODES: THREE YEARS EXPERIENCE AT HEMATOLOGY WARDS**

**USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS**

**TOXOPLASMOSIS DISEASE AFTER ALLO-HSCT. WHAT HAVE WE LEARNT?**

**TUBERCULOSIS IN PATIENTS WHO RECEIVE AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. TWO CASE REPORT**

**POLYOMAVIRUS BK INFECTION IN BONE MARROW TRANSPLANTATION RECIPIENTS. A COMPARATIVE ANALYSIS ON CHILDREN AND ADULTS**

**LEFLUNOMIDE, SUCCESSFUL PRE-EMPTIVE THERAPY IN RESISTANT CYTOMEGALOVIRUS REACTIVATION IN A HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT**

**LETERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**INFECTIOUS COMPLICATIONS IN HEMATOLOGIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EARLY MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA - A SINGLE CENTER EXPERIENCE**

**CMV RETINITIS IN A STEM CELL TRANSPLANT RECIPIENT TREATED WITH FOSCARNET INTRAVITREAL INJECTION AND CMV SPECIFIC IMMUNOGLOBULIN**

## Scientific Programme

e-Posters  
08:30 - 19:00

ePoster Area

### Lymphoma

**LONG TERM SURVIVAL AFTER 2 YEARS EVENT FREE SURVIVAL IN RELAPSED DLBCL AFTER AUTOLOGOUS TRANSPLANTATION IN THE TWO RANDOMIZED TRIALS LY.12 AND CORAL**

**EXPLORATORY ANALYSIS OF BRENTUXIMAB VEDOTIN PLUS CHP (A+CHP) AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS (ECHELON-2): IMPACT OF CONSOLIDATIVE STEM CELL TRANSPLANT**

**BRENTUXIMAB VEDOTIN FOR RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN LYMPHOMA: A STUDY OF THE LWP-EBMT**

**ALLOGENEIC STEM CELL TRANSPLANTATION AS A CURATIVE OPTION IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH/GELTAMO STUDY**

**ADAM17 INHIBITOR INCB7839 WITH RITUXIMAB AS CONSOLIDATION AFTER AUTOLOGOUS HCT FOR DIFFUSE LARGE B CELL LYMPHOMA: A NOVEL RELAPSE PREVENTION STRATEGY**

**COMPARISON OF REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A CIBMTR ANALYSIS**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH NON-HODGKIN LYMPHOMA: THE SPANISH EXPERIENCE**

**EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS AFFECTED BY ADVANCED LYMPHOID MALIGNANCIES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY**

**BRENTUXIMAB-VEDOTIN IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY PRIOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HODGKIN LYMPHOMA: REAL-WORLD DATA FROM A TWO CENTERS STUDY**

**NON-MYELOABLATIVE CONDITIONING REGIMEN BEFORE T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ADVANCED LYMPHOMA**

**IMPACT OF KIR LIGAND MISMATCH AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY IN 383 PATIENTS FROM THE SFGM-TC**

**THE IMPACT AND CHALLENGES OF PERFORMING BEAM CONDITIONED AUTOLOGOUS TRANSPLANTS IN 'OLDER' PATIENTS WITH LYMPHOMA**

**ACCESSIBILITY AND IMPACT ON LONG-TERM OVERALL SURVIVAL OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS: A SINGLE INSTITUTION INTENTION-TO-TREAT ANALYSIS**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TRANSFORMED FOLLICULAR LYMPHOMA (FL): RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY FROM GELTH/GELTAMO GROUP**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSE AFTER AUTOLOGOUS TRANSPLANTATION**

**SIGNIFICANT ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA**

## **Scientific Programme**

**HIGH DOSE CHEMOTHERAPY TEAM FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA: RESULTS OF A PROSPECTIVE STUDY**

**AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIV+ AND HIV- LYMPHOMA PATIENTS: A PROPENSITY SCORE MATCHED ANALYSIS**

**AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR DOUBLE HIT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS**

**ALLOGENEIC STEM CELL TRANSPLANTATION CAN BE SUCCESSFULLY DELIVERED FOLLOWING BTKI THERAPY FAILURE FOLLOWING R-BAC RE-INDUCTION CHEMOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA**

**CLINICAL OUTCOMES OF EBV+ PTLD PATIENTS FOLLOWING HCT WHO FAIL RITUXIMAB: A RETROSPECTIVE CHART REVIEW STUDY FROM FRANCE**

**THE IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) ON THE OUTCOME OF POOR-RISK NON-HODGKIN LYMPHOMA (NHL): UPDATE OF A RETROSPECTIVE INTENT-TO-TRANSPLANT (ITT) ANALYSIS**

**REDUCING THE COST OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMAS AT LIMITED-RESOURCE CENTERS IN DEVELOPING COUNTRIES**

**COMPARISON OF MITOXANTRONE - MELPHALAN AND BEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS**

**NIVOLUMAB RE-CHALLENGE IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: WHERE IS THE PLACE FOR ALLOHSCT?**

**OUTCOME OF TRANSPLANT ELIGIBLE MANTLE CELL LYMPHOMA PATIENTS WITH FIRST-LINE REGIMENS IN A REAL-WORLD SETTING: A PORTUGUESE MULTICENTER RETROSPECTIVE ANALYSIS**

**EVALUATION OF FRACTIONATED ICE AS AN ALTERNATIVE OUTPATIENT OPTION FOR RELAPSED/REFRACTORY LYMPHOMAS**

**EFFICACY OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA**

**RISK FACTORS FOR INTENSIVE CARE UNIT ADMISSION IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

**AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA**

**DIFFERENT OUTCOMES WITH DIFFERENT DONORS IN ALLOGENEIC STEM CELL TRANSPLANTATIONS IN MALIGNANT LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE**

**THE IRISH EXPERIENCE OF THIOTEPA, CARMUSTINE AND ETOPOSIDE CONDITIONING PRIOR TO ASCT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS**

**TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA**

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS TREATMENT OPTION FOR RARE TRANSDIFFERENTIATION OF LYMPHOID NEOPLASMS INTO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS TO ACHIEVE LONG-TERM SURVIVAL**

**OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH PERIPHERAL T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)**

## Scientific Programme

**TREATMENT OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. A STUDY OF THE POLISH LYMPHOMA RESEARCH GROUP**

**PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH T-CELL LYMPHOMAS: PAVLOV UNIVERSITY EXPERIENCE**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA: TOXICITY AND SURVIVAL STUDY**

**AUTOIMMUNE COMPLICATIONS IN CHILDREN WITH HODGKIN DISEASE (HD) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT)**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIV-RELATED LYMPHOMA**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS OF 23 PATIENTS**

**NIVOLUMAB BASED RESPONSE ADAPTED TREATMENT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS**

**AUTOLOGOUS STEM CELL TRANSPLANT IN A SEROPOSITIVE A PATIENT WITH PLASMABLASTIC LYMPHOMA (PBL)**

**COMPARING THE EFFICACY AND TOXICITY BETWEEN TWO CONDITIONING REGIMEN IN LYMPHOMA PATIENTS IN WEST OF IRAN (BENDAMUSTIN) OR (CCNU) WITH (ETOPOSIDE, CITARABINE, MELPHALANE)**

e-Posters  
08:30 - 19:00

ePoster Area

### **Minimal residual disease, tolerance, chimerism and immune reconstitution**

**T CELL CHIMERISM AFTER HCT DOES NOT PREDICT FOR GRAFT LOSS IN NON-MALIGNANT DISEASES, AND IS A FAILURE OF MYELOSUPPRESSION RATHER GRAFT REJECTION**

**FASTER ENGRAFTMENT AND RECONSTITUTION OF INNATE-IMMUNITY AFTER ANTI-T -LYMPHOCYTE GLOBULINE (ATLG) THAN POST-TRANSPLANT-CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS AFTER MYELOABLATIVE CONDITIONING (MAC) PERIPHERAL-BLOOD-STEM-CELL (PBSC) ALLOGENEIC-TRANSPLANTATION (ALLO-SCT)**

**CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENEIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMIVIR**

**COMPARING OUTCOMES OF PATIENTS HAVING MIXED T CHIMERISM AND UNRELATED DONOR ALLOGRAFTS FOR ACUTE LEUKAEMIA/MDS TO PATIENTS WITH COMPLETE CHIMERISM - SINGLE CENTRE RETROSPECTIVE STUDY**

**CMV INFECTION IS ASSOCIATED WITH REDUCED THYMIC FUNCTION AND LESS REGULATORY T CELLS AFTER PEDIATRIC ALLOGENEIC HSCT**

**IMPACT OF PRE-TRANSPLANT MRD BURDEN MEASURED BY MULTICOLOR FLOW CYTOMETRY ON RELAPSE AND SURVIVAL IN AML PATIENTS UNDERGOING ALLO-SCT IN CR**

**FLOW-BASED PRE-TRANSPLANT MRD DETECTION STRONGLY IMPACTS ON THE OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION WITH AB T CELL DEPLETION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA**

## **Scientific Programme**

**CMV-SPECIFIC T CELL COUNTS EARLY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION STRATIFY THE RISK OF SUBSEQUENT CMV REACTIVATIONS: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY**

**IMPROVED RELAPSE-FREE-SURVIVAL IN PATIENTS WITH HIGH NATURAL KILLER CELL DOSES IN GRAFTS AND DURING EARLY IMMUNE RECONSTITUTION AFTER ALLOGENEIC TRANSPLANTATION WITH PERIPHERAL BLOOD STEM CELLS**

**POTENTIAL INFLUENCE OF IMMUNODEFICIENCY-RELATED HEREDITARY PREDISPOSITION GENE VARIANTS ON RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**COMPARABLE RESULTS OF PREEMPTIVE RECOMBINANT IL-2 AND DONOR LYMPHOCYTE INFUSION IN HEMATOLOGICAL MALIGNANCY PATIENTS WITH LATE-ONSET MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**SURVIVAL ANALYSIS ACCORDING TO MINIMAL RESIDUAL DISEASE BY FLOW CYTOMETRY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA**

**IMPACT OF RESIDUAL CIRCULATING TUMOR DNA STATUS POST ALLOGENEIC SCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: INTERIM RESULTS OF A PROSPECTIVE STUDY**

**EARLY CD4+ T CELL RECONSTRUCTION AS PREDICTOR FOR OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS: A VALIDATION COHORT ANALYSIS**

**PATTERN OF RECONSTITUTION OF RECENT THYMIC EMIGRANTS AFTER REDUCED INTENSITY CONDITIONING BASED ON TARGETED BUSULFAN IN PAEDIATRIC RECIPIENTS OF ALLOGENEIC HAEMATOPOETIC STEM CELL TRANSPLANTATION**

**A RISK SCORE SYSTEM BASED ON POST-TRANSPLANTATION MINIMAL RESIDUAL DISEASE FOR STRATIFICATION OF RELAPSE IN B-ALL PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION**

**OUTCOME OF CHILDREN WITH HEMATOLOGICAL MALIGNANCIES WHO DEVELOP MIXED DONOR CHIMERSIM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROPHYLACTIC HIGH-DOSE DONOR CD45RO+ MEMORY T-CELLS INFUSION AFTER ALLOGENEIC TRANSPLANTATION: SAFETY AND OUTCOME**

**MULTICOLOR FLOW CYTOMETRY PANEL WITH CD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT**

**NON-INVASIVE MONITORING OF MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE BY CIRCULATING CELL-FREE NUCLEIC ACIDS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**TORQUE TENO VIRUS AS BIOMARKER TO PREDICT COMPLICATIONS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PREEMPTIVE INTERFERON- $\alpha$  TREATMENT COULD PROTECT AGAINST RELAPSE AND IMPROVE SURVIVAL OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THE ADDITION OF BUSULFAN REDUCES THE INCIDENCE OF MIXED CHIMERISM FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA**

**A NEW MULTIVARIATE MODEL TO DESCRIBE IMPACT OF IMMUNE RECONSTITUTION ON THE DEVELOPMENT OF RELAPSE IN CHILDREN UNDERGOING ALLO-HSCT FOR HEMATOLOGIC MALIGNANCIES AT DAY +100**

## Scientific Programme

**ACQUISITION OF COMPLETE CHIMERISM IN BONE MARROW, PERIPHERAL BLOOD AND LEUKOCYTE SUBSETS DEPENDS ON THE TRANSPLANT SETTING AND CORRELATES WITH THE CLINICAL OUTCOME**

**EARLY LYMPHOID SUBSETS RECONSTITUTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AS PREDICTOR OF RELAPSE AND SURVIVAL IN ACUTE LEUKEMIAS**

**COMPARISON OF IMMUNE RECONSTITUTION BETWEEN 30MG/KG AND 60MG/KG ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANSPLANTATION**

**FUNCTIONAL IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COMPARISON OF PRE- AND POST-TRANSPLANTATION CYTOKINE RESPONSES IN STIMULATED WHOLE-BLOOD**

**MEASURABLE RESIDUAL DISEASE (MRD) TESTING FOR ACUTE LEUKEMIA IN EBMT TRANSPLANT CENTERS: A SURVEY ON BEHALF OF THE ALWP OF THE EBMT**

**TBF REGIMEN INDUCES FULL DONOR CHIMERISM AFTER ALLOGRAFTS IN MYELOFIBROSIS**

**REAL WORLD UTILITY OF TREATING MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA**

**COMPARISON OF IMMUNE RECOVERY IN CORD BLOOD AND T AND B DEPLETED HAPLOIDENTICAL GRAFTS RECIPIENTS**

**THE BCR-ABL P210 CHIMERIC TRANSCRIPT IN VITRO TRANSFER INTO BONE MARROW MESENCHYMAL STROMAL CELLS VIA EXOSOMES**

**PROGNOSTIC SIGNIFICANCE OF DONOR-SPECIFIC ISOAGGLUTININ RE-APPEARANCE IN ABO-MISMATCHED STEM CELL TRANSPLANT RECIPIENTS**

Maryam Pourabdollah, Christine Cserti, [Dennis Dong Hwan Kim](#), Eshetu Atenafu, Ivan Pasic, Zeyad Al-Shaibani, Aijun Law, Wilson Lam, Armin Gerbitz, Jeffery Lipton, Auro Viswabandya, Rajat Kumar, Jonas Mattson, Fotios Michelis, Nayana Soni, Jacob Pendergrast (Canada)

**IMMUNE-RECONSTITUTION OF LYMPHOCYTE SUBPOPULATIONS WITH RESPECT TO MSC-TREATMENT FOR STEROID REFRACTORY GVHD FOLLOWING HSCT**

**DAY+100 FULL DONOR CHIMERISM IN THE BONE MARROW CONFERS BETTER OVERALL SURVIVAL IN REDUCED INTENSITY CONDITIONED WITH ALEMTUZUMAB ALLOGENEIC STEM CELL TRANSPLANTATION FOR LYMPHOMAS**

**DONOR FACTORS INFLUENCE OUTCOMES OF PATIENTS RECEIVING DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION**

**DETERMINE PATIENTS AT RISK OF RELAPSE AND DEATH IN ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME USING CHIMERISM ON BONE MARROW SAMPLES AT DAY 28 AFTER HSCT**

**CONCURRENT- SYNERGISTIC ASSESSMENT OF TWO TECHNIQUES IN MONITORING MINIMAL RESIDUAL DISEASE FOR PH(-) ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANTATION LEADS TO FAVORABLE CLINICAL OUTCOMES**

**DONOR CHIMERISM EVALUATION OF MRD-SUSPECTED CELLS ISOLATED BY FLOW CELL SORTING IS AN ACCESSIBLE TOOL FOR MRD VERIFICATION IN PATIENTS AFTER ALLOGENEIC HSCT**

**ONE-STEP CHECK PURITY OF CD3+ SORTED CELLS ALONG MONITORING HEMATOPOIETIC CHIMAERISM AFTER HSCT**

## Scientific Programme

**DONOR LYMPHOCYTE INFUSIONS AUGMENT GRAFT VERSUS MALIGNANCY EFFECT FOLLOWING ALEMTUZUMAB-BASED REDUCED INTENSITY ALLOGRAFTS: REFLECTIONS ON A SINGLE CENTRE STUDY**

**MYELOID-DERIVED SUPPRESSOR CELLS RECOVER QUICKLY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS**

**PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY**

e-Posters  
08:30 - 19:00

ePoster Area

### Multiple myeloma

**DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF HIGH-RISK PATIENTS IN CASSIOPEIA**

**EVALUATION OF PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (PET/CT) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PHASE 3 CASSIOPEIA STUDY PATIENTS: CASSIOPET STUDY RESULTS**

**CONCORDANCE OF POSTCONSOLIDATION MINIMAL RESIDUAL DISEASE RATES BY MULTIPARAMETRIC FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING IN CASSIOPEIA**

**LONG-TERM FOLLOW-UP OF THE RANDOMIZED PHASE 3 PETHEMA/GEM 2005MENOS65 STUDY SUPPORTS THE USE OF VTD (BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE) AS PRETRANSPLANT INDUCTION REGIMEN FOR MULTIPLE MYELOMA (MM)**

**DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE**

**HOW TO ASSESS RISK OF PROGRESSION IN MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE REMISSION AFTER AUTOLOGOUS TRANSPLANT: SUB ANALYSIS FROM THE GEM2012MENOS65 PHASE III CLINICAL TRIAL**

**OUTCOMES OF ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS**

**25 YEARS OF AUTOLOGOUS TRANSPLANTATION FOR MYELOMA IN EBMT CENTRES - CHANGING PRACTICE PATTERNS**

**PROGNOSIS IN DIFFERENT RISK-GROUPS OF MULTIPLE MYELOMA WITH MINIMAL RESIDUAL DISEASE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BORTEZOMIB-INTEGRATED CONDITIONING: A SINGLE-CENTER EXPERIENCE**

**UNINTERRUPTED MOBILIZATION AND TRANSPLANTATION PROCEDURE WITH NON-CRYOPRESERVED YIELD IS FEASIBLE WITHOUT INCREASEMENT OF COMPLICATION RISK IN MULTIPLE MYELOMA PATIENTS**

**CONDITIONING WITH BORTEZOMIB-MEL200 IN COMPARISON TO MEL200 IMPROVES SURVIVAL AMONG MYELOMA PATIENTS IN  $\leq$ PR PRIOR TO AUTO-HCT: A STUDY FROM THE CMWP OF THE EBMT**

**RESULTS OF DEFERRED AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED STAGES OF SYSTEMIC AL AMYLOIDOSIS**

## **Scientific Programme**

**IN VITRO STIMULATION WITH CD40L/IL-21 CAN RETRIEVE B-CELL DYSFUNCTION IN MULTIPLE MYELOMA PATIENTS SUFFERING FROM SECONDARY IMMUNODEFICIENCY**

**ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA; EXCELLENT OUTCOMES FOR EARLY TRANSPLANTATION**

**SEQUENTIAL HEART TRANSPLANTATION FOLLOWED BY HIGH DOSE CHEMOTHERAPY PLUS AUTOLOGOUS STEM CELL REINFUSION IN CARDIAC AL AMYLOIDOSIS**

**AUTOGRAFT CELLULAR COMPOSITION AND OUTCOME IN MYELOMA PATIENTS: RESULTS OF THE PROSPECTIVE MULTICENTER GOA STUDY**

**RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE**

**PHASE 3, OPEN-LABEL, NONINFERIORITY STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): BODY WEIGHT SUBGROUP ANALYSIS OF COLUMBA**

**ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) IS A RELIABLE PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION**

**ABERRANT PHENOTYPE PLASMA CELL MULTIPARAMETRIC FLOW CYTOMETRY (MFC) DETECTION IN AUTOGRAFT PRODUCTS OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)**

**RETROSPECTIVE MULTI-CENTER STUDY OF ADOLESCENT AND YOUNG ADULT (AYA) MULTIPLE MYELOMA IN KANSAI MYELOMA FORUM REGISTRY**

**MAINTENANCE THERAPY WITH ELOTUZUMAB AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA**

**AUTOLOGOUS STEM CELL TRASPLANTATION CANDIDACY IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS**

**NOVEL PROTOCOL FOR AUTOLOGOUS HSCT IN MULTIPLE MYELOMA ACHIEVES 'ZERO' CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS (CLABSI)**

**OUTCOMES OF NON-CRYOPRESERVED VERSUS CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA**

**DOWN REGULATION OF AUTOPHAGY ENHANCES BORTEZOMIB-INDUCED APOPTOSIS OF MYELOMA CELL BY UP REGULATION OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES**

**RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE**

**FAVORABLE LONG-TERM OUTCOMES WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HIGH RISK PATIENTS WITH MULTIPLE MYELOMA WHO ARE POSITIVE AT FDG-PET/CT**

**LONG TERM SURVIVAL OF MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELATION TO AVAILABILITY OF NOVEL DRUGS**

**MULTIPLE MYELOMA (MM) IN FIRST RELAPSE PATIENTS. ROLE OF THE SECOND AUTOLOGOUS STEM-CELL TRASPLANT (ASCT) IN REAL LIFE: EXPERIENCE OF TWO SPANISH CENTERS**

**ROLE OF ANALYSIS OF CHIMERISM IN MULTIPLE MYELOMA PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE**

## Scientific Programme

**USE OF NETUPITRANT/PALONOSETRON IN MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE**

**THE EFFECT OF UCP-2 AND NR3C1 GENES ON TREATMENT EFFICACY AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA**

**SAFETY AND EFFECTIVENESS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA IN FIRST LINE**

**PLASMAPHERESIS ASSISTED THE TREATMENT OF 1 CASE OF HYPERGLOBULINEMIA AFTER CART THERAPY**

e-Posters  
08:30 - 19:00

ePoster Area

### Myelodysplastic syndromes

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OF ADULT PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA: A NORDIC RETROSPECTIVE STUDY**

**DECITABINE MONOTHERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION RESULTED IN SUPERIOR SURVIVAL FOR MYELOYDYSPLASTIC SYNDROME PATIENTS WITH EXCESS BLASTS**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM: A STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT**

**IMPACT OF MUTATION PROFILE IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**NEW INSIGHTS OF MYELOYDYSPLASTIC SYNDROME (MDS) WITH ERYTHROID PREDOMINANCE BASED ON THE NEXT-GENERATION SEQUENCING AND SINGLE-CELL RNA SEQUENCING**

**IMPACT OF TREATMENT PRIOR TO ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MYELOYDYSPLASTIC SYNDROME: RESULTS OF THE LATIN AMERICAN BONE MARROW TRANSPLANT REGISTRY**

**RESULTS OF LATIN AMERICAN RECORD OF BONE MARROW TRANSPLANTATION IN MYELOYDYSPLASTIC SYNDROME**

**OUTCOME AND MUTATIONAL PROFILE IN MDS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

e-Posters  
08:30 - 19:00

ePoster Area

### New drug- and cell-based immune therapies

**NIVOLUMAB INCREASES ANTIGEN SPECIFIC IMMUNE RESPONSES AGAINST LEUKEMIC PROGENITOR AND STEM CELLS (LSC/LPC)**

**PROPHYLACTIC OR PREEMPTIVE LOW-DOSE AZACITIDINE AND DONOR LYMPHOCYTE INFUSION TO PREVENT DISEASE RELAPSE FOLLOWING ALLOGENEIC TRANSPLANTATION IN 60 PATIENTS WITH HIGH RISK AML OR MDS**

## Scientific Programme

**ELTROMBOPAG FOR THE TREATMENT OF POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTS: A MULTICENTER SURVEY UPDATE**

**DONOR NK CELLS INFUSION AS A STRATEGY OF IMMUNOTHERAPY TO PREVENT HHV6 REACTIVATION IN PEDIATRIC PATIENTS AFTER CD45RA-DEPLETED TRANSPLANTATION**

**DEVELOPMENT OF CELL VACCINE BASED ON AUTOLOGOUS DENDRITIC CELLS LOADED WITH LIPID NANOPARTICLES CONTAINING CMV PP65 MESSENGER RNA**

**SMAC MIMETICS (SM) AND NATURAL KILLER (NK) CELLS - A PROMISING COMBINATION TO OVERCOME CELL DEATH RESISTANCE OF RHABDOMYOSARCOMA (RMS) CELLS**

**'KIT'-MEDIATED BLASTMODULATION TO LEUKEMIA-DERIVED DC SIGNIFICANTLY IMPROVES ANTILEUKEMIC ACTIVITIES IN WHOLE BLOOD INDEPENDENT OF AML-PATIENTS' SUBTYPES**

**ROLE OF EXOSOMES AS PROMOTORS OR BIOMARKERS TO STUDY ACTIVATION OF LEUKEMIA-DERIVED DENDRITIC CELLS (DCLEU)-MEDIATED ANTILEUKEMIC ACTIVATION OF ADAPTIVE AND INNATE IMMUNE-REACTIVE CELLS AGAINST AML-BLASTS**

**HIGHER INCIDENCE OF SEVERE AUTOIMMUNE HEMOLYTIC ANEMIA AFTER TCR $\alpha\beta$ + /CD19+ CELL DEPLETED HAPLOIDENTICAL-HSCT AND POSTGRAFT CELLULAR IMMUNOTHERAPIES: CTLA4-IG VERY EFFECTIVE THERAPEUTIC OPTION FOR THIS LIFE-THREATENING DISEASE**

**BLINATUMOMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM A SINGLE CENTER**

**IMMUNOMODULATION OF BLASTS WITH CLINICALLY APPROVED RESPONSE MODIFIERS TO IMPROVE ANTILEUKEMIC T-CELL REACTIVITY IN AML: AN EX VIVO SIMULATION OF THE CLINICAL SITUATION**

**IFNY SECRETION OF ADAPTIVE AND INNATE IMMUNE CELLS AS A PARAMETER TO DISPLAY LEUKAEMIA DERIVED DENDRITIC CELL (DC<SUB>LEU</SUB>) MEDIATED IMMUNE RESPONSES IN AML**

**TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721)**

e-Posters  
08:30 - 19:00

ePoster Area

### Non-haematopoietic stem cells

**THE POTENTIAL ROLES OF MUCOSA-ASSOCIATED INVARIANT T CELLS IN THE PATHOGENESIS OF GUT GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**FACTORS INFLUENCING THE PRESENCE OF BONE MARROW MESENCHYMAL STEM CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**ANALYSIS OF THE GENETIC STABILITY OF DONORS' BONE MARROW STROMA MESENCHYMAL CELLS DURING CULTIVATION**

**EFFECT OF MATERNAL AND NEONATAL FACTORS ON THE YIELD OF WHARTON'S JELLY MESENCHYMAL STEM CELLS**

**THE POLISH EXPERIENCE OF WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF PAEDIATRIC PATIENTS**

## Scientific Programme

**THE POLISH EXPERIENCE OF WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF ADULT PATIENTS**

**A RETROSPECTIVE ANALYSIS OF BONE MARROW EXAMINATION RESULTS FROM A SINGLE CENTER INSTITUTION: CAN WE REDUCE THE OCCURRENCE OF UNNECESSARY BONE MARROW EXAMINATIONS?**

e-Posters  
08:30 - 19:00

ePoster Area

### Non-infectious early complications

**IMPACT OF DONOR-DIRECTED HLA ALLO-ANTIBODIES ON PRIMARY GRAFT FAILURE AFTER UNRELATED DONOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION**

**ELTROMBOPAG TREATMENT AIDED IN PLATELET RECOVERY AND REDUCED PLATELET INFUSION FOR PATIENTS WITH POST-TRANSPLANTATION THROMBOCYTOPENIA**

**IMPACT OF FLUID OVERLOAD (FO) IN POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL DISEASES**

**INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS**

**USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT**

**REDUCED POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSES IN T-CELL REPLETE HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**ABO ISOAGGLUTININ LEVELS IN GUIDED MANAGEMENT OF ABO INCOMPATIBILITY IN ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION**

**METHYLPREDNISOLONE STRATIFIED INTERVENTION BASED ON RISK CLASSIFICATION IN THE TREATMENT OF PRE-ENGRAFTMENT SYNDROME AFTER UNRELATED CORD BLOOD TRANSPLANTATION: A PROSPECTIVE, NON-RANDOMIZED, AND OPEN-LABEL STUDY**

**PRETRANSPLANT NUTRITION MEASURES AND SYSTEMIC INFLAMMATORY RESPONSE PREDICT OUTCOME AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION**

**A MULTI-CENTRE, MULTI-NATIONAL, PROSPECTIVE OBSERVATIONAL REGISTRY STUDY OF DEFIBROTIDE IN PATIENTS DIAGNOSED WITH SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)**

**DEFIBROTIDE TREATMENT FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES BY SEVERITY AND MULTI-ORGAN FAILURE STATUS IN AN OBSERVATIONAL REGISTRY STUDY**

**INTRODUCTION OF NEW PEDIATRIC EBMT CRITERIA FOR VOD <b>Diagnosis: </b> IS IT LIFE-SAVING OR MONEY-WASTING?**

**PROSPECTIVE PILOT STUDY ON FRAILTY AND FUNCTION ASSESSMENT DURING CLINICS IN ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION**

## Scientific Programme

**HISTOLOGIC FEATURES OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY WITH AND WITHOUT CONCOMITANT ACUTE GRAFT-VERSUS-HOST DISEASE**

**HIGH SURVIVAL RATE OF PEDIATRIC PATIENTS WITH PRIMARY GRAFT FAILURE WHO UNDERGO A SECOND PROCEDURE. THE EXPERIENCE OF 3 SPANISH PEDIATRIC TRANSPLANT UNITS**

**CHEMOTHERAPY-INDUCED GUT MUCOSAL INJURY INITIATES MICROBIAL DISRUPTION IN STEM CELL TRANSPLANT RECIPIENTS**

**BACTERIAL AND METABOLIC PROFILING OF THE SALIVA IDENTIFIES UNIQUE PATTERNS OF MICROBIOTA INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT WITH SEVERE ORAL MUCOSITIS**

**DIAGNOSIS AND MANAGEMENT OF SECONDARY HLH/MAS FOLLOWING HSCT AND CAR-T CELL THERAPY IN ADULTS: AN EBMT-WIDE SURVEY ON BEHALF OF THE ADWP AND TCWP**

**IMPACT OF ABO INCOMPATIBILITY ON COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION- RETROSPECTIVE, INTERNATIONAL, MULTICENTER ANALYSIS BY THE TRANSPLANT COMPLICATIONS WORKING PARTY EBMT**

**HYPOALBUMINEMIA PRIOR ALLOHCT IS A RELEVANT NEGATIVE PREDICTOR FOR SURVIVAL**

**INCIDENCE AND CLINICAL IMPACT OF ATRIAL FIBRILLATION DIAGNOSED DURING HOSPITAL STAY FOR ALLOGENEIC STEM CELL TRANSPLANTATION**

**TRANSPLANTATION-ASSOCIATED MICROANGIOPATHY (TAM) IN RECIPIENTS OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS USING PTCY FOR GVHD PROPHYLAXIS: INCIDENCE AND OUTCOME**

**IGF-1 AND IGFBP-3 GENE POLYMORPHISMS PREDICT CIRCULATING IGF LEVELS AND SYSTEMIC INFLAMMATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**LOW RISK OF EARLY TOXICITY AND UNPLANNED 100-DAY READMISSIONS AFTER MATCHED AND MISMATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

**KERATINOCYTE GROWTH FACTOR DECREASES HOSPITAL READMISSION AND REGIMEN-RELATED TOXICITIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA**

**ELTROMBOPAG FOR TREATING THROMBOCYTOPENIA AFTER HEMATOPOETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

**SYSTEMIC CORTICOSTEROID THERAPY IS UNLIKELY TO BE THE PRIMARY CAUSE OF HYPERGLYCEMIA FOLLOWING TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE**

**COST-EFFECTIVENESS ANALYSIS OF DEFIBROTIDE FOR THE TREATMENT OF SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME IN SPAIN**

**NEUROLOGIC COMPLICATIONS IN 169 CONSECUTIVE ALLOGENEIC STEM CELL TRANSPLANTS: ETIOLOGY, CLINICAL SYNDROMES AND OUTCOME**

**VENETOCLAX, HYPOMETHYLATING AGENTS AND DLI FOR SALVAGE TREATMENT OF MYELOID MALIGNANCIES RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EVALUATION OF TGF-BETA LEVEL AFTER SUPPLEMENTATION WITH WHEY PROTEIN CONCENTRATE FOR ORAL MUCOSITIS PROPHYLAXIS**

**TREOSULFAN-INDUCED MYALGIA IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## Scientific Programme

**VALIDATION OF EARLY INCREASE OF SC5B-9 AS A PREDICTIVE MARKER FOR LATER TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY**

**DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**EARLY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION IMPROVES OUTCOME OF VERY SEVERE HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER UNMANIPULATED HAPLOIDENTICAL HSCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

**DOES THE TYPE OF NUTRITIONAL SUPPORT AFFECT THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION? A PEDIATRIC CENTER EXPERIENCE**

**NEUROLOGICAL COMPLICATIONS IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY**

**ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO THE INTENSIVE CARE UNIT - REAPPRAISAL OF PROGNOSIS AND PROGNOSTIC FACTORS: A SINGLE CENTER STUDY**

**ENTERAL VERSUS PARENTERAL NUTRITION IN ADULT HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS SUFFERING FROM GASTROINTESTINAL MUCOSITIS**

**DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS**

**THE USEFULNESS OF LIVER STIFFNESS MEASUREMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT SINUSOIDAL OBSTRUCTION SYNDROME**

**ENDOTHELIAL CELL COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION, A SINGLE CENTRE ANALYSIS ON 99 CONSECUTIVE PATIENTS UNDERGOING ALLO-SCT**

*Giorgia Mancini, Matteo Candelora, Giuseppina Urbano, Francesco Saraceni, Monica Poiani, Marianna Mariani, Irene Federici, Giuseppe Tarantino, Ilaria Scortechini, Attilio Olivieri (Italy)*

**INFLUENCE OF ABO-INCOMPATIBILITY ON THE OUTCOME OF STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY ON CHILDREN AND YOUNG ADULTS**

**EASIX IS USEFUL FOR PREDICTING THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS**

**SECOND TRANSPLANTATION USING A NOVEL CONDITIONING REGIMEN WITH DIFFERENT DONOR FOR GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**A SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME**

**VENO-OCCLUSIVE DISEASE: ONLINE, INTERPROFESSIONAL, CASE-BASED EDUCATION SIGNIFICANTLY IMPROVES KNOWLEDGE AND SKILLS OF THE ENTIRE CARE TEAM**

**HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME**

**EASIX AS A PREDICTIVE BIOMARKER OF COMPLICATIONS AND OUTCOME IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**SURVIVAL WITH NORMAL PULMONARY FUNCTION IS POSSIBLE DESPITE SIGNIFICANT AND PROLONGED RESPIRATORY SUPPORT, INCLUDING PROLONGED HIGH FREQUENCY OSCILLATORY VENTILATION (HFOV) IN CHILDREN**

## **Scientific Programme**

**USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION**

**CURRENT PRACTICE IN NUTRITION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AUSTRIA, GERMANY AND SWITZERLAND**

**INCIDENCE AND SEVERITY OF CYTOKINE RELEASE SYNDROME FOLLOWING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL INFUSION**

**ENGRAFTMENT SYNDROME FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY FROM A SINGLE CENTER**

**WERNICKE'S ENCEPHALOPATHY IN A CHILD WITH B LYMPHOBLASTIC LYMPHOMA AFTER HAPLO-HSCT**

**ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE**

**IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN TERMS OF SINUSOIDAL OBSTRUCTION SYNDROME (SOS)**

**ISCHEMIC STROKE IN CHILDREN AND YOUNG ADULTS WITH MALIGNANT HEMATOLOGICAL AND ONCOLOGICAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**MELPHALAN DOSE ADJUSTMENT AND CRYOTHERAPY REDUCE ORAL MUCOSITIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CLINICAL FEATURES AND RISK FACTORS OF ENGRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**REAL-LIFE EXPERIENCE OF TWO ITALIAN HEMATOLOGY CENTRES ON EFFICACY AND SAFETY OF ORAL NEPA (NETUPITANT/PALONOSETRON) IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EARLY TREATMENT WITH DARATUMUMAB FOR REFRACTORY POST-ALLOGENEIC STEM CELL TRANSPLANT PURE RED CELL APLASIA**

**PROGNOSTIC FACTORS FOR EARLY MORTALITY OF HEMATOLOGICAL PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT: PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTER STUDY**

**ACUTE KIDNEY INJURY DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS: INCIDENCE AND RISK FACTORS**

**T-PA/UROKINASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA**

**HEMOPHAGOCYTIC SYNDROME AFTER EX-VIVO LYMPHODEPLETED HEMATOPOIETIC TRANSPLANTATION**

**IMMUNOADSORPTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MAJOR ABO INCOMPATIBILITY**

**IMMUNE-MEDIATED FEVER AFTER T-CELL REplete HAPLOIDENTICAL HSCT USING PERIPHERAL BLOOD STEM CELL GRAFTS AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

e-Posters  
08:30 - 19:00

ePoster Area

**Non-infectious late effects, quality of life and fertility**

## **Scientific Programme**

**EASIX-1YEAR- THE FIRST BIOMARKER PREDICTING LATE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**AN UPDATED REPORT ON SECONDARY SOLID CANCER FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMIA MAJOR**

**ALLOGENEIC STEM-CELL TRANSPLANTATION IN AML AND MDS USING CONDITIONING REGIMENS WITH DIFFERENT DOSE-INTENSITIES; 15 YEARS LATER**

**EMPLOYMENT STATUS AND RETURN TO WORK AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A NATIONWIDE SURVEY**

**FUNCTIONAL OUTCOME MEASURES IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): FOCUS ON THE 2-MINUTE WALK TEST**

**FERTILITY IN ADULT FEMALE ALLOGENEIC STEM CELL RECIPIENTS**

**A RISK SCORE MODEL (HAD-TCG) TO EVALUATE THE RISK OF STROKE IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**BRONCHIOLITIS OBLITERANS SYNDROME IN THE CHANGING LANDSCAPE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CURRENT STATUS AND NEEDS OF LONG-TERM FOLLOW-UP CLINICS FOR HEMATOPOIETIC CELL TRANSPLANT SURVIVORS: RESULTS OF A NATIONWIDE SURVEY IN JAPAN**

**SURVIVORSHIP CARE FOR ALLOGENEIC TRANSPLANT PATIENTS IN THE UK: CURRENT SERVICE PROVISION AND BARRIERS TO IMPLEMENTATION**

**CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN EPSTEIN-BARR VIRUS RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (EBV-PTLD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)**

**INCIDENCE, RISK FACTORS AND OUTCOMES OF DIFFUSE ALVEOLAR HEMORRHAGE AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION**

**WHOLE BODY VIBRATION TRAINING DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - THE EFFECTS ON PATIENTS' PHYSICAL CAPACITY, FATIGUE, BODY COMPOSITION AND QUALITY OF LIFE**

**MULTI-MORBIDITY IN ADULT SURVIVORS OF STEM CELL TRANSPLANTATION (SCT)**

**GONADOTOXICITY AFTER TREOSULFAN-BASED MYELOABLATIVE CONDITIONING REGIMEN FOR ALLOGENEIC HSCT IN GIRLS WITH LEUKEMIA**

**REDUCED-INTENSITY TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH HIGH-RISK OR ADVANCED HEMATOLOGICAL MALIGNANCIES IN LAST 10 YEARS - SINGLE CENTRE EXPERIENCE**

**FATHERHOOD AFTER A MYELOABLATIVE TREOSULFAN BASED ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS ON 453 PATIENTS**

**COMPARISON OF CENTRAL NERVOUS SYSTEM RELAPSE OUTCOMES FOLLOWING HAPLOIDENTICAL VS IDENTICAL-SIBLING TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA**

**OLDER AGE AND PERIPHERAL BLOOD AS A STEM CELL SOURCE ARE THE MAJOR NEGATIVE PREDICTORS OF SURVIVAL LONG TERM**

**PREVALENCE OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLOHSCT) IN THE US, EUROPE AND JAPAN**

## Scientific Programme

**NETUPITANT-PALONOSETRON (NEPA) TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MULTIPLE MYELOMA (MM) PATIENTS RECEIVING HIGH-DOSE (HD) MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)**

**MOST FREQUENT LATE EFFECTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA DOES NOT SEEM TO WORSEN PERFORMANCE STATUS**

**INVOLVING STEM CELL TRANSPLANT PATIENTS AND THEIR FAMILIES TO IMPROVE THE ANTHONY NOLAN MY TRANSPLANT TRACKER APP**

**EARLY MENOPAUSE AND RISK FACTORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PREMENOPAUSAL ADULT WOMEN**

**MUSCULOSKELETAL COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

**CLINICAL CHARACTERISTICS AND MANAGEMENT OF LATE RELAPSE OF ACUTE MYELOID LEUKAEMIA MORE THAN FIVE YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**FOLLOWING UP WITH ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING 5+ YEARS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**LOW BACK PAIN AND LASER ACUPUNCTURE IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELLS TRANSPLANTATION**

**EFFECTS OF CONTROLLED EXERCISE ON PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANT IN AN ASIAN POPULATION: A SINGLE-CENTER EXPERIENCE**

**DEVELOPMENT OF GUILLAIN-BARRE-LIKE SYNDROME IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELLS TRANSPLANTATION**

e-Posters  
08:30 - 19:00

ePoster Area

## Paediatric issues

**PROSPECTIVE OPEN-LABEL PHASE II TRIAL OF INDIVIDUALIZED ANTI-THYMOCYTE GLOBULIN SHOWS IMPROVED EARLY CD4+ T-CELL RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE PARACHUTE-TRIAL**

**EBMT LESSONS FROM 40 YEARS OF HIGH DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN NEUROBLASTOMA: A REPORT FROM THE PAEDIATRIC WORKING PARTY**

Ruth Ladenstein, Ulrike Poetschger, Penelope Brock, Roberto Luksch, Victoria Castel, Shifra Ash, Vassilios Papadakis, Geneviève Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz de Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Evgenia Glogova, Dominique Valteau-Couanet, Selim Corbacioglu (Austria)

**INCIDENCE OF SECONDARY MALIGNANCIES AFTER TBI/VP16 CONDITIONING FOR CHILDHOOD ALL: RESULTS OF THE PROSPECTIVE ALL-SCT-BFM-2003 TRIAL**

**OUTCOME AND RISK FACTORS OF AUTOIMMUNE CYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY**

## Scientific Programme

### **EBMT SURVEY ON 40 YEARS OF HIGH-DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN EWING TUMOURS (ET). A REPORT FROM THE PAEDIATRIC WORKING PARTY**

Ruth Ladenstein, Evgenia Glogova, Christelle Dufour, Edoardo Lanino, Jean Michon, Paul Veys, Roberto Luksch, Uta Dirksen, Krzysztof Kalwak, Stefan Burdach, Henk van den Berg, Boris Afanasyev, Franco Locatelli, Emmanuelle Nicolas-Virelizier, Shifra Ash, Nathalie Gaspar, Jeremy Whelan, Philippe Brault, Ulrike Poetschger, Selim Corbacioglu (Austria)

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN - RETROSPECTIVE REPORT ON BEHALF OF I-BFM SCT COMMITTEE AND EBMT PEDIATRIC DISEASES WP**

#### **IS THE EBMT RISK SCORE PREDICTIVE OF OUTCOMES IN PAEDIATRIC ACUTE LEUKEMIA?**

#### **TCR $\alpha\beta$ + /CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION**

#### **THE GREAT ORMOND STREET (GOS) PAEDIATRIC CO-MORBIDITY SCORE FOR OUTCOME POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION**

#### **HIGH PREVALENCE OF CAROTID PLAQUES IN YOUNG ADULTS AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD**

#### **HAPLOIDENTICAL DONOR OR UNRELATED DONOR FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY?**

#### **A 'RISK-ADJUSTED' CYTOREDUCTION WITHOUT RADIATION FOR PATIENTS WITH FANCONI ANEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT)**

#### **USE OF RUXOLITINIB IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD)**

#### **HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN REFRACTORY CYTOPENIA OF CHILDHOOD (RCC): IMPROVED ENGRAFTMENT FOLLOWING A TREOSULFAN BASED CONDITIONING REGIMEN**

#### **PHARMACOKINETICS OF ACTIVE ATG IMPACTS T-CELL RECOVERY AFTER TCR $\alpha\beta$ /CD19-DEPLETED HSCT IN PAEDIATRIC PATIENTS**

#### **HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A MULTICENTRE STUDY FROM INDIA**

#### **IMMUNE RECOVERY AND LONG-TERM SURVIVAL FOLLOWING HAPLOIDENTICAL T AND B CELL DEPLETED STEM CELL TRANSPLANTATION - INFLUENCE OF VARIOUS ATG DOSES**

#### **OUTCOMES OF HAPLOIDENTICAL VS MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC HIGH-RISK ALL AND AML IN 1ST AND 2ND CR**

#### **COMBINED TCR ALPHA BETA AND CD45RA DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BENIGN HAEMATOLOGICAL CONDITIONS, SINGLE CENTRE EXPERIENCE**

#### **GENETIC SUSCEPTIBILITY TO HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC PATIENTS UNDERGOING HSCT**

#### **HAPLO HSCT WITH IN VIVO T-CELL DEPLETION AFTER REDUCED INTENSITY CONDITIONING REGIMEN AND MYELOABLATIVE MUD AND MMUD DONOR HSCT IN PEDIATRIC PATIENTS AFFECTED BY MALIGNANCIES**

## Scientific Programme

**THINKING BEYOND HLH: CLINICAL FEATURES OF PATIENTS WITH CONCURRENT PRESENTATION OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND THROMBOTIC MICROANGIOPATHY**

**LANDMARK ANALYSIS IN HIGH RISK CHILDHOOD ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE STUDY**

**DEFIBROTIDE IN HEMATOPOIETIC STEM CELL TRANSPLANT: AN STUDY OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH) AND GRUPO ESPAÑOL DE TRASPLANTE DE MEDULA EN NIÑOS (GETMON)**

**NIVOLUMAB-BASED THERAPY PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC HODGKIN'S LYMPHOMA**

**HUMAN LEUKOCYTE ANTIGEN DISPARITIES REDUCE RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA**

**SCHOOL DURING AND AFTER ALLOGENEIC HSCT: A SURVEY OF PRACTICES IN THREE EUROPEAN COUNTRIES**

**HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HURLER SYNDROME: SINGLE CENTER EXPERIENCE**

**HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FANCONI ANAEMIA: EXPERIENCE OF THE SPANISH WORKING GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETMON)**

**IMPACT OF MEMORY T-CELL DOSES INFUSED WITH T-CELL DEPLETED HAPLOIDENTICAL STEM CELL GRAFTS ON TRANSPLANT OUTCOMES**

**THE ROLE OF DONOR KIR GENOTYPING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISORDERS**

**SINGLE-CENTER EXPERIENCE OF TCR $\alpha\beta$ /CD19 DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANEMIA**

**DETECTION OF RECIPIENT-SPECIFIC  $\alpha/\beta$ -T-CELLS DURING THE PRE-ENGRAFTMENT PHASE DOES NOT PREDICT GRAFT REJECTION IN PATIENTS AFTER HAPLOSCT: PRELIMINARY RESULTS OF SINGLE CENTRE PROSPECTIVE TRIAL**

**IMPROVED SURVIVAL AFTER MIBG THERAPY IN COMBINATION WITH MEGACHEMOTHERAPY THAN AFTER STAND-ALONE THERAPY IN CHILDREN WITH NEUROBLASTOMA - POLISH NATION-WIDE RETROSPECTIVE STUDY**

**THE IMPACT OF HOUSEHOLD INCOME ON ACUTE HOSPITALIZATION DAYS IN PEDIATRIC ALLOGENEIC TRANSPLANT RECIPIENTS**

**USE OF RIC REGIMENS COMBINED WITH TCR $\alpha\beta$  DEPLETION AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC MISMATCHED SCT**

**THE ROLE OF HLA-DP MATCHING IN DONOR SELECTION FOR MUD-HSCT IN CHILDREN WITH HEMATOLOGIC MALIGNANT DISEASES**

**CLINICAL IMPLICATION ON RECOVERY OF  $\gamma\delta$  T CELLS AFTER TCR $\alpha\beta$ -DEPLETED HAPLOIDENTICAL HSCT IN PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE**

**EARLY INITIATION OF CYCLOSPORINE-MYCOPHENOLATE PLUS ANTITHYMOCYTE GLOBULIN IN HAPLO TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: LOW INCIDENCE OF SEVERE ACUTE GVHD WITH ENCOURAGING SURVIVAL**

**FEASIBILITY AND SAFETY OF SURGICAL FERTILITY PRESERVATION TECHNIQUES PROXIMAL TO INITIATION OF CONDITIONING THERAPY IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT**

## **Scientific Programme**

**VENO-OCCLUSIVE DISEASE WITH EMPHASIS ON RENAL MANIFESTATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: A SINGLE CENTER EXPERIENCE**

**OUTCOME AFTER HSCT IN CHILDREN WITH JMML FROM A HISTORICAL POINT OF VIEW**

**THE IMPACT RECOVERY ABSOLUTE LYMPHOCYTE COUNT AT DAYS +21 ON OUTCOME ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALL**

**T-CELL-RICH HAPLOIDENTICAL STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN CHILDREN WITH ACUTE LEUKEMIA RELAPSED AFTER ALLOGENEIC TRANSPLANTATION**

**HIGH PREVALENCE OF VITAMIN C DEFICIENCY IN A LARGE PAEDIATRIC COHORT UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE FROM 2003-2019**

**EX VIVO T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE**

**LONG-TERM ERYTHROPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: HOST DETERMINES RESULT**

**BOOST WITH CD34+ CELLS FOR POOR GRAFT FUNCTION TREATMENT AFTER HSCT IN PAEDIATRIC PATIENTS. A MULTICENTER STUDY**

**NO DIFFERENCE IN SURVIVAL AFTER HLA MISMATCHED VERSUS HLA MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION**

**ALLOGENIC STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE**

**STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-ANAPLASTIC PERIPHERAL T-CELL LYMPHOMA ON BEHALF OF THE EBMT-PEDIATRIC DISEASES WORKING PARTY**

**FIRST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RASGRP1 DEFICIENCY  
SUCCESSFUL HSCT IN IMMUNE DISREGULATORY DISEASES**

**LEVOFLOXACIN BASED PROPHYLAXIS IN CHILDREN RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT AFFECT THE INCIDENCE OF ACUTE GVHD AND BLOODSTREAM INFECTIONS**

**RITUXIMAB-INDUCED SECONDARY HYPOGAMMAGLOBULINEMIA: MEMORIAL SLOAN KETTERING'S 10-YEAR EXPERIENCE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

**'INCURABLE' PAEDIATRIC MYELOID LEUKAEMIA TREATED WITH NOVEL CELL-BASED THERAPEUTICS**

**EFFECT OF SERUM PANEL REACTIVE ANTIBODIES ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE**

**SINGLE CENTRE EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR INHERITED BONE MARROW FAILURE SYNDROMES**

**IS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A GOOD INDICATION FOR PATIENTS WITH SIFD SYNDROME?**

**TIME COURSE AND IMPACT OF BODY WEIGHT CHANGE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HIGH RISK EWING SARCOMA, A SINGLE CENTER EXPERIENCE**

## Scientific Programme

**CONDITIONING FOR RETRANSPLANTATION FROM THE SAME DONOR AFTER PARTIAL AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH PID: IMMUNOSUPPRESSION IS NOT REQUIRED**

**TOCILIZUMAB TREATMENT FOR CRS IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**IDIOPATHIC PNEUMONIA SYNDROME (IPS) AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM UNRELATED DONOR FOR HURLER SYNDROME (MUCOPOLYSACCHARIDOSIS TYPE 1) SUCCESSFULLY TREATED WITH ETANERCEPT AND STEROIDS**

**EFFECT OF DESENSITIZATION PROTOCOL ON TRANSPLANTATION SUCCESS IN CHILDREN WITH ANTI-HLA ANTIBODIES**

**OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOHSCT) WITH DIFFERENT INTENSITY CONDITIONING REGIMENS IN INFANT AML**

**VENETOCLAX/DECITABINE FOR PEDIATRIC MDR-AML RELAPSED AFTER TWO ALLO HSCTS**

**HIGHER INCIDENCE OF CMV AND BKV REACTIVATION IN HAPLOIDENTICAL TRANSPLANTS COMPARATIVE TO MUD OR MSD TRANSPLANTS - SINGLE CENTRE RETROSPECTIVE ANALYSIS**

**USE OF POLYCLONAL IGM-ENRICHED IMMUNOGLOBULINS FOR THE TREATMENT OF SEPTIC EPISODES IN CHILDREN WITH ONCOHEMATOLOGICAL DISEASES**

**PAEDIATRIC BONE MARROW TRANSPLANT CARE ON BMT VERSUS NON-BMT PAEDIATRIC WARDS**

**CHRONIC HEALTH PROBLEMS IN CHILDREN AFTER ALLOGENEIC HSCT: THE TOP OF THE ICEBERG?**

**HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE-CENTER SERIES OF 14 CASES**

**NON-WHITE HISPANIC ETHNICITY AS A RISK FACTOR FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC TRANSPLANT**

**THE CHALLENGES AND OUTCOMES SURROUNDING INTRAVESICULAR CIDOFOVIR ADMINISTRATION: A PAEDIATRIC PHARMACY PERSPECTIVE**

**THE EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RARE HEMATOLOGIC DISEASE**

**SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH DNA LIGASE IV DEFICIENCY WITH NONMYELOABLATIVE CONDITIONING REGIMEN**

**PNEUMATOSIS INTESTINALIS AS A RARE POST-TRANSPLANT COMPLICATION IN PEDIATRIC PATIENTS**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT-HD-CYCLOPHOSPHAMIDE FOR RELAPSED B-LYMPHOBLASTIC LYMPHOMA (B-LBL) WITH MLL-REARRANGEMENT IN 1 Y.O. CHILD: A CLINICAL CASE**

e-Posters  
08:30 - 19:00

ePoster Area

## Pharmacology

**ELTROMBOPAG THERAPY IN STEM CELL TRANSPLANT RECIPIENTS SHOWS EFFECTIVE IRON MOBILISATION**

## Scientific Programme

**CLINICAL IMPACT OF MODEL PK GUIDED-CYCLOSPORINE DOSE INDIVIDUALIZATION IN CHILDREN UNDERGOING HSCT**

**INFLUENCE OF CYP2D6 METABOLIZER STATUS ON THE CONTROL OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING BY ONDANSETRON ON PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ESTIMATION OF GLOMERULAR FILTRATION RATE IN ADULTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CYSTATIN C VERSUS CREATININE**

**USE OF SUBLINGUAL TACROLIMUS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH HISTORY OF ANAPHYLAXIS TO INTRAVENOUS CYCLOSPORINE**

**ORAL CLONAZEPAM FOR SEIZURE PROPHYLAXIS IN ADULT PATIENTS TREATED WITH HIGH DOSE BUSULFAN**

**DISSOLUTION TIME FOR CONVENTIONAL AND LYOPHILIZED CYCLOPHOSPHAMIDE: A SINGLE CENTER STUDY**

**OUTCOMES OF EBV VIREMIA AND PTLD AFTER RITUXIMAB: A PHARMACO-COST ANALYSIS**

**PHARMACOLOGICAL INTERACTIONS IN THE POST-TRANSPLANT PHASE OF HEMATOPOIETIC PROGENITORS TRANSPLANTATION**

**EVALUATION OF SIDE EFFECTS AND EFFICACY OF LOMUSTINE (CCNU) AND BANDAMUSTINE IN PATIENTS WITH LYMPHOMA**

e-Posters  
08:30 - 19:00

ePoster Area

## Psychological issues

**INVESTIGATING THE LONG-TERM OUTCOMES OF ADULT PATIENTS WHO UNDERWENT HAEMATOPOIETIC STEM CELL TRANSPLANT FOR PRIMARY IMMUNODEFICIENCY DURING CHILDHOOD**

**THE IMPACT OF MEDICAL AND SOCIAL REHABILITATION ON THE QUALITY OF LIFE IN CHILDREN WITH ONCOLOGIC AND HEMATOLOGIC DISEASES**

**THE IMPACT OF PRE-TRANSPLANT DEPRESSION AND ANXIETY ON THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION, A STUDY OF THE TCWP OF THE EBMT**

**ASSOCIATIONS BETWEEN FAMILY FUNCTION DOMAINS AND COPING STRATEGIES OF ADOLESCENTS UNDERGOING HSCT**

**HOW PATIENTS' VIEWS ARE HELPING SHAPE PLANS FOR A NEW TRANSPLANT PSYCHOLOGY SERVICE**

**CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: TWO DIFFERENT ANALYTICAL APPROACHES**

**ARC CLINIC: APPLYING PSYCHOLOGICAL INSIGHTS TO PROMOTE EARLY REHABILITATION IN MYELOMA POST-TRANSPLANT**

**FROM HOSPITALIZATION TO RETURN HOME: A TRANSITIONAL ACTION RESEARCH IN THE HEMATOLOGY SECTOR**

**1000 IN 10 . 10 YEARS OF CLINICAL PSYCHOLOGY PRACTICE WITH 1000 PATIENTS IN THE SAME BMT UNIT IN MARSEILLE, FRANCE**

## Scientific Programme

**IMPLEMENTATION OF PSYCHOLOGICAL SUPPORT AND DEVELOPMENT OF EDUCATIONAL PROGRAM FOR CHILDREN AND ADOLESCENTS UNDERGOING HSCT AND THEIR PARENTS IN RUSSIA**

e-Posters  
08:30 - 19:00

ePoster Area

## Quality Management

**COMPARING COMPLIANCE FOR COLLECTION FACILITY JACIE STANDARDS 6.1 AND 7TH EDITIONS**

**INTEGRATION OF THEORY AND PRACTICE: SCENARIO-BASED SKILL TRAINING IN ADMINISTERING CAR-T CELLS**

**"TPFMEA", AN INTERNATIONAL MODEL FOR ASSESSING RISKS IN A STEM CELL TRANSPLANT PROGRAM**

**DEFINING PATIENT-IMPORTANT OUTCOMES AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT**

**IMPLEMENTATION OF JACIE ACCREDITATION AT A NOVEL TRANSPLANT PROGRAM: THE IMPACT ON THE CLINICAL PRACTICE**

**HOW ONE PROCESSING CENTRE PREPARED FOR ITS FIRST JACIE INSPECTION?**

**TIPS FOR GENERATING SUCCESSFUL 'TEAMWORKING' IN OUR HEALTHCARE FACILITIES: THE EXPERIENCE OF A HOSPITAL UNIT IN A FRENCH CANCER CENTER**

**IMPLEMENTATION OF A QUALITY SYSTEM FOR RUNNING A CELL AND GENE THERAPY CLINICAL TRIAL WITHIN A JACIE-ACCREDITED TRANSPLANT PROGRAM**

**NEW ONLINE PLATFORMS IN QUALITY MANAGEMENT: COORDINATION AND MULTIDISCIPLINARY CARE**

**RISK MANAGEMENT ASSESSMENT IN IMPLEMENTING CAR-T CELL THERAPY IN A CLINICAL UNIT**

**FEBRILE REACTION AFTER HSC INFUSION IS MORE FREQUENT IF NO STEROID PREMEDICATION IS GIVEN WHICH RESULTS IN MORE FREQUENT USE OF ANTIBIOTICS EARLY POST-TRANSPLANT**

**SEARCHING FOR OTHER TOPICS OF QUALIFICATION PLANS IN THE TRANSPLANT PROGRAM CLINICAL PART - THE ONE CENTER EXPERIENCE**

**PRACTICE PATTERNS IN CHRONIC GVHD PATIENT MANAGEMENT AND PATIENT REPORTED OUTCOME MEASURES ACROSS THE EBMT ALLOGENEIC TRANSPLANTATION NETWORK**

**MAINTAINING DONOR SAFETY AND WELFARE THROUGHOUT CELLULAR THERAPY PRODUCT DONATION**

**DIGITAL JACIE AT THE CHRISTIE**

**INTEGRATION OF CELLULAR THERAPY IN THE JACIE (JOINT ACCREDITATION COMMITTEE ISCT-EBMT) QUALITY MANAGEMENT PLAN. SINGLE CENTER EXPERIENCE**

**AUDIT - A METHOD TO EVALUATE INTERVENTIONS - EXPERIENCES FROM AN ATTEMPT TO IMPROVE NUTRITIONAL STATUS IN PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## Scientific Programme

**QUALITY OF LIFE ASSESSMENT AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RETROSPECTIVE ANALYSIS OF TIME TO ALTERNATIVE DONOR IDENTIFICATION AND HEMATOPOIETIC STEM CELLS PROCUREMENT IN THE ABSENCE OF MATCHED-SIBLING DONORS IN A SINGLE CENTER IN SPAIN**

**GOVERNANCE, RISKS AND REGULATORY ASPECTS OF UNLICENSED LENTIVIRAL VECTOR-MODIFIED AUTOLOGOUS STEM CELL TREATMENT**

**UNIQUE SUPPORTIVE CARE ALGORITHMS FOR CHILDREN UNDERGOING HAPLOIDENTICAL HSCT FOR BENIGN HAEMATOLOGICAL DISORDERS**

**QUALITY OF LIFE IN PARENTS OF TURKISH AND SYRIAN PEDIATRIC BONE MARROW TRANSPLANT AND ONCOLOGY PATIENTS**

**COLLECTION OF AUTOLOGOUS MONONUCLEAR CELLS IN NON-CYTOKINE STIMULATED DONORS: COMPARING TWO APHERESIS METHODS**

**EFFECTIVE CAR-T CELL DELIVERY: A MULTIDISCIPLINARY APPROACH AT MFT**

**HAEMOPOIETIC PROGENITOR CELL PROFICIENCY TESTING**

**VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ALERT (R) 3D (TM) AND VIRTUO (TM) MICROBIAL BIOBURDEN SYSTEMS FOR HAEMATOPOIETIC PROGENITOR CELLS (HPC)**

**START-UP OF AN ADHERENCE RECEPTION FOR ALLOGENIC STEM CELL TRANSPLANTED PATIENTS AT THE HEMATOLOGICAL DEPARTMENT LINKÖPING, SWEDEN**

**ENUMERATION OF RESIDUAL RED BLOOD CELLS IN MIS-MATCHED ALLOGENEIC PBSC COLLECTIONS - TRADITIONAL HAEMATOLOGY ANALYSER VS FLOW CYTOMETRY**

**INVESTIGATION AND ANALYSIS OF FACTORS AFFECTING GASTROINTESTINAL NUTRITION RECOVERY AFTER MULTIPLE MYELOMA AUTOLOGOUS STEM CELL TRANSPLANTATION AND EFFECTS OF NUTRITIONAL INTERVENTION**

**CHARACTERISTICS OF IRON DEFICIENCY ANEMIA IN PRE-MENOPAUSAL WOMEN IN KOREA  
LEUKEMIA AND ITS TYPES**

e-Posters  
08:30 - 19:00

ePoster Area

## Regenerative medicine

**WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL THERAPY IMPROVES THE QUALITY OF LIFE AND SELF-SUFFICIENCY OF CHILDREN WITH AUTISM SPECTRUM DISORDER**

**MARROW DERIVED CELLS BRING A LONG LASTING RELIEF WHEN INJECTED INTRAARTICULARLY TO THE JOINTS WITH DEGENERATIVE ARTHRITIS**

**OSTEOGENIC DIFFERENTIATION CAPACITY OF ADIPOSE-DERIVED STEM CELLS AFFECTED WITH COLD STORAGE**

## Scientific Programme

e-Posters  
08:30 - 19:00

ePoster Area

### Solid tumours

**SUCCESSFUL KIR ALLOREACTIVE HSCT IN A CHILD WITH RESISTANT EWING SARCOMA**

**TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS**

**VOC PATTERN RECOGNITION OF LUNG CANCER: A COMPARATIVE EVALUATION OF DIFFERENT DOG- AND ENOSE-BASED STRATEGIES USING DIFFERENT SAMPLING MATERIALS**

e-Posters  
08:30 - 19:00

ePoster Area

### Statistics

**USE OF VARIABLE SELECTION METHODS TO IDENTIFY CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THE CLINICAL OUTCOME OF PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THE IMPACT OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON WORK AND PRODUCTIVITY LOSS IN PATIENTS WITH ACUTE LEUKAEMIA: RESULTS FROM A RAPID REVIEW**

**GEOGRAPHIC AND SOCIOECONOMIC IMPACTS ON SURVIVAL AMONG ALLOGENEIC TRANSPLANT RECIPIENTS**

e-Posters  
08:30 - 19:00

ePoster Area

### Stem cell donor

**DONOR-RECIPIENT HLA MATCHING FOR UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION <b>Outcomes: </b> A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY (CTIWP) OF THE EBMT**

**PRESENCE OF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN DONOR DOES NOT INCREASE THE RISK OF LATE SECONDARY MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Kyoung Ha Kim, Tae Hyung Kim, Jae-Sook Ahn, Ivan Pasic, Zeyad Al-Shaibani, Arjun Law, Wilson Lam, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Zhaolei Zhang, Tamir Biezuner, Liran Shlush, Dennis Dong Hwan Kim (Canada)

**SERIOUS EVENTS AND ADVERSE REACTIONS IN RELATION TO BLOOD STEM CELL DONATION REPORTED TO WMDA IN 2018**

**THE IMPROVEMENT IN OVERALL SURVIVAL FROM UNRELATED DONOR TRANSPLANT IN AUSTRALIA AND NEW ZEALAND IS DRIVEN BY A REDUCTION IN TRANSPLANT RELATED MORTALITY**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING, UNRELATED AND HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA, A COMPARATIVE STUDY OF THE ALWP EBMT**

**ALLOREACTIVITY AGAINST HLA-DPB1 IN HOST-VERSUS-GRAFT DIRECTION IS ASSOCIATED WITH INCREASED RISK OF GRAFT FAILURE AFTER MATCHED UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES**

## **Scientific Programme**

**IMPACT OF KIR ON PATIENTS WITH LYMPHOID DISEASES AFTER T-CELL REPLETE  
HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**INDICATIONS AND SAFETY OF MULTIPLE BONE MARROW HARVESTS IN PEDIATRIC DONORS  
FOR MATCHED SIBLING RECIPIENT TRANSPLANTATION**

**HEALTHY VOLUNTARY STEM CELL DONORS: FOLLOW UP AFTER HPC APHERESIS DONATION:  
THE EXPERIENCE OF ITALIAN BONE MARROW DONOR REGISTRY**

**ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH POST-  
TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH INHERITED DISORDERS**

**HAPLOIDENTICAL REDUCED-INTENSITY HEMATOPOIETIC CELL TRANSPLANTATION USING  
BUSULFAN, FLUDARABINE, AND ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ACUTE  
MYELOID LEUKEMIA**

**THE RESULTS OF A TELECONFERENCE ABOUT THE EXPERIENCES AND EXPECTATIONS OF  
RELATED HEMATOPOIETIC STEM CELL DONORS AFTER DONATION**

**IMPACT OF THE ESTABLISHMENT OF THE TURKISH NATIONAL DONOR REGISTRY (TURKOK)  
ON A SINGLE CENTER'S TRANSPLANT OUTCOME: INTERNATIONAL STEM CELL DONORS  
VERSUS NATIONAL**

**YOUNG MALE DONORS MAY RESULT IN BETTER OUTCOMES OF HAPLOIDENTICAL  
HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA WITH PT-CY**

**DONORS OF PERIPHERAL HEMATOPOIETIC STEM CELLS, OUR EXPERIENCE FOR LAST 10  
YEARS**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS OVER 70 YEARS  
:A MONOCENTRIC EXPERIENCE OF 48 PATIENTS**

**COMPARISON OF TRANSPLANT OUTCOMES AND ECONOMIC COSTS IN ALLOGENEIC STEM  
CELL TRANSPLANTATION FOR AML AND MDS BETWEEN THE DIFFERENT TYPE OF DONORS**

**HIGH DISEASE-FREE SURVIVAL OF THE SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL  
TRANSPLANTATION WITH DONOR CHANGE AND MAINLY REDUCED-INTENSITY CONDITIONING  
IN RELAPSED HEMATOLOGICAL MALIGNANCIES**

**EPIDEMIOLOGICAL STUDY OF RARE ANTIGENS OF THE MAIN HISTOCOMPATIBILITY COMPLEX  
AMONG HEMATOPOIETIC STEM CELL DONORS IN BELARUS**

**IMPACT OF DONOR-RECIPIENT SEX MISMATCH IN PATIENTS RECEIVING PARTIAL T-CELL  
DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY:  
A RETROSPECTIVE MONOCENTRIC STUDY**

**HAPLOIDENTICAL DONOR SELECTION AND ITS IMPLICATIONS IN TRANSPLANTATION  
OUTCOME. OUR EXPERIENCE AT HUDGC DR. NEGRIN**

**OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ACCORDING TO DONOR  
AVAILABILITY, DURATION FROM DIAGNOSIS TO TRANSPLANT AND DONOR-SPECIFIC  
PARAMETERS - A SINGLE CENTER ANALYSIS**

**THE BENEFITS OF HLA-MATCHED RELATED DONORS FOR PATIENTS LACKING HLA-IDENTICAL  
SIBLING IN THE ABSENCE OF POWERFUL LOCAL UNRELATED REGISTRY IN COUNTRIES WITH  
PREVALENT COUSIN MARRIAGES**

**DONOR AGE INFLUENCES THE GRAFT-VERSUS-HOST-DISEASE-FREE AND RELAPSE-FREE  
SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ELDERLY PATIENTS IN LATIN  
AMERICA**

**A STUDY OF THE UNCERTAINTY, UNCERTAINTY APPRAISAL AND GROWTH AND THE  
AFFECTED FACTORS ON HEMATOPOIETIC STEM CELL DONORS**

## Scientific Programme

**WITHDRAWAL OF VOLUNTEER DONORS FROM THE INTERNATIONAL REGISTRIES: A SINGLE CENTRE EXPERIENCE**

**OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION FOR AML AND MYELOYDYSPLASTIC SYNDROME IN ELDERLY WITH REDUCED-INTENSITY CONDITIONING**

**HAPLOIDENTICAL VS UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS WITH HEMATOLOGIC MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS**

**HEPATITIS E VIRUS (HEV) CONTAMINATED HEMATOPOIETIC STEM CELL GRAFT IN A MATCHED UNRELATED DONOR TRANSPLANTATION**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MATCH RELATED DONORS IN CHILDHOOD: SINGLE CENTER EXPERIENCE**

**FIRST EXPERIENCE WITH UNRELATED STEM CELL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A TRANSPLANT CENTER FROM NORTH MACEDONIA**

e-Posters  
08:30 - 19:00

ePoster Area

## Stem cell mobilization, collection and engineering

**TWO YEAR ANALYSIS OF A PROSPECTIVE PHASE I/II CLINICAL TRIAL IN ADULTS USING TCR ALPHA/BETA DEPLETED STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONORS**

**A NEW BSA-BASED THRESHOLD PREDICTS OPTIMAL PBSC COLLECTION IN T-CELL DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

**PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILIZATION AND COLLECTION OF CD34+ HSCS WITHOUT G-CSF**

**DEPLETION OF  $\alpha\beta$  T-CELLS AND B-CELLS BEFORE HLA-HAPLOIDENTICAL HSCT IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT OF 473 PROCEDURES**

**ACOUSTOPHORESIS ENABLES THE LABEL-FREE SEPARATION OF DISTINCT SUBSETS FROM CULTURED BONE MARROW STROMAL CELLS**

**FEASIBILITY OF MODIFIED CD45RA NEGATIVE DONOR LYMPHOCYTES INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**BEYOND STEM CELLS - DOES IT MATTER WHAT'S IN THE BAG IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA AND LYMPHOMA?**

**EXPRESSIONS OF CO-INHIBITORY MARKERS INCREASE EFFECTOR MEMORY T CELLS IN G-CSF MOBILIZED PERIPHERAL STEM CELLS**

**LIPEGFILGRASTIM COMBINED WITH CHEMOTHERAPY WAS MORE COST-EFFECTIVE THAN PEGFILGRASTIM IN THE MOBILIZATION OF CD34+ CELLS IN NHL PATIENTS**

**MOBILIZATION AND HARVEST OF PERIPHERAL BLOOD STEM CELLS (PBSC) FOR ALLOGENEIC STEM CELL TRANSPLANTATION FROM 335 PEDIATRIC SIBLING HEALTHY DONORS**

## **Scientific Programme**

**A COMPARISON OF CHEMO-FREE STRATEGY WITH G-CSF PLUS PLERIXAFOR ON DEMAND VERSUS ID-CYCLOPHOSPHAMIDE AND G-CSF AS PBSC MOBILIZATION IN MULTIPLE MYELOMA: AN EXPLORATIVE COST ANALYSIS**

**EVALUATION OF VIA FREEZETM QUAD FOR LIQUID NITROGEN-FREE CGMP-COMPATIBLE CONTROLLED-RATE FREEZING OF HEMATOPOIETIC PROGENITOR CELL GRAFTS**

**CD34 + CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS**

**PLERIXAFOR ON DEMAND IN COMBINATION WITH LOW-DOSE CYCLOPHOSPHAMIDE AND G-CSF FOR THE MOBILIZATION OF HSC IN MULTIPLE MYELOMA PATIENTS: HIGH EFFICACY AND LOW TOXICITY**

**PERFORMANCE QUALIFICATION OF LOVOTM MEDICAL DEVICE FOR WASHING AND CONCENTRATING 3 AND MORE HEMATOPOIETIC PROGENITOR CELL CRYOPRESERVED BAGS**

**FROM WORK-UP REQUEST TO DONATION IN THREE WEEKS: A DEDICATED REGISTRY INTEGRATED UNRELATED DONOR STEM CELL COLLECTION CENTER IS SAFE, EFFICIENT AND CONVENIENT FOR DONORS**

**LOW-DOSE CYCLOPHOSPHAMIDE + G-CSF IS NO MORE EFFECTIVE THAN G-CSF ALONE WHEN MOBILIZING AND COLLECTING STEM CELLS FOR AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS**

**FIRST INTERIM RESULTS OF NIS OPTIMOB - NATIONWIDE TRIAL OF MOBILIZATION AND COLLECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS**

**THE IMPACT OF PLERIXAFOR 'ON DEMAND' ON THE HEMATOPOIETIC STEM CELL (HSC) COLLECTION, PRODUCT'S QUALITY AND ENGRAFTMENT**

**ELEVATED SERUM LACTATE DEHYDROGENASE AFTER STEM CELL MOBILISATION PREDICTS SUCCESSFUL STEM CELL COLLECTION IN CHILDREN**

**INFLUENCE OF THE DMSO WASH STRATEGY ON ADVERSE REACTIONS DURING INFUSION OF HEMATOPOIETIC PROGENITORS**

**BONE MARROW DONOR CHARACTERISTICS: INFLUENCE ON HARVEST YIELD AND DONOR RECOVERY**

**PLERIXAFOR SALVAGES AUTOLOGOUS STEM CELL MOBILISATION PROCEDURES IN MYELOMA PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE OR AUTOLOGOUS HSCT: COST-EFFECTIVENESS OF UPFRONT USE SHOULD BE EXPLORED**

**EFFECT OF SHIPPING TIME AND TRANSPORT CONDITIONS ON THE VIABILITY OF CORD BLOOD LEUKOCYTES**

**OPTIMIZATION OF A STEM CELL MOBILIZATION STRATEGY FOR PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA**

**AUTOLOGOUS LYMPHAPHERESIS FOR THE PRODUCTION OF CAR-T CELLS**

**RED BLOOD CELL DEPLETION AND/OR VOLUME REDUCTION IN BONE MARROW PROCESSING: A COMPARISON OF TWO METHODS**

**CORRELATION OF INTRA-OPERATIVE TOTAL NUCLEATED COUNT AND DONOR CHARACTERISTICS WITH FINAL ALLOGENEIC BONE MARROW GRAFT CHARACTERISTICS AND RECIPIENT CLINICAL OUTCOMES**

**MULTICENTRE EVALUATION OF THE HPC MODUS (XN-20) FOR TIMING THE HARVEST OF STEM CELLS FROM PERIPHERAL BLOOD**

## Scientific Programme

**IMPACT OF CHANGE OF MOBILISATION METHOD ON ADEQUACY OF STEM CELL COLLECTION IN MULTIPLE MYELOMA PATIENTS: SINGLE CENTRE EXPERIENCE**

**TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE**

**AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS (PBSCS) MOBILIZATION AND COLLECTION- PRINCESS NOORAH ONCOLOGY CENTER EXPERIENCE, KAMC - JEDDAH - SAUDI ARABIA**

**REVIEW OF PLERIXAFOR USE IN A TERTIARY PAEDIATRIC ONCOLOGY CENTRE**

**UNUSUAL HIGH COUNT OF CD34+ AFTER CHEMO MOBILIZATION WITH MATRIX IN PATIENT WITH PRIMARY CNS LYMPHOMA IS ASSOCIATED WITH PROMPT AND ROBUST ENGRAFTMENT**

**LEUKOCYTAPHERESIS - ONE TECHNIQUE, DIVERSE OPPORTUNITIES IN THE THERAPY OF PATIENTS**

**COMPARISON OF CONTINUOUS MONONUCLEAR CELL COLLECTION (CMNC) AND MONONUCLEAR CELL CELL (MNC) METHODS FOR CELL PROLIFERATION (APHERESIS) IN PATIENTS WITH BONE MARROW TRANSPLANTATION**

e-Posters  
08:30 - 19:00

ePoster Area

### Stem cell source

**OPTIMIZING OUTCOMES OF ACUTE LEUKEMIA AFTER TRANSPLANTS WITH SINGLE UNRELATED CORD BLOOD UNITS SELECTED ACCORDING TO CURRENT INTERNATIONAL RECOMMENDATIONS FOR CELL DOSE AND HLA MATCH**

**IMPACT OF HLA-MISMATCH ON OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE ANALYSIS BY THE JSHCT HLA WORKING GROUP**

**CLINICAL IMPACT OF DONOR EPITOPE-SPECIFIC HLA ANTIBODIES AND THIRD-PARTY HLA ANTIBODIES IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION**

**ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS**

**THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION**

**COMPARATIVE STUDY OF HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETION VS UNRELATED CORD BLOOD TRANSPLANT FOR ADULTS WITH HAEMATOLOGICAL MALIGNANCIES**

**USE OF G-CSF MOBILIZED BONE MARROW GRAFTS IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION (BMT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) DECREASES RISK OF SEVERE ACUTE GVHD**

**CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION**

**REDUCED INTENSITY (RIC) VS MYELOABLATIVE CONDITIONING (MAC) IN CORD BLOOD TRANSPLANTATION FOR AML (40-60 YEARS) ACROSS MISMATCHED HLA BARRIERS - ANALYSIS BY CTIWP/EUROCORD OF EBMT**

## Scientific Programme

**COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL WORLD: AN ANALYSIS USING THE JAPANESE NATIONAL DATABASE**

**ASSOCIATION BETWEEN THE DOSE OF CD3+ AND CD34+ CELLS IN THE GRAFT AND POST-TRANSPLANT OUTCOMES**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A RELATED DONOR WITH HLA-1 ANTIGEN MISMATCH IN THE GRAFT-VERSUS-HOST DIRECTION USING LOW-DOSE ANTI-THYMOCYTE GLOBULIN: MULTICENTER PHASE II TRIAL**

**INTRA-BONE CORD-BLOOD TRANSPLANT OF UNWASHED UNITS WITH ATG-FREE AND SIROLIMUS-BASED GVHD PROPHYLAXIS: FAST IMMUNE-RECONSTITUTION AND LONG-TERM DISEASE CONTROL IN 22 PATIENTS WITH HIGH-RISK DISEASES**

**ANTI-HLA DONOR SPECIFIC ANTIBODIES (DSA) DOES NOT AFFECT GRAFT AND SURVIVAL IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) WITH ORIGINAL POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) SCHEDULE**

**MESENCHYMAL STEM/STROMAL CELL PRODUCTION COMPLIANT WITH GOOD MANUFACTURING PRACTICE: COMPARISON BETWEEN BONE MARROW AND WHARTON'S JELLY**

**EFFICIENT DMSO REMOVAL AND HIGH CELL RECOVERY WITH LOVO CELL PROCESSING SYSTEM IN HPC-A CONCENTRATES: A SINGLE CENTRE EXPERIENCE**

e-Posters  
08:30 - 19:00

ePoster Area

## Nurses Posters - Adult

**ROLE OF QUICKSOFA IN PREDICTING SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL PATIENTS**

**BOLUS: TARGETED SPECIALIST HAEMATOLOGY/BMT PODCASTS: AN EFFECTIVE METHOD OF EDUCATION**

**A PATHWAY FOR RECOVERY: D+100 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT) FOLLOW UP PILOT FOR LYMPHOMA**

**REDUCING ACCIDENTAL FALLS CAUSED BY ORTHOSTATIC HYPOTENSION IN BONE MARROW TRANSPLANT RECIPIENTS**

**THE EFFECT OF MOTIVATIONAL INTERVIEW PERFORMED AFTER STEM CELL TRANSPLANTATION ON SEXUAL EXPERIENCE, SEXUAL SELF-AWARENESS AND SEXUAL SELF-EFFICACY**

**STUDY ON COGNITIVE FUNCTION AND RELATED FACTORS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THE EFFECT OF RELAXING BREATHING EXERCISES ON PAIN, FATIGUE AND LEUKOCYTE COUNT IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**UNDERSTANDING OF PROGNOSIS, QUALITY OF LIFE AND PSYCHIATRIC STATUS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY OF 348 PATIENTS**

**AN OUTPATIENT MODEL OF CARE TO SAFELY DELIVER AUTOLOGOUS STEM CELL TRANSPLANTATION**

**EFFECTS OF TREATMENTS FOR HAEMATOLOGICAL MALIGNANCIES ON SEXUALITY AND FERTILITY: WHEN DO PATIENTS NEED IT AND WHOM REALLY WANTS TO KNOW?**

## **Scientific Programme**

**EFFICACY OF THERAPEUTIC EDUCATION TO REDUCE RISKS AND COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY**

**SELF-EFFICACY AND SELF-CARE PRACTICES OF PATIENTS WHO HAVE BEEN TRANSPLANTED WITH ALLOGENEIC HEMATOPOIETIC STEM CELLS ACCORDING TO THE DEVELOPMENT OF AN INDIVIDUAL EDUCATION PROGRAM**

**DETERMINING THE SYMPTOMS AND COPING METHODS OF PATIENTS AT HOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THE EFFECT OF ORAL CARE PROTOCOL ON ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) WITHIN AN AMBULATORY CARE SETTING; A PATIENTS' PERSPECTIVE**

**REDUCING ANTITHYMOCYTE GLOBULIN ( ATG) INFUSION RELATED REACTION BY INCREASING THE INFUSION DURATION IN ADULT SCT PATIENTS ; A SINGLE INSTITUTION EXPERIENCE FROM SAUDI ARABIA**

**NURSE LED TELEPHONE FOLLOW UP FOR LATE EFFECTS SERVICE**

**NURSING CARE OF 15 PATIENTS WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CHIMERIC ANTIGEN RECEPTOR T CELLS**

**NURSING CARE OF A PATIENT WITH HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY COMPLICATED WITH AXONAL DEGENERATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EFFECT OF NURSES EDUCATION PROGRAM ON CATHETER RELATED BLOOD STREAM INFECTIONS**

**THE CURRENT SITUATION AND INFLUENCING FACTORS OF MANAGEMENT OF CENTER VENOUS ACCESS DEVICE-ASSOCIATED SKIN IMPAIRMENT DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EXERCISE SUPPORT FOR PEOPLE POST TREATMENT AS PART OF THEIR RETURN TO WORK JOURNEY: A CASE STUDY EXEMPLAR**

**ONCOSAFETY: A NEW TOOL FOR HEMATOLOGY NURSES TO AVOID CHEMOTHERAPY ERRORS**

**PATIENT INFORMATION SHEET FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: THE IMPACT OF THE DISEASE AND TREATMENT ON SEXUAL FUNCTION AND SEXUALITY**

**CHANGING PRACTICE BY USING CYCLOPRIME 1.5G/M2 PRIMING REGIME UP FRONT FOR LYMPHOMA PATIENTS TO ENSURE GOOD MOBILISATION OF STEM CELLS**

**THE CHALLENGES OF LOOKING AFTER AN INCREASING NUMBER OF SURVIVORS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION**

**VENO-OCCLUSIVE DISEASE (VOD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT NURSING CONSIDERATIONS AND MANAGEMENT: A CASE STUDY**

**RECOGNIZING LOW HEALTH SKILLS AND LOW LITERACY DURING CONSULTATION**

**PRE-HABILITATION PRIOR TO STEM CELL TRANSPLANT - ONE CENTRES EXPERIENCE**

**THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY**

## Scientific Programme

**PLASMAPHERESIS: TAKING THE EDGE OFF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTIBODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

**INCIDENCE & CHARACTERISTICS OF VARICELLA ZOSTER VIRUS INFECTION POST HEMATOPOIETIC STEM CELL TRANSPLANTATION; EXPERIENCE OF A SINGLE CENTER IN SAUDI ARABIA**

**SEMI-STRUCTURED INTERVIEW ASSESSMENT OF THE CLINICAL NURSE EDUCATOR ROLE IN SUPPORTING NEWLY QUALIFIED NURSES DURING TRANSITION TO POST-REGISTRATION PRACTICE INSIDE THE BONE MARROW TRANSPLANT SETTING**

**TRAINING NURSING PROGRAMME IN NEW THERAPIES: CAR T CELLS**

**NURSES' ROLE IN IMPROVING PATIENTS' FOOD INTAKE IN THE ACUTE HSCT PHASE**

**USE THE AVAILABLE KNOWLEDGE - ENSURE THAT THE PATIENT RECEIVES THE BEST CARE IN STEM CELL TRANSPLANTATION**

**THE PSYCHO EMOTIONAL DISAGUE IN ADULT PATIENTS SUBJECT TO MIDOLLO TRANSPLANT: INITIAL STUDY OF A SINGLE CENTER**

**NURSING CARE OF 15 PATIENTS WITH HEMATOLOGICAL MALIGNANT TUMOR COMPLICATED WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CAR-T CELLS**

**RETROSPECTIVE OBSERVATIONAL STUDY ON THE TRANSMISSION OF HEALTHCARE ASSOCIATED INFECTIONS AMONG NEUTROPENIC PATIENTS WITHIN THE HEMATOLOGY UNIT OF PIACENZA HOSPITAL**

**GUIDE FOR PATIENTS AND DONORS BEFORE A PERIPHERAL BLOOD STEM CELL COLLECTION**

Natalia Lorente del Río, Cristina Alberquilla Ramos, Salvadora Aleza Esteras, Isabel María Fernández Morales, M<sup>a</sup> Del Carmen Freire Mourón, Ana García Carulla, Carmen Granado Rodilla, Mercedes Jiménez Meoro, Rosario López López, Marta Vela Garicano, Jesús Zalvide Torrente, Laura Bibiloni Martínez (Spain)

**IMPACT OF AN IMPROVEMENT PLAN ON THE REDUCTION OF BACTERIEMIA BY CENTRAL CATHETER IN A PATIENT RECEIVER OF A CELLULAR THERAPY**

**ARE TYMPANIC THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?**

**RELATIONSHIPS BETWEEN THE HEALTHCARE NEEDS AND QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS**

**PAIN ASSESSMENT DURING BONE MARROW BIOPSY PROCEDURE AND BONE MARROW ASPIRATE PROCEDURE: A SPECIFIC NURSING ASSESSMENT**

**AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION IN SYSTEMIC SCLEROSIS: CASE STUDY**

**LEADERSHIP - LEADING THE TEAM**

**PAIN ASSESSMENT IN ONCO\_HEMATOLOGICAL PATIENT SUBJECTED TO CENTRAL VENOUS CATHETER POSITIONING (CVC) OR PERIPHERALLY INSERTED CENTRAL CATHETER POSITIONING (PICC)**

**TOCILIZUMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME**

**COMPLICATIONS ASSOCIATED WITH THE COLLECTION OF PERIPHERAL BLOOD PROGENITOR CELLS**

**IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS!**

**INCIDENCE OF ACUTE GUT GVHD IN PATIENTS WHO HAVE UNDERGONE ALLOGENIC STEM CELL TRANSPLANT: CASE STUDY**

## Scientific Programme

**COMPLETION TIME TO HLA TYPING**

**GYNECOLOGICAL TREATMENT EXPERIENCE OF MENOPAUSAL SYNDROME AND SEXUAL DISORDERS IN FEMALE PATIENTS WHO UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION**

e-Posters  
08:30 - 19:00

ePoster Area

### Nurses Posters - Paediatric

**TRANSITION STRATEGY: FROM PEDIATRIC TO ADULT HEALTH CARE AND LONG TERM FOLLOW-UP**

**CAREGIVER EDUCATION AND TRAINING FOR SELF ADMINISTRATION OF ORAL DRUGS IN A PAEDIATRIC CENTER**

**EXERCISE THERAPY ON CANCER-RELATED FATIGUE AND QUALITY OF LIFE IN CHILDREN UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION**

**SEXUAL HEALTH FOR YOUNG PEOPLE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EVALUATION OF A PREVENTIVE SKIN CARE PROTOCOL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA**

**CAR-T: THE DUTCH PEDIATRIC NURSING EXPERIENCE**

**SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEIPIENTS: A SINGLE CENTER EXPERIENCE**

**PEDIATRIC PHOTOAPHAERESIS: THE DILEMMA OF VASCULAR ACCESSES**

**TOTALLY IMPLANTABLE VASCULAR ACCESS DEVICES RUPTURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: PROPHYLAXIS AND TREATMENT**

**USE OF VOLUMETRIC PUMPS FOR THE INFUSION OF HEMATOPOIETIC STEM CELLS AS A STANDARD METHOD IN PEDIATRIC PATIENTS**

**PEDIATRIC PATIENT TRANSFER FROM A TPH WARD TO ICU: HOW CAN WE IMPROVE OUR COMMUNICATION?**

**CARING FOR MINOR SIBLING DONORS**

**EFFECTIVE MOBILISATION WITH PLERIXAFOR FOLLOWING CRANIA-SACRAL RADIOTHERAPY AND HIGH-DOSE CHEMOTHERAPY: A CASE REPORT OF AN ELEVEN-YEAR OLD BOY WITH GLIOBLASTOMA MULTIFORME**

**EARLY RECOGNITION OF PEDIATRIC GVHD: EDUCATION AND AWARENESS AMONGST NURSES**

**RISK ASSESSING PAEDIATRIC PATIENTS' NUTRITIONAL NEEDS PRIOR TO BONE MARROW TRANSPLANT**

e-Posters  
08:30 - 19:00

ePoster Area

### Nurses Posters - Research

## **Scientific Programme**

**FAMILY CAREGIVERS SUPPORT NEEDS DURING ALLO-HSCT - A LONGITUDINAL STUDY (PRELIMINARY RESULTS)**

**PAIN AND ANXIETY MANAGEMENT DURING BONE MARROW ASPIRATES IN ITALIAN TRANSPLANT PROGRAMS. A NATIONWIDE SURVEY ON BEHALF OF GITMO NG**

**PREVALENCE, PREDICTORS AND OUTCOMES OF CLABSI AMONG HSCT PATIENTS**

**CREATION OF THE LABMT NURSES GROUP**

**SYMPTOMS AND QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY**

**SOCIAL SUPPORT MODERATES THE EFFECTS OF HEALTH STRESSORS ON HEALTH CARE ADHERENCE AND PSYCHOLOGICAL DISTRESS IN LONG-TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS**

**SYMPTOM DISTRESS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY**

**NURSE INVOLVEMENT AND IMPACT OF JACIE ACCREDITATION ON NURSE PRACTICE**

**CONSTRUCTION OF QUALITY INDICATORS SYSTEM OF NUTRITION CARE FOR ADULT PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH AN EVIDENCE-BASED APPROACH**

**ARE CAREGIVERS RECEIVING ENOUGH INFORMATION TO CARE? A PILOT STUDY ON A HAEMATOLOGICAL TRANSPLANT UNIT**

**MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A THREE YEARS FOLLOWING UP**

**VENOUS ACCESS IN AUTOLOGOUS VERSUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONORS: A RETROSPECTIVE STUDY OF AN Apheresis UNIT**

**A STUDY TO ASSESS THE LEVEL OF BURNOUT AMONG NURSES WORKING IN BONE MARROW TRANSPLANT (BMT) UNIT OF A TERTIARY CARE CANCER HOSPITAL**

**DO WE KNOW ENOUGH ABOUT THE BONE MARROW DONATION?**

**ASSOCIATION OF AIR BORN PARTICLE SIZE AND PARTICLE COUNT WITH INCIDENCE OF INFECTIONS IN HEPA FILTERED ROOMS-A SINGLE CENTRE EXPERIENCE**

**SYSTEMATIC REVIEW OF SIGNS AND SYMPTOMS OF THE HUMAN HERPES VIRUS 6 AND THEIR ASSESSMENT TOOLS**

**A STUDY TO ASSESS PERCEIVED STRESSORS AND COPING STRATEGIES ADOPTED BY PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL INFUSION IN SELECTED CANCER HOSPITAL, INDIA**

**ROLE OF THERAPEUTIC APHERESIS IN ALLOGENEIC TRANSPLANTATION: A CASE REPORT**

**SYMPTOMS OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER INDUCTION CHEMOTHERAPY**

## Scientific Programme

CME Symposium  
08:45 - 10:00

Auditorium 3

### IS3, GMMG CME Symposium: Stem cell transplantation in Multiple Myeloma

**Chairs:**

Hartmut Goldschmidt (Germany)

<b>Role of allo-TPX in Multiple Myeloma</b> Nicolaus Kröger (Germany)	<b>08:45 - 08:59</b>
<b>Impact of age on the decision of auto-TPX in Multiple Myeloma</b> Hans Salwender (Germany)	<b>08:59 - 09:13</b>
<b>Predictive factors in Multiple Myeloma</b> Hartmut Goldschmidt (Germany)	<b>09:13 - 09:27</b>
<b>Treatment of high-risk Multiple Myeloma</b> Katja Weisel (Germany)	<b>09:27 - 09:41</b>
<b>Cellular Therapy in Multiple Myeloma</b> Christoph Scheid (Germany)	<b>09:41 - 09:55</b>
<b>Q&amp;A</b>	<b>09:55 - 10:00</b>

Industry Symposium  
10:30 - 12:00

Auditorium 2

### IS4, Practical considerations for CAR-T Cell Therapy use in lymphomas - Novartis Industry Symposium

**Chairs:**

Anna Sureda (Spain)

<b>Introduction and opening remarks</b> Anna Sureda (Spain)	<b>10:30 - 10:35</b>
<b>CAR-T Cell Therapy in the DLBCL continuum of care: Efficacy and safety in key clinical trials and the real world</b> Matthew Frigault (United States)	<b>10:35 - 10:55</b>
<b>Patient selection for CAR-T Cell Therapy: What we know and what we have yet to find out</b> Anna Sureda (Spain)	<b>10:55 - 11:10</b>
<b>Treatment landscape in DLBCL: New developments, and when to take the CAR instead?</b> Edmund K Waller (United States)	<b>11:10 - 11:30</b>
<b>How to apply CAR-T Cell Therapy in DLBCL: Interactive case-based panel</b> Pere Barba (Spain)	<b>11:30 - 11:45</b>
<b>Panel discussion</b>	<b>11:45 - 11:55</b>
<b>Closing remarks</b> Anna Sureda (Spain)	<b>11:55 - 12:00</b>

## Scientific Programme

Industry Symposium  
10:30 - 11:15

Auditorium 3

### **IS5, Maintenance of complete remission in AML - Celgene | Bristol Myers Squibb Industry Symposium**

**Chairs:**

Martin Bornhäuser (Germany)

<b>Welcome and introduction</b>	<b>10:30 - 10:35</b>
Martin Bornhäuser (Germany)	
<b>Kinetics of clonal evolution and relapse in AML patients in complete response</b>	<b>10:35 - 10:50</b>
Maria Teresa Voso (Italy)	
<b>Current and upcoming pharmacological options to prolong complete response in AML</b>	<b>10:50 - 11:05</b>
Charles Craddock (United Kingdom)	
<b>Closing remarks</b>	<b>11:05 - 11:15</b>
Martin Bornhäuser (Germany)	
Maria Teresa Voso (Italy)	
Charles Craddock (United Kingdom)	

Industry Symposium  
10:30 - 12:00

Auditorium 4

### **IS6, Case Studies on Innovative Treatment Approaches for CMV in HCT: A Clinical Forum - Industry Symposium supported by an educational grant from Takeda**

**Chairs:**

Jan Styczynski (Poland)

<b>Welcome and Introductions</b>	<b>10:30 - 10:35</b>
Jan Styczynski (Poland)	
<b>HCT CASE 1 - Patient with Refractory or Resistant Disease and Panel Discussion</b>	<b>10:35 - 11:05</b>
Per Ljungman (Sweden)	
<b>Audience Q&amp;A</b>	<b>11:05 - 11:10</b>
<b>HCT CASE 2 - Patient with Late CMV Disease and Panel Discussion</b>	<b>11:10 - 11:40</b>
Johan Maertens (Belgium)	
<b>Audience Q&amp;A, Closing Remarks</b>	<b>11:40 - 12:00</b>

## Scientific Programme

Industry Symposium  
10:30 - 12:00

Auditorium 5

### IS7, Your decisions in action: The reality of severe hepatic VOD management - Jazz Pharmaceuticals Industry Symposium

#### Chairs:

Mohamad Mohty (France)

<b>Welcome and introduction</b>	<b>10:30 - 10:35</b>
Mohamad Mohty (France)	
<b>The patient: your important initial choices in action</b>	<b>10:35 - 10:50</b>
Rafael Duarte (Spain)	
<b>Assessment and monitoring, what now?</b>	<b>10:50 - 11:05</b>
Rafael Duarte (Spain)	
Mohamad Mohty (France)	
<b>Outcome: the reality of severe hepatic VOD</b>	<b>11:05 - 11:20</b>
Mohamad Mohty (France)	
<b>Informed decision-making for paediatric hepatic VOD</b>	<b>11:20 - 11:35</b>
Selim Corbacioglu (Germany)	
<b>Live Q&amp;A</b>	<b>11:35 - 11:55</b>
<b>Summary and close</b>	<b>11:55 - 12:00</b>
Mohamad Mohty (France)	

Patient, Family Donor Day  
10:30 - 12:40

Auditorium 6

### PFD1, Patient, Family and Donor Day

#### Chairs:

Sarah Hutton (United Kingdom)  
Guy Bouguet (France)

<b>Welcome by moderators</b>	<b>10:30 - 10:35</b>
Guy Bouguet (France)	
Sarah Hutton (United Kingdom)	
<b>Patient's testimony on impact on life and self</b>	<b>10:35 - 10:45</b>
Agnès Huet-Vicens (France)	
<b>Introduction to speaker</b>	<b>10:45 - 10:46</b>
<b>Overview HSCT and GVHD</b>	<b>10:46 - 11:06</b>
Régis Peffault de Latour (France)	
<b>Q&amp;A</b>	<b>11:06 - 11:21</b>
<b>Break</b>	<b>11:21 - 11:26</b>
<b>Introduction to speaker</b>	<b>11:26 - 11:27</b>

## Scientific Programme

<b>Psychological well-being on transplant patients</b> Anna Barata (United States)	<b>11:27 - 11:47</b>
<b>Q&amp;A</b>	<b>11:47 - 12:02</b>
<b>Introduction to speaker</b>	<b>12:02 - 12:03</b>
<b>CAR-T Cell Therapy</b> Jürgen Kuball (Netherlands)	<b>12:03 - 12:23</b>
<b>Q&amp;A</b>	<b>12:23 - 12:38</b>
<b>Closing remarks</b>	<b>12:38 - 12:40</b>

Industry Symposium  
12:30 - 14:00

Auditorium 1

### **IS8, Improving outcomes: Transplant and beyond in patients with high-risk AML\* - Jazz Pharmaceuticals Industry Symposium**

\*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

#### **Chairs:**

Charles Craddock (United Kingdom)

#### **Welcome and introduction**

Charles Craddock (United Kingdom)

#### **Current considerations for patient selection for HSCT**

Fabio Ciceri (Italy)

#### **Strategies for optimising long-term outcomes from HSCT in patients with high-risk AML**

Charles Craddock (United Kingdom)

#### **Optimising outcomes with pre-transplant treatment selection in high-risk AML**

Donal McLornan (United Kingdom)

#### **Q&A**

#### **Summary and close**

Charles Craddock (United Kingdom)

Industry Symposium  
12:30 - 14:00

Auditorium 2

### **IS9, Steroid-refractory GvHD: Current challenges and future advances - Novartis Industry Symposium**

#### **Chairs:**

Franco Locatelli (Italy)

#### **Welcome and introduction**

Franco Locatelli (Italy)

**12:30 - 12:35**

## Scientific Programme

<b>GvHD and steroid-refractory GvHD in 2020</b> Jeff Szer (Australia)	<b>12:35 - 12:55</b>
<b>Today's challenges in managing acute and chronic steroid-refractory GvHD</b> Franco Locatelli (Italy)	<b>12:55 - 13:00</b>
<b>Panel discussion</b>	<b>13:00 - 13:10</b>
<b>The future of steroid-refractory GvHD: Acute and chronic GvHD</b> Madan Jagasia (United States) Robert Zeiser (Germany)	<b>13:10 - 13:40</b>
<b>Panel discussion</b>	<b>13:40 - 13:55</b>
<b>Concluding remarks</b> Franco Locatelli (Italy)	<b>13:55 - 14:00</b>

Industry Symposium  
12:30 - 14:00

Auditorium 3

### **IS10, Current status and potential of CAR T cell therapies in B-cell malignancies - Celgene | Bristol Myers Squibb Industry Symposium**

#### **Chairs:**

Catherine Thieblemont (France)

<b>Welcome and introduction</b> Catherine Thieblemont (France)	<b>12:30 - 12:35</b>
<b>CAR T in DLBCL: The latest data and future perspectives</b> Pere Barba (Spain)	<b>12:35 - 12:55</b>
<b>Beyond DLBCL: CAR T in high-risk or relapsing B-cell malignancies</b> Tom van Meerten (Netherlands)	<b>12:55 - 13:15</b>
<b>The impact of CAR T on patient care organization</b> Catherine Thieblemont (France)	<b>13:15 - 13:35</b>
<b>Summary and Q&amp;A</b> Catherine Thieblemont (France)	<b>13:35 - 14:00</b>

Industry Symposium  
12:30 - 14:00

Auditorium 4

### **IS11, Established and cutting-edge applications for cell therapies - Miltenyi Biotec Industry Symposium**

#### **Chairs:**

Rafael Duarte (Spain)

<b>Welcome and introduction</b> Rafael Duarte (Spain)	<b>12:30 - 12:40</b>
--	----------------------

## Scientific Programme

<b>Picking your favorite tapas: Which cell populations to include in the allograft</b>	<b>12:40 - 12:55</b>
Miguel-Angel Perales (United States)	
<b>Discussion - Q/A</b>	<b>12:55 - 13:00</b>
<b>TCR<math>\alpha</math>/<math>\beta</math> CD19 depleted haploidentical HSCT in adult patients - Final results of the TCRalpha/beta-Haplo2010 study</b>	<b>13:00 - 13:15</b>
Wolfgang Bethge (Germany)	
<b>Discussion - Q/A</b>	<b>13:15 - 13:20</b>
<b>Improved survival rate in T cell-depleted haploidentical hematopoietic cell transplantation utilizing CD45RA-depleted grafts</b>	<b>13:20 - 13:35</b>
Brandon Triplett (United States)	
<b>Discussion - Q/A</b>	<b>13:35 - 13:40</b>
<b>Semi-automated CAR T cell manufacturing: focus on the UCL CAR T-cell programme</b>	<b>13:40 - 13:55</b>
Claire Roddie (United Kingdom)	
<b>Discussion - Q/A</b>	<b>13:55 - 14:00</b>

Industry Symposium  
12:30 - 14:00

Auditorium 5

### IS12, GVHD: What's new in 2020? - Sanofi Genzyme Industry Symposium

#### Chairs:

Mohamad Mohty (France)

<b>Welcome and introduction</b>	<b>12:30 - 12:40</b>
Mohamad Mohty (France)	
<b>The mycobiota: A new player in GVHD pathophysiology</b>	<b>12:40 - 12:55</b>
Florent Malard (France)	
<b>ATG and/or post-Cy for GVHD prophylaxis</b>	<b>12:55 - 13:10</b>
Mohamad Mohty (France)	
<b>Personalized ATG dosage: The PARACHUTE trial</b>	<b>13:10 - 13:25</b>
Jaap Jan Boelens (United States)	
<b>Nutritional support for GVHD patients</b>	<b>13:25 - 13:40</b>
Zinaida Peric (Croatia)	
<b>Round table discussion</b>	<b>13:40 - 14:00</b>

Social Events  
12:50 - 13:23

Auditorium 6

### Health with Every Bite - Nutrition and healing

## Scientific Programme

Industry Symposium  
14:30 - 16:00

Auditorium 1

### IS13, Curative intent in R/R DLBCL: A case-based discussion - Kite Industry Symposium

**Chairs:**

Frederick Locke (United States)

<b>Introduction</b>	<b>14:30 - 14:33</b>
Frederick Locke (United States)	
<b>Curative intent for DLBCL patients at 3rd-line: What are the current data?</b>	<b>14:33 - 14:53</b>
Frederick Locke (United States)	
<b>Patient case session</b>	<b>14:53 - 15:38</b>
Francis Ayuk (Germany)	
Ibrahim Yakoub-Agha (France)	
Nuria Martínez-Cibrian (Spain)	
Pierre Sesques (France)	
<b>Panel discussion and live Q&amp;A: Review of the cases - what have we learnt?</b>	<b>15:38 - 15:58</b>
<b>Meeting close</b>	<b>15:58 - 16:00</b>
Frederick Locke (United States)	

Industry Symposium  
14:30 - 16:00

Auditorium 2

### IS14, From kilometer zero - Navigating the myeloma treatment journey - Amgen Industry Symposium

**Chairs:**

Mohamad Mohty (France)

<b>Introduction</b>	<b>14:30 - 14:40</b>
Mohamad Mohty (France)	
<b>Off to a good start - Optimal induction regimen for transplant eligible patients</b>	<b>14:40 - 15:05</b>
Francesca Gay (Italy)	
<b>The road beyond relapse - Therapeutic options for hard-to-treat patients</b>	<b>15:05 - 15:30</b>
Mohamad Mohty (France)	
<b>Panel discussion</b>	<b>15:30 - 16:00</b>

## Scientific Programme

Industry Symposium  
14:30 - 16:00

Auditorium 3

### **IS15, Targeted therapy for adult ALL: New horizons in the setting of alloHSCT - Amgen Industry Symposium**

**Chairs:**

Josep M. Ribera (Spain)

<b>Welcome and introduction</b>	<b>14:30 - 14:35</b>
Josep M. Ribera (Spain)	
<b>Overview of conventional approaches</b>	<b>14:35 - 14:45</b>
Josep M. Ribera (Spain)	
<b>Antibody-drug conjugates</b>	<b>14:45 - 15:05</b>
Matthias Stelljes (Germany)	
<b>T-cell engaging immuno-oncology (BiTE® and CAR T)</b>	<b>15:05 - 15:35</b>
Nicola Gökbuget (Germany)	
<b>Live Q&amp;A</b>	<b>15:35 - 16:00</b>

Industry Symposium  
14:30 - 16:00

Auditorium 4

### **IS16, Targeted interventions in the natural history of Hodgkin Lymphoma - Takeda Industry Symposium**

**Chairs:**

Anton Hagenbeek (Netherlands)

<b>Welcome and introduction</b>	<b>14:30 - 14:40</b>
Anton Hagenbeek (Netherlands)	
<b>Latest developments in first-line treatment of Hodgkin lymphoma</b>	<b>14:40 - 15:05</b>
Martin Hutchings (Denmark)	
<b>Prolongation of remission with post-ASCT strategies in Hodgkin lymphoma</b>	<b>15:05 - 15:30</b>
Anna Sureda (Spain)	
<b>Concluding remarks, panel discussion and audience Q&amp;A</b>	<b>15:30 - 16:00</b>
Anton Hagenbeek (Netherlands)	
Martin Hutchings (Denmark)	
Anna Sureda (Spain)	

Industry Symposium  
14:30 - 16:00

Auditorium 5

### **IS17, Nurse Symposium: Power of knowledge: Nurses at the forefront of patient survival of severe hepatic VOD - Jazz Pharmaceuticals Industry Symposium**

**Chairs:**

Michelle Kenyon (United Kingdom)

## Scientific Programme

<b>Welcome and introduction</b> Michelle Kenyon (United Kingdom)	<b>14:30 - 14:34</b>
<b>Joint discussion - Nurses at the forefront: Whose responsibility is it to identify patients with hepatic VOD?</b> Michelle Kenyon (United Kingdom) Mairead Ni Chonghaile (Ireland)	<b>14:34 - 14:59</b>
<b>Knowledge is power: paediatric hepatic VOD</b> Selim Corbacioglu (Germany)	<b>14:59 - 15:14</b>
<b>Knowledge is power: paediatric hepatic VOD</b> Zofia Szmit (Poland)	<b>15:14 - 15:24</b>
<b>The knowledge of the nurse: a case of severe hepatic VOD</b> Emmanouil Nikolousis (United Kingdom)	<b>15:24 - 15:39</b>
<b>Live Q&amp;A</b>	<b>15:39 - 15:59</b>
<b>Close</b> Michelle Kenyon (United Kingdom)	<b>15:59 - 16:00</b>

Industry Symposium  
16:30 - 18:00

Auditorium 1

### IS18, The role of ECP in the treatment of GVHD - Therakos Industry Symposium

#### Chairs:

Andrea Bacigalupo (Italy)

<b>Introduction</b> Andrea Bacigalupo (Italy)	<b>16:30 - 16:35</b>
<b>GVHD: Treatment goals and current definitions</b> Madan Jagasia (United States)	<b>16:35 - 17:00</b>
<b>ECP role in GVHD treatment</b> Hildegard Greinix (Austria)	<b>17:00 - 17:25</b>
<b>ECP in combination therapies</b> Robert Zeiser (Germany)	<b>17:25 - 17:50</b>
<b>Q&amp;A</b>	<b>17:50 - 18:00</b>

Industry Symposium  
16:30 - 18:00

Auditorium 2

### IS19, Cellular immune therapies for multiple myeloma - Celgene | Bristol Myers Squibb Industry Symposium

#### Chairs:

María-Victoria Mateos (Spain)

## Scientific Programme

<b>Welcome and introduction</b> María-Victoria Mateos (Spain)	<b>16:30 - 16:35</b>
<b>State-of-the-art therapy in multiple myeloma and unmet needs in 2020</b> María-Victoria Mateos (Spain)	<b>16:35 - 16:55</b>
<b>Overview of CAR T cell treatment strategies in multiple myeloma</b> Xavier Leleu (France)	<b>16:55 - 17:10</b>
<b>Management and optimization of CAR T cell therapy</b> Michel Delforge (Belgium)	<b>17:10 - 17:25</b>
<b>Summary and Q&amp;A</b>	<b>17:25 - 18:00</b>

Industry Symposium  
16:30 - 18:00

Auditorium 3

### IS20, CMV prophylaxis in transplantation - From implementation to follow up - MSD Industry Symposium

#### Chairs:

Catherine Cordonnier (France)

<b>Welcome and introduction</b> Catherine Cordonnier (France)	<b>16:30 - 16:35</b>
<b>CMV prophylaxis in allogeneic stem cell transplantation: How to optimize clinical care?</b> Rafael Duarte (Spain)	<b>16:35 - 16:55</b>
<b>Real-life experience with CMV prophylaxis in allogeneic stem cell transplantation</b> Michael Schmitt (Germany)	<b>16:55 - 17:15</b>
<b>Evolving strategies in CMV prevention</b> Miguel-Angel Perales (United States)	<b>17:15 - 17:35</b>
<b>Panel discussion</b>	<b>17:35 - 17:45</b>
<b>Live Q&amp;A and closing remarks</b>	<b>17:45 - 18:00</b>

Industry Symposium  
16:30 - 18:00

Auditorium 5

### IS21, Nurse Symposium: Optimising the patient's CAR T-cell therapy journey - Kite Industry Symposium

<b>Introduction: Meet our patient</b> Graham Collins (United Kingdom)	<b>16:30 - 16:35</b>
<b>Starting the journey: DLBCL diagnosis and first-line therapy</b> Graham Collins (United Kingdom) Stephen Scowcroft (United Kingdom) Órla Stewart (United Kingdom)	<b>16:35 - 16:45</b>

## Scientific Programme

<b>Salvage chemotherapy and planning for transplant</b>	<b>16:45 - 17:00</b>
Graham Collins (United Kingdom) Claire Roddie (United Kingdom) Órla Stewart (United Kingdom)	
<b>Choosing CAR T with curative intent</b>	<b>17:00 - 17:15</b>
Graham Collins (United Kingdom) Claire Roddie (United Kingdom) Surabhi Chaturvedi (United Kingdom) Órla Stewart (United Kingdom)	
<b>Linking referral and delivery for optimal care</b>	<b>17:15 - 17:30</b>
Graham Collins (United Kingdom) Claire Roddie (United Kingdom) Órla Stewart (United Kingdom) Surabhi Chaturvedi (United Kingdom) Jackie Chappell (United Kingdom)	
<b>Navigating the first 28 days post-infusion together</b>	<b>17:30 - 17:45</b>
Claire Roddie (United Kingdom) Órla Stewart (United Kingdom) Surabhi Chaturvedi (United Kingdom) Jackie Chappell (United Kingdom) Antony Wilson (United Kingdom)	
<b>Life beyond CAR T: the road ahead</b>	<b>17:45 - 18:00</b>
Graham Collins (United Kingdom) Claire Roddie (United Kingdom) Stephen Scowcroft (United Kingdom) Surabhi Chaturvedi (United Kingdom) Órla Stewart (United Kingdom)	

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### MTE8, Meet the Expert Session 8 - Room MTE1

<b>HSCT in high-risk MDS</b>	<b>18:00 - 19:00</b>
David Valcárcel Ferreiras (Spain)	

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### MTE9, Meet the Expert Session 9 - Room MTE2

<b>Prophylaxis of acute graft versus host disease: ATG or not ATG?</b>	<b>18:00 - 19:00</b>
Francesca Bonifazi (Italy)	

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### MTE10, Meet the Expert Session 10 - Room MTE3

## Scientific Programme

**Clinical hurdles for academic development of clinical Advanced Therapies: The perspective from the GMP Lab**  
Fermín Sánchez-Guijo (Spain)

**18:00 - 19:00**

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### **MTE11, Meet the Expert Session 11 - Room MTE4**

**The fast changing paradigm of myeloma treatment: What's best in 2020?**  
Sergio Giralt (United States)

**18:00 - 19:00**

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### **MTE12, Meet the Expert Session 12 - Room MTE5**

**How I manage double hit lymphomas**  
Andrew Davies (United Kingdom)

**18:00 - 19:00**

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### **MTE13, Meet the Expert Session 13 - Room MTE6**

**The role of HSCT in mantle cell lymphoma in 2020**  
Olivier Hermine (France)

**18:00 - 19:00**

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### **MTE14, Meet the Expert Session 14 - Room MTE7**

**Maintenance strategies after allogeneic HSCT in patients with AML**  
Ali Bazarbachi (Lebanon)

**18:00 - 19:00**

## Scientific Programme

### Monday, 31 August 2020

---

Educational  
09:30 - 10:30

Auditorium 1

#### **E5, Emerging and personalized approaches in MDS and MF**

**Chairs:**

Juan Carlos Hernández-Boluda (Spain)  
Christoph Scheid (Germany)

<b>Allogeneic transplantation in myelofibrosis</b>	<b>09:30 - 09:42</b>
Nicolaus Kröger (Germany)	
<b>Microtransplantation</b>	<b>09:42 - 09:54</b>
Micha Srouf (France)	
<b>Emerging and personalized cellular therapy approaches for myeloid diseases</b>	<b>09:54 - 10:06</b>
Marco Davila (United States)	
<b>Risk assessment of patients with CMML</b>	<b>10:06 - 10:18</b>
Francesco Onida (Italy)	
<b>Q&amp;A</b>	<b>10:18 - 10:30</b>

How do I ... ?  
09:30 - 10:30

Auditorium 2

#### **HDI1, How Do I... mobilize autologous stem cells - Supported through an unrestricted educational grant by Sanofi Genzyme**

**Chairs:**

Carmen Martínez Chamorro (Spain)  
Adrián Alegre (Spain)

<b>After antibody and ImiDS based induction in MM patients</b>	<b>09:30 - 09:45</b>
Francesca Gay (Italy)	
<b>If tandem transplant is planned in myeloma</b>	<b>09:45 - 10:00</b>
Patrick Wuchter (Germany)	
<b>By optimizing apheresis centre time</b>	<b>10:00 - 10:15</b>
José Luis Bueno (Spain)	
<b>Q&amp;A</b>	<b>10:15 - 10:30</b>

## Scientific Programme

Nurses Group  
09:30 - 10:30

Auditorium 3

### NG04, Nurses Programme Opening Session

#### Chairs:

John Murray (United Kingdom)  
Julia Ruiz Pato (Spain)

<b>Welcome and overview</b>	<b>09:30 - 09:40</b>
John Murray (United Kingdom)	
<b>Presentation of the 12th Distinguished Merit Award</b>	<b>09:40 - 09:50</b>
John Murray (United Kingdom)	
<b>Nursing and lockdown</b>	<b>09:50 - 10:20</b>
Julia Ruiz Pato (Spain)	
Isabel Salcedo (Spain)	
<b>Q&amp;A</b>	<b>10:20 - 10:30</b>

Cell therapy  
09:30 - 10:30

Auditorium 4

### CTD1, Cell Therapy Day: Biotechnological developments

#### Chairs:

Annalisa Ruggeri (France)

<b>Evolving technologies for gene modification / gene editing of haematopoietic stem cells and immune effector cells</b>	<b>09:30 - 09:50</b>
Chiara Bonini (Italy)	
<b>Where are we with mesenchymal stem cells in 2020?</b>	<b>09:50 - 10:16</b>
Francesco Dazzi (United Kingdom)	
<b>Q&amp;A</b>	<b>10:16 - 10:30</b>

Transplant Coordinator Day  
09:30 - 10:30

Auditorium 5

### TCD1, EBMT-WMDA Transplant Coordinators Day: Lessons learnt from COVID-19 - Continuity of care: How to ensure provision of stem cells

#### Chairs:

Annette Rasche (Germany)

<b>The European start of the pandemic - Italian experience</b>	<b>09:30 - 09:45</b>
Nicoletta Sacchi (Italy)	
<b>Donor care - Medical aspects in COVID-19 pandemic</b>	<b>09:45 - 10:00</b>
Rachel Pawson (United Kingdom)	
<b>Patient Care - Alternative grafts</b>	<b>10:00 - 10:15</b>
Irina Evseeva (United Kingdom)	

## Scientific Programme

**Text chat Q&A**

**10:15 - 10:30**

Special Session  
09:30 - 10:30

Auditorium 6

### **SS3, Multi-stakeholder Forum on Innovative Cellular Therapies**

#### **Chairs:**

Christian Chabannon (France)  
Harry Dolstra (Netherlands)

**EMA's Regulatory Science to 2025 in the area HSCT and gene/cellular therapies**

**09:30 - 09:42**

Jordi Llinares (Netherlands)

**The regulatory framework for innovative cellular therapies**

**09:42 - 09:54**

Sol Ruiz (Spain)

**How are cellular therapies translated from academia to industrial partners. Pitfalls and opportunities**

**09:54 - 10:06**

Jürgen Kuball (Netherlands)

**Where's the access bottleneck for CART cells: centres, industry, authorities?**

**10:06 - 10:18**

Joaquín Martínez-López (Spain)

**Q&A**

**10:18 - 10:30**

Industrial Theatre  
09:30 - 19:00

Industry Theatre

### **IT1, TLS in the context of new treatments in hematology - Sanofi Genzyme Industry Theatre Session**

Industrial Theatre  
09:30 - 19:00

Industry Theatre

### **IT3, Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite Industry Theatre Session**

Industrial Theatre  
09:30 - 19:00

Industry Theatre

### **IT2, Clinical Data on Treosulfan-based Conditioning Treatment (Trecondi®) in Paediatric Patients - Medac Industry Theatre Session**

## Scientific Programme

Industrial Theatre  
09:30 - 19:00

Industry Theatre

### IT4, KYMRIA<sup>®</sup> in the Real World - Novartis Industry Theatre Session

Industrial Theatre  
09:30 - 19:00

Industry Theatre

### IT5, How I manage CMV in HSCT patients - MSD Industry Theatre Session

Industrial Theatre  
09:30 - 19:00

Industry Theatre

### IT6, Gene therapy: From clinical trials to clinical practice - Bluebirdbio Industry Theatre Session

#### Chairs:

Franco Locatelli (Italy)

e-Posters  
09:30 - 19:00

ePoster Area

## Acute leukaemia

**ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HIV-INFECTION: AN UPDATED PAIR-MATCHED COHORT STUDY BY THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION**

**COMPARABLE OUTCOMES OF AML PATIENTS RECEIVING HAPLO-HCT WITH THIOTEPA/BUSULFAN/FLUDARABINE CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS A MATCHED UNRELATED DONOR WITH FLUDARABINE/BUSULFAN CONDITIONING, REGARDLESS OF DISEASE STATUS**

**TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT: IMPROVED SURVIVAL FOR YOUNG PATIENTS IN RECENT YEARS**

**ANTI-CD3/CD33 BISPECIFIC ANTIBODIES EFFICIENTLY REDIRECT DONOR T CELLS AGAINST HLA LOSS LEUKEMIA RELAPSES**

**POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) EMERGES AS A KEY DRIVER OF HLA CLASS II NEGATIVE POST-TRANSPLANTATION RELAPSE**

**ALLOGENEIC HCT FOR ADULTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA HARBORING *IKZF1* GENE MUTATIONS: A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**

**ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN CHILDREN AND ADULTS WITH RELAPSED/REFRACTORY B-ALL: FOCUS ON ANTI-CD19, ANTI-CD22 MONOCLONAL ANTIBODIES**

**THE VALUE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH AND WITHOUT *ASXL1*, *RUNX1* AND *TP53* MUTATIONS**

## Scientific Programme

**ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT**

**RIC COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE PROVIDES HIGHER GVHD-FREE/RELAPSE FREE SURVIVAL IN FIT YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA**

**LOW-DOSE MEMORY DONOR LYMPHOCYTE INFUSION AFTER  $\alpha\beta$  T CELL-DEPLETED HSCT AMONG CHILDREN WITH HIGH-RISK LEUKEMIA: RESULTS OF A PROSPECTIVE RANDOMIZED SINGLE-CENTER TRIAL**

**DEVELOPMENT OF A CORD BLOOD STEM CELL-DERIVED DENDRITIC CELL VACCINE TO PREVENT RELAPSE AFTER CORD BLOOD TRANSPLANTATION IN AML**

**THE BRAZILIAN EXPERIENCE WITH HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTS (HAPLO-HCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**BETTER LEUKEMIA-FREE SURVIVAL WITH ALLOGENEIC THAN WITH AUTOLOGOUS HCT IN AML PATIENTS WITH ISOLATED TRISOMY 8: A STUDY FROM THE ALWP OF THE EBMT**

**ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML PATIENTS WITH RUNX1 MUTATION IN FIRST COMPLETE REMISSION: A STUDY ON BEHALF OF THE ALWP OF THE EBMT**

Johanna Waidhauser, Myriam Labopin, Jordi Esteve, Nicolaus Kröger, Jan Cornelissen, Tobias Gedde-Dahl, Gwendolyn Van Gorkom, Jürgen Finke, Montserrat Rovira, Nicolaas Schaap, Eefke Petersen, Dietrich Beelen, Donald Bunjes, Christoph Schmid, Arnon Nagler, Mohamad Mohty (Germany)

**GRAFT FAILURE AFTER UNMANIPULATED HAPLO-HSCT WITH PT-CY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION, ON BEHALF OF THE ALWP-EBMT**

Annalisa Ruggeri, Myriam Labopin, Emanuele Angelucci, Didier Blaise, Fabio Ciceri, Yener Koc, Jose Luiz Diez-Martin, Luca Castagna, Benedetto Bruno, Zafer Gülbaz, Andrea Bacigalupo, Arnon Nagler, Mohamad Mohty (Italy)

**IMPLICATIONS OF NOVEL RISKS SCORES (AML-DRG AND AML-HCT-CR) IN ALLOGENEIC CD34+ SELECTED GRAFT TRANSPLANT OUTCOMES**

Rosalía Alonso Trillo, Marta Garcia Recio, Martina Pennisi, Christina Cho, Sean M. Devlin, Josel D. Ruiz, Molly A. Maloy, Ana Alarcon Tomas, Nerea Castillo, Richard J. Lin, Ioannis Politikos, Miriam Sanchez Escamilla, Michael Scordo, Gunjan L. Shah, Juliet N. Barker, Hugo Castro-Malaspina, Boglarka Gyurkocza, Parastoo B. Dahi, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Craig S. Sauter, Brian C. Shaffer, Roni Shouval, Roni Tamari, Marcel R. M. van den Brink, James W. Young, Sergio A. Giral, Miguel Perales (Spain)

**DOWNREGULATION OF HLA-DR IN BLASTS OF PATIENTS WITH ACUTE LEUKAEMIA RELAPSING AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ESTABLISHMENT OF A NATIONAL STEM CELL TRANSPLANT CLINICAL TRIALS NETWORK: THE UK IMPACT PARTNERSHIP FOR ACCELERATED CELLULAR THERAPIES**

David I Marks, Shamyla Siddique, Ronjon Chakraverty, Aimee Jackson, Victoria Potter, Ram Malladi, Andy Peniket, Pares Vyas, Pamela Kearns, [Charles Craddock](#) (United Kingdom)

**DIFFERENTIAL IMPACT OF NPM1 MUTATION ON THE POST-TRANSPLANT OUTCOME OF ADULT FLT3ITD MUTATED AML RECEIVING ALLOGENEIC TRANSPLANT IN CR1 AND AFTER CR1**

Su-Peng Yeh, Ming Yao, Bor-Sheng Ko, Jyh-Pyng Gau, Tzeon-Jye Chiou, Tran-Der Tan, Po-Nan Wang, Yeu-Chin Chen, Chieh-Lin Teng, Ciyuan-Jheng Wang, Tsai-Yun Chen, Ta-Chih Liu, Ming-Sun Yu, Wei-Han Huang (Taiwan, Republic of China)

## Scientific Programme

### **A REGION-WIDE RETROSPECTIVE ANALYSIS OF OUTCOME FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA**

Shuichi Ota, Akio Shigematsu, Ryoji Kobayashi, Takeshi Kondo, Tomoyuki Endo, Yutaka Tsutsumi, Hajime Kobayashi, Yasutaka Kakinoki, Satoshi Yamamoto, Yuichi Konuma, Takuto Miyagishima, Tetsuyuki Igarashi, Takanori Oda, Hajime Sakai, Toshimichi Ishihara, Masahiro Yoshida, Takahiro Nagashima, Kazuya Sato, Yuji Kanisawa, Yoshihito Haseyama, Yasuo Hirayama, Mitsutoshi Kurosawa (Japan)

### **PRE-HARVEST HIGHER DONOR FOXP3 MRNA AND LOWER CD4+ T CELL CONCENTRATION PREDICT INCREASED RISK OF ALL RELAPSE AFTER MYELOABLATIVE HCT WITH T-REPLETE BONE MARROW GRAFTS**

Niels Jacobsen, Tina Frisch, Niels Keiding, Carsten Heilman, Henrik Sengeløv, Hans Madsen, Hanne Marquart, Mette Andersen, Claus Christiansen, Lars Ryder (Denmark)

### **EPIDEMIOLOGY, MANAGEMENT AND ECONOMIC IMPACT OF ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME IN SPAIN: A CLAIMS DATABASE ANALYSIS**

### **PRE-TRANSPLANT BONE MARROW CELLULARITY AND BLOOD COUNT RECOVERY ARE NOT ASSOCIATED WITH RELAPSE OR SURVIVAL RISK FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT FOR AML IN CR1**

Igor Novitzky Basso, Shiyi Chen, Jeffrey Lipton, Dennis Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun Law, Zeyad Al-Shaibani, Armin Gerbitz, Ivan Pasic, Jonas Mattsson, Fotios Michelis (Canada)

### **IMMUNOTHERAPY SALVAGE FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS BY THE ALWP OF THE EBMT**

### **COMPARISON OF PRE-TRANSPLANT COMORBIDITY INDICES IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Zeynep Arzu Yeğin, Asena Dikyar, Lale Aydin Kaynar, Zübeyde Nur Özkurt, Münci Yağcı (Turkey)

### **SALVAGE USE OF VENETOCLAX-BASED THERAPY FOR RELAPSED AML POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT**

### **FACTORS PREDICTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA**

Olga Pirogova, Ksenia Afanaseva, Elena Morozova, Sergey Bondarenko, Inna Markova, Ivan Moiseev, Boris Afanasyev (Russian Federation)

### **ROLE OF CHIMERISM AND FLOW-CYTOMETRIC MONITORING OF MEASURABLE RESIDUAL DISEASE (MRD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN PREDICTING RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)**

Guldane Cengiz Seval, Eliz Bahar Ulas, Selami Kocak Toprak, Sinem Civriz Bozdog, Meltem Kurt Yuksel, Pervin Topcuoglu, Klara Dalva, Onder Arslan, Muhit Ozcan, Taner Demirel, Osman Ilhan, Hamdi Akan, Meral Beksac, Gunhan Gurman (Turkey)

### **SORAFENIB PROLONGED MAINTENANCE IN FLT3-MUTATED AML POST TRANSPLANTATION**

Carmine Liberatore, Matteo Giovanni Carrabba, Federica Ardizzoia, Andrea Assanelli, Carlo Messina, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Fabio Ciceri, Maria Teresa Lupo Stanghellini (Italy)

### **PULMONARY COMPLICATIONS (PC) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN CHILDREN WITH HIGH-RISK ACUTE LEUKEMIA (AL)**

### **MORE THAN TWO CYCLES OF CONSOLIDATION THERAPY PRE-TRANSPLANTATION BENEFITS AML PATIENTS IN CR1 WHO UNDERWENT HLA-MATCHED SIBLING ALLOGRAFTS: A MULTICENTER STUDY**

## Scientific Programme

### **WHAT CAN CNV ANALYSIS ADD TO THE ROUTINE GENETIC DESCRIPTION OF AML CASES?**

Emilia Jaskula, Mariola Sedzimirska, Monika Mordak-Domagala, Janusz Lange, Krzysztof Suchnicki, Anna Sobczynska-Konefal, Marta Lemieszewska, Helena Pakos, Agnieszka Tarnowska, Andrzej Lange (Poland)

### **COMPARISON OF THE PROGNOSTIC ABILITY OF THE HCT-CI THE MODIFIED EBMT AND THE EBMT-ADT PRE-TRANSPLANT RISK SCORES FOR ACUTE LEUKEMIA**

Eshrak Al-Shaibani, Sunu Cyriac, Shiyi Chen, Jeffrey H. Lipton, Dennis D. Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun Law, Zeyad Al-Shaibani, Armin Gerbitz, Ivan Pasic, Jonas Mattsson, Fotios V. Michelis (Canada)

### **GO-FLAG REGIMEN AS A BRIDGE THERAPY TO ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS**

Bella Ayubova, Sergey Bondarenko, Ivan Moiseev, Olga Uspenskaya, Elena Karyagina, Elena Misyurina, Evgeniya Zhelnova, Alexander Alyanskiy, Elena Babenko, Ildar Barkhatov, Tatyana Gindina, Alexander Kulagin, Boris Afanasyev (Russian Federation)

### **THE IMPACT OF ALLOGENEIC TRANSPLANTATION IN AML AND MDS WITH CHROMOSOME 3 ABNORMALITIES**

Maria Rhida Bautista, Shiyi Chen, Wilson Lam, Fotios Michelis, Dennis Kim, Jeffrey Lipton, Auro Viswabandya, Rajat Kumar, Ivan Pasic, Armin Gerbitz, Jonas Mattson, Zeyad Al-Shaibani, Arjun Law (Canada)

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY-ALONE IN THE TREATMENT OF PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS WITH MIXED LINEAGE LEUKEMIA (MLL) REARRANGEMENTS: SINGLE CENTER EXPERIENCE**

### **POSTTRANSPLANTATION BENDAMUSTINE FOR GVHD PROPHYLAXIS IN REFRACTORY ACUTE LEUKEMIA PATIENTS**

Ivan Moiseev, Sergey Bondarenko, Elena Darskaya, Alexandr Alyanskiy, Anastasiya Beynarovich, Evgeniya Borzenkova, Anna Dotcenko, Olga Kudyasheva, Varvara Ovechkina, Olga Pirogova, Valentina Porunova, Tatyana Rudakova, Olesya Smikova, Boris Afanasyev (Russian Federation)

### **IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE**

### **FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS**

### **TYROSINE KINASE INHIBITOR TREATMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA**

Yu-Hsiang Chang, Xiu-Wen Liao, Jia-Hau Liu, Ming Yao, Bor-Sheng Ko, Chi-Cheng Li, Cheng-Hong Tsai, Shang-Ju Wu, Hui-Hsuan Huang, Tai-Chung Huang, Hsin-An Hou, Wen-Chien Chou, Feng-Ming Tien, Yun-Chu Lin, Meng-Yao Lu, Kai-Hsin Lin, Jih-Luh Tang (Taiwan, Republic of China)

### **OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR CYTOGENETIC INTERMEDIATE-RISK AML ACCORDING TO THE MOLECULAR RISK BASED ON ELN 2017 RISK STRATIFICATION SYSTEM; SINGLE CENTER EXPERIENCE IN KOREA**

Haerim Chung, Ji Eun Jang, SooJeong Kim, Jin Seok Kim, Yoo Hong Min, June-Won Cheong (Korea, Republic of)

### **THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY WT1 GENE EXPRESSION IN PERIPHERAL BLOOD BEFORE AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS**

## Scientific Programme

### **IMPACT OF POSTTRANSPLANT TYROSINE KINASE INHIBITORS ADMINISTRATION ON LONG TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**

Kseniia Afanaseva, Elena Morozova, Olga Pirogova, Yulia Vlasova, Anna Smirnova, Sergey Bondarenko, Ivan Moiseev, Boris Afanasyev (Russian Federation)

### **THE INFLUENCE OF ANTI-THYMOCYTE GLOBULIN (ATG) ON THE OUTCOMES OF PATIENTS WITH AML W/WO MEASURABLE RESIDUAL DISEASE (MRD) AT THE TIME OF UNRELATED DONOR TRANSPLANTATION**

Guldane Cengiz Seval, Ekin Kircali, Mehmet Akif Baltaci, Sinem Civriz Bozdog, Meltem Kurt Yuksel, Pervin Topcuoglu, Klara Dalva, Onder Arslan, Muhit Ozcan, Taner Demirel, Gunhan Gurman, Osman Ilhan, Hamdi Akan, Meral Beksac, Selami Kocak Toprak (Turkey)

### **MLL-AF6 FUSION GENE POSITIVE AML TREATED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS EXCELLENT OVERALL SURVIVAL**

Wei Ma, Xingyu Cao, Wei Zhang, Min Xiong, Jianping Zhang, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Yanli Zhao, Jiarui Zhou (China)

### **BENEFICIAL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM**

### **INDUCTION OF SYNERGISTIC APOPTOSIS AND OVERCOMING OF DRUG RESISTANCE BY COTARGETING OF BCL-2 AND NA/H EXCHANGER 1 PATHWAY IN ACUTE MYELOID LEUKEMIA CELLS**

Shin Young Hyun, Eun Jung Na, Ji Eun Jang, Haerim Chung, Soo Jeong Kim, Jin Seok Kim, Yoo Hong Min, June-Won Cheong (Korea, Republic of)

### **GEMTUZUMAB-OZOGAMICIN FOR BRIDGING TO TRANSPLANT IN REFRACTORY/RELAPSED CD33 POSITIVE ACUTE LEUKEMIA - IS IT WORTHWHILE?**

Michael Stadler, Vanessa Oberstaedt, Elke Dammann, Lothar Hambach, Eva M. Weissinger, Catherina Lueck, Gernot Beutel, Matthias Eder, Arnold Ganzer (Germany)

### **THE EFFECTS OF CYTOMEGALOVIRUS INFECTION ON TRANSPLANT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **AZACYTIDINE AND DONOR LYMPHOCYTES INFUSIONS IN RELAPSED AML AFTER ALLOGENEIC HSCT: RESULTS IN 40 PATIENTS**

Carmine Liberatore, Francesca Lorentino, Matteo Giovanni Carrabba, Carlo Messina, Luca Vago, Sara Mastaglio, Raffaella Greco, Francesca Pavesi, Sarah Marktel, Francesca Farina, Raffaella Milani, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Maria Teresa Lupo Stanghellini, Fabio Ciceri (Italy)

### **THE RESULTS OF AML RELAPSE AFTER ALLOGENEIC TRANSPLANTATION TREATMENT, SINGLE CENTRE APPROACH EVALUATION**

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE CENTER ANALYSIS**

### **THE OPTIMAL TIME FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA**

Sergey Bondarenko, Ivan Moiseev, Elena Morozova, Olga Pirogova, Elena Darskaya, Anna Smirnova, Nikolai Tsvetkov, Anastasiya Beynarovich, Irina Samorodova, Tatyana Gindina, Elena Babenko, Ildar Barkhatov, Alexander Alyanskiy, Alexander Kulagin, Boris Afanasyev (Russian Federation)

### **IMPACT OF ABO MISMATCH ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTRE EXPERIENCE**

Fahad Shaikh, Ganapathi Bhat, Suresh Advani, Samir Shah, Reetu Jain (India)

## Scientific Programme

### **DONOR SOURCE IMPACTS ON LONG TERM SURVIVAL FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN AML PATIENTS AGED 60 AND ABOVE**

William Hayhurst, Asterios Giotas, Chloe Anthias, Sandra Easdale, David Taussig, Mike Potter, Mark Ethell, Joy Brennan, Maria Mulligan, Kim Davis, Emma Thistlethwayte, Emma Nicholson (United Kingdom)

### **EXTRA-MEDULLARY RECURRENCE OF ACUTE MYELOID LEUKEMIA AS MYELOID SARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE SERIES**

### **SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA: SINGLE CENTER EXPERIENCE**

Zeynep Tugba Guven, Serhat Çelik, Leylagul Kaynar, Bulent Eser, Mustafa Cetin, Ali Unal (Turkey)

### **ALLOGENEIC STEM CELL TRANSPLANTS IN ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE EXPERIENCE**

### **ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA NOT RESPONDING TO FIRST INDUCTION THERAPY**

e-Posters  
09:30 - 19:00

ePoster Area

## Aplastic anaemia

### **LNP023 - A NEW ORAL COMPLEMENT FACTOR-B INHIBITOR NORMALIZES HEMOGLOBIN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH POOR RESPONSE TO ECULIZUMAB, BOTH AS ADD-ON AND MONOTHERAPY**

### **EPIGENETIC AGING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH SEVERE APLASTIC ANEMIA: RESULTS FROM DNA-METHYLATION GRIMAGE**

### **GVHD AND RELAPSE FREE SURVIVAL (GRFS) AFTER ALLOGENEIC TRANSPLANTATION FOR IDIOPATHIC SEVERE APLASTIC ANEMIA: AN ANALYSIS FROM THE SAAWP DATA QUALITY INITIATIVE PROGRAM OF EBMT**

### **OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP**

### **REDUCED INTENSITY CONDITIONING IS EFFECTIVE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND-BLACKFAN ANEMIA**

### **PROSPECTIVE STUDY OF ECULIZUMAB BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA / APLASTIC ANEMIA**

### **OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT FOR FANCONI ANEMIA IN INDIA**

### **ALTERNATE DONOR HSCT FOR 109 CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA: A SINGLE CENTER RETROSPECTIVE ANALYSIS**

### **SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH REFRACTORY ACTIVE INFECTION: A PROSPECTIVE MULTICENTER CLINICAL STUDY IN CHINA**

### **INCIDENCE AND MANAGEMENT OF APLASTIC ANEMIA IN SPAIN (IMAS). AN AMBISPECTIVE STUDY OF BIODONOSTIA / PETHEMA**

Carlos Vallejo, Ana Rosell, Blanca Xicoy, Carmen García, Carmen Albo, Marta Polo, Isidro Jarque (Spain)

## Scientific Programme

### **ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS FOR CHILDREN WITH APLASTIC ANEMIA**

Atsushi Narita, Hideki Muramatsu, Masayuki Imae, Ayako Yamamori, Taro Yoshida, Manabu Wakamatsu, Shunsuke Miwata, Koutaro Narita, Hironobu Kitazawa, Rieko Taniguchi, Motoharu Hamada, Daisuke Ichikawa, Eri Nishikawa, Nozomu Kawashima, Yusuke Okuno, Nobuhiro Nishio, Seiji Kojima, Yoshiyuki Takahashi (Japan)

### **OUTCOME OF PEDIATRIC ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE**

### **OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR SEVERE APLASTIC ANEMIA IN PAKISTAN: DATA FROM A DEVELOPING COUNTRY**

### **IMPACT OF CD34+-STEM CELL BOOST ON OUTCOME AND HEMATOLOGICAL RECONSTITUTION IN PATIENTS WITH SEVERE APLASTIC ANEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY**

Rashit Bogdanov, Mareike Gocht, Amin Turki, Markus Ditschkowski, Dietrich W. Beelen (Germany)

### **HEMATOPOIETIC STEM CELL TRANSPLANT IN ADULTS WITH ACQUIRED SEVERE APLASTIC ANEMIA**

Gilbert Wilfred, Sen Mui Tan, Tee-Chuan Ong, Sh. Shahnaz Syed Abd Kadir, Kim Wah Ho, Boon Liaw Kian, Jameela Sathar (Malaysia)

### **HEMATOPOIETIC STEM CELL TRANSPLANT IN FANCONI ANEMIA USING MATCHED RELATED AND HAPLOIDENTICAL DONORS- A SINGLE CENTRE EXPERIENCE**

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC SEVERE APLASTIC ANEMIA: RESULTS OF A SINGLE CENTER**

### **EFFECT OF SINGLE UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION ON APLASTIC ANEMIA IN CHILDREN**

### **IMMUNOSUPPRESSIVE THERAPY IN PEDIATRIC APLASTIC ANEMIA, SINGLE CENTRE EXPERIENCE**

### **CYCLOSPORINE, DANAZOL AND ROMIPLOSTIM IN SEVERE APLASTIC ANEMIA IN PRETRANSPLANT PERIOD: RETROSPECTIVE ANALYSIS OF FIVE CASES**

Nilesh Wasekar, Girish Badarkhe, Sudarshan Pandit, Raj Nagarkar (India)

e-Posters  
09:30 - 19:00

ePoster Area

## Autoimmune diseases

### **AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR STIFF PERSON SYNDROME**

### **BEAM VS CYCLOPHOSPHAMIDE-BASED CONDITIONING REGIMEN IN AGGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE ANALYSIS OF EUROPEAN BLOOD AND MARROW TRANSPLANTATION SOCIETY**

### **A NOVEL TARGETED APPROACH TO ACHIEVE IMMUNE SYSTEM RESET: CD45-TARGETED ANTIBODY DRUG CONJUGATES AMELIORATE DISEASE IN PRECLINICAL AUTOIMMUNE DISEASE MODELS AND ENABLE AUTOHSCT**

### **LONG TERM FOLLOW UP OF SYSTEMIC SCLEROSIS FRENCH PATIENTS INCLUDED IN THE ASTIS TRIAL USING SCOT TRIAL GLOBAL RANK COMPOSITE SCORE (GRCS)**

## Scientific Programme

### **ADVANCES IN MULTIPLE SCLEROSIS (MS) TREATMENT: CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION**

### **POST TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES OUTCOME AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ANIMAL MODEL OF MULTIPLE SCLEROSIS**

### **THE LONG-TERM SAFETY AND EFFICACY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS INDIRECTLY COMPARED TO ALEMTUZUMAB: A SYSTEMATIC REVIEW**

Owain Greaves, Amit Patel (United Kingdom)

### **RECONSTITUTION OF NATURAL OR VACCINATION-DRIVEN IMMUNITY AFTER AHSCT IN MULTIPLE SCLEROSIS**

### **HIGH-DOSE IMMUNODEPLETION WITH AUTOLOGOUS STEM CELL RESCUE FOR TREATMENT OF AGGRESSIVE MULTIPLE SCLEROSIS**

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT CHANGE THE EXPRESSION OF ENDOTHELIAL MARKERS IN SKIN BIOPSIES OF SYSTEMIC SCLEROSIS PATIENTS**

Maynara Santana, Djulio Zanin, Deisy Silva, Marianna Vasconcelos, Daniela Moraes, Juliana Dias, Vanessa Leopoldo, Marília Oliveria, Álvaro Henrique-Neto, Kelen Farias, Leandra Ramalho, Maria Carolina Oliveira (Brazil)

### **AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NON HEMATOLOGICAL DISEASES. THE DUTCH EXPERIENCE OF MS PATIENTS GOING ABROAD**

Ellen P.A. Kramer, Bram Platel, Frederike J.A.E Ambagtsheer, Gerald J.D. Hengstman, Otto Visser (Netherlands)

### **ANALYSIS OF COST AND CHARGES FOR NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES**

Richard Burt, Kathleen Quigley, Indira Arnautovic, Xiaolang Han (United States)

### **AUTOLOGOUS STEM CELL TRANSPLANTATION IN BEHÇET'S DISEASE: A RETROSPECTIVE STUDY**

Mathieu Puyade, Amit Patel, Yeong Ler Lim, Norbert Blank, Manuela Badoglio, Francesca Gualandi, David Ma, Natalia Maximova, Tobias Alexander, John Snowden (France)

### **SAFETY AND TOLERABILITY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE SCLEROSIS: A SINGLE CENTER EXPERIENCE**

Pawan Kumar Singh, Isha Gambhir, Ragesh Radhakrishnan Nair, Rohan Halder, Zahier Ahmad Shekib, Manish Mahajan, Sumit Singh (India)

### **OUTCOME OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY TAKAYASU ARTERITIS, A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT**

### **AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS IN NORWAY**

Maiken Schultz, Øyvind Midtvedt, Øyvind Molberg, Tobias Gedde-Dahl, Ragnar Gunnarsson, Yngvar Fløisand (Norway)

### **THE USE OF AUTOLOGOUS HAEMOPOETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS AFTER ALEMTUZUMAB TREATMENT FAILURE: A CASE SERIES**

## Scientific Programme

### **AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF SYSTEMIC SCLEROSIS, AN OPTION FOR REFRACTORY PATIENTS**

Claudia Sossa, Javier Figueroa, Juan Manuel Herrera, Angela M Peña, Luis A Salazar, Manuel Rosales, Enrique Pedraza, Elena Mora, Xueyi Chen, Maria Luna-Gonzalez, Jose Patricio Lopez-Lopez (Colombia)

### **A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE**

Richard Burt, Kathleen Quigley, Indira Arnautovic, Xiaoqiang Han (United States)

e-Posters  
09:30 - 19:00

ePoster Area

## **CAR-based Cellular Therapy - clinical**

**KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS FROM PHASE 2 OF ZUMA-2**

**SAFETY AND EFFICACY RESULTS FROM TRANSCEND NHL 001, A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA**

**CD19/CD22 DUAL TARGETED (CHIMERIC ANTIGEN RECEPTOR) CAR-T THERAPY FOR RELAPSED OR RE FRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)**

**AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE. ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP)**

**THIRD-GENERATION CAR T CELLS WITHIN THE HEIDELBERG CAR TRIAL 1 (HD-CAR-1) DISPLAY AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS**

**OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL IN 3 CLINICAL STUDIES OF RELAPSED/REFRACTORY LARGE B-CELL NHL, INCLUDING SECOND-LINE TRANSPLANT NONELIGIBLE PATIENTS: TRANSCEND NHL 001, OUTREACH, AND PILOT**

**CORRELATIVE ANALYSES OF PATIENT AND CLINICAL CHARACTERISTICS ASSOCIATED WITH EFFICACY IN TISAGENLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE JULIET TRIAL**

**CAR T CELLS (CART) OR ALLOGENEIC TRANSPLANTATION (ALLOHCT) FOR MULTIPLY RELAPSED DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)? A RETROSPECTIVE INTENT-TO-TREAT (ITT) COMPARISON**

**HIGH ACTIVATION OF BCMA CAR-T CELLS CONTRIBUTES TO INCREASED RESPONSE RATE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**

**A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL; AXI-CEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL)**

**CD19-TARGETED CAR-T CELL THERAPY FOR 32 B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)**

**INTERNATIONAL PROGNOSTIC INDEX PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACTORY LARGE DIFFUSE B CELL LYMPHOMA TREATED WITH COMMERCIAL CAR T CELLS**

**THE PHASE 1B PORTIA STUDY: SAFETY AND EFFICACY OF TISAGENLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA**

## Scientific Programme

### **REAL-WORLD EVIDENCE OF THE USE OF TISAGENLECLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS. THE SPANISH EXPERIENCE**

### **NATIONAL IMPLEMENTATION OF THE USE OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN NATIONAL HEALTH SERVICE ENGLAND (NHSE)**

Caroline Louise Furness, Rachael Hough, Michelle Cummins, Gillian Murphy, Sara Ghorashian, Persis Amrolia, Claire Roddie, Maeve O'Reilly, Robert Wynn, Denise Bonney, David Marks, Sridhar Chaganti, Geoff Shenton, Anna Castleton, Eleni Tholouli, Deborah Yallop, Peter Clark, John Snowden (United Kingdom)

### **REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA**

Shafqat Inam, Sean Apap Mangion, Victoria Potter, Reuben Benjamin, Andrea Kuhn, Robert Hadden, Robin Sanderson (United Kingdom)

### **CORRELATIVE MARKERS OF TOXICITY IN PATIENTS WITH DLBCL TREATED WITH CD19 CAR T CELL THERAPY**

Rawan Faramand, Michael Jain, Verena Staedtke, Hiroshi Kotani, Renyuan Bai, Saebom Lee, Kayla Reid, Kristen Spitler, Julio Chavez, Farhad Khimani, Aleksandr Lazaryan, Bijal Shah, Christina Bachmeier, Marian Dam, Brigett Brandjes, Ricardo Gonzalez, John Mullinax, Xuefeng Wang, Mohammad Hussaini, Frederick Lock, Marco Davila (United States)

### **EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)**

### **ASSOCIATION OF AXI-CEL CAR-T CELL CONCENTRATION WITH TREATMENT RESPONSE AND SIDE EFFECTS AND IMPACT OF DEXAMETHASONE TREATMENT ON KINETICS**

Francis Ayuk, Anita Badbaran, Carolina Berger, Tanja Sonntag, Kristoffer Riecken, Maria Geffken, Dominic Wichmann, Nicolaus Kröger, Boris Fehse (Germany)

### **SIMPLIFIED-EASIX (SEASIX) IS AN EARLY PREDICTOR OF SEVERE CYTOKINE RELEASE SYNDROME AND IMMUNE-EFFECTOR-CELLS-ASSOCIATED NEUROTOXICITY SYNDROME IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T CELLS**

Martina Pennisi, Miriam Sanchez-Escamilla, Jessica Flynn, Roni Shouval, Yakup Batlevi, Mari Lynn Silverberg, Connie Batlevi, Renier Brentjens, Parastoo B Dahi, Sean M Devlin, Claudia Diamonte, Sergio Giralt, Elizabeth Halton, Tania Jain, Molly Maloy, Elena Mead, Maria Lia Palomba, Bianca D Santomaso, Craig Sauter, Micheal Scordo, Gunjan Shah, Jae H Park, Lucrecia Yanez San Segundo, Miguel Angel Perales (United States)

### **NIVOLUMAB AS SALVAGE THERAPY IN PATIENTS WHO FAILED TO ACHIEVE COMPLETE REMISSION AFTER ANTI-CD19 CAR T-CELL THERAPY FOR DLBCL**

### **SURVEILLANCE OF MINIMAL RESIDUAL DISEASE (MRD) IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY CIRCULATING TUMOR DNA (CTDNA) PROFILING AFTER CHIMERIC ANTIGEN RECEPTOR T (CAR-T)**

Houli Zhao, Yongxian Hu, Wei Ding, Arnon Nagler, He Huang (China)

### **A DIGITAL-PCR ASSAY FOR PRECISE IN-VIVO QUANTIFICATION OF ADOPTIVELY TRANSFERRED CD19-CAR T CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**

Boris Fehse, Anita Badbaran, Carolina Berger, Tanja Sonntag, Kristoffer Riecken, Maria Geffken, Nicolaus Kröger, Francis A. Ayuk (Germany)

### **FEASIBILITY OF MANUFACTURING TISAGENLECLEUCEL IN PATIENTS LESS THAN 3 YEARS OF AGE WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA**

## Scientific Programme

### **AXICABTAGENE CILOLEUCEL CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: REAL-WORLD OUTCOMES, TOXICITY AND PREDICTORS OF RESPONSE FROM A PROSPECTIVE UK COHORT**

Robin Sanderson, Reuben Benjamin, Piers Patten, Victoria Potter, Deborah Yallup, Kirsty Cuthill, Orla Stewart, Tony Pagliuca, Pramila Krishnamurphy, Shafqat Inam, Mili Shah, Shu Wong, Catherine Hockings, Victoria Metaxa, Andrea Kuhn (United Kingdom)

### **MARKERS OF INITIAL AND LONG-TERM RESPONSES TO IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) IN THE CRB-401 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA**

### **SINUSOIDAL OBSTRUCTION SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) TREATED WITH ARI-0001 CELLS**

Valentín Ortiz-Maldonado, Anna Alonso-Saladrigues, Miguel Caballero-Baños, Maria Castella, Anna Boronat, Enric García-Rey, Tycho Baumann, Marina Díaz-Beyá, Montserrat Torrealbadell, Anna Faura, Albert Català, Federico Ramos, Alicia Palomino, Marta Gómez-Hernando, Carlos Jiménez-Vicente, Joan Cid, Miquel Lozano, Cristina Llanos, Adrián Téllez, Sara Fernández, Pedro Castro, Iolanda Jordán, Jordi Esteve, Josep Maria Canals, Esteve Trias, Jordi Yagüe, Maria Suárez-Lledó, Montserrat Rovira, Alvaro Urbano-Ispizua, Manel Juan, Susana Rives, Julio Delgado (Spain)

### **HUMORAL IMMUNE RESPONSE IN PATIENTS WITH CD19-POSITIVE RELAPSED/REFRACTORY B-CELL MALIGNANCIES RECRUITED INTO THE CART19-BE-01 CLINICAL TRIAL, AN ACADEMIC CAR19**

Nela Klein-González, E. Azucena González-Navarro, Ariadna Bartoló-Ibars, Valentín Ortiz-Maldonado, Montserrat Torrealbadell, Maria Castellà, Daniel Benítez, Miguel Caballero-Baños, Raquel Cabezon, Marta Español-Rego, Tycho Baumann, Eva Giné, Pedro Castro, Jordi Esteve, Jordi Yagüe, Susana Rives, Álvaro Urbano-Ispizua, Julio Delgado, Manel Juan (Spain)

### **REAL-WORLD DATA FROM KINGS COLLEGE HOSPITAL: INFECTION COMPLICATIONS POST CAR-T TREATMENT IN HIGH-GRADE B CELL NON-HODGKIN LYMPHOMA**

Shu Min Wong, Mili Shah, Shafqat Inam, Andrea Kuhn, Robin Sanderson (United Kingdom)

### **SENESCENT/EXHAUSTED PHENOTYPE OF CD19-TARGETED CAR-T CELLS AND IMMUNOREGULATORY ENVIRONMENT CORRELATE WITH REDUCED RESPONSE TO CAR-T CELL THERAPY IN RELAPSED/REFRACTORY B CELL MALIGNANCIES**

### **CHARACTERISATION OF EARLY AND LATE CYTOPENIAS IN LYMPHOMA PATIENTS FOLLOWING TREATMENT WITH ANTI-CD19 CAR-T THERAPY**

Catherine Hockings, Andrea Kuhn, Shu Wong, Mili Shah, Shafqat Inam, Piers Patten, Kirsty Cuthill, Tony Pagliuca, Deborah Yallop, Reuben Benjamin, Victoria Potter, Robin Sanderson (United Kingdom)

### **CD4+ CAR-T CELLS MAINTAIN MEMORY PHENOTYPES AND MEDIATE LONGER-TERM ANTITUMOR ACTIVITY IN VIVO**

### **IMPACT OF ETHNICITY IN R/R DLBCL AND B-CELL ALL PATIENTS TREATED WITH TISAGENLEUCEL**

Ahmed Abdelhady, Hidefumi Hiramatsu, Takanori Teshima, Koji Izutsu, Koji Kato, Satoshi Saida, Tatsuya Kamitori, Keiji Tasaka, Itaru Kato, Katsutsugu Umeda, Souichi Adachi, Karen Thudium, Edward Waldron, Alessandra Forcina, Andrea Chassot Agostinho, Stephan Grupp, Richard T. Maziarz (United States)

### **IMPACT OF DIFFERENT CHEMOTHERAPY REGIMENS AND DURATION OF DLBCL ON LYMPHOPHERESIS AND CAR-T T-CELL IMMUNOPHENOTYPING**

### **CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA**

## Scientific Programme

### **CHALLENGES IN PROVIDING GOOD LEUKAPHERESIS PRODUCTS FOR THE PRODUCTION OF CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY NHL OR ALL**

Felix Korell, Sascha Laier, Sandra Sauer, Sonia Jaramillo-Segura, Elisabeth Lasitschka, Kaya Veelken, Hannah Hennemann, Marie-Luisa Schubert, Tim Sauer, Petra Pavel, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt (Germany)

### **NKG2D CAR T CELLS ARE NOT AFFECTED BY SOLUBLE NKG2D LIGANDS**

Adrián Fernández, Lucía Fernández, Isabel Mirones, Adela Escudero, Leila Cardoso, Gloria Estes, Raquel De Paz, Joaquín Martínez-López, Mar Valés, Antonio Pérez-Martínez (Spain)

### **EMERGING CYTOKINE RELEASE SYNDROME IS ASSOCIATED WITH REDUCTION OF CD4+CD25HIGH127DIM T REGULATORY CELLS IN PATIENTS AFTER CAR T CELL THERAPY**

Christian R Schultze-Florey, Victoria Panagiota, Ivan Odak, Sultan Bektas, Tabea C Froehlich, Aleksandra Gladysz, Zhixiong Li, Gernot Beutel, Matthias Eder, Immo Prinz, Reinhold Foerster, Arnold Ganser, Christian Koenecke (Germany)

### **EXCELLENT PROLIFERATION AND PERSISTENCE OF ALLOGENEIC CAR-T CELLS DESPITE IMMUNOSUPPRESSION WITH CYCLOSPORINE A**

Francis Ayuk, Boris Fehse, Dietlinde Janson, Carolina Berger, Kristoffer Riecken, Nicolaus Kröger (Germany)

### **A FRENCH BIOBANKING NETWORK TO CREATE A UNIQUE COLLECTION OF SAMPLES OF PATIENTS TREATED WITH CAR-T CELLS**

### **CAR T CELL THERAPY DIRECTED AGAINST CD19 IN PATIENTS WITH B-CELL LYMPHOMA AFTER AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IS FEASIBLE AND SAFE**

### **LYMPHOCYTE COLLECTION FOR GENERATION OF CAR T-CELLS IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE**

Giovanna Del Principe, Giovanna Leone, Annalisa Ruggeri, Simone Biagini, Elia Girolami, Stefania Lazzaro, Antonella Meschini, Francesca Del Bufalo, Manuel Broglia, David Malaspina, Katia Feri, Federica Galaverna, Pietro Merli, Valentina Bertina, Mattia Algeri, Mauro Montanari, Andrea Onetti Muda, Giuseppina Li Pira, Franco Locatelli (Italy)

### **BASELINE HYPOALBUMINEMIA DOES NOT APPEAR TO BE AN ADVERSE PROGNOSTIC FACTOR IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMAS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**

Megan Melody, Sangeetha Gandhi, Zaid Abdel Rahman, Paula Lengerke Diaz, Nicole Gannon, Allison Rosenthal, Taun Truong, Mattia Novo, Eva Brandes, Gina Lange, Breana Etsby, Patrick Johnston, Steve Ansell, N. Nora Bennani, Jonas Paludo, Jose Villasboas Bisneto, Ernesto Ayala, Han W. Tun, Hemant Murthy, Vivek Roy, James Foran, Januario Castro, Yi Lin, Mohamed Kharfan-Dabaja (United States)

### **FACTORS PREDICTING CD3+ COLLECTION FOR THE PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS**

### **CYTOPENIAS AFTER TISAGENLEUCEL IN PAEDIATRIC/YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSE B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): A REAL-LIFE SINGLE-CENTRE EXPERIENCE**

Ignacio Gómez-Centurión, Saskia Burridge, Juliana Silva, Arina Lazareva, María Gabelli, Oana Mirici-Danicar, Giovanna Lucchini, Robert Chiesa, Kanchan Rao, Sujith Samarasinghe, Paul Veys, Ajay Vora, Persis Amrolia, Sara Ghorashian (Spain)

### **THE RISK OF HEPATITIS B REACTIVATION IS CONTROLLABLE IN B-CELL MALIGNANCIES PATIENTS WITH CONCOMITANT HEPATITIS B VIRUS INFECTION AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY**

Fang Ni, Yongxian Hu, Alex Hong Chang, He Huang (China)

## Scientific Programme

### **CUMULATIVE RITUXIMAB EXPOSURE PRIOR TO AXICABTAGENE CILOLEUCEL IS NOT ASSOCIATED WITH PERSISTENT LEUKOPENIA AND THROMBOCYTOPENIA AT DAY +90 POST INFUSION**

Madiha Iqbal, Sangeetha Gandhi, Abdullah Alselah, Muhamad Alhaj Moustafa, Ernesto Ayala, Hemant Murthy, Allison Rosenthal, Jilan Kubusek, Justin Haynes, Tuan Troung, Patrick Johnston, Stephen Ansell, Nora Bennani, Jonas Paludo, Jose Villasboas Bisneto, Breana Estby, Eva Brandes, Gina Lange, Januario Castro, Yi Lin, Mohamed Kharfan-Dabaja (United States)

### **COMPREHENSIVE IMMUNE CELL MONITORING REVEALS AN ALTERED LYMPHOCYTE SUBSET PHENOTYPE IN PATIENTS NOT RESPONDING TO TISAGENLEUCEL ONE MONTH POST INFUSION**

Christian R Schultze-Florey, Victoria Panagiota, Ivan Odak, Sultan Bektas, Tabea C Froehlich, Aleksandra Gladysz, Zhixiong Li, Gernot Beutel, Matthias Eder, Immo Prinz, Reinhold Foerster, Arnold Ganser, Christian Koenecke (Germany)

### **NEUROTOXICITY ASSOCIATED WITH CAR T CELL THERAPY: NEUROLOGICAL MANAGEMENT AND WORK-UP OF 11 ADULT PATIENTS**

### **NUTRITIONAL ASSESSMENT OF PATIENTS UNDERGOING CD19-TARGETED CAR-T THERAPY FOR NON-HODGKIN'S LYMPHOMA AND THE SHORT TERM EFFECT OF TREATMENT ON NUTRITIONAL STATUS**

### **EFFECTIVENESS OF AUTOLOGOUS LEUKAPHERESIS COLLECTIONS FOR CAR T-CELL MANUFACTURING IN PATIENTS WITH B-CELL MALIGNANCIES**

### **DEFINITION AND IMPLEMENTATION OF CLINICAL AND QUALITY ENDPOINTS IN CENTERS ADMINISTERING A COMMERCIAL CAR-T PRODUCT**

### **CAR-T IN BREAST AND OTHER EXTRA-MEDULLARY RELAPSED/REFRACTORY ALL**

Francesco Paolo Tambaro, Sajad Khazal, Dristhi Ragoonanan, Priti Tewari, Demetrios Petropoulos, Jeffrey A Miller, William G Wierda, Richard E Champlin, Kris M Mahadeo (Italy)

### **PREDICTING CAR T-CELL INFUSION AFTER SUCCESSFUL MANUFACTURING: REAL-WORLD DATA**

Georg-Nikolaus Franke, Eberhard Schleyer, Konstantin Weibl, Hansjakob Fries, Sophia Michel, Rosmarie Pointner, Dominic Brauer, Sandra Otto, Uwe Platzbecker, Vladan Vucinic (Germany)

### **EVALUATION OF THE INTEREST OF A DRUG RECONCILIATION ACTIVITY IN PATIENTS TREATED WITH CAR T-CELLS: A DESCRIPTIVE STUDY**

e-Posters  
09:30 - 19:00

ePoster Area

## **CAR-based Cellular Therapy - preclinical**

### **MODULATION OF CYTOSOLIC CA<sup>2+</sup> REGULATES CAR-T CELL DIFFERENTIATION AND THERAPEUTIC POTENCY**

### **BREAKING PD-L1-MEDIATED RESISTANCE IN ANTI-CD19 AND ANTI-CD22 CAR T CELLS WITH PD-1/CD28 FUSION RECEPTORS**

### **ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR-INVARIANT NATURAL KILLER T CELLS EXERT BOTH DIRECT AND INDIRECT ANTITUMOR EFFECTS THROUGH HOST CD8 T CELL CROSS-PRIMING**

Federico Simonetta, Toshihito Hirai, Juliane K. Lohmeyer, Kristina Maas-Bauer, Maite Alvarez, Arielle S. Wenokur, Jeanette Baker, Amin Aalipour, Samuel Haile, Crystal L. Mackall, Robert S. Negrin (United States)

## Scientific Programme

**DUVELISIB GENERATES CAR T CELLS WITH ENHANCED MITOCHONDRIAL BIOGENESIS AND REDUCED EXPRESSION OF PD-1, TIM-3, AND LAG-3, ENABLING GREATER ANTI-LEUKEMIA CYTOTOXICITY AGAINST CLL**

**NKG2D CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS**

**CLINICAL-GRADE MANUFACTURING OF ROR1 CAR T-CELLS USING A NOVEL VIRUS-FREE PROTOCOL**

Katrin Mestermann, Marie Eichler, Markus Machwirth, Kati Kebbel, Ulrike Köhl, Hermann Einsele, Claudia Müller, Jörg Lehmann, Tamás Raskó, Felix Lundberg, Zsuzsanna Izsvák, Gernot Schmiedeknecht, Michael Hudecek (Germany)

**LENTIVIRALLY AND ALPHARETROVIRALLY ENGINEERED CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS ARE HIGHLY CYTOTOXIC AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA**

**NOVEL STRATEGIES TO ENHANCE THE SAFETY OF CAR T-CELL IMMUNOTHERAPY: THE IMSAVAR PROJECT**

Miriam Alb, Jonathan Moggs, Lars Wallstabe, Benedikte Hatz, Hermann Einsele, Peter Loskill, Andries van der Meer, Scott Wagers, Ulrike Köhl, Michael Hudecek (Germany)

**ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIC CELLS**

Lara Herrera, Silvia Santos, Miguel Ángel Vesga, Juan Anguita, Itziar Martin-Ruiz, Tomás Carrascosa, Manel Juan, Cristina Eguizabal (Spain)

**ENHANCEMENT OF CYTOTOXICITY, EXPANSION AND PERSISTENCE OF CD19 CAR-T CELLS VIA PRE-SENSITIZATION OF B CELL MALIGNANCIES BY BCL-2 SELECTIVE INHIBITORS**

**TYROSINE KINASE INHIBITOR FOLLOWED BY CART THERAPY FOR THE TREATMENT OF RELAPSED PHILADELPHIA CHROMOSOME-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

e-Posters  
09:30 - 19:00

ePoster Area

## Cellular Therapies other than CARs

**CTLA4IG PRIMED SEQUENTIAL DLI IMPROVES GVHD AND RELAPSE-FREE SURVIVAL COMPARED TO UNPRIMED DLI IN PATIENTS UNDERGOING PTCY-BASED HAPLOIDENTICAL HCT FOR ADVANCED HEMATOLOGICAL MALIGNANCIES**

**HLA-MISMATCHED MOBILIZED CELLULAR THERAPY (MICROTRANSPLANT, MST) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES**

**DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PTCY: A STUDY ON BEHALF OF THE CTIWP OF THE EBMT**

**SAFETY, EFFECTIVENESS AND PERSISTENCE OF LOW-DOSE DONOR MEMORY T CELL INFUSIONS AFTER AB T CELL-DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER T-CELL-REplete ALLOGENEIC HSCT PREVENTS DISEASE RELAPSE AND PROLONGS SURVIVAL IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIA**

**BASELINE IMMUNE STATUS PREDICTS RESPONSE TO ADOPTIVE THERAPY WITH CMV CTLs FOR REFRACTORY CMV**

## Scientific Programme

**EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY ON BEHALF OF GETH (GRUPO ESPAÑOL TRASPLANTE HEMATOPOYÉTICO)**

**PHASE I STUDY OF ADOPTIVE TRANSFER OF HAPLOIDENTICAL EXPANDED NK CELLS**

**OFF-TARGET HLA CROSS-REACTIVITY BY (THIRD PARTY) VIRUS-SPECIFIC T CELLS IS SURPRISINGLY AFFECTED BY HLA RESTRICTION AND HLA BACKGROUND BUT NOT BY VIRUS SPECIFICITY**

**ADOPTIVE IMMUNOTHERAPY OF REFRACTORY VIRAL INFECTIONS AFTER ALLOGENEIC HSCT: AN ACADEMIC NETWORK FRAMING THE USE OF AN ATMP UNDER HOSPITAL EXEMPTION**

**HOW TO BENEFIT FROM EXHAUSTION: PATIENT-DERIVED INHIBITED T CELLS AS A NOVEL SOURCE OF TUMOR-REACTIVE T CELL CLONES**

Francesco Manfredi, Lorena Stasi, Danilo Abbati, Sara Mastaglio, Fabio Ciceri, Eliana Ruggiero, Chiara Bonini (Italy)

**EFFICIENT CRISPR/CAS9-MEDIATED INACTIVATION OF THE GLUCOCORTICOID RECEPTOR FOR ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY**

**COMPARISON OF OUTCOME POST-SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION VERSUS DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS**

Eshrak Al-Shaibani, Jeffrey H. Lipton, Dennis D. Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun Law, Zeyad Al-Shaibani, Armin Gerbitz, Ivan Pasic, Jonas Mattsson, , Fotios V. Michelis (Canada)

**AUTOMATED APPLICATION FOR DEPLETION OF TCRAB+, CD19+ AND CD45RA+ CELLS FROM APHERESIS PRODUCTS USING THE CLINIMACS PRODIGY (R)**

Julia Dzionek, Carina Thießen, Felix Hebbeker, Stephanie Soltenborn, Joanna Justyna Stenzel, Burgund Kauling, René Meißner, Nikolas Kaltz, Kirsten Langeveld, Michaela Malchow, Mario Assenmacher, Andreas Bosio, Eleni Papanikolaou (Germany)

**THE FIRST FUNCTIONAL HLA-A\*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES**

**GOOD RESPONSE RATES OF WJ-MSC, COMPARABLE TO BM-MSC, IN THE TREATMENT OF REFRACTORY GVHD**

Silvia Torrents, Laura Alonso, Joaquim Vives, Luciano Rodríguez, Georgina Morón-Cazalilla, Izaskun Elorza, Maria Luz Uribe, Maria Isabel Benítez, Rocío Parody, Guillermo Ortí, Maria Trabazo, Jesús Fernandez-Sojo, Margarita Codinach, Laura Medina, Isabel Badell, Cristina Díaz de Heredia, Sergi Querol (Spain)

**AN 'ALL IN ONE' T-CELL PRODUCT FROM NON-TRANSPLANTABLE CORD BLOOD UNITS FOR VIRUS- AND LEUKEMIA-SPECIFIC T-CELL IMMUNOTHERAPY**

**CLINICAL SUCCESS OF GRANULOCYTE TRANSFUSIONS IN ADULT NEUTROPENIC PATIENTS AFTER CHEMOTHERAPY AND/OR ALLOGENEIC TRANSPLANTATION - TIME MATTERS!**

Kira Inkari Thies, Michael Kramer, Friedrich Stölzel, Martin Bornhäuser, Johannes Schetelig, Simone von Bonin, Ralph Schneider, Kristina Hölig (Germany)

**IMPACT OF LONG-TERM CRYOPRESERVATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS PRODUCTS**

**OPTIMIZING LENTIVIRAL VECTOR TRANSDUCTION TO GENE MODIFY CORD BLOOD CD8+ T CELLS FOR OFF-THE-SHELF ADOPTIVE CELL THERAPY TO TREAT CANCER**

Vania Lo Presti, Ester Dunnebach, Maud Plantinga, Annelisa Cornel, Jurgen Kuball, Jaap Jan Boelens, Niek van Til \*, Stefan Nierkens \* (Netherlands)

**DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTRE EXPERIENCE**

## Scientific Programme

### **CASE REPORT: CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION (CAEBV) CONTROLLED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) AND TRANSFUSION OF EBV-SPECIFIC T-CELLS**

Elisabeth Meedt, Daniela Weber, Britta Eiz-Vesper, Britta Maecker-Kolhoff, Agnes Bonifacius, Klaus Schwarz, Myriam Lorenz, Susanne Delecluse, Henri-Jacques Delecluse, Ernst Holler, Wolfgang Herr, Matthias Edinger, Daniel Wolff (Germany)

e-Posters  
09:30 - 19:00

ePoster Area

## **Chronic leukaemia and other myeloproliferative disorders**

### **TIMING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A JOINT STUDY FROM THE INTERNATIONAL MDS/MPN WORKING GROUP AND EBMT**

### **RELAPSE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IN THE PATHWAY INHIBITOR (PI) ERA: NO LONGER A DEAD-END STREET**

### **THE 10-YEARS <u>E</u>BMT <u>L</u>ANDSCAPE OF <u>A</u>LLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) FOR <u>C</u>HRONIC LYMPHOCYTIC LEUKEMIA**

### **DETERMINANTS OF SURVIVAL IN MYELOFIBROSIS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT**

### **SPLENECTOMY DOESN'T PRECLUDE SUBSEQUENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELOFIBROSIS PATIENTS: A FRENCH NATIONWIDE STUDY USING A MULTISTATE MODEL**

### **INCIDENCE OF LATE RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS**

Isik Kaygusuz Atagunduz, Anita Badbaran, Gaby Zeck, Christine Wolschke, Francis Ayuk, Maximilian Christopeit, Nicolaus Kröger (Germany)

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: THE EXPERIENCE OF THREE UNIVERSITY TRANSPLANT CENTRES IN ROME**

### **AUSTRALASIAN TRENDS IN ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS IN MOLECULAR ERA**

Yadanar Lwin, Simon He, Andrew Spencer, Duncan Purtill, Ashley Mcewan, Peter Browett, Andrew Butler, John Carter, Peter Bardy, Glen Kennedy, Jeffrey Szer, David Ritchie, Matthew Greenwood, Stephen Larsen, Sam Milliken, Hock Lai, David Gottlieb, John Kwan, Donna Aarons, Steven Tran, Nada Hamad (Australia)

### **CML RELAPSE AFTER ALLOGENEIC HSCT: SURVIVAL, TREATMENT EFFICACY AND PROGNOSTIC FACTORS FOR OUTCOME**

Dunja Kampelmann, Dietrich W. Beelen, Rashit Bogdanov, Vesna Klisanin, Michael Koldehoff, Lambros Kordelas, Rudolf Trenschele, Markus Ditschkowski (Germany)

### **CHRONIC MYELOID LEUKEMIA: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE ERA OF TYROSINE KINASE INHIBITORS**

## Scientific Programme

### **REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT WITH CAMPATH T-CELL DEPLETION FOR MYELOFIBROSIS IN THE ERA OF JAK INHIBITORS- A SINGLE CENTRE EXPERIENCE**

Claire Horgan, Shereef Elmoamly, Alex Kanellopoulos, Richard Lovell, Shankara Paneesha, Bhuvan Kishore, Mary Dillon, Katie O'Collins, Kathy Holder, Emmanouil Nikolousis (United Kingdom)

### **ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS**

Christoph Buhl, Emin Abdullayev, Johanna Kerschbaum, Herrad Baurmann, Andreas Reiter, Bertram Glaß (Germany)

### **ALLOGENEIC STEM CELL TRANSPLANTATION FOR IDIOPATIC MYELOFIBROSIS: A SINGLE CENTRE EXPERIENCE**

### **A CASE OF SUCCESSFUL SECOND HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AFTER SECONDARY GRAFT FAILURE IN A PATIENT WITH REFRACTORY CHRONIC MYELOID LEUKEMIA**

Nadezhda Shnalieva, Anna Melikhova, Iurii Osipov, Galina Salogub, Vladimir Ivanov, Elza Lomaia (Russian Federation)

e-Posters  
09:30 - 19:00

ePoster Area

## Conditioning regimens

### **THE IMPACT OF CONDITIONING IN CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY "FORUM" ON BEHALF OF AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP**

### **POPULATION PHARMACOKINETIC ESTIMATION OF ATG EXPOSURE PREDICTS IMMUNE RECONSTITUTION AND SURVIVAL IN ADULTS UNDERGOING EX VIVO CD34-SELECTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

### **FLAMSA-BASED REDUCED INTENSITY CONDITIONING VERSUS MYELOABLATIVE CONDITIONING IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH ACTIVE DISEASE AT THE TIME OF TRANSPLANTATION: AN ALWP/EBMT ANALYSIS**

### **TOTAL BODY IRRADIATION/FLUDARABINE VERSUS THIOTEPA/BUSULFAN/FLUDARABINE FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH HAPLOIDENTICAL HCT. A STUDY BY ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**

### **BUSULFAN-CYCLOPHOSPHAMIDE VERSUS CYCLOPHOSPHAMIDE-BUSULFAN AS CONDITIONING REGIMEN BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A PROSPECTIVE RANDOMIZED TRIAL**

### **RABBIT ANTI-THYMOCYTE GLOBULIN (ATG) EXPOSURE AFTER EX VIVO T-CELL-DEPLETED HEMATOPOIETIC CELL TRANSPLANTATION IS VARIABLE AND IMPACTS IMMUNE RECONSTITUTION AND SURVIVAL IN CHILDREN AND YOUNG ADULTS**

### **A RETROSPECTIVE COMPARATIVE STUDY OF BEAM VS FEAM VS TEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT**

### **REDUCED INTENSITY VERSUS MYELOABLATIVE CONDITIONING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS < 60 WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTI-CENTER CANADIAN EXPERIENCE**

## Scientific Programme

### **COMBINING CLOFARABINE AND FLUDARABINE WITH EXPOSURE TARGETED BUSULFAN FOR PEDIATRIC LEUKEMIA: AN EFFECTIVE, LOW TOXIC, TBI-FREE CONDITIONING REGIMEN**

Anne Birgitta Versluys, Coco de Koning, [Marc Bierings](#), Stefan Nierkens, Caroline Lindemans, Dorine Bresters, Wouter Kollen, Arjan Lankester, Jaap Jan Boelens (Netherlands)

### **BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II STUDY**

### **REDUCED-TOXICITY CONDITIONING WITH FLUDARABINE, THIOTEPA AND MELPHALAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH IMPAIRED LUNG FUNCTION**

[Jesus Duque-Afonso](#), Gabriele Ihorst, Miguel Waterhouse, Robert Zeiser, Ralph Wäsch, Hartmut Bertz, Mehtap Yücel, Thomas Köhler, Joachim Müller-Quernheim, Reinhard Marks, Jürgen Finke (Germany)

### **ALLOGENEIC STEM CELL TRANSPLANT WITH MINIMAL-INTENSITY CONDITIONING IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA: A SINGLE CENTRE RETROSPECTIVE REVIEW**

[Marianne Gallanagh](#), Amy Brown, Angharad Pryce, Richard Szydlo, Stephen Morris, Renuka Palanicawandar, Edward Kanfer (United Kingdom)

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%.A STUDY FROM THE ALWP-EBMT**

### **A PROSPECTIVE COHORT STUDY COMPARING LONG-TERM OUTCOMES WITH AND WITHOUT PALIFERMIN IN PATIENTS RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES**

[Wael Saber](#), Patricia Steinert, Mei-Jie Zhang, Min Chen, Andrea Pope, Armand Keating, John Wingard, Karen Ballen, Patrick Stiff, Miguel-Angel Perales, Stephen Forman, Richard Champlin, Amelia Langston, Torbjörn Kullenberg, Mattias Rudebeck, Mary Horowitz (United States)

### **PHARMACOKINETICS OF MELPHALAN IN LYMPHOMA PATIENTS UNDERGOING BEAM AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT**

[Parastoo Dahj](#), Andrew Lin, Jessica Flynn, Christian Uruburo, Ian Mcgeary, Ryan Schofield, Valkal Bhatt, Lauren Derespiris, Bradley Figgins, Meagan Griffin, Carmen Lau, Anthony Proli, Dean Carlow, Christina Cho, Oscar Lahoud, Miguel Perales, Craig Sauter, Michael Scordo, Gunjan Shah (United States)

### **MELPHALAN IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION: DOES ONE SIZE FIT ALL?**

[Roni Tamari](#), Andrew Lin, Valkal Bhatt, Boglarka Gyurkocza, Esperanza Papadopoulos, Ann Jakubowski, Christina Cho, Brian Shaffer, Doris Ponce, Sergio Giralt, Gunjan Shah (United States)

### **COMPARISON OF TOTAL BODY IRRADIATION- VS CHEMOTHERAPY-BASED CONDITIONINGS FOR EARLY COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ALL**

### **DIFFERENTIAL ALEMTUZUMAB DOSAGES IN T-CELL DEplete ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTS FOR MYELOID MALIGNANCIES**

[Varun Mehra](#), Daniele Avenoso, Ximena C Castellano, Adrian Choy, Stefani Widya, Mili Shah, Shafqat Inam, Shreyans Gandhi, Austin Kulasekararaj, Pramila Krishnamurthy, Francesco Dazzi, Hugues de Lavallade, Victoria Potter, Ghulam J Mufti, Tony Pagliuca (United Kingdom)

### **THE INFLUENCE OF TDM ON ACHIEVING BUSULFAN TARGET EXPOSURE AND RELATED DETERMINANTS, IN BOTH CHILDREN AND ADULTS WHO UNDERWENT AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

Jill Boss, Arief Lalmohamed, Paul van der Linden, Jaap Jan Boelens, [Erik van Maarseveen](#) (Netherlands)

## Scientific Programme

### **NOVEL REDUCED INTENSITY CONDITIONING (RIC) APPROACH TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH BENIGN AND MALIGNANT DISORDERS OF T CELL PROLIFERATION OR DYSREGULATION**

Dimana Dimitrova, Gulbu Uzel, Luigi D. Notarangelo, Amanda K. Ombrello, Deborah Stone, Mark Parta, Ellen Carroll, Jennifer Wilder, Stephanie N. Hicks, Jennifer L. Sadler, Daniel H. Fowler, Ronald E. Gress, Christopher G. Kanakry, Jennifer A. Kanakry (United States)

### **PROFOUND LYMPHOPENIA AT THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION IS NOT PREDICTIVE OF SURVIVALS AFTER ALLO-TRANSPLANTATION**

### **LIPID CORE NANOPARTICLES AS VEHICLE FOR ETOPOSIDE IN THE CONDITIONING REGIMEN OF MARROW TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA NOT RESPONDING TO INDUCTION THERAPY: A PILOT STUDY**

Sandra Serson Rohr, Raul Cavalcante Maranhao, Thauany Martins Tavoni, Aleksandra Tiemi Morikawa, Debora Fernandes Deus, Jose Salvador Rodrigues Oliveira (Brazil)

### **A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF SHORT-TERM EVEROLIMUS IN ADDITION TO POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-EVER)**

### **ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS $\geq 65$ YEARS WITH HEMATOLOGICAL MALIGNANCIES AFTER MYELOABLATIVE TREOSULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS**

Simona Piemontese, Lorenzo Lazzari, Magda Marcatti, Fabio Giglio, Raffaella Greco, Daniela Clerici, Maria Teresa Lupo Stanghellini, Andrea Assanelli, Francesca Farina, Francesca Lorentino, Sara Mastaglio, Sarah Marktel, Matteo Carrabba, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Fabio Ciceri (Italy)

### **BUTYRYLCHOLINESTERASE ACTIVITY AFTER CYCLOPHOSPHAMIDE CONDITIONING AS A PREDICTIVE MARKER OF LIVER TRANSPLANT-RELATED COMPLICATIONS AND ITS CORRELATION WITH TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS**

Antonio Grasso, Giulia Caddeo, Davide Zanon, Alessandra Maestro, Roberto Simenone, Natalia Maximova (Italy)

### **FLUDARABINE-MELPHALAN CONDITIONING RESULTS IN FAVORABLE LEUKEMIA-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH ACTIVE OR MEASURABLE RESIDUAL AML**

### **SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS)**

### **INCREASED NON-RELAPSE MORTALITY AND POOR OVERALL SURVIVAL IN ELDERLY PATIENTS TREATED WITH FLUDARABINE AND MYELOABLATIVE DOSE OF BUSULFAN: TRANSPLANT COMPLICATIONS WORKING GROUP OF THE JSHCT**

Akihito Shinohara, Michiho Ebihara, Nobuaki Nakano, Emiko Sakaida, Naoyuki Uchida, Kentaro Fukushima, Hitoshi Sakai, Takashi Ashida, Yoshinobu Kanda, Junji Tanaka, Takahiro Fukuda, Yoshiko Atsuta, Hideki Nakasone (Japan)

### **TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA**

Anthony Stein, Ni-Chun Tsai, Joycelynne Palmer, Ibrahim Aldoss, Haris Ali, Ahmed Aribi, Len Farol, Chatchada Karanes, Samer Khaled, An Liu, Guido Marcucci, Ryotaro Nakamura, Vinod Pullarkat, Eric Radany, Joseph Rosenthal, Amandeep Salhotra, Ricardo Spielberger, David S Snyder, Stephen J Forman, Monzr M Al Malki, Jeffrey Wong (United States)

## Scientific Programme

### **A CD45-TARGETED ANTIBODY DRUG CONJUGATE ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS A SINGLE AGENT IN MICE**

Sharon Hyzy, Rahul Palchaudhuri, Jennifer Proctor, Bradley Pearse, Ganapathy Sarma, Geoff Gillard, Asim Saha, Tahirih Lamothe, Melissa Brooks, Katelyn Hammond, Anjali Bhat, Charlotte McDonagh, Hans-Peter Kiem, John Wagner, Bruce Blazar, Anthony Boitano, Michael Cooke (United States)

### **INFLUENCE OF THE CELL SOURCE TYPE AND CONDITIONING TYPE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME**

Fernando Barroso Duarte, Anna Thawanny Gadelha Moura, Vaneuza Araújo Moreira Funke, Virgílio Antônio Rensi Colturato, Nelson Hamerschlag, Neysimélia Costa Vilela, Luiz Fernando Lopes, Maria Cristina Martins de Almeida Macedo, Afonso Celso Vigorito, Rodolfo Daniel de Almeida Soares, Alessandra Paz, Mariana Stevenazzi, Lilián Diaz, Abrahao Elias Hallack Neto, Gustavo Bettarello, Breno Moreno de Gusmão, Marco Aurélio Salvino, Rodolfo Froes Calixto, Maria Cláudia Rodrigues Moreira, Gustavo Machado Teixeira, Cinthya Corrêa da Silva, Anderson Simioni, Romélia Pinheiro Gonçalves Lemes (Brazil)

### **PRECONDITIONING INTENSITY IMPACTS ON IMMUNE RECONSTITUTION AND OUTCOMES FOLLOWING CORD BLOOD TRANSPLANTATION**

Taiki Ando, Taisei Suzuki, Takayoshi Tachibana, Masatsugu Tanaka, Heiwa Kanamori, Hideaki Nakajima (Japan)

### **FINAL RESULTS OF A PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY ON THIOTEPA-BASED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (ASCT) FOR CNS OR NON-CNS LYMPHOMA**

Herbert Gottfried Sayer, Mathias Witzens-Harig, Mohammad Wattad, Agnieszka Korfel, Inken Hilgendorf, Georg-Nikolaus Franke, Gerald Illerhaus, Michael Heinsch, Bernd Metzner, Eva Bettina Zinngrebe, Nadezda Basara, Mascha Binder, Mark Ringhoffer, Alexander Röth, Thomas Geer, Volker Schmidt, Peter Dreger (Germany)

### **POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY), CYCLOSPORIN (CSA) AND MYCOPHENOLATE (MMF) FOR PATIENTS GRAFTED FROM HLA IDENTICAL SIBLINGS OR MATCHED UNRELATED DONORS**

### **COMPARISON OF FLUDARABINE + BUSULFAN AND FLUDARABINE+BUSUFAN+ LOW-DOSE ATG CONDITIONING REGIMENS IN PATIENTS WITH MYELOID MALIGNANCIES WHO HAD ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

Zafer Gulbas, Elif Birtas Atesoglu, Imran Dora, Cigdem Eren, Suat Celik, Gokhan Kusdemir, Kader Caliskan (Turkey)

### **CONDITIONING REGIMEN COMPARISON FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA**

Kristen Peterson, Andrew Lin, Josel Ruiz, Junting Zheng, Sean Devlin, Gunjan Shah, Michael Scordo, Craig Sauter, Miguel Perales, Sergio Giralte, Larry Buie, Parastoo Dahi (United States)

### **PK-GUIDED BUSULFAN CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) WITH PTCY AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

### **A THIOTEPA BASED INTENSIFIED REDUCED INTENSITY CONDITIONING REGIME IN ADULT CORD BLOOD TRANSPLANT IS A PROMISING ALTERNATIVE IN PATIENTS UNABLE TO RECEIVE MYELOABLATIVE CONDITIONING**

Ian Wu, Tangia Muquith, Yeh Ching Linn, Michelle Poon, Lip Kun Tan, Belinda Tan, Yelly Yelly, Teck Guan Soh, Davanaliz Gonzales Ramos, William Hwang, Liang-Piu Koh (Singapore)

### **HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE USING AS CONDITIONING FLUDARABINE MELPHALAN PLUS LOW DOSES OF TOTAL BODY IRRADIATION. LONG TERM FOLLOW-UP OF 60 PATIENTS**

Amado Jose Karduss, Rosendo Perez, Giovanni Ruiz, Angelica Cardona, Juan Alejo Jimenez, Luis Rodolfo Gomez, Pedro Reyes (Colombia)

## Scientific Programme

### **TREOSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE**

Frances Yeap, Chintan Tarunkumar Vyas, Cheryl Neoh, Mariflor S Villegas, Poh Lin Tan (Singapore)

### **COMPARISON OF BEAM AND TEAM AS CONDITIONING REGIMEN FOR LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

### **ASSESSMENT OF THE SAFETY AND EFFICACY OF THE CONDITIONING REGIMEN BEEAC BEFORE AUTO-HSCT FOR THE TREATMENT OF PRIMARY-REFRACTORY AND RELAPSED FORMS OF MALIGNANT LYMPHOMAS**

Anastasiia Samoylova, Vladislav Sarzhevsky, Vladimir Melnichenko, Nikita Mochkin, Julia Dubinina, Elena Smirnova, Anna Bannikova, Vladimir Bogatyrev (Russian Federation)

### **ALLOGENEIC STEM CELL TRANSPLANTATION AFTER TOTAL-BODY IRRADIATION USING HELICAL TOMOTHERAPY: A SINGLE CENTER EXPERIENCE**

Thomas Heinicke, Ana-Maria Waldleben, Denise Wolleschak, Thomas Brunner, Günther Gademann, Thomas Fischer, Hans-Joachim Ochel (Germany)

### **FEASIBILITY OF CLAMSA-RIC AS AN ALTERNATIVE CONDITIONING REGIMEN COMPARED TO FLAMSA-RIC IN HEAVILY PRETREATED REFRACTORY AML PATIENTS - A RETROSPECTIVE SINGLE CENTER ANALYSIS**

### **THIOTEPA, BUSULPHAN AND FLUDARABINE CONDITIONING IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA**

### **FLAMSA-BASED HIGH-DOSE SEQUENTIAL CONDITIONING REGIMEN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): IS IT EFFECTIVE IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE LEUKEMIA?**

Guldane Cengiz Seval, Ekin Kircali, Sinem Civriz Bozdog, Selami Kocak Toprak, Meltem Kurt Yuksel, Onder Arslan, Muhit Ozcan, Taner Demirel, Gunhan Gurman, Osman Ilhan, Hamdi Akan, Meral Beksac, Pervin Topcuoglu (Turkey)

### **INCREASING IN SERUM TOTAL AMYLASE LEVELS AFTER TOTAL BODY IRRADIATION CONDITIONING REGIMEN AS A PREDICTIVE MARKER OF TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS**

Antonio Grasso, Rossella Vidimari, Francesca Ciriello, Roberto Simenone, Fabrizio Cupardo, Natalia Maximova (Italy)

### **EVOLUTION OF DONOR CHIMERISM AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT - CLINICAL CORRELATIONS**

Carla Alves, Nuno Miranda, Pedro Sousa, Isabelina Ferreira, Gilda Teixeira, Ana Sofia Jorge, Maria Joao Gutierrez, Fernando Leal-da-Costa, Manuel Abecasis (Portugal)

### **THIOTEPA-BUSULFAN-FLUDARABINE AS CONDITIONING REGIMEN FOR PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

### **THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA-HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE REGIMEN IN CHILDREN**

### **ANALYSIS OF DIFFERENCES IN PREVENTIVE MEASURES AFTER HIGH-DOSE CYCLOPHOSPHAMIDE AMONG BELGIAN STEM CELL TRANSPLANT CENTRES**

Eva De Backer, Dries Deeren (Belgium)

### **IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION**

Susanne Aydin, Ingo Müller (Germany)

## Scientific Programme

### **LOW GRAFT CD4 CELL DOSE PREDICTS RELAPSE IN THE ATG-BASED MYELOABLATIVE CONDITIONING REGIMEN**

Nabil Yafour, Faiza Serradj, Soufi Osmani, Mohamed Brahimi, Sihem Bekadja, Amel Mihoubi, Rachid Bouhass, Abdessamad Arabi, Mohamed Amine Bekadja (Algeria)

### **CLINICAL EFFICACY OF HAPLOID TRANSPLANTATION WITH BU/CY/MEL PRETREATMENT SCHEME TO IMPROVE 68 CASES OF UNICENTRIC REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA**

### **REDUCING INTENSITY CONDITIONING (RIC) PROTOCOL HARMONISATION IN THE UK**

Nick Duncan, Amritpal Atwal, Sumantha Gabriel, Matthew Collin (United Kingdom)

### **HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN HIGH-RISK HEMATOLOGICAL MALIGNANCIES, ALGERIAN EXPERIENCE**

### **INTERRUPTION OF CONDITIONING FOR ALLO-HCT DOES NOT AFFECT CLINICAL OUTCOMES OTHER THAN CHRONIC GVHD**

Satoru Matsushima, Ryoji Kobayashi, Daiki Hori, Masato Yanagi, Koya Kodama, Daisuke Suzuki, Atsushi Manabe, Kunihiko Kobayashi (Japan)

### **THERAPEUTIC DRUG MONITORING OF BUSULFAN IN PEDIATRIC POPULATION**

Gulen Tuysuz Kintrup, Funda Tayfun Kupesiz, Hilal Akbas, Ayse Nur Akinel, Cigdem Sivrice, Elif Guler, Alphan Kupesiz (Turkey)

### **REDUCED INTENSITY CONDITIONING FOLLOWED BY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (RIC-HAPLOHCT) AND POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS, FOR HEMATOLOGICAL DISORDERS: SINGLE CENTRE EXPERIENCE**

Vinod Patil, Reghu Sukumaran, Mita Roychowdhury, Sayak Chaudhuri, Jeevan Kumar, Saurabh Bhawe, Rizwan Javed, Niharendu Ghara, Reena Nair, Vivek Radhakrishnan, Mammen Chandy (India)

### **HIGH DOSE TREATMENT WITH LEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION DURING THE SHORTAGE OF MOSTLY USED AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA**

### **REDUCED DOSE ALEMTUZUMAB IN REDUCED INTENSITY CONDITIONING VOLUNTEER DONOR UNRELATED TRANSPLANT FOR MYELOID MALIGNANCIES IS SAFE AND EFFICACIOUS. A SINGLE CENTRE EXPERIENCE**

### **DESCRIBE AND EXPLORE A PATIENTS' OUTLOOK ON DENTAL CARE IN THE CONTEXT OF THEIR MEDICAL DIAGNOSIS AND TREATMENT PRIOR TO AND FOLLOWING ALLOGENEIC HSCT**

Charlotte Wilson-Dewhurst, Amit Patel, Shelagh Thompson (United Kingdom)

### **SAFETY AND EFFICACY OF LOW-DOSE BENDA-EAM AS COMPARED TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION OF REFRACTORY/RELAPSED LYMPHOMA PATIENTS**

### **CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS**

Alix Pianka, Peter Herhaus, Krischan Braitsch, Katrin Holzhauser, Katharina Götze, Florian Bassermann, Mareike Verbeek (Germany)

### **OUTCOMES OF UNRELATED DONOR STEM CELL TRANSPLANTATION WITH OR WITHOUT ANTI-THYMOCYTE GLOBULIN USED AS GRAFT-VERSUS HOST DISEASE (GVHD) PROPHYLAXIS: A SINGLE CENTER EXPERIENCE**

Georgina Gener Ricós, Montserrat Batlle Massana, Mireia Morgades de la Fe, María Josefa Jiménez Lorenzo, Christelle Ferrà Coll, Juan Manuel Sancho Cía, Mireia Franch Sarto, Mireia Santos Gómez, Susana Vives Polo, Miriam Moreno Velázquez, Anna Torrent Catarineu, Blanca Xicoy Cirici, Laura Abril Sabater, Gladys Ibarra Fernández, Alicia Senín Magán, Albert Oriol Rocafiguera, Josep Maria Ribera Santasusana (Spain)

## Scientific Programme

### **BUSULFAN-FLUDARABINE CONDITIONING REGIMEN FOR CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE TWO-CENTER STUDY**

### **ATG IN CONDITIONING FOR SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

Lazar Chadievski, Aleksandra Pivkova Veljanovska, Irina Panovska Stavridis, Zlate Stojanoski, Lidija Cevreska, Nevenka Ridova, Marija Popova Labacevska, Zaklina Ancevska, Gabriela Trajkovska, Borce Georgievski (North Macedonia, the Republic of)

e-Posters  
09:30 - 19:00

ePoster Area

## Gene Therapy

### **CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT $\beta$ -THALASSEMIA**

### **LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY (HSPC-GT) FOR METACHROMATIC LEUKODYSTROPHY (MLD): CLINICAL OUTCOMES FROM 33 PATIENTS**

### **A SINGLE DOSE OF SHORT HALF-LIFE CD117 ANTIBODY DRUG CONJUGATE ENABLES HEMATOPOIETIC STEM CELL BASED GENE THERAPY IN NONHUMAN PRIMATES**

### **LENTI-D HEMATOPOIETIC STEM CELL GENE THERAPY STABILIZES NEUROLOGIC FUNCTION IN BOYS WITH CEREBRAL ADRENOLEUKODYSTROPHY**

### **SAFETY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH GENE ADDITION THERAPY FOR TRANSFUSION-DEPENDENT $\beta$ -THALASSEMIA, SICKLE CELL DISEASE, AND CEREBRAL ADRENOLEUKODYSTROPHY**

### **EX-VIVO AUTOLOGOUS HAEMATOPOIETIC STEM CELL GENE THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE IIIA**

Jane Kinsella, Simon Jones, Heather Church, Ceri Jones, Stuart Ellison, Claire Booth, Karen Buckland, Diego Leon Rico, Brian Bigger, Adrian J Thrasher, Robert Wynn (United Kingdom)

e-Posters  
09:30 - 19:00

ePoster Area

## Graft-versus-host disease - clinical

### **KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) - LONG-TERM FOLLOW-UP OF A PHASE 2A STUDY (KD025-208)**

### **A PHASE 2 STUDY OF F-652, A NOVEL TISSUE-TARGETED RECOMBINANT HUMAN INTERLEUKIN-22 (IL-22) DIMER, FOR TREATMENT OF NEWLY DIAGNOSED ACUTE LOWER GI GVHD**

### **THE MAGIC BIOMARKER ALGORITHM PREDICTS OUTCOMES FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE**

### **A NOVEL TREATMENT IN CHRONIC OCULAR GRAFT-VS-HOST DISEASE (OGVHD): A PHASE II CLINIC TRIAL WITH TRANSDERMAL PROGESTERONE**

### **EARLY CD4+ T-CELL RECONSTITUTION IS AN EXCELLENT PREDICTOR OF OUTCOMES IN PEDIATRIC PATIENTS WHO DEVELOP MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST-DISEASE: A DUAL CENTER VALIDATION**

## Scientific Programme

**EFFECT OF SINGLE OR DOUBLE MISMATCHES AT EACH HLA LOCUS ON THE OUTCOMES AFTER SINGLE CORD BLOOD TRANSPLANTATION: THE JSHCT HLA WG STUDY**

**INTERIM ANALYSIS OF KD025-213: A PHASE 2, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KD025 IN SUBJECTS WITH CGVHD (THE ROCKSTAR STUDY)**

**ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) AND RITUXIMAB FOR IMMUNOMODULATION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT FAILURE IN PATIENTS WITH NON-MALIGNANT DISORDERS: RESULTS OF A MULTICENTRE, RANDOMIZED, OPEN-LABEL STUDY**

**EXPERIENCE USING DUAL T-CELL DEPLETION WITH ATG AND PTCY FOR GVHD PROPHYLAXIS IN RIC ALLOHCT USING IN 10/10 MATCHED RELATED AND UNRELATED DONORS**

**MACHINE LEARNING APPLIED TO THE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE IMPROVES SURVIVAL ESTIMATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**SINGLE-CELL MOLECULAR ANALYSIS DEFINES CHARACTERIZATION OF SPECIFIC T CELL SUBSETS CORRELATE WITH HUMAN CHRONIC GVHD AND BRONCHIOLITIS OBLITERANS**

**A PHASE II TRIAL EVALUATING THE USE OF THE HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PREVENTION**

**REDUCED CALCIUM SIGNALING IS ASSOCIATED WITH GVHD: RESULTS FROM PRECLINICAL ALLOSCT MODELS AND FROM A PROSPECTIVE MULTICENTER STUDY**

**IDENTIFICATION OF PREDICTIVE MODELS INCLUDING POLYMORPHISMS IN CYTOKINES GENES ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND OVERALL SURVIVAL AFTER IDENTICAL HLA-ALLOGENEIC STEM-CELL TRANSPLANTATION**

**SEARCH FOR CIRCULATING ENDOTHELIAL CELLS OF DONOR ORIGIN AFTER ALLO-HSCT: POTENTIAL CLINICALLY RELEVANT IMPLICATIONS IN THE CONTEXT OF GRAFT-VERSUS-HOST DISEASE**

**DOUBLE LUNG TRANSPLANTATION IN ADULTS FOR CHRONIC PULMONARY GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Ram Vasudevan Nampoothiri, Peter Riddell, Susan Chernenko, Matthew Binnie, Lianne Singer, Stephen Juvet, Jeffrey Howard Lipton (Canada)

**REDUCED INFLAMMATORY TISSUE INFILTRATION DURING INTESTINAL STEROID-REFRACTORY GVHD**

Katarina Riesner, Steffen Cordes, Maria Bartosova, Martina Kalupa, Sarah Mertlitz, Lars Bullinger, Igor Wolfgang Blau, Claus Peter Schmitt, Gernot Beutel, Olaf Penack (Germany)

**IMPACT OF ANTITHYMOCYTE GLOBULIN DOSE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN STEM CELL TRANSPLANTATION FROM UNRELATED DONORS**

**DECREASED SOLUBLE HLA-E LEVELS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH SEVERE ACUTE AND EXTENDED CHRONIC GRAFT-VERSUS-HOST DISEASE AND INFERIOR OVERALL SURVIVAL**

**EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON PRODUCTION OF SERUM SOLUBLE CD163: RELATIONSHIP TO IMMUNOSUPPRESSION AND DISEASE ACTIVITY IN CHRONIC GRAFT VERSUS HOST DISEASE**

Nick C. Matthews, Charlotte Burton, Arun Alfred (United Kingdom)

**POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE OVERCOMES THE DETRIMENTAL EFFECT OF A SINGLE-LOCUS HLA MISMATCHED IN UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## Scientific Programme

### **ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: 'SIR-PTCY' RESULTS IN 249 PATIENTS**

Raffaella Greco, Serena Albanese, Francesca Lorentino, Maria Teresa Lupo Stanghellini, Fabio Giglio, Simona Piemontese, Magda Marcatti, Daniela Clerici, Lorenzo Lazzari, Rosamaria Nitti, Carmine Liberatore, Sara Mastaglio, Andrea Assanelli, Luca Vago, Chiara Bonini, Consuelo Corti, Massimo Bernardi, Fabio Ciceri, Jacopo Peccatori (Italy)

### **A NEW HOPE IN THE TREATMENT OF STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE (SR-GVHD) AFTER ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION (AHSCT): RUXOLITINIB**

Osman Ilhan, Guldane Cengiz Seval, Sinem Civriz Bozdog, Burak Devenci, Mustafa Pehlivan, Leylagul Kaynar, Irfan Yavasoglu, Huseyin Bekoz, Ipek Yonal Hindilerden, Zeynep Arzu Yegin, Simten Dagdas, Ayse Avsar, Atilla Hasan Ozkan, Tulin Firat Tuglular, Hakan Goker, Zafer Golbas (Turkey)

### **AZACITIDINE IS SAFE AND ACTIVE IN THE TREATMENT OF STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST-DISEASE - INTERIM RESULTS OF THE PHASE II AZTEC TRIAL**

### **BASILIXIMAB AS TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **EFFICACY AND TOLERANCE OF Nilotinib IN PATIENTS WITH REFRACTORY CHRONIC GVHD WHO ARE REFRACTORY/INTOLERANT TO IMATINIB: A PROSPECTIVE MULTICENTER PHASE II STUDY OF THE SFGM-TC**

### **EVALUATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC ASSESSMENT OF ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE UPPER GASTROINTESTINAL TRACT ACCORDING TO LERNER EARLY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

Abed Alahad Sarraf, Renate Schmelz, Henning Baldauf, Daniela Aust, Friedrich Stölzel, Jan Moritz Middeke, Katja Sockel, Raphael Teipel, Stefan Brückner, Marco Berning, Sebastian Zeissig, Jana Babatz, Christian Kirsch, Gustavo Baretton, Martin Bornhäuser, Jochen Hampe, Johannes Schetelig (Germany)

### **CYCLOSPORINE A ALONE VERSUS MYCOPHENOLATE MOFETIL PLUS CYCLOSPORINE A BASED GVHD PROPHYLAXIS FOR PATIENTS WITH AML UNDERGOING MUD TRANSPLANTATION. A STUDY FROM THE ALWP**

### **TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE**

Eleni Gavrilaki, Ioanna Sakellari, Zoi Bousiou, Thomas Chatzikonstantinou, Despina Mallouri, Marianna Masmanidou, Anna Vardi, Eudoxia-Evangelia Koravou, Foteini Kika, Tasoula Touloumenidou, Apostolia Papalexandri, Evangelia Yannaki, Ioannis Batsis, Achilles Anagnostopoulos (Greece)

### **DIAGNOSTIC SIGNIFICANCE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD)**

Georg Evers, Wolfgang Roll, Joern Christian Albring, Christian Reicherts, Rebecca Strotmann, Georg Lenz, Michael Schaefer, Matthias Stelljes (Germany)

### **LONG TERM OUTCOMES OF RUXOLITINIB THERAPY IN STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN AND ADULTS**

Tatiana Bykova, Ivan Moiseev, Elena Morozova, Elena Darskaya, Olesya Paina, Anna Smirnova, Anna Dotcenko, Evgenia Borzenkova, Alexander Galimov, Yana Gudognikova, Kirill Ekushev, Polina Kozhokar, Anna Osipova, Olga Pirogova, Tatiana Rudakova, Olesya Shakeeva, Nikolay Tcvetkov, Egor Kulagin, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

## Scientific Programme

### **INVESTIGATING ANTIBIOTIC EXPOSURE AND RISK OF SEVERE ACUTE GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Razan Mohty, Rémy Duléry, Giorgia Battipaglia, Eolia Brissot, Clémence Médiavilla, Simona Sestilli, Tounes Ledraa, Beatrice Gaugler, Agnes Bonnin, Mohamad Mohty, Florent Malard (France)

### **EFFICACY AND TOXICITY OF RUXOLITINIB IN PATIENTS WITH STEROID-RESISTANT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION**

### **PATIENT CHARACTERIZATION AND SURVIVAL OUTCOMES IN PAEDIATRIC CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS: A POPULATION-BASED STUDY IN SWEDEN**

Frida Schain, Nurgul Batyrbekova, Annica Dominicus, Simona Baculea, Mats Remberger, Jonas Mattsson, Jacek Toporski (Sweden)

### **CYTOKINE LEVELS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A MATCH-PAIR ANALYSIS OF HOME CARE VERSUS HOSPITAL CARE**

Olle Ringden, Mats Remberger, Johan Torlen, Sigrun Finnbogadottir, Britt-Marie Svahn, Behnam Sadeghi (Sweden)

### **FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH STEROID-RESISTANT GRAFT VERSUS HOST DISEASE COLONIZED BY ANTIBIOTIC-RESISTANT BACTERIA - SINGLE-CENTER ANALYSIS OF 15 PROCEDURES**

Jarosław Biliński, Karol Lis, Agnieszka Tomaszewska, Pawel Grzesiowski, Aleksandra Pechcinska, Tomasz Dzieciatkowski, Kazimierz Halaburda, Magdalena Tormanowska, Martyna Tyszk, Krzysztof Mądry, Ewa Karakulska-Prystupik, Alicja Walesiak, Wiesław Wiktor Jedrzejczak, Grzegorz W. Basak (Poland)

### **INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE: RESULTS FROM A PROSPECTIVE MULTICENTRE ANALYSIS OF 2 COHORTS**

Antonela Lelas, Ronja Langer, Michael Rittenschober, Lana Desnica, Hildegard Greinix, Anne Dickinson, Marit Inngjerdingen, Anita Lawitschka, Radovan Vrhovac, Drazen Pulanic, Stefan Klein, Jan Moritz Middeke, Matthias Edinger, Daniel Wolff (Croatia)

### **THE CXCL9 POLYMORPHISM RS884304 COUNTERACTS CALCINEURIN-INHIBITOR REPRESSION OF EARLY CXCL9 RECONSTITUTION AND ASSOCIATES WITH SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE**

Hao Dai, Sivaramakrishna P. Rachakonda, Olaf Penack, Olga Blau, Aleksandar Radujkovic, Carsten Müller-Tidow, Peter Dreger, Rajiv Kumar, Thomas Luft (Germany)

### **EARLY INTRODUCTION OF RUXOLITINIB FOR CHILDREN WITH GRAFT VERSUS HOST DISEASE - A STITCH IN TIME SAVES NINE**

Revathi Raj, Ramya Uppuluri, Venkateswaran Vellaichamy, Nikila Ravichandran, Kesavan Iyer (India)

### **POST-TRANSPLANT CYCLOPHOSPHAMIDE AS AN EFFECTIVE STRATEGY FOR GVHD PREVENTION IN BOTH HLA-MATCHED AND MISMATCHED ALLOGENEIC TRANSPLANTS**

Irene García-Cadenas, Albert Esquirol, Rahinatu Awol, Silvana Saavedra, Silvana Novelli, Ana Garrido, Jordi López, Carol Moreno, Miquel Granell, Javier Briones, Salut Brunet, Jordi Sierra, Rodrigo Martino (Spain)

### **SERUM AUTOANTIBODIES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY**

Ivan Pasic, Ashley Di Meo, Ioannis Prassas, Ihor Batruch, Leeann Wilson, Eleftherios P. Diamandis, Fotios V. Michelis (Canada)

### **OPTIMIZED STARTING DOSE OF CYCLOSPORINE REDUCES RISK OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

Jérémy Héritier, Michael Medinger, Dominik Heim, Helen Baldomero, Christian Arranto, Jörg Halter, Jakob R. Passweg, Martina Kleber (Switzerland)

## Scientific Programme

### **SUCCESS OF IMMUNOSUPPRESSION IN PATIENTS WITH CHRONIC GVHD: ANALYSIS ON 108 ADULT LONG-TERM SURVIVORS AFTER MATCHED AND HAPLO HSCT**

Maria Teresa Lupo-Stanghellini, Francesca Lorentino, Fabio Serpenti, Andrea Assanelli, Carlo Messina, Sara Mastaglio, Stefania Girlanda, Fabio Giglio, Raffaella Greco, Sarah Marktel, Francesca Lunghi, Elena Guggiari, Magda Marcatti, Matteo G. Carrabba, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri (Italy)

### **INCIDENCE AND OUTCOME OF LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE DURING TAPERING OR AFTER STOPPING CALCINEURIN INHIBITORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

Kazuki Yoshimura, Shun-Ichi Kimura, Masakatsu Kawamura, Shunto Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Shinpei Matsumi, Ayumi Gomyo, Yu Akahoshi, Masaharu Tamaki, Machiko Kusuda, Kazuaki Kameda, Hidenori Wada, Koji Kawamura, Miki Sato, Kiriko Terasako-Saito, Aki Tanihara, Hideki Nakasone, Shinichi Kako, Yoshinobu Kanda (Japan)

### **POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING AND MATCHED UNRELATED COMPARED TO HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, A STUDY ON BEHALF OF GETH**

Mi Kwon, Rebeca Bailén, Maria Jesus Pascual Cascon, Lucia Lopez Corral, Arancha Bermudez, Pilar Herrera, Antonia Sampol, Inmaculada Heras, Carmen Martin Calvo, Jaime Sanz, Isabel Sanchez Ortega, Melissa Torres, Jose Rifon Roca, Kareem Humala, Cristina Muñoz, Ignacio Gomez Centurion, Gillen Oarbeacoa, Nieves Dorado, Jose Luis Diez Martin (Spain)

### **MESENCHYMAL STROMAL CELLS (MSC) FOR STEROID-REFRACTORY ACUTE GVHD, A SINGLE CENTER PHASE I/II TRIAL**

### **T-LYMPHOCYTE TRANSCRIPTIONAL SIGNATURE IN ECP-TREATED PAEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE**

Aisling M Flinn, Janet Chou, Anna Ehrlich, Xiao Nong Wang, Raif S Geha, Andrew R Gennery (United Kingdom)

### **EFFICACY OF LOW-DOSE RUXOLITINIB AS SAVAGE THERAPY IN HEAVILY PRETREATED PATIENTS WITH MODERATE/SEVERE STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE**

Yanmin Zhao, Jimin Shi, Yi Luo, Yamin Tan, Jian Yu, Huarui Fu, Xiaoyu Lai, He Huang (China)

### **RESTRICTIVE USE OF INTRAVENOUS ANTIBIOTICS IN ALLOGENEIC SCT PTS WITH FEVER DUE TO CYTOKINE RELEASE SYNDROME ALLOWS MICROBIOTA PROTECTION WITHOUT INCREASE OF INFECTIONS AND TRM**

Ernst Holler, Daniela Weber, Joachim Hahn, Cornelia Mittermaier, Klaus-Georg Kreitmeier, Andreas Hiergeist, Bernd Salzberger, Daniel Wolff, Andre Gessner, Wolfgang Herr, Matthias Edinger (Germany)

### **EXTRACORPOREAL PHOTOPHERESIS (ECP) AS FIRST-LINE TREATMENT FOR ACUTE GVHD (AGVHD) IN PEDIATRIC PATIENTS WHO UNDERWENT T-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (APLO-HSCT)**

### **EFFICACY OF METHOXSALEN STERILE SOLUTION IN CONJUNCTION WITH THE THERAKOS (R) CELLEX (R) PHOTOPHERESIS SYSTEM IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: INTERIM ANALYSIS**

Carrie Lynn Kitko, Stefania Gaspari (United States)

### **MICRO RNA PROFILING OF ACOUSTICALLY-ISOLATED EXTRACELLULAR VESICLES IDENTIFIES POTENTIAL BIOMARKERS FOR POST-ALLO-HSCT COMPLICATIONS**

Hooi Ching Lim, Shamit Soneji, Robert Palmason, Stig Lenhoff, Thomas Laurell, Stefan Scheduling (Sweden)

### **COLONIZATION PLAYS AN IMPORTANT ROLE IN THE OUTCOME OF ALLOGENEIC TRANSPLANTATION**

## Scientific Programme

### **ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) SCORE AT THE ONSET OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PREDICTING OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION-A RETROSPECTIVE ANALYSIS**

### **CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS**

Avichai Shimon, Noga Shem-Tov, Ivetta Danylesko, Ronit Yerushalmi, Arnon Nagler (Israel)

### **COMPARISON OF EXCLUSIVE POSTTRANSPLANT CYCLOPHOSPHAMIDE VERSUS A CALCINEURIN INHIBITOR BASED REGIMEN AS GVHD PROPHYLAXIS IN ALLOGENEIC BONE MARROW TRANSPLANTATION FROM HLA IDENTICAL SIBLING**

### **SIROLIMUS VERSUS CYCLOSPORINE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND MYCOPHENOLATE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL TRANSPLANTS: A RETROSPECTIVE ANALYSIS OF ONE SINGLE INSTITUTION**

Mario Andres Sanchez Salinas, Rafael Hernani Morales, Ana Benzaquen Vallejos, Juan Carlos Hernandez Boluda, Ariadna Perez Martinez, Paula Amat Martinez, Montserrat Gomez Calafat, Rosa Goterris Vicedo, Carlos Solano Vercet (Spain)

### **TARGETED SEQUENCE CAPTURE METAGENOMICS (VIROCAP) TO DETECT VIRUS IN STOOL SAMPLES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS**

Suze A. Jansen, Wouter Nijhuis, Helen Leavis, Annelies Riezebos-Brilman, Caroline A. Lindemans, Rob Schuurman (Netherlands)

### **EXTRACORPOREAL PHOTOPHERESIS AND PRODUCTION OF SERUM IL-34 AND ELAFIN IN CHRONIC GRAFT VERSUS HOST DISEASE**

Charlotte Burton, Nick C. Matthews, Arun Alfred (United Kingdom)

### **IMPACT OF UPPER AND LOWER ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE ON GRADING AND OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS IN 122 CONSECUTIVE PATIENTS**

Monica Poiani, Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Marianna Mariani, Giorgia Micucci, Chiara Montagna, Giuseppina Urbano, Federica Monaco, Giuseppe Tarantino, Irene Federici, Attilio Olivieri (Italy)

### **PRELIMINARY EXPERIENCE WITH THE USE OF RUXOLITINIB, IBRUTINIB OR IMATINIB FOR THE TREATMENT OF ACUTE OR CHRONIC GVHD**

Carolina Secreto, Martina Tonelli, Alessandro Busca, Matilde Scaldaferrì, Chiara Della Casa, Luisa Giaccone, Lucia Brunello, Sara Butera, Giorgia Iovino, Francesco Cattel, Benedetto Bruno (Italy)

### **RUXOLITINIB WITH OR WITHOUT IBRUTINIB AS AN ALTERNATIVE FIRST LINE THERAPY FREE OF CORTICOSTEROIDS OR CALCINEURIN INHIBITORS IN TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE**

Rong Xie, Qin Liu, Dan Han, Wenlan Chen, Han Yan, Fanjun Cheng, Yong You, Ping Zou, Zhaodong Zhong (China)

### **CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS**

Chiara Montagna, Maria Teresa Lupo Stanghellini, Ilaria Scortechini, Magda Marcatti, Raffaella Greco, Fabio Giglio, Andrea Assanelli, Consuelo Corti, Monica Poiani, Federica Monaco, Giuseppina Urbano, Giorgia Mancini, Irene Federici, Jacopo Peccatori, Fabio Ciceri, Attilio Olivieri, Simona Piemontese (Italy)

### **IMPACT OF KIR/HLA INCOMPATIBILITIES AFTER POSTTRANSPLANT CYCLOPHOSPHAMIDE BASED T CELL-REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## Scientific Programme

### **ELEVATED PTH LEVELS AMONG CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS AND OTHER LONG TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Antonela Lelas, Lana Desnica, Ivan Sabol, Zlatko Giljevic, Tina Dusek, Dina Ljubas Kelecic, Irena Karas, Nadira Durakovic, Zinaida Peric, Ranka Serventi Seiwert, Radovan Vrhovac, Steven Z. Pavletic, Drazen Pulanic (Croatia)

### **CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION**

Mohammad Sheikh, Shahrukh Hashmi (Pakistan)

### **ACUTE GVHD INCIDENCE IN MISMATCHED UNRELATED DONOR HSCT IN PAEDIATRIC ADULT PATIENTS: A STUDY FROM THE TURIN METROPOLITAN TRANSPLANT CENTER**

Massimo Berger, Marta Barone, Francesco Saglio, Fabrizio Carnevale-Schianca, Marco De Gobbi, Luca Parnuzzo, Paolo Nicoli, Manuela Spadea, Daniela Caravelli, Elena Ernestina Vassallo, Massimo Aglietta, Franca Fagioli (Italy)

### **PRACTICAL IMPLEMENTATION OF THE NIH DIAGNOSTIC CRITERIA FOR ORAL CHRONIC GVHD IN A MULTIDISCIPLINARY TEAM IN THE LATE FOLLOW UP OF ALLOGENIC HSCT PATIENTS**

### **THE IMPACT OF ANTIBIOTIC-MEDIATED MODIFICATION OF THE INTESTINAL MICROBIOME ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SYSTEMATIC REVIEW AND META-ANALYSIS**

Maria Gavriilaki, Ioanna Sakellari, Achilles Anagnostopoulos, Eleni Gavriilaki (Greece)

### **CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON'S JELLY IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE**

Michał Piątek, Izabela Zdolińska-Malinowska, Maciej Rojek, Monika Mielcarek-Siedziuk, Krzysztof Kałwak, Katarzyna Drabko, Agnieszka Zaucha-Prażmo, Dominik Grabowski, Janina Marta Choma, Mirosław Markiewicz, Monika Dzierżak Mietla, Jolanta Goździk, Szymon Skoczeń, Krzysztof Czyżewski, Robert Dębski, Anna Krenska, Jan Styczyński, Mariusz Wysocki, Dariusz Borucki (Poland)

### **PREDICTIVE ROLE OF ENDOSCOPIC/HISTOLOGICAL EXAMINATIONS FOR GASTRO-INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELLS TRANSPLANT: 'A POSTERIORI' ANALYSIS IN A SINGLE CENTER**

### **THE INCIDENCE, RISK FACTORS, AND OUTCOMES OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **PROGNOSTIC CT FINDINGS AROUND THE ONSET OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE**

Shinpei Harada, Koichiro Minauchi, Hajime Senjo, Naoki Miyashita, Tomohiro Yamakawa, Junko Iwasaki, Shojiro Takahashi, Kohei Okada, Akio Shigematsu, Masahiro Imamura, Naoki Kobayashi, Shuichi Ota (Japan)

### **THYMOGLOBULIN AND GRAFALON EFFECT ON ALLOGENEIC STEM CELL TRANSPLANT - POOLED DATA FROM WROCLAW MEDICAL UNIVERSITY, POLAND AND UNIVERSITY MEDICAL CENTER LJUBLJANA, SLOVENIA**

### **THE ROLE OF LOW-DOSE ANTI-THYMOCYTE GLOBULIN IN MATCHED SIBLING DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES**

Daihong Liu, Liping Dou, Lu Wang, Fei Li, Lijun Wang (China)

### **NEPHROTIC SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AS A FORM OF CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE**

## Scientific Programme

### **CORRELATION AMONG TOTAL NUCLEATED CELLS (TNC), CD34+, CD3+ CELL CONTENT IN G-CSF-PRIMED BONE MARROW COLLECTIONS AND THEIR RELATIVE INFLUENCE ON DEVELOPMENT OF ACUTE GVHD**

Stalin Ramprakash, Rajat Kumar Agarwal, C P Raghuram, Pallavi Mehta, Paula Tacia, S Sandeep, Rakesh Dhanya, Lawrence Faulkner (India)

### **PREDICTION FOR LETHAL ACUTE GRAFT VERSUS HOST DISEASE AND NON-RELAPSE MORTALITY BY EARLY PLASMA BIOMARKERS: A SINGLE CENTER RETROSPECTIVE STUDY IN JAPAN**

Hideaki Yoshimura, Atsushi Satake, Masaaki Hotta, Takahisa Nakanishi, Aya Nakaya, Shinya Fujita, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura (Japan)

### **RUXOLITINIB IN THE TREATMENT OF CORTICOSTEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD): ONE SINGLE CENTER EXPERIENCE**

Melissa Torres Ochoa, Paula Fernández-Caldas González, Haridian de la Nuez Melián, Cynthia Acosta Fleitas, Santiago Jiménez Bravo de Laguna, María Perera Álvarez, Leslie González Pinedo, Luisa Guerra Domínguez, Alexia Suárez Cabrera, Luz María González del Castillo, Leonor Pérez Ortiz, Teresa Molero Labarta (Spain)

### **OUTCOME OF PATIENTS ALIVE AT 1-YEAR POST ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM A SINGLE INSTITUTION**

### **RUXOLITINIB IN STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: EXPERIENCE IN OUR CENTRE**

### **LOW-DOSE OF RUXOLITINIB: AN EFFECTIVE THERAPY FOR REFRACTORY BOS PATIENTS**

Yanping Ji, Baolin Tang, Xiaoyu Zhu, Huilan Liu, Kaidi Song, Xiang Wan, Wen Yao, Guangyu Sun, Zimin Sun (China)

### **SIROLIMUS BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PAEDIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR BENIGN DISEASE**

Gaurav Kharya, Archana Rauthan, Manju Joseph, Himshikha Yadav, Bharti Sharma, Atish Bakane (India)

### **DETECTION OF BIOMARKERS PREDICTIVE OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY**

### **OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) AFTER PD-1 BLOCKADE IN RELAPSED/REFRACTORY (R/R) LYMPHOMAS: A SINGLE CENTER EXPERIENCE**

Xabier Gutiérrez López de Ocariz, Elena Vera-Guerrero, María Calbacho, Jose María Sánchez-Pina, Ana Jiménez-Ubieto, Antonia Rodríguez, Sara Redondo, Marta Hidalgo-Soto, Rodrigo De Nicolás, Nieves López-Muñoz, Buenaventura Buendía-Ureña, Joaquín Martínez-López (Spain)

### **CD3+ DOSE IN PERIPHERAL BLOOD PROGENITOR CELLS PRODUCTS FOR ALLOTRANSPLANT FROM MATCHED UNRELATED DONORS FOR AML: IMPACT ON CHRONIC GRAFT VERSUS HOST DISEASE AND SURVIVAL**

### **CYCLOPHOSPHAMIDE FOR SALVAGE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE: A RETROSPECTIVE ANALYSIS**

Matthias Alexander Fante, Tobias Wertheimer, Anna-Sophia Kattner, Daniela Weber, Barbara Holler, Ernst Holler, Matthias Edinger, Wolfgang Herr, Daniel Wolff (Germany)

### **A ROLE OF METHOTREXATE IN THE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE - A MULTICENTER OBSERVATIONAL STUDY ON BEHALF OF POLISH ADULT LEUKEMIA GROUP (PALG)**

### **EVALUATION OF EXTRACORPOREAL PHOTOPHERESIS USED AS SECOND-LINE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HSCT IN A BRAZILIAN CENTER**

## Scientific Programme

### **THE OPTIMAL GVHD PROPHYLAXIS IN UNRELATED TRANSPLANTATIONS OF NON-MANIPULATED HEMATOPOIETIC STEM CELLS IN CHILDREN**

#### **ANALYSIS OF HISTOLOGY'S IMPACT IN PATIENTS WITH ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Elena María Gámez Jiménez, Pedro Antonio González Sierra, Elisa López Fernández, Lucía Moratalla López, Zoraida Mesa Morales, Antonio Romero Aguilar, Manuel Jurado Chacón (Spain)

#### **RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE**

#### **IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT). UNICENTRIC EXPERIENCE**

#### **FECAL MICROBIOTA TRANSPLANTATION FOR TREATING STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE OF THE GUT: A PILOT STUDY**

Won-Hyoung Seo, Ik-Chan Song, Myung-Won Lee, Sang-Hoon Yeon, Yoon-Seok Choi, Bu-Yeon Heo, Jaeyul Kwon, Deog-Yeon Jo (Korea, Republic of)

#### **EARLY RECOVERY OF LYMPHOCYTES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS RISK FACTOR OF CGVHD**

Masato Yanagi, Ryoji Kobayashi, Satoru Matsushima, Daiki Hori, Koya Kodama, Daisuke Suzuki, Kunihiro Kobayashi (Japan)

#### **FAVORABLE OUTCOME USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN HAPLOIDENTICAL (HAPLO-SCT) AND MATCHED RELATED DONORS (MRD): SINGLE CENTER EXPERIENCE IN CHILE**

Matias Sanchez, Marcela Vargas, Javiera Donoso, Natalia Aranguiz, Alejandro Berkowits, Sebastian Ewoldt, Veronica Bustamante, Laura Paredes, Teresa Dibarrart, Patricia Lobos, Leonardo Cabrera (Chile)

#### **COMBINED THERAPY WITH MSC INFUSIONS TO OVERCOME STEROID-DEPENDENCY IN A CASE OF SEVERE PULMONARY CGVHD**

Francesca Compagno, Antonia Avanzini, Elena Bergami, Stella Boghen, Tommaso Mina, Santina Recupero, Elisa Lenta, Stefania Croce, Laura Catenacci, Alessandra Tolva, Federico Bonetti, Giovanna Giorgiani, Patrizia Comoli, Marco Zecca (Italy)

#### **MULTIPLE STRICTURES OF THE SMALL INTESTINE DEMANDING SURGICAL INTERVENTION AS A COMPLICATION OF GRAFT VERSUS HOST DISEASE: A CASE REPORT**

#### **A REMARKABLY LONG REMISSION ACHIEVED WITH IBRUTINIB MONOTHERAPY IN A PATIENT WHO WAS DIAGNOSED WITH STEROID REFRACTORY SCLEROSING CHRONIC GVHD**

#### **INCREASED RISK OF ACUTE GVHD IN PATIENTS WITH MYELOFIBROSIS AFTER ALLO TRANSPLANT IN THE ABSENCE OF JAK-STAT INHIBITION**

Sami Brake (United States)

#### **AUTOIMMUNE MYOSITIS AS PARANEOPLASTIC COMPLICATION OF A SQUAMOUS CELL CARCINOMA OF THE TONGUE AFTER SEVERE CHRONIC GRAFT VERSUS HOST DISEASE**

#### **UNUSUAL CAUSE OF DYSPNEA IN POST-TRANSPLANT PATIENT**

e-Posters  
09:30 - 19:00

ePoster Area

## **Graft-versus-host disease - preclinical and animal models**

#### **DIETARY STEARIC ACID LEADS TO A SEVERE AGVHD BY MODULATING THE GUT MICROBIOTA AND GLUCOSE METABOLISM**

## Scientific Programme

### **GRANULOCYTE COLONY-STIMULATING FACTOR-PRIMED DONOR T CELLS ATTENUATE MURINE ACUTE GVHD THROUGH REGULATING T CELL DIFFERENTIATION IN TARGET ORGANS**

### **MTOR REGULATE GENERATION AND FUNCTION OF PMN-MDSCS AND PLAY PROTECTION ROLE IN ACUTE GRAFT-VERSUS-HOST DISEASE**

### **FULL REGULATORY T CELL RECONSTITUTION BEFORE T CELL TRANSFER PREVENTS GRAFT-VERSUS-HOST DISEASE BY SUPPRESSING COSTIMULATION AND T CELL ACTIVATION IN A HAPLOIDENTICAL MODEL**

### **TARGETING OF CHEMOKINE RECEPTOR 7 PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE**

### **ENHANCING REGULATORY T CELL FUNCTION AND HOMING TO THE GUT TO IMPROVE GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER ADOPTIVE TRANSFER IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION**

Antonella Mancusi, Samanta Bonato, Rachele Del Sordo, Sara Piccinelli, Eni Hoxha, Tiziana Zei, Roberta Iacucci Ostini, Franca Falzetti, Alessandra Carotti, Loredana Ruggeri, Michele Giansanti, Robert S. Negrin, Massimo F. Martelli, Andrea Velardi, Antonio Pierini (Italy)

### **LYG1-DEFICIENT DONOR SPLENOCYTES ATTENUATED THE SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE VIA SKEWING CD4+ T CELL POLARIZATION TOWARDS TREG CELLS**

Huihui Liu, Zhengyu Yu, Bo Tang, Shengchao Miao, Chenchen Qin, Miao Yan, Zhengyang Song, Hanyun Ren, Yujun Dong (China)

### **ATTENUATION OF MURINE CHRONIC GRAFT VERSUS HOST DISEASE BY THE NRF2 ACTIVATOR MANGIFERIN**

Kang Sun, Ping Chen, Mengran Lee, Jun Ruan, Yuxue Xia, Mei Hong, Jun Fang, Hao Tang (China)

### **CHEMOTHERAPY AND INFLAMMATION INDUCED DAMAGE OF INTESTINAL EPITHELIUM IS ASSOCIATED WITH INCREASED T CELL CHEMOTAXIS**

Suze A. Jansen, Marliek van Hoesel, Michal Mokry, Leire Saiz Sierra, Shuichiro Takashima, Edward E.S. Nieuwenhuis, Alan M. Hanash, Caroline A. Lindemans (Netherlands)

### **INKT CELLS PROMOTE IMMUNE TOLERANCE BY SELECTIVE DENDRITIC CELL APOPTOSIS**

Emmanuelle Moraes Ribeiro, Hannes Schmid, Ruoyun Dong, Kathy-Ann Secker, Hildegard Keppeler, Corina Schneidawind, Dominik Schneidawind (Germany)

### **ACTIVE PARTICIPATION OF CXCR4+ T LYMPHOCYTES IN ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC TRANSPLANTATION**

### **A MURINE MODEL REVEALS A CRITICAL ROLE FOR REACTIVE OXYGEN SPECIES IN HYPERACUTE GRAFT-VERSUS-HOST DISEASE**

### **MAPPING THE ROAD OF GVHD AND GVT. A LONGITUDINAL STUDY OF IMMUNE-TRANSCRIPTOME SIGNATURES AS NOVEL APPROACH TO SOLVE POST-ALLOGENEIC TRANSPLANTATION DILEMMAS**

Merav Bar, Mohammed Toufiq, Darawan Rinchai, Mohammed Elanbari, Sabri Boughorbel, Valentina Mattei, Rebecca Mathew, Irene Cavattoni, Sabine Forer, Clarisa Brown, Marco Zecca, Patrizia Comoli, Giovanni Grillo, Catherine Cole, Chiara Cugno, Sara Tomei, Damien Chaussabel, Sara Deola (Qatar)

### **CELL-FREE DNA LEVELS ARE INCREASED IN ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS AND MICE**

Anna Kroeze, Anne Cornelissen, Fernanda Pascutti, Sjoerd Klarenbeek, Achia Ait Soussan, Tom van der Poll, Mette Hazenberg, Erfan Nur, Ellen van der Schoot, Carlijn Voermans, Sacha Zeerleder (Switzerland)

### **DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION**

### **ENDOTHELIAL MICROPARTICLES DELIVERING LNCRNA NEAT1 ARE INVOLVED IN THE PATHOPHYSIOLOGY OF AGVHD FOLLOWING ALLO-HSCT**

## Scientific Programme

### **B-T CELL INTERACTIONS IN GRAFT-VERSUS-HOST DISEASE**

Dhanya Kizhakayil, Abbirami Sathappan, Zoltan Pos, Nikolett Lupsa, Christophe M Raynaud, Giusy Gentilcore, Mohammad A Al-Aghbar, Cristina Maccalli, Jean-Charles Grivel, Nicholas van Panhuys, [Sara Deola](#) (Qatar)

### **IDENTIFICATION OF POTENTIAL MICROBIOME MARKERS FOR AGVHD EARLY DIAGNOSIS**

Dhinoth K Bangarusamy, Arun P Lakshmanan, [Sara Deola](#), Dhanya Kizhakayil, Zoltan Pos, Nikolett Lupsa, Annalisa Terranegra (Qatar)

e-Posters  
09:30 - 19:00

ePoster Area

## Granulocyte and osteoclast disorders

### **HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR OSTEOPETROSIS**

[Ehud Even-Or](#), Irina Zaidman, Polina Stepensky (Israel)

e-Posters  
09:30 - 19:00

ePoster Area

## Haemoglobinopathy and inborn errors

### **SUCCESSFUL HLA-MISMATCHED HSCT IN PAEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES USING ATG SEROTHERAPY AND POSTTRANSPLANT CYCLOPHOSPHAMIDE**

### **OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH CEREBRAL ADRENOLEUKODYSTROPHY VARY BY DONOR CELL SOURCE, CONDITIONING REGIMEN, AND STAGE OF CEREBRAL DISEASE STATUS**

### **OUTCOME OF NON MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE: A 100 PATIENT EXPERIENCE FROM SAUDI ARABIA**

### **HIGH DOSE STEM CELL THERAPIES, LIKE MGTA-456, ENABLE COMPLETE NEURAL AND PERIPHERAL DISEASE CROSS-CORRECTION THROUGH RAPID AND ROBUST HEMATOPOIETIC ENGRAFTMENT**

### **HLA SET-UP IS A MAJOR PREDICTOR OF ENGRAFTMENT IN HAPLO-IDENTICAL TRANSPLANT FOR SEVERE THALASSEMIA (ST) USING POST-CYCLOPHOSPHAMIDE (PTCY)**

[Stalin Ramprakash](#), C P Raghuram, Pallavi Mehta, Paula Tacia, Priya Mawah, Rajpreet Soni, Deepa Trivedi, Vaibhav Shah, Rakesh Dhanya, Rajat Kumar Agarwal, Lawrence Faulkner (India)

### **CTLA4IG-BASED T CELL COSTIMULATION BLOCKADE IN PTCY BASED HAPLOIDENTICAL HCT FOR THALASSEMIA MAJOR [TM] AND SICKLE CELL DISEASE [SCD] RESULTS IN IMPROVED DISEASE-FREE SURVIVAL WITHOUT GVHD**

[Sarita Rani Jaiswal](#), Prakash Bhakuni, Hema Malini Aiyer, Aditi Chakrabarti, Satish Bansil, Suparno Chakrabarti (India)

### **LENTIGLOBIN GENE THERAPY TREATMENT OF TWO PATIENTS WITH TRANSFUSION-DEPENDENT $\beta$ -THALASSEMIA**

[Mattia Algeri](#), Richard A. Colvin, Weijian Liu, Ge Tao, Franco Locatelli (Italy)

## Scientific Programme

### **BONE MARROW TRANSPLANT IN PATIENTS WITH SICKLE CELL ANAEMIA. EXPERIENCE IN ONE CENTRE**

Marina García Morín, Laura Escobar Fernández, Eduardo Bardón Cancho, Cristina Beléndez Bieler, Jorge Huerta Aragonés, Carmen Garrido Colino, Cristina Mata Fernández, Elena Cela de Julián (Spain)

### **OUTCOMES IN CEREBRAL ADRENOLEUKODYSTROPHY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

### **NEURODEVELOPMENTAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MUCOPOLYSACCHARIDOSIS TYPE II: A PROSPECTIVE, LONGITUDINAL STUDY**

Maria Escolar, Nicholas Bascou, Bridget Kiely, Aleksandra Safonova, Maria Beltran, Michele Poe, Paul Szabolcs (United States)

### **HEMATOPOIETIC RECOVERY AND TRANSFUSION NEED AFTER HAPLOIDENTICAL TRANSPLANTATION IN BETA THALASSEMIA PATIENTS**

### **PRE- AND POST-TRANSPLANT RITUXIMAB REDUCES THE HIGH INCIDENCE OF PRIMARY GRAFT FAILURE AND IMMUNE-MEDIATED CYTOPENIA FOLLOWING CORD BLOOD TRANSPLANT FOR LYSOSOMAL STORAGE DISEASE IN CHILDREN**

Hemalatha Doss, Denise Bonney, Helen Campbell, David Deambrosis, Simon James, Kay Poulton, Wendy Ogden, Wynn Robert F (United Kingdom)

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: THE SPANISH EXPERIENCE**

### **LONG-TERM QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD**

Oruc Ali Quliyev, Gulcihan Ozek, Savas Kansoy, Serap Aksoylar (Turkey)

### **HIGH INCIDENCE OF AUTOIMMUNE CYTOPENIAS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE: THE IMPACT OF MATCHED UNRELATED DONOR**

Christina Oikonomopoulou, Anna Paisiou, Eleni-Dikaia Ioannidou, Aikaterini Kaisari, Anna Komitopoulou, Maria Theodosaki, Eftichia Petrakou, Ioulia Peristeri, George Vessalas, Evgenios Goussetis, Vassiliki Kitra-Roussou (Greece)

### **ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI MAY REDUCE RISK OF GRAFT FAILURE IN MATCHED SIBLING DONOR ALLOGENEIC HSCT IN ADULT SICKLE CELL PATIENTS**

Erfan Nur, Sacha Sergio Zeerleder, Aafke Gaartman, Caroline Rutten, Liesbeth Suijk, Charlotte van Tuijn, Judith Wentholt, Mette Hazenberg, Bart Biemond (Netherlands)

### **A PHASE II STRATIFIED TRIAL TO ASSESS HAPLOIDENTICAL T-DEPLETED STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE WITH NO AVAILABLE SIBLING DONOR**

Jürgen Föll, Katharina Kleinschmidt, Anja Tröger, Petra Turowski, Rainer Spachtholz, Norbert Ahrens, Andreas-Michael Brosig, Matthias Evert, René Schmidt, Daniel Wolff, Matthias Edinger, Matthias Eyrich, Rupert Handgretinger, Susanne Ellinger, Selim Corbacioglu (Germany)

### **COMBINED UMBILICAL CORD BLOOD AND BONE MARROW FROM HLA-IDENTICAL SIBLING DONORS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA MAJOR**

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF METABOLISM USING ALTERNATE DONORS: A PROSPECTIVE SINGLE STUDY**

### **UMBILICAL CORD BLOOD TRANSPLANTATION IN CHILDREN WITH LEUKODYSTROPHIES: SINGLE CENTER EXPERIENCE IN CHINA**

Xiaowen Zhai, Xiaowen Qian, Ping Wang, Hongsheng Wang, Wenjin Jiang (China)

## Scientific Programme

### **PEARSON SYNDROME IN A PATIENT TRANSPLANTED FOR DIAMOND-BLACKFAN ANEMIA**

### **CHALLENGES AND SUCCESSES WITH PRE-TRANSPLANT IMMUNE SUPPRESSION IN ALTERNATIVE DONOR TRANSPLANTS**

Gaurav Kharya, Archana Rauthan, Manju Joseph, Himshikha Yadav, Bharti Sharma, Atish Bakane (India)

### **HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CLASS 3 THALASSEMIA MAJOR USING POST-TRANSPLANT CYCLOPHOSPHAMIDE**

Eman Khattab, Rula Najjar, Abdelghani Tbakhi, Rawad Rihani, Mayada Abu Shanap, Hasan Hashem, Aram Ahmod, Nilly Hussein, Iyad Sultan (Jordan)

e-Posters

09:30 - 19:00

ePoster Area

## Multiple myeloma

### **DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF HIGH-RISK PATIENTS IN CASSIOPEIA**

### **EVALUATION OF PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (PET/CT) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PHASE 3 CASSIOPEIA STUDY PATIENTS: CASSIOPET STUDY RESULTS**

### **CONCORDANCE OF POSTCONSOLIDATION MINIMAL RESIDUAL DISEASE RATES BY MULTIPARAMETRIC FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING IN CASSIOPEIA**

### **LONG-TERM FOLLOW-UP OF THE RANDOMIZED PHASE 3 PETHEMA/GEM 2005MENOS65 STUDY SUPPORTS THE USE OF VTD (BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE) AS PRETRANSPLANT INDUCTION REGIMEN FOR MULTIPLE MYELOMA (MM)**

### **DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE**

### **HOW TO ASSESS RISK OF PROGRESSION IN MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE REMISSION AFTER AUTOLOGOUS TRANSPLANT: SUB ANALYSIS FROM THE GEM2012MENOS65 PHASE III CLINICAL TRIAL**

### **OUTCOMES OF ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS**

### **25 YEARS OF AUTOLOGOUS TRANSPLANTATION FOR MYELOMA IN EBMT CENTRES - CHANGING PRACTICE PATTERNS**

### **PROGNOSIS IN DIFFERENT RISK-GROUPS OF MULTIPLE MYELOMA WITH MINIMAL RESIDUAL DISEASE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BORTEZOMIB-INTEGRATED CONDITIONING: A SINGLE-CENTER EXPERIENCE**

### **UNINTERRUPTED MOBILIZATION AND TRANSPLANTATION PROCEDURE WITH NON-CRYOPRESERVED YIELD IS FEASIBLE WITHOUT INCREASEMENT OF COMPLICATION RISK IN MULTIPLE MYELOMA PATIENTS**

Zübeyde Nur Özkurt, Ayşe Asena Dikyar, Zeynep Arzu Yeğin, Lale Aydin Kaynar, Özlem Karacaoglu, Emin Ateş (Turkey)

## Scientific Programme

### **CONDITIONING WITH BORTEZOMIB-MEL200 IN COMPARISON TO MEL200 IMPROVES SURVIVAL AMONG MYELOMA PATIENTS IN≤PR PRIOR TO AUTO-HCT: A STUDY FROM THE CMWP OF THE EBMT**

Meral Beksac, Diderik-Jan Eikema, Zubeyde Nur Ozkurt, Linda Koster, Didier Blaise, Patrice Chevallier, Lionel Karlin, Cyrille Hulin, Kim Orchard, Xavier Poiré, Xavier Leleu, Mohamad Mohty, Rose-Marie Hamladji, Malgorzata Wach, Marco Casini, Karim Belhadj, Gunhan Gurman, Tessa Kerre, Alexandros Spyridonidis, Emmanuelle Nicolas-Virelizier, José M<sup>a</sup> Moraleda, Liesbeth C. de Wreede, Patrick Hayden, Stefan Schönland, Ibrahim Yakoub-Agha (Turkey)

### **RESULTS OF DEFERRED AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED STAGES OF SYSTEMIC AL AMYLOIDOSIS**

### **IN VITRO STIMULATION WITH CD40L/IL-21 CAN RETRIEVE B-CELL DYSFUNCTION IN MULTIPLE MYELOMA PATIENTS SUFFERING FROM SECONDARY IMMUNODEFICIENCY**

Clarissa Heck, Sophie Steiner, Marco Frentsch, Friedrich Wittenbecher, Carmen Scheibenbogen, Axel Nogai, Philipp le Coutre, Lars Bullinger, Igor Wolfgang Blau, Il-Kang Na (Germany)

### **ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA; EXCELLENT OUTCOMES FOR EARLY TRANSPLANTATION**

### **SEQUENTIAL HEART TRANSPLANTATION FOLLOWED BY HIGH DOSE CHEMOTHERAPY PLUS AUTOLOGOUS STEM CELL REINFUSION IN CARDIAC AL AMYLOIDOSIS**

### **AUTOGRAFT CELLULAR COMPOSITION AND OUTCOME IN MYELOMA PATIENTS: RESULTS OF THE PROSPECTIVE MULTICENTER GOA STUDY**

Antti Turunen, Anu Partanen, Jaakko Valtola, Antti Ropponen, Timo Siitonen, Mervi Putkonen, Marja Sankelo, Eeva-Riitta Savolainen, Marja Pyörälä, Taru Kuittinen, Raija Silvennoinen, Karri Penttilä, Anu Sikiö, Lasse Ågren, Pentti Mäntymäa, Jukka Pelkonen, Ville Varmavuo, Esa Jantunen (Finland)

### **RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE**

### **PHASE 3, OPEN-LABEL, NONINFERIORITY STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): BODY WEIGHT SUBGROUP ANALYSIS OF COLUMBA**

Maria-Victoria Mateos, Saad Z. Usmani, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar Bahlis, Max Flogegard, Joan Bladé, Philippe Moreau, Martin Kaiser, Shinsuke Iida, Jacob Laubach, Tara Masterson, Kristen Lantz, Lisa O'Rourke, Xiang Qin, Dolly A Parasrampur, Christoph Heuck, Ming Qi, Hareth Nahi (Spain)

### **ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) IS A RELIABLE PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION**

### **ABERRANT PHENOTYPE PLASMA CELL MULTIPARAMETRIC FLOW CYTOMETRY (MFC) DETECTION IN AUTOGRAFT PRODUCTS OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)**

### **RETROSPECTIVE MULTI-CENTER STUDY OF ADOLESCENT AND YOUNG ADULT (AYA) MULTIPLE MYELOMA IN KANSAI MYELOMA FORUM REGISTRY**

Aya Nakaya, Takae Kohara, Hirohiko Shibayama, Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Toru Kida, Satoru Kosugi, Jun Ishikawa, Ryosuke Yamamura, Yutaka Shimazu, Hirokazu Tanaka, Shin-Ichi Fuchida, Yuji Shimura, Miki Kiyota, Katsuya Wada, Tomoki Ito, Nobuhiko Uoshima, Hideo Yagi, Satoshi Yoshihara, Kensuke Ohta, Chihiro Shimazaki, Masayuki Hino, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura (Japan)

### **MAINTENANCE THERAPY WITH ELOTUZUMAB AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA**

Nobuhiro Tsukada, Junichiro Nashimoto, Yui Uto, Kota Sato, Kanji Miyazaki, Mizuki Ogura, Yumiko Yoshiki, Yu Abe, Kiyoshi Okazuka, Tadao Ishida, Kenshi Suzuki (Japan)

## Scientific Programme

### **AUTOLOGOUS STEM CELL TRANSPLANTATION CANDIDACY IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS**

#### **NOVEL PROTOCOL FOR AUTOLOGOUS HSCT IN MULTIPLE MYELOMA ACHIEVES 'ZERO' CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS (CLABSI)**

Emilian Snarski, Agnieszka Tomaszewska, Martyna Maciejewska, Michał Górka, Anna Brodziak, Sara Zawadzka-Leska, Anna Waszczuk-Gajda, Jarosław Biliński, Marcin Jasiński, Karol Lis, Kamila Skwierawska, Hubert Heleniak, Mateusz Ziarkiewicz, Dorota Zduńczyk, Wojciech Sachs, Elżbieta Urbanowska, Magdalena Feliksbrodt - Bratosiewicz, Małgorzata Król, Maria Król, Wiesław Wiktor-Jędrzejczak, Grzegorz Basak (Poland)

#### **OUTCOMES OF NON-CRYOPRESERVED VERSUS CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA**

Pokpong Piriyakhuntorn, Adisak Tantiworawit, Thanawat Rattanathammethee, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Ekarat Rattarittamrong, Lalita Norasetthada (Thailand)

#### **DOWN REGULATION OF AUTOPHAGY ENHANCES BORTEZOMIB-INDUCED APOPTOSIS OF MYELOMA CELL BY UP REGULATION OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES**

Yeung-Chul Mun, Jee-Young Ahn, Eun Sun Yoo, Kyoung Eun Lee, Eunmi Nam, Soon Nam Lee, Hyun Ae Woo, Sue Goo Rhee, Chu Myong Seong (Korea, Republic of)

#### **RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE**

Ayşe Tülin Tuğlular, Tayfun Elibol, Arda Bayar, Belgin Aldag, Ozen Oruc, Tarik Ercan, Yildiz Ipek, Fatma Arıkan, Asu Fergün Yılmaz, Işık Atagündüz, Tayfur Toptas (Turkey)

#### **FAVORABLE LONG-TERM OUTCOMES WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HIGH RISK PATIENTS WITH MULTIPLE MYELOMA WHO ARE POSITIVE AT FDG-PET/CT**

Hee Jeong Cho, Dong Won Baek, Ju Hyung Kim, Sung Hoon Jung, Sang Kyun Sohn, Joon Ho Moon (Korea, Republic of)

#### **LONG TERM SURVIVAL OF MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELATION TO AVAILABILITY OF NOVEL DRUGS**

Ozren Jaksic, Zeljko Prka, Mario Pirsic, Zdravko Mitrovic, Ena Soric, David Cicic, Tamara Vasilj, Zeljko Jonjic, Marko Lucijanic, Ivana Maricic, Gorana Dzepina, Rajko Kusec, Vlatko Pejisa (Croatia)

#### **MULTIPLE MYELOMA (MM) IN FIRST RELAPSE PATIENTS. ROLE OF THE SECOND AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT) IN REAL LIFE: EXPERIENCE OF TWO SPANISH CENTERS**

N Amer, MT Villalobos, R Del Campo, Jb Borràs, A Porcel, Jm Guerra, A Jaramillo, A Cladera, M Mascaró, J Perales-Amengual, M Canet, P Vélez, J Perales, A Muntanola, Ja Soler, M López, M Díaz, F Vall-Ilovera, Jm Martí, J Bargay (Spain)

#### **ROLE OF ANALYSIS OF CHIMERISM IN MULTIPLE MYELOMA PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION**

#### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE**

#### **USE OF NETUPITRANT/PALONOSETRON IN MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE**

#### **THE EFFECT OF UCP-2 AND NR3C1 GENES ON TREATMENT EFFICACY AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA**

İlknur Demir, Sacide Pehlivan, Vahap Okan, Handan Sahin, Sertac Durusoy, Yasemin Oyacı, Mustafa Pehlivan (Turkey)

#### **SAFETY AND EFFECTIVENESS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA IN FIRST LINE**

## Scientific Programme

### **PLASMAPHERESIS ASSISTED THE TREATMENT OF 1 CASE OF HYPERGLOBULINEMIA AFTER CART THERAPY**

Xiuyan Tao, Wenwen Ma, Limei Gao, Jiajia Yue, Yuehui Lin (China)

e-Posters  
09:30 - 19:00

ePoster Area

## Myelodysplastic syndromes

### **ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OF ADULT PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA: A NORDIC RETROSPECTIVE STUDY**

### **DECITABINE MONOTHERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION RESULTED IN SUPERIOR SURVIVAL FOR MYELODYSPLASTIC SYNDROME PATIENTS WITH EXCESS BLASTS**

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM: A STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT**

Marie Robin, Junfeng Wang, Linda Koster, Dietrich Beelen, Martin Bornhaeuser, Nicolaus Kroeger, Uwe Platzbecker, Jurgen Finke, Arnold Ganser, Didier Blaise, Fabio Ciceri, Johan Maertens, Hélène Labussière, Patrice Chevallier, Jakob Passweg, Jan J Cornelissen, Carmen Botella, Amandine Charbonnier, Francesca Bonifazi, Katya Mauff, Liesbeth de Wreede, Patrick Hayden, Christoph Scheid, Ibrahim Yakoub-Agha (France)

### **IMPACT OF MUTATION PROFILE IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

Nico Gagelmann, Anita Badbaran, Rashit Bogdanov, Friedrich Stölzel, Christina Rautenberg, Olivier Nibourel, Heiko Becker, Aleksandar Radujkovic, Peter Dreger, Maximilian Christopeit, Jürgen Finke, Uwe Platzbecker, Guido Kobbe, Michael Koldehoff, Markus Ditschkowski, Dietrich Beelen, Marie Robin, Nicolaus Kröger (Germany)

### **NEW INSIGHTS OF MYELODYSPLASTIC SYNDROME (MDS) WITH ERYTHROID PREDOMINANCE BASED ON THE NEXT-GENERATION SEQUENCING AND SINGLE-CELL RNA SEQUENCING**

### **IMPACT OF TREATMENT PRIOR TO ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: RESULTS OF THE LATIN AMERICAN BONE MARROW TRANSPLANT REGISTRY**

Fernando Barroso Duarte, Anna Thawanny Gadelha Moura, Vaneuza Araújo Moreira Funke, Virgílio Antônio Rensi Colturato, Nelson Hamerschlag, Neysimélia Costa Vilela, Luiz Fernando Lopes, Maria Cristina Martins de Almeida Macedo, Afonso Celso Vigorito, Rodolfo Daniel de Almeida Soares, Alessandra Paz, Mariana Stevenazzi, Lilián Díaz, Abrahao Elias Hallack Neto, Gustavo Bettarello, Breno Moreno de Gusmão, Marco Aurélio Salvino, Rodolfo Froes Calixto, Maria Cláudia Rodrigues Moreira, Gustavo Machado Teixeira, Cinthya Corrêa da Silva, Anderson João Simioni, Romélia Pinheiro Gonçalves Lemes (Brazil)

### **RESULTS OF LATIN AMERICAN RECORD OF BONE MARROW TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME**

Fernando Barroso Duarte, Anna Thawanny Gadelha Moura, Vaneuza Araújo Moreira Funke, Virgílio Antônio Rensi Colturato, Nelson Hamerschlag, Neysimélia Costa Vilela, Luiz Fernando Lopes, Maria Cristina Martins de Almeida Macedo, Afonso Celso Vigorito, Rodolfo Daniel de Almeida Soares, Alessandra Paz, Mariana Stevenazzi, Lilián Díaz, Abrahao Elias Hallack Neto, Gustavo Bettarello, Breno Moreno de Gusmão, Marco Aurélio Salvino, Rodolfo Froes Calixto, Maria Cláudia Rodrigues Moreira, Gustavo Machado Teixeira, Cinthya Corrêa da Silva, Anderson João Simioni, Romélia Pinheiro Gonçalves Lemes (Brazil)

## Scientific Programme

### **OUTCOME AND MUTATIONAL PROFILE IN MDS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Nikolai Tsvetkov, Elena Morozova, Ildar Barkhatov, Ivan Moiseev, Maria Barabanshikova, Artem Tishkov, Dmitriy Bug, Ekaterina Izmailova, Sergey Bondarenko, Boris Afanasyev (Russian Federation)

e-Posters  
09:30 - 19:00

ePoster Area

## **Non-infectious late effects, quality of life and fertility**

### **EASIX-1YEAR- THE FIRST BIOMARKER PREDICTING LATE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

### **AN UPDATED REPORT ON SECONDARY SOLID CANCER FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMIA MAJOR**

### **ALLOGENEIC STEM-CELL TRANSPLANTATION IN AML AND MDS USING CONDITIONING REGIMENS WITH DIFFERENT DOSE-INTENSITIES; 15 YEARS LATER**

### **EMPLOYMENT STATUS AND RETURN TO WORK AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A NATIONWIDE SURVEY**

### **FUNCTIONAL OUTCOME MEASURES IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): FOCUS ON THE 2-MINUTE WALK TEST**

### **FERTILITY IN ADULT FEMALE ALLOGENEIC STEM CELL RECIPIENTS**

### **A RISK SCORE MODEL (HAD-TCG) TO EVALUATE THE RISK OF STROKE IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

### **BRONCHIOLITIS OBLITERANS SYNDROME IN THE CHANGING LANDSCAPE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Egor Kulagin, Alisa Volkova, Ilya Nikolaev, Julia Rabik, Victoria Timchick, Anna Smirnova, Tatiana Bykova, Tatiana Rudakova, Elena Darskaya, Alexander Alyanskiy, Ivan Moiseev, Sergey Bondarenko, Vasilii Trofimov, Boris Afanasyev (Russian Federation)

### **CURRENT STATUS AND NEEDS OF LONG-TERM FOLLOW-UP CLINICS FOR HEMATOPOIETIC CELL TRANSPLANT SURVIVORS: RESULTS OF A NATIONWIDE SURVEY IN JAPAN**

Saiko Kurosawa, Ayako Mori, Mayumi Tsukagoshi, Yasushi Onishi, Chikako Ohwada, Takehiko Mori, Hideki Goto, Yuki Asano-Mori, Yuichiro Nawa, Masayuki Hino, Tomoko Fukuchi, Yasuo Mori, Reiko Yamahana, Yoshihiro Inamoto, Takahiro Fukuda (Japan)

### **SURVIVORSHIP CARE FOR ALLOGENEIC TRANSPLANT PATIENTS IN THE UK: CURRENT SERVICE PROVISION AND BARRIERS TO IMPLEMENTATION**

Fiona Dignan, Angela Hamblin, Amelia Chong, Julia Perry, Michelle Kenyon, Paul Miller, Maria Gilleece, Hannah Hunter, John Snowden (United Kingdom)

### **CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN EPSTEIN-BARR VIRUS RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (EBV-PTLD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)**

### **INCIDENCE, RISK FACTORS AND OUTCOMES OF DIFFUSE ALVEOLAR HEMORRHAGE AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION**

### **WHOLE BODY VIBRATION TRAINING DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - THE EFFECTS ON PATIENTS' PHYSICAL CAPACITY, FATIGUE, BODY COMPOSITION AND QUALITY OF LIFE**

### **MULTI-MORBIDITY IN ADULT SURVIVORS OF STEM CELL TRANSPLANTATION (SCT)**

## Scientific Programme

### **GONADOTOXICITY AFTER TREOSULFAN-BASED MYELOABLATIVE CONDITIONING REGIMEN FOR ALLOGENEIC HSCT IN GIRLS WITH LEUKEMIA**

Irina Kostareva, Yulia Skvortsova, Elena Iliina, Nataliya Radlevich, Lyudmila Papusha, Dmitriy Balashov, Anna Livshits, Andrey Abrosimov, Larisa Shelikhova, Darya Shasheleva, Kirill Voronin, Michael Maschan, Aleksey Maschan (Russian Federation)

### **REDUCED-INTENSITY TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH HIGH-RISK OR ADVANCED HEMATOLOGICAL MALIGNANCIES IN LAST 10 YEARS - SINGLE CENTRE EXPERIENCE**

Michal Karas, Katerina Steinerova, Marcela Hrabetova, Daniel Lysak, Alexandra Jungova, Lekaa Mohammad, Jiri Sramek, Pavel Jindra (Czech Republic)

### **FATHERHOOD AFTER A MYELOABLATIVE TREOSULFAN BASED ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS ON 453 PATIENTS**

Maria Teresa Lupo-Stanghellini, Andrea Assanelli, Fabio Giglio, Carlo Messina, Raffaella Greco, Daniela T. Clerici, Sara Mastaglio, Francesca Pavesi, Francesca Farina, Stefania Girlanda, Francesca Lorentino, Simona Piemontese, Sarah Marktel, Francesca Lunghi, Matteo G Carrabba, Magda Marcatti, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri (Italy)

### **COMPARISON OF CENTRAL NERVOUS SYSTEM RELAPSE OUTCOMES FOLLOWING HAPLOIDENTICAL VS IDENTICAL-SIBLING TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA**

### **OLDER AGE AND PERIPHERAL BLOOD AS A STEM CELL SOURCE ARE THE MAJOR NEGATIVE PREDICTORS OF SURVIVAL LONG TERM**

### **PREVALENCE OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLOHSCT) IN THE US, EUROPE AND JAPAN**

Emilie Hofstetter, Dominik Kappeler, Noreen Roth Henig, Anne Bergeron (Germany)

### **NETUPITANT-PALONOSETRON (NEPA) TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MULTIPLE MYELOMA (MM) PATIENTS RECEIVING HIGH-DOSE (HD) MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)**

Vincenzo Apolito, Simone Ferrero, Mattia D'Agostino, Giusy Cetani, Francesca Bonello, Federica Martella, Danilo Faraci, Sara Butera, Giuseppe Lanzarone, Alessandra Larocca, Stefania Oliva, Lucia Brunello, Luisa Giaccone, Mario Boccadoro, Dario Ferrero, Benedetto Bruno, Marco Cerrano (Italy)

### **MOST FREQUENT LATE EFFECTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA DOES NOT SEEM TO WORSEN PERFORMANCE STATUS**

Irati Ormazabal Velez, Marina Quesada Sánchez, Angela Figuera Álvarez (Spain)

### **INVOLVING STEM CELL TRANSPLANT PATIENTS AND THEIR FAMILIES TO IMPROVE THE ANTHONY NOLAN MY TRANSPLANT TRACKER APP**

### **EARLY MENOPAUSE AND RISK FACTORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PREMENOPAUSAL ADULT WOMEN**

Yoo Jin Lee, Jeong Sook Kim, Jae-Cheol Jo, Jaekyoung Cheon, Su Jin Koh, Young Joo Min, Kukju Kweon, Sang-Hyuk Park, Jun-Woo Ahn, Yunsuk Choi (Korea, Republic of)

### **MUSCULOSKELETAL COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

### **CLINICAL CHARACTERISTICS AND MANAGEMENT OF LATE RELAPSE OF ACUTE MYELOID LEUKAEMIA MORE THAN FIVE YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

Shafqat Inam, Shu Wong, Michelle Kenyon, Victoria Potter, Austin Kulasekararaj (United Kingdom)

## Scientific Programme

### **FOLLOWING UP WITH ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING 5+ YEARS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

Yuta Katayama, Ryouta Imanaka, Koji Iwato, Tatsuya Terasaki, Takuya Nunomura, Fumiaki Jinnouchi, Takeshi Okatani, Kohei Kyo, Mitsuhiro Itagaki, Shinya Katsutani, Tsuyoshi Muta, Hideki Asaoku (Japan)

### **LOW BACK PAIN AND LASER ACUPUNCTURE IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELLS TRANSPLANTATION**

### **EFFECTS OF CONTROLLED EXERCISE ON PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANT IN AN ASIAN POPULATION: A SINGLE-CENTER EXPERIENCE**

Melinda Tan, Jeffrey Quek, Yeh Ching Linn, William Hwang, Yvonne Loh, Yeow Tee Goh, Jing Jing Lee, Aloysius Ho (Singapore)

### **DEVELOPMENT OF GUILLAIN-BARRE-LIKE SYNDROME IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELLS TRANSPLANTATION**

e-Posters  
09:30 - 19:00

ePoster Area

## Psychological issues

### **INVESTIGATING THE LONG-TERM OUTCOMES OF ADULT PATIENTS WHO UNDERWENT HAEMATOPOIETIC STEM CELL TRANSPLANT FOR PRIMARY IMMUNODEFICIENCY DURING CHILDHOOD**

### **THE IMPACT OF MEDICAL AND SOCIAL REHABILITATION ON THE QUALITY OF LIFE IN CHILDREN WITH ONCOLOGIC AND HEMATOLOGIC DISEASES**

### **THE IMPACT OF PRE-TRANSPLANT DEPRESSION AND ANXIETY ON THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION, A STUDY OF THE TCWP OF THE EBMT**

### **ASSOCIATIONS BETWEEN FAMILY FUNCTION DOMAINS AND COPING STRATEGIES OF ADOLESCENTS UNDERGOING HSCT**

### **HOW PATIENTS' VIEWS ARE HELPING SHAPE PLANS FOR A NEW TRANSPLANT PSYCHOLOGY SERVICE**

### **CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: TWO DIFFERENT ANALYTICAL APPROACHES**

### **ARC CLINIC: APPLYING PSYCHOLOGICAL INSIGHTS TO PROMOTE EARLY REHABILITATION IN MYELOMA POST-TRANSPLANT**

Alex King, Julian Jacob, Lizzie Jones, Anna Bootle, Vijai Glackin, Angela Daniel, Clair LeBoutillier (United Kingdom)

### **FROM HOSPITALIZATION TO RETURN HOME: A TRANSITIONAL ACTION RESEARCH IN THE HEMATOLOGY SECTOR**

Sandrine Letrecher (France)

### **1000 IN 10 . 10 YEARS OF CLINICAL PSYCHOLOGY PRACTICE WITH 1000 PATIENTS IN THE SAME BMT UNIT IN MARSEILLE, FRANCE**

Patrick Ben Soussan, Yolande Arnault, Laurence Caymaris, Didier Blaise (France)

## Scientific Programme

### **IMPLEMENTATION OF PSYCHOLOGICAL SUPPORT AND DEVELOPMENT OF EDUCATIONAL PROGRAM FOR CHILDREN AND ADOLESCENTS UNDERGOING HSCT AND THEIR PARENTS IN RUSSIA**

Natalia Klipinina, Natalia Nikolskaya, Larisa Shelikhova, Zhanna Shekhovtsova, Maria Ilushina, Rimma Khismatullina, Ekaterina Shutkova, Alina Khain (Russian Federation)

e-Posters  
09:30 - 19:00

ePoster Area

### **Nurses Posters - Adult**

#### **ROLE OF QUICKSOFA IN PREDICTING SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL PATIENTS**

#### ***<i>BOLUS:</i>* TARGETED SPECIALIST HAEMATOLOGY/BMT PODCASTS: AN EFFECTIVE METHOD OF EDUCATION**

#### **A PATHWAY FOR RECOVERY: D+100 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT) FOLLOW UP PILOT FOR LYMPHOMA**

#### **REDUCING ACCIDENTAL FALLS CAUSED BY ORTHOSTATIC HYPOTENSION IN BONE MARROW TRANSPLANT RECIPIENTS**

#### **THE EFFECT OF MOTIVATIONAL INTERVIEW PERFORMED AFTER STEM CELL TRANSPLANTATION ON SEXUAL EXPERIENCE, SEXUAL SELF-AWARENESS AND SEXUAL SELF-EFFICACY**

#### **STUDY ON COGNITIVE FUNCTION AND RELATED FACTORS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

#### **THE EFFECT OF RELAXING BREATHING EXERCISES ON PAIN, FATIGUE AND LEUKOCYTE COUNT IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

#### **UNDERSTANDING OF PROGNOSIS, QUALITY OF LIFE AND PSYCHIATRIC STATUS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY OF 348 PATIENTS**

Xia Yan, Ting Wang, Wei Hu, Xiaodong Xu, Shujia Liu (China)

#### **AN OUTPATIENT MODEL OF CARE TO SAFELY DELIVER AUTOLOGOUS STEM CELL TRANSPLANTATION**

#### **EFFECTS OF TREATMENTS FOR HAEMATOLOGICAL MALIGNANCIES ON SEXUALITY AND FERTILITY: WHEN DO PATIENTS NEED IT AND WHOM REALLY WANTS TO KNOW?**

C Eeltink, B Lissenberg, I Nauta, J Rood, L Incrocci, I Verdonck- de Leeuw, S Zweegman (Netherlands)

#### **EFFICACY OF THERAPEUTIC EDUCATION TO REDUCE RISKS AND COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY**

Marco Cioce, Laura Orlando, Stefano Botti, Gianpaolo Gargiulo (Switzerland)

#### **SELF-EFFICACY AND SELF-CARE PRACTICES OF PATIENTS WHO HAVE BEEN TRANSPLANTED WITH ALLOGENEIC HEMATOPOIETIC STEM CELLS ACCORDING TO THE DEVELOPMENT OF AN INDIVIDUAL EDUCATION PROGRAM**

#### **DETERMINING THE SYMPTOMS AND COPING METHODS OF PATIENTS AT HOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Kader Caliskan, Gulbeyaz Can (Turkey)

## Scientific Programme

### **THE EFFECT OF ORAL CARE PROTOCOL ON ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Kwan Suk Jo, Seung Nam Zang, Ga Yeon Kim, Hye Yun Cho, Yang Sook You (Korea, Republic of)

### **PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) WITHIN AN AMBULATORY CARE SETTING; A PATIENTS' PERSPECTIVE**

Noemi Gianni, Tania Arthurs, Yvonne Patefield-Smith, Kirsten Rendall, Jo Wyatt, Rachel Miller (United Kingdom)

### **REDUCING ANTITHYMOCYTE GLOBULIN ( ATG) INFUSION RELATED REACTION BY INCREASING THE INFUSION DURATION IN ADULT SCT PATIENTS ; A SINGLE INSTITUTION EXPERIENCE FROM SAUDI ARABIA**

Suha Alkhraisat, Moussab Damraj, Maybelle Balili, Samer Ghazi, Innaam Shehab eddine, Isam Mahasneh, Bader Ahmari, Heba Alshobaki, Mohsen Alzahrani (Saudi Arabia)

### **NURSE LED TELEPHONE FOLLOW UP FOR LATE EFFECTS SERVICE**

### **NURSING CARE OF 15 PATIENTS WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CHIMERIC ANTIGEN RECEPTOR T CELLS**

### **NURSING CARE OF A PATIENT WITH HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY COMPLICATED WITH AXONAL DEGENERATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **EFFECT OF NURSES EDUCATION PROGRAM ON CATHETER RELATED BLOOD STREAM INFECTIONS**

Roberta Gironi, Marco Fabbrini, Daniela Clerici, Chiara Oltolini, Raffaella Greco, Consuelo Corti, Fabio Ciceri, Antonella Biella (Italy)

### **THE CURRENT SITUATION AND INFLUENCING FACTORS OF MANAGEMENT OF CENTER VENOUS ACCESS DEVICE-ASSOCIATED SKIN IMPAIRMENT DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Ting Wang, Xia Yan, Linnan Wang, Xinxin He, Boning Liu (China)

### **EXERCISE SUPPORT FOR PEOPLE POST TREATMENT AS PART OF THEIR RETURN TO WORK JOURNEY: A CASE STUDY EXEMPLAR**

### **ONCOSAFETY: A NEW TOOL FOR HEMATOLOGY NURSES TO AVOID CHEMOTHERAPY ERRORS**

Llora Roca Gimeno, Elisabeth Lazaro Lora, Marta Yusta Arnal, Iria Gonzalez Alvarez (Spain)

### **PATIENT INFORMATION SHEET FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: THE IMPACT OF THE DISEASE AND TREATMENT ON SEXUAL FUNCTION AND SEXUALITY**

C Eeltink, L Incrocci, I Verdonck- de Leeuw, S Zweegman (Netherlands)

### **CHANGING PRACTICE BY USING CYCLOPRIME 1.5G/M2 PRIMING REGIME UP FRONT FOR LYMPHOMA PATIENTS TO ENSURE GOOD MOBILISATION OF STEM CELLS**

Jennefer Rose, Sophie Jones, Wendy Ingram (United Kingdom)

### **THE CHALLENGES OF LOOKING AFTER AN INCREASING NUMBER OF SURVIVORS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION**

Lara Rowley, Amanda Ellis, Denise Wareham, Daja Barton, Emma Shaw, Olivia Hilsdon, Francesca Toselli, Shirley Hudson (United Kingdom)

### **VENO-OCCLUSIVE DISEASE (VOD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT NURSING CONSIDERATIONS AND MANAGEMENT: A CASE STUDY**

Marie Waller, Christopher Heron, Hayley Dyos, Eleni Tholouli (United Kingdom)

### **RECOGNIZING LOW HEALTH SKILLS AND LOW LITERACY DURING CONSULTATION**

Lian Schoonhoven-Bos (Netherlands)

## Scientific Programme

### **PRE-HABILITATION PRIOR TO STEM CELL TRANSPLANT - ONE CENTRES EXPERIENCE**

### **THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY**

### **PLASMAPHERESIS: TAKING THE EDGE OFF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTIBODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

Sinju Thomas, Adrien Quintela, Arthi Anand, Karen Bradley (United Kingdom)

### **INCIDENCE & CHARACTERISTICS OF VARICELLA ZOSTER VIRUS INFECTION POST HEMATOPOIETIC STEM CELL TRANSPLANTATION; EXPERIENCE OF A SINGLE CENTER IN SAUDI ARABIA**

### **SEMI-STRUCTURED INTERVIEW ASSESSMENT OF THE CLINICAL NURSE EDUCATOR ROLE IN SUPPORTING NEWLY QUALIFIED NURSES DURING TRANSITION TO POST-REGISTRATION PRACTICE INSIDE THE BONE MARROW TRANSPLANT SETTING**

Luke White, Kathryn Vowden (United Kingdom)

### **TRAINING NURSING PROGRAMME IN NEW THERAPIES: CAR T CELLS**

### **NURSES' ROLE IN IMPROVING PATIENTS' FOOD INTAKE IN THE ACUTE HSCT PHASE**

### **USE THE AVAILABLE KNOWLEDGE - ENSURE THAT THE PATIENT RECEIVES THE BEST CARE IN STEM CELL TRANSPLANTATION**

Anncarin Svanberg (Sweden)

### **THE PSYCHO EMOTIONAL DISAGUE IN ADULT PATIENTS SUBJECT TO MIDOLLO TRANSPLANT: INITIAL STUDY OF A SINGLE CENTER**

### **NURSING CARE OF 15 PATIENTS WITH HEMATOLOGICAL MALIGNANT TUMOR COMPLICATED WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CAR-T CELLS**

### **RETROSPECTIVE OBSERVATIONAL STUDY ON THE TRANSMISSION OF HEALTCARE ASSOCIATED INFECTIONS AMONG NEUTROPENIC PATIENTS WITHIN THE HEMATOLOGY UNIT OF PIACENZA HOSPITAL**

Lorella Cappucciati, Chiara Buraschi, Cinzia Merlini, Sabrina Sbizzirro, Silvia Fava, Stefano Gandolfi, Donatella Petrucci, Luca Pasquali, Mirella Gubellini, Andrea Contini (Italy)

### **GUIDE FOR PATIENTS AND DONORS BEFORE A PERIPHERAL BLOOD STEM CELL COLLECTION**

Natalia Lorente del Río, Cristina Alberquilla Ramos, Salvadora Aleza Esteras, Isabel María Fernández Morales, M<sup>a</sup> Del Carmen Freire Mourón, Ana García Carulla, Carmen Granado Rodilla, Mercedes Jiménez Meoro, Rosario López López, Marta Vela Garicano, Jesús Zalvide Torrente, Laura Bibiloni Martínez (Spain)

### **IMPACT OF AN IMPROVEMENT PLAN ON THE REDUCTION OF BACTERIEMIA BY CENTRAL CATHETER IN A PATIENT RECEIVER OF A CELLULAR THERAPY**

### **ARE TYMPANIC THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?**

Marina Sedlar, Marijana Maric, Lana Desnica, Radovan Vrhovac, Ivan Sabol, Nurka Rustan (Croatia)

### **RELATIONSHIPS BETWEEN THE HEALTHCARE NEEDS AND QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS**

### **PAIN ASSESSMENT DURING BONE MARROW BIOPSY PROCEDURE AND BONE MARROW ASPIRATE PROCEDURE: A SPECIFIC NURSING ASSESSMENT**

Lorella Cappucciati, Fabio Pollini, Vincenzo Matteo Quitadamo, Ramona Patras, Angelica Cravedi, Maria Teresa Borsotti, Ilaria Filati, Rosaria Scopelliti, Cinzia Merlini, Andrea Contini, Mirella Gubellini (Italy)

### **AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION IN SYSTEMIC SCLEROSIS: CASE STUDY**

Lucilia Carreiro, Rosa Romão, Candida Damião (Portugal)

## Scientific Programme

### LEADERSHIP - LEADING THE TEAM

Klara Kabatova Maxova (Czech Republic)

### PAIN ASSESSMENT IN ONCO\_HEMATOLOGICAL PATIENT SUBJECTED TO CENTRAL VENOUS CATHETER POSITIONING (CVC) OR PERIPHERALLY INSERTED CENTRAL CATHETER POSITIONING (PICC)

Lorella Cappucciati, Giovanna Buonanno, Corrado Gozzo, Francesco Oleari, Raffaella Maestri, Noemi Paladini, Patrizio Imbriani, Lucrezia Maria Zagnoni, Sara Posla, Mirella Gubbelini, Andrea Contini (Italy)

### TOCILIZUMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME

### COMPLICATIONS ASSOCIATED WITH THE COLLECTION OF PERIPHERAL BLOOD PROGENITOR CELLS

Lucília Carreiro, Carla Gonçalves, Fátima Pereira, Rosa Romão, Cândida Damião (Portugal)

### IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS!

Isabel Salcedo, Esther Ortiz, Juana María Acebes, Mari Luz Pascual, Beatriz Sanchez Sevillano, Almudena Laiglesia, Ana Alarcón, Rafael F Duarte (Spain)

### INCIDENCE OF ACUTE GUT GVHD IN PATIENTS WHO HAVE UNDERGONE ALLOGENIC STEM CELL TRANSPLANT: CASE STUDY

Poonam Thorat, Meera Sharad Achrekar, Deepti Ghonge (India)

### COMPLETION TIME TO HLA TYPING

### GYNECOLOGICAL TREATMENT EXPERIENCE OF MENOPAUSAL SYNDROME AND SEXUAL DISORDERS IN FEMALE PATIENTS WHO UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION

e-Posters  
09:30 - 19:00

ePoster Area

## Nurses Posters - Paediatric

### TRANSITION STRATEGY: FROM PEDIATRIC TO ADULT HEALTH CARE AND LONG TERM FOLLOW-UP

### CAREGIVER EDUCATION AND TRAINING FOR SELF ADMINISTRATION OF ORAL DRUGS IN A PAEDIATRIC CENTER

### EXERCISE THERAPY ON CANCER-RELATED FATIGUE AND QUALITY OF LIFE IN CHILDREN UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION

### SEXUAL HEALTH FOR YOUNG PEOPLE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION

### EVALUATION OF A PREVENTIVE SKIN CARE PROTOCOL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA

Kim van der Niet, Lisa Rozendaal, Dagmar Berghuis, Eileen van der Stoep-Yap, Erik von Asmuth, Maria de Taeye-Veldhuizen, Arjan Lankester, Hilda Mekelenkamp (Netherlands)

### CAR-T: THE DUTCH PEDIATRIC NURSING EXPERIENCE

Ida Bremer Ophorst, Tineke Terlouw (Netherlands)

### SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEIPIENTS: A SINGLE CENTER EXPERIENCE

Rosanna Ceresoli, Stefano Benvenuti, Patrizia Bevilacqua, Mirella Savoldi, Fulvio Porta (Italy)

## Scientific Programme

### **PEDIATRIC PHOTOAPHAERESIS: THE DILEMMA OF VASCULAR ACCESSES**

Rosanna Ceresoli, Stefano Benvenuti, Emilio Ferrari, Fulvio Porta (Italy)

### **TOTALLY IMPLANTABLE VASCULAR ACCESS DEVICES RUPTURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: PROPHYLAXIS AND TREATMENT**

### **USE OF VOLUMETRIC PUMPS FOR THE INFUSION OF HEMATOPOIETIC STEM CELLS AS A STANDARD METHOD IN PEDIATRIC PATIENTS**

Nuria Caballero, Marian Cerezuela, Isabel Badell Serra (Spain)

### **PEDIATRIC PATIENT TRANSFER FROM A TPH WARD TO ICU: HOW CAN WE IMPROVE OUR COMMUNICATION?**

Almudena Pérez, Alba Martínez, Anna Negre, Laura Lahuerta (Spain)

### **CARING FOR MINOR SIBLING DONORS**

Eugenia Trigos Arjona, Estrella Larios Reyes, Maria Sol Abert Velert (Spain)

### **EFFECTIVE MOBILISATION WITH PLERIXAFOR FOLLOWING CRANIA-SACRAL RADIOTHERAPY AND HIGH-DOSE CHEMOTHERAPY: A CASE REPORT OF AN ELEVEN-YEAR OLD BOY WITH GLIOBLASTOMA MULTIFORME**

Anna Tailby, Julia Nixon, Alison Bridgman, Angela Burns, Abigail Cotton, Hannah Ezard, Josephine Nicholls, Melanie Rooney, Elisabeth Thomas, Ilan Uri, Marita Macken, Sarah Lawson, Martin English (United Kingdom)

### **EARLY RECOGNITION OF PEDIATRIC GVHD: EDUCATION AND AWARENESS AMONGST NURSES**

Bart Maertzdorf, Anouk Jongekrijg (Netherlands)

### **RISK ASSESSING PAEDIATRIC PATIENTS' NUTRITIONAL NEEDS PRIOR TO BONE MARROW TRANSPLANT**

e-Posters  
09:30 - 19:00

ePoster Area

## Nurses Posters - Research

### **FAMILY CAREGIVERS SUPPORT NEEDS DURING ALLO-HSCT - A LONGITUDINAL STUDY (PRELIMINARY RESULTS)**

### **PAIN AND ANXIETY MANAGEMENT DURING BONE MARROW ASPIRATES IN ITALIAN TRANSPLANT PROGRAMS. A NATIONWIDE SURVEY ON BEHALF OF GITMO NG**

### **PREVALENCE, PREDICTORS AND OUTCOMES OF CLABSI AMONG HSCT PATIENTS**

### **CREATION OF THE LABMT NURSES GROUP**

### **SYMPTOMS AND QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY**

### **SOCIAL SUPPORT MODERATES THE EFFECTS OF HEALTH STRESSORS ON HEALTH CARE ADHERENCE AND PSYCHOLOGICAL DISTRESS IN LONG-TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS**

### **SYMPTOM DISTRESS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY**

## Scientific Programme

### **NURSE INVOLVEMENT AND IMPACT OF JACIE ACCREDITATION ON NURSE PRACTICE**

Carmen Conde, Ariadna Domenech, Iria González, Verónica Linde Blazquez, Eugenia Trigos Arjona, Julia Ruiz Pato (Spain)

### **CONSTRUCTION OF QUALITY INDICATORS SYSTEM OF NUTRITION CARE FOR ADULT PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH AN EVIDENCE-BASED APPROACH**

Yun Fang, Minjie Liu, Chen Xie (China)

### **ARE CAREGIVERS RECEIVING ENOUGH INFORMATION TO CARE? A PILOT STUDY ON A HAEMATOLOGICAL TRANSPLANT UNIT**

### **MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A THREE YEARS FOLLOWING UP**

Yaya Song, Xiaming Zhu, Yin Lu, Yongqin Ge, Qin Li, Fang Tang, Ying Chen, Yaohong Li (China)

### **VENOUS ACCESS IN AUTOLOGOUS VERSUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONORS: A RETROSPECTIVE STUDY OF AN APHERESIS UNIT**

Isabel Salcedo, Angela Salas, Laura Vicente, Lucia Paola Cuéllar, Virginia Infante, Carmen de la Puente, Jose Luis Bueno (Spain)

### **A STUDY TO ASSESS THE LEVEL OF BURNOUT AMONG NURSES WORKING IN BONE MARROW TRANSPLANT (BMT) UNIT OF A TERTIARY CARE CANCER HOSPITAL**

Shreya Ludbe, Meera Sharad Achrekar, Rynel Quadras (India)

### **DO WE KNOW ENOUGH ABOUT THE BONE MARROW DONATION?**

### **ASSOCIATION OF AIR BORN PARTICLE SIZE AND PARTICLE COUNT WITH INCIDENCE OF INFECTIONS IN HEPA FILTERED ROOMS-A SINGLE CENTRE EXPERIENCE**

### **SYSTEMATIC REVIEW OF SIGNS AND SYMPTOMS OF THE HUMAN HERPES VIRUS 6 AND THEIR ASSESSMENT TOOLS**

Rodrigo Serrano Villegas, Beatriz del Amo Mateos, Claudia Pina Pino, María Teresa Abellán Garrido, Gema Hernández Sanchez, María Cabezas López de Sosoaga, Montserrat Pilar Barrilero Lopez (Spain)

### **A STUDY TO ASSESS PERCEIVED STRESSORS AND COPING STRATEGIES ADOPTED BY PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL INFUSION IN SELECTED CANCER HOSPITAL, INDIA**

Bhushan Shelar (India)

### **ROLE OF THERAPEUTIC APHERESIS IN ALLOGENEIC TRANSPLANTATION: A CASE REPORT**

Cristina Alberquilla Ramos, Salvadora Aleza Estera, Josefa Navarrete Ruiz, Beatriz Alonso González, Rocio Rico Muñoz, Ana Isabel Torre Polo, Pilar Herreros López, Julia Ruiz Pato (Spain)

### **SYMPTOMS OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER INDUCTION CHEMOTHERAPY**

Yaohong Li, Xiaming Zhu, Yin Lu, Fang Tang, Yongqin Ge, Qin Li, Ying Chen, Yaya Song (China)

e-Posters  
09:30 - 19:00

ePoster Area

## Solid tumours

### **SUCCESSFUL KIR ALLOREACTIVE HSCT IN A CHILD WITH RESISTANT EWING SARCOMA**

## Scientific Programme

### **TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS**

Sara Redondo Velao, María Calbacho Robles, Doris Elizabeth Cueva Arica, Maria Liz Paciello Coronel, Buenaventura Buendía Ureña, Ana Jimenez, José María Sanchez Pina, Daniel Castellano, Guillermo De Velasco, Rosa Ayala Díaz, Joaquín Martínez López (Spain)

### **VOC PATTERN RECOGNITION OF LUNG CANCER: A COMPARATIVE EVALUATION OF DIFFERENT DOG- AND ENOSE-BASED STRATEGIES USING DIFFERENT SAMPLING MATERIALS**

Wiebke Biehl, Akira Hattesoht, Rudolf Jörres, Thomas Duell, Ulrike Althöhn, Rembert Koczulla, Helga Schmetzer (Germany)

e-Posters  
09:30 - 19:00

ePoster Area

## Stem cell donor

### **DONOR-RECIPIENT HLA MATCHING FOR UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION <b>Outcomes: </b> A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY (CTIWP) OF THE EBMT**

### **PRESENCE OF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN DONOR DOES NOT INCREASE THE RISK OF LATE SECONDARY MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Kyoung Ha Kim, Tae Hyung Kim, Jae-Sook Ahn, Ivan Pasic, Zeyad Al-Shaibani, Arjun Law, Wilson Lam, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Zhaolei Zhang, Tamir Biezuner, Liran Shlush, Dennis Dong Hwan Kim (Canada)

### **SERIOUS EVENTS AND ADVERSE REACTIONS IN RELATION TO BLOOD STEM CELL DONATION REPORTED TO WMDA IN 2018**

### **THE IMPROVEMENT IN OVERALL SURVIVAL FROM UNRELATED DONOR TRANSPLANT IN AUSTRALIA AND NEW ZEALAND IS DRIVEN BY A REDUCTION IN TRANSPLANT RELATED MORTALITY**

### **POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING, UNRELATED AND HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA, A COMPARATIVE STUDY OF THE ALWP EBMT**

### **ALLOREACTIVITY AGAINST HLA-DPB1 IN HOST-VERSUS-GRAFT DIRECTION IS ASSOCIATED WITH INCREASED RISK OF GRAFT FAILURE AFTER MATCHED UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES**

### **IMPACT OF KIR ON PATIENTS WITH LYMPHOID DISEASES AFTER T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Yanmin Zhao, Fei Gao, Yibo Wu, Jimin Shi, Yi Luo, Yamin Tan, Jian Yu, Xiaoyu Lai, He Huang (China)

### **INDICATIONS AND SAFETY OF MULTIPLE BONE MARROW HARVESTS IN PEDIATRIC DONORS FOR MATCHED SIBLING RECIPIENT TRANSPLANTATION**

### **HEALTHY VOLUNTARY STEM CELL DONORS: FOLLOW UP AFTER HPC APHERESIS DONATION: THE EXPERIENCE OF ITALIAN BONE MARROW DONOR REGISTRY**

Aurora Vassanelli, Denise Pavone, Simona Pollichieni, Nicoletta Sacchi (Italy)

### **ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH INHERITED DISORDERS**

Tatiana Bykova, Anna Osipova, Varvara Ovetchkina, Anna Dotcenko, Alexander Galimov, Alexander Alyanskiy, Ivan Moiseev, Alexander Kulagin, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

## Scientific Programme

### **HAPLOIDENTICAL REDUCED-INTENSITY HEMATOPOIETIC CELL TRANSPLANTATION USING BUSULFAN, FLUDARABINE, AND ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**

Min Kyoung Kim, Sung Hwa Bae, Je-Hwan Lee, Ho Sup Lee, Sung-Nam Lim, Won Sik Lee, Jung-Hee Lee, Eun-Ji Choi, Han-Seung Park, Sun-Hye Ko, Kyoo-Hyung Lee (Korea, Republic of)

### **THE RESULTS OF A TELECONFERENCE ABOUT THE EXPERIENCES AND EXPECTATIONS OF RELATED HEMATOPOIETIC STEM CELL DONORS AFTER DONATION**

### **IMPACT OF THE ESTABLISHMENT OF THE TURKISH NATIONAL DONOR REGISTRY (TURKOK) ON A SINGLE CENTER'S TRANSPLANT OUTCOME: INTERNATIONAL STEM CELL DONORS VERSUS NATIONAL**

Mutlu Arat, Nurcan Ozcelik, Deniz Goren Sahin, Tulay Ozcelik (Turkey)

### **YOUNG MALE DONORS MAY RESULT IN BETTER OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA WITH PT-CY**

### **DONORS OF PERIPHERAL HEMATOPOIETIC STEM CELLS, OUR EXPERIENCE FOR LAST 10 YEARS**

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS OVER 70 YEARS :A MONOCENTRIC EXPERIENCE OF 48 PATIENTS**

Samia Harbi, Raynier Devillier, Sabine Furst, Angela Granata, Thomas Pagliardini, Luca Castagna, Faezeh Legrand, Christian Chabannon, Claude Lemarie, Boris Calmels, Maud Cecile, Cecile Braticevic, Pierre Jean Weiller, Didier Blaise (France)

### **COMPARISON OF TRANSPLANT OUTCOMES AND ECONOMIC COSTS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML AND MDS BETWEEN THE DIFFERENT TYPE OF DONORS**

Yolanda Gonzalez Romero, Joan Manuel Mora, Sara Fernandez-Luis, David Gomez-Lamas, Jose Calvo-Sanchez, Sergio Fernandez-Garcia, Jose Luis Arroyo, Aranzazu Bermudez, Enrique Ocio, Lucrecia Yañez (Spain)

### **HIGH DISEASE-FREE SURVIVAL OF THE SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DONOR CHANGE AND MAINLY REDUCED-INTENSITY CONDITIONING IN RELAPSED HEMATOLOGICAL MALIGNANCIES**

Yongqiang Zhao, Yanzhi Song, Fan Yang, Zhihui Li, Min Jiang, Tong Wu (China)

### **EPIDEMIOLOGICAL STUDY OF RARE ANTIGENS OF THE MAIN HISTOCOMPATIBILITY COMPLEX AMONG HEMATOPOIETIC STEM CELL DONORS IN BELARUS**

Alena Hláz, Ihar Iskrou, Olga Krasko, Anatoly Uss (Belarus)

### **IMPACT OF DONOR-RECIPIENT SEX MISMATCH IN PATIENTS RECEIVING PARTIAL T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE MONOCENTRIC STUDY**

### **HAPLOIDENTICAL DONOR SELECTION AND ITS IMPLICATIONS IN TRANSPLANTATION OUTCOME. OUR EXPERIENCE AT HUDGC DR. NEGRIN**

### **OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ACCORDING TO DONOR AVAILABILITY, DURATION FROM DIAGNOSIS TO TRANSPLANT AND DONOR-SPECIFIC PARAMETERS - A SINGLE CENTER ANALYSIS**

Jennifer Kaivers, Isabela Niculae, Elke Porbadnik, Christina Rautenberg, Esther Schuler, Jürgen Enczmann, Rüdiger Sorg, Johannes Fischer, Mustafa Kondakci, Rainer Haas, Ulrich Germing, Thomas Schroeder, Guido Kobbe (Germany)

## Scientific Programme

### **THE BENEFITS OF HLA-MATCHED RELATED DONORS FOR PATIENTS LACKING HLA-IDENTICAL SIBLING IN THE ABSENCE OF POWERFUL LOCAL UNRELATED REGISTRY IN COUNTRIES WITH PREVALENT COUSIN MARRIAGES**

Amir Ali Hamidieh, Alieh Safari-Sharari, Rashin Mohseni, Mahnaz Jamee, Zeynab Nikfetrat, Leila Hejazipour, Hamideh Keykani, Fahimeh Jafari, Pouria Salajegheh, Maryam Behfar (Iran, Islamic Republic of)

### **DONOR AGE INFLUENCES THE GRAFT-VERSUS-HOST-DISEASE-FREE AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ELDERLY PATIENTS IN LATIN AMERICA**

### **A STUDY OF THE UNCERTAINTY, UNCERTAINTY APPRAISAL AND GROWTH AND THE AFFECTED FACTORS ON HEMATOPOIETIC STEM CELL DONORS**

Eun Jung Joo, Jongheon Jung (Korea, Republic of)

### **WITHDRAWAL OF VOLUNTEER DONORS FROM THE INTERNATIONAL REGISTRIES: A SINGLE CENTRE EXPERIENCE**

### **OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION FOR AML AND MYELODYSPLASTIC SYNDROME IN ELDERLY WITH REDUCED-INTENSITY CONDITIONING**

Seug Yun Yoon, Seong Kyu Park, Se Hyung Kim, Sung Hee Lim, Jong Ho Won, Dae Sik Hong (Korea, Republic of)

### **HAPLOIDENTICAL VS UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS WITH HEMATOLOGIC MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS**

Seug Yun Yoon, Min-Young Lee, Namsu Lee, Sung Kyu Park, Jong-Ho Won (Korea, Republic of)

### **HEPATITIS E VIRUS (HEV) CONTAMINATED HEMATOPOIETIC STEM CELL GRAFT IN A MATCHED UNRELATED DONOR TRANSPLANTATION**

Ksenia Boriskina, Per Ljungman, Lyda Osorio Fernandez, Stephan Mielke (Sweden)

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MATCH RELATED DONORS IN CHILDHOOD: SINGLE CENTER EXPERIENCE**

### **FIRST EXPERIENCE WITH UNRELATED STEM CELL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A TRANSPLANT CENTER FROM NORTH MACEDONIA**

Aleksandra Pivkova Veljanovska, Irina Panovska Stavridis, Lazar Chadievski, Gabriela Trajkovska, Zlate Stojanoski, Lidija Cevreska, Zaklina Trajkovska Ancevska, Marija Popova Labachevska, Nevenka Ridova, Sanja Trajkova, Radica Grubovic, Aleksandar Petlichkovski, Borce Georgievski (North Macedonia, the Republic of)

e-Posters  
09:30 - 19:00

ePoster Area

## Stem cell source

### **OPTIMIZING OUTCOMES OF ACUTE LEUKEMIA AFTER TRANSPLANTS WITH SINGLE UNRELATED CORD BLOOD UNITS SELECTED ACCORDING TO CURRENT INTERNATIONAL RECOMMENDATIONS FOR CELL DOSE AND HLA MATCH**

### **IMPACT OF HLA-MISMATCH ON OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE ANALYSIS BY THE JSHCT HLA WORKING GROUP**

Itaru Kato, Hirotohi Sakaguchi, Shunichi Kato, Maho Sato, Maiko Noguchi, Nao Yoshida, Masami Inoue, Yoshiko Hashii, Ken Tabuchi, Yoshiko Atsuta, Satoko Morishima, Junya Kanda (Japan)

## Scientific Programme

### **CLINICAL IMPACT OF DONOR EPITOPE-SPECIFIC HLA ANTIBODIES AND THIRD-PARTY HLA ANTIBODIES IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION**

Michiko Taniguchi, Dongyun Yang, Salman Otoukesh, Haris Ali, Shukaib Arslan, Chatchada Karanes, David Snyder, Guido Marcucci, Stephen J. Forman, Ryotaro Nakamura, Auayporn Nademanee, Ketevan Gendzekhadze, Monzr M. Al Malki (United States)

### **ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS**

### **THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION**

### **COMPARATIVE STUDY OF HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETION VS UNRELATED CORD BLOOD TRANSPLANT FOR ADULTS WITH HAEMATOLOGICAL MALIGNANCIES**

Yin Jie Koh, Ian Wu, Yeh Ching Linn, Lip Kun Tan, Michelle Poon, Liang Piu Koh (Singapore)

### **USE OF G-CSF MOBILIZED BONE MARROW GRAFTS IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION (BMT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) DECREASES RISK OF SEVERE ACUTE GVHD**

### **CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION**

Nelli Bejanyan, Irina St Louis, Hesham Mohei, Qing Cao, Najla El Jurdi, Claudio Brunstein (United States)

### **REDUCED INTENSITY (RIC) VS MYELOABLATIVE CONDITIONING (MAC) IN CORD BLOOD TRANSPLANTATION FOR AML (40-60 YEARS) ACROSS MISMATCHED HLA BARRIERS - ANALYSIS BY CTIWP/EUROCORD OF EBMT**

Vipul Sheth, Fernanda Volt, Jaime Sanz, Laurence Clement, Jan Cornelissen,, Didier Blaise, Jorge Sierra, Mauricette Michallet, Riccardo Saccardi, Eliane Gluckman, Christian Chabannon, Annalisa Ruggeri (United States)

### **COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL WORLD: AN ANALYSIS USING THE JAPANESE NATIONAL DATABASE**

Mizuki Watanabe, Shosuke Ohtera, Junya Kanda, Shusuke Hiragi, Tomohide Iwao, Tomohiro Kuroda, Akifumi Takaori-Kondo, Genta Kato (Japan)

### **ASSOCIATION BETWEEN THE DOSE OF CD3+ AND CD34+ CELLS IN THE GRAFT AND POST-TRANSPLANT OUTCOMES**

Tomoe Ichiki, Tatsunori Goto, Yosuke Domon, Kohei Ishigiwa, Kenichiro Takeda, Motohito Okabe, Yuka Kawaguchi, Rena Matsumoto, Marie Ohbiki, Masahide Osaki, Takanobu Morishita, Yukiyasu Ozawa, Koichi Miyamura (Japan)

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A RELATED DONOR WITH HLA-1 ANTIGEN MISMATCH IN THE GRAFT-VERSUS-HOST DIRECTION USING LOW-DOSE ANTI-THYMOCYTE GLOBULIN: MULTICENTER PHASE II TRIAL**

Junya Kanda, Toshihiko Ando, Shun-Ichi Kimura, Shin-Ichiro Fujiwara, Kazunori Imada, Shin Fujisawa, Takayoshi Tachibana, Yoshiko Atsuta, Yoshinobu Kanda (Japan)

### **INTRA-BONE CORD-BLOOD TRANSPLANT OF UNWASHED UNITS WITH ATG-FREE AND SIROLIMUS-BASED GVHD PROPHYLAXIS: FAST IMMUNE-RECONSTITUTION AND LONG-TERM DISEASE CONTROL IN 22 PATIENTS WITH HIGH-RISK DISEASES**

### **ANTI-HLA DONOR SPECIFIC ANTIBODIES (DSA) DOES NOT AFFECT GRAFT AND SURVIVAL IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) WITH ORIGINAL POST-TRANSPLANT CYCLOFOSFAMIDE (PT-CY) SCHEDULE**

### **MESENCHYMAL STEM/STROMAL CELL PRODUCTION COMPLIANT WITH GOOD MANUFACTURING PRACTICE: COMPARISON BETWEEN BONE MARROW AND WHARTON'S JELLY**

## Scientific Programme

### **EFFICIENT DMSO REMOVAL AND HIGH CELL RECOVERY WITH LOVO CELL PROCESSING SYSTEM IN HPC-A CONCENTRATES: A SINGLE CENTRE EXPERIENCE**

Maria Bianchi, Nicoletta Orlando, Caterina Giovanna Valentini, Fernando Scavone, Silvano Rovardi, Fabio Del Mondo, Sabrina Sparnacci, Luciana Teofili (Italy)

e-Posters  
09:30 - 19:00

ePoster Area

## Pharmacology

### **ELTROMBOPAG THERAPY IN STEM CELL TRANSPLANT RECIPIENTS SHOWS EFFECTIVE IRON MOBILISATION**

### **CLINICAL IMPACT OF MODEL PK GUIDED-CYCLOSPORINE DOSE INDIVIDUALIZATION IN CHILDREN UNDERGOING HSCT**

### **INFLUENCE OF CYP2D6 METABOLIZER STATUS ON THE CONTROL OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING BY ONDANSETRON ON PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Andrea Edwards, Ashley Teusink-Cross, Lisa Martin, Parinda A. Mehta, Cynthia Prows, Laura Ramsey (United States)

### **ESTIMATION OF GLOMERULAR FILTRATION RATE IN ADULTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CYSTATIN C VERSUS CREATININE**

Claudia Langebrake, Daria Jilani, Christine Wolschke, Maximilian Christopeit, Francis Ayuk, Nicolaus M. Kröger (Germany)

### **USE OF SUBLINGUAL TACROLIMUS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH HISTORY OF ANAPHYLAXIS TO INTRAVENOUS CYCLOSPORINE**

Rajesh Patil, H.N. Ramya, Pranoti Kini, Ratna Sharma, Santosh Khude, Amit Jain, Liza Bulsara, Mamta Manglani (India)

### **ORAL CLONAZEPAM FOR SEIZURE PROPHYLAXIS IN ADULT PATIENTS TREATED WITH HIGH DOSE BUSULFAN**

### **DISSOLUTION TIME FOR CONVENTIONAL AND LYOPHILIZED CYCLOPHOSPHAMIDE: A SINGLE CENTER STUDY**

### **OUTCOMES OF EBV VIREMIA AND PTLD AFTER RITUXIMAB: A PHARMACO-COST ANALYSIS**

### **PHARMACOLOGICAL INTERACTIONS IN THE POST-TRANSPLANT PHASE OF HEMATOPOYETIC PROGENITORS TRANSPLANTATION**

Maria Saez-Garrido, Alberto Espuny-Miro, Agustina Ruiz-Gomez, Miguel Almanchel-Rivadeneira, Andres Sanchez-Salinas, Maria Sacramento Diaz-Carrasco (Spain)

### **EVALUATION OF SIDE EFFECTS AND EFFICACY OF LOMUSTINE (CCNU) AND BANDAMUSTINE IN PATIENTS WITH LYMPHOMA**

Mehrdad Payandeh, Sakineh Ghorbani, Azam Elahi, Nastaran Ahmadi Rad, Roya Chagneh Lorestani (Iran, Islamic Republic of)

e-Posters  
09:30 - 19:00

ePoster Area

## Quality Management

## Scientific Programme

### **COMPARING COMPLIANCE FOR COLLECTION FACILITY JACIE STANDARDS 6.1 AND 7TH EDITIONS**

### **INTEGRATION OF THEORY AND PRACTICE: SCENARIO-BASED SKILL TRAINING IN ADMINISTERING CAR-T CELLS**

### **"TPFMEA", AN INTERNATIONAL MODEL FOR ASSESSING RISKS IN A STEM CELL TRANSPLANT PROGRAM**

### **DEFINING PATIENT-IMPORTANT OUTCOMES AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT**

### **IMPLEMENTATION OF JACIE ACCREDITATION AT A NOVEL TRANSPLANT PROGRAM: THE IMPACT ON THE CLINICAL PRACTICE**

### **HOW ONE PROCESSING CENTRE PREPARED FOR ITS FIRST JACIE INSPECTION?**

Tina Cirman, Vesna Galvani, Primož Požnenel, Marko Cukjati (Slovenia)

### **TIPS FOR GENERATING SUCCESSFUL 'TEAMWORKING' IN OUR HEALTHCARE FACILITIES: THE EXPERIENCE OF A HOSPITAL UNIT IN A FRENCH CANCER CENTER**

### **IMPLEMENTATION OF A QUALITY SYSTEM FOR RUNNING A CELL AND GENE THERAPY CLINICAL TRIAL WITHIN A JACIE-ACCREDITED TRANSPLANT PROGRAM**

Simone Biagini, Mario D'Angelo, Giuseppina Li Pira, Elia Girolami, Valentina Cirillo, Maria Giuseppina Cefalo, Gianpiero Conflitti, Pietro Merli, Mattia Algeri, Federica Galaverna, Annalisa Ruggeri, Vincenzo Iaconianni, Franco Locatelli (Italy)

### **NEW ONLINE PLATFORMS IN QUALITY MANAGEMENT: COORDINATION AND MULTIDISCIPLINARY CARE**

### **RISK MANAGEMENT ASSESSMENT IN IMPLEMENTING CAR-T CELL THERAPY IN A CLINICAL UNIT**

Ann-Mari Berthelsen, Jeanette Holder, Camilla Borch Jacobsen, Søren Lykke Petersen, Anne Fischer-Nielsen (Denmark)

### **FEBRILE REACTION AFTER HSC INFUSION IS MORE FREQUENT IF NO STEROID PREMEDICATION IS GIVEN WHICH RESULTS IN MORE FREQUENT USE OF ANTIBIOTICS EARLY POST-TRANSPLANT**

### **SEARCHING FOR OTHER TOPICS OF QUALIFICATION PLANS IN THE TRANSPLANT PROGRAM CLINICAL PART - THE ONE CENTER EXPERIENCE**

Marie Dobrovolna, Jan Vydra (Czech Republic)

### **PRACTICE PATTERNS IN CHRONIC GVHD PATIENT MANAGEMENT AND PATIENT REPORTED OUTCOME MEASURES ACROSS THE EBMT ALLOGENEIC TRANSPLANTATION NETWORK**

Ivan Sabol, Vladimir Perovic, Magdalena Grce, Marit Inngjerdengen, Drazen Pulanic, Christophe Peczynski, Emmanuelle Polge, Zinaida Peric, Christian Koenecke, Anne Dickinson, Hildegard Greinix, Grzegorz Basak, Olaf Penack, Angela Scherwath, Anna Barata, Attilio Olivieri, Anita Lawitschka, Patrycja Mensah-Glanowska, Hajnalka Andrikovics, Miklos Laszlo Udvardy, Helene Schoemans, Daniel Wolff (Serbia)

### **MAINTAINING DONOR SAFETY AND WELFARE THROUGHOUT CELLULAR THERAPY PRODUCT DONATION**

### **DIGITAL JACIE AT THE CHRISTIE**

### **INTEGRATION OF CELLULAR THERAPY IN THE JACIE (JOINT ACCREDITATION COMMITTEE ISCT-EBMT) QUALITY MANAGEMENT PLAN. SINGLE CENTER EXPERIENCE**

## Scientific Programme

### **AUDIT - A METHOD TO EVALUATE INTERVENTIONS - EXPERIENCES FROM AN ATTEMPT TO IMPROVE NUTRITIONAL STATUS IN PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Lea Brandt Kristensen, Stine Skriver Bregenov (Denmark)

### **QUALITY OF LIFE ASSESSMENT AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **RETROSPECTIVE ANALYSIS OF TIME TO ALTERNATIVE DONOR IDENTIFICATION AND HEMATOPOIETIC STEM CELLS PROCUREMENT IN THE ABSENCE OF MATCHED-SIBLING DONORS IN A SINGLE CENTER IN SPAIN**

Gracia Bravo, María Jesús Lorenzo, Emilio Ojeda, María Esther Martínez-Muñoz, Guiomar Bautista, Carlos de Miguel, Carlos Vilches, Rafael Cabrera, Rafael Duarte (Spain)

### **GOVERNANCE, RISKS AND REGULATORY ASPECTS OF UNLICENSED LENTIVIRAL VECTOR-MODIFIED AUTOLOGOUS STEM CELL TREATMENT**

Beatriz Duran Jimenez, Jane Kinsella, Wendy Ogden, Simon Jones, Brian Bigger, Robert Wynn (United Kingdom)

### **UNIQUE SUPPORTIVE CARE ALGORITHMS FOR CHILDREN UNDERGOING HAPLOIDENTICAL HSCT FOR BENIGN HAEMATOLOGICAL DISORDERS**

### **QUALITY OF LIFE IN PARENTS OF TURKISH AND SYRIAN PEDIATRIC BONE MARROW TRANSPLANT AND ONCOLOGY PATIENTS**

Gülray Sezgin, Asiye Yaylaci, Ilker Ünal, Ibrahim Bayram (Turkey)

### **COLLECTION OF AUTOLOGOUS MONONUCLEAR CELLS IN NON-CYTOKINE STIMULATED DONORS: COMPARING TWO APHERESIS METHODS**

### **EFFECTIVE CAR-T CELL DELIVERY: A MULTIDISCIPLINARY APPROACH AT MFT**

Wendy Ogden, Beatrix Duran (United Kingdom)

### **HAEMOPOIETIC PROGENITOR CELL PROFICIENCY TESTING**

Karishma Kabani, Kon Zarkos, Craig Wright, Stephen Larsen (Australia)

### **VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ALERT (R) 3D (TM) AND VIRTUO (TM) MICROBIAL BIOBURDEN SYSTEMS FOR HAEMATOPOIETIC PROGENITOR CELLS (HPC)**

Craig Wright, Julie Allerton, Karishma Kabani, Kon Zarkos (Australia)

### **START-UP OF AN ADHERENCE RECEPTION FOR ALLOGENIC STEM CELL TRANSPLANTED PATIENTS AT THE HEMATOLOGICAL DEPARTMENT LINKÖPING, SWEDEN**

Malene Bokinge (Sweden)

### **ENUMERATION OF RESIDUAL RED BLOOD CELLS IN MIS-MATCHED ALLOGENEIC PBSC COLLECTIONS - TRADITIONAL HAEMATOLOGY ANALYSER VS FLOW CYTOMETRY**

James Pittson (United Kingdom)

### **INVESTIGATION AND ANALYSIS OF FACTORS AFFECTING GASTROINTESTINAL NUTRITION RECOVERY AFTER MULTIPLE MYELOMA AUTOLOGOUS STEM CELL TRANSPLANTATION AND EFFECTS OF NUTRITIONAL INTERVENTION**

### **CHARACTERISTICS OF IRON DEFICIENCY ANEMIA IN PRE-MENOPAUSAL WOMEN IN KOREA**

Hyun Jung Lee, Myung Hee Chang, Hae Yong Pak (Korea, Republic of)

### **LEUKEMIA AND ITS TYPES**

## Scientific Programme

e-Posters  
09:30 - 19:00

ePoster Area

### Data Management

**SUPPORTING TOOLS FOR ACCURATE DATA COLLECTION - DO WE GET THE BENEFIT?**

**ARE TRANSPLANTS TRULY AVAILABLE TO ALL, REGARDLESS OF GEOGRAPHY, SOCIOECONOMIC STATUS AND ETHNIC GROUP? A BSBMTCT REPORT**

**MISMATCHED DONOR AND GRADE 2 TO 4 ACUTE GVHD AS TWO-RISK MODEL FOR CYTOMEGALOVIRUS VIREMIA AND DISEASE AFTER ALLOGENEIC TRANSPLANTATION - SINGLE INSTITUTE ANALYSIS OF 1180 PATIENTS**

e-Posters  
09:30 - 19:00

ePoster Area

### Experimental stem cell transplantation

**LOW-DOSE DECITABINE IMPROVES REFRACTORY PROLONGED ISOLATED THROMBOCYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A RANDOMIZED MULTICENTER CLINICAL TRIAL**

**AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY**

**2ND ALLO-HSCT FOR PATIENTS WHO DIAGNOSED RECURRENCE ALL AFTER THE 1ST ALLO-HSCT**

**ESTABLISHING A TRANSPLANT SHARING PROGRAM**

e-Posters  
09:30 - 19:00

ePoster Area

### Experimental transplantation

**SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTICS**

**IMPACT OF GUT FUNGAL COMPOSITION ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**MONITORING HEMATOPOIETIC CELL MICROPARTICLES IN ALLOGRAFTS AND TRANSPLANT RECIPIENTS**

**EARLY HEPATIC COMPLICATIONS DURING THE FIRST YEAR AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITH LEUKEMIA**

**PERFORMANCE OF BONE MARROW TRANSPLANTATION CENTER IN IMAM REZA HOSPITAL, KERMANSHAH, IRAN**

e-Posters  
09:30 - 19:00

ePoster Area

### Haematopoietic stem cells

## Scientific Programme

**HAPLOIDENTICAL DONOR BEATS MATCHED SIBLING DONOR FOR PRE-TRANSPLANTATION MRD POSITIVE ALL: A PHASE 3 BIOLOGICALLY RANDOMIZED STUDY**

**RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED RELATED DONOR WITH TCR $\alpha\beta$ + /CD19+-DEPLETION AND A FIXED DOSE MEMORY T CELL (CD45RA-DEPLETED) ADD-BACK**

**CLONAL DYNAMICS AND GENOMIC INTEGRITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN HUMAN ALLOGENEIC TRANSPLANTATION RECIPIENTS**

**ALLOGENEIC TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELL GRAFTS RESULTS IN A MASSIVE DECREASE OF PRIMITIVE HEMATOPOIETIC PROGENITOR FREQUENCIES IN RECONSTITUTED BONE MARROWS**

**TREATMENT OF PURE RED CELL APLASIA AFTER MAJOR ABO INCOMPATIBLE ALLOGENIC STEM CELL TRANSPLANTATION: A FRENCH RETROSPECTIVE STUDY**

**FEASIBILITY AND OUTCOMES OF A THIRD ALLOGENEIC HAEMATOPOETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM THE ALWP OF EBMT**

**CHANGES IN VIABILITY MARKERS OF HAEMATOPOIETIC STEM CELLS FOLLOWING LONG-TERM CRYOPRESERVATION**

**HIGH PRE-TRANSPLANT INTERLEUKIN-18 IS ASSOCIATED WITH POOR HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND PREDICTS INCREASED NON-RELAPSE MORTALITY**

**MICROBIAL DIVERSITY, SURVIVAL, AND ACUTE GVHD IN ADULT RECIPIENTS OF ALLO-HSCT AFTER MYELOABLATIVE CONDITIONING: RESULTS OF A NUTRITIONAL INTERVENTION TRIAL**

**UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS**

**RECONSTRUCTION OF THE DONOR-RECIPIENT HAEMATOPOIETIC CELL PHYLOGENY USING SOMATIC MUTATIONS TO ESTABLISH NUMBERS OF ENGRAFTING LONG-TERM HSCS IN REAL-WORLD TRANSPLANTATION**

**SUCCESSFUL CLEARANCE OF DONOR SPECIFIC ANTI-HLA ANTIBODIES AFTER DESENSITIZATION WITH RITUXIMAB, VELCADE AND PLASMA-EXCHANGE FOLLOWED BY A HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

**IMPACT OF PRE-TRANSPLANTATION MINIMAL RESIDUAL DISEASE DETERMINED BY FLOW CYTOMETRY ON OUTCOME OF ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**ECONOMIC BURDEN OF CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SPANISH MULTICENTER, RETROSPECTIVE STUDY**

**INCIDENCE AND OUTCOME OF CLONAL AND MALIGNANT TRANSFORMATION (CMT) AMONG PEDIATRIC PATIENTS WITH INHERITED BONE MARROW FAILURE SYNDROMES (IBMFSS)**

**IMPACT OF POST-TRANSPLANT IMMUNOSUPPRESSION WEAN VS. BOOST IN EARLY MIXED CHIMERISM FOLLOWING G-CSF-PRIMED MARROW TRANSPLANT IN THALASSEMIC PATIENTS**

**COMPARISON OF THE CONDITIONING REGIMENS WITH TMLI, NON-RADIATION AND TBI FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**VALIDATION OF DISEASE RISK COMORBIDITY INDEX (DRCI) FOR OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) WITH PARTIALLY T-CELL DEPLETED GRAFT**

## Scientific Programme

**ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PRETREATED WITH JAK1/JAK2 INHIBITORS**

**THE DETERMINATIVE ROLE OF PATIENT-CONTROLLED-ANALGESIA (PCA) IN THE EARLY COURSE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HIGH SURVIVAL RATE AND LOW INCIDENCE OF AGVHD AFTER CD34+ STEM CELLS SELECTION AND CD3+ T CELLS ADDBACK IN PEDIATRIC MUD HSCT**

**IMPACT OF ABO INCOMPATIBILITY ON OUTCOMES AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA**

**COMPARISON OF OUTCOMES AFTER HAPLOIDENTICAL VERSUS UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER REVIEW**

**EFFECT OF DIFFERENT TIMINGS OF UMBILICAL CORD CLAMPING ON THE LEVEL OF CD34+ CELLS IN FULL-TERM NEONATES**

**SEQUENTIAL CONDITIONING REGIMEN (FLAMSA-BU-MEL) IN HLA-MATCHED OR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY MYELOID DISEASE**

**SEQUENCE CYTOREDUCTIVE CHEMOTHERAPY FOLLOWED BY MA CONDITIONING REGIMEN HSCT WITH INTERMEDIATE - OR ADVERSE RISK AML IN CR: A SINGLE CENTER STUDY**

**INVESTIGATION OF VIROLOGICAL FEATURES AND CLINICAL OUTCOMES ASSOCIATED WITH PRE-ENGRAFTMENT CYTOMEGALOVIRUS DNAEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS**

**CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE AS A PREDICTOR OF ENGRAFTMENT AND SURVIVAL IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

**USE OF PLERIXAFOR IN POOR MOBILIZER PATIENTS WITH MYELOMA AND LYMPHOMA: CLONOGENIC CAPACITY AND ENGRAFTMENT DATA**

**OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRICS: A SINGLE CENTER EXPERIENCE FROM INDIA**

**RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: LONG TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA**

**PRE-EMPTIVE USE OF SORAFENIB COMBINED WITH DLI POST HSCT IN AML FLT3+: A SINGLE CENTER EXPERIENCE**

**USE OF ELTROMBOPAG FOR THE MANAGEMENT OF POOR GRAFT FUNCTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN**

**TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH ELTROMBOPAG**

**EFFICACY OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED TO CHEMOTHERAPY AS POST-REMISSION TREATMENT FOR CHILDREN WITH INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION**

**THE TREATMENT OF BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA IRREVERSIBLY DEPLETES NAÏVE T LYMPHOCYTES**

## **Scientific Programme**

**DESENSITIZATION PROTOCOL IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH ANTI-HLA DONOR-SPECIFIC ANTIBODIES (DSA): A SINGLE-CENTER EXPERIENCE**

**ASSOCIATION BETWEEN METABOLIC ALTERATION WITH TYPE AND INDICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR PATIENTS RECEIVING UMBILICAL CORD BLOOD TRANSPLANTS AT THE ROYAL MARSDEN HOSPITAL BETWEEN 2007 AND 2017**

**HIGHER COST AND NO SURVIVAL BENEFIT WITH ADDITION OF RITUXIMAB TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL**

**ASSOCIATION BETWEEN METABOLIC ALTERATIONS WITH AGE AND GENDER OF PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HAPLOIDENTICAL HSCT IN CHILDREN WITH VERY HIGH-RISK HAEMATOLOGIC MALIGNANCIES: A SINGLE-CENTRE EXPERIENCE**

**COMPARATIVE STUDY OF THE HEMATOPOIETIC RECONSTITUTION**

**INFUSED TOTAL NUCLEATED CELL DOSE IS NOT ASSOCIATED WITH ENGRAFTMENT IN AUTOLOGOUS STEM CELL TRANSPLANTATION**

**A COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND BFM 95 CHEMOTHERAPY PROTOCOL IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA**

**THE IMPACT OF CD34+ CELL AND IMMUNEFFECTOR CELL DOSE ON TRANSPLANT OUTCOMES**

**TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANTATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY**

**OUTCOME OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**MOTIVATION FOR ANTIFUNGAL USE IN PEDIATRIC HSCT PATIENTS IN AN INSTITUTION IN SOUTHERN BRAZIL**

**IMPACT OF THE USE OF GRANULOCYTIC COLONY-STIMULATING FACTOR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RARE FORMS OF PRIMARY IMMUNODEFICIENCIES (PIDS) IN ARGENTINA**

**PHASE II STUDY OF PLERIXAFLOL AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL, PET POSITIVE AFTER TWO R-DHAP**

**THE EFFECT OF CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE ON THE HEMATOPOIETIC RECOVERY AND SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION**

**THE EVENTUAL ROLE OF DONOR AND RECIPIENT VITAMIN D LEVELS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SETTING**

**AVERAGE LENGTH OF HOSPITAL STAY FOR PEDIATRIC BLOOD AND MARROW TRANSPLANTS IN THE BACKDROP OF CELL SOURCE, TRANSPLANT TYPE AND OUTCOME**

**ONE CENTER EXPERIENCE IN OFFLINE TECHNIQUE VALIDATION WITH BIOLOGICAL QUALITY TESTS**

## **Scientific Programme**

**A MONOCENTRIC CLINICAL OBSERVATION OF ALLOGENEIC TRANSPLANTATION IN 22 PATIENTS WITH ACUTE MEGAKARYOCYTIC LEUKEMIA**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN SCIENTIFIC CENTRE OF PEDIATRICS AND CHILD SURGERY**

**THE OUTCOME OF ALLOTRANSPLANT USING TBF CONDITIONING FROM MATCHED SIBLING RELATED DONORS IN HIGH RISK MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE SINGLE CENTER EXPERIENCE**

**EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA: RETROSPECTIVE ANALYSIS IN OUR CENTER**

**CARDIOVASCULAR RISK IN PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**INFECTIONS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS IN PERU: EXPERIENCE OF A REFERRAL CENTER**

**HAEMATOPOIETIC STEM CELL PRODUCT VIABILITY: A COMPARATIVE STUDY BETWEEN BAGS AND VIALS**

**TRANSFUSION SUPPORT IN THE FIRST 30 AND 100 DAYS AFTER HAPLOIDENTICAL VERSUS HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MACS IN A PERUVIAN HEALTH CHILDRENS INSTITUTE: THREE-YEAR EXPERIENCE**

**COLLECTION, CRYOPRESERVATION AND AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELLS IN KAUNAS, LITHUANIA 2015-2019**

**EVALUATION OF OVERALL SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT): UNICENTRIC EXPERIENCE**

**MONITORING OF THE EXPRESSION OF THE VEGF-A GENE (VASCULAR ENDOTHELIAL GROWTH FACTOR) DURING THE EVOLUTION OF PEDIATRIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION. A PILOT STUDY**

**REFRACTORY T-CELL CUTANEOUS LYMPHOMA TREATED WITH ALLOGENEIC HAPLOIDENTIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT**

**VITAMIN D DEFICIENCY AND OUTCOMES IN ADULT ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE OVER LAST YEARS**

**CAUSES OF COMPLICATIONS IN ADULTS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

e-Posters  
09:30 - 19:00

ePoster Area

## **Immunodeficiency diseases and macrophages**

## Scientific Programme

**IMPACT OF DIFFERENT *EX VIVO* T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY**

**OUTCOMES AND IMMUNE RECONSTITUTION AFTER T-CELL REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FOR PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCIES**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY IN JAPAN: OVERVIEW OF A NATIONWIDE RETROSPECTIVE ANALYSIS**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY IN JAPAN: A NATIONWIDE RETROSPECTIVE ANALYSIS**

**UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY: SINGLE-INSTITUTION EXPERIENCE IN CHINA**

**IMMUNODEFICIENCY - CENTROMERIC INSTABILITY - FACIAL DYSMORPHISM (ICF) SYNDROME: EVALUATION OF CHARACTERISTICS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THIOTEPA VERSUS MELPHALAN CONTAINING CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATIONS WITH TCR $\alpha\beta$ /CD19 GRAFT DEPLETION FOR PRIMARY IMMUNODEFICIENCIES**

**IMPROVED TRANSPLANT SURVIVAL AND LONG-TERM DISEASE OUTCOME FOR CHILDREN WITH CD40 LIGAND DEFICIENCY**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES INCLUDING IMMUNE RECONSTITUTION IN PRIMARY IMMUNODEFICIENCIES: 5 YEARS OF SINGLE CENTRE EXPERIENCE**

**OUTCOMES OF STEM CELL TRANSPLANT FOR RIPK1 DEFICIENCY: A SINGLE CENTRE EXPERIENCE**

**IMPROVING THE RESULT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY WITH SERIOUS INFECTION IN DEVELOPING COUNTRIES USING RIC REGIMENT**

**SINGLE-CENTER EXPERIENCE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCR  $\alpha\beta$  DEPLETION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY SYNDROMES**

**HAPLO-IDENTICAL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY - A TERTIARY CARE CENTRE EXPERIENCE FROM SOUTH INDIA**

**NECROTIZING ENTEROCOLITIS IN A TWO-MONTH-OLD SCID PATIENT AFTER BONE MARROW TRANSFUSION - SURGICAL INTERVENTION AT DAY +1: YES OR NO?**

**UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH TWO DIFFERENT CONDITIONING REGIMEN FOR CHRONIC GRANULOMATOUS DISEASE: SINGLE-INSTITUTION EXPERIENCE IN CHINA**

**THE OUTCOMES OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE IN CHILDREN WITH RAG GENE MUTATION**

**LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) IN ADA-SCID PATIENTS: THE SHADOW OF MALIGNANCIES**

**HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR X-LINKED AGAMMAGLOBULINAEMIA COMPLICATED BY CHRONIC NOROVIRUS ENTEROPATHY**

## Scientific Programme

**HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CD40 LIGAND DEFICIENCY**  
**DIAGNOSTIC MARKERS FOR AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME**  
**ALLOGENEIC HEMOTOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR CHRONIC GRANULOMATOUS DISEASE (CGD) IN CHILDHOOD**

e-Posters  
09:30 - 19:00

ePoster Area

### Infectious complications

**PNEUMOCYSTIS PNEUMONIA AFTER ALLOGENEIC HCT: A CASE-CONTROL STUDY ON RISK FACTORS, TIMING, AND PCR USE, FROM THE IDWP OF EBMT**

**UPPER AND/OR LOWER RESPIRATORY TRACT INFECTION CAUSED BY HUMAN CORONAVIRUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**SUCCESSFUL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH JCV-TARGETED T-CELL THERAPY**

**EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY**

**TUBERCULOSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT**

**FAECAL MICROBIOTA TRANSPLANT (FMT) CAN REDUCE THE HIGH NRM ASSOCIATED WITH MULTI-DRUG RESISTANT ORGANISM (MDRO) COLONISATION PRIOR TO ALLOGENEIC HCT**

**EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY**

**USE OF LETERMIVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY**

**RISK OF INFECTIOUS COMPLICATIONS IN ADULT PATIENTS AFTER ALLOGENEIC HSCT DEPENDING ON THE SITE OF CENTRAL VENOUS CATHETER INSERTION - MULTICENTRE PROSPECTIVE STUDY**

**INFECTION PREVENTION PRACTICES AMONG EBMT HEMATOPOIETIC CELL TRANSPLANT CENTERS: A SURVEY OF THE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT**

**PRIMARY LETERMIVIR PROPHYLAXIS IN CMV SEROPOSITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE**

**HEV INFECTION IN HCT RECIPIENTS - RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) OF EBMT**

**THE ROLE OF COMBINATION PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTION AFTER EX VIVO AB T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT (HHCT) IN CHILDREN**

**IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY**

## **Scientific Programme**

**COMPARISON OF IMMUNE CELL RESPONSE TO CYTOMEGALOVIRUS PROTEINS VERSUS PEPTIDES USING AN IFN- $\gamma$  ELISPOT ASSAY TO MONITOR CYTOMEGALOVIRUS-SPECIFIC IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HUMAN HERPESVIRUS TYPE 6 REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION: RISK FACTORS AND CLINICAL IMPACT**

**INCREMENTAL INPATIENT HEALTHCARE RESOURCE USE AND COSTS AMONG CMV SEROPOSITIVE ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS MANAGED THROUGH PREEMPTIVE APPROACH**

**POOR RECOVERY AND IMPAIRED FUNCTION OF V $\delta$ 1+ T CELLS IN REFRACTORY/RECURRENT CMV REACTIVATION AFTER HEMATOPOIETIC TRANSPLANTATION**

**SAFETY AND EFFICACY OF BRINCIDOFOVIR FOR REFRACTORY ADENOVIRUS INFECTION IN CHILDREN RECEIVING ALLOGENEIC SCT: A RETROSPECTIVE ANALYSES FROM THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION (AIEOP)**

**ALLOPLUS: RESULTS OF THE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS -POSITIVE PATIENTS, A RETROSPECTIVE STUDY OF THE SFGM-TC**

**SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A PROSPECTIVE STUDY TO MEASURE FEASIBILITY, SAFETY AND HEALTH CARE RESOURCE USE**

**FREQUENCY, RISK FACTORS AND OUTCOME OF ACTIVE TUBERCULOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**INFECTIOUS COMPLICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA AFTER NEW AGENTS' THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION**

**SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION**

**CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION**

**FECAL MICROBIOTA TRANSPLANTATION IN CHILDREN TO TREAT ACUTE GVHD OR MULTI-DRUG RESISTANT BACTERIA COLONIZATION**

**VACCINATION AGAINST TICK-BORNE ENCEPHALITIS (TBE) AFTER AUTOLOGOUS AND ALLOGENEIC BONE MARROW TRANSPLANTATION**

**RIFAXIMIN USE FAVOURED MICAFUNGIN RESISTANT CANDIDA SPP INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT**

**IMPACT OF HHV-6 REACTIVATION AFTER T-REG/T-CON IMMUNOTHERAPY IN ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY**

**ADENOVIRUS INFECTIONS AFTER HCT: INFECTIOUS DISEASES WORKING PARTY RETROSPECTIVE EBMT REGISTRY STUDY**

**CLINICAL IMPACT OF COLONIZATION BY MULTIDRUG-RESISTANT ENTEROBACTERIACEAE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## **Scientific Programme**

**POST-ALLOGENEIC TRANSPLANTATION PROGRESSIVE MULTIFOCAL  
LEUKOENCEPHALOPATHY, CLINICAL AND BIOLOGICAL FEATURES, TREATMENT AND  
OUTCOMES: A RETROSPECTIVE STUDY FROM THE SFGM-TC**

**RESPIRATORY VIRAL INFECTIONS IN ADULT PATIENTS UNDERGOING UMBILICAL CORD BLOOD  
TRANSPLANTATION FROM UNRELATED DONORS AFTER MYELOABLATIVE CONDITIONING  
REGIMEN**

**EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC  
HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS  
AMONG JAPANESE PATIENTS**

**RISK FACTORS AND CLINICAL OUTCOMES OF CYTOMEGALOVIRUS REACTIVATION AFTER  
HAPLOIDENTICAL AND MATCHED-SIBLING PERIPHERAL BLOOD STEM CELL  
TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**STANDARDIZED MONITORING OF CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY CAN  
IMPROVE RISK STRATIFICATION OF RECURRENT CYTOMEGALOVIRUS REACTIVATION AFTER  
HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**IMPACT OF LEVOFLOXACIN FOR PROPHYLAXIS OF PRE-ENGRAFTMENT BLOODSTREAM  
INFECTIONS AFTER ALLOGENEIC HSCT: A SINGLE-CENTER MATCHED ANALYSIS IN AN  
ENDEMIC COUNTRY FOR CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA**

**PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) AFTER HCT - A RETROSPECTIVE  
STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT**

**ORAL RIBAVIRIN IS A HIGHLY EFFICACIOUS TREATMENT FOR LOWER RESPIRATORY TRACT  
INFECTION DUE TO RESPIRATORY SYNCYTIAL OR PARAINFLUENZA VIRUS IN ALLOGENEIC  
STEM CELL TRANSPLANT RECIPIENTS**

**TIMING OF INDUCTION TREATMENT FOR REACTIVATION OF CYTOMEGALOVIRUS IMPACTS  
OVERALL SURVIVAL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT**

**PREDICTION OF BLOODSTREAM INFECTION RISK USING CITRULLINE AS BIOMARKER OF  
INTESTINAL MUCOSITIS IN HEMATO-ONCOLOGY PATIENTS**

**PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT**

**COMPARISON OF INFECTIOUS COMPLICATIONS AMONG PATIENTS RECEIVING  
UNMANIPULATED HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT  
CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETED HAPLOIDENTICAL  
TRANSPLANT**

**THE CUMULATIVE INCIDENCE OF MULTIPLE DNA VIRUS REACTIVATION IS NOT DIFFERENT IN  
NON-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION AND UNRELATED  
ALLOGENEIC STEM CELL TRANSPLANTATION**

**NEUTROPHILS RESPONSE TO HUMAN CMV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC  
STEM CELL TRANSPLANT RECIPIENTS**

**CLINICAL EFFICACY OF LETERMOVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENEIC  
HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**AT-HOME FOSCARNET ADMINISTRATION IN ALLOGENEIC HEMATOPOIETIC  
TRANSPLANTATION PATIENTS WITH CYTOMEGALOVIRUS INFECTION: A SAFETY FEASIBLE  
MODEL**

**EFFECTS OF THE ANTIBIOTICS CHANGE OR THE ADDITION OF ANTI-MRSA DRUGS FOR  
PERSISTENT FEBRILE NEUTROPENIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION**

**THERAPEUTIC DRUG MONITORING OF POSACONAZOLE AND SUBSEQUENT DOSING IN  
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

## Scientific Programme

**IS PREEMPTIVE STRATEGY ENOUGH? RELATIONSHIP BETWEEN CMV REACTIVATION AND STEROID THERAPY FOR GHVD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: 97 PATIENTS FROM TURKEY**

**PROPHYLAXIS WITH AZITHROMYCIN IN ALLOGENEIC CORD BLOOD TRANSPLANT AND ASSOCIATION WITH RELAPSE RATE AND TRANSPLANT OUTCOMES**

**REACTIVATED VARICELLA ZOSTER (VZV) INFECTION (SHINGLES), AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT) FOR HAEMATOLOGICAL DISEASE IN CHILDREN: A SIGNIFICANT PROBLEM AND PROPOSAL FOR FUTURE MANAGEMENT**

**LETERMOVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE**

**ANALYSIS OF CMV REACTIVATION RISK AFTER T CELL REPLETE HAPLOIDENTICAL AND MATCHED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ASPERGILLUS NON-FUMIGATUS INVASIVE ASPERGILLOSIS IN CHILDREN AND ADULTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) & CHEMOTHERAPY**

**INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS JIROVECI PROPHYLAXIS IN HEMATOLOGICAL PATIENTS TREATED WITH CHEMOTHERAPY, HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) AND CAR-T CELL THERAPY**

**INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS**

**LOW RELAPSE RISK FOR REDUCED INTENSITY CONDITIONED ALEMTUZUMAB-BASED ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMAS IS OFFSET BY CYTOMEGALOVIRUS RISK: DATA FROM SINGLE CENTRE STUDY**

**PROPHYLACTIC DOSE TRIMETHOPRIM/SULFAMETHOXAZOLE DOES NOT LEAD TO DELAYED NEUTROPHIL AND PLATELET ENGRAFTMENT IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

**HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EPIDEMIOLOGICAL SCREENING FOR BACTERIAL RESISTANCE BY DIFFERENT TECHNIQUES IN ALLO-HSCT PATIENTS**

**INVASIVE MOLD DISEASE IN A REAL-WORLD HEMATO-ONCOLOGY SETTING: VALUE OF A DIAGNOSTIC-DRIVEN CARE PATHWAY**

**SINGLE CENTER ANALYSIS ON THE MANAGEMENT OF ACYCLOVIR RESISTANT HERPES SIMPLEX VIRUS STOMATITIS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**EARLY BACTEREMIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION WITHOUT THE USE OF PROPHYLACTIC ANTIBIOTIC: CHANGING EPIDEMIOLOGY AND ANTIMICROBIAL RESISTANCE (2016-2018)**

**DIAGNOSTIC YIELD OF BRONCHOALVEOLAR LAVAGE (BAL) IN HAEMATOLOGICAL PATIENTS AFTER ALLOGENEIC/ AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) - COMPARISON WITH BAL PERFORMANCE IN NON-TRANSPLANTED PATIENTS**

**A NOVEL EFFICIENCY STRATEGY TO PREVENT HBV-RELATED HEPATITIS AFTER ALLOGENEIC HSCT FROM HBSAG- POSITIVE DONORS TO RECIPIENTS**

## **Scientific Programme**

**BK VIRUS EFFECT ON DEVELOPING LATE HEMORRHAGIC CYSTITIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS: SINGLE CENTER EXPERIENCE**

**VERSATILE EFFECTS OF LETERMIVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS**

**IMPACT OF A CHANGE IN ANTIBACTERIAL PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION IN ONE SINGLE CENTER**

**INTRAVESICAL INSTILLATION OF CIDOVIFIR IS EFFICIENT FOR THE TREATMENT OF BK VIRUS HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC TRANSPLANTATION**

**MANAGEMENT OF BK POLYOMA VIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE**

**RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RISK FACTORS FOR CYTOMEGALOVIRUS INFECTION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**IMPACT OF HYPOGAMMAGLOBULINEMIA ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**

**THE USE OF RIFAXIMINE IN ANTI-BACTERIAL PROPHYLAXIS IN PATIENT UNDERGOING HSCT**

**BKV VIRUS - HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: INCIDENCE, SEVERITY AND RISK FACTORS**

**RUXOLITINIB FOR STEROID-REFRACTORY GVHD ABOLISHES ANTIVIRAL IMMUNE RESPONSE FOLLOWING T-CELL TRANSFER FOR REFRACTORY ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

**RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMIVIR PROPHYLAXIS**

**ISAVUCONAZOLE (ISA) USE IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) RECIPIENTS: A SINGLE-CENTER EXPERIENCE**

**TIME- AND THERAPY-DEPENDENT BACTERIURIA IN CHILDREN AND YOUNG ADULTS FOLLOWING ALLOGENEIC HSCT**

**PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF MARIBAVIR COMPARED WITH VALGANCICLOVIR FOR TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS (STUDY DESIGN)**

**INCIDENCE AND RISK FACTORS OF VIRAL COMPLICATIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM HUNGARY**

**CONTRIBUTING FACTORS TO PRE ENGRAFTMENT BACTEREMIA AND PNEUMONIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A LEBANESE SINGLE CENTER EXPERIENCE**

**UNICENTRIC STUDY: PROPHYLAXIS STRATEGY AGAINST GVHD WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (CPYT) AND ITS RELATIONSHIP WITH CYTOMEGALOVIRUS**

**EPIDEMIOLOGY AND CLINICAL FEATURES OF FEBRILE NEUTROPENIC EPISODES: THREE YEARS EXPERIENCE AT HEMATOLOGY WARDS**

## Scientific Programme

**USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS**

**TOXOPLASMOSIS DISEASE AFTER ALLO-HSCT. WHAT HAVE WE LEARNT?**

**TUBERCULOSIS IN PATIENTS WHO RECEIVE AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. TWO CASE REPORT**

**POLYOMAVIRUS BK INFECTION IN BONE MARROW TRANSPLANTATION RECIPIENTS. A COMPARATIVE ANALYSIS ON CHILDREN AND ADULTS**

**LEFLUNOMIDE, SUCCESSFUL PRE-EMPTIVE THERAPY IN RESISTANT CYTOMEGALOVIRUS REACTIVATION IN A HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT**

**LETERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**INFECTIOUS COMPLICATIONS IN HEMATOLOGIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EARLY MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA - A SINGLE CENTER EXPERIENCE**

**CMV RETINITIS IN A STEM CELL TRANSPLANT RECIPIENT TREATED WITH FOSCARNET INTRAVITREAL INJECTION AND CMV SPECIFIC IMMUNOGLOBULIN**

e-Posters  
09:30 - 19:00

ePoster Area

## Lymphoma

**LONG TERM SURVIVAL AFTER 2 YEARS EVENT FREE SURVIVAL IN RELAPSED DLBCL AFTER AUTOLOGOUS TRANSPLANTATION IN THE TWO RANDOMIZED TRIALS LY.12 AND CORAL**

**EXPLORATORY ANALYSIS OF BRENTUXIMAB VEDOTIN PLUS CHP (A+CHP) AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS (ECHELON-2): IMPACT OF CONSOLIDATIVE STEM CELL TRANSPLANT**

**BRENTUXIMAB VEDOTIN FOR RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN LYMPHOMA: A STUDY OF THE LWP-EBMT**

**ALLOGENEIC STEM CELL TRANSPLANTATION AS A CURATIVE OPTION IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH/GELTAMO STUDY**

**ADAM17 INHIBITOR INCB7839 WITH RITUXIMAB AS CONSOLIDATION AFTER AUTOLOGOUS HCT FOR DIFFUSE LARGE B CELL LYMPHOMA: A NOVEL RELAPSE PREVENTION STRATEGY**

**COMPARISON OF REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A CIBMTR ANALYSIS**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH NON-HODGKIN LYMPHOMA: THE SPANISH EXPERIENCE**

**EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS AFFECTED BY ADVANCED LYMPHOID MALIGNANCIES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY**

## Scientific Programme

**BRENTUXIMAB-VEDOTIN IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY PRIOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HODGKIN LYMPHOMA: REAL-WORLD DATA FROM A TWO CENTERS STUDY**

**NON-MYELOABLATIVE CONDITIONING REGIMEN BEFORE T-CELL REplete HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ADVANCED LYMPHOMA**

**IMPACT OF KIR LIGAND MISMATCH AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY IN 383 PATIENTS FROM THE SFGM-TC**

**THE IMPACT AND CHALLENGES OF PERFORMING BEAM CONDITIONED AUTOLOGOUS TRANSPLANTS IN 'OLDER' PATIENTS WITH LYMPHOMA**

**ACCESSIBILITY AND IMPACT ON LONG-TERM OVERALL SURVIVAL OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS: A SINGLE INSTITUTION INTENTION-TO-TREAT ANALYSIS**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TRANSFORMED FOLLICULAR LYMPHOMA (FL): RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY FROM GELTH/GELTAMO GROUP**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSE AFTER AUTOLOGOUS TRANSPLANTATION**

**SIGNIFICANT ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA**

**HIGH DOSE CHEMOTHERAPY TEAM FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA: RESULTS OF A PROSPECTIVE STUDY**

**AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIV+ AND HIV- LYMPHOMA PATIENTS: A PROPENSITY SCORE MATCHED ANALYSIS**

**AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR DOUBLE HIT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS**

**ALLOGENEIC STEM CELL TRANSPLANTATION CAN BE SUCCESSFULLY DELIVERED FOLLOWING BTKI THERAPY FAILURE FOLLOWING R-BAC RE-INDUCTION CHEMOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA**

**CLINICAL OUTCOMES OF EBV+ PTLD PATIENTS FOLLOWING HCT WHO FAIL RITUXIMAB: A RETROSPECTIVE CHART REVIEW STUDY FROM FRANCE**

**THE IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) ON THE OUTCOME OF POOR-RISK NON-HODGKIN LYMPHOMA (NHL): UPDATE OF A RETROSPECTIVE INTENT-TO-TRANSPLANT (ITT) ANALYSIS**

**REDUCING THE COST OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMAS AT LIMITED-RESOURCE CENTERS IN DEVELOPING COUNTRIES**

**COMPARISON OF MITOXANTRONE - MELPHALAN AND BEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS**

**NIVOLUMAB RE-CHALLENGE IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: WHERE IS THE PLACE FOR ALLOHSCT?**

**OUTCOME OF TRANSPLANT ELIGIBLE MANTLE CELL LYMPHOMA PATIENTS WITH FIRST-LINE REGIMENS IN A REAL-WORLD SETTING: A PORTUGUESE MULTICENTER RETROSPECTIVE ANALYSIS**

## **Scientific Programme**

**EVALUATION OF FRACTIONATED ICE AS AN ALTERNATIVE OUTPATIENT OPTION FOR RELAPSED/REFRACTORY LYMPHOMAS**

**EFFICACY OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA**

**RISK FACTORS FOR INTENSIVE CARE UNIT ADMISSION IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

**AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA**

**DIFFERENT OUTCOMES WITH DIFFERENT DONORS IN ALLOGENEIC STEM CELL TRANSPLANTATIONS IN MALIGNANT LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE**

**THE IRISH EXPERIENCE OF THIOTEPA, CARMUSTINE AND ETOPOSIDE CONDITIONING PRIOR TO ASCT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS**

**TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA**

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS TREATMENT OPTION FOR RARE TRANSDIFFERENTIATION OF LYMPHOID NEOPLASMS INTO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS TO ACHIEVE LONG-TERM SURVIVAL**

**OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH PERIPHERAL T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)**

**TREATMENT OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. A STUDY OF THE POLISH LYMPHOMA RESEARCH GROUP**

**PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH T-CELL LYMPHOMAS: PAVLOV UNIVERSITY EXPERIENCE**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA: TOXICITY AND SURVIVAL STUDY**

**AUTOIMMUNE COMPLICATIONS IN CHILDREN WITH HODGKIN DISEASE (HD) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT)**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIV-RELATED LYMPHOMA**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS OF 23 PATIENTS**

**NIVOLUMAB BASED RESPONSE ADAPTED TREATMENT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS**

**AUTOLOGOUS STEM CELL TRANSPLANT IN A SEROPOSITIVE A PATIENT WITH PLASMABLASTIC LYMPHOMA (PBL)**

**COMPARING THE EFFICACY AND TOXICITY BETWEEN TWO CONDITIONING REGIMEN IN LYMPHOMA PATIENTS IN WEST OF IRAN (BENDAMUSTIN) OR (CCNU) WITH (ETOPOSIDE, CITARABINE, MELPHALANE)**

## Scientific Programme

e-Posters  
09:30 - 19:00

ePoster Area

### Minimal residual disease, tolerance, chimerism and immune reconstitution

**T CELL CHIMERISM AFTER HCT DOES NOT PREDICT FOR GRAFT LOSS IN NON-MALIGNANT DISEASES, AND IS A FAILURE OF MYELOSUPPRESSION RATHER GRAFT REJECTION**

**FASTER ENGRAFTMENT AND RECONSTITUTION OF INNATE-IMMUNITY AFTER ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) THAN POST-TRANSPLANT-CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS AFTER MYELOABLATIVE CONDITIONING (MAC) PERIPHERAL-BLOOD-STEM-CELL (PBSC) ALLOGENEIC-TRANSPLANTATION (ALLO-SCT)**

**CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENEIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMIVIR**

**COMPARING OUTCOMES OF PATIENTS HAVING MIXED T CHIMERISM AND UNRELATED DONOR ALLOGRAFTS FOR ACUTE LEUKAEMIA/MDS TO PATIENTS WITH COMPLETE CHIMERISM - SINGLE CENTRE RETROSPECTIVE STUDY**

**CMV INFECTION IS ASSOCIATED WITH REDUCED THYMIC FUNCTION AND LESS REGULATORY T CELLS AFTER PEDIATRIC ALLOGENEIC HSCT**

**IMPACT OF PRE-TRANSPLANT MRD BURDEN MEASURED BY MULTICOLOR FLOW CYTOMETRY ON RELAPSE AND SURVIVAL IN AML PATIENTS UNDERGOING ALLO-SCT IN CR**

**FLOW-BASED PRE-TRANSPLANT MRD DETECTION STRONGLY IMPACTS ON THE OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION WITH AB T CELL DEPLETION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA**

**CMV-SPECIFIC T CELL COUNTS EARLY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION STRATIFY THE RISK OF SUBSEQUENT CMV REACTIVATIONS: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY**

**IMPROVED RELAPSE-FREE-SURVIVAL IN PATIENTS WITH HIGH NATURAL KILLER CELL DOSES IN GRAFTS AND DURING EARLY IMMUNE RECONSTITUTION AFTER ALLOGENEIC TRANSPLANTATION WITH PERIPHERAL BLOOD STEM CELLS**

**POTENTIAL INFLUENCE OF IMMUNODEFICIENCY-RELATED HEREDITARY PREDISPOSITION GENE VARIANTS ON RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**COMPARABLE RESULTS OF PREEMPTIVE RECOMBINANT IL-2 AND DONOR LYMPHOCYTE INFUSION IN HEMATOLOGICAL MALIGNANCY PATIENTS WITH LATE-ONSET MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**SURVIVAL ANALYSIS ACCORDING TO MINIMAL RESIDUAL DISEASE BY FLOW CYTOMETRY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA**

**IMPACT OF RESIDUAL CIRCULATING TUMOR DNA STATUS POST ALLOGENEIC SCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: INTERIM RESULTS OF A PROSPECTIVE STUDY**

**EARLY CD4+ T CELL RECONSTRUCTION AS PREDICTOR FOR OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS: A VALIDATION COHORT ANALYSIS**

**PATTERN OF RECONSTITUTION OF RECENT THYMIC EMIGRANTS AFTER REDUCED INTENSITY CONDITIONING BASED ON TARGETED BUSULFAN IN PAEDIATRIC RECIPIENTS OF ALLOGENEIC HAEMATOPOETIC STEM CELL TRANSPLANTATION**

## Scientific Programme

**A RISK SCORE SYSTEM BASED ON POST-TRANSPLANTATION MINIMAL RESIDUAL DISEASE FOR STRATIFICATION OF RELAPSE IN B-ALL PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**OUTCOME OF CHILDREN WITH HEMATOLOGICAL MALIGNANCIES WHO DEVELOP MIXED DONOR CHIMERISM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROPHYLACTIC HIGH-DOSE DONOR CD45RO+ MEMORY T-CELLS INFUSION AFTER ALLOGENEIC TRANSPLANTATION: SAFETY AND OUTCOME**

**MULTICOLOR FLOW CYTOMETRY PANEL WITH CCD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT**

**NON-INVASIVE MONITORING OF MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE BY CIRCULATING CELL-FREE NUCLEIC ACIDS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**TORQUE TENO VIRUS AS BIOMARKER TO PREDICT COMPLICATIONS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PREEMPTIVE INTERFERON- $\alpha$  TREATMENT COULD PROTECT AGAINST RELAPSE AND IMPROVE SURVIVAL OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THE ADDITION OF BUSULFAN REDUCES THE INCIDENCE OF MIXED CHIMERISM FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA**

**A NEW MULTIVARIATE MODEL TO DESCRIBE IMPACT OF IMMUNE RECONSTITUTION ON THE DEVELOPMENT OF RELAPSE IN CHILDREN UNDERGOING ALLO-HSCT FOR HEMATOLOGIC MALIGNANCIES AT DAY +100**

**ACQUISITION OF COMPLETE CHIMERISM IN BONE MARROW, PERIPHERAL BLOOD AND LEUKOCYTE SUBSETS DEPENDS ON THE TRANSPLANT SETTING AND CORRELATES WITH THE CLINICAL OUTCOME**

**EARLY LYMPHOID SUBSETS RECONSTITUTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AS PREDICTOR OF RELAPSE AND SURVIVAL IN ACUTE LEUKEMIAS**

**COMPARISON OF IMMUNE RECONSTITUTION BETWEEN 30MG/KG AND 60MG/KG ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANSPLANTATION**

**FUNCTIONAL IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COMPARISON OF PRE- AND POST-TRANSPLANTATION CYTOKINE RESPONSES IN STIMULATED WHOLE-BLOOD**

**MEASURABLE RESIDUAL DISEASE (MRD) TESTING FOR ACUTE LEUKEMIA IN EBMT TRANSPLANT CENTERS: A SURVEY ON BEHALF OF THE ALWP OF THE EBMT**

**TBF REGIMEN INDUCES FULL DONOR CHIMERISM AFTER ALLOGRAFTS IN MYELOFIBROSIS**

**REAL WORLD UTILITY OF TREATING MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA**

**COMPARISON OF IMMUNE RECOVERY IN CORD BLOOD AND T AND B DEPLETED HAPLOIDENTICAL GRAFTS RECIPIENTS**

**THE BCR-ABL P210 CHIMERIC TRANSCRIPT IN VITRO TRANSFER INTO BONE MARROW MESENCHYMAL STROMAL CELLS VIA EXOSOMES**

## Scientific Programme

### **PROGNOSTIC SIGNIFICANCE OF DONOR-SPECIFIC ISOAGGLUTININ RE-APPEARANCE IN ABO-MISMATCHED STEM CELL TRANSPLANT RECIPIENTS**

Maryam Pourabdollah, Christine Cserti, Dennis Dong Hwan Kim, Eshetu Atenafu, Ivan Pasic, Zeyad Al-Shaibani, Aijun Law, Wilson Lam, Armin Gerbitz, Jeffery Lipton, Auro Viswabandya, Rajat Kumar, Jonas Mattson, Fotios Michelis, Nayana Sondi, Jacob Pendergrast (Canada)

### **IMMUNE-RECONSTITUTION OF LYMPHOCYTE SUBPOPULATIONS WITH RESPECT TO MSC-TREATMENT FOR STEROID REFRACTORY GVHD FOLLOWING HSCT**

### **DAY+100 FULL DONOR CHIMERISM IN THE BONE MARROW CONFERS BETTER OVERALL SURVIVAL IN REDUCED INTENSITY CONDITIONED WITH ALEMTUZUMAB ALLOGENEIC STEM CELL TRANSPLANTATION FOR LYMPHOMAS**

### **DONOR FACTORS INFLUENCE OUTCOMES OF PATIENTS RECEIVING DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION**

### **DETERMINE PATIENTS AT RISK OF RELAPSE AND DEATH IN ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME USING CHIMERISM ON BONE MARROW SAMPLES AT DAY 28 AFTER HSCT**

### **CONCURRENT- SYNERGISTIC ASSESSMENT OF TWO TECHNIQUES IN MONITORING MINIMAL RESIDUAL DISEASE FOR PH(-) ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANTATION LEADS TO FAVORABLE CLINICAL OUTCOMES**

### **DONOR CHIMERISM EVALUATION OF MRD-SUSPECTED CELLS ISOLATED BY FLOW CELL SORTING IS AN ACCESSIBLE TOOL FOR MRD VERIFICATION IN PATIENTS AFTER ALLOGENEIC HSCT**

### **ONE-STEP CHECK PURITY OF CD3+ SORTED CELLS ALONG MONITORING HEMATOPOIETIC CHIMERISM AFTER HSCT**

### **DONOR LYMPHOCYTE INFUSIONS AUGMENT GRAFT VERSUS MALIGNANCY EFFECT FOLLOWING ALEMTUZUMAB-BASED REDUCED INTENSITY ALLOGRAFTS: REFLECTIONS ON A SINGLE CENTRE STUDY**

### **MYELOID-DERIVED SUPPRESSOR CELLS RECOVER QUICKLY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS**

### **PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY**

e-Posters  
09:30 - 19:00

ePoster Area

## **New drug- and cell-based immune therapies**

### **NIVOLUMAB INCREASES ANTIGEN SPECIFIC IMMUNE RESPONSES AGAINST LEUKEMIC PROGENITOR AND STEM CELLS (LSC/LPC)**

### **PROPHYLACTIC OR PREEMPTIVE LOW-DOSE AZACITIDINE AND DONOR LYMPHOCYTE INFUSION TO PREVENT DISEASE RELAPSE FOLLOWING ALLOGENEIC TRANSPLANTATION IN 60 PATIENTS WITH HIGH RISK AML OR MDS**

### **ELTROMBOPAG FOR THE TREATMENT OF POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTS: A MULTICENTER SURVEY UPDATE**

### **DONOR NK CELLS INFUSION AS A STRATEGY OF IMMUNOTHERAPY TO PREVENT HHV6 REACTIVATION IN PEDIATRIC PATIENTS AFTER CD45RA-DEPLETED TRANSPLANTATION**

## Scientific Programme

**DEVELOPMENT OF CELL VACCINE BASED ON AUTOLOGOUS DENDRITIC CELLS LOADED WITH LIPID NANOPARTICLES CONTAINING CMV PP65 MESSENGER RNA**

**SMAC MIMETICS (SM) AND NATURAL KILLER (NK) CELLS - A PROMISING COMBINATION TO OVERCOME CELL DEATH RESISTANCE OF RHABDOMYOSARCOMA (RMS) CELLS**

**'KIT'-MEDIATED BLASTMODULATION TO LEUKEMIA-DERIVED DC SIGNIFICANTLY IMPROVES ANTILEUKEMIC ACTIVITIES IN WHOLE BLOOD INDEPENDENT OF AML-PATIENTS' SUBTYPES**

**ROLE OF EXOSOMES AS PROMOTORS OR BIOMARKERS TO STUDY ACTIVATION OF LEUKEMIA-DERIVED DENDRITIC CELLS (DCLEU)-MEDIATED ANTILEUKEMIC ACTIVATION OF ADAPTIVE AND INNATE IMMUNE-REACTIVE CELLS AGAINST AML-BLASTS**

**HIGHER INCIDENCE OF SEVERE AUTOIMMUNE HEMOLYTIC ANEMIA AFTER TCR $\alpha\beta$ + /CD19+ CELL DEPLETED HAPLOIDENTICAL-HSCT AND POSTGRAFT CELLULAR IMMUNOTHERAPIES: CTLA4-IG VERY EFFECTIVE THERAPEUTIC OPTION FOR THIS LIFE-THREATENING DISEASE**

**BLINATUMOMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM A SINGLE CENTER**

**IMMUNOMODULATION OF BLASTS WITH CLINICALLY APPROVED RESPONSE MODIFIERS TO IMPROVE ANTILEUKEMIC T-CELL REACTIVITY IN AML: AN EX VIVO SIMULATION OF THE CLINICAL SITUATION**

**IFNY SECRETION OF ADAPTIVE AND INNATE IMMUNE CELLS AS A PARAMETER TO DISPLAY LEUKAEMIA DERIVED DENDRITIC CELL (DC<SUB>LEU</SUB>) MEDIATED IMMUNE RESPONSES IN AML**

**TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721)**

e-Posters  
09:30 - 19:00

ePoster Area

## Non-haematopoietic stem cells

**THE POTENTIAL ROLES OF MUCOSA-ASSOCIATED INVARIANT T CELLS IN THE PATHOGENESIS OF GUT GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**FACTORS INFLUENCING THE PRESENCE OF BONE MARROW MESENCHYMAL STEM CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**ANALYSIS OF THE GENETIC STABILITY OF DONORS' BONE MARROW STROMA MESENCHYMAL CELLS DURING CULTIVATION**

**EFFECT OF MATERNAL AND NEONATAL FACTORS ON THE YIELD OF WHARTON'S JELLY MESENCHYMAL STEM CELLS**

**THE POLISH EXPERIENCE OF WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF PAEDIATRIC PATIENTS**

**THE POLISH EXPERIENCE OF WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF ADULT PATIENTS**

**A RETROSPECTIVE ANALYSIS OF BONE MARROW EXAMINATION RESULTS FROM A SINGLE CENTER INSTITUTION: CAN WE REDUCE THE OCCURRENCE OF UNNECESSARY BONE MARROW EXAMINATIONS?**

## Scientific Programme

e-Posters  
09:30 - 19:00

ePoster Area

### Non-infectious early complications

**IMPACT OF DONOR-DIRECTED HLA ALLO-ANTIBODIES ON PRIMARY GRAFT FAILURE AFTER UNRELATED DONOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION**

**ELTROMBOPAG TREATMENT AIDED IN PLATELET RECOVERY AND REDUCED PLATELET INFUSION FOR PATIENTS WITH POST-TRANSPLANTATION THROMBOCYTOPENIA**

**IMPACT OF FLUID OVERLOAD (FO) IN POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL DISEASES**

**INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS**

**USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT**

**REDUCED POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSES IN T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**ABO ISOAGGLUTININ LEVELS IN GUIDED MANAGEMENT OF ABO INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**METHYLPREDNISOLONE STRATIFIED INTERVENTION BASED ON RISK CLASSIFICATION IN THE TREATMENT OF PRE-ENGRAFTMENT SYNDROME AFTER UNRELATED CORD BLOOD TRANSPLANTATION: A PROSPECTIVE, NON-RANDOMIZED, AND OPEN-LABEL STUDY**

**PRETRANSPLANT NUTRITION MEASURES AND SYSTEMIC INFLAMMATORY RESPONSE PREDICT OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**A MULTI-CENTRE, MULTI-NATIONAL, PROSPECTIVE OBSERVATIONAL REGISTRY STUDY OF DEFIBROTIDE IN PATIENTS DIAGNOSED WITH SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)**

**DEFIBROTIDE TREATMENT FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES BY SEVERITY AND MULTI-ORGAN FAILURE STATUS IN AN OBSERVATIONAL REGISTRY STUDY**

**INTRODUCTION OF NEW PEDIATRIC EBMT CRITERIA FOR VOD <b>Diagnosis: </b> IS IT LIFE- SAVING OR MONEY-WASTING?**

**PROSPECTIVE PILOT STUDY ON FRAILTY AND FUNCTION ASSESSMENT DURING CLINICS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**HISTOLOGIC FEATURES OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY WITH AND WITHOUT CONCOMITANT ACUTE GRAFT- VERSUS-HOST DISEASE**

**HIGH SURVIVAL RATE OF PEDIATRIC PATIENTS WITH PRIMARY GRAFT FAILURE WHO UNDERGO A SECOND PROCEDURE. THE EXPERIENCE OF 3 SPANISH PEDIATRIC TRANSPLANT UNITS**

**CHEMOTHERAPY-INDUCED GUT MUCOSAL INJURY INITIATES MICROBIAL DISRUPTION IN STEM CELL TRANSPLANT RECIPIENTS**

## Scientific Programme

**BACTERIAL AND METABOLIC PROFILING OF THE SALIVA IDENTIFIES UNIQUE PATTERNS OF MICROBIOTA INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT WITH SEVERE ORAL MUCOSITIS**

**DIAGNOSIS AND MANAGEMENT OF SECONDARY HLH/MAS FOLLOWING HSCT AND CAR-T CELL THERAPY IN ADULTS: AN EBMT-WIDE SURVEY ON BEHALF OF THE ADWP AND TCWP**

**IMPACT OF ABO INCOMPATIBILITY ON COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION- RETROSPECTIVE, INTERNATIONAL, MULTICENTER ANALYSIS BY THE TRANSPLANT COMPLICATIONS WORKING PARTY EBMT**

**HYPOALBUMINEMIA PRIOR ALLOHCT IS A RELEVANT NEGATIVE PREDICTOR FOR SURVIVAL**

**INCIDENCE AND CLINICAL IMPACT OF ATRIAL FIBRILLATION DIAGNOSED DURING HOSPITAL STAY FOR ALLOGENEIC STEM CELL TRANSPLANTATION**

**TRANSPLANTATION-ASSOCIATED MICROANGIOPATHY (TAM) IN RECIPIENTS OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS USING PTCY FOR GVHD PROPHYLAXIS: INCIDENCE AND OUTCOME**

**IGF-1 AND IGFBP-3 GENE POLYMORPHISMS PREDICT CIRCULATING IGF LEVELS AND SYSTEMIC INFLAMMATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**LOW RISK OF EARLY TOXICITY AND UNPLANNED 100-DAY READMISSIONS AFTER MATCHED AND MISMATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

**KERATINOCYTE GROWTH FACTOR DECREASES HOSPITAL READMISSION AND REGIMEN-RELATED TOXICITIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA**

**ELTROMBOPAG FOR TREATING THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

**SYSTEMIC CORTICOSTEROID THERAPY IS UNLIKELY TO BE THE PRIMARY CAUSE OF HYPERGLYCEMIA FOLLOWING TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE**

**COST-EFFECTIVENESS ANALYSIS OF DEFIBROTIDE FOR THE TREATMENT OF SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME IN SPAIN**

**NEUROLOGIC COMPLICATIONS IN 169 CONSECUTIVE ALLOGENEIC STEM CELL TRANSPLANTS: ETIOLOGY, CLINICAL SYNDROMES AND OUTCOME**

**VENETOCLAX, HYPOMETHYLATING AGENTS AND DLI FOR SALVAGE TREATMENT OF MYELOID MALIGNANCIES RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EVALUATION OF TGF-BETA LEVEL AFTER SUPPLEMENTATION WITH WHEY PROTEIN CONCENTRATE FOR ORAL MUCOSITIS PROPHYLAXIS**

**TREOSULFAN-INDUCED MYALGIA IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**VALIDATION OF EARLY INCREASE OF SC5B-9 AS A PREDICTIVE MARKER FOR LATER TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY**

**DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**EARLY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION IMPROVES OUTCOME OF VERY SEVERE HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER UNMANIPULATED HAPLOIDENTICAL HSCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

## Scientific Programme

**DOES THE TYPE OF NUTRITIONAL SUPPORT AFFECT THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION? A PEDIATRIC CENTER EXPERIENCE**

**NEUROLOGICAL COMPLICATIONS IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY**

**ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO THE INTENSIVE CARE UNIT - REAPPRAISAL OF PROGNOSIS AND PROGNOSTIC FACTORS: A SINGLE CENTER STUDY**

**ENTERAL VERSUS PARENTERAL NUTRITION IN ADULT HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS SUFFERING FROM GASTROINTESTINAL MUCOSITIS**

**DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS**

**THE USEFULNESS OF LIVER STIFFNESS MEASUREMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT SINUSOIDAL OBSTRUCTION SYNDROME**

**ENDOTHELIAL CELL COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION, A SINGLE CENTRE ANALYSIS ON 99 CONSECUTIVE PATIENTS UNDERGOING ALLO-SCT**

Giorgia Mancini, Matteo Candelora, Giuseppina Urbano, Francesco Saraceni, Monica Poiani, Marianna Mariani, Irene Federici, Giuseppe Tarantino, Ilaria Scortechini, Attilio Olivieri (Italy)

**INFLUENCE OF ABO-INCOMPATIBILITY ON THE OUTCOME OF STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY ON CHILDREN AND YOUNG ADULTS**

**EASIX IS USEFUL FOR PREDICTING THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS**

**SECOND TRANSPLANTATION USING A NOVEL CONDITIONING REGIMEN WITH DIFFERENT DONOR FOR GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**A SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME**

**VENO-OCCLUSIVE DISEASE: ONLINE, INTERPROFESSIONAL, CASE-BASED EDUCATION SIGNIFICANTLY IMPROVES KNOWLEDGE AND SKILLS OF THE ENTIRE CARE TEAM**

**HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME**

**EASIX AS A PREDICTIVE BIOMARKER OF COMPLICATIONS AND OUTCOME IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**SURVIVAL WITH NORMAL PULMONARY FUNCTION IS POSSIBLE DESPITE SIGNIFICANT AND PROLONGED RESPIRATORY SUPPORT, INCLUDING PROLONGED HIGH FREQUENCY OSCILLATORY VENTILATION (HFOV) IN CHILDREN**

**USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION**

**CURRENT PRACTICE IN NUTRITION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AUSTRIA, GERMANY AND SWITZERLAND**

**INCIDENCE AND SEVERITY OF CYTOKINE RELEASE SYNDROME FOLLOWING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL INFUSION**

**ENGRAFTMENT SYNDROME FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY FROM A SINGLE CENTER**

## Scientific Programme

**WERNICKE'S ENCEPHALOPATHY IN A CHILD WITH B LYMPHOBLASTIC LYMPHOMA AFTER HAPLO-HSCT**

**ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE**

**IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN TERMS OF SINUSOIDAL OBSTRUCTION SYNDROME (SOS)**

**ISCHEMIC STROKE IN CHILDREN AND YOUNG ADULTS WITH MALIGNANT HEMATOLOGICAL AND ONCOLOGICAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**MELPHALAN DOSE ADJUSTMENT AND CRYOTHERAPY REDUCE ORAL MUCOSITIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CLINICAL FEATURES AND RISK FACTORS OF ENGRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**REAL-LIFE EXPERIENCE OF TWO ITALIAN HEMATOLOGY CENTRES ON EFFICACY AND SAFETY OF ORAL NEPA (NETUPITANT/PALONOSETRON) IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EARLY TREATMENT WITH DARATUMUMAB FOR REFRACTORY POST-ALLOGENEIC STEM CELL TRANSPLANT PURE RED CELL APLASIA**

**PROGNOSTIC FACTORS FOR EARLY MORTALITY OF HEMATOLOGICAL PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT: PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTER STUDY**

**ACUTE KIDNEY INJURY DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS: INCIDENCE AND RISK FACTORS**

**T-PA/UROKINASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA**

**HEMOPHAGOCYTIC SYNDROME AFTER EX-VIVO LYMPHODEPLETED HEMATOPOIETIC TRANSPLANTATION**

**IMMUNOADSORPTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MAJOR ABO INCOMPATIBILITY**

**IMMUNE-MEDIATED FEVER AFTER T-CELL REplete HAPLOIDENTICAL HSCT USING PERIPHERAL BLOOD STEM CELL GRAFTS AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

e-Posters  
09:30 - 19:00

ePoster Area

## Paediatric issues

**PROSPECTIVE OPEN-LABEL PHASE II TRIAL OF INDIVIDUALIZED ANTI-THYMOCYTE GLOBULIN SHOWS IMPROVED EARLY CD4+ T-CELL RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE PARACHUTE-TRIAL**

**EBMT LESSONS FROM 40 YEARS OF HIGH DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN NEUROBLASTOMA: A REPORT FROM THE PAEDIATRIC WORKING PARTY**

Ruth Ladenstein, Ulrike Poetschger, Penelope Brock, Roberto Luksch, Victoria Castel, Shifra Ash, Vassilios Papadakis, Geneviève Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz de Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Evgenia Glogova, Dominique Valteau-Couanet, Selim Corbacioglu (Austria)

## Scientific Programme

**INCIDENCE OF SECONDARY MALIGNANCIES AFTER TBI/VP16 CONDITIONING FOR CHILDHOOD ALL: RESULTS OF THE PROSPECTIVE ALL-SCT-BFM-2003 TRIAL**

**OUTCOME AND RISK FACTORS OF AUTOIMMUNE CYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY**

**EBMT SURVEY ON 40 YEARS OF HIGH-DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN EWING TUMOURS (ET). A REPORT FROM THE PAEDIATRIC WORKING PARTY**

Ruth Ladenstein, Evgenia Glogova, Christelle Dufour, Edoardo Lanino, Jean Michon, Paul Veys, Roberto Luksch, Uta Dirksen, Krzysztof Kalwak, Stefan Burdach, Henk van den Berg, Boris Afanasyev, Franco Locatelli, Emmanuelle Nicolas-Virelizier, Shifra Ash, Nathalie Gaspar, Jeremy Whelan, Philippe Brault, Ulrike Poetschger, Selim Corbacioglu (Austria)

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN - RETROSPECTIVE REPORT ON BEHALF OF I-BFM SCT COMMITTEE AND EBMT PEDIATRIC DISEASES WP**

**IS THE EBMT RISK SCORE PREDICTIVE OF OUTCOMES IN PAEDIATRIC ACUTE LEUKEMIA?**

**TCR $\alpha\beta$ + / CD19+ - DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION**

**THE GREAT ORMOND STREET (GOS) PAEDIATRIC CO-MORBIDITY SCORE FOR OUTCOME POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**HIGH PREVALENCE OF CAROTID PLAQUES IN YOUNG ADULTS AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD**

**HAPLOIDENTICAL DONOR OR UNRELATED DONOR FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY?**

**A 'RISK-ADJUSTED' CYTOREDUCTION WITHOUT RADIATION FOR PATIENTS WITH FANCONI ANEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT)**

**USE OF RUXOLITINIB IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD)**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN REFRACTORY CYTOPENIA OF CHILDHOOD (RCC): IMPROVED ENGRAFTMENT FOLLOWING A TREOSULFAN BASED CONDITIONING REGIMEN**

**PHARMACOKINETICS OF ACTIVE ATG IMPACTS T-CELL RECOVERY AFTER TCR $\alpha\beta$ /CD19-DEPLETED HSCT IN PAEDIATRIC PATIENTS**

**HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A MULTICENTRE STUDY FROM INDIA**

**IMMUNE RECOVERY AND LONG-TERM SURVIVAL FOLLOWING HAPLOIDENTICAL T AND B CELL DEPLETED STEM CELL TRANSPLANTATION - INFLUENCE OF VARIOUS ATG DOSES**

**OUTCOMES OF HAPLOIDENTICAL VS MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC HIGH-RISK ALL AND AML IN 1ST AND 2ND CR**

**COMBINED TCR ALPHA BETA AND CD45RA DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BENIGN HAEMATOLOGICAL CONDITIONS, SINGLE CENTRE EXPERIENCE**

**GENETIC SUSCEPTIBILITY TO HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC PATIENTS UNDERGOING HSCT**

## Scientific Programme

**HAPLO HSCT WITH IN VIVO T-CELL DEPLETION AFTER REDUCED INTENSITY CONDITIONING REGIMEN AND MYELOABLATIVE MUD AND MMUD DONOR HSCT IN PEDIATRIC PATIENTS AFFECTED BY MALIGNANCIES**

**THINKING BEYOND HLH: CLINICAL FEATURES OF PATIENTS WITH CONCURRENT PRESENTATION OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND THROMBOTIC MICROANGIOPATHY**

**LANDMARK ANALYSIS IN HIGH RISK CHILDHOOD ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE STUDY**

**DEFIBROTIDE IN HEMATOPOIETIC STEM CELL TRANSPLANT: AN STUDY OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH) AND GRUPO ESPAÑOL DE TRASPLANTE DE MEDULA EN NIÑOS (GETMON)**

**NIVOLUMAB-BASED THERAPY PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC HODGKIN'S LYMPHOMA**

**HUMAN LEUKOCYTE ANTIGEN DISPARITIES REDUCE RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA**

**SCHOOL DURING AND AFTER ALLOGENEIC HSCT: A SURVEY OF PRACTICES IN THREE EUROPEAN COUNTRIES**

**HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HURLER SYNDROME: SINGLE CENTER EXPERIENCE**

**HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FANCONI ANAEMIA: EXPERIENCE OF THE SPANISH WORKING GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETMON)**

**IMPACT OF MEMORY T-CELL DOSES INFUSED WITH T-CELL DEPLETED HAPLOIDENTICAL STEM CELL GRAFTS ON TRANSPLANT OUTCOMES**

**THE ROLE OF DONOR KIR GENOTYPING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISORDERS**

**SINGLE-CENTER EXPERIENCE OF TCR $\alpha\beta$ /CD19 DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANEMIA**

**DETECTION OF RECIPIENT-SPECIFIC  $\alpha/\beta$ -T-CELLS DURING THE PRE-ENGRAFTMENT PHASE DOES NOT PREDICT GRAFT REJECTION IN PATIENTS AFTER HAPLOSCT: PRELIMINARY RESULTS OF SINGLE CENTRE PROSPECTIVE TRIAL**

**IMPROVED SURVIVAL AFTER MIBG THERAPY IN COMBINATION WITH MEGACHEMOTHERAPY THAN AFTER STAND-ALONE THERAPY IN CHILDREN WITH NEUROBLASTOMA - POLISH NATION-WIDE RETROSPECTIVE STUDY**

**THE IMPACT OF HOUSEHOLD INCOME ON ACUTE HOSPITALIZATION DAYS IN PEDIATRIC ALLOGENEIC TRANSPLANT RECIPIENTS**

**USE OF RIC REGIMENS COMBINED WITH TCR $\alpha\beta$  DEPLETION AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC MISMATCHED SCT**

**THE ROLE OF HLA-DP MATCHING IN DONOR SELECTION FOR MUD-HSCT IN CHILDREN WITH HEMATOLOGIC MALIGNANT DISEASES**

**CLINICAL IMPLICATION ON RECOVERY OF  $\gamma\delta$  T CELLS AFTER TCR $\alpha\beta$ -DEPLETED HAPLOIDENTICAL HSCT IN PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE**

**EARLY INITIATION OF CYCLOSPORINE-MYCOPHENOLATE PLUS ANTITHYMOCYTE GLOBULIN IN HAPLO TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: LOW INCIDENCE OF SEVERE ACUTE GVHD WITH ENCOURAGING SURVIVAL**

## **Scientific Programme**

**FEASIBILITY AND SAFETY OF SURGICAL FERTILITY PRESERVATION TECHNIQUES PROXIMAL TO INITIATION OF CONDITIONING THERAPY IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT**

**VENO-OCCLUSIVE DISEASE WITH EMPHASIS ON RENAL MANIFESTATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: A SINGLE CENTER EXPERIENCE**

**OUTCOME AFTER HSCT IN CHILDREN WITH JMML FROM A HISTORICAL POINT OF VIEW**

**THE IMPACT RECOVERY ABSOLUTE LYMPHOCYTE COUNT AT DAYS +21 ON OUTCOME ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALL**

**T-CELL-RICH HAPLOIDENTICAL STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN CHILDREN WITH ACUTE LEUKEMIA RELAPSED AFTER ALLOGENEIC TRANSPLANTATION**

**HIGH PREVALENCE OF VITAMIN C DEFICIENCY IN A LARGE PAEDIATRIC COHORT UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE FROM 2003-2019**

**EX VIVO T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE**

**LONG-TERM ERYTHROPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: HOST DETERMINES RESULT**

**BOOST WITH CD34+ CELLS FOR POOR GRAFT FUNCTION TREATMENT AFTER HSCT IN PAEDIATRIC PATIENTS. A MULTICENTER STUDY**

**NO DIFFERENCE IN SURVIVAL AFTER HLA MISMATCHED VERSUS HLA MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION**

**ALLOGENIC STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE**

**STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-ANAPLASTIC PERIPHERAL T-CELL LYMPHOMA ON BEHALF OF THE EBMT-PEDIATRIC DISEASES WORKING PARTY**

**FIRST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RASGRP1 DEFICIENCY**

**SUCCESSFUL HSCT IN IMMUNE DISREGULATORY DISEASES**

**LEVOFLOXACIN BASED PROPHYLAXIS IN CHILDREN RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT AFFECT THE INCIDENCE OF ACUTE GVHD AND BLOODSTREAM INFECTIONS**

**RITUXIMAB-INDUCED SECONDARY HYPOGAMMAGLOBULINEMIA: MEMORIAL SLOAN KETTERING'S 10-YEAR EXPERIENCE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

**'INCURABLE' PAEDIATRIC MYELOID LEUKAEMIA TREATED WITH NOVEL CELL-BASED THERAPEUTICS**

**EFFECT OF SERUM PANEL REACTIVE ANTIBODIES ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE**

**SINGLE CENTRE EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR INHERITED BONE MARROW FAILURE SYNDROMES**

**IS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A GOOD INDICATION FOR PATIENTS WITH SIFD SYNDROME?**

## **Scientific Programme**

**TIME COURSE AND IMPACT OF BODY WEIGHT CHANGE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HIGH RISK EWING SARCOMA, A SINGLE CENTER EXPERIENCE**

**CONDITIONING FOR RETRANSPLANTATION FROM THE SAME DONOR AFTER PARTIAL AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH PID: IMMUNOSUPPRESSION IS NOT REQUIRED**

**TOCILIZUMAB TREATMENT FOR CRS IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**IDIOPATHIC PNEUMONIA SYNDROME (IPS) AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM UNRELATED DONOR FOR HURLER SYNDROME (MUCOPOLYSACCHARIDOSIS TYPE 1) SUCCESSFULLY TREATED WITH ETANERCEPT AND STEROIDS**

**EFFECT OF DESENSITIZATION PROTOCOL ON TRANSPLANTATION SUCCESS IN CHILDREN WITH ANTI-HLA ANTIBODIES**

**OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOHSCT) WITH DIFFERENT INTENSITY CONDITIONING REGIMENS IN INFANT AML**

**VENETOCLAX/DECITABINE FOR PEDIATRIC MDR-AML RELAPSED AFTER TWO ALLO HSCTS**

**HIGHER INCIDENCE OF CMV AND BKV REACTIVATION IN HAPLOIDENTICAL TRANSPLANTS COMPARATIVE TO MUD OR MSD TRANSPLANTS - SINGLE CENTRE RETROSPECTIVE ANALYSIS**

**USE OF POLYCLONAL IGM-ENRICHED IMMUNOGLOBULINS FOR THE TREATMENT OF SEPTIC EPISODES IN CHILDREN WITH ONCOHEMATOLOGICAL DISEASES**

**PAEDIATRIC BONE MARROW TRANSPLANT CARE ON BMT VERSUS NON-BMT PAEDIATRIC WARDS**

**CHRONIC HEALTH PROBLEMS IN CHILDREN AFTER ALLOGENEIC HSCT: THE TOP OF THE ICEBERG?**

**HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE-CENTER SERIES OF 14 CASES**

**NON-WHITE HISPANIC ETHNICITY AS A RISK FACTOR FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC TRANSPLANT**

**THE CHALLENGES AND OUTCOMES SURROUNDING INTRAVESICULAR CIDOFOVIR ADMINISTRATION: A PAEDIATRIC PHARMACY PERSPECTIVE**

**THE EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RARE HEMATOLOGIC DISEASE**

**SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH DNA LIGASE IV DEFICIENCY WITH NONMYELOABLATIVE CONDITIONING REGIMEN**

**PNEUMATOSIS INTESTINALIS AS A RARE POST-TRANSPLANT COMPLICATION IN PEDIATRIC PATIENTS**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT-HD-CYCLOPHOSPHAMIDE FOR RELAPSED B-LYMPHOBLASTIC LYMPHOMA (B-LBL) WITH MLL-REARRANGEMENT IN 1 Y.O. CHILD: A CLINICAL CASE**

## Scientific Programme

e-Posters  
09:30 - 19:00

ePoster Area

### Regenerative medicine

**WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL THERAPY IMPROVES THE QUALITY OF LIFE AND SELF-SUFFICIENCY OF CHILDREN WITH AUTISM SPECTRUM DISORDER**

**MARROW DERIVED CELLS BRING A LONG LASTING RELIEF WHEN INJECTED INTRAARTICULARLY TO THE JOINTS WITH DEGENERATIVE ARTHRITIS**

**OSTEOGENIC DIFFERENTIATION CAPACITY OF ADIPOSE-DERIVED STEM CELLS AFFECTED WITH COLD STORAGE**

e-Posters  
09:30 - 19:00

ePoster Area

### Statistics

**USE OF VARIABLE SELECTION METHODS TO IDENTIFY CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THE CLINICAL OUTCOME OF PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**THE IMPACT OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON WORK AND PRODUCTIVITY LOSS IN PATIENTS WITH ACUTE LEUKAEMIA: RESULTS FROM A RAPID REVIEW**

**GEOGRAPHIC AND SOCIOECONOMIC IMPACTS ON SURVIVAL AMONG ALLOGENEIC TRANSPLANT RECIPIENTS**

e-Posters  
09:30 - 19:00

ePoster Area

### Stem cell mobilization, collection and engineering

**TWO YEAR ANALYSIS OF A PROSPECTIVE PHASE I/II CLINICAL TRIAL IN ADULTS USING TCR ALPHA/BETA DEPLETED STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONORS**

**A NEW BSA-BASED THRESHOLD PREDICTS OPTIMAL PBSC COLLECTION IN T-CELL DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

**PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILIZATION AND COLLECTION OF CD34+ HSCS WITHOUT G-CSF**

**DEPLETION OF  $\alpha\beta$  T-CELLS AND B-CELLS BEFORE HLA-HAPLOIDENTICAL HSCT IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT OF 473 PROCEDURES**

**ACOUSTOPHORESIS ENABLES THE LABEL-FREE SEPARATION OF DISTINCT SUBSETS FROM CULTURED BONE MARROW STROMAL CELLS**

**FEASIBILITY OF MODIFIED CD45RA NEGATIVE DONOR LYMPHOCYTES INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**BEYOND STEM CELLS - DOES IT MATTER WHAT'S IN THE BAG IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA AND LYMPHOMA?**

## Scientific Programme

**EXPRESSIONS OF CO-INHIBITORY MARKERS INCREASE EFFECTOR MEMORY T CELLS IN G-CSF MOBILIZED PERIPHERAL STEM CELLS**

**LIPEGFILGRASTIM COMBINED WITH CHEMOTHERAPY WAS MORE COST-EFFECTIVE THAN PEGFILGRASTIM IN THE MOBILIZATION OF CD34+ CELLS IN NHL PATIENTS**

**MOBILIZATION AND HARVEST OF PERIPHERAL BLOOD STEM CELLS (PBSC) FOR ALLOGENEIC STEM CELL TRANSPLANTATION FROM 335 PEDIATRIC SIBLING HEALTHY DONORS**

**A COMPARISON OF CHEMO-FREE STRATEGY WITH G-CSF PLUS PLERIXAFOR ON DEMAND VERSUS ID-CYCLOPHOSPHAMIDE AND G-CSF AS PBSC MOBILIZATION IN MULTIPLE MYELOMA: AN EXPLORATIVE COST ANALYSIS**

**EVALUATION OF VIA FREEZETM QUAD FOR LIQUID NITROGEN-FREE CGMP-COMPATIBLE CONTROLLED-RATE FREEZING OF HEMATOPOIETIC PROGENITOR CELL GRAFTS**

**CD34 + CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS**

**PLERIXAFOR ON DEMAND IN COMBINATION WITH LOW-DOSE CYCLOPHOSPHAMIDE AND G-CSF FOR THE MOBILIZATION OF HSC IN MULTIPLE MYELOMA PATIENTS: HIGH EFFICACY AND LOW TOXICITY**

**PERFORMANCE QUALIFICATION OF LOVOTM MEDICAL DEVICE FOR WASHING AND CONCENTRATING 3 AND MORE HEMATOPOIETIC PROGENITOR CELL CRYOPRESERVED BAGS**

**FROM WORK-UP REQUEST TO DONATION IN THREE WEEKS: A DEDICATED REGISTRY INTEGRATED UNRELATED DONOR STEM CELL COLLECTION CENTER IS SAFE, EFFICIENT AND CONVENIENT FOR DONORS**

**LOW-DOSE CYCLOPHOSPHAMIDE + G-CSF IS NO MORE EFFECTIVE THAN G-CSF ALONE WHEN MOBILIZING AND COLLECTING STEM CELLS FOR AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS**

**FIRST INTERIM RESULTS OF NIS OPTIMOB - NATIONWIDE TRIAL OF MOBILIZATION AND COLLECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS**

**THE IMPACT OF PLERIXAFOR 'ON DEMAND' ON THE HEMATOPOIETIC STEM CELL (HSC) COLLECTION, PRODUCT'S QUALITY AND ENGRAFTMENT**

**ELEVATED SERUM LACTATE DEHYDROGENASE AFTER STEM CELL MOBILISATION PREDICTS SUCCESSFUL STEM CELL COLLECTION IN CHILDREN**

**INFLUENCE OF THE DMSO WASH STRATEGY ON ADVERSE REACTIONS DURING INFUSION OF HEMATOPOIETIC PROGENITORS**

**BONE MARROW DONOR CHARACTERISTICS: INFLUENCE ON HARVEST YIELD AND DONOR RECOVERY**

**PLERIXAFOR SALVAGES AUTOLOGOUS STEM CELL MOBILISATION PROCEDURES IN MYELOMA PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE OR AUTOLOGOUS HSCT: COST-EFFECTIVENESS OF UPFRONT USE SHOULD BE EXPLORED**

**EFFECT OF SHIPPING TIME AND TRANSPORT CONDITIONS ON THE VIABILITY OF CORD BLOOD LEUKOCYTES**

**OPTIMIZATION OF A STEM CELL MOBILIZATION STRATEGY FOR PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA**

**AUTOLOGOUS LYMPHAPHERESIS FOR THE PRODUCTION OF CAR-T CELLS**

## Scientific Programme

**RED BLOOD CELL DEPLETION AND/OR VOLUME REDUCTION IN BONE MARROW PROCESSING: A COMPARISON OF TWO METHODS**

**CORRELATION OF INTRA-OPERATIVE TOTAL NUCLEATED COUNT AND DONOR CHARACTERISTICS WITH FINAL ALLOGENEIC BONE MARROW GRAFT CHARACTERISTICS AND RECIPIENT CLINICAL OUTCOMES**

**MULTICENTRE EVALUATION OF THE HPC MODUS (XN-20) FOR TIMING THE HARVEST OF STEM CELLS FROM PERIPHERAL BLOOD**

**IMPACT OF CHANGE OF MOBILISATION METHOD ON ADEQUACY OF STEM CELL COLLECTION IN MULTIPLE MYELOMA PATIENTS: SINGLE CENTRE EXPERIENCE**

**TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE**

**AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS (PBSCS) MOBILIZATION AND COLLECTION- PRINCESS NOORAH ONCOLOGY CENTER EXPERIENCE, KAMC - JEDDAH - SAUDI ARABIA**

**REVIEW OF PLERIXAFOR USE IN A TERTIARY PAEDIATRIC ONCOLOGY CENTRE**

**UNUSUAL HIGH COUNT OF CD34+ AFTER CHEMO MOBILIZATION WITH MATRIX IN PATIENT WITH PRIMARY CNS LYMPHOMA IS ASSOCIATED WITH PROMPT AND ROBUST ENGRAFTMENT**

**LEUKOCYTAPHERESIS - ONE TECHNIQUE, DIVERSE OPPORTUNITIES IN THE THERAPY OF PATIENTS**

**COMPARISON OF CONTINUOUS MONONUCLEAR CELL COLLECTION (CMNC) AND MONONUCLEAR CELL CELL (MNC) METHODS FOR CELL PROLIFERATION (APHERESIS) IN PATIENTS WITH BONE MARROW TRANSPLANTATION**

Educational  
11:00 - 12:00

Auditorium 1

### **E6, Allogeneic transplantation from family donors**

#### **Chairs:**

Marie Robin (France)  
Antònia Sampol (Spain)

<b>Chinese experience on matched siblings vs. haploidentical</b> Xiaojun Huang (China)	<b>11:00 - 11:15</b>
<b>Matched siblings vs. haploidentical in AML</b> Arnon Nagler (Israel)	<b>11:15 - 11:30</b>
<b>Matched siblings vs. haploidentical in lymphoma</b> Didier Blaise (France)	<b>11:30 - 11:45</b>
<b>Q&amp;A</b>	<b>11:45 - 12:00</b>

## Scientific Programme

How do I ... ?  
11:00 - 12:00

Auditorium 2

### **HDI2, How Do I... manufacture T-cells for cellular therapies - Supported through an unrestricted educational grant by Miltenyi Biotec**

**Chairs:**

João Lacerda (Portugal)

<b>Home-brew CAR T-Cells</b>	<b>11:00 - 11:15</b>
Michael Schmitt (Germany)	
<b>Generating antiviral T-cells for clinical application</b>	<b>11:15 - 11:30</b>
Britta Eiz-Vesper (Germany)	
<b>Generation of T regulatory cells</b>	<b>11:30 - 11:45</b>
Mauro Di Ianni (Italy)	
<b>Q&amp;A</b>	<b>11:45 - 12:00</b>

Nurses Group  
11:00 - 12:00

Auditorium 3

### **NG05, Care of the caregivers**

**Chairs:**

Janet Baker (United Kingdom)

<b>Empowering the caregivers: Social worker</b>	<b>11:00 - 11:25</b>
Rebecca Parker (United Kingdom)	
<b>Implementation of a tool to support parents of your patients</b>	<b>11:25 - 11:50</b>
Marijke Quaghebeur (Belgium)	
<b>Q&amp;A</b>	<b>11:50 - 12:00</b>

Cell therapy  
11:00 - 12:00

Auditorium 4

### **CTD2, Cell Therapy Day: Conditions for implementation of innovative haematopoietic cellular therapies**

**Chairs:**

Jürgen Kuball (Netherlands)  
Éliane Gluckman (France)

<b>Law and ethics beyond gene editing</b>	<b>11:00 - 11:20</b>
Aurélié Mahalatchimy (France)	
<b>Integration of care and research leading to individualized treatment</b>	<b>11:20 - 11:40</b>
Cornelis Punt (Netherlands)	
<b>Q&amp;A</b>	<b>11:40 - 12:00</b>

## Scientific Programme

Transplant Coordinator Day  
11:00 - 12:00

Auditorium 5

### **TCD2, EBMT-WMDA Transplant Coordinators Day: Lessons learnt from COVID-19 - Transport: Crossing borders in Corona pandemic**

#### **Chairs:**

Irina Evseeva (United Kingdom)

<b>Ensuring continuity of care - Transport of stem cells between EU Member States</b>	<b>11:00 - 11:15</b>
Fabian Bosbach (Germany)	
<b>Ensuring continuity of care - Transport of stem cells between continents</b>	<b>11:15 - 11:30</b>
Ray Hornung (United States)	
<b>What has changed at the transplant centre side?</b>	<b>11:30 - 11:45</b>
Effie Petersdorf (United States)	
<b>Text chat Q&amp;A</b>	<b>11:45 - 12:00</b>

How do I ... ?  
11:00 - 12:15

Auditorium 6

### **HDI3, How Do I... reduce therapeutic toxicity in GVHD therapy - Supported through an unrestricted educational grant by Mallinckrodt**

#### **Chairs:**

Daniel Wolff (Germany)

<b>Strategies to avoid CNI as GVHD prophylaxis</b>	<b>11:00 - 11:25</b>
Olaf Penack (Germany)	
<b>Cell based option to treat GVHD</b>	<b>11:25 - 12:05</b>
Hildegard Greinix (Austria)	
<b>Q&amp;A</b>	<b>12:05 - 12:15</b>

Social Events  
12:15 - 12:48

Auditorium 1

### **Health with Every Bite - Nutrition and healing**

CME Symposium  
13:00 - 14:00

Auditorium 2

### **IS22, Gene Therapy for $\beta$ -Thalassemia: The future is now - CME Symposium**

#### **Chairs:**

Evangelia Yannaki (Greece)

<b>Test your knowledge</b>	<b>13:00 - 13:10</b>
Evangelia Yannaki (Greece)	

## Scientific Programme

<b>Gene Therapy strategies: Past, present, future</b> Christof von Kalle (Germany)	<b>13:10 - 13:20</b>
<b>Gene Therapy in <math>\beta</math>-Thalassemia: The clinical data</b> Franco Locatelli (Italy)	<b>13:20 - 13:35</b>
<b>The nuts and bolts of implementing Gene Therapy: Patient-case studies</b> Evangelia Yannaki (Greece) Franco Locatelli (Italy)	<b>13:35 - 13:50</b>
<b>Audience Q&amp;A</b>	<b>13:50 - 14:00</b>

Industry Symposium  
13:00 - 14:00

Auditorium 3

### IS23, Nurse Symposium: Therakos ECP Immunomodulation - How and why - Therakos Industry Symposium

#### Chairs:

John Murray (United Kingdom)

<b>Welcome and introduction</b> John Murray (United Kingdom)	<b>13:00 - 13:05</b>
<b>The role of nurses in delivering ECP - Special patient conditions</b> Britt Storm Tråsdahl (Denmark)	<b>13:05 - 13:20</b>
<b>ECP: evaluation of cell collection efficiency</b> Nina Worel (Austria)	<b>13:20 - 13:40</b>
<b>My GVHD and ECP journey - A patient story</b> Wilfred Emmanuel-Jones (United Kingdom)	<b>13:40 - 13:55</b>
<b>Q&amp;A</b>	<b>13:55 - 14:00</b>

Statistics  
13:00 - 14:00

Auditorium 5

### Stat1, Statistics symposium

#### Chairs:

Hein Putter (Netherlands)

<b>Methods for missing data in competing risks</b> <u>É. F. Bonneville</u> , M Resche-Rigon, L. C. de Wreede, H. Putter (Netherlands)	<b>13:00 - 13:20</b>
<b>Bayesian methods for early detection of treatment effects in phase 3 trials with survival endpoints</b> Lucie Biard (France)	<b>13:20 - 13:40</b>
<b>Text chat Q&amp;A</b>	<b>13:40 - 14:00</b>

## Scientific Programme

Industry Symposium  
13:00 - 14:00

Meet the Expert Rooms

### IS24, Celgene Industry Meet the Expert Lunch - Room MTE1

Pre-registration required via the general registration form (free of charge). <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>  
If you have already registered, you can modify your bookings on the official registration form: <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>

**Management of cellular therapies in RRMM**  
Paula Rodríguez Otero (Spain)

**13:00 - 14:00**

Industry Symposium  
13:00 - 14:00

Meet the Expert Rooms

### IS25, Takeda Industry Meet the Expert Lunch - Room MTE2

Pre-registration required via the general registration form (free of charge). <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>  
If you have already registered, you can modify your bookings on the official registration form: <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>

**Treatment paradigm in higher-risk MDS**  
Guillermo Sanz Santillana (Spain)

**13:00 - 14:00**

Industry Symposium  
13:00 - 14:00

Meet the Expert Rooms

### IS26, MSD Industry Meet the Expert Lunch 1 - Room MTE3

Pre-registration required via the general registration form (free of charge). <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>  
If you have already registered, you can modify your bookings on the official registration form: <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>

**Roundtable Discussion: CMV Management**  
Roy Chemaly (United States)

**13:00 - 14:00**

General  
14:30 - 16:00

Auditorium 1

### GS2, Presidential Symposium

**Van Bakkum Award - Introduction**  
Nicolaus Kröger (Germany)

**14:30 - 14:33**

## Scientific Programme

<b>RESULTS OF THE EBMT SAAWP PHASE III PROSPECTIVE RANDOMIZED MULTICENTER RACE STUDY OF HORSE ATG AND CICLOSPORIN WITH OR WITHOUT ELTROMBOPAG IN NAÏVE SAA PATIENTS</b>	<b>14:33 - 14:50</b>
<u>Régis Peffault de Latour</u> , Judith Marsh, Simona Iacobelli, Sofie Terwel, Anita Hill, Constantijn J.M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Juan Carlos Vallejo Llamas, Beatrice Dresler, Jean Baptiste Mear, Maria Teresa Van Lint, Reinier A.P. Raymakers, Marco R De Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H Russell, Louis Terriou, Anna Paola Iori, Isabel Sánchez- Ortega, Blanca Xicoy, Isidro Jarque, James Cavenagh, Flore Sicre de Fontbrune, Austin Kulasekararaj, Serena Marotta, Talha Munir, Jennifer M.L. Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Alexander E Smith, Riley Cook, Luana Marano, Morag Griffin, Elena Palmisani, Petra Muus, Fabiana Cacace, Jakob R. Passweg, Gerard Socie, Ghulam J. Mufti, Carlo Dufour, Antonio Risitano (France)	
<b>Basic Science Award - Introduction</b>	<b>14:50 - 14:53</b>
Rafael Duarte (Spain)	
<b>JUN ACTIVATION IN DERMAL FIBROBLASTS PROMOTES FIBROSIS AND INFLAMMATION IN SCLERODERMATOUS GRAFT-VS-HOST DISEASE IN MICE AND HUMANS</b>	<b>14:53 - 15:04</b>
<u>Antonia Müller</u> , Lu Cui, Tristan Lerbs, Megan King, Claire Muscat, Tyler Shibata, Jessica Chen Lee, Ryanne Brown, Sebastian Fernandez-Pol, Sally Arai, Judith Shizuru, Gerlinde Wernig (Switzerland)	
<b>SUPERIOR EVENT-FREE SURVIVAL WITH BLINATUMOMAB VERSUS CHEMOTHERAPY IN CHILDREN WITH HIGH-RISK FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A RANDOMIZED, CONTROLLED PHASE 3 TRIAL</b>	<b>15:04 - 15:14</b>
<u>Franco Locatelli</u> , Gerhard Zugmaier, Carmelo Rizzari, Joan Morris, Bernd Gruhn, Thomas Klingebiel, Rosanna Parasole, Christin Linderkamp, Christian Flotho, Arnaud Petit, Concetta Micalizzi, Noemi Mergen, Abeera Mohammad, Cornelia Eckert, Anja Möricke, Mary Sartor, Ondrej Hrusak, Christina Peters, Vaskar Saha, Arend von Stackelberg (Italy)	
<b>RESULTS OF BMT CTN PROTOCOL 1101 A MULTICENTER PHASE III RANDOMIZED TRIAL OF TRANSPLANTATION OF DOUBLE UMBILICAL CORD BLOOD VS. HLA-HAPLOIDENTICAL-RELATED BONE MARROW</b>	<b>15:14 - 15:24</b>
Claudio Brunstein, Paul V. O'Donnell, Mary Eapen, Brent Logan, Joseph H. Antin, Peter Dawson, Steven Devine, Nancy DiFronzo, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John M. Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Ephraim J. Fuchs (United States)	
<b>TREOSULFAN EXPOSURE IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH EARLY TOXICITY BUT NOT WITH EVENT-FREE SURVIVAL</b>	<b>15:24 - 15:34</b>
<u>Eileen van der Stoep</u> , Alice Bertaina, Dirk Jan Moes, Mattia Algeri, Robbert Bredius, Frans Smiers, Henk-Jan Guchelaar, Franco Locatelli, Juliette Zwaveling, Arjan Lankester (Netherlands)	
<b>RANDOMIZED PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT VS HOST DISEASE (AGVHD)</b>	<b>15:34 - 15:44</b>
<u>Robert Zeiser</u> , Nikolas von Bubnoff, Jason Butler, Mohamad Mohty, Dietger Niederwieser, Reuven Or, Jeff Szer, Eva Maria Wagner, Tsila Zuckerman, Bruyère Mahuzier, Judith Xu, Kunal K. Gandhi, Gérard Socie (Germany)	

## Scientific Programme

### **HOST T CELLS IN SKIN AND GUT SURVIVE STEM CELL TRANSPLANTATION AND CONTRIBUTE TO ACUTE GVHD** **15:44 - 15:54**

Sherrie Divito, Anders Aasebo, Tiago Matos, Pei-Chen Hsieh, Christopher Elco, John O'Malley, Espen Baekkevold, Henrik Reims, Tobias Gedde-Dahl, Michael Hagerstrom, Jude Hilaire, Edgar Milford, Geraldine Pinkus, Vincent Ho, Robert Soiffer, Haesook Kim, Martin Mihm, Jerome Ritz, Indira Guleria, Corey Cutler, Rachael Clark, Frode Jahnsen, Thomas Kupper (United States)

Nurses Group  
14:30 - 16:00

Auditorium 3

### **NG06, Back to basics: How can I improve my skills?**

#### **Chairs:**

Sandra Schoenfeld (Switzerland)

#### **Oral care during inpatient haematopoietic cell transplantation** **14:30 - 14:50**

Barry Quinn (United Kingdom)

#### **Recognising sepsis** **14:50 - 15:10**

Jan Styczynski (Poland)

#### **CVC management** **15:10 - 15:30**

Emilian Snarski (Poland)

#### **Tumor lysis** **15:30 - 15:50**

Janet Baker (United Kingdom)

#### **Q&A** **15:50 - 16:00**

Cell therapy  
14:30 - 15:50

Auditorium 4

### **CTD3, Cell Therapy Day: Large-scale access to marketed CAR T-Cells**

#### **Chairs:**

Olaf Penack (Germany)

Manel Juan (Spain)

#### **Collecting autologous MNC for industry manufactured CAR T-cells: When and how** **14:30 - 14:50**

Elad Jacoby (Israel)

#### **Addressing bottlenecks in CAR T-cell manufacturing** **14:50 - 15:10**

Ulrike Köhl (Germany)

#### **Management of OOS CAR T-cell products** **15:10 - 15:30**

Alexey Bersenev (United States)

#### **Q&A** **15:30 - 15:50**

## Scientific Programme

Transplant Coordinator Day  
14:30 - 16:00

Auditorium 5

### **TCD3, EBMT-WMDA Transplant Coordinators Day: Lessons learnt from COVID-19 - Cryopreservation: Reality for the next 18 months?**

**Chairs:**

Bronwen Shaw (United States)  
Suzanna M. van Walraven (Netherlands)

<b>Cryopreservation - View from the donor centre</b>	<b>14:30 - 14:55</b>
Thilo Mengling (Germany)	
<b>Cryopreservation - View from an Australian transplant centre</b>	<b>14:55 - 15:20</b>
Jeff Szer (Australia)	
<b>Cryopreservation - View from a European transplant centre</b>	<b>15:20 - 15:45</b>
Jesús Fernández Sojo (Spain)	
<b>Panel discussion and Q&amp;A</b>	<b>15:45 - 16:00</b>

Educational  
16:30 - 18:00

Auditorium 1

### **E7, Gene Therapy for Inherited Disorders in 2020**

**Chairs:**

Cristina Díaz de Heredia (Spain)  
Arjan Lankester (Netherlands)

<b>Gene therapy in Fanconi Anaemia</b>	<b>16:30 - 16:50</b>
Juan Bueren (Spain)	
<b>Gene therapy in leucodystrophies and other metabolic disorders</b>	<b>16:50 - 17:10</b>
M. Ester Bernardo (Italy)	
<b>Haemoglobinopathies</b>	<b>17:10 - 17:30</b>
Selim Corbacioglu (Germany)	
<b>The future of gene therapy for primary immunodeficiencies</b>	<b>17:30 - 17:50</b>
Claire Booth (United Kingdom)	
<b>Q&amp;A</b>	<b>17:50 - 18:00</b>

CME Symposium  
16:30 - 18:00

Auditorium 2

### **IS27, Antibody Therapy in Acute Leukemia: Understanding Clinical Considerations for Use in Conjunction with HSCT - CME Symposium, supported by an educational grant from Pfizer, ECMEC® Symposium**

**Chairs:**

David I. Marks (United Kingdom)

## Scientific Programme

<b>Welcome and introduction</b> David I. Marks (United Kingdom)	<b>16:30 - 16:35</b>
<b>MasterClass 1: Understanding the transplant context in AML and considerations with antibody therapy</b> Farhad Ravandi (United States)	<b>16:35 - 17:00</b>
<b>MasterClass 2: Insights on the integration of novel antibodies as options for transplant-eligible patients with ALL</b> David I. Marks (United Kingdom)	<b>17:00 - 17:25</b>
<b>Practicum: A case-based exploration of antibody therapy in AML/ALL transplant recipients</b> David I. Marks (United Kingdom) Farhad Ravandi (United States) Matthias Stelljes (Germany)	<b>17:25 - 17:50</b>
<b>Summary and reflection</b> David I. Marks (United Kingdom)	<b>17:50 - 18:00</b>

Industry Symposium  
16:30 - 18:00

Auditorium 3

### IS28, HSCT-TMA - Omeros Industry Symposium

#### Chairs:

Rafael Duarte (Spain)

<b>Welcome and introduction</b> Rafael Duarte (Spain)	<b>16:30 - 16:35</b>
<b>Complement activation in Endothelial Injury Syndromes</b> Eleni Gavrilaki (Greece)	<b>16:35 - 17:00</b>
<b>Diagnostic challenges in HSCT-TMA</b> Sonata Jodele (United States)	<b>17:00 - 17:20</b>
<b>MASP-2 inhibition with the investigational agent narsoplimab for the treatment of HSCT-TMA: Overview of data and case discussion</b> Rafael Duarte (Spain)	<b>17:20 - 17:50</b>
<b>Question-and-Answer session</b>	<b>17:50 - 18:00</b>

Cell therapy  
16:30 - 17:50

Auditorium 4

### CTD4, Cell Therapy Day: Modern developments in immunogenetics and immunology in the context of HSCT

#### Chairs:

Katharina Fleischhauer (Germany)  
Luca Vago (Italy)

## Scientific Programme

<b>Immunogenetics in the era of NGS and haplo-mismatched transplantations</b>	<b>16:30 - 16:50</b>
Valérie Dubois (France)	
<b>Immunogenetics of haematopoietic stem cell transplantation</b>	<b>16:50 - 17:10</b>
Effie Petersdorf (United States)	
<b>Immune monitoring of patients treated with immune effector cells</b>	<b>17:10 - 17:30</b>
Raffaella Greco (Italy)	
<b>Q&amp;A</b>	<b>17:30 - 17:50</b>

Joint Session  
16:30 - 17:50

Auditorium 5

### **JS2, Joint session WBMT: International access to HCT drugs: Impact on transplant practice and patients**

#### **Chairs:**

Daniel Weisdorf (United States)  
Carlos Solano (Spain)

<b>Causes of drug shortages</b>	<b>16:30 - 16:45</b>
Daniel Weisdorf (United States)	
<b>How can pharmacists help the HCT team in drug shortages and cost of medications</b>	<b>16:45 - 17:10</b>
Gunar Stemer (Austria)	
<b>Successful models of cooperation to offer essential drugs in the care of HCT patients: Role of WBMT</b>	<b>17:10 - 17:35</b>
Hildegard Greinix (Austria)	
<b>Q&amp;A</b>	<b>17:35 - 17:50</b>

Industry Symposium  
16:30 - 18:00

Auditorium 6

### **HDI4, How Do I... Expect, predict and improve survival of severe hepatic VOD? - Supported by Jazz Pharmaceuticals**

#### **Chairs:**

Nicolaus Kröger (Germany)

<b>Welcome and introduction</b>	<b>16:30 - 16:34</b>
Nicolaus Kröger (Germany)	
<b>Expect severe hepatic VOD</b>	<b>16:34 - 16:49</b>
Antonio Colecchia (Italy)	
<b>Ultrasound and Doppler in action</b>	<b>16:49 - 17:14</b>
Nathalie Lassau (France)	

## Scientific Programme

<b>Predict severe hepatic VOD - EASIX biomarker panel</b> Thomas Luft (Germany)	<b>17:14 - 17:29</b>
<b>Predict severe hepatic VOD - EBMT severity grading</b> Emmanouil Nikolousis (United Kingdom)	<b>17:29 - 17:44</b>
<b>Improve survival of severe hepatic VOD</b> Emmanouil Nikolousis (United Kingdom)	<b>17:44 - 17:59</b>
<b>Close</b> Nicolaus Kröger (Germany)	<b>17:59 - 18:00</b>

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### MTE16, Meet the Expert session 16 - Room MTE2

<b>HSCT and gene therapy in inherited metabolic diseases</b> Robert Wynn (United Kingdom)	<b>18:00 - 19:00</b>
--	----------------------

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### MTE17, Meet the Expert session 17 - Room MTE3

<b>Current challenges facing emerging donor registries in 2020</b> Mahmoud Aljurf (Saudi Arabia)	<b>18:00 - 19:00</b>
---	----------------------

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### MTE18, Meet the Expert session 18 - Room MTE4

<b>HSCT indications in paediatric MDS</b> Charlotte Niemeyer (Germany)	<b>18:00 - 19:00</b>
---	----------------------

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### MTE19, Meet the Expert session 19 - Room MTE5

<b>Ex vivo cellular manipulation and therapy as the platform of choice for allogeneic HSCT in 2020</b> Stephan Mielke (Sweden)	<b>18:00 - 19:00</b>
---	----------------------

## Scientific Programme

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### MTE20, Meet the Expert session 20 - Room MTE6

**Current role of mesenchymal stromal cells in HSCT**  
Peter Bader (Germany)

**18:00 - 19:00**

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### MTE21, Meet the Expert session 21 - Room MTE7

**HSCT in MS and immune-mediated neurological diseases: Patient selection and follow-up**  
Basil Sharrack (United Kingdom)

**18:00 - 19:00**

Meet the Expert  
18:00 - 19:00

Meet the Expert Rooms

### MTE15, Meet the Expert Session 15 - Room MTE1

**Fungal infections in HSCT recipients - The challenges in 2020**  
Livio Pagano (Italy)

**18:00 - 19:00**

Abstract Awards  
18:05 - 18:35

Auditorium 1

### AA1, Abstracts Awards Ceremony

**Jian-Jian Luan Award - Introduction**  
Bertram Glass (Germany)

**18:05 - 18:08**

**OFATUMUMAB AS PART OF REDUCED INTENSITY CONDITIONING IN HIGH RISK B-CELL LYMPHOMA PATIENTS: RESULTS FROM A PROSPECTIVE MULTICENTER PHASE-II TRIAL**

**18:08 - 18:18**

Monica Cabrero, Estefania Perez-Lopez, Isidro Jarque, Fatima de la Cruz-Vicente, Ana Africa Martin-Lopez, David Valcarcel, Jaime Sanz, Alejandro Martin, Ildefonso Espigado, Guillermo Orti, Carmen Martín-Calvo, Carlos Grande, Lucia Lopez-Corral, Dolores Caballero (Spain)

**Jon J. van Rood Award - Introduction**  
Christian Chabannon (France)

**18:18 - 18:21**

**Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation**

**18:21 - 18:31**

Cristina Toffalori (Italy)

**Best Young Abstracts**

**18:31 - 18:35**

Harry Dolstra (Netherlands)

## Scientific Programme

### Tuesday, 01 September 2020

---

Educational  
09:30 - 10:30

Auditorium 1

#### **E8, Bone marrow failure: From diagnosis to treatment in 2020**

**Chairs:**

Carlos Vallejo (Spain)  
Andrea Bacigalupo (Italy)

<b>Constitutional BMF diagnosis work-up in the era of NGS and gene panels</b> Carlo Dufour (Italy)	<b>09:30 - 09:45</b>
<b>Guidelines for the use of eltrombopag in aplastic anaemia in Europe</b> Régis Peffault de Latour (France)	<b>09:45 - 10:00</b>
<b>New complement inhibitors: Time for the show</b> Antonio Risitano (Italy)	<b>10:00 - 10:15</b>
<b>Q&amp;A</b>	<b>10:15 - 10:30</b>

Educational  
09:30 - 10:30

Auditorium 2

#### **E9, Novel immunotherapies in Multiple Myeloma**

**Chairs:**

Ibrahim Yakoub-Agha (France)

<b>CD38-targeting monoclonal antibodies</b> Niels van de Donk (Netherlands)	<b>09:30 - 09:46</b>
<b>Bispecific antibodies and BiTEs</b> Mohamad Mohty (France)	<b>09:46 - 09:58</b>
<b>CAR T-cells</b> Noopur Raje (United States)	<b>09:58 - 10:10</b>
<b>How should we position immunotherapies in the changing paradigm of myeloma treatment?</b> Meral Beksac (Turkey)	<b>10:10 - 10:22</b>
<b>Q&amp;A</b>	<b>10:22 - 10:30</b>

Nurses Group  
09:30 - 10:30

Auditorium 3

#### **NG07, Nurse Care**

**Chairs:**

Michelle Kenyon (United Kingdom)

## Scientific Programme

<b>Mindfulness and tips and trick for self-care</b>	<b>09:30 - 09:45</b>
Troy Chase (United Kingdom)	
<b>Leadership</b>	<b>09:45 - 10:00</b>
Klara Kabatova Maxova (Czech Republic)	
<b>Q&amp;A</b>	<b>10:00 - 10:30</b>

Paediatric Day  
09:30 - 10:30

Auditorium 4

### Paediatrics1, Paediatric Diseases Working Party Session

#### Chairs:

Selim Corbacioglu (Germany)  
Christina Peters (Austria)

<b>PDWP update on prospective activities</b>	
<b>PDWP activities and next events</b>	<b>09:30 - 09:37</b>
Selim Corbacioglu (Germany)	
<b>Cell based therapies in children</b>	
<b>Overview of novel developments in CAR T</b>	<b>09:37 - 09:44</b>
Patrick Schlegel (Germany)	
<b>CD5- and CD7-directed CAR T Cells for T-cell malignancies</b>	<b>09:44 - 09:51</b>
Maksim Mamonkin (United States)	
<b>Adoptive transfer of multivirus-specific T-cells</b>	<b>09:51 - 09:58</b>
Tobias Feuchtinger (Germany)	
<b>Real world Data: Relapse after CAR T</b>	<b>09:58 - 10:05</b>
Susana Rives (Spain)	
<b>"Real World Data" on CAR T: HSCT vs. CAR T in leukaemia</b>	<b>10:05 - 10:12</b>
Peter Bader (Germany)	
<b>Q&amp;A</b>	<b>10:12 - 10:27</b>

Educational  
09:30 - 10:30

Auditorium 5

### E10, Waldenström Macroglobulinaemia

#### Chairs:

Anna Sureda (Spain)

<b>How biology in Waldenström Macroglobulinaemia may affect treatment strategy?</b>	<b>09:30 - 09:45</b>
Véronique Leblond (France)	
<b>Conventional and new drugs</b>	<b>09:45 - 10:00</b>
Ramón García-Sanz (Spain)	

## Scientific Programme

<b>Haematopoietic stem cell transplantation in Waldenström Macroglobulinaemia</b>	<b>10:00 - 10:18</b>
Charalampia Kyriakou (United Kingdom)	
<b>Q&amp;A</b>	<b>10:18 - 10:30</b>

Joint Session  
09:30 - 10:30

Auditorium 6

### JS3, Joint session EHA: Moving CAR T-Cell Therapy in Europe

#### Chairs:

John Gribben (United Kingdom)  
Nicolaus Kröger (Germany)

<b>Academic CAR T-cell development in Europe</b>	<b>09:30 - 09:45</b>
Álvaro Urbano-Ispizua (Spain)	
<b>The CART cell process in Europe: Guidance for centers</b>	<b>09:45 - 10:00</b>
Jorge Sierra (Spain)	
<b>Sharing CAR T-cell data: Governance structure of EBMT Cellular Therapy registry</b>	<b>10:00 - 10:15</b>
Jürgen Kuball (Netherlands)	
<b>Q&amp;A</b>	<b>10:15 - 10:30</b>

Industrial Theatre  
09:30 - 18:00

Industry Theatre

### IT1, TLS in the context of new treatments in hematology - Sanofi Genzyme Industry Theatre Session

Industrial Theatre  
09:30 - 18:00

Industry Theatre

### IT3, Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite Industry Theatre Session

Industrial Theatre  
09:30 - 18:00

Industry Theatre

### IT2, Clinical Data on Treosulfan-based Conditioning Treatment (Trecondi®) in Paediatric Patients - Medac Industry Theatre Session

## Scientific Programme

Industrial Theatre  
09:30 - 18:00

Industry Theatre

### IT4, KYMRIA<sup>®</sup> in the Real World - Novartis Industry Theatre Session

Industrial Theatre  
09:30 - 18:00

Industry Theatre

### IT5, How I manage CMV in HSCT patients - MSD Industry Theatre Session

Industrial Theatre  
09:30 - 18:00

Industry Theatre

### IT6, Gene therapy: From clinical trials to clinical practice - Bluebirdbio Industry Theatre Session

#### Chairs:

Franco Locatelli (Italy)

e-Posters  
09:30 - 18:00

ePoster Area

### New drug- and cell-based immune therapies

**NIVOLUMAB INCREASES ANTIGEN SPECIFIC IMMUNE RESPONSES AGAINST LEUKEMIC PROGENITOR AND STEM CELLS (LSC/LPC)**

**PROPHYLACTIC OR PREEMPTIVE LOW-DOSE AZACITIDINE AND DONOR LYMPHOCYTE INFUSION TO PREVENT DISEASE RELAPSE FOLLOWING ALLOGENEIC TRANSPLANTATION IN 60 PATIENTS WITH HIGH RISK AML OR MDS**

**ELTROMBOPAG FOR THE TREATMENT OF POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTS: A MULTICENTER SURVEY UPDATE**

**DONOR NK CELLS INFUSION AS A STRATEGY OF IMMUNOTHERAPY TO PREVENT HHV6 REACTIVATION IN PEDIATRIC PATIENTS AFTER CD45RA-DEPLETED TRANSPLANTATION**

Mercedes Gasior Kabat, Luisa Sisinni, Raquel De Paz, David Bueno, Yasmina Mozo, Antonio Marcos, Ana Belen Romero, Aida Constanzo, Victor Jimenez Yuste, Antonio Pérez-Martínez (Spain)

**DEVELOPMENT OF CELL VACCINE BASED ON AUTOLOGOUS DENDRITIC CELLS LOADED WITH LIPID NANOPARTICLES CONTAINING CMV PP65 MESSENGER RNA**

Ruslan Nikolaev, Yana Bayzyanova, Natalya Khripkova, Mariya Efimenko, Timofei Zatsepin, Elena Osipova, Michael Maschan (Russian Federation)

**SMAC MIMETICS (SM) AND NATURAL KILLER (NK) CELLS - A PROMISING COMBINATION TO OVERCOME CELL DEATH RESISTANCE OF RHABDOMYOSARCOMA (RMS) CELLS**

Vinzenz Särchen, Lisa Marie Reindl, Jonas Heck, Meike Vogler, Thomas Bukur, Valesca Bukur, Thomas Klingebiel, Simone Fulda, Evelyn Ullrich (Germany)

## Scientific Programme

### **'KIT'-MEDIATED BLASTMODULATION TO LEUKEMIA-DERIVED DC SIGNIFICANTLY IMPROVES ANTILEUKEMIC ACTIVITIES IN WHOLE BLOOD INDEPENDENT OF AML-PATIENTS' SUBTYPES**

Selda Ugur, Lara Kristina Klauer, Christian Blasi, Fatemah Doraneh-Gard, Caroline Plett, Carina Gunsilius, Daniel Amberger, Melanie Weinmann, Olga Schutti, Zuzanna Stankova, Erdem Özkaya, Michael Atzler, Elena Pepeldjiyska, Antje Völker, Jörg Schmohl, Andreas Rank, Christoph Schmid, Doris Kraemer, [Helga Maria Schmetzer](#) (Germany)

### **ROLE OF EXOSOMES AS PROMOTORS OR BIOMARKERS TO STUDY ACTIVATION OF LEUKEMIA-DERIVED DENDRITIC CELLS (DCLEU)-MEDIATED ANTILEUKEMIC ACTIVATION OF ADAPTIVE AND INNATE IMMUNE-REACTIVE CELLS AGAINST AML-BLASTS**

### **HIGHER INCIDENCE OF SEVERE AUTOIMMUNE HEMOLYTIC ANEMIA AFTER TCR $\alpha\beta$ + /CD19+ CELL DEPLETED HAPLOIDENTICAL-HSCT AND POSTGRAFT CELLULAR IMMUNOTHERAPIES: CTLA4-IG VERY EFFECTIVE THERAPEUTIC OPTION FOR THIS LIFE-THREATENING DISEASE**

[Laszlo Gopcsa](#), Aniko Barta, Zoltan Csukly, Zita Farkas, Aniko Fodor, Apor Hardi, Lilla Lengyel, Melinda Paksi, Marienn Reti, Eszter Sari, Janos Sinko, Eva Torbagyi, Ildiko Zsigmond-Soos, Istvan Valyi-Nagy, Tamas Masszi, Peter Remenyi (Hungary)

### **BLINATUMOMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: REPORT FROM A SINGLE CENTER**

### **IMMUNOMODULATION OF BLASTS WITH CLINICALLY APPROVED RESPONSE MODIFIERS TO IMPROVE ANTILEUKEMIC T-CELL REACTIVITY IN AML: AN EX VIVO SIMULATION OF THE CLINICAL SITUATION**

Christoph Kugler, [Helga Schmetzer](#) (Germany)

### **IFNY SECRETION OF ADAPTIVE AND INNATE IMMUNE CELLS AS A PARAMETER TO DISPLAY LEUKAEMIA DERIVED DENDRITIC CELL (DC<SUB>LEU</SUB>) MEDIATED IMMUNE RESPONSES IN AML**

### **TREATMENT OF SEVERE HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA) WITH THE MASP-2 INHIBITOR NARSOPLIMAB (OMS721)**

e-Posters  
09:30 - 18:00

ePoster Area

## Non-infectious early complications

### **IMPACT OF DONOR-DIRECTED HLA ALLO-ANTIBODIES ON PRIMARY GRAFT FAILURE AFTER UNRELATED DONOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION**

### **ELTROMBOPAG TREATMENT AIDED IN PLATELET RECOVERY AND REDUCED PLATELET INFUSION FOR PATIENTS WITH POST-TRANSPLANTATION THROMBOCYTOPENIA**

### **IMPACT OF FLUID OVERLOAD (FO) IN POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL DISEASES**

### **INCIDENCE, RISK FACTORS, AND OUTCOMES OF PATIENTS WITH TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY AFTER STEM CELL TRANSPLANT: A MULTI-INSTITUTIONAL ANALYSIS**

### **USE OF ECULIZUMAB IN CHILDREN WITH HAEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY - A MULTICENTER RETROSPECTIVE STUDY ON BEHALF OF IEWP AND PDWP EBMT**

## Scientific Programme

**REDUCED POST-TRANSPLANT CYCLOPHOSPHAMIDE DOSES IN T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**ABO ISOAGGLUTININ LEVELS IN GUIDED MANAGEMENT OF ABO INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**METHYLPREDNISOLONE STRATIFIED INTERVENTION BASED ON RISK CLASSIFICATION IN THE TREATMENT OF PRE-ENGRAFTMENT SYNDROME AFTER UNRELATED CORD BLOOD TRANSPLANTATION: A PROSPECTIVE, NON-RANDOMIZED, AND OPEN-LABEL STUDY**

**PRETRANSPLANT NUTRITION MEASURES AND SYSTEMIC INFLAMMATORY RESPONSE PREDICT OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**A MULTI-CENTRE, MULTI-NATIONAL, PROSPECTIVE OBSERVATIONAL REGISTRY STUDY OF DEFIBROTIDE IN PATIENTS DIAGNOSED WITH SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)**

**DEFIBROTIDE TREATMENT FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES BY SEVERITY AND MULTI-ORGAN FAILURE STATUS IN AN OBSERVATIONAL REGISTRY STUDY**

**INTRODUCTION OF NEW PEDIATRIC EBMT CRITERIA FOR VOD <b>Diagnosis: </b> IS IT LIFE- SAVING OR MONEY-WASTING?**

**PROSPECTIVE PILOT STUDY ON FRAILTY AND FUNCTION ASSESSMENT DURING CLINICS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**HISTOLOGIC FEATURES OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY WITH AND WITHOUT CONCOMITANT ACUTE GRAFT- VERSUS-HOST DISEASE**

**HIGH SURVIVAL RATE OF PEDIATRIC PATIENTS WITH PRIMARY GRAFT FAILURE WHO UNDERGO A SECOND PROCEDURE. THE EXPERIENCE OF 3 SPANISH PEDIATRIC TRANSPLANT UNITS**

**CHEMOTHERAPY-INDUCED GUT MUCOSAL INJURY INITIATES MICROBIAL DISRUPTION IN STEM CELL TRANSPLANT RECIPIENTS**

**BACTERIAL AND METABOLIC PROFILING OF THE SALIVA IDENTIFIES UNIQUE PATTERNS OF MICROBIOTA INJURY IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT WITH SEVERE ORAL MUCOSITIS**

Roni Shouval, Adi Eshel, Amir Kuperman, Ivetta Danylesko, Bar Dubovski, Joshua A Fein, Shalev Fried, Mika Geva, Elizaveta Kouniavsky, Efrat Muller, Elhanan Borenstein, Yoram Louzoun, Omry Koren, Arnon Nagler (Israel)

**DIAGNOSIS AND MANAGEMENT OF SECONDARY HLH/MAS FOLLOWING HSCT AND CAR-T CELL THERAPY IN ADULTS: AN EBMT-WIDE SURVEY ON BEHALF OF THE ADWP AND TCWP**

**IMPACT OF ABO INCOMPATIBILITY ON COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION- RETROSPECTIVE, INTERNATIONAL, MULTICENTER ANALYSIS BY THE TRANSPLANT COMPLICATIONS WORKING PARTY EBMT**

Michal Gorka, Christophe Peczynski, Emmanuelle Polge, Karol Lis, Riitta Niittyvuopio, Hélène Labussière Wallet, Zinaida Peric, Helene Schoemans, Olaf Penack, Nina Worel, Christian Koenecke, Grzegorz Wladyslaw Basak (Poland)

**HYPOALBUMINEMIA PRIOR ALLOHCT IS A RELEVANT NEGATIVE PREDICTOR FOR SURVIVAL**

## Scientific Programme

### **INCIDENCE AND CLINICAL IMPACT OF ATRIAL FIBRILLATION DIAGNOSED DURING HOSPITAL STAY FOR ALLOGENEIC STEM CELL TRANSPLANTATION**

Catherina Lueck, Gernot Beutel, Victoria Panagiota, Elke Dammann, Dominik Markel, Maleen Beck, Souheila Tayeb, Adrian Schwarzer, Daniel Kharazipour, Michael Stadler, Arnold Ganser, Matthias Eder (Germany)

### **TRANSPLANTATION-ASSOCIATED MICROANGIOPATHY (TAM) IN RECIPIENTS OF UNMANIPULATED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTS USING PTCY FOR GVHD PROPHYLAXIS: INCIDENCE AND OUTCOME**

### **IGF-1 AND IGFBP-3 GENE POLYMORPHISMS PREDICT CIRCULATING IGF LEVELS AND SYSTEMIC INFLAMMATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Maria Schou Ebbesen, Christian Enevold, Anders Juul, Carsten Heilmann, Henrik Sengeløv, Klaus Müller (Denmark)

### **LOW RISK OF EARLY TOXICITY AND UNPLANNED 100-DAY READMISSIONS AFTER MATCHED AND MISMATCHED RELATED AND UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

Irene García-Cadenas, Albert Esquirol, Rahinatu Awol, Silvana Saavedra, Silvana Novelli, Ana Garrido, Jordi López, Carol Moreno, Miquel Granell, Javier Briones, Salut Brunet, Jordi Sierra, Rodrigo Martino (Spain)

### **KERATINOCYTE GROWTH FACTOR DECREASES HOSPITAL READMISSION AND REGIMEN-RELATED TOXICITIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA**

Najla El Jurdi, Christina Fair, John Rogosheske, Ryan Shanley, Daniel Weisdorf, Shernan Holtan, Mukta Arora, Veronika Bachanova, Claudio Brunstein (United States)

### **ELTROMBOPAG FOR TREATING THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

Zeynep Tugba Guven, Serhat Celik, Leylagül Kaynar, Bulent Eser, Mustafa Cetin, Ali Ünal (Turkey)

### **SYSTEMIC CORTICOSTEROID THERAPY IS UNLIKELY TO BE THE PRIMARY CAUSE OF HYPERGLYCEMIA FOLLOWING TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE**

Anna Guo, LaQuisa Hill, Gabriela Rondon, Richard E. Champlin, Amin M. Alousi, Rima M. Saliba (United States)

### **COST-EFFECTIVENESS ANALYSIS OF DEFIBROTIDE FOR THE TREATMENT OF SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME IN SPAIN**

David Carcedo Rodriguez, Teresa Artola Urain, Anabelle Chinea Rodriguez, Estefanía García Torres, Marta González Vicent, Gonzalo Gutiérrez-García, Alexandra Regueiro García, Marcos Calvo Hidalgo, Alba Villacampa (Spain)

### **NEUROLOGIC COMPLICATIONS IN 169 CONSECUTIVE ALLOGENEIC STEM CELL TRANSPLANTS: ETIOLOGY, CLINICAL SYNDROMES AND OUTCOME**

### **VENETOCLAX, HYPOMETHYLATING AGENTS AND DLI FOR SALVAGE TREATMENT OF MYELOID MALIGNANCIES RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Esther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, Gesine Bug, Martina Crysandt, Sabine Dressler, Andreas Hausmann, Daniela Heidenreich, Klaus Hirschbühl, Matthias Hoepting, Edgar Jost, Jennifer Kaivers, Stefan Klein, Lambros Kordelas, Oliver Kriege, Lutz Müller, Christina Rautenberg, Judith Schaffrath, Christoph Schmid, Daniel Wolff, Rainer Haas, Martin Bornhäuser, Thomas Schroeder, Guido Kobbe (Germany)

### **EVALUATION OF TGF-BETA LEVEL AFTER SUPPLEMENTATION WITH WHEY PROTEIN CONCENTRATE FOR ORAL MUCOSITIS PROPHYLAXIS**

Ana Carolina Amaral de Sao Jose Perrone, Clarissa Ferreira Cunha, Ana Paula da Silva Pinheiro, Ítalo Tuler Perrone, Leonardo Barbosa de Almeida, Kelli Borges dos Santos, Rodrigo Stephani, Henrique Couto Teixeira, Paula Alexandra da Graça Morais, Antonio Fernandes de Carvalho, Abraham Elias Hallack Neto (Brazil)

## Scientific Programme

### **TREOSULFAN-INDUCED MYALGIA IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Eileen van der Stoep, Dagmar Berghuis, Robbert Bredius, Emmeline Buddingh, Henk-Jan Guchelaar, Alex Mohseny, Irene Klaassen, Frans Smiers, Arjan Lankester, Juliette Zwaveling (Netherlands)

### **VALIDATION OF EARLY INCREASE OF SC5B-9 AS A PREDICTIVE MARKER FOR LATER TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY**

### **DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

### **EARLY TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION IMPROVES OUTCOME OF VERY SEVERE HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER UNMANIPULATED HAPLOIDENTICAL HSCT WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

Ignacio Gómez-Centurión, Cristina Muñoz, Arturo Álvarez Luque, Miguel Echenagusia Boyra, Diego Rincón, Nieves Dorado, Rebeca Bailén, Gillen Oarbeascoa, Javier Anguita, José Luis Díez-Martín, Mi Kwon (Spain)

### **DOES THE TYPE OF NUTRITIONAL SUPPORT AFFECT THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION? A PEDIATRIC CENTER EXPERIENCE**

### **NEUROLOGICAL COMPLICANTIONS IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY**

### **ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO THE INTENSIVE CARE UNIT - REAPPRAISAL OF PROGNOSIS AND PROGNOSTIC FACTORS: A SINGLE CENTER STUDY**

### **ENTERAL VERSUS PARENTERAL NUTRITION IN ADULT HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS SUFFERING FROM GASTROINTESTINAL MUCOSITIS**

Lenneke van Groningen, Doris Kalter, Wim Tissing, Walter van der Velden, Nicole Blijlevens (Netherlands)

### **DELAYED ENGRAFTMENT AND PROLONGED HOSPITAL STAY FOLLOWING OMISSION OF FOLINIC ACID AFTER METHOTREXATE FOR GVHD PROPHYLAXIS IN ALLOGENEIC TRANSPLANT RECIPIENTS**

Duncan Purtill, Ghassan Zammar, Hutchison Andrew, Julian Cooney, Paul Cannell, Matthew Wright (Australia)

### **THE USEFULNESS OF LIVER STIFFNESS MEASUREMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT SINUSOIDAL OBSTRUCTION SYNDROME**

Vera Radici, Chiara Rosignoli, Rossella Stella, Maria Vittoria Dubbini, Alessandra Sperotto, Michela Cerno, Antonella Geromin, Marta Lisa Battista, Giorgio Soardo, Laura Scatà, Renato Fanin, Francesca Patriarca (Italy)

### **ENDOTHELIAL CELL COMPLICATIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION, A SINGLE CENTRE ANALYSIS ON 99 CONSECUTIVE PATIENTS UNDERGOING ALLO-SCT**

Giorgia Mancini, Matteo Candelora, Giuseppina Urbano, Francesco Saraceni, Monica Poiani, Marianna Mariani, Irene Federici, Giuseppe Tarantino, Ilaria Scortechini, Attilio Olivieri (Italy)

### **INFLUENCE OF ABO-INCOMPATIBILITY ON THE OUTCOME OF STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY ON CHILDREN AND YOUNG ADULTS**

Volker Witt, Herbert Pichler (Austria)

### **EASIX IS USEFUL FOR PREDICTING THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS**

Michiyo Ebihara, Akihito Shinohara, Satoko Osanai, Michiko Ryuzaki, Yuki Izuka, Aya Watanabe, Norina Tanaka, Midori Ishiyama, Hiroshi Kazama, Shotaro Hagiwara, Kentaro Yoshinaga, Masayuki Shiseki, Junji Tanaka (Japan)

## Scientific Programme

### **SECOND TRANSPLANTATION USING A NOVEL CONDITIONING REGIMEN WITH DIFFERENT DONOR FOR GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

#### **A SYSTEMATIC REVIEW OF STUDIES ON DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME**

Selim Corbacioglu, Saurabh Aggarwal, Ozlem Topaloglu, William Tappe (Germany)

#### **VENO-OCCLUSIVE DISEASE: ONLINE, INTERPROFESSIONAL, CASE-BASED EDUCATION SIGNIFICANTLY IMPROVES KNOWLEDGE AND SKILLS OF THE ENTIRE CARE TEAM**

Lauren Willis, Mindy Tanzola, Tristin Abair, Pan Chen, Cathryn Jennissen, Alison Bemis, Angela R. Smith (United States)

### **HYPERHEMOLYSIS SYNDROME IS A NOVEL CAUSE OF SEVERE HEMOLYTIC ANEMIA AFTER ALLOGENEIC TRANSPLANTATION WITH VERY POOR RESPONSE TO TREATMENT AND OUTCOME**

José Luis Bueno, Azucena Losa, Clara González Santillana, Begoña Perez de Camino, Guiomar Bautista, Irene Romera, Ana Alarcón, Daniel Naya, Cristina Teresa Fernández-Maqueda, Carlos de Miguel, María Esther Martínez-Muñoz, Almudena De Laiglesia, Laura Vicente, José Antonio García-Marco, Rafael Forés, José Rafael Cabrera, Rafael F Duarte (Spain)

### **EASIX AS A PREDICTIVE BIOMARKER OF COMPLICATIONS AND OUTCOME IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

#### **SURVIVAL WITH NORMAL PULMONARY FUNCTION IS POSSIBLE DESPITE SIGNIFICANT AND PROLONGED RESPIRATORY SUPPORT, INCLUDING PROLONGED HIGH FREQUENCY OSCILLATORY VENTILATION (HFOV) IN CHILDREN**

Ramya Nataraj, Praveen Kurup, Alok Ekka, Gayathri Subramanian, Omendra Narayan, Denise Bonney, Helen Campbell, Hemalatha Doss, Robert Wynn (United Kingdom)

### **USE OF INTRAVESICAL HYALURONIC ACID TO TREAT HEMORRHAGIC CYSTITIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION**

#### **CURRENT PRACTICE IN NUTRITION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AUSTRIA, GERMANY AND SWITZERLAND**

Rosa Toenges, Matthias Edinger, Gesine Bug, Anita Lawitschka, Hildegard Greinix, Jörg Halter, Jann Arends, Francis Ayuk, Stefan Klein, Jan-Moritz Middeke, Eva Wagner-Drouet, Inken Hilgendorf, Annic Baumgartner, Daniel Wolff (Germany)

### **INCIDENCE AND SEVERITY OF CYTOKINE RELEASE SYNDROME FOLLOWING HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL INFUSION**

Frank Cirrone, Jamie Pavlonis, Kelli Cole, Maher Abdul-Hay, Doyun Park, A Samer Al-Homsi (United States)

### **ENGRAFTMENT SYNDROME FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY FROM A SINGLE CENTER**

Dorra Belloumi, Rimel Kanoun, Rim Cherni, Rym El Fatmi, Lamia Torjemane, Nour Abdeljelil, Amel Lakhal, Saloua Ladeb, Tarek Ben Othman (Tunisia)

### **WERNICKE'S ENCEPHALOPATHY IN A CHILD WITH B LYMPHOBLASTIC LYMPHOMA AFTER HAPLO-HSCT**

Natalya Natrusova, Evgeny Burtsev, Bulat Kurmanov, Inna Schederkina, Gleb Bronin (Russian Federation)

### **ECULIZUMAB FOR THE TREATMENT OF SEVERE TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: MULTICENTER EXPERIENCE**

### **IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN TERMS OF SINUSOIDAL OBSTRUCTION SYNDROME (SOS)**

## Scientific Programme

### **ISCHEMIC STROKE IN CHILDREN AND YOUNG ADULTS WITH MALIGNANT HEMATOLOGICAL AND ONCOLOGICAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Alexey Polushin, Oleg Goloshchapov, Tatiana Khutornaya, Olesya Paina, Tatiana Bykova, Asmik Gevorgian, Zhamal Rahmanova, Anastasia Frolova, Maria Vladovskaya, [Ivan Moiseev](#), Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

### **MELPHALAN DOSE ADJUSTMENT AND CRYOTHERAPY REDUCE ORAL MUCOSITIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Marcin Jasiński, Martyna Maciejewska, Michał Górka, Anna Brodziak, Kamila Skwierawska, Wiesław Wiktor-Jędrzejczak, Agnieszka Tomaszewska, Grzegorz Basak, [Emilian Snarski](#) (Poland)

### **CLINICAL FEATURES AND RISK FACTORS OF ENGRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

[Berta Michael Fernández](#), Valentín García Gutiérrez, Irene García García, Fernando Martín Moro, Adolfo Sáez Marín, Alejandro Luna de Abia, Claudia Núñez-Torrón Stock, Pilar Herrera Puente, Anabelle Chinea Rodríguez, Gemma Moreno Jiménez, Javier López Jiménez (Spain)

### **REAL-LIFE EXPERIENCE OF TWO ITALIAN HEMATOLOGY CENTRES ON EFFICACY AND SAFETY OF ORAL NEPA (NETUPITANT/PALONOSETRON) IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **EARLY TREATMENT WITH DARATUMUMAB FOR REFRACTORY POST-ALLOGENEIC STEM CELL TRANSPLANT PURE RED CELL APLASIA**

[Rahinatu Awol](#), Irene Garcia-Cadenas, Albert Esquirrol Santfeliu, Silvana Saavedra Gerosa, Jordi Sierra Gil, Rodrigo Martino Bufarull (Spain)

### **PROGNOSTIC FACTORS FOR EARLY MORTALITY OF HEMATOLOGICAL PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT: PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTER STUDY**

### **ACUTE KIDNEY INJURY DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULTS: INCIDENCE AND RISK FACTORS**

### **T-PA/UROKINASE IN COMBINATION WITH TPE AS A SUBSTITUTIONAL THERAPY FOR TREATMENT OF TA-TMA**

Fei Zhou, [Xuefeng He](#) (China)

### **HEMOPHAGOCYTIC SYNDROME AFTER EX-VIVO LYMPHODEPLETED HEMATOPOIETIC TRANSPLANTATION**

[Luisa Sisinni](#), Yasmina Mozo, David Bueno, Raquel De Paz, Eduardo Lopez-Granados, Antonio Perez-Martinez (Spain)

### **IMMUNOADSORPTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MAJOR ABO INCOMPATIBILITY**

[Martina Crysandt](#), Eva Jennes, Klaus Strathmann, Uta Kunter, Stefan Wilop, Gerda Silling, Tim H Brümmendorf, Fabian Beier, Edgar Jost (Germany)

### **IMMUNE-MEDIATED FEVER AFTER T-CELL REPLETE HAPLOIDENTICAL HSCT USING PERIPHERAL BLOOD STEM CELL GRAFTS AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

[Prashant Mehta](#), Rahul Arora, Vikash Kumar, Siddharth Sood, Swati Pabbi, Jagsahib Kaur (India)

e-Posters  
09:30 - 18:00

ePoster Area

## Experimental stem cell transplantation

## Scientific Programme

**LOW-DOSE DECITABINE IMPROVES REFRACTORY PROLONGED ISOLATED THROMBOCYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A RANDOMIZED MULTICENTER CLINICAL TRIAL**

**AUTOPHAGY IN ENDOTHELIAL CELLS REGULATES THEIR HAEMATOPOIESIS-SUPPORTING ABILITY**

**2ND ALLO-HSCT FOR PATIENTS WHO DIAGNOSED RECURRENCE ALL AFTER THE 1ST ALLO-HSCT**

**ESTABLISHING A TRANSPLANT SHARING PROGRAM**

e-Posters  
09:30 - 18:00

ePoster Area

## Experimental transplantation

**SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD) WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA BIOTHERAPEUTICS**

**IMPACT OF GUT FUNGAL COMPOSITION ON OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

Florent Malard, Aonghus Lavelle, Giorgia Battipaglia, Béatrice Gaugler, Rémy Dulery, Eolia Brissot, Tounes Ledraa, Razan Mohty, Harry Sokol, Mohamad Mohty (France)

**MONITORING HEMATOPOIETIC CELL MICROPARTICLES IN ALLOGRAFTS AND TRANSPLANT RECIPIENTS**

**EARLY HEPATIC COMPLICATIONS DURING THE FIRST YEAR AFTER BONE MARROW TRANSPLANTATION IN PATIENTS WITH LEUKEMIA**

Mehrdad Payandeh, Sakineh Ghorbani, Azam Elahi, Roya Chagneh Lorestani (Iran, Islamic Republic of)

**PERFORMANCE OF BONE MARROW TRANSPLANTATION CENTER IN IMAM REZA HOSPITAL, KERMANSHAH, IRAN**

Mehrdad Payandeh, Sakineh Ghorbani, Farzaneh Chahardoli, Fouzieh Rahimzadeh (Iran, Islamic Republic of)

e-Posters  
09:30 - 18:00

ePoster Area

## Haematopoietic stem cells

**HAPLOIDENTICAL DONOR BEATS MATCHED SIBLING DONOR FOR PRE-TRANSPLANTATION MRD POSITIVE ALL: A PHASE 3 BIOLOGICALLY RANDOMIZED STUDY**

**RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED RELATED DONOR WITH TCR $\alpha\beta$ + / CD19+ - DEPLETION AND A FIXED DOSE MEMORY T CELL (CD45RA-DEPLETED) ADD-BACK**

**CLONAL DYNAMICS AND GENOMIC INTEGRITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN HUMAN ALLOGENEIC TRANSPLANTATION RECIPIENTS**

Flavia Peci, Markus J. van Roosmalen, Rurika Oka, Marc Bierings, Ruben Boxtel, Mirjam Belderbos (Netherlands)

## Scientific Programme

### **ALLOGENEIC TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELL GRAFTS RESULTS IN A MASSIVE DECREASE OF PRIMITIVE HEMATOPOIETIC PROGENITOR FREQUENCIES IN RECONSTITUTED BONE MARROWS**

### **TREATMENT OF PURE RED CELL APLASIA AFTER MAJOR ABO INCOMPATIBLE ALLOGENIC STEM CELL TRANSPLANTATION: A FRENCH RETROSPECTIVE STUDY**

### **FEASIBILITY AND OUTCOMES OF A THIRD ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM THE ALWP OF EBMT**

### **CHANGES IN VIABILITY MARKERS OF HAEMATOPOIETIC STEM CELLS FOLLOWING LONG-TERM CRYOPRESERVATION**

Lisa O'Connor, Nicola Gardiner, Ashique Khan, Valerie Broderick, Paul Browne, [Patrick J. Hayden](#) (Ireland)

### **HIGH PRE-TRANSPLANT INTERLEUKIN-18 IS ASSOCIATED WITH POOR HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND PREDICTS INCREASED NON-RELAPSE MORTALITY**

### **MICROBIAL DIVERSITY, SURVIVAL, AND ACUTE GVHD IN ADULT RECIPIENTS OF ALLO-HSCT AFTER MYELOABLATIVE CONDITIONING: RESULTS OF A NUTRITIONAL INTERVENTION TRIAL**

Kristin Skaarud, Johannes R. Hov, Simen H. Hansen, Martin Kummen, [Tobias Gedde-Dahl](#), Asta Bye, Vemund Paulsen, Knut E. A. Lundin, Marius Trøseid, Geir E. Tjønnfjord, Per O. Iversen (Norway)

### **UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS**

Zohreh Nademi, Kanchan Rao, Su Han Lum, Stephen Jolles, Colin Steward, Stephen Hughes, Robert Wynn, Winnie Ip, Austen Worth, Paul Veys, Arjan Lankester, Maria Elena Maccari, Terry Flood, Sophie Hambleton, Andrew Gennery, Mary Slatter (United Kingdom)

### **RECONSTRUCTION OF THE DONOR-RECIPIENT HAEMATOPOIETIC CELL PHYLOGENY USING SOMATIC MUTATIONS TO ESTABLISH NUMBERS OF ENGRAFTING LONG-TERM HSCS IN REAL-WORLD TRANSPLANTATION**

[Michael Spencer Chapman](#), C. Matthias Wilk, Steffen Boettcher, Markus G. Manz, Peter Campbell (United Kingdom)

### **SUCCESSFUL CLEARANCE OF DONOR SPECIFIC ANTI-HLA ANTIBODIES AFTER DESENSITIZATION WITH RITUXIMAB, VELCADE AND PLASMA-EXCHANGE FOLLOWED BY A HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

### **IMPACT OF PRE-TRANSPLANTATION MINIMAL RESIDUAL DISEASE DETERMINED BY FLOW CYTOMETRY ON OUTCOME OF ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

[Tangia Muquith](#), Michele Lm Poon, Tan Lip Kun, Koh Liang piu (Singapore)

### **ECONOMIC BURDEN OF CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A SPANISH MULTICENTER, RETROSPECTIVE STUDY**

### **INCIDENCE AND OUTCOME OF CLONAL AND MALIGNANT TRANSFORMATION (CMT) AMONG PEDIATRIC PATIENTS WITH INHERITED BONE MARROW FAILURE SYNDROMES (IBMFSS)**

### **IMPACT OF POST-TRANSPLANT IMMUNOSUPPRESSION WEAN VS. BOOST IN EARLY MIXED CHIMERISM FOLLOWING G-CSF-PRIMED MARROW TRANSPLANT IN THALASSEMIC PATIENTS**

[Paula Arruda Tacla](#), Rajat Kumar Agarwal, Rakesh Dhanya, C P Raghuram, Pallavi Mehta, Deepa Deepa Trivedi, Vaibhav Shah, Priya Marwah, Rajpreet Soni, Sadaf Khalid, S Sandeep, Sarah Sarah Khan Gilani, Aliya Batool, Lallindra Gooneratne, Ruwangi Dissanayake, Fatima Itra, Tatheer Zahra, Lawrence Faulkner, Stalin Ramprakash (Brazil)

## Scientific Programme

### **COMPARISON OF THE CONDITIONING REGIMENS WITH TMLI, NON-RADIATION AND TBI FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

### **VALIDATION OF DISEASE RISK COMORBIDITY INDEX (DRCI) FOR OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) WITH PARTIALLY T-CELL DEPLETED GRAFT**

### **ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PRETREATED WITH JAK1/JAK2 INHIBITORS**

Maria Barabanshikova, Elena Morozova, [Ivan Moiseev](#), Julia Vlasova, Vadim Baykov, Inna Ushal, Gennadij Rodionov, Sergey Moiseev, Ildar Barkhatov, Ksenija Afanasyeva, Sergey Bondarenko, Boris Afanasyev (Russian Federation)

### **THE DETERMINATIVE ROLE OF PATIENT-CONTROLLED-ANALGESIA (PCA) IN THE EARLY COURSE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Kübra Haşımoğlu, Ferda Can, Oktay Tertemiz, Asena Dikyar, Didem Akçalı, Zübeyde Nur Özkurt, [Zeynep Arzu Yeğin](#) (Turkey)

### **HIGH SURVIVAL RATE AND LOW INCIDENCE OF AGVHD AFTER CD34+ STEM CELLS SELECTION AND CD3+ T CELLS ADDBACK IN PEDIATRIC MUD HSCT**

### **IMPACT OF ABO INCOMPATIBILITY ON OUTCOMES AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA**

### **COMPARISON OF OUTCOMES AFTER HAPLOIDENTICAL VERSUS UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER REVIEW**

Seyed Asadollah Mousavi, [Maryam Barkhordar](#), Tanaz Bahri, Sahar Tavakoli, Leila Mirzakhani, Leyla Sharifi Aliabadi (Iran, Islamic Republic of)

### **EFFECT OF DIFFERENT TIMINGS OF UMBILICAL CORD CLAMPING ON THE LEVEL OF CD34+ CELLS IN FULL-TERM NEONATES**

### **SEQUENTIAL CONDITIONING REGIMEN (FLAMSA-BU-MEL) IN HLA-MATCHED OR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN REFRACTORY MYELOID DISEASE**

[Ludovic Jondreville](#), Laetitia Souchet, Françoise Norol, Madalina Uzunov, Stéphanie Nguyen (France)

### **SEQUENCE CYTOREDUCTIVE CHEMOTHERAPY FOLLOWED BY MA CONDITIONING REGIMEN HSCT WITH INTERMEDIATE - OR ADVERSE RISK AML IN CR: A SINGLE CENTER STUDY**

### **INVESTIGATION OF VIROLOGICAL FEATURES AND CLINICAL OUTCOMES ASSOCIATED WITH PRE-ENGRAFTMENT CYTOMEGALOVIRUS DNAEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS**

[Carlos Solano](#), Lourdes Vázquez, Estela Giménez, Eliseo Albert, Montserrat Rovira, Ildelfonso Espigado, Carmen Martín, Anabelle Chinea, Albert Esquirol, Ariadna Pérez, Aranzazu Bermúdez, Rafael De la Cámara, Raquel Saldaña, Inmaculada Heras, Ana Julia González-Huerta, Tamara Torrado, Monserrat Batlle, Santiago Jiménez, Carlos Vallejo, Pere Barba, María Ángeles Cuesta, José Luis Piñana, David Navarro (Spain)

### **CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE AS A PREDICTOR OF ENGRAFTMENT AND SURVIVAL IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

Elifcan Aladag, Haluk Demiroglu, Yahya Buyukasik, [Hakan Goker](#) (Turkey)

### **USE OF PLERIXAFOR IN POOR MOBILIZER PATIENTS WITH MYELOMA AND LYMPHOMA: CLONOGENIC CAPACITY AND ENGRAFTMENT DATA**

[Laura M. Pezzetti](#), Giambattista Bertani, Liliana Intropido, Tiziana Lamacchia, Francesca Bosè, Elisa Zucchetti, Giovanni Grillo, Mauro Turrini, Michela Anghilieri, Roberto Cairoli (Italy)

## Scientific Programme

### **OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRICS: A SINGLE CENTER EXPERIENCE FROM INDIA**

### **RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: LONG TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA**

### **PRE-EMPTIVE USE OF SORAFENIB COMBINED WITH DLI POST HSCT IN AML FLT3+: A SINGLE CENTER EXPERIENCE**

### **USE OF ELTROMBOPAG FOR THE MANAGEMENT OF POOR GRAFT FUNCTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN**

### **TREATMENT OF THROMBOCYTOPENIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH ELTROMBOPAG**

Ekin Kircali, Guldane Cengiz Seval, Derya Koyun, Cemaleddin Ozturk, Atilla Uslu, Sinem Civriz Bozdog, Selami Kocak Toprak, Pervin Topcuoglu, Onder Arslan, Muhit Ozcan, Taner Demirel, Hamdi Akan, Osman Ilhan, Gunhan Gurman, Meral Beksac, Meltem Kurt Yuksel (Turkey)

### **EFFICACY OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED TO CHEMOTHERAPY AS POST-REMISSION TREATMENT FOR CHILDREN WITH INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION**

### **THE TREATMENT OF BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE**

Barbaros Sahin Karagun, Bulent Antmen, Ilgen Sasmaz (Turkey)

### **AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA IRREVERSIBLY DEPLETES NAÏVE T LYMPHOCYTES**

M<sup>a</sup> Del Pilar Sanz Martín, Yaiza Pérez García, Paula Díaz Fernandez, Víctor López Huete, Lorena Vega Píris, Ana Arteché López, Adrián Alegre Amor, Cecilia Muñoz Calleja (Spain)

### **DESENSITIZATION PROTOCOL IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH ANTI-HLA DONOR-SPECIFIC ANTIBODIES (DSA): A SINGLE-CENTER EXPERIENCE**

### **ASSOCIATION BETWEEN METABOLIC ALTERATION WITH TYPE AND INDICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Claudia Sossa, Ardila-Baez Manuel, Wandurraga Edwin, Sergio Serrano, Maria Luna-Gonzalez, Luis A Salazar, Jimenez Sara I, Manuel Rosales, Angela M Peña, Xueyi Chen, Juan J Rey, Maria A Chacon (Colombia)

### **RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES FOR PATIENTS RECEIVING UMBILICAL CORD BLOOD TRANSPLANTS AT THE ROYAL MARSDEN HOSPITAL BETWEEN 2007 AND 2017**

Sandra Easdale, Chloe Anthias Anthias, Emma Nicholson, Joy Brennan, Maria Mulligan, Mike Potter, Mark Ethell (United Kingdom)

### **HIGHER COST AND NO SURVIVAL BENEFIT WITH ADDITION OF RITUXIMAB TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL**

Cristian Rodriguez-Arocho, Brandon Blue, Neil Mason, Ariel.F Grajales-Cruz, Franco Garcia, Mahrukh Naqvi, Hanna Bailey, Erjeta Toska, Michael L Nieder, Joseph Pidala, Mohamed Kharfan-Dabaja, Ernesto Ayala, Nelli Bejanyan, Frederick Locke, Asmita Mishra, Hany Elmariah, Farhad Khimani, Taiga Nishihori, Aleksandr Lazaryan (United States)

### **ASSOCIATION BETWEEN METABOLIC ALTERATIONS WITH AGE AND GENDER OF PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Claudia Sossa, Manuel Ardila-Baez, Edwin Wandurraga, Sergio Serrano, Maria Luna-Gonzalez, Luis A Salazar, Sara I Jimenez, Manuel Rosales, Angela M Peña, Xueyi Chen, Juan J Rey, Maria A Chacon (Colombia)

## Scientific Programme

### **HAPLOIDENTICAL HSCT IN CHILDREN WITH VERY HIGH-RISK HAEMATOLOGIC MALIGNANCIES: A SINGLE-CENTRE EXPERIENCE**

Sie Chong Doris Lau, Seong Lin Khaw, Chia Huan Ng, David Hughes, Jacqueline Fleming, Diane Hanna, Rachel Conyers, Francoise Mechinaud (Australia)

### **COMPARATIVE STUDY OF THE HEMATOPOIETIC RECONSTITUTION**

Miguel Angel Martínez Hernández, Dennis Lumpuy Obregón, Agnerys López Sacerio, Bárbaro Andrés Medina Rodríguez, Carlos Rodríguez Fadrage, Jorge Félix Guerra Rodríguez (Cuba)

### **INFUSED TOTAL NUCLEATED CELL DOSE IS NOT ASSOCIATED WITH ENGRAFTMENT IN AUTOLOGOUS STEM CELL TRANSPLANTATION**

### **A COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND BFM 95 CHEMOTHERAPY PROTOCOL IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA**

Haluk Demiroglu, Elifcan Aladag, Yahya Buyukasik, Salih Aksu, Hakan Goker (Turkey)

### **THE IMPACT OF CD34+ CELL AND IMMUNEFFECTOR CELL DOSE ON TRANSPLANT OUTCOMES**

### **TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANTATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY**

Yolanda Gonzalez Romero, Lucrecia Yañez, Miguel Angel Cortes, Andres Insunza, Joan Manuel Mora, Miriam Sanchez-Escamilla, Sara Fernandez-Luis, David Gomez-Lamas, Jose Calvo-Sanchez, Sergio Fernandez-Garcia, Guillermo Martin-Sanchez, Mercedes Colorado, Enrique Ocio, Aranzazu Bermudez (Spain)

### **OUTCOME OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Zofia Szmit, Anna Król, Krzysztof Kałwak, Marek Ussowicz, Małgorzata Salamonowicz-Bodzioch, Jowita Frączkiewicz, Monika Mielcarek-Siedziuk, Justyna Miśkiewicz-Bujna, Izabella Miśkiewicz-Migoń, Ewa Gorczyńska (Poland)

### **MOTIVATION FOR ANTIFUNGAL USE IN PEDIATRIC HSCT PATIENTS IN AN INSTITUTION IN SOUTHERN BRAZIL**

### **IMPACT OF THE USE OF GRANULOCYTIC COLONY-STIMULATING FACTOR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN RARE FORMS OF PRIMARY IMMUNODEFICIENCIES (PIDS) IN ARGENTINA**

Silvia Pizzi, Mariana Roizen, Danila Labonia, Analia Julia, Carlos Figueroa Turienzo, Agustin Gonzalez Correas, Valeria Santidrian, German Carli, Ana Laura Naso, Raquel Staciuk (Argentina)

### **PHASE II STUDY OF PLERIXAFLOX AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL, PET POSITIVE AFTER TWO R-DHAP**

### **THE EFFECT OF CD34+ HEMATOPOIETIC PROGENITOR CELL DOSE ON THE HEMATOPOIETIC RECOVERY AND SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION**

Elifcan Aladag, Haluk Demiroglu, Yahya Buyukasik, Salih Aksu, Hakan Goker (Turkey)

### **THE EVENTUAL ROLE OF DONOR AND RECIPIENT VITAMIN D LEVELS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SETTING**

Azena Dikyar, Erhan Hocaoglu, Lale Aydın Kaynar, Zübeyde Nur Özkurt, Zeynep Arzu Yeğin (Turkey)

### **AVERAGE LENGTH OF HOSPITAL STAY FOR PEDIATRIC BLOOD AND MARROW TRANSPLANTS IN THE BACKDROP OF CELL SOURCE, TRANSPLANT TYPE AND OUTCOME**

## Scientific Programme

### **ONE CENTER EXPERIENCE IN OFFLINE TECHNIQUE VALIDATION WITH BIOLOGICAL QUALITY TESTS**

María Liz Paciello Coronel, Alejandra Leivas Aldea, Sara Redondo Velao, Encarnación Güemes Arce, Yolanda Paredes, Patricia Pérez Tomás, Mercedes Hernández, Borja Andrades Velazquez, Desire Sánchez Lozano, Maria Nieves Elvira Cortaberria, Consuelo Carralero, Joaquín Martínez López (Spain)

### **A MONOCENTRIC CLINICAL OBSERVATION OF ALLOGENEIC TRANSPLANTATION IN 22 PATIENTS WITH ACUTE MEGAKARYOCYTIC LEUKEMIA**

Zhijie Wei, Fei Pan, Rong Yang, Guanlan Yue, Kang Gao, Hui Li, Shuquan Ji, Peihua Lu (China)

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN IN SCIENTIFIC CENTRE OF PEDIATRICS AND CHILD SURGERY**

Aigul Tulebayeva, Ergaly Sarsekbaev, Riza Boranbayeva, Kulan Omarova (Kazakhstan)

### **THE OUTCOME OF ALLOTRANSPLANT USING TBF CONDITIONING FROM MATCHED SIBLING RELATED DONORS IN HIGH RISK MYELODYSPLASIA AND ACUTE MYELID LEUKEMIA: A RETROSPECTIVE SINGLE CENTER EXPERIENCE**

Khalid Halahleh, Waleed Da'ana, Husam Abu-jazar, Mohamad Ma'koseh, Salwa Saadeh, Rozan Al Far, Abdelghani Tbakhi (Jordan)

### **EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA: RETROSPECTIVE ANALYSIS IN OUR CENTER**

Yolanda Gonzalez Romero, Joan Manuel Mora, Miguel Angel Cortes, Sara Fernandez-Luis, David Gomez-Lamas, Aranzazu Bermudez, Andres Insunza, Lucrecia Yañez, Cristina Amunarriz, Mercedes Colorado, Enrique Ocio, Guillermo Martin-Sanchez (Spain)

### **CARDIOVASCULAR RISK IN PATIENTS BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Claudia Sossa, Manuel Ardila-Baez, Edwin Wandurraga, Sergio Serrano, Maria Luna-Gonzalez, Luis A Salazar, Sara I Jimenez, Manuel Rosales, Angela M Peña, Xueyi Chen, Juan J Rey, Maria A Chacon (Colombia)

### **INFECTIONS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS IN PERU: EXPERIENCE OF A REFERRAL CENTER**

Essy Maradiegue, Sharon Chávez (Peru)

### **HAEMATOPOIETIC STEM CELL PRODUCT VIABILITY: A COMPARATIVE STUDY BETWEEN BAGS AND VIALS**

Nadia Tanya Glatt, Colwyn Poole, Bibi Rhode, Matlhodi Moalosi, Khensani Mathye (South Africa)

### **TRANSFUSION SUPPORT IN THE FIRST 30 AND 100 DAYS AFTER HAPLOIDENTICAL VERSUS HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Mireia Santos Gómez, Agueda Ancochea Serra, Eva Alonso Nogués, Joan Ramon Grifols Ronda, Mireia Morgades de la Fe, Mireia Franch Sarto, Georgina Gener Ricós, Christelle Ferrà Coll, Susana Vives Polo, Anna Torrent Catarineu, Miriam Moreno Velázquez, Montserrat Batlle Massana, Blanca Xicoy Cirici, Laura Abril Sabater, Gladys Ibarra Fernández, Alicia Senín Magán, Albert Oriol Rocafiguera, Josep Maria Ribera Santasusana, Juan Manuel Sancho Cia (Spain)

### **HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MACS IN A PERUVIAN HEALTH CHILDRENS INSTITUTE: THREE-YEAR EXPERIENCE**

Sergio Murillo-Vizcarra, Karina Rojas-Fernandez, Carolina Benavides-Vallve, Karina Pinto-Gossin, Carlos Vidurizaga-De Amezaga (Peru)

## Scientific Programme

### **COLLECTION, CRYOPRESERVATION AND AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL BLOOD STEM CELLS IN KAUNAS, LITHUANIA 2015-2019**

Ieva Golubickaite, Birute Sabaniene, Inga Valanciute, Elona Juozaityte, Rolandas Gerbutavicius, Domas Vaitiekus, Aurija Kalasauskiene, Diana Remeikiene, Jonas Surkus, Ruta Leksiene, Milda Rudzianskiene, Martyna Beitneriene, Vilma Svetickiene, Ruta Dambrauskiene, Vaida Didziariekiene, Daiva Urboniene, Dietger Niederwieser (Lithuania)

### **EVALUATION OF OVERALL SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT): UNICENTRIC EXPERIENCE**

### **MONITORING OF THE EXPRESSION OF THE VEGF-A GENE (VASCULAR ENDOTHELIAL GROWTH FACTOR) DURING THE EVOLUTION OF PEDIATRIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION. A PILOT STUDY**

### **REFRACTORY T-CELL CUTANEOUS LYMPHOMA TREATED WITH ALLOGENEIC HAPLOIDENTIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT**

Marcia Silva, Natalia Laso, Maria Claudia Moreira, Simone Lermontov, Rita De cassia Barbosa, Simone Maradei, Marta Colares, Yung Gonzaga, Leonardo Arcuri, Renato Araujo, Decio Lerner (Brazil)

### **VITAMIN D DEFICIENCY AND OUTCOMES IN ADULT ACUTE LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE OVER LAST YEARS**

### **CAUSES OF COMPLICATIONS IN ADULTS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Bosco Martin McNally Guillen, Brenda Lizeth Acosta Maldonado, Liliana Mey Rivera Fong, José Manuel Téllez Araujo, Oyuky Gissell Aguirre Reyes, José Luis Estrada Rico, Alejandra Mendoza Torres, Luis Manuel Valero Saldaña (Mexico)

e-Posters  
09:30 - 18:00

ePoster Area

## Immunodeficiency diseases and macrophages

### **IMPACT OF DIFFERENT *EX VIVO* T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY**

### **OUTCOMES AND IMMUNE RECONSTITUTION AFTER T-CELL REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FOR PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCIES**

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY IN JAPAN: OVERVIEW OF A NATIONWIDE RETROSPECTIVE ANALYSIS**

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY IN JAPAN: A NATIONWIDE RETROSPECTIVE ANALYSIS**

Satoshi Miyamoto, Masakatsu Yanagimachi, Katsutsugu Umeda, Akihiro Iguchi, Yoji Sasahara, Hidetoshi Takada, Yoshiyuki Takahashi, Michiko Kajiwara, Masami Inoue, Koji Kato, Yoshiko Hashii, Yoshiko Atsuta, Hiromasa Yabe, Kohsuke Imai, Tomohiro Morio (Japan)

### **UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY: SINGLE-INSTITUTION EXPERIENCE IN CHINA**

Xiaowen Zhai, Xiaowen Qian, Hongsheng Wang, Wenjin Jiang, Ping Wang (China)

## Scientific Programme

### **IMMUNODEFICIENCY - CENTROMERIC INSTABILITY - FACIAL DYSMORPHISM (ICF) SYNDROME: EVALUATION OF CHARACTERISTICS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Dagmar Berghuis, Lisanne van Leeuwen, Jorinde Hoogenboom, Corry Weemaes, Mary Slatter, Reem Elfeky, Michael Albert, Roland Meisel, Alexandra Laberko, Akif Yesilipek, Lubna Mehyar, Andrew Gennery, Arjan Lankester (Netherlands)

### **THIOTEPA VERSUS MELPHALAN CONTAINING CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATIONS WITH TCR $\alpha\beta$ /CD19 GRAFT DEPLETION FOR PRIMARY IMMUNODEFICIENCIES**

Alexandra Laberko, Elvira Sultanova, Yulia Skvortsova, Irina Shipitsina, Svetlana Kozlovskaya, Svetlana Radygina, Anna Livshits, Aishat Kantulaeva, Elena Kurnikova, Anna Shcherbina, Alexei Maschan, Michael Maschan, Dmitry Balashov (Russian Federation)

### **IMPROVED TRANSPLANT SURVIVAL AND LONG-TERM DISEASE OUTCOME FOR CHILDREN WITH CD40 LIGAND DEFICIENCY**

Su Han Lum, Sahar Habibollah, Peter McNaughton, Zohreh Nademi, Terry Flood, Andrew Cant, Mario Abinun, Sophie Hambleton, Mary Slatter, Andrew Gennery (United Kingdom)

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES INCLUDING IMMUNE RECONSTITUTION IN PRIMARY IMMUNODEFICIENCIES: 5 YEARS OF SINGLE CENTRE EXPERIENCE**

### **OUTCOMES OF STEM CELL TRANSPLANT FOR RIPK1 DEFICIENCY: A SINGLE CENTRE EXPERIENCE**

Peter McNaughton, Su Han Lum, Zohreh Nademi, Terry Flood, Eleri Williams, Andrew Cant, Mario Abinun, Andrew R Gennery, Sophie Hambleton, Mary Slatter, Stephen Owens (United Kingdom)

### **IMPROVING THE RESULT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY IMMUNODEFICIENCY WITH SERIOUS INFECTION IN DEVELOPING COUNTRIES USING RIC REGIMENT**

### **SINGLE-CENTER EXPERIENCE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCR $\alpha\beta$ DEPLETION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY SYNDROMES**

### **HAPLO-IDENTICAL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY - A TERTIARY CARE CENTRE EXPERIENCE FROM SOUTH INDIA**

Stalin Ramprakash, C P Raghuram, Chetan Ginigeri, Fulvio Porta, Sagar Bhattad (India)

### **NECROTIZING ENTEROCOLITIS IN A TWO-MONTH-OLD SCID PATIENT AFTER BONE MARROW TRANSFUSION - SURGICAL INTERVENTION AT DAY +1: YES OR NO?**

### **UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH TWO DIFFERENT CONDITIONING REGIMEN FOR CHRONIC GRANULOMATOUS DISEASE: SINGLE-INSTITUTION EXPERIENCE IN CHINA**

Xiaowen Qian, Xiaowen Zhai, Hongsheng Wang, Wenjin Jiang, Ping Wang (China)

### **THE OUTCOMES OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY DISEASE IN CHILDREN WITH RAG GENE MUTATION**

Xiaowen Qian, Xiaowen Zhai, Chaofan Liu, Hongsheng Wang, Ping Wang, Wenjin Jiang (China)

### **LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) IN ADA-SCID PATIENTS: THE SHADOW OF MALIGNANCIES**

### **HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR X-LINKED AGAMMAGLOBULINAEMIA COMPLICATED BY CHRONIC NOROVIRUS ENTEROPATHY**

### **HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CD40 LIGAND DEFICIENCY**

## Scientific Programme

### **DIAGNOSTIC MARKERS FOR AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME**

Emese Molnar, Nesrine Radwan, Gabor Kovacs, Siobhan Burns, Hajnalka Andrikovics, Matthew Buckland, Kimberly Gilmour (United Kingdom)

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR CHRONIC GRANULOMATOUS DISEASE (CGD) IN CHILDHOOD**

e-Posters  
09:30 - 18:00

ePoster Area

## Infectious complications

### **PNEUMOCYSTIS PNEUMONIA AFTER ALLOGENEIC HCT: A CASE-CONTROL STUDY ON RISK FACTORS, TIMING, AND PCR USE, FROM THE IDWP OF EBMT**

### **UPPER AND/OR LOWER RESPIRATORY TRACT INFECTION CAUSED BY HUMAN CORONAVIRUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

### **SUCCESSFUL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH JCV-TARGETED T-CELL THERAPY**

### **EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY**

### **TUBERCULOSIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT**

### **FAECAL MICROBIOTA TRANSPLANT (FMT) CAN REDUCE THE HIGH NRM ASSOCIATED WITH MULTI-DRUG RESISTANT ORGANISM (MDRO) COLONISATION PRIOR TO ALLOGENEIC HCT**

### **EPIDEMIOLOGY, RISK FACTORS AND OUTCOMES OF CMV INFECTION IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT): A SINGLE INSTITUTIONAL COHORT STUDY**

### **USE OF LETERMIVIR IN OFF-LABEL INDICATIONS: INFECTIOUS DISEASES WORKING PARTY EBMT RETROSPECTIVE STUDY**

### **RISK OF INFECTIOUS COMPLICATIONS IN ADULT PATIENTS AFTER ALLOGENEIC HSCT DEPENDING ON THE SITE OF CENTRAL VENOUS CATHETER INSERTION - MULTICENTRE PROSPECTIVE STUDY**

Emilian Snarski, Jacqui Stringer, Małgorzata Mikulska, Lidia Gil, Gloria Tidello, Paul Bosman, Jennifer Hoek, Michał Karas, Samo Zver, Catherina Lueck, Nicole Blijlevens, Iria González, Małgorzata Ociepa-Wasilkowska, Michał Górka, Isabel Sánchez-Ortega, Inger Andersson, Lucrecia Yáñez, Mohamed Amine Bekadja, Jan Styczynski (Poland)

### **INFECTION PREVENTION PRACTICES AMONG EBMT HEMATOPOIETIC CELL TRANSPLANT CENTERS: A SURVEY OF THE INFECTIOUS DISEASES WORKING PARTY OF THE EBMT**

Moshe Yeshurun, Uri Rozovski, Liat Shargian, Oren Pasvolsky, Diana Averbuch, Steffie van der Werf, Nina Knelange, Małgorzata Mikulska, Jan Styczynski (Poland)

### **PRIMARY LETERMIVIR PROPHYLAXIS IN CMV SEROPOSITIVE PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REAL LIFE EXPERIENCE**

### **HEV INFECTION IN HCT RECIPIENTS - RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY (IDWP) OF EBMT**

Małgorzata Mikulska, Olaf Penack, Lotus Wendel, Nina Knelange, J.J. Cornelissen, Nicole Blijlevens, Jakob Passweg, Nicolaus Kroger, Anke Bruns, Arnold Ganser, Marc Bierings, Helen Labussière-Wallet, Gilles Salles, Jan Styczynski (Italy)

## Scientific Programme

### **THE ROLE OF COMBINATION PROPHYLAXIS IN PREVENTING CYTOMEGALOVIRUS (CMV) INFECTION AFTER EX VIVO AB T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANT (HHCT) IN CHILDREN**

Sung Han Kang, Jae Won Yoo, Jin Kyung Seo, Hyery Kim, Kyung-Nam Ko, Eun Seok Choi, Seongsoo Jang, Chan-Jeoung Park, Jong Jin Seo, Ho Joon Im (Korea, Republic of)

### **IMPACT OF CMV SEROSTATUS AND CMV REACTIVATION AFTER HAPLOIDENTICAL-SCT WITH PT-CY**

### **COMPARISON OF IMMUNE CELL RESPONSE TO CYTOMEGALOVIRUS PROTEINS VERSUS PEPTIDES USING AN IFN- $\gamma$ ELISPOT ASSAY TO MONITOR CYTOMEGALOVIRUS-SPECIFIC IMMUNITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Eva Wagner, Daniel Teschner, Christine Wolschke, Dietlinde Janson, Kerstin Schäfer-Eckart, Johannes Gärtner, Stephan Mielke, Martin Schreder, Guido Kobbe, Mustafa Kondakci, Inken Hilgendorf, Marie von Lilienfeld-Toal, Stefan Klein, Daniela Heidenreich, Sebastian Kreil, Mareike Verbeek, Sandra Grass, Markus Ditschkowski, Tanja Gromke, Martina Koch, Monika Lindemann, Thomas Hünig, Traudel Schmidt, Anne Rascle, Harald Guldán, Sascha Barabas, Ludwig Deml, Ralf Wagner, Daniel Wolff (Germany)

### **HUMAN HERPESVIRUS TYPE 6 REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION: RISK FACTORS AND CLINICAL IMPACT**

### **INCREMENTAL INPATIENT HEALTHCARE RESOURCE USE AND COSTS AMONG CMV SEROPOSITIVE ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS MANAGED THROUGH PREEMPTIVE APPROACH**

Jiaqi Fang, Phaeton D. Zavras, Yiqi Su, Amit Raval, Yuexin Tang, Anat Stern, Miguel-Angel Perales, Sergio Giralt, Genovefa A. Papanicolaou (United States)

### **POOR RECOVERY AND IMPAIRED FUNCTION OF V $\delta$ 1+ T CELLS IN REFRACTORY/RECURRENT CMV REACTIVATION AFTER HEMATOPOIETIC TRANSPLANTATION**

### **SAFETY AND EFFICACY OF BRINCIDOFOVIR FOR REFRACTORY ADENOVIRUS INFECTION IN CHILDREN RECEIVING ALLOGENEIC SCT: A RETROSPECTIVE ANALYSES FROM THE ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION (AIEOP)**

### **ALLOPLUS: RESULTS OF THE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS -POSITIVE PATIENTS, A RETROSPECTIVE STUDY OF THE SFGM-TC**

Ana Berceanu, Kevin Bouiller, Etienne Daguindau, Anne Thiebaut-Bertrand, Regis Peffault de Latour, Felipe Suarez, Bruno Lioure, Helene Labussière-Wallet, Marion Simonet, Sylvain Chantepie, Florence Beckerich, Marie-Therese Rubio, Stephanie Nguyen- Quoc (France)

### **SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT): A PROSPECTIVE STUDY TO MEASURE FEASIBILITY, SAFETY AND HEALTH CARE RESOURCE USE**

Ivan Pasic, Wael Alanazi, George Dranitsaris, Lani Lieberman, Auro Viswabandya, Dennis D. Kim, Jeffrey H. Lipton, Fotios V. Michelis (Canada)

### **FREQUENCY, RISK FACTORS AND OUTCOME OF ACTIVE TUBERCULOSIS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **INFECTIOUS COMPLICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA AFTER NEW AGENTS' THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION**

Yuliya Rogacheva, Marina Popova, Kirill Lepik, Yuriy Zalylov, Lilia Stelmakh, Alisa Volkova, Iliya Nikolaev, Anastasiia Beinarovich, Olga Pirogova, Evgeniya Borzenkova, Oleg Goloshchapov, Sergey Bondarenko, Ivan Moiseev, Vadim Baykov, Nataliya Mikhailova, Nikolay Klimko, Boris Afanasyev (Russian Federation)

### **SURVEILLANCE FOR REACTIVATION OF TOXOPLASMA GONDII USING POLYMERASE CHAIN REACTION ASSAY AND PRE-EMPTIVE THERAPY AVOIDS UNIVERSAL PROPHYLAXIS AND PREVENTS SYMPTOMATIC INFECTION**

## Scientific Programme

### **CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION**

### **FECAL MICROBIOTA TRANSPLANTATION IN CHILDREN TO TREAT ACUTE GVHD OR MULTI-DRUG RESISTANT BACTERIA COLONIZATION**

### **VACCINATION AGAINST TICK-BORNE ENCEPHALITIS (TBE) AFTER AUTOLOGOUS AND ALLOGENEIC BONE MARROW TRANSPLANTATION**

Sigrun Einarsdottir, Malin Nicklasson, Malin Veje, Tomas Bergström, Per Ljungman, Berit Johansson, Mikael Olsson, Björn Andreasson, Marie Studahl, Benedicte Piauger, Anette Roth, Mats Brune (Sweden)

### **RIFAXIMIN USE FAVOURED MICAFUNGIN RESISTANT CANDIDA SPP INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

### **BASELINE CHARACTERISTICS AND EARLY POLY-FUNCTIONAL ASSESSMENT OF T CELLS TO IDENTIFY PATIENTS AT HIGHER RISK TO DEVELOP SEVERE HCMV REACTIVATION AFTER ALLOGENEIC HSCT**

Elisa Gabanti, Oscar Borsani, Daniela Caldera, Anna Amelia Colombo, Virginia Ferretti, Emilio Paolo Alessandrino, Paolo Bernasconi, Daniele Lilleri (Italy)

### **IMPACT OF HHV-6 REACTIVATION AFTER T-REG/T-CON IMMUNOTHERAPY IN ALLOGENEIC TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY**

Chiara Camerini, Alessandra Carotti, Loredana Ruggeri, Adelmo Terenzi, Franca Falzetti, Silvia Bozza, Roberto Castronari, Samanta Bonato, Genni Casarola, Rita Felicini, Mario Griselli, Francesca Marzuttini, Matteo Paradiso, Sara Tricarico, Antonella Mencacci, Andrea Velardi, Antonio Pierini (Italy)

### **ADENOVIRUS INFECTIONS AFTER HCT: INFECTIOUS DISEASES WORKING PARTY RETROSPECTIVE EBMT REGISTRY STUDY**

Jan Styczynski, Gloria Tridello, Nina Knelange, Joan Hendrik Veelken, Gerard Socie, Stephan Mielke, Benedicte Neven, John A. Snowden, Jean-Hugues Dalle, Marie Thérèse Rubio, Charles Crawley, Johan Maertens, Jurgen Kuball, Patrice Chevallier, Gérard Michel, Peter J. Shaw, Ram Malladi, Robert F. Wynn, Yves Bertrand, Nicole Blijlevens, Charlotte Jubert, Tobias Gedde-Dahl, Ibrahim Yakoub-Agha, Maija Itälä-Remes, Lidia Gil, Simone Cesaro, Malgorzata Mikulska (Poland)

### **CLINICAL IMPACT OF COLONIZATION BY MULTIDRUG-RESISTANT ENTEROBACTERIACEAE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **POST-ALLOGENEIC TRANSPLANTATION PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, CLINICAL AND BIOLOGICAL FEATURES, TREATMENT AND OUTCOMES: A RETROSPECTIVE STUDY FROM THE SFGM-TC**

Alexis Genthon, Sylvain Chantepie, Amandine Le Bourgeois, Jacques Olivier Bay, Marie-Thérèse Rubio, Ali Bazarbachi, Stephanie Nguyen, Yves Beguin, Xavier Poiré, Amandine Charbonnier, Nathalie Fegueux, Michaël Loschi, Micha Srouf, Eolia Brissot (France)

### **RESPIRATORY VIRAL INFECTIONS IN ADULT PATIENTS UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION FROM UNRELATED DONORS AFTER MYELOABLATIVE CONDITIONING REGIMEN**

### **EFFICACY OF LETERMOVIR FOR PROPHYLAXIS OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTI CENTER RETROSPECTIVE ANALYSIS AMONG JAPANESE PATIENTS**

Yasuo Mori, Goichi Yoshimoto, Tetsuya Eto, Koji Nagafuji, Hiromi Iwasaki, Yoshikiyo Ito, Yuju Ohno, Tomohiko Kamimura, Ryosuke Ogawa, Akihiko Numata, Koji Kato, Katsuto Takenaka, Toshihiro Miyamoto, Koichi Akashi (Japan)

### **RISK FACTORS AND CLINICAL OUTCOMES OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL AND MATCHED-SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

## Scientific Programme

### **STANDARDIZED MONITORING OF CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY CAN IMPROVE RISK STRATIFICATION OF RECURRENT CYTOMEGALOVIRUS REACTIVATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Eva Wagner, Daniel Teschner, Christine Wolschke, Dietlinde Janson, Kerstin Schäfer-Eckart, Johannes Gärtner, Stephan Mielke, Martin Schreder, Guido Kobbe, Mustafa Kondakci, Inken Hilgendorf, Marie von Lilienfeld-Toal, Stefan Klein, Daniela Heidenreich, Sebastian Kreil, Mareike Verbeek, Sandra Grass, Markus Ditschkowski, Tanja Gromke, Martina Koch, Monika Lindemann, Thomas Hünig, Traudel Schmidt, Anne Rasclé, Harald Guldan, Sascha Barabas, Ludwig Deml, Ralf Wagner, Daniel Wolff (Germany)

### **IMPACT OF LEVOFLOXACIN FOR PROPHYLAXIS OF PRE-ENGRAFTMENT BLOODSTREAM INFECTIONS AFTER ALLOGENEIC HSCT: A SINGLE-CENTER MATCHED ANALYSIS IN AN ENDEMIC COUNTRY FOR CARBAPENEM-RESISTANT GRAM-NEGATIVE BACTERIA**

### **PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) AFTER HCT - A RETROSPECTIVE STUDY OF INFECTIOUS DISEASES WORKING PARTY EBMT**

### **ORAL RIBAVIRIN IS A HIGHLY EFFICACIOUS TREATMENT FOR LOWER RESPIRATORY TRACT INFECTION DUE TO RESPIRATORY SYNCYTIAL OR PARAINFLUENZA VIRUS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS**

Ioannis Tsonis, Ioannis Baltadakis, Maria Stamouli, Konstantinos Gkirkas, Christina Economopoulou, Dimitra Gardeli, Thomas Thomopoulos, Anna Paisiou, Dimitra Oikonomopoulou, Tatiana Tzenou, Nikolaos Siafakas, Spyridon Pournaras, Anastasia Antoniadou, Aggeliki Karagiannidi, Eirini Grispou, Joseph Meletiadis, Dimitra Kavatha, Stavros Gigantes, Evgenios Goussetis, Dimitrios Karakasis, Panagiotis Tsirigotis (Greece)

### **TIMING OF INDUCTION TREATMENT FOR REACTIVATION OF CYTOMEGALOVIRUS IMPACTS OVERALL SURVIVAL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT**

Christine Camacho-Bydume, Irene Rodriguez-Sanchez, Audrey Mauguen, Genovefa Papanicolaou, Susan Prockop, Elizabeth Klein, Nancy Kernan, Jaap-Jan Boelen, Maria Cancio (United States)

### **PREDICTION OF BLOODSTREAM INFECTION RISK USING CITRULLINE AS BIOMARKER OF INTESTINAL MUCOSITIS IN HEMATO-ONCOLOGY PATIENTS**

Charlotte de Mooij, Walter van der Velden, Antonius de Haan, Lenneke van Groningen, Nicole Blijlevens (Netherlands)

### **PREDICTION OF CMV REACTIVATION BY THE RECIPIENT IGG TITER BEFORE ALLO-HCT**

Shunto Kawamura, Hideki Nakasone, Shun-Ichi Kimura, Masakatsu Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura, Shinpei Matsumi, Ayumi Gomyo, Yu Akahoshi, Masaharu Tamaki, Machiko Kusuda, Hidenori Wada, Koji Kawamura, Aki Tanihara, Shinichi Kako, Yoshinobu Kanda (Japan)

### **COMPARISON OF INFECTIOUS COMPLICATIONS AMONG PATIENTS RECEIVING UNMANIPULATED HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETED HAPLOIDENTICAL TRANSPLANT**

Louis-Pierre Girard, Yin Jie Koh, Xin Liu, Davanaliz Gonzales Ramos, Teck Guan Soh, Lip Kun Tan, Michelle LM Poon, Lionel Lum, Liang Piu Koh (United Kingdom)

### **THE CUMULATIVE INCIDENCE OF MULTIPLE DNA VIRUS REACTIVATION IS NOT DIFFERENT IN NON-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION AND UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION**

### **NEUTROPHILS RESPONSE TO HUMAN CMV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

### **CLINICAL EFFICACY OF LETERMIVIR PROPHYLAXIS FOR CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

Atsushi Satake, Jun Ichikawa, Ryo Saito, Akiko Konishi, Masaaki Hotta, Takahisa Nakanishi, Aya Nakaya, Shinya Fujita, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura (Japan)

## Scientific Programme

### **AT-HOME FOSCARNET ADMINISTRATION IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION PATIENTS WITH CYTOMEGALOVIRUS INFECTION: A SAFETY FEASIBLE MODEL**

#### **EFFECTS OF THE ANTIBIOTICS CHANGE OR THE ADDITION OF ANTI-MRSA DRUGS FOR PERSISTENT FEBRILE NEUTROPENIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION**

Nozomu Yoshino, Koji Kawamura, Masakatu Kawamura, Syunto Kawamura, Junko Takeshita, Yukiko Misaki, Kazuki Yoshimura, Shinpei Matsumi, Ayumi Gomyo, Yu Akahoshi, Masaharu Tamaki, Machiko Kusuda, Kazuaki Kameda, Hidenori Wada, Hideki Nakasone, Shinichi Kako, Yoshinobu Kanda (Japan)

#### **THERAPEUTIC DRUG MONITORING OF POSACONAZOLE AND SUBSEQUENT DOSING IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

#### **IS PREEMPTIVE STRATEGY ENOUGH? RELATIONSHIP BETWEEN CMV REACTIVATION AND STEROID THERAPY FOR GHVD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: 97 PATIENTS FROM TURKEY**

Muhammet Erdem, [Vildan Ozkocaman](#), Ismail Anaç, Fahir Özkalemkaş (Turkey)

#### **PROPHYLAXIS WITH AZITHROMYCIN IN ALLOGENEIC CORD BLOOD TRANSPLANT AND ASSOCIATION WITH RELAPSE RATE AND TRANSPLANT OUTCOMES**

[José Miguel Mateos Pérez](#), José Ramon Álamo Moreno, Carlos De Miguel Jiménez, Clara González Santillana, Alonso Trillo Rosalia, Sara Garrido Paniagua, Ángela Benítez Fernández, Lucía Núñez Martín-Buitrago, Ana Bocanegra Pérez-Vizcaíno, Marta Liébana Villela, Ana Alarcón Tomás, María Esther Martínez, Ana Fernandez-Cruz, Guiomar Bautista Carrascosa, José Rafael Cabrera Marín, Antonio Ramos Marínez, Rafael F. Duarte (Spain)

#### **REACTIVATED VARICELLA ZOSTER (VZV) INFECTION (SHINGLES), AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HCT) FOR HAEMATOLOGICAL DISEASE IN CHILDREN: A SIGNIFICANT PROBLEM AND PROPOSAL FOR FUTURE MANAGEMENT**

[Dafydd Stonehewer](#), Joanne Ellis, Tasneem Khalid, Stephen Hughes, Robert Wynn (United Kingdom)

#### **LETERMOVIR PROPHYLAXIS REDUCES INPATIENT RESOURCE CONSUMPTION BY BEING EFFECTIVE IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER REAL-WORLD EXPERIENCE**

[Patrick Derigs](#), Maria-Luisa Schubert, Paul Schnitzler, Tilman Schöning, Carsten Müller-Tidow, Thomas Luft, Peter Dreger, Michael Schmitt (Germany)

#### **ANALYSIS OF CMV REACTIVATION RISK AFTER T CELL REPLETE HAPLOIDENTICAL AND MATCHED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

#### **INCIDENCE AND IMPACT OF EPSTEIN-BARR VIRUS EVENTS IN THE EARLY PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

#### **ASPERGILLUS NON-FUMIGATUS INVASIVE ASPERGILLOSIS IN CHILDREN AND ADULTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) & CHEMOTHERAPY**

#### **INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS JIROVECI PROPHYLAXIS IN HEMATOLOGICAL PATIENTS TREATED WITH CHEMOTHERAPY, HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) AND CAR-T CELL THERAPY**

[Nieves López Muñoz](#), Elena Vera Guerrero, Marta Hidalgo Soto, María Calbacho, Jose María Sánchez Pina, Joaquín Martínez-López (Spain)

#### **INTENSIFICATION OF CMV PROPHYLAXIS WITH THE USE OF GANCICLOVIR DURING THE CONDITIONING IN HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE. COMPARISON WITH A STANDARD STRATEGY. 113 PATIENTS**

[Amado Karduss](#), Angela Trujillo, Angelica Cardona, Rosendo Perez, Giovanni Ruiz, Gloria Suarez (Colombia)

#### **LOW RELAPSE RISK FOR REDUCED INTENSITY CONDITIONED ALEMTUZUMAB-BASED ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMAS IS OFFSET BY CYTOMEGALOVIRUS RISK: DATA FROM SINGLE CENTRE STUDY**

## Scientific Programme

### **PROPHYLACTIC DOSE TRIMETHOPRIM/SULFAMETHOXAZOLE DOES NOT LEAD TO DELAYED NEUTROPHIL AND PLATELET ENGRAFTMENT IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

Rachael Biggart, Sarah Bird, Chloe Anthias, Sandra Easdale, Michael Potter, Joy Brennan, Maria Mulligan, Emma Thistlethwaite, Kim Davis, Mark Ethell, Unell Riley, Emma Nicholson (United Kingdom)

### **HIGH DOSE VALACICLOVIR AS CMV PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

Genevieve Douglas, Michelle Yong, Shioyen Tio, Maggie Chau, Joe Sasadeusz, Monica Slavin, David Ritchie, Lynette Chee (Australia)

### **EPIDEMIOLOGICAL SCREENING FOR BACTERIAL RESISTANCE BY DIFFERENT TECHNIQUES IN ALLO-HSCT PATIENTS**

### **INVASIVE MOLD DISEASE IN A REAL-WORLD HEMATO-ONCOLOGY SETTING: VALUE OF A DIAGNOSTIC-DRIVEN CARE PATHWAY**

Elizabeth de Kort, Walter van der Velden, Paul Verweij, Nicole Blijlevens (Netherlands)

### **SINGLE CENTER ANALYSIS ON THE MANAGEMENT OF ACYCLOVIR RESISTANT HERPES SIMPLEX VIRUS STOMATITIS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

Daniela Heidenreich, Sebastian Kreil, Nadine Mueller, Mohamad Jawhar, Florian Nolte, Wolf-Karsten Hofmann, Stefan A. Klein (Germany)

### **EARLY BACTEREMIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION WITHOUT THE USE OF PROPHYLACTIC ANTIBIOTIC: CHANGING EPIDEMIOLOGY AND ANTIMICROBIAL RESISTANCE (2016-2018)**

Nour Ben Abdeljelil, Rihab Ouerghi, Dorra Belloumi, Amel Lakhal, Lamia Torjemane, Rym El Fatmi, Wafa Achour, Saloua Ladeb, Tarek Ben Othman (Tunisia)

### **DIAGNOSTIC YIELD OF BRONCHOALVEOLAR LAVAGE (BAL) IN HAEMATOLOGICAL PATIENTS AFTER ALLOGENEIC/ AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) - COMPARISON WITH BAL PERFORMANCE IN NON-TRANSPLANTED PATIENTS**

### **A NOVEL EFFICIENCY STRATEGY TO PREVENT HBV-RELATED HEPATITIS AFTER ALLOGENEIC HSCT FROM HBSAG- POSITIVE DONORS TO RECIPIENTS**

### **BK VIRUS EFFECT ON DEVELOPING LATE HEMORRHAGIC CYSTITIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS: SINGLE CENTER EXPERIENCE**

Ismail Anac, Vildan Ozkocaman, Muhammet Erdem, Fahir Ozkalemkas (Turkey)

### **VERSATILE EFFECTS OF LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-INSTITUTION ANALYSIS**

Fumiaki Jinnouchi, Yuta Katayama, Ryota Imanaka, Tatsuya Terasaki, Takuya Nunomura, Takeshi Okatani, Kohei Kyo, Mitsuhiro Itagaki, Shinya Katsutani, Tsuyoshi Muta, Hideki Asaoku, Koji Iwato (Japan)

### **IMPACT OF A CHANGE IN ANTIBACTERIAL PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION IN ONE SINGLE CENTER**

### **INTRAVESICAL INSTILLATION OF CIDOVOFIR IS EFFICIENT FOR THE TREATMENT OF BK VIRUS HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC TRANSPLANTATION**

### **MANAGEMENT OF BK POLYOMA VIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE**

## Scientific Programme

### **RISK FACTORS AND OUTCOME OF EARLY CLOSTRIDIUM DIFFICILE INFECTION IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Chiara Rosignoli, Vera Radici, Rossella Stella, Alessandra Sperotto, Antonella Geromin, Marta Lisa Battista, Michela Cerno, Renato Fanin (Italy)

### **RISK FACTORS FOR CYTOMEGALOVIRUS INFECTION IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Bernd Gruhn, Pania Mokthari (Germany)

### **IMPACT OF HYPOGAMMAGLOBULINEMIA ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**

### **THE USE OF RIFAXIMINE IN ANTI-BACTERIAL PROPHYLAXIS IN PATIENT UNDERGOING HSCT**

Magdalena Dutka, Agata Szymańska, Patryk Sobieralski, Maria Bieniaszewska (Poland)

### **BKV VIRUS - HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: INCIDENCE, SEVERITY AND RISK FACTORS**

### **RUXOLITINIB FOR STEROID-REFRACTORY GVHD ABOLISHES ANTIVIRAL IMMUNE RESPONSE FOLLOWING T-CELL TRANSFER FOR REFRACTORY ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

Rebecca E. Schultze-Florey, Sabine Tischer-Zimmermann, Hans-Gert Heuft, Christoph Priesner, Britta Lamottke, Albert Heim, Martin Sauer, Karl-Walter Sykora, Rainer Blasczyk, Britta Eiz-Vesper, Britta Maecker-Kolhoff (Germany)

### **RISK FACTORS FOR CMV REACTIVATION AND DISEASE AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS - DEFINING THE TARGET POPULATION FOR LETERMIVIR PROPHYLAXIS**

### **ISAVUCONAZOLE (ISA) USE IN ADULT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) RECIPIENTS: A SINGLE-CENTER EXPERIENCE**

### **TIME- AND THERAPY-DEPENDENT BACTERIURIA IN CHILDREN AND YOUNG ADULTS FOLLOWING ALLOGENEIC HSCT**

### **PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF MARIBAVIR COMPARED WITH VALGANCICLOVIR FOR TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS (STUDY DESIGN)**

### **INCIDENCE AND RISK FACTORS OF VIRAL COMPLICATIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE FROM HUNGARY**

### **CONTRIBUTING FACTORS TO PRE ENGRAFTMENT BACTEREMIA AND PNEUMONIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A LEBANESE SINGLE CENTER EXPERIENCE**

### **UNICENTRIC STUDY: PROPHYLAXIS STRATEGY AGAINST GVHD WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (CPYT) AND ITS RELATIONSHIP WITH CYTOMEGALOVIRUS**

Ana Lerna Verdejo, Clara Cuéllar Pérez-Ávila, Begoña Pérez de Camino Gaisse, Javier Cornago Navascués (Spain)

### **EPIDEMIOLOGY AND CLINICAL FEATURES OF FEBRILE NEUTROPENIC EPISODES: THREE YEARS EXPERIENCE AT HEMATOLOGY WARDS**

### **USE OF CMV-HYPERIMMUNE GLOBULINS (CMV-HYG) AS PRE-EMPTIVE THERAPY OR TREATMENT OF CMV INFECTION IN HSCT RECIPIENTS**

### **TOXOPLASMOSIS DISEASE AFTER ALLO-HSCT. WHAT HAVE WE LEARNT?**

Laura Escobar Fernandez, Marina García Morín, Eduardo Bardón Cancho, Jorge Huerta Aragonés, Cristina Beléndez Bieler, Elena Rincón López, María Stocker Barrio, Elena Cela de Julián (Spain)

## Scientific Programme

### **TUBERCULOSIS IN PATIENTS WHO RECEIVE AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. TWO CASE REPORT**

Haridian de la Nuez Melián, [Melissa Torres Ochando](#), Leslie González Pinedo, Santiago Jiménez Bravo de Laguna, Maria Del Mar Perera Álvarez, Paula Fernández-Caldas González, Leonor Pérez Ortiz, Joan González Fernández, Asunción Borrero Borrego, Juan Francisco López Rodríguez, Luisa Guerra Domínguez, Teresa Molero Labarta (Spain)

### **POLYOMAVIRUS BK INFECTION IN BONE MARROW TRANSPLANTATION RECIPIENTS. A COMPARATIVE ANALYSIS ON CHILDREN AND ADULTS**

### **LEFLUNOMIDE, SUCCESSFUL PRE-EMPTIVE THERAPY IN RESISTANT CYTOMEGALOVIRUS REACTIVATION IN A HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT**

Gloria Elena Mora, Maria Jose Lopez Mora, Enrique Pedraza, Herman Esguerra, Javier Figueroa, Oscar Peña, Sergio Ardila, Angie Guarín, Diego Orlando Díaz, Licet Villamizar, Cesar Lamadrid, Gustavo Adolfo Lopez (Colombia)

### **LETERMOVIR AS PRE-EMPTIVE THERAPY FOR RESISTANT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

### **INFECTIOUS COMPLICATIONS IN HEMATOLOGIC PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION**

[Vitalii Chebotkevich](#), Alena Kuleshova, Anastasia Zhernyakova, Catherine Kiseleva, Sergey Gritsaev, Stanislav Bessmeltsev (Russian Federation)

### **EARLY MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA - A SINGLE CENTER EXPERIENCE**

[Zlate Stojanoski](#), Aleksandra Pivkova Veljanovska, Lazar Cadievski, Sonja Genadieva-Stavrik, Aleksandar Stojanovik, Oliver Karanfilski, Martin Ivanovski, Irina Panovska-Stavridis, Lidija Cevreska, Borce Georgievski (North Macedonia, the Republic of)

### **CMV RETINITIS IN A STEM CELL TRANSPLANT RECIPIENT TREATED WITH FOSCARNET INTRAVITREAL INJECTION AND CMV SPECIFIC IMMUNOGLOBULIN**

Francesco Vassallo, Alessandro Busca, Chiara Della Casa, Lucia Brunello, Luisa Giaccone, Sara Butera, Giorgia Iovino, Francesco Giuseppe De Rosa, Raffaele Nuzzi, Ilaria Cattani, Benedetto Bruno (Italy)

e-Posters  
09:30 - 18:00

ePoster Area

## Lymphoma

### **LONG TERM SURVIVAL AFTER 2 YEARS EVENT FREE SURVIVAL IN RELAPSED DLBCL AFTER AUTOLOGOUS TRANSPLANTATION IN THE TWO RANDOMIZED TRIALS LY.12 AND CORAL**

### **EXPLORATORY ANALYSIS OF BRENTUXIMAB VEDOTIN PLUS CHP (A+CHP) AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS (ECHELON-2): IMPACT OF CONSOLIDATIVE STEM CELL TRANSPLANT**

### **BRENTUXIMAB VEDOTIN FOR RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN LYMPHOMA: A STUDY OF THE LWP-EBMT**

### **ALLOGENEIC STEM CELL TRANSPLANTATION AS A CURATIVE OPTION IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH/GELTAMO STUDY**

### **ADAM17 INHIBITOR INCB7839 WITH RITUXIMAB AS CONSOLIDATION AFTER AUTOLOGOUS HCT FOR DIFFUSE LARGE B CELL LYMPHOMA: A NOVEL RELAPSE PREVENTION STRATEGY**

## Scientific Programme

### **COMPARISON OF REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A CIBMTR ANALYSIS**

### **HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH NON-HODGKIN LYMPHOMA: THE SPANISH EXPERIENCE**

### **EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS AFFECTED BY ADVANCED LYMPHOID MALIGNANCIES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY**

Elisa Diral, Raynier Devillier, Sabine Furst, Angela Granata, Stefania Bramanti, Samia Harbi, Jacopo Mariotti, Chiara De Philippis, Barbara Sarina, Thomas Pagliardini, Valerio Maisano, Rocco Piazza, Reda Bouabdallah, Carmelo Carlo-Stella, Armando Santoro, Didier Blaise, Luca Castagna (France)

### **BRENTUXIMAB-VEDOTIN IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY PRIOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HODGKIN LYMPHOMA: REAL-WORLD DATA FROM A TWO CENTERS STUDY**

### **NON-MYELOABLATIVE CONDITIONING REGIMEN BEFORE T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ADVANCED LYMPHOMA**

### **IMPACT OF KIR LIGAND MISMATCH AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY IN 383 PATIENTS FROM THE SFGM-TC**

Jean-Edouard Martin, Stéphane Morisset, Régis Peffault De La Tour, Nathalie Fegueux, Edouard Forcade, Sylvie François, Jean-Baptiste Mear, Patrice Chevallier, Eric Deconink, Hélène Labussière-Wallet, Claude-Eric Bulabois, Jacques-Olivier Bay, Mohamad Mohty, Marie-Thérèse Rubio, Didier Blaise, Stéphanie Nguyen (France)

### **THE IMPACT AND CHALLENGES OF PERFORMING BEAM CONDITIONED AUTOLOGOUS TRANSPLANTS IN 'OLDER' PATIENTS WITH LYMPHOMA**

David Davies, Keith Wilson, Sarah Doherty, Emma Kempshall, Hamdi Sati, Wendy Ingram (United Kingdom)

### **ACCESSIBILITY AND IMPACT ON LONG-TERM OVERALL SURVIVAL OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS: A SINGLE INSTITUTION INTENTION-TO-TREAT ANALYSIS**

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TRANSFORMED FOLLICULAR LYMPHOMA (FL): RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY FROM GELTH/GELTAMO GROUP**

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANTATION**

Masatoshi Sakurai, Takehiko Mori, Souichi Shiratori, Toshio Wakayama, Naoyuki Uchida, Hikaru Kobayashi, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Eisei Kondo (Japan)

### **SIGNIFICANT ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA**

Dae Sik Kim, Sung-Hoon Jung, Deok-Hwan Yang, Youngil Koh, Junshik Hong, Ho-Young Yhim, Won Sik Lee, Yoo Jin Lee, Jeong-Ok Lee, Hye Jin Kang, Sung Yong Oh, Yun-Suk Choi, Ho Sup Lee, Jung-Hee Lee, Yong Park, Byung Bae Park, Young Rok Do, Ho-Jin Shin (Korea, Republic of)

### **HIGH DOSE CHEMOTHERAPY TEAM FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA: RESULTS OF A PROSPECTIVE STUDY**

### **AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIV+ AND HIV- LYMPHOMA PATIENTS: A PROPENSITY SCORE MATCHED ANALYSIS**

## Scientific Programme

### **AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR DOUBLE HIT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS**

### **ALLOGENEIC STEM CELL TRANSPLANTATION CAN BE SUCCESSFULLY DELIVERED FOLLOWING BTKI THERAPY FAILURE FOLLOWING R-BAC RE-INDUCTION CHEMOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA**

### **CLINICAL OUTCOMES OF EBV+ PTLD PATIENTS FOLLOWING HCT WHO FAIL RITUXIMAB: A RETROSPECTIVE CHART REVIEW STUDY FROM FRANCE**

Gérard Socié, Arnaud Pigneux, Charles Herbaux, Paul Chauvet, Hairong Xu, Dhanalakshmi Thirumalai, Norma Guzman-Becerra, Arie Barlev, John Reitan, Mohamad Mohty (France)

### **THE IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) ON THE OUTCOME OF POOR-RISK NON-HODGKIN LYMPHOMA (NHL): UPDATE OF A RETROSPECTIVE INTENT-TO-TRANSPLANT (ITT) ANALYSIS**

Lorenz Selberg, Peter Stadtherr, Sascha Dietrich, Thomas Luft, Ute Hegenbart, Andrea Bondong, Julia Meissner, Nora Liebers, Michael Schmitt, Carsten Müller-Tidow, Peter Dreger (Germany)

### **REDUCING THE COST OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMAS AT LIMITED-RESOURCE CENTERS IN DEVELOPING COUNTRIES**

Eucario Leon Rodriguez, Monica Magdalena Rivera Franco (Mexico)

### **COMPARISON OF MITOXANTRONE - MELPHALAN AND BEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS**

Ahmet Kursad Gunes, Ilknur Demir, Serpil Sarifakioglu, Salih Sertac Durusoy, Dervis Murat Akkurt, Idris Ince, Gulkan Ozkan, Mustafa Pehlivan (Turkey)

### **NIVOLUMAB RE-CHALLENGE IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: WHERE IS THE PLACE FOR ALLOHSCT?**

Liudmila Fedorova, Kirill Lepik, Natalia Mikhailova, Elena Kondakova, Yuri Zalyalov, Vadim Baykov, Elena Babenko, Evgeniya Borzenkova, Lilia Stelmakh, Boris Afanasyev (Russian Federation)

### **OUTCOME OF TRANSPLANT ELIGIBLE MANTLE CELL LYMPHOMA PATIENTS WITH FIRST-LINE REGIMENS IN A REAL-WORLD SETTING: A PORTUGUESE MULTICENTER RETROSPECTIVE ANALYSIS**

Pedro Chorão, Teresa Ribeiro, Maria Gomes Silva, Raquel Guilherme, Filipa Saraiva, Joana Vieira, Inês Carvalhais, Sérgio Chacim, José Mário Mariz, Daniela Coelho, Marília Gomes, Manuela Mafra, Mariana Leal Fernandes, Ana Mata, Daniela Alves, Fernando Príncipe (Portugal)

### **EVALUATION OF FRACTIONATED ICE AS AN ALTERNATIVE OUTPATIENT OPTION FOR RELAPSED/REFRACTORY LYMPHOMAS**

Reyad Dada, Ehab Abdelghany, Tarek Boubakr, Emily Lenore Goldman-Heaphy, Azhar Nawaz (Saudi Arabia)

### **EFFICACY OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA**

Anastasiya Beynarovich, Kirill Lepik, Natalia Mikhailova, Elena Kondakova, Yurii Zalyalov, Eugenia Borzenkova, Elena Babenko, Elena Darskaya, Alexander Aliynskiy, Ivan Moiseev, Boris Afanasyev (Russian Federation)

### **RISK FACTORS FOR INTENSIVE CARE UNIT ADMISSION IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

### **AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA**

### **DIFFERENT OUTCOMES WITH DIFFERENT DONORS IN ALLOGENEIC STEM CELL TRANSPLANTATIONS IN MALIGNANT LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE**

## Scientific Programme

### **THE IRISH EXPERIENCE OF THIOTEPA, CARMUSTINE AND ETOPOSIDE CONDITIONING PRIOR TO ASCT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS**

### **TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA**

### **ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS TREATMENT OPTION FOR RARE TRANSDIFFERENTIATION OF LYMPHOID NEOPLASMS INTO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS TO ACHIEVE LONG-TERM SURVIVAL**

Andriyana Bankova, Urs Schanz, Eugenia Haralambieva, Ewerton Maggio, Corinne Widmer (United States)

### **OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH PERIPHERAL T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)**

### **TREATMENT OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. A STUDY OF THE POLISH LYMPHOMA RESEARCH GROUP**

Joanna Romejko-Jarosinska, Ewa Paszkiewicz-Kozik, Małgorzata Krawczyk-Kulis, Patrycja Mensah-Glanowska, Lukasz Targonski, Agnieszka Giza, Tomasz Czerw, Katarzyna Domanska-Czyz, Kseniya Kviatkouskaya, Paulina Magda, Włodzimierz Mentrek, Beata Ostrowska, Maria Sadus-Wojciechowska, Sebastian Giebel, Jan Walewski (Poland)

### **PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH T-CELL LYMPHOMAS: PAVLOV UNIVERSITY EXPERIENCE**

Elena Lepik, Andrey Kozlov, Evgenia Borzenkova, Yuri Zalyalov, Kirill Lepik, Elena Kondakova, Vadim Baykov, Aleksander Alyanskiy, Ivan Moiseev, Tatiana Schneider, Natalia Mikhaylova, Boris Afanasyev (Russian Federation)

### **AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA: TOXICITY AND SURVIVAL STUDY**

Khouloud Touihri, Rym El Fatmi, Lamia Torjemane, Dorra Belloumi, Nour Ben Abdeljelil, Amel Lakhal, Saloua Ladeb, Tarek Ben Othman (Tunisia)

### **AUTOIMMUNE COMPLICATIONS IN CHILDREN WITH HODGKIN DISEASE (HD) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT)**

Nataliia Kavardakova, Oleg Ryzhak, Julia Basaluk, Sofia Matsiboh, Olena Kreminska, Tatiana Ponomarenko, Tatiana Smolenska, Alexandra Sharamok, Olena Zinchuk, Olga Kohut, Svitlana Donska (Ukraine)

### **AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIV-RELATED LYMPHOMA**

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS OF 23 PATIENTS**

Dariusz Kata, Agata Wieczorkiewicz-Kabut, Grzegorz Helbig, Małgorzata Kopera, Aleksandra Zimnoch, Kamil Witosz (Poland)

### **NIVOLUMAB BASED RESPONSE ADAPTED TREATMENT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS**

### **AUTOLOGOUS STEM CELL TRANSPLANT IN A SEROPOSITIVE A PATIENT WITH PLASMA BLASTIC LYMPHOMA (PBL)**

Fahad Shaikh, Reetu Jain, Samir Shah, Ganapathi Bhat (India)

## Scientific Programme

### **COMPARING THE EFFICACY AND TOXICITY BETWEEN TWO CONDITIONING REGIMEN IN LYMPHOMA PATIENTS IN WEST OF IRAN (BENDAMUSTIN) OR (CCNU) WITH (ETOPOSIDE, CITARABINE, MELPHALANE)**

Sakine Ghorbani, [Mehrddad Payandeh](#), Nastaran Ahmadi, Mehrnoush Aeinfar (Iran, Islamic Republic of)

e-Posters  
09:30 - 18:00

ePoster Area

## **Minimal residual disease, tolerance, chimerism and immune reconstitution**

### **T CELL CHIMERISM AFTER HCT DOES NOT PREDICT FOR GRAFT LOSS IN NON-MALIGNANT DISEASES, AND IS A FAILURE OF MYELOSUPPRESSION RATHER GRAFT REJECTION**

### **FASTER ENGRAFTMENT AND RECONSTITUTION OF INNATE-IMMUNITY AFTER ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) THAN POST-TRANSPLANT-CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS AFTER MYELOABLATIVE CONDITIONING (MAC) PERIPHERAL-BLOOD-STEM-CELL (PBSC) ALLOGENEIC-TRANSPLANTATION (ALLO-SCT)**

### **CMV SEROPOSITIVITY DRIVES T CELL RECONSTITUTION AFTER CD34-SELECTED ALLOGENEIC HCT DESPITE REDUCTION OF VIREMIA WITH LETERMIVIR**

### **COMPARING OUTCOMES OF PATIENTS HAVING MIXED T CHIMERISM AND UNRELATED DONOR ALLOGRAFTS FOR ACUTE LEUKAEMIA/MDS TO PATIENTS WITH COMPLETE CHIMERISM - SINGLE CENTRE RETROSPECTIVE STUDY**

### **CMV INFECTION IS ASSOCIATED WITH REDUCED THYMIC FUNCTION AND LESS REGULATORY T CELLS AFTER PEDIATRIC ALLOGENEIC HSCT**

[Katrine Kielsen](#), Dina Leth Møller, Anders Elm Pedersen, Marianne Ifversen, Claus H. Nielsen, Lars P. Ryder, Klaus Müller (Denmark)

### **IMPACT OF PRE-TRANSPLANT MRD BURDEN MEASURED BY MULTICOLOR FLOW CYTOMETRY ON RELAPSE AND SURVIVAL IN AML PATIENTS UNDERGOING ALLO-SCT IN CR**

[Evgeny Klyuchnikov](#), Maximilian Christopeit, Anita Badbaran, Ute-Marie von Pein, Urike Fritzsche-Friedland, Christine Wolschke, Nicolaus Kröger (Germany)

### **FLOW-BASED PRE-TRANSPLANT MRD DETECTION STRONGLY IMPACTS ON THE OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION WITH AB T CELL DEPLETION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA**

[Larisa Shelikhova](#), M Ilyushina, A Popov, Z Shekhovtsova, D Balashov, A Kazachenok, I Muzalevsky, I Shipitsina, D Shasheleva, S Kozlovskaya, R Khismatullina, E Kurnikova, J Abugova, A Bogoyavlenskaya, S Blagov, Y Skvortsova, D Pershin, D Kobzyeva, A Nechesnyuk, N Myakova, D Litvinov, G Novichkova, A Maschan, M Maschan (Russian Federation)

### **CMV-SPECIFIC T CELL COUNTS EARLY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION STRATIFY THE RISK OF SUBSEQUENT CMV REACTIVATIONS: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY**

### **IMPROVED RELAPSE-FREE-SURVIVAL IN PATIENTS WITH HIGH NATURAL KILLER CELL DOSES IN GRAFTS AND DURING EARLY IMMUNE RECONSTITUTION AFTER ALLOGENEIC TRANSPLANTATION WITH PERIPHERAL BLOOD STEM CELLS**

[Lia Minculescu](#), Anne Fischer-Nielsen, Eva Haastrup, Lars Peter Ryder, Niels Smedegaard Andersen, Ida Schjoedt, Lone Smidstrup Friis, Brian Thomas Kornblit, Søren Lykke Petersen, Hanne Vibeke Marquart, Henrik Sengelov (Denmark)

### **POTENTIAL INFLUENCE OF IMMUNODEFICIENCY-RELATED HEREDITARY PREDISPOSITION GENE VARIANTS ON RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

[Zhihui Li](#), Tong Wu, Qinglong Zheng, Caiyan Zhang, Yongqiang Zhao, Yanzhi Song (China)

## Scientific Programme

### **COMPARABLE RESULTS OF PREEMPTIVE RECOMBINANT IL-2 AND DONOR LYMPHOCYTE INFUSION IN HEMATOLOGICAL MALIGNANCY PATIENTS WITH LATE-ONSET MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **SURVIVAL ANALYSIS ACCORDING TO MINIMAL RESIDUAL DISEASE BY FLOW CYTOMETRY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA**

### **IMPACT OF RESIDUAL CIRCULATING TUMOR DNA STATUS POST ALLOGENEIC SCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES: INTERIM RESULTS OF A PROSPECTIVE STUDY**

Miho Ogawa, Kazuaki Yokoyama, Hiroto Ishii, Takayoshi Tachibana, Taisei Suzuki, Kiyoshi Okazuka, Yuri Tamura, Takuya Miyazaki, Chikako Ohwada, Mai Mizusawa, Kensuke Usuki, Heiwa Kanamori, Chiaki Nakaseko, Tatsuki Tomikawa, Yu Akahoshi, Yuhei Nagao, Shokichi Tsukamoto, Masahiro Takeuchi, Emiko Sakaida, Makoto Onizuka, Susumu Tanoue, Shingo Yano, Satoko Osanai, Akihito Shinohara, Junji Tanaka, Sachiko Seo, Nobuyuki Aotsuka, Nobuhiro Tsukada, Shin Fujisawa, Nozomi Yusa, Kanya Kondoh, Tomomi Takei, Sousuke Nakamura, Mika Ito, Rika Kasajima, Mako Yamamoto, Eigo Shimizu, Masamichi Isobe, Takaaki Konuma, Seiko Kato, Rui Yamaguchi, Seiya Imoto, Satoshi Takahashi, Satoru Miyano, Arinobu Tojo, Shinichiro Okamoto (Japan)

### **EARLY CD4+ T CELL RECONSTRUCTION AS PREDICTOR FOR OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC AND YOUNG ADULT PATIENTS: A VALIDATION COHORT ANALYSIS**

Susan Prockop, Ichelle van Roessel, Elizabeth Klein, Farid Boulad, Andromachi Scaradavou, Barbara Spitzer, Andrew Kung, Kevin Curran, Maria Cancio, Richard O'Reilly, Nancy Kernan, Jaap Jan Boelens (United States)

### **PATTERN OF RECONSTITUTION OF RECENT THYMIC EMIGRANTS AFTER REDUCED INTENSITY CONDITIONING BASED ON TARGETED BUSULFAN IN PAEDIATRIC RECIPIENTS OF ALLOGENEIC HAEMATOPOETIC STEM CELL TRANSPLANTATION**

Daniel Drozdov, Katrin Petermann, Leonhard Held, Tayfun Güngör, Mathias Hauri-Hohl (Switzerland)

### **A RISK SCORE SYSTEM BASED ON POST-TRANSPLANTATION MINIMAL RESIDUAL DISEASE FOR STRATIFICATION OF RELAPSE IN B-ALL PATIENTS AFTER ALLOGENIC STEM CELL TRANSPLANTATION**

Yang Zhou, Le-Qing Cao, Yan-Rong Liu, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Kai-Yan Liu, Qiao-Zhen Fan, Ying-Jun Chang, Xiao-Jun Huang (China)

### **OUTCOME OF CHILDREN WITH HEMATOLOGICAL MALIGNANCIES WHO DEVELOP MIXED DONOR CHIMERSIM AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Amit Dotan, Danna Zevy, Kuang-Yueh Chiang, Tal Schechter-Finkelstein, Muhammed Ali, Joerg Krueger (Israel)

### **PROPHYLACTIC HIGH-DOSE DONOR CD45RO+ MEMORY T-CELLS INFUSION AFTER ALLOGENEIC TRANSPLANTATION: SAFETY AND OUTCOME**

Mercedes Gasior Kabat, Luisa Sisinni, Raquel De Paz, David Bueno, Yasmina Mozo, Beatriz De La Cruz, Antonio Marcos, Ana Belen Romero, Victor Jimenez Yuste, Antonio Pérez-Martínez (Spain)

### **MULTICOLOR FLOW CYTOMETRY PANEL WITH CCD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT**

### **NON-INVASIVE MONITORING OF MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE BY CIRCULATING CELL-FREE NUCLEIC ACIDS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

Miguel Waterhouse, Sandra Patricia Pennisi, Dietmar Pfeifer, Justus Duyster, Hartmut Bertz, Jürgen Finke, Jesus Duque-Afonso (Germany)

## Scientific Programme

### **TORQUE TENO VIRUS AS BIOMARKER TO PREDICT COMPLICATIONS AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Amandine Pradier, Stavroula Masouridi-Levrat, Carine Bosshard, Carole Dantin, Diem-Lan Vu, Marie-Céline Zanella, Elsa Boely, Caroline Tapparel, Laurent Kaiser, Yves Chalandon, [Federico Simonetta](#), Eddy Roosnek (Switzerland)

### **PREEMPTIVE INTERFERON- $\alpha$ TREATMENT COULD PROTECT AGAINST RELAPSE AND IMPROVE SURVIVAL OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

[Si-Ning Liu](#), Xue-Yi Luo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Dong Mo (China)

### **THE ADDITION OF BUSULFAN REDUCES THE INCIDENCE OF MIXED CHIMERISM FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA**

### **A NEW MULTIVARIATE MODEL TO DESCRIBE IMPACT OF IMMUNE RECONSTITUTION ON THE DEVELOPMENT OF RELAPSE IN CHILDREN UNDERGOING ALLO-HSCT FOR HEMATOLOGIC MALIGNANCIES AT DAY +100**

[Manuela Spadea](#), Francesco Saglio, Massimo Berger, Francesca Carraro, Rosanna Pessolano, Emanuela Ricotti, Elena Ernestina Vassallo, Franca Fagioli (Italy)

### **ACQUISITION OF COMPLETE CHIMERISM IN BONE MARROW, PERIPHERAL BLOOD AND LEUKOCYTE SUBSETS DEPENDS ON THE TRANSPLANT SETTING AND CORRELATES WITH THE CLINICAL OUTCOME**

[Almudena Navarro-Bailon](#), Diego Carbonell, Julia Suárez-González, María Chicano, Mi Kwon, Rebeca Bailén, Nieves Dorado, José Luis Díez-Martín, Carolina Martínez-Laperche, Ismael Buño (Spain)

### **EARLY LYMPHOID SUBSETS RECONSTITUTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AS PREDICTOR OF RELAPSE AND SURVIVAL IN ACUTE LEUKEMIAS**

### **COMPARISON OF IMMUNE RECONSTITUTION BETWEEN 30MG/KG AND 60MG/KG ANTI-T-LYMPHOCYTE GLOBULINE (ATLG) AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANSPLANTATION**

### **FUNCTIONAL IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COMPARISON OF PRE- AND POST-TRANSPLANTATION CYTOKINE RESPONSES IN STIMULATED WHOLE-BLOOD**

Lars Klingen Gjørde, Sisse Rye Ostrowski, Niels Smedegaard Andersen, Lone Smidstrup Friis, Brian Thomas Kornblit, Søren Lykke Petersen, Ida Schjødt, Henrik Sengeløv (Denmark)

### **MEASURABLE RESIDUAL DISEASE (MRD) TESTING FOR ACUTE LEUKEMIA IN EBMT TRANSPLANT CENTERS: A SURVEY ON BEHALF OF THE ALWP OF THE EBMT**

[Arnon Nagler](#), Myriam Labopin, Emmanuelle Polge, Jordi Esteve, Ali Bazarbachi, Eolia Brissot, Gesine Bug, Fabio Ciceri, Sebastian Giebel, Maria Gilleece, Norbert-Claude Gorin, Francesco Lanza, Zina Peric, Annalisa Ruggeri, Jaime Sanz, Bipin Savani, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Frederic Baron, Mohamad Mohty (Israel)

### **TBF REGIMEN INDUCES FULL DONOR CHIMERISM AFTER ALLOGRAFTS IN MYELOFIBROSIS**

### **REAL WORLD UTILITY OF TREATING MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA**

### **COMPARISON OF IMMUNE RECOVERY IN CORD BLOOD AND T AND B DEPLETED HAPLOIDENTICAL GRAFTS RECIPIENTS**

[Chiara Mainardi](#), Giulia Reggiani, Manuela Tumino, Antonio Marzollo, Elisabetta Calore, Marta Pillon, Maria Vittoria Gazzola, Roberta Destro, Daniela Bovo, Piero Marson, Tiziana Tison, Anna Colpo, Alessandra Biffi (Italy)

### **THE BCR-ABL P210 CHIMERIC TRANSCRIPT IN VITRO TRANSFER INTO BONE MARROW MESENCHYMAL STROMAL CELLS VIA EXOSOMES**

## Scientific Programme

### **PROGNOSTIC SIGNIFICANCE OF DONOR-SPECIFIC ISOAGGLUTININ RE-APPEARANCE IN ABO-MISMATCHED STEM CELL TRANSPLANT RECIPIENTS**

Maryam Pourabdollah, Christine Cserti, [Dennis Dong Hwan Kim](#), Eshetu Atenafu, Ivan Pasic, Zeyad Al-Shaibani, Aijun Law, Wilson Lam, Armin Gerbitz, Jeffery Lipton, Auro Viswabandya, Rajat Kumar, Jonas Mattson, Fotios Michelis, Nayana Sondi, Jacob Pendergrast (Canada)

### **IMMUNE-RECONSTITUTION OF LYMPHOCYTE SUBPOPULATIONS WITH RESPECT TO MSC-TREATMENT FOR STEROID REFRACTORY GVHD FOLLOWING HSCT**

### **DAY+100 FULL DONOR CHIMERISM IN THE BONE MARROW CONFERS BETTER OVERALL SURVIVAL IN REDUCED INTENSITY CONDITIONED WITH ALEMTUZUMAB ALLOGENEIC STEM CELL TRANSPLANTATION FOR LYMPHOMAS**

### **DONOR FACTORS INFLUENCE OUTCOMES OF PATIENTS RECEIVING DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION**

[Jose Ros Soto](#), John A Snowden, Richard Szydlo, Emma Nicholson, Alejandro Madrigal, Sandra Easdale, Mark Ethell, Mike Potter, Chloe Anthias (United Kingdom)

### **DETERMINE PATIENTS AT RISK OF RELAPSE AND DEATH IN ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME USING CHIMERISM ON BONE MARROW SAMPLES AT DAY 28 AFTER HSCT**

### **CONCURRENT- SYNERGISTIC ASSESSMENT OF TWO TECHNIQUES IN MONITORING MINIMAL RESIDUAL DISEASE FOR PH(-) ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANTATION LEADS TO FAVORABLE CLINICAL OUTCOMES**

### **DONOR CHIMERISM EVALUATION OF MRD-SUSPECTED CELLS ISOLATED BY FLOW CELL SORTING IS AN ACCESSIBLE TOOL FOR MRD VERIFICATION IN PATIENTS AFTER ALLOGENEIC HSCT**

[Alexandra Semchenkova](#), Vladimir Zhogov, Varvara Brilliantova, Olga Illarionova, Larisa Shelikhova, Michael Maschan, Alexander Popov (Russian Federation)

### **ONE-STEP CHECK PURITY OF CD3+ SORTED CELLS ALONG MONITORING HEMATOPOIETIC CHIMAERISM AFTER HSCT**

### **DONOR LYMPHOCYTE INFUSIONS AUGMENT GRAFT VERSUS MALIGNANCY EFFECT FOLLOWING ALEMTUZUMAB-BASED REDUCED INTENSITY ALLOGRAFTS: REFLECTIONS ON A SINGLE CENTRE STUDY**

Rebecca Lloyd, Graham McIlroy, Nervana Abou-Zeid, Claire Horgan, Richard Lovell, Bhuvan Kishore, Julie Suhr, Charmaine Campbell, Kathleen Holder, Beena Salhan, Shankara Paneesha, Emmanouil Nikolousis, Alexandros Kanellopoulos (United Kingdom)

### **MYELOID-DERIVED SUPPRESSOR CELLS RECOVER QUICKLY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS**

### **PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY**

[Etai Adam](#), Elad Jacoby, Bella Bielgorai, Natalia Ilin, Daphna Hutt, Amos Toren (Israel)

e-Posters  
09:30 - 18:00

ePoster Area

## Non-haematopoietic stem cells

### **THE POTENTIAL ROLES OF MUCOSA-ASSOCIATED INVARIANT T CELLS IN THE PATHOGENESIS OF GUT GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## Scientific Programme

### **FACTORS INFLUENCING THE PRESENCE OF BONE MARROW MESENCHYMAL STEM CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

Judith Schaffrath, Ole Vollstädt, Jana Lützkendorf, Christiane Katzerke, Josephine Schneider, Lisa Maria Siol, Mascha Binder, Lutz P. Müller (Germany)

### **ANALYSIS OF THE GENETIC STABILITY OF DONORS' BONE MARROW STROMA MESENCHYMAL CELLS DURING CULTIVATION**

### **EFFECT OF MATERNAL AND NEONATAL FACTORS ON THE YIELD OF WHARTON'S JELLY MESENCHYMAL STEM CELLS**

### **THE POLISH EXPERIENCE OF WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF PAEDIATRIC PATIENTS**

Maciej Rojek, Michał Piątek, Izabela Zdolińska-Malinowska, Dariusz Boruczkowski (Poland)

### **THE POLISH EXPERIENCE OF WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL TREATMENT OF ADULT PATIENTS**

### **A RETROSPECTIVE ANALYSIS OF BONE MARROW EXAMINATION RESULTS FROM A SINGLE CENTER INSTITUTION: CAN WE REDUCE THE OCCURRENCE OF UNNECESSARY BONE MARROW EXAMINATIONS?**

Seug Yun Yoon, Sung Kyu Park, Jong-Ho Won (Korea, Republic of)

e-Posters  
09:30 - 18:00

ePoster Area

## Paediatric issues

### **PROSPECTIVE OPEN-LABEL PHASE II TRIAL OF INDIVIDUALIZED ANTI-THYMOCYTE GLOBULIN SHOWS IMPROVED EARLY CD4+ T-CELL RECONSTITUTION AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE PARACHUTE-TRIAL**

### **EBMT LESSONS FROM 40 YEARS OF HIGH DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN NEUROBLASTOMA: A REPORT FROM THE PAEDIATRIC WORKING PARTY**

Ruth Ladenstein, Ulrike Poetschger, Penelope Brock, Roberto Luksch, Victoria Castel, Shifra Ash, Vassilios Papadakis, Geneviève Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz de Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Evgenia Glogova, Dominique Valteau-Couanet, Selim Corbacioglu (Austria)

### **INCIDENCE OF SECONDARY MALIGNANCIES AFTER TBI/VP16 CONDITIONING FOR CHILDHOOD ALL: RESULTS OF THE PROSPECTIVE ALL-SCT-BFM-2003 TRIAL**

### **OUTCOME AND RISK FACTORS OF AUTOIMMUNE CYTOPENIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR CHILDREN WITH PRIMARY IMMUNODEFICIENCY**

### **EBMT SURVEY ON 40 YEARS OF HIGH-DOSE CHEMOTHERAPY (HDT) AND STEM CELL TRANSPLANTATION (SCT) IN EWING TUMOURS (ET). A REPORT FROM THE PAEDIATRIC WORKING PARTY**

Ruth Ladenstein, Evgenia Glogova, Christelle Dufour, Edoardo Lanino, Jean Michon, Paul Veys, Roberto Luksch, Uta Dirksen, Krzysztof Kalwak, Stefan Burdach, Henk van den Berg, Boris Afanasyev, Franco Locatelli, Emmanuelle Nicolas-Virelizier, Shifra Ash, Nathalie Gaspar, Jeremy Whelan, Philippe Brault, Ulrike Poetschger, Selim Corbacioglu (Austria)

### **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN CHILDREN - RETROSPECTIVE REPORT ON BEHALF OF I-BFM SCT COMMITTEE AND EBMT PEDIATRIC DISEASES WP**

## Scientific Programme

### **IS THE EBMT RISK SCORE PREDICTIVE OF OUTCOMES IN PAEDIATRIC ACUTE LEUKEMIA?**

#### **TCR $\alpha\beta$ +/-CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION**

#### **THE GREAT ORMOND STREET (GOS) PAEDIATRIC CO-MORBIDITY SCORE FOR OUTCOME POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION**

#### **HIGH PREVALENCE OF CAROTID PLAQUES IN YOUNG ADULTS AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD**

#### **HAPLOIDENTICAL DONOR OR UNRELATED DONOR FOR INFANTS WITH SEVERE COMBINED IMMUNODEFICIENCY?**

Su Han Lum, Zohreh Nademi, Terry Flood, Andrew Cant, Sophie Hambleton, Andrew Gennery, Mary Slatter (United Kingdom)

#### **A 'RISK-ADJUSTED' CYTOREDUCTION WITHOUT RADIATION FOR PATIENTS WITH FANCONI ANEMIA UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION (HCT)**

#### **USE OF RUXOLITINIB IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD)**

#### **HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN REFRACTORY CYTOPENIA OF CHILDHOOD (RCC): IMPROVED ENGRAFTMENT FOLLOWING A TREOSULFAN BASED CONDITIONING REGIMEN**

Brigitte Strahm, Ayami Yoshimi, Miriam Erlacher, Michael Albert, Jochen Buechner, Birgit Burkhardt, Barbara De Moerloose, Kristian Kallay, Peter Lang, Ricardo Masetti, Roland Meisel, Herbert Pichler, Ansgar Schulz, Karl-Walter Sykora, Dominik Turkiewicz, Franco Locatelli, Charlotte Niemeyer (Germany)

#### **PHARMACOKINETICS OF ACTIVE ATG IMPACTS T-CELL RECOVERY AFTER TCR $\alpha\beta$ /CD19-DEPLETED HSCT IN PAEDIATRIC PATIENTS**

Lisa V.E. Oostenbrink, Alexandra Laberko, Elvira Sultanova, Els C.M. Jol-van der Zijde, Anja M. Jansen-Hoogendijk, Carly Vervat, Dmitry Pershin, Maria Fadeeva, Ivan Vladimirov, Robbert G.M. Bredius, Maarten J.D. van Tol, Michael Maschan, Marco W. Schilham, Dmitry Balashov, Arjan C. Lankester (Netherlands)

#### **HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A MULTICENTRE STUDY FROM INDIA**

Sunil Bhat, Revathi Raj, Arun Danewa, Gaurav Kharya, Biju George, Mehdi Intezar, Neha Rastogi, Vikram Mathews, Badiger Shobha, Atish Bakane, Ramya Uppuluri, Satya Prakash Yadav (India)

#### **IMMUNE RECOVERY AND LONG-TERM SURVIVAL FOLLOWING HAPLOIDENTICAL T AND B CELL DEPLETED STEM CELL TRANSPLANTATION - INFLUENCE OF VARIOUS ATG DOSES**

Claus-Philipp Maier, Friedhelm Schuster, Bernd Gruhn, Roland Meisel, Patrick Schlegel, Anne-Marie Lang, Wolfgang Schwinger, Tobias F. Feuchtinger, Holger Martinius, Rupert Handgretinger, Peter Lang (Germany)

#### **OUTCOMES OF HAPLOIDENTICAL VS MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC HIGH-RISK ALL AND AML IN 1ST AND 2ND CR**

Olesia Paina, Zhemal Rakhmanova, Polina Kozhokar, Anastasia Frolova, Lubov Tsvetkova, Kirill Ekushov, Inna Markova, Sergey Bondarenko, Elena Babenko, Aleksandr Alyanskiy, Ildar Barkhatov, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

#### **COMBINED TCR ALPHA BETA AND CD45RA DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BENIGN HAEMATOLOGICAL CONDITIONS, SINGLE CENTRE EXPERIENCE**

Rajat Bhattacharyya, Ah Moy Tan, Michaela Su Fern Seng, Mya Nwe Soe, Prasad Iyer, Anh Thi Ngoc, Vijayakumari K, Wing Leung (Singapore)

## Scientific Programme

### **GENETIC SUSCEPTIBILITY TO HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC PATIENTS UNDERGOING HSCT**

Marc Ansari, Kateryna Petrykey, Mohamad Aziz Rezgui, Veronica Del Vecchio, Jacques Cortyl, Reginald-Olivier Ralph, [Tiago Nava](#), Patrick Beaulieu, Pascal St-Onge, Simona Jurkovic Mlakar, Patricia Huezo-Diaz Curtis, Chakradhara Rao S. Uppugunduri, Laurence Lesne, Yves Théoret, Yves Chalandon, Imke H. Bartelink, Jaap-Jan Boelens, Robbert G. M. Bredius, Jean-Hughes Dalle, Victor Lewis, Bill S. Kangarloo, Christina Peters, Daniel Sinnet, Henrike Bittencourt, Maja Krajcinovic (Switzerland)

### **HAPLO HSCT WITH IN VIVO T-CELL DEPLETION AFTER REDUCED INTENSITY CONDITIONING REGIMEN AND MYELOABLATIVE MUD AND MMUD DONOR HSCT IN PEDIATRIC PATIENTS AFFECTED BY MALIGNANCIES**

[Francesco Saglio](#), Massimo Berger, Manuela Spadea, Francesca Carraro, Rosanna Pessolano, Paola Quarello, Elena Vassallo, Franca Fagioli (Italy)

### **THINKING BEYOND HLH: CLINICAL FEATURES OF PATIENTS WITH CONCURRENT PRESENTATION OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND THROMBOTIC MICROANGIOPATHY**

Nicholas Gloude, Christopher Dandoy, Stella Davies, Kasiani Myers, Michael Jordan, Rebecca Marsh, Ashish Kumar, Jack Bleasing, Ashley Teusink-Cross, [Sonata Jodele](#) (United States)

### **LANDMARK ANALYSIS IN HIGH RISK CHILDHOOD ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. A RETROSPECTIVE STUDY**

[Blanca Molina Angulo](#), Marta Gonzalez Vicent, Ivan Lopez Torija, Ana Castillo, Manuel Ramirez, Miguel Angel Diaz Perez (Spain)

### **DEFIBROTIDE IN HEMATOPOIETIC STEM CELL TRANSPLANT: AN STUDY OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO (GETH) AND GRUPO ESPAÑOL DE TRASPLANTE DE MEDULA EN NIÑOS (GETMON)**

[Marta Gonzalez Vicent](#), Cristina Diaz de Heredia, Jesus Gonzalez de Pablo, Blanca Molina, Alexandra Regueiro, Antonio Perez, Pilar Palomo, Laura Prieto, Estefania Garcia, José María Fernández, Ariadna Pérez, María José Jiménez, Manuel Regueiro, Carlos Vallejo, Ana Isabel Gallardo, Oriana López, Ana Benito, Julia Marsal, Mónica Lopez, Leyre Bento, Isabel Badell, Alexandra Pedraza, Ana Jimenez, Pedro Gonzalez, Mi Kwon, Lissette Costilla, Cristina Belendez, Albert Esquirol, Ildefonso Espigado, Esperanza Lavilla, Miguel Angel Diaz (Spain)

### **NIVOLUMAB-BASED THERAPY PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC HODGKIN'S LYMPHOMA**

### **HUMAN LEUKOCYTE ANTIGEN DISPARITIES REDUCE RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH JUVENILE MYELOMONOCYTIC LEUKEMIA**

### **SCHOOL DURING AND AFTER ALLOGENEIC HSCT: A SURVEY OF PRACTICES IN THREE EUROPEAN COUNTRIES**

[Fanette Bernard](#), Caroline de Pestiers, Claire Galambrun, Mary Slatter, Charlotte Jubert, Nicolas Von der Weid, Eva De Berranger, Cecile Renard, Ben Carpenter, Benedicte Neven, Fanny Rialland, Jean-Hugues Dalle, Persis Amrolia, Marc Ansari, Catherine Paillard (Switzerland)

### **HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HURLER SYNDROME: SINGLE CENTER EXPERIENCE**

### **HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FANCONI ANAEMIA: EXPERIENCE OF THE SPANISH WORKING GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETMON)**

### **IMPACT OF MEMORY T-CELL DOSES INFUSED WITH T-CELL DEPLETED HAPLOIDENTICAL STEM CELL GRAFTS ON TRANSPLANT OUTCOMES**

[Poh Lin Tan](#), Chintan Vyas, Mariflor Villegas, Frances Yeap, Teck Guan Soh (Singapore)

### **THE ROLE OF DONOR KIR GENOTYPING IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-MALIGNANT DISORDERS**

## Scientific Programme

### **SINGLE-CENTER EXPERIENCE OF TCR $\alpha\beta$ /CD19 DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANEMIA**

Svetlana Radygina, Larisa Shelikhova, Irina Shipitsina, Yulia Skvortsova, Anna Vasilieva, Svetlana Kozlovskaya, Rimma Khismatullina, Anna Livshits, Alexei Maschan, Michael Maschan, Dmitry Balashov (Russian Federation)

### **DETECTION OF RECIPIENT-SPECIFIC $\alpha/\beta$ -T-CELLS DURING THE PRE-ENGRAFTMENT PHASE DOES NOT PREDICT GRAFT REJECTION IN PATIENTS AFTER HAPLOSCT: PRELIMINARY RESULTS OF SINGLE CENTRE PROSPECTIVE TRIAL**

Ladislav Król, Dominik Turkiewicz, Stig Lenhoff, Annika Hult, Annika Kisch, Mari-Louise Römbo, Lisette Hollender, Ingrid Øra, Josefina Dykes (Sweden)

### **IMPROVED SURVIVAL AFTER MIBG THERAPY IN COMBINATION WITH MEGACHEMOTHERAPY THAN AFTER STAND-ALONE THERAPY IN CHILDREN WITH NEUROBLASTOMA - POLISH NATION-WIDE RETROSPECTIVE STUDY**

Marek Ussowicz, Aleksandra Wieczorek, Agnieszka Dłużniewska, Anna Pieczonka, Katarzyna Drabko, Robert Dębski, Jolanta Goździk, Jacek Wachowiak, Walentyna Balwierz, Daria Handkiewicz-Junak (Poland)

### **THE IMPACT OF HOUSEHOLD INCOME ON ACUTE HOSPITALIZATION DAYS IN PEDIATRIC ALLOGENEIC TRANSPLANT RECIPIENTS**

### **USE OF RIC REGIMENS COMBINED WITH TCRAB DEPLETION AND POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC MISMATCHED SCT**

Peter Lang, Michaela Doering, Anne-Marie Lang, Patrick Schlegel, Christian Seitz, Robin Fischer, Marina Schmidt, Martin Ebinger, Ursula Holzer, Ines Brecht, Rupert Handgretinger (Germany)

### **THE ROLE OF HLA-DP MATCHING IN DONOR SELECTION FOR MUD-HSCT IN CHILDREN WITH HEMATOLOGIC MALIGNANT DISEASES**

Manuela Tumino, Giulia Reggiani, Chiara Mainardi, Elisabetta Calore, Antonio Marzollo, Elisa Carraro, Maria Vittoria Gazzola, Roberta Destro, Matteo Barioni, Aurora Strano, Marta Pilon, Alessandra Biffi (Italy)

### **CLINICAL IMPLICATION ON RECOVERY OF $\gamma\delta$ T CELLS AFTER TCR $\alpha\beta$ -DEPLETED HAPLOIDENTICAL HSCT IN PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE**

Eun Seok Choi, Sung Han Kang, Jin Kyung Suh, Hyeri Kim, Kyung Nam Koh, Ho Joon Im (Korea, Republic of)

### **EARLY INITIATION OF CYCLOSPORINE-MYCOPHENOLATE PLUS ANTITHYMOCYTE GLOBULIN IN HAPLO TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN: LOW INCIDENCE OF SEVERE ACUTE GVHD WITH ENCOURAGING SURVIVAL**

Angela María Trujillo Gaviria, Amado Jose Karduss U, Gloria Suarez, Angelica Cardona, Monica Ramirez, Jose Betancurt (Colombia)

### **FEASIBILITY AND SAFETY OF SURGICAL FERTILITY PRESERVATION TECHNIQUES PROXIMAL TO INITIATION OF CONDITIONING THERAPY IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT**

Katelynn Brodigan, Lindsay Frazier, Christine Duncan, Richard Yu, Marc Laufer, Brent Weil, Elizabeth Ginsburg, Serene Srouji, Leslie Lehmann (United States)

### **VENO-OCCLUSIVE DISEASE WITH EMPHASIS ON RENAL MANIFESTATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: A SINGLE CENTER EXPERIENCE**

Aharon Gefen, Shirley Pollack, Irina Zeidman, Neta Nevo, Israel Eisenstein, Daniella Magen, Myriam Weyl-Ben Arush (Israel)

### **OUTCOME AFTER HSCT IN CHILDREN WITH JMML FROM A HISTORICAL POINT OF VIEW**

## Scientific Programme

### **THE IMPACT RECOVERY ABSOLUTE LYMPHOCYTE COUNT AT DAYS +21 ON OUTCOME ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALL**

Lubov Tsvetkova, Olesia Paina, Zhemal Rakhmanova, Polina Kozhokar, Anastasia Frolova, Kirill Ekushov, Inna Markova, Sergey Bondarenko, Elena Babenko, Aleksandr Alyanskiy, Ildar Barkhatov, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

### **T-CELL-RICH HAPLOIDENTICAL STEM CELL TRANSPLANTATION IMPROVES SURVIVAL IN CHILDREN WITH ACUTE LEUKEMIA RELAPSED AFTER ALLOGENEIC TRANSPLANTATION**

Nobuhisa Takahashi, Shogo Kobayashi, Hideki Sano, Kazuhiro Mochizuki, Yoshihiro Ohara, Hitoshi Ohto, Kazuhiko Ikeda, Atsushi Kikuta (Japan)

### **HIGH PREVALENCE OF VITAMIN C DEFICIENCY IN A LARGE PAEDIATRIC COHORT UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE FROM 2003-2019**

Rebecca Fisher, Jun Cai, Peter Shaw, Melissa Gabriel (Australia)

### **EX VIVO T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-MALIGNANT DISEASE**

Ho Joon Im, Eun Seok Choi, Sung Han Kang, Jin Kyung Suh, Hyery Kim, Kyung-Nam Koh (Korea, Republic of)

### **LONG-TERM ERYTHROPOIETIC RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: HOST DETERMINES RESULT**

Erik von Asmuth, Marco Schilham, Hein Putter, Alexander Mohseny, Arjan Lankester (Netherlands)

### **BOOST WITH CD34+ CELLS FOR POOR GRAFT FUNCTION TREATMENT AFTER HSCT IN PAEDIATRIC PATIENTS. A MULTICENTER STUDY**

Massimo Berger, Francesco Saglio, Maura Faraci, Aracangelo Prete, Franca Fagioli (Italy)

### **NO DIFFERENCE IN SURVIVAL AFTER HLA MISMATCHED VERSUS HLA MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION**

Uwe Thiel, Sebastian Schober, Andreas Ranft, Susanne Jabar, Hendrik Gaßmann, Peter Bader, Ewa Koscielniak, Bernd Gruhn, Uta Dirksen, Jürgens Heribert, Stefan Burdach, Peter Lang (Germany)

### **ALLOGENIC STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE**

Eman Khattab, Abdelghani Tbakhi, Rula Najjar, Mayada Abu Shanap, Rawad Rihani, Hasan Hashem, Wafa Hdeib, Rawan Abed Alrahman, Du'A Darabseh, Nilly Hussein, Iyad Sultan (Jordan)

### **STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH NON-ANAPLASTIC PERIPHERAL T-CELL LYMPHOMA ON BEHALF OF THE EBMT-PEDIATRIC DISEASES WORKING PARTY**

Olga Moser, Arnaud Dalissier, Wilhelm Woessmann, Birgit Burkhardt, Karin Mellgren, Andre Manfred Willasch, Udo Kontny (Germany)

### **FIRST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RASGRP1 DEFICIENCY SUCCESSFUL HSCT IN IMMUNE DISREGULATORY DISEASES**

### **LEVOFLOXACIN BASED PROPHYLAXIS IN CHILDREN RECEIVING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT AFFECT THE INCIDENCE OF ACUTE GVHD AND BLOODSTREAM INFECTIONS**

Davide Leardini, Daniele Zama, Edoardo Muratore, Andrea Tozzi, Teresa Papaleo, Francesco Bacelli, Tamara Belotti, Elena Legnani, Arcangelo Prete, Andrea Pession, Riccardo Masetti (Italy)

## Scientific Programme

### **RITUXIMAB-INDUCED SECONDARY HYPOGAMMAGLOBULINEMIA: MEMORIAL SLOAN KETTERING'S 10-YEAR EXPERIENCE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

Zahra Hudda, Montserrat Cols Vidal, Susan Prockop, Richard O'Reilly, Nancy Kernan, Jayanta Chaudhuri (United States)

### **'INCURABLE' PAEDIATRIC MYELOID LEUKAEMIA TREATED WITH NOVEL CELL-BASED THERAPEUTICS**

Mariflor Villegas, Yeap Frances, Doris Tan, Poh Lin Tan (Singapore)

### **EFFECT OF SERUM PANEL REACTIVE ANTIBODIES ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-CENTER EXPERIENCE**

### **SINGLE CENTRE EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR INHERITED BONE MARROW FAILURE SYNDROMES**

Cristina Jercan, Ana Maria Bica, Letitia-Elena Radu, Alexandra Ionete, Ileana Constantinescu, Carmen Calugaroiu, Aurora Dragomiristeanu, Anca Colita (Romania)

### **IS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A GOOD INDICATION FOR PATIENTS WITH SIFD SYNDROME?**

Victoria Bordon, Patrick Verloo, Catharina Dhooge (Belgium)

### **TIME COURSE AND IMPACT OF BODY WEIGHT CHANGE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS**

Kenji Kishimoto, Daiichiro Hasegawa, Sayaka Nakamura, Akihiro Tamura, Aiko Kozaki, Asturo Saito, Toshiaki Ishida, Takeshi Mori, Yoshiyuki Kosaka (Japan)

### **AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC HIGH RISK EWING SARCOMA, A SINGLE CENTER EXPERIENCE**

Hila Rosenfeld Keidar, Amit Dotan, Sabina Edelman, Ronit Elhasid (Israel)

### **CONDITIONING FOR RETRANSPLANTATION FROM THE SAME DONOR AFTER PARTIAL AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH PID: IMMUNOSUPPRESSION IS NOT REQUIRED**

Sarah Maria Bauer, Mehtap Sirin, Kerstin Felgentreff, Eva-Maria Jacobsen, Klaus-Michael Debatin, Ansgar Schulz, Manfred Hoenig (Germany)

### **TOCILIZUMAB TREATMENT FOR CRS IN HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

### **IDIOPATHIC PNEUMONIA SYNDROME (IPS) AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM UNRELATED DONOR FOR HURLER SYNDROME (MUCOPOLYSACCHARIDOSIS TYPE 1) SUCCESSFULLY TREATED WITH ETANERCEPT AND STEROIDS**

Kinan Kafa, Claudia Bettoni da Cunha-Riehm, Tayfun Güngör, Jan-Henning Klusmann (Germany)

### **EFFECT OF DESENSITIZATION PROTOCOL ON TRANSPLANTATION SUCCESS IN CHILDREN WITH ANTI-HLA ANTIBODIES**

### **OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOHSCT) WITH DIFFERENT INTENSITY CONDITIONING REGIMENS IN INFANT AML**

Zhemal Rakhmanova, Olesia Paina, Polina Kozhokar, Anastasia Frolova, Lubov Tsvetkova, Kirill Ekushov, Elena Babenko, Tatyana Gindina, Aleksandr Alyanskiy, Ildar Barkhatov, Elena Semenova, Ludmila Zubarovskaya, Boris Afanasyev (Russian Federation)

### **VENETOCLAX/DECITABINE FOR PEDIATRIC MDR-AML RELAPSED AFTER TWO ALLO HSCTS**

Johannes Raedler, Sita Heyde, Marie Kolokythas, Anna Eichinger, Vera Binder, Tobias Feuchtinger, Michael Albert (Germany)

## Scientific Programme

### **HIGHER INCIDENCE OF CMV AND BKV REACTIVATION IN HAPLOIDENTICAL TRANSPLANTS COMPARATIVE TO MUD OR MSD TRANSPLANTS - SINGLE CENTRE RETROSPECTIVE ANALYSIS**

### **USE OF POLYCLONAL IGM-ENRICHED IMMUNOGLOBULINS FOR THE TREATMENT OF SEPTIC EPISODES IN CHILDREN WITH ONCOHEMATOLOGICAL DISEASES**

Nicoletta Abram, Valentina Baretta, Federico Mercolini, Gloria Tridello, Margherita Mauro, [Simone Cesaro](#) (Italy)

### **PAEDIATRIC BONE MARROW TRANSPLANT CARE ON BMT VERSUS NON-BMT PAEDIATRIC WARDS**

### **CHRONIC HEALTH PROBLEMS IN CHILDREN AFTER ALLOGENEIC HSCT: THE TOP OF THE ICEBERG?**

[Victoria Bordon](#), Kathleen De Waele, Sophie Van Lancker, Catharina Dhooge (Belgium)

### **HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: SINGLE-CENTER SERIES OF 14 CASES**

### **NON-WHITE HISPANIC ETHNICITY AS A RISK FACTOR FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC TRANSPLANT**

[Iván López Torija](#), Marta González Vicent, Blanca Molina Angulo, Jesús González de Pablos, Miguel Ángel Díaz Pérez (Spain)

### **PNEUMATOSIS INTESTINALIS AS A RARE POST-TRANSPLANT COMPLICATION IN PEDIATRIC PATIENTS**

[Johanna Schepp](#), Mehtap Sirin, Kerstin Felgentreff, Carolin Grimm, Klaus-Michael Debatin, Ansgar Schulz, Manfred Hoenig (Germany)

### **THE CHALLENGES AND OUTCOMES SURROUNDING INTRAVESICULAR CIDOFOVIR ADMINISTRATION: A PAEDIATRIC PHARMACY PERSPECTIVE**

[Poonam Lumb](#), Neil Tickner, Josu De La Fuente, Leena Karnik, Sandrine Bremathas (United Kingdom)

### **THE EXPERIENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RARE HEMATOLOGIC DISEASE**

### **SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A CHILD WITH DNA LIGASE IV DEFICIENCY WITH NONMYELOABLATIVE CONDITIONING REGIMEN**

### **HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT-HD-CYCLOPHOSPHAMIDE FOR RELAPSED B-LYMPHOBLASTIC LYMPHOMA (B-LBL) WITH MLL-REARRANGEMENT IN 1 Y.O. CHILD: A CLINICAL CASE**

e-Posters  
09:30 - 18:00

ePoster Area

## Regenerative medicine

### **WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELL THERAPY IMPROVES THE QUALITY OF LIFE AND SELF-SUFFICIENCY OF CHILDREN WITH AUTISM SPECTRUM DISORDER**

[Izabela Zdolińska-Malinowska](#), Magdalena Chrościńska-Krawczyk, Michał Piątek, Maciej Rojek, Dariusz Boruckowski (Poland)

### **MARROW DERIVED CELLS BRING A LONG LASTING RELIEF WHEN INJECTED INTRAARTICULARLY TO THE JOINTS WITH DEGENERATIVE ARTHRITIS**

Agata Borowik, Arkadiusz Janusz, Janusz Lange, Danuta Sosnowska, Emilia Jaskula, [Andrzej Lange](#) (Poland)

## Scientific Programme

### **OSTEOGENIC DIFFERENTIATION CAPACITY OF ADIPOSE-DERIVED STEM CELLS AFFECTED WITH COLD STORAGE**

Hee-Hoon Yoon, In Keun Jang, O Kyu Noh, Jang Hoon Lee, Kwang Chul Lee, [Jun Eun Park](#) (Korea, Republic of)

e-Posters  
09:30 - 18:00

ePoster Area

## **Stem cell mobilization, collection and engineering**

### **TWO YEAR ANALYSIS OF A PROSPECTIVE PHASE I/II CLINICAL TRIAL IN ADULTS USING TCR ALPHA/BETA DEPLETED STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONORS**

### **A NEW BSA-BASED THRESHOLD PREDICTS OPTIMAL PBSC COLLECTION IN T-CELL DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

### **PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILIZATION AND COLLECTION OF CD34+ HSCS WITHOUT G-CSF**

### **DEPLETION OF $\alpha\beta$ T-CELLS AND B-CELLS BEFORE HLA-HAPLOIDENTICAL HSCT IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISORDERS: A REPORT OF 473 PROCEDURES**

### **ACOUSTOPHORESIS ENABLES THE LABEL-FREE SEPARATION OF DISTINCT SUBSETS FROM CULTURED BONE MARROW STROMAL CELLS**

Franziska Olm, Hooi Ching Lim, Katharina Schallmoser, Dirk Strunk, Thomas Laurell, [Stefan Scheduling](#) (Sweden)

### **FEASIBILITY OF MODIFIED CD45RA NEGATIVE DONOR LYMPHOCYTES INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

### **BEYOND STEM CELLS - DOES IT MATTER WHAT'S IN THE BAG IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA AND LYMPHOMA?**

Holly Emms, Dara Qadir, Rowayda Peters, Claire Wiggins, Oliver Gittner, Andy Drake, [Matthias Klammer](#) (United Kingdom)

### **EXPRESSIONS OF CO-INHIBITORY MARKERS INCREASE EFFECTOR MEMORY T CELLS IN G-CSF MOBILIZED PERIPHERAL STEM CELLS**

[Jeong-A Kim](#), Misuk Yang, Youngrok Park, Young Hoon Park, Jae-Yong Kwak (Korea, Republic of)

### **LIPEGFILGRASTIM COMBINED WITH CHEMOTHERAPY WAS MORE COST-EFFECTIVE THAN PEGFILGRASTIM IN THE MOBILIZATION OF CD34+ CELLS IN NHL PATIENTS**

[Anu Partanen](#), Antti Turunen, Jaakko Valtola, Kaija Vasala, Lasse Ågren, Karri Penttilä, Marja Pyörälä, Taru Kuittinen, Pentti Mäntymaa, Jukka Peltonen, Esa Jantunen, Ville Varmavuo (Finland)

### **MOBILIZATION AND HARVEST OF PERIPHERAL BLOOD STEM CELLS (PBSC) FOR ALLOGENEIC STEM CELL TRANSPLANTATION FROM 335 PEDIATRIC SIBLING HEALTHY DONORS**

### **A COMPARISON OF CHEMO-FREE STRATEGY WITH G-CSF PLUS PLERIXAFOR ON DEMAND VERSUS ID-CYCLOPHOSPHAMIDE AND G-CSF AS PBSC MOBILIZATION IN MULTIPLE MYELOMA: AN EXPLORATIVE COST ANALYSIS**

## Scientific Programme

### **EVALUATION OF VIA FREEZETM QUAD FOR LIQUID NITROGEN-FREE CGMP-COMPATIBLE CONTROLLED-RATE FREEZING OF HEMATOPOIETIC PROGENITOR CELL GRAFTS**

Bechara Mfarrej, Olivier Vicari, Sophie Thevenet, Kerjean Elodie, Claude Lemarie, Christian Chabannon, Boris Calmels (France)

### **CD34 + CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS**

### **PLERIXAFOR ON DEMAND IN COMBINATION WITH LOW-DOSE CYCLOPHOSPHAMIDE AND G-CSF FOR THE MOBILIZATION OF HSC IN MULTIPLE MYELOMA PATIENTS: HIGH EFFICACY AND LOW TOXICITY**

### **PERFORMANCE QUALIFICATION OF LOVOTM MEDICAL DEVICE FOR WASHING AND CONCENTRATING 3 AND MORE HEMATOPOIETIC PROGENITOR CELL CRYOPRESERVED BAGS**

Bechara Mfarrej, Guillaume Bouchet, Jerome Couquiaud, Lionel Regimbaud, Sophie Thevenet, Elodie Kerjean, Claude Lemarie, Christian Chabannon, Boris Calmels (France)

### **FROM WORK-UP REQUEST TO DONATION IN THREE WEEKS: A DEDICATED REGISTRY INTEGRATED UNRELATED DONOR STEM CELL COLLECTION CENTER IS SAFE, EFFICIENT AND CONVENIENT FOR DONORS**

Isaac Yaniv, Tsippi Kestenbom, Sigal Manor, Bracha Zisser (Israel)

### **LOW-DOSE CYCLOPHOSPHAMIDE + G-CSF IS NO MORE EFFECTIVE THAN G-CSF ALONE WHEN MOBILIZING AND COLLECTING STEM CELLS FOR AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA PATIENTS**

Antonio José Palma Vallellano, Rocío Zapata Bautista, Carmen Beltrán, Margarita Bendala, Ana R. Carranco, Miguel A. Castilla, Bianca Díaz, Juan Francisco Dominguez, Francisco Fernández, Encarnación Gil, Karol Gómez, Susana Ramírez, Juan Nicolás Rodríguez, María Solé, Pilar Velarde (Spain)

### **FIRST INTERIM RESULTS OF NIS OPTIMOB - NATIONWIDE TRIAL OF MOBILIZATION AND COLLECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS**

### **THE IMPACT OF PLERIXAFOR 'ON DEMAND' ON THE HEMATOPOIETIC STEM CELL (HSC) COLLECTION, PRODUCT'S QUALITY AND ENGRAFTMENT**

### **ELEVATED SERUM LACTATE DEHYDROGENASE AFTER STEM CELL MOBILISATION PREDICTS SUCCESSFUL STEM CELL COLLECTION IN CHILDREN**

### **INFLUENCE OF THE DMSO WASH STRATEGY ON ADVERSE REACTIONS DURING INFUSION OF HEMATOPOIETIC PROGENITORS**

### **BONE MARROW DONOR CHARACTERISTICS: INFLUENCE ON HARVEST YIELD AND DONOR RECOVERY**

### **PLERIXAFOR SALVAGES AUTOLOGOUS STEM CELL MOBILISATION PROCEDURES IN MYELOMA PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE OR AUTOLOGOUS HSCT: COST-EFFECTIVENESS OF UPFRONT USE SHOULD BE EXPLORED**

Paul Miller, Janet Baker, Crischi Magsipoc, Joy Brennan, Maria Mulligan, Janet Wells, Helen McDonald, Kevin Boyd, Martin Kaiser, Mark Ethell, Mike Potter, Sandra Easdale, Chloe Anthias, Emma Nicholson (United Kingdom)

### **EFFECT OF SHIPPING TIME AND TRANSPORT CONDITIONS ON THE VIABILITY OF CORD BLOOD LEUKOCYTES**

Izabela Zdolińska-Malinowska, Maciej Rojek, Michał Piątek, Dariusz Boruckowski (Poland)

### **OPTIMIZATION OF A STEM CELL MOBILIZATION STRATEGY FOR PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA**

### **AUTOLOGOUS LYMPHAPHERESIS FOR THE PRODUCTION OF CAR-T CELLS**

## Scientific Programme

### **RED BLOOD CELL DEPLETION AND/OR VOLUME REDUCTION IN BONE MARROW PROCESSING: A COMPARISON OF TWO METHODS**

Limor Horev Azaria, Yakov Sverdlov, Michal Pearl-Yafe, Orad Shemesh, Alon Kalo, Dana Greenfeld, Jerry Stein (Israel)

### **CORRELATION OF INTRA-OPERATIVE TOTAL NUCLEATED COUNT AND DONOR CHARACTERISTICS WITH FINAL ALLOGENEIC BONE MARROW GRAFT CHARACTERISTICS AND RECIPIENT CLINICAL OUTCOMES**

Jacob Kalin, Anh Thy Nguyen, Benjamin Oshrine (United States)

### **MULTICENTRE EVALUATION OF THE HPC MODUS (XN-20) FOR TIMING THE HARVEST OF STEM CELLS FROM PERIPHERAL BLOOD**

Kathleen Deiteren, Jean-Philippe Defour, Kornelia Hummel, Holger Boysen, Hans Salwender, Jan-Dirk Studt, Antoine Mairesse, Katrien Vermeulen, Dominik Heim, Dimitrios A. Tsakiris (Switzerland)

### **IMPACT OF CHANGE OF MOBILISATION METHOD ON ADEQUACY OF STEM CELL COLLECTION IN MULTIPLE MYELOMA PATIENTS: SINGLE CENTRE EXPERIENCE**

Valarmathi Anandhan, Emma Searle, Jaya Sudhir, Alberto Rocci (United Kingdom)

### **TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE**

Carmen Albo López, Concepción Andon, Dolores Vilariño, Esperanza Lavilla, Julio Del Río, Cristina Fonte, Angeles Cobas (Spain)

### **AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS (PBSCS) MOBILIZATION AND COLLECTION- PRINCESS NOORAH ONCOLOGY CENTER EXPERIENCE, KAMC - JEDDAH - SAUDI ARABIA**

Mona Najib, Ahmed Alsaeed, Ihab Hemaidi, Sameer Al Amoudi, Mohammed Mohammadi (Saudi Arabia)

### **REVIEW OF PLERIXAFOR USE IN A TERTIARY PAEDIATRIC ONCOLOGY CENTRE**

Eileen Butler, Noeleen Comey, Cormac Owens (Ireland)

### **UNUSUAL HIGH COUNT OF CD34+ AFTER CHEMO MOBILIZATION WITH MATRIX IN PATIENT WITH PRIMARY CNS LYMPHOMA IS ASSOCIATED WITH PROMPT AND ROBUST ENGRAFTMENT**

Naziha Menasria, Javid Gaziev, Ruba Yasin Taha, Karama Makni, Halima El Omri, Afraa Mustafa Suleiman Fadul, Weam Zaid El Roz, Ayan Guled, Manal Yaghmour, Rola Sami Al Chahabi, Ajaeb Dakhilalla M H Al-Nabet (Qatar)

### **LEUKOCYTAPHERESIS - ONE TECHNIQUE, DIVERSE OPPORTUNITIES IN THE THERAPY OF PATIENTS**

Zdenka Gasova, Zdenka Bhuiyan-Ludvikova, Martina Bohmova, Marketa Sloukova, Pavla Pecherkova, Jan Vydra (Czech Republic)

### **COMPARISON OF CONTINUOUS MONONUCLEAR CELL COLLECTION (CMNC) AND MONONUCLEAR CELL CELL (MNC) METHODS FOR CELL PROLIFERATION (APHERESIS) IN PATIENTS WITH BONE MARROW TRANSPLANTATION**

Mehrdad Payandeh, Sakineh Ghorbani, Azam Elahi, Roya Chagneh Lorestani (Iran, Islamic Republic of)

e-Posters  
09:30 - 18:00

ePoster Area

## Data Management

### **SUPPORTING TOOLS FOR ACCURATE DATA COLLECTION - DO WE GET THE BENEFIT?**

Camilla Roepstorff, Heidi Petersen (Denmark)

## Scientific Programme

### **ARE TRANSPLANTS TRULY AVAILABLE TO ALL, REGARDLESS OF GEOGRAPHY, SOCIOECONOMIC STATUS AND ETHNIC GROUP? A BSBMTCT REPORT**

Rachel Pearce, Julia Lee, Ruth Paul, Marie Wilson, Clementina Abamba, Kim Orchard (United Kingdom)

### **MISMATCHED DONOR AND GRADE 2 TO 4 ACUTE GVHD AS TWO-RISK MODEL FOR CYTOMEGALOVIRUS VIREMIA AND DISEASE AFTER ALLOGENEIC TRANSPLANTATION - SINGLE INSTITUTE ANALYSIS OF 1180 PATIENTS**

Xiu-Wen Liao, Jia-Hau Liu, Ming Yao, Bor-Sheng Ko, Cheng-Hong Tsai, Shang-Ju Wu, Shang-Yi Huang, Sheng-Chieh Chou, Hui-Hsuan Huang, Tai-Chung Huang, Hsin-An Ho, Wen-Chien Chou, Feng-Ming Tien, Jih-Luh Tang (Taiwan, Republic of China)

e-Posters  
09:30 - 18:00

ePoster Area

## Statistics

### **USE OF VARIABLE SELECTION METHODS TO IDENTIFY CLINICAL AND IMMUNOLOGICAL FACTORS ASSOCIATED WITH THE CLINICAL OUTCOME OF PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Chloé Pasin, Ran Reshef, Andrew J Yates (United States)

### **THE IMPACT OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON WORK AND PRODUCTIVITY LOSS IN PATIENTS WITH ACUTE LEUKAEMIA: RESULTS FROM A RAPID REVIEW**

### **GEOGRAPHIC AND SOCIOECONOMIC IMPACTS ON SURVIVAL AMONG ALLOGENEIC TRANSPLANT RECIPIENTS**

e-Posters  
09:30 - 18:00

ePoster Area

## Nurses Posters - Adult

### **ROLE OF QUICKSOFA IN PREDICTING SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL PATIENTS**

### **<i>BOLUS:</i> TARGETED SPECIALIST HAEMATOLOGY/BMT PODCASTS: AN EFFECTIVE METHOD OF EDUCATION**

### **A PATHWAY FOR RECOVERY: D+100 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT) FOLLOW UP PILOT FOR LYMPHOMA**

### **REDUCING ACCIDENTAL FALLS CAUSED BY ORTHOSTATIC HYPOTENSION IN BONE MARROW TRANSPLANT RECIPIENTS**

### **THE EFFECT OF MOTIVATIONAL INTERVIEW PERFORMED AFTER STEM CELL TRANSPLANTATION ON SEXUAL EXPERIENCE, SEXUAL SELF-AWARENESS AND SEXUAL SELF-EFFICACY**

### **STUDY ON COGNITIVE FUNCTION AND RELATED FACTORS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **THE EFFECT OF RELAXING BREATHING EXERCISES ON PAIN, FATIGUE AND LEUKOCYTE COUNT IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

## Scientific Programme

### **UNDERSTANDING OF PROGNOSIS, QUALITY OF LIFE AND PSYCHIATRIC STATUS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY OF 348 PATIENTS**

Xia Yan, Ting Wang, Wei Hu, Xiaodong Xu, Shujia Liu (China)

### **AN OUTPATIENT MODEL OF CARE TO SAFELY DELIVER AUTOLOGOUS STEM CELL TRANSPLANTATION**

### **EFFECTS OF TREATMENTS FOR HAEMATOLOGICAL MALIGNANCIES ON SEXUALITY AND FERTILITY: WHEN DO PATIENTS NEED IT AND WHOM REALLY WANTS TO KNOW?**

C Eeltink, B Lissenberg, I Nauta, J Rood, L Incrocci, I Verdonck- de Leeuw, S Zweegman (Netherlands)

### **EFFICACY OF THERAPEUTIC EDUCATION TO REDUCE RISKS AND COMPLICATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OBSERVATIONAL PROSPECTIVE COHORT STUDY**

Marco Cioce, Laura Orlando, Stefano Botti, Gianpaolo Gargiulo (Switzerland)

### **SELF-EFFICACY AND SELF-CARE PRACTICES OF PATIENTS WHO HAVE BEEN TRANSPLANTED WITH ALLOGENEIC HEMATOPOIETIC STEM CELLS ACCORDING TO THE DEVELOPMENT OF AN INDIVIDUAL EDUCATION PROGRAM**

### **DETERMINING THE SYMPTOMS AND COPING METHODS OF PATIENTS AT HOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Kader Caliskan, Gulbeyaz Can (Turkey)

### **THE EFFECT OF ORAL CARE PROTOCOL ON ORAL MUCOSITIS IN PATIENTS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Kwan Suk Jo, Seung Nam Zang, Ga Yeon Kim, Hye Yun Cho, Yang Sook You (Korea, Republic of)

### **PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) WITHIN AN AMBULATORY CARE SETTING; A PATIENTS' PERSPECTIVE**

Noemi Gianni, Tania Arthurs, Yvonne Patefield-Smith, Kirsten Rendall, Jo Wyatt, Rachel Miller (United Kingdom)

### **REDUCING ANTITHYMOCYTE GLOBULIN ( ATG) INFUSION RELATED REACTION BY INCREASING THE INFUSION DURATION IN ADULT SCT PATIENTS ; A SINGLE INSTITUTION EXPERIENCE FROM SAUDI ARABIA**

Suha Alkhraisat, Moussab Damlaj, Maybelle Balili, Samer Ghazi, Innaam Shehab eddine, Isam Mahasneh, Bader Ahmari, Heba Alshobaki, Mohsen Alzahrani (Saudi Arabia)

### **NURSE LED TELEPHONE FOLLOW UP FOR LATE EFFECTS SERVICE**

### **NURSING CARE OF 15 PATIENTS WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CHIMERIC ANTIGEN RECEPTOR T CELLS**

### **NURSING CARE OF A PATIENT WITH HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY COMPLICATED WITH AXONAL DEGENERATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION**

### **EFFECT OF NURSES EDUCATION PROGRAM ON CATHETER RELATED BLOOD STREAM INFECTIONS**

Roberta Gironi, Marco Fabbrini, Daniela Clerici, Chiara Oltolini, Raffaella Greco, Consuelo Corti, Fabio Ciceri, Antonella Biella (Italy)

### **THE CURRENT SITUATION AND INFLUENCING FACTORS OF MANAGEMENT OF CENTER VENOUS ACCESS DEVICE-ASSOCIATED SKIN IMPAIRMENT DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Ting Wang, Xia Yan, Linnan Wang, Xinxin He, Boning Liu (China)

### **EXERCISE SUPPORT FOR PEOPLE POST TREATMENT AS PART OF THEIR RETURN TO WORK JOURNEY: A CASE STUDY EXEMPLAR**

## Scientific Programme

### **ONCOSAFETY: A NEW TOOL FOR HEMATOLOGY NURSES TO AVOID CHEMOTHERAPY ERRORS**

Llora Roca Gimeno, [Elisabeth Lazaro Lora](#), Marta Yusta Arnal, Iria Gonzalez Alvarez (Spain)

### **PATIENT INFORMATION SHEET FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION: THE IMPACT OF THE DISEASE AND TREATMENT ON SEXUAL FUNCTION AND SEXUALITY**

[C Eeltink](#), L Incrocci, I Verdonck- de Leeuw, S Zweegman (Netherlands)

### **CHANGING PRACTICE BY USING CYCLOPRIME 1.5G/M2 PRIMING REGIME UP FRONT FOR LYMPHOMA PATIENTS TO ENSURE GOOD MOBILISATION OF STEM CELLS**

[Jennefer Rose](#), Sophie Jones, Wendy Ingram (United Kingdom)

### **THE CHALLENGES OF LOOKING AFTER AN INCREASING NUMBER OF SURVIVORS FOLLOWING ALLOGENIC BONE MARROW TRANSPLANTATION**

Lara Rowley, Amanda Ellis, Denise Wareham, Daja Barton, Emma Shaw, Olivia Hilsdon, Francesca Toselli, Shirley Hudson (United Kingdom)

### **VENO-OCCLUSIVE DISEASE (VOD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT NURSING CONSIDERATIONS AND MANAGEMENT: A CASE STUDY**

[Marie Waller](#), Christopher Heron, Hayley Dyos, Eleni Tholouli (United Kingdom)

### **RECOGNIZING LOW HEALTH SKILLS AND LOW LITERACY DURING CONSULTATION**

[Lian Schoonhoven-Bos](#) (Netherlands)

### **PRE-HABILITATION PRIOR TO STEM CELL TRANSPLANT - ONE CENTRES EXPERIENCE**

### **THE IMPORTANCE OF NURSES TRAINING IN NEW THERAPY USING THE EXAMPLE OF CAR-T CELL THERAPY**

### **PLASMAPHERESIS: TAKING THE EDGE OFF GRAFT FAILURE IN PATIENTS WITH ANTI-HLA ANTIBODIES UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION**

[Sinju Thomas](#), Adrien Quintela, Arthi Anand, Karen Bradley (United Kingdom)

### **INCIDENCE & CHARACTERISTICS OF VARICELLA ZOSTER VIRUS INFECTION POST HEMATOPOEITIC STEM CELL TRANSPLANTATION; EXPERIENCE OF A SINGLE CENTER IN SAUDI ARABIA**

### **SEMI-STRUCTURED INTERVIEW ASSESSMENT OF THE CLINICAL NURSE EDUCATOR ROLE IN SUPPORTING NEWLY QUALIFIED NURSES DURING TRANSITION TO POST-REGISTRATION PRACTICE INSIDE THE BONE MARROW TRANSPLANT SETTING**

[Luke White](#), Kathryn Vowden (United Kingdom)

### **TRAINING NURSING PROGRAMME IN NEW THERAPIES: CAR T CELLS**

### **NURSES' ROLE IN IMPROVING PATIENTS' FOOD INTAKE IN THE ACUTE HSCT PHASE**

### **USE THE AVAILABLE KNOWLEDGE - ENSURE THAT THE PATIENT RECEIVES THE BEST CARE IN STEM CELL TRANSPLANTATION**

[Anncarin Svanberg](#) (Sweden)

### **THE PSYCHO EMOTIONAL DISAGUE IN ADULT PATIENTS SUBJECT TO MIDOLLO TRANSPLANT: INITIAL STUDY OF A SINGLE CENTER**

### **NURSING CARE OF 15 PATIENTS WITH HEMATOLOGICAL MALIGNANT TUMOR COMPLICATED WITH SEVERE CYTOKINE RELEASE SYNDROME TREATED BY CAR-T CELLS**

## Scientific Programme

### **RETROSPECTIVE OBSERVATIONAL STUDY ON THE TRANSMISSION OF HEALTHCARE ASSOCIATED INFECTIONS AMONG NEUTROPENIC PATIENTS WITHIN THE HEMATOLOGY UNIT OF PIACENZA HOSPITAL**

Lorella Cappucciati, Chiara Buraschi, Cinzia Merlini, Sabrina Sbizzirro, Silvia Fava, Stefano Gandolfi, Donatella Petrucci, Luca Pasquali, Mirella Gubbelini, Andrea Contini (Italy)

### **GUIDE FOR PATIENTS AND DONORS BEFORE A PERIPHERAL BLOOD STEM CELL COLLECTION**

Natalia Lorente del Río, Cristina Alberquilla Ramos, Salvadora Aleza Esteras, Isabel María Fernández Morales, M<sup>a</sup> Del Carmen Freire Mourón, Ana García Carulla, Carmen Granado Rodilla, Mercedes Jiménez Meoro, Rosario López López, Marta Vela Garicano, Jesús Zalvide Torrente, Laura Bibiloni Martínez (Spain)

### **IMPACT OF AN IMPROVEMENT PLAN ON THE REDUCTION OF BACTERIEMIA BY CENTRAL CATHETER IN A PATIENT RECEIVER OF A CELLULAR THERAPY**

### **ARE TYMPANIC THERMOMETERS RELIABLE IN HEMATOPOIETIC STEM CELL RECIPIENTS?**

Marina Sedlar, Marijana Maric, Lana Desnica, Radovan Vrhovac, Ivan Sabol, Nurka Rustan (Croatia)

### **RELATIONSHIPS BETWEEN THE HEALTHCARE NEEDS AND QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS**

### **PAIN ASSESSMENT DURING BONE MARROW BIOPSY PROCEDURE AND BONE MARROW ASPIRATE PROCEDURE: A SPECIFIC NURSING ASSESSMENT**

Lorella Cappucciati, Fabio Pollini, Vincenzo Matteo Quitadamo, Ramona Patras, Angelica Cravedi, Maria Teresa Borsotti, Ilaria Filati, Rosaria Scopelliti, Cinzia Merlini, Andrea Contini, Mirella Gubellini (Italy)

### **AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION IN SYSTEMIC SCLEROSIS: CASE STUDY**

Lucilia Carreiro, Rosa Romão, Candida Damião (Portugal)

### **LEADERSHIP - LEADING THE TEAM**

Klara Kabatova Maxova (Czech Republic)

### **PAIN ASSESSMENT IN ONCO HEMATOLOGICAL PATIENT SUBJECTED TO CENTRAL VENOUS CATHETER POSITIONING (CVC) OR PERIPHERALLY INSERTED CENTRAL CATHETER POSITIONING (PICC)**

Lorella Cappucciati, Giovanna Buonanno, Corrado Gozzo, Francesco Oleari, Raffaella Maestri, Noemi Paladini, Patrizio Imbriani, Lucrezia Maria Zagnoni, Sara Posla, Mirella Gubbelini, Andrea Contini (Italy)

### **TOCILIZUMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME**

### **COMPLICATIONS ASSOCIATED WITH THE COLLECTION OF PERIPHERAL BLOOD PROGENITOR CELLS**

Lucília Carreiro, Carla Gonçalves, Fátima Pereira, Rosa Romão, Cândida Damião (Portugal)

### **IS IT WORTH FIGHTING TOGETHER FOR AN INDIVIDUAL ACCESS TO A MEDICINE WITH A NON REIMBURSEMENT DECISION? YES IT IS!**

Isabel Salcedo, Esther Ortiz, Juana María Acebes, Mari Luz Pascual, Beatriz Sanchez Sevillano, Almudena Laiglesia, Ana Alarcón, Rafael F Duarte (Spain)

### **INCIDENCE OF ACUTE GUT GVHD IN PATIENTS WHO HAVE UNDERGONE ALLOGENIC STEM CELL TRANSPLANT: CASE STUDY**

Poonam Thorat, Meera Sharad Achrekar, Deepti Ghonge (India)

### **COMPLETION TIME TO HLA TYPING**

### **GYNECOLOGICAL TREATMENT EXPERIENCE OF MENOPAUSAL SYNDROME AND SEXUAL DISORDERS IN FEMALE PATIENTS WHO UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION**

## Scientific Programme

e-Posters  
09:30 - 18:00

ePoster Area

### Nurses Posters - Paediatric

#### **TRANSITION STRATEGY: FROM PEDIATRIC TO ADULT HEALTH CARE AND LONG TERM FOLLOW-UP**

#### **CAREGIVER EDUCATION AND TRAINING FOR SELF ADMINISTRATION OF ORAL DRUGS IN A PAEDIATRIC CENTER**

#### **EXERCISE THERAPY ON CANCER-RELATED FATIGUE AND QUALITY OF LIFE IN CHILDREN UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION**

#### **SEXUAL HEALTH FOR YOUNG PEOPLE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

#### **EVALUATION OF A PREVENTIVE SKIN CARE PROTOCOL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS RECEIVING THIOTEPA**

Kim van der Niet, Lisa Rozendaal, Dagmar Berghuis, Eileen van der Stoep-Yap, Erik von Asmuth, Maria de Taeye-Veldhuizen, Arjan Lankester, Hilda Mekelenkamp (Netherlands)

#### **CAR-T: THE DUTCH PEDIATRIC NURSING EXPERIENCE**

Ida Bremer Ophorst, Tineke Terlouw (Netherlands)

#### **SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEIPIENTS: A SINGLE CENTER EXPERIENCE**

Rosanna Ceresoli, Stefano Benvenuti, Patrizia Bevilacqua, Mirella Savoldi, Fulvio Porta (Italy)

#### **PEDIATRIC PHOTOAPHAERESIS: THE DILEMMA OF VASCULAR ACCESSES**

Rosanna Ceresoli, Stefano Benvenuti, Emilio Ferrari, Fulvio Porta (Italy)

#### **TOTALLY IMPLANTABLE VASCULAR ACCESS DEVICES RUPTURE IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: PROPHYLAXIS AND TREATMENT**

#### **USE OF VOLUMETRIC PUMPS FOR THE INFUSION OF HEMATOPOIETIC STEM CELLS AS A STANDARD METHOD IN PEDIATRIC PATIENTS**

Nuria Caballero, Marian Cerezuela, Isabel Badell Serra (Spain)

#### **PEDIATRIC PATIENT TRANSFER FROM A TPH WARD TO ICU: HOW CAN WE IMPROVE OUR COMMUNICATION?**

Almudena Pérez, Alba Martínez, Anna Negre, Laura Lahuerta (Spain)

#### **CARING FOR MINOR SIBLING DONORS**

Eugenia Trigos Arjona, Estrella Larios Reyes, Maria Sol Abert Velert (Spain)

#### **EFFECTIVE MOBILISATION WITH PLERIXAFOR FOLLOWING CRANIA-SACRAL RADIOTHERAPY AND HIGH-DOSE CHEMOTHERAPY: A CASE REPORT OF AN ELEVEN-YEAR OLD BOY WITH GLIOBLASTOMA MULTIFORME**

Anna Tailby, Julia Nixon, Alison Bridgman, Angela Burns, Abigail Cotton, Hannah Ezard, Josephine Nicholls, Melanie Rooney, Elisabeth Thomas, Ilan Uri, Marita Macken, Sarah Lawson, Martin English (United Kingdom)

#### **EARLY RECOGNITION OF PEDIATRIC GVHD: EDUCATION AND AWARENESS AMONGST NURSES**

Bart Maertzdorf, Anouk Jongekrijg (Netherlands)

#### **RISK ASSESSING PAEDIATRIC PATIENTS' NUTRITIONAL NEEDS PRIOR TO BONE MARROW TRANSPLANT**

## Scientific Programme

e-Posters  
09:30 - 18:00

ePoster Area

### Nurses Posters - Research

**FAMILY CAREGIVERS SUPPORT NEEDS DURING ALLO-HSCT - A LONGITUDINAL STUDY (PRELIMINARY RESULTS)**

**PAIN AND ANXIETY MANAGEMENT DURING BONE MARROW ASPIRATES IN ITALIAN TRANSPLANT PROGRAMS. A NATIONWIDE SURVEY ON BEHALF OF GITMO NG**

**PREVALENCE, PREDICTORS AND OUTCOMES OF CLABSI AMONG HSCT PATIENTS**

**CREATION OF THE LABMT NURSES GROUP**

**SYMPTOMS AND QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY**

**SOCIAL SUPPORT MODERATES THE EFFECTS OF HEALTH STRESSORS ON HEALTH CARE ADHERENCE AND PSYCHOLOGICAL DISTRESS IN LONG-TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS**

**SYMPTOM DISTRESS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY**

**NURSE INVOLVEMENT AND IMPACT OF JACIE ACCREDITATION ON NURSE PRACTICE**

Carmen Conde, Ariadna Domenech, Iria González, Verónica Linde Blazquez, Eugenia Trigos Arjona, Julia Ruiz Pato (Spain)

**CONSTRUCTION OF QUALITY INDICATORS SYSTEM OF NUTRITION CARE FOR ADULT PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH AN EVIDENCE-BASED APPROACH**

Yun Fang, Minjie Liu, Chen Xie (China)

**ARE CAREGIVERS RECEIVING ENOUGH INFORMATION TO CARE? A PILOT STUDY ON A HAEMATOLOGICAL TRANSPLANT UNIT**

**MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A THREE YEARS FOLLOWING UP**

Yaya Song, Xiaming Zhu, Yin Lu, Yongqin Ge, Qin Li, Fang Tang, Ying Chen, Yaohong Li (China)

**VENOUS ACCESS IN AUTOLOGOUS VERSUS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONORS: A RETROSPECTIVE STUDY OF AN APHERESIS UNIT**

Isabel Salcedo, Angela Salas, Laura Vicente, Lucia Paola Cuéllar, Virginia Infante, Carmen de la Puente, Jose Luis Bueno (Spain)

**A STUDY TO ASSESS THE LEVEL OF BURNOUT AMONG NURSES WORKING IN BONE MARROW TRANSPLANT (BMT) UNIT OF A TERTIARY CARE CANCER HOSPITAL**

Shreya Ludbe, Meera Sharad Achrekar, Rynel Quadras (India)

**DO WE KNOW ENOUGH ABOUT THE BONE MARROW DONATION?**

**ASSOCIATION OF AIR BORN PARTICLE SIZE AND PARTICLE COUNT WITH INCIDENCE OF INFECTIONS IN HEPA FILTERED ROOMS-A SINGLE CENTRE EXPERIENCE**

**SYSTEMATIC REVIEW OF SIGNS AND SYMPTOMS OF THE HUMAN HERPES VIRUS 6 AND THEIR ASSESSMENT TOOLS**

Rodrigo Serrano Villegas, Beatriz del Amo Mateos, Claudia Pina Pino, María Teresa Abellán Garrido, Gema Hernández Sanchez, María Cabezas López de Sosoaga, Montserrat Pilar Barrilero Lopez (Spain)

## Scientific Programme

### **A STUDY TO ASSESS PERCEIVED STRESSORS AND COPING STRATEGIES ADOPTED BY PATIENTS WHO HAVE UNDERGONE HEMATOPOIETIC STEM CELL INFUSION IN SELECTED CANCER HOSPITAL, INDIA**

Bhushan Shelar (India)

### **ROLE OF THERAPEUTIC APHERESIS IN ALLOGENEIC TRANSPLANTATION: A CASE REPORT**

Cristina Alberquilla Ramos, Salvadora Aleza Estera, Josefa Navarrete Ruiz, Beatriz Alonso González, Rocio Rico Muñoz, Ana Isabel Torre Polo, Pilar Herreros López, Julia Ruiz Pato (Spain)

### **SYMPTOMS OF ELDERLY PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER INDUCTION CHEMOTHERAPY**

Yaohong Li, Xiaming Zhu, Yin Lu, Fang Tang, Yongqin Ge, Qin Li, Ying Chen, Yaya Song (China)

e-Posters  
09:30 - 18:00

ePoster Area

## Acute leukaemia

### **ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HIV-INFECTION: AN UPDATED PAIR-MATCHED COHORT STUDY BY THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION**

### **COMPARABLE OUTCOMES OF AML PATIENTS RECEIVING HAPLO-HCT WITH THIOTEPA/BUSULFAN/FLUDARABINE CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS A MATCHED UNRELATED DONOR WITH FLUDARABINE/BUSULFAN CONDITIONING, REGARDLESS OF DISEASE STATUS**

### **TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT: IMPROVED SURVIVAL FOR YOUNG PATIENTS IN RECENT YEARS**

### **ANTI-CD3/CD33 BISPECIFIC ANTIBODIES EFFICIENTLY REDIRECT DONOR T CELLS AGAINST HLA LOSS LEUKEMIA RELAPSES**

### **POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) EMERGES AS A KEY DRIVER OF HLA CLASS II NEGATIVE POST-TRANSPLANTATION RELAPSE**

### **ALLOGENEIC HCT FOR ADULTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA HARBORING *IKZF1* GENE MUTATIONS: A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**

### **ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN CHILDREN AND ADULTS WITH RELAPSED/REFRACTORY B-ALL: FOCUS ON ANTI-CD19, ANTI-CD22 MONOCLONAL ANTIBODIES**

### **THE VALUE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH AND WITHOUT *ASXL1*-, *RUNX1*- AND *TP53* MUTATIONS**

### **ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%. A STUDY FROM THE ALWP-EBMT**

### **RIC COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE PROVIDES HIGHER GVHD-FREE/RELAPSE FREE SURVIVAL IN FIT YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA**

## Scientific Programme

**LOW-DOSE MEMORY DONOR LYMPHOCYTE INFUSION AFTER  $\alpha\beta$  T CELL-DEPLETED HSCT AMONG CHILDREN WITH HIGH-RISK LEUKEMIA: RESULTS OF A PROSPECTIVE RANDOMIZED SINGLE-CENTER TRIAL**

**DEVELOPMENT OF A CORD BLOOD STEM CELL-DERIVED DENDRITIC CELL VACCINE TO PREVENT RELAPSE AFTER CORD BLOOD TRANSPLANTATION IN AML**

**THE BRAZILIAN EXPERIENCE WITH HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTS (HAPLO-HCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**

**BETTER LEUKEMIA-FREE SURVIVAL WITH ALLOGENEIC THAN WITH AUTOLOGOUS HCT IN AML PATIENTS WITH ISOLATED TRISOMY 8: A STUDY FROM THE ALWP OF THE EBMT**

**ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML PATIENTS WITH RUNX1 MUTATION IN FIRST COMPLETE REMISSION: A STUDY ON BEHALF OF THE ALWP OF THE EBMT**

**GRAFT FAILURE AFTER UNMANIPULATED HAPLO-HSCT WITH PT-CY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION, ON BEHALF OF THE ALWP-EBMT**

**IMPLICATIONS OF NOVEL RISKS SCORES (AML-DRG AND AML-HCT-CR) IN ALLOGENEIC CD34+ SELECTED GRAFT TRANSPLANT OUTCOMES**

Rosalía Alonso Trillo, Marta Garcia Recio, Martina Pennisi, Christina Cho, Sean M. Devlin, Josel D. Ruiz, Molly A. Maloy, Ana Alarcon Tomas, Nerea Castillo, Richard J. Lin, Ioannis Politikos, Miriam Sanchez Escamilla, Michael Scordo, Gunjan L. Shah, Juliet N. Barker, Hugo Castro-Malaspina, Boglarka Gyurkocza, Parastoo B. Dahi, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Craig S. Sauter, Brian C. Shaffer, Roni Shouval, Roni Tamari, Marcel R. M. van den Brink, James W. Young, Sergio A. Giralt, Miguel Perales (Spain)

**DOWNREGULATION OF HLA-DR IN BLASTS OF PATIENTS WITH ACUTE LEUKAEMIA RELAPSING AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ESTABLISHMENT OF A NATIONAL STEM CELL TRANSPLANT CLINICAL TRIALS NETWORK: THE UK IMPACT PARTNERSHIP FOR ACCELERATED CELLULAR THERAPIES**

**DIFFERENTIAL IMPACT OF NPM1 MUTATION ON THE POST-TRANSPLANT OUTCOME OF ADULT FLT3ITD MUTATED AML RECEIVING ALLOGENEIC TRANSPLANT IN CR1 AND AFTER CR1**

**A REGION-WIDE RETROSPECTIVE ANALYSIS OF OUTCOME FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA**

**PRE-HARVEST HIGHER DONOR FOXP3 MRNA AND LOWER CD4+ T CELL CONCENTRATION PREDICT INCREASED RISK OF ALL RELAPSE AFTER MYELOABLATIVE HCT WITH T-REPLETE BONE MARROW GRAFTS**

**EPIDEMIOLOGY, MANAGEMENT AND ECONOMIC IMPACT OF ACUTE MYELOID LEUKAEMIA AND MYELOYDYSPLASTIC SYNDROME IN SPAIN: A CLAIMS DATABASE ANALYSIS**

**PRE-TRANSPLANT BONE MARROW CELLULARITY AND BLOOD COUNT RECOVERY ARE NOT ASSOCIATED WITH RELAPSE OR SURVIVAL RISK FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT FOR AML IN CR1**

**IMMUNOTHERAPY SALVAGE FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS BY THE ALWP OF THE EBMT**

**COMPARISON OF PRE-TRANSPLANT COMORBIDITY INDICES IN ACUTE LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**SALVAGE USE OF VENETOCLAX-BASED THERAPY FOR RELAPSED AML POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT**

## **Scientific Programme**

**FACTORS PREDICTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA**

**ROLE OF CHIMERISM AND FLOW-CYTOMETRIC MONITORING OF MEASURABLE RESIDUAL DISEASE (MRD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN PREDICTING RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)**

**SORAFENIB PROLONGED MAINTENANCE IN FLT3-MUTATED AML POST TRANSPLANTATION**

**PULMONARY COMPLICATIONS (PC) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN CHILDREN WITH HIGH-RISK ACUTE LEUKEMIA (AL)**

**MORE THAN TWO CYCLES OF CONSOLIDATION THERAPY PRE-TRANSPLANTATION BENEFITS AML PATIENTS IN CR1 WHO UNDERWENT HLA-MATCHED SIBLING ALLOGRAFTS: A MULTICENTER STUDY**

**WHAT CAN CNV ANALYSIS ADD TO THE ROUTINE GENETIC DESCRIPTION OF AML CASES?**

**COMPARISON OF THE PROGNOSTIC ABILITY OF THE HCT-CI THE MODIFIED EBMT AND THE EBMT-ADT PRE-TRANSPLANT RISK SCORES FOR ACUTE LEUKEMIA**

**GO-FLAG REGIMEN AS A BRIDGE THERAPY TO ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS**

**THE IMPACT OF ALLOGENEIC TRANSPLANTATION IN AML AND MDS WITH CHROMOSOME 3 ABNORMALITIES**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY-ALONE IN THE TREATMENT OF PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS WITH MIXED LINEAGE LEUKEMIA (MLL) REARRANGEMENTS: SINGLE CENTER EXPERIENCE**

**POSTTRANSPLANTATION BENDAMUSTINE FOR GVHD PROPHYLAXIS IN REFRACTORY ACUTE LEUKEMIA PATIENTS**

**IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE**

**FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS**

**TYROSINE KINASE INHIBITOR TREATMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA**

**OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR CYTOGENETIC INTERMEDIATE-RISK AML ACCORDING TO THE MOLECULAR RISK BASED ON ELN 2017 RISK STRATIFICATION SYSTEM; SINGLE CENTER EXPERIENCE IN KOREA**

**THE PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY WT1 GENE EXPRESSION IN PERIPHERAL BLOOD BEFORE AND AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS**

**IMPACT OF POSTTRANSPLANT TYROSINE KINASE INHIBITORS ADMINISTRATION ON LONG TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**

**THE INFLUENCE OF ANTI-THYMOCYTE GLOBULIN (ATG) ON THE OUTCOMES OF PATIENTS WITH AML W/WO MEASURABLE RESIDUAL DISEASE (MRD) AT THE TIME OF UNRELATED DONOR TRANSPLANTATION**

**MLL-AF6 FUSION GENE POSITIVE AML TREATED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS EXCELLENT OVERALL SURVIVAL**

## Scientific Programme

**BENEFICIAL OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM**

**INDUCTION OF SYNERGISTIC APOPTOSIS AND OVERCOMING OF DRUG RESISTANCE BY COTARGETING OF BCL-2 AND NA/H EXCHANGER 1 PATHWAY IN ACUTE MYELOID LEUKEMIA CELLS**

**GEMTUZUMAB-OZOGAMICIN FOR BRIDGING TO TRANSPLANT IN REFRACTORY/RELAPSED CD33 POSITIVE ACUTE LEUKEMIA - IS IT WORTHWHILE?**

**THE EFFECTS OF CYTOMEGALOVIRUS INFECTION ON TRANSPLANT OUTCOMES IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**AZACYTIDINE AND DONOR LYMPHOCYTES INFUSIONS IN RELAPSED AML AFTER ALLOGENEIC HSCT: RESULTS IN 40 PATIENTS**

**THE RESULTS OF AML RELAPSE AFTER ALLOGENEIC TRANSPLANTATION TREATMENT, SINGLE CENTRE APPROACH EVALUATION**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A SINGLE CENTER ANALYSIS**

**THE OPTIMAL TIME FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA**

**IMPACT OF ABO MISMATCH ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTRE EXPERIENCE**

**DONOR SOURCE IMPACTS ON LONG TERM SURVIVAL FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN AML PATIENTS AGED 60 AND ABOVE**

**EXTRA-MEDULLARY RECURRENCE OF ACUTE MYELOID LEUKEMIA AS MYELOID SARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE SERIES**

**SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA: SINGLE CENTER EXPERIENCE**

**ALLOGENEIC STEM CELL TRANSPLANTS IN ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE EXPERIENCE**

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA NOT RESPONDING TO FIRST INDUCTION THERAPY**

e-Posters  
09:30 - 18:00

ePoster Area

## Aplastic anaemia

**LNP023 - A NEW ORAL COMPLEMENT FACTOR-B INHIBITOR NORMALIZES HEMOGLOBIN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH POOR RESPONSE TO ECULIZUMAB, BOTH AS ADD-ON AND MONOTHERAPY**

**EPIGENETIC AGING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH SEVERE APLASTIC ANEMIA: RESULTS FROM DNA-METHYLATION GRIMAGE**

**GVHD AND RELAPSE FREE SURVIVAL (GRFS) AFTER ALLOGENEIC TRANSPLANTATION FOR IDIOPATHIC SEVERE APLASTIC ANEMIA: AN ANALYSIS FROM THE SAAWP DATA QUALITY INITIATIVE PROGRAM OF EBMT**

## Scientific Programme

**OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH FANCONI ANAEMIA: A STUDY ON BEHALF OF THE EBMT SAAWP AND PDWP**

**REDUCED INTENSITY CONDITIONING IS EFFECTIVE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH DIAMOND-BLACKFAN ANEMIA**

**PROSPECTIVE STUDY OF ECULIZUMAB BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA / APLASTIC ANEMIA**

**OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT FOR FANCONI ANEMIA IN INDIA**

**ALTERNATE DONOR HSCT FOR 109 CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA: A SINGLE CENTER RETROSPECTIVE ANALYSIS**

**SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH REFRACTORY ACTIVE INFECTION: A PROSPECTIVE MULTICENTER CLINICAL STUDY IN CHINA**

**INCIDENCE AND MANAGEMENT OF APLASTIC ANEMIA IN SPAIN (IMAS). AN AMBISPECTIVE STUDY OF BIODONOSTIA / PETHEMA**

**ALLOGENEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS FOR CHILDREN WITH APLASTIC ANEMIA**

**OUTCOME OF PEDIATRIC ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE**

**OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANT FOR SEVERE APLASTIC ANEMIA IN PAKISTAN: DATA FROM A DEVELOPING COUNTRY**

**IMPACT OF CD34+-STEM CELL BOOST ON OUTCOME AND HEMATOLOGICAL RECONSTITUTION IN PATIENTS WITH SEVERE APLASTIC ANEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE STUDY**

**HEMATOPOIETIC STEM CELL TRANSPLANT IN ADULTS WITH ACQUIRED SEVERE APLASTIC ANEMIA**

**HEMATOPOIETIC STEM CELL TRANSPLANT IN FANCONI ANEMIA USING MATCHED RELATED AND HAPLOIDENTICAL DONORS- A SINGLE CENTRE EXPERIENCE**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC SEVERE APLASTIC ANEMIA: RESULTS OF A SINGLE CENTER**

**EFFECT OF SINGLE UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION ON APLASTIC ANEMIA IN CHILDREN**

**IMMUNOSUPPRESSIVE THERAPY IN PEDIATRIC APLASTIC ANEMIA, SINGLE CENTRE EXPERIENCE**

**CYCLOSPORINE, DANAZOL AND ROMIPLOSTIM IN SEVERE APLASTIC ANEMIA IN PRETRANSPLANT PERIOD: RETROSPECTIVE ANALYSIS OF FIVE CASES**

e-Posters  
09:30 - 18:00

ePoster Area

### Autoimmune diseases

**AUTOLOGOUS NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR STIFF PERSON SYNDROME**

## **Scientific Programme**

**BEAM VS CYCLOPHOSPHAMIDE-BASED CONDITIONING REGIMEN IN AGGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE ANALYSIS OF EUROPEAN BLOOD AND MARROW TRANSPLANTATION SOCIETY**

**A NOVEL TARGETED APPROACH TO ACHIEVE IMMUNE SYSTEM RESET: CD45-TARGETED ANTIBODY DRUG CONJUGATES AMELIORATE DISEASE IN PRECLINICAL AUTOIMMUNE DISEASE MODELS AND ENABLE AUTOHSCT**

**LONG TERM FOLLOW UP OF SYSTEMIC SCLEROSIS FRENCH PATIENTS INCLUDED IN THE ASTIS TRIAL USING SCOT TRIAL GLOBAL RANK COMPOSITE SCORE (GRCS)**

**ADVANCES IN MULTIPLE SCLEROSIS (MS) TREATMENT: CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION**

**POST TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES OUTCOME AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ANIMAL MODEL OF MULTIPLE SCLEROSIS**

**THE LONG-TERM SAFETY AND EFFICACY OF AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS INDIRECTLY COMPARED TO ALEMTUZUMAB: A SYSTEMATIC REVIEW**

**RECONSTITUTION OF NATURAL OR VACCINATION-DRIVEN IMMUNITY AFTER AHSCT IN MULTIPLE SCLEROSIS**

**HIGH-DOSE IMMUNODEPLETION WITH AUTOLOGOUS STEM CELL RESCUE FOR TREATMENT OF AGGRESSIVE MULTIPLE SCLEROSIS**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION DOES NOT CHANGE THE EXPRESSION OF ENDOTHELIAL MARKERS IN SKIN BIOPSIES OF SYSTEMIC SCLEROSIS PATIENTS**

**AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NON HEMATOLOGICAL DISEASES. THE DUTCH EXPERIENCE OF MS PATIENTS GOING ABROAD**

**ANALYSIS OF COST AND CHARGES FOR NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES**

**AUTOLOGOUS STEM CELL TRANSPLANTATION IN BEHÇET'S DISEASE: A RETROSPECTIVE STUDY**

**SAFETY AND TOLERABILITY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE SCLEROSIS: A SINGLE CENTER EXPERIENCE**

**OUTCOME OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY TAKAYASU ARTERITIS, A RETROSPECTIVE SURVEY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS IN NORWAY**

**THE USE OF AUTOLOGOUS HAEMOPOETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS AFTER ALEMTUZUMAB TREATMENT FAILURE: A CASE SERIES**

**AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF SYSTEMIC SCLEROSIS, AN OPTION FOR REFRACTORY PATIENTS**

**A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE**

## Scientific Programme

e-Posters  
09:30 - 18:00

ePoster Area

### CAR-based Cellular Therapy - clinical

**KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): RESULTS FROM PHASE 2 OF ZUMA-2**

**SAFETY AND EFFICACY RESULTS FROM TRANSCEND NHL 001, A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA**

**CD19/CD22 DUAL TARGETED (CHIMERIC ANTIGEN RECEPTOR) CAR-T THERAPY FOR RELAPSED OR RE FRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)**

**AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE. ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP)**

**THIRD-GENERATION CAR T CELLS WITHIN THE HEIDELBERG CAR TRIAL 1 (HD-CAR-1) DISPLAY AN EXCELLENT SAFETY PROFILE AND MIGHT IMPROVE PERSISTENCE OF CAR T CELLS**

**OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL IN 3 CLINICAL STUDIES OF RELAPSED/REFRACTORY LARGE B-CELL NHL, INCLUDING SECOND-LINE TRANSPLANT NONELIGIBLE PATIENTS: TRANSCEND NHL 001, OUTREACH, AND PILOT**

**CORRELATIVE ANALYSES OF PATIENT AND CLINICAL CHARACTERISTICS ASSOCIATED WITH EFFICACY IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE JULIET TRIAL**

**CAR T CELLS (CART) OR ALLOGENEIC TRANSPLANTATION (ALLOHCT) FOR MULTIPLY RELAPSED DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)? A RETROSPECTIVE INTENT-TO-TREAT (ITT) COMPARISON**

**HIGH ACTIVATION OF BCMA CAR-T CELLS CONTRIBUTES TO INCREASED RESPONSE RATE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**

**A COMPARISON OF 2-YEAR OUTCOMES IN ZUMA-1 (AXICABTAGENE CILOLEUCEL; AXI-CEL) AND SCHOLAR-1 IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA (LBCL)**

**CD19-TARGETED CAR-T CELL THERAPY FOR 32 B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)**

**INTERNATIONAL PROGNOSTIC INDEX PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACTORY LARGE DIFFUSE B CELL LYMPHOMA TREATED WITH COMMERCIAL CAR T CELLS**

**THE PHASE 1B PORTIA STUDY: SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA**

**REAL-WORLD EVIDENCE OF THE USE OF TISAGENLECLEUCEL FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS. THE SPANISH EXPERIENCE**

**NATIONAL IMPLEMENTATION OF THE USE OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN NATIONAL HEALTH SERVICE ENGLAND (NHSE)**

**REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA**

## Scientific Programme

**CORRELATIVE MARKERS OF TOXICITY IN PATIENTS WITH DLBCL TREATED WITH CD19 CAR T CELL THERAPY**

**EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R LBCL)**

**ASSOCIATION OF AXI-CEL CAR-T CELL CONCENTRATION WITH TREATMENT RESPONSE AND SIDE EFFECTS AND IMPACT OF DEXAMETHASONE TREATMENT ON KINETICS**

**SIMPLIFIED-EASIX (SEASIX) IS AN EARLY PREDICTOR OF SEVERE CYTOKINE RELEASE SYNDROME AND IMMUNE-EFFECTOR-CELLS-ASSOCIATED NEUROTOXICITY SYNDROME IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T CELLS**

**NIVOLUMAB AS SALVAGE THERAPY IN PATIENTS WHO FAILED TO ACHIEVE COMPLETE REMISSION AFTER ANTI-CD19 CAR T-CELL THERAPY FOR DLBCL**

**SURVEILLANCE OF MINIMAL RESIDUAL DISEASE (MRD) IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) BY CIRCULATING TUMOR DNA (CTDNA) PROFILING AFTER CHIMERIC ANTIGEN RECEPTOR T (CAR-T)**

**A DIGITAL-PCR ASSAY FOR PRECISE IN-VIVO QUANTIFICATION OF ADOPTIVELY TRANSFERRED CD19-CAR T CELLS AFTER TREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**

**FEASIBILITY OF MANUFACTURING TISAGENLECLEUCEL IN PATIENTS LESS THAN 3 YEARS OF AGE WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA**

**AXICABTAGENE CILOLEUCEL CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: REAL-WORLD OUTCOMES, TOXICITY AND PREDICTORS OF RESPONSE FROM A PROSPECTIVE UK COHORT**

**MARKERS OF INITIAL AND LONG-TERM RESPONSES TO IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) IN THE CRB-401 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA**

**SINUSOIDAL OBSTRUCTION SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) TREATED WITH ARI-0001 CELLS**

**HUMORAL IMMUNE RESPONSE IN PATIENTS WITH CD19-POSITIVE RELAPSED/REFRACTORY B-CELL MALIGNANCIES RECRUITED INTO THE CART19-BE-01 CLINICAL TRIAL, AN ACADEMIC CAR19**

**REAL-WORLD DATA FROM KINGS COLLEGE HOSPITAL: INFECTION COMPLICATIONS POST CAR-T TREATMENT IN HIGH-GRADE B CELL NON-HODGKIN LYMPHOMA**

**SENESCENT/EXHAUSTED PHENOTYPE OF CD19-TARGETED CAR-T CELLS AND IMMUNOREGULATORY ENVIRONMENT CORRELATE WITH REDUCED RESPONSE TO CAR-T CELL THERAPY IN RELAPSED/REFRACTORY B CELL MALIGNANCIES**

**CHARACTERISATION OF EARLY AND LATE CYTOPENIAS IN LYMPHOMA PATIENTS FOLLOWING TREATMENT WITH ANTI-CD19 CAR-T THERAPY**

**CD4+ CAR-T CELLS MAINTAIN MEMORY PHENOTYPES AND MEDIATE LONGER-TERM ANTITUMOR ACTIVITY IN VIVO**

**IMPACT OF ETHNICITY IN R/R DLBCL AND B-CELL ALL PATIENTS TREATED WITH TISAGENLECLEUCEL**

**IMPACT OF DIFFERENT CHEMOTHERAPY REGIMENS AND DURATION OF DLBCL ON LYMPHOPHERESIS AND CAR-T T-CELL IMMUNOPHENOTYPING**

**CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA**

## Scientific Programme

**CHALLENGES IN PROVIDING GOOD LEUKAPHERESIS PRODUCTS FOR THE PRODUCTION OF CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY NHL OR ALL**

**NKG2D CAR T CELLS ARE NOT AFFECTED BY SOLUBLE NKG2D LIGANDS**

**EMERGING CYTOKINE RELEASE SYNDROME IS ASSOCIATED WITH REDUCTION OF CD4+CD25HIGH127DIM T REGULATORY CELLS IN PATIENTS AFTER CAR T CELL THERAPY**

**EXCELLENT PROLIFERATION AND PERSISTENCE OF ALLOGENEIC CAR-T CELLS DESPITE IMMUNOSUPPRESSION WITH CYCLOSPORINE A**

**A FRENCH BIOBANKING NETWORK TO CREATE A UNIQUE COLLECTION OF SAMPLES OF PATIENTS TREATED WITH CAR-T CELLS**

**CAR T CELL THERAPY DIRECTED AGAINST CD19 IN PATIENTS WITH B-CELL LYMPHOMA AFTER AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IS FEASIBLE AND SAFE**

**LYMPHOCYTE COLLECTION FOR GENERATION OF CAR T-CELLS IN PEDIATRIC PATIENTS: A SINGLE CENTER EXPERIENCE**

**BASELINE HYPOALBUMINEMIA DOES NOT APPEAR TO BE AN ADVERSE PROGNOSTIC FACTOR IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMAS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**

**FACTORS PREDICTING CD3+ COLLECTION FOR THE PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS**

**CYTOPENIAS AFTER TISAGENLECLEUCEL IN PAEDIATRIC/YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSE B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL): A REAL-LIFE SINGLE-CENTRE EXPERIENCE**

**THE RISK OF HEPATITIS B REACTIVATION IS CONTROLLABLE IN B-CELL MALIGNANCIES PATIENTS WITH CONCOMITANT HEPATITIS B VIRUS INFECTION AFTER CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY**

**CUMULATIVE RITUXIMAB EXPOSURE PRIOR TO AXICABTAGENE CILOLEUCEL IS NOT ASSOCIATED WITH PERSISTENT LEUKOPENIA AND THROMBOCYTOPENIA AT DAY +90 POST INFUSION**

**COMPREHENSIVE IMMUNE CELL MONITORING REVEALS AN ALTERED LYMPHOCYTE SUBSET PHENOTYPE IN PATIENTS NOT RESPONDING TO TISAGENLECLEUCEL ONE MONTH POST INFUSION**

**NEUROTOXICITY ASSOCIATED WITH CAR T CELL THERAPY: NEUROLOGICAL MANAGEMENT AND WORK-UP OF 11 ADULT PATIENTS**

**NUTRITIONAL ASSESSMENT OF PATIENTS UNDERGOING CD19-TARGETED CAR-T THERAPY FOR NON-HODGKIN'S LYMPHOMA AND THE SHORT TERM EFFECT OF TREATMENT ON NUTRITIONAL STATUS**

**EFFECTIVENESS OF AUTOLOGOUS LEUKAPHERESIS COLLECTIONS FOR CAR T-CELL MANUFACTURING IN PATIENTS WITH B-CELL MALIGNANCIES**

**DEFINITION AND IMPLEMENTATION OF CLINICAL AND QUALITY ENDPOINTS IN CENTERS ADMINISTERING A COMMERCIAL CAR-T PRODUCT**

**CAR-T IN BREAST AND OTHER EXTRA-MEDULLARY RELAPSED/REFRACTORY ALL**

**PREDICTING CAR T-CELL INFUSION AFTER SUCCESSFUL MANUFACTURING: REAL-WORLD DATA**

## Scientific Programme

### EVALUATION OF THE INTEREST OF A DRUG RECONCILIATION ACTIVITY IN PATIENTS TREATED WITH CAR T-CELLS: A DESCRIPTIVE STUDY

e-Posters  
09:30 - 18:00

ePoster Area

### CAR-based Cellular Therapy - preclinical

**MODULATION OF CYTOSOLIC CA<sup>2+</sup> REGULATES CAR-T CELL DIFFERENTIATION AND THERAPEUTIC POTENCY**

**BREAKING PD-L1-MEDIATED RESISTANCE IN ANTI-CD19 AND ANTI-CD22 CAR T CELLS WITH PD-1/CD28 FUSION RECEPTORS**

**ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR-INVARIANT NATURAL KILLER T CELLS EXERT BOTH DIRECT AND INDIRECT ANTITUMOR EFFECTS THROUGH HOST CD8 T CELL CROSS-PRIMING**

**DUVELISIB GENERATES CAR T CELLS WITH ENHANCED MITOCHONDRIAL BIOGENESIS AND REDUCED EXPRESSION OF PD-1, TIM-3, AND LAG-3, ENABLING GREATER ANTI-LEUKEMIA CYTOTOXICITY AGAINST CLL**

**NKG2D CHIMERIC ANTIGEN RECEPTOR-EXPRESSING LYMPHOCYTES TARGET ACUTE MYELOID LEUKEMIA CELLS**

**CLINICAL-GRADE MANUFACTURING OF ROR1 CAR T-CELLS USING A NOVEL VIRUS-FREE PROTOCOL**

**LENTIVIRALLY AND ALPHARETROVIRALLY ENGINEERED CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS ARE HIGHLY CYTOTOXIC AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA**

**NOVEL STRATEGIES TO ENHANCE THE SAFETY OF CAR T-CELL IMMUNOTHERAPY: THE IMSAVAR PROJECT**

**ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD NK CELLS ARE GOOD SOURCES FOR EFFECTIVE CAR THERAPY AGAINST CD19 POSITIVE LEUKEMIC CELLS**

**ENHANCEMENT OF CYTOTOXICITY, EXPANSION AND PERSISTENCE OF CD19 CAR-T CELLS VIA PRE-SENSITIZATION OF B CELL MALIGNANCIES BY BCL-2 SELECTIVE INHIBITORS**

**TYROSINE KINASE INHIBITOR FOLLOWED BY CART THERAPY FOR THE TREATMENT OF RELAPSED PHILADELPHIA CHROMOSOME-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

e-Posters  
09:30 - 18:00

ePoster Area

### Cellular Therapies other than CARs

**CTLA4IG PRIMED SEQUENTIAL DLI IMPROVES GVHD AND RELAPSE-FREE SURVIVAL COMPARED TO UNPRIMED DLI IN PATIENTS UNDERGOING PTCY-BASED HAPLOIDENTICAL HCT FOR ADVANCED HEMATOLOGICAL MALIGNANCIES**

**HLA-MISMATCHED MOBILIZED CELLULAR THERAPY (MICROTRANSPLANT, MST) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES**

## Scientific Programme

**DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH PTCY: A STUDY ON BEHALF OF THE CTIWP OF THE EBMT**

**SAFETY, EFFECTIVENESS AND PERSISTENCE OF LOW-DOSE DONOR MEMORY T CELL INFUSIONS AFTER AB T CELL-DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER T-CELL-REPLETE ALLOGENEIC HSCT PREVENTS DISEASE RELAPSE AND PROLONGS SURVIVAL IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIA**

**BASELINE IMMUNE STATUS PREDICTS RESPONSE TO ADOPTIVE THERAPY WITH CMV CTLs FOR REFRACTORY CMV**

**EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY ON BEHALF OF GETH (GRUPO ESPAÑOL TRASPLANTE HEMATOPOYÉTICO)**

**PHASE I STUDY OF ADOPTIVE TRANSFER OF HAPLOIDENTICAL EXPANDED NK CELLS**

**OFF-TARGET HLA CROSS-REACTIVITY BY (THIRD PARTY) VIRUS-SPECIFIC T CELLS IS SURPRISINGLY AFFECTED BY HLA RESTRICTION AND HLA BACKGROUND BUT NOT BY VIRUS SPECIFICITY**

**ADOPTIVE IMMUNOTHERAPY OF REFRACTORY VIRAL INFECTIONS AFTER ALLOGENEIC HSCT: AN ACADEMIC NETWORK FRAMING THE USE OF AN ATMP UNDER HOSPITAL EXEMPTION**

**HOW TO BENEFIT FROM EXHAUSTION: PATIENT-DERIVED INHIBITED T CELLS AS A NOVEL SOURCE OF TUMOR-REACTIVE T CELL CLONES**

**EFFICIENT CRISPR/CAS9-MEDIATED INACTIVATION OF THE GLUCOCORTICOID RECEPTOR FOR ANTIGEN-SPECIFIC T-CELL IMMUNOTHERAPY**

**COMPARISON OF OUTCOME POST-SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION VERSUS DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS**

**AUTOMATED APPLICATION FOR DEPLETION OF TCRAB+, CD19+ AND CD45RA+ CELLS FROM APHERESIS PRODUCTS USING THE CLINIMACS PRODIGY (R)**

**THE FIRST FUNCTIONAL HLA-A\*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES**

**GOOD RESPONSE RATES OF WJ-MSC, COMPARABLE TO BM-MSC, IN THE TREATMENT OF REFRACTORY GVHD**

**AN 'ALL IN ONE' T-CELL PRODUCT FROM NON-TRANSPLANTABLE CORD BLOOD UNITS FOR VIRUS- AND LEUKEMIA-SPECIFIC T-CELL IMMUNOTHERAPY**

**CLINICAL SUCCESS OF GRANULOCYTE TRANSFUSIONS IN ADULT NEUTROPENIC PATIENTS AFTER CHEMOTHERAPY AND/OR ALLOGENEIC TRANSPLANTATION - TIME MATTERS!**

**IMPACT OF LONG-TERM CRYOPRESERVATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS PRODUCTS**

**OPTIMIZING LENTIVIRAL VECTOR TRANSDUCTION TO GENE MODIFY CORD BLOOD CD8+ T CELLS FOR OFF-THE-SHELF ADOPTIVE CELL THERAPY TO TREAT CANCER**

**DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. SINGLE CENTRE EXPERIENCE**

**CASE REPORT: CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION (CAEBV) CONTROLLED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) AND TRANSFUSION OF EBV-SPECIFIC T-CELLS**

## Scientific Programme

e-Posters  
09:30 - 18:00

ePoster Area

### Chronic leukaemia and other myeloproliferative disorders

**TIMING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A JOINT STUDY FROM THE INTERNATIONAL MDS/MPN WORKING GROUP AND EBMT**

**RELAPSE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) IN THE PATHWAY INHIBITOR (PI) ERA: NO LONGER A DEAD-END STREET**

**THE 10-YEARS <u>E</u>BMT <u>L</u>ANDSCAPE OF <u>A</u>LLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) FOR <u>C</u>HRONIC LYMPHOCYTIC LEUKEMIA**

**DETERMINANTS OF SURVIVAL IN MYELOFIBROSIS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY BY THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT**

**SPLENECTOMY DOESN'T PRECLUDE SUBSEQUENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MYELOFIBROSIS PATIENTS: A FRENCH NATIONWIDE STUDY USING A MULTISTATE MODEL**

**INCIDENCE OF LATE RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: THE EXPERIENCE OF THREE UNIVERSITY TRANSPLANT CENTRES IN ROME**

**AUSTRALASIAN TRENDS IN ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS IN MOLECULAR ERA**

**CML RELAPSE AFTER ALLOGENEIC HSCT: SURVIVAL, TREATMENT EFFICACY AND PROGNOSTIC FACTORS FOR OUTCOME**

**CHRONIC MYELOID LEUKEMIA: ALLOGENEIC HEMOPOIETIC STEM CELLS TRANSPLANTATION IN THE ERA OF TYROSINE KINASE INHIBITORS**

**REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT WITH CAMPATH T-CELL DEPLETION FOR MYELOFIBROSIS IN THE ERA OF JAK INHIBITORS- A SINGLE CENTRE EXPERIENCE**

**ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS**

**ALLOGENEIC STEM CELL TRANSPLANTATION FOR IDIOPATIC MYELOFIBROSIS: A SINGLE CENTRE EXPERIENCE**

**A CASE OF SUCCESSFUL SECOND HAPLOIDENTICAL BONE MARROW TRANSPLANTATION AFTER SECONDARY GRAFT FAILURE IN A PATIENT WITH REFRACTORY CHRONIC MYELOID LEUKEMIA**

e-Posters  
09:30 - 18:00

ePoster Area

### Conditioning regimens

## Scientific Programme

**THE IMPACT OF CONDITIONING IN CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY "FORUM" ON BEHALF OF AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP**

**POPULATION PHARMACOKINETIC ESTIMATION OF ATG EXPOSURE PREDICTS IMMUNE RECONSTITUTION AND SURVIVAL IN ADULTS UNDERGOING EX VIVO CD34-SELECTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**FLAMSA-BASED REDUCED INTENSITY CONDITIONING VERSUS MYELOABLATIVE CONDITIONING IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH ACTIVE DISEASE AT THE TIME OF TRANSPLANTATION: AN ALWP/EBMT ANALYSIS**

**TOTAL BODY IRRADIATION/FLUDARABINE VERSUS THIOTEPA/BUSULFAN/FLUDARABINE FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH HAPLOIDENTICAL HCT. A STUDY BY ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**

**BUSULFAN-CYCLOPHOSPHAMIDE VERSUS CYCLOPHOSPHAMIDE-BUSULFAN AS CONDITIONING REGIMEN BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A PROSPECTIVE RANDOMIZED TRIAL**

**RABBIT ANTI-THYMOCYTE GLOBULIN (ATG) EXPOSURE AFTER EX VIVO T-CELL-DEPLETED HEMATOPOIETIC CELL TRANSPLANTATION IS VARIABLE AND IMPACTS IMMUNE RECONSTITUTION AND SURVIVAL IN CHILDREN AND YOUNG ADULTS**

**A RETROSPECTIVE COMPARATIVE STUDY OF BEAM VS FEAM VS TEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT**

**REDUCED INTENSITY VERSUS MYELOABLATIVE CONDITIONING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS < 60 WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTI-CENTER CANADIAN EXPERIENCE**

**COMBINING CLOFARABINE AND FLUDARABINE WITH EXPOSURE TARGETED BUSULFAN FOR PEDIATRIC LEUKEMIA: AN EFFECTIVE, LOW TOXIC, TBI-FREE CONDITIONING REGIMEN**

**BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II STUDY**

**REDUCED-TOXICITY CONDITIONING WITH FLUDARABINE, THIOTEPA AND MELPHALAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH IMPAIRED LUNG FUNCTION**

**ALLOGENEIC STEM CELL TRANSPLANT WITH MINIMAL-INTENSITY CONDITIONING IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA: A SINGLE CENTRE RETROSPECTIVE REVIEW**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND KARNOFSKY PERFORMANCE STATUS SCORE EQUAL OR LOWER THAN 80%.A STUDY FROM THE ALWP-EBMT**

**A PROSPECTIVE COHORT STUDY COMPARING LONG-TERM OUTCOMES WITH AND WITHOUT PALIFERMIN IN PATIENTS RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES**

**PHARMACOKINETICS OF MELPHALAN IN LYMPHOMA PATIENTS UNDERGOING BEAM AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT**

**MELPHALAN IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION: DOES ONE SIZE FIT ALL?**

**COMPARISON OF TOTAL BODY IRRADIATION- VS CHEMOTHERAPY-BASED CONDITIONINGS FOR EARLY COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH ALL**

## Scientific Programme

**DIFFERENTIAL ALEMTUZUMAB DOSAGES IN T-CELL DEplete ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTS FOR MYELOID MALIGNANCIES**

**THE INFLUENCE OF TDM ON ACHIEVING BUSULFAN TARGET EXPOSURE AND RELATED DETERMINANTS, IN BOTH CHILDREN AND ADULTS WHO UNDERWENT AN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**NOVEL REDUCED INTENSITY CONDITIONING (RIC) APPROACH TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH BENIGN AND MALIGNANT DISORDERS OF T CELL PROLIFERATION OR DYSREGULATION**

**PROFOUND LYMPHOPENIA AT THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION IS NOT PREDICTIVE OF SURVIVALS AFTER ALLO-TRANSPLANTATION**

**LIPID CORE NANOPARTICLES AS VEHICLE FOR ETOPOSIDE IN THE CONDITIONING REGIMEN OF MARROW TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA NOT RESPONDING TO INDUCTION THERAPY: A PILOT STUDY**

**A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF SHORT-TERM EVEROLIMUS IN ADDITION TO POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-EVER)**

**ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS  $\geq 65$  YEARS WITH HEMATOLOGICAL MALIGNANCIES AFTER MYELOABLATIVE TREOSULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS**

**BUTYRYLCHOLINESTERASE ACTIVITY AFTER CYCLOPHOSPHAMIDE CONDITIONING AS A PREDICTIVE MARKER OF LIVER TRANSPLANT-RELATED COMPLICATIONS AND ITS CORRELATION WITH TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS**

**FLUDARABINE-MELPHALAN CONDITIONING RESULTS IN FAVORABLE LEUKEMIA-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH ACTIVE OR MEASURABLE RESIDUAL AML**

**SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS)**

**INCREASED NON-RELAPSE MORTALITY AND POOR OVERALL SURVIVAL IN ELDERLY PATIENTS TREATED WITH FLUDARABINE AND MYELOABLATIVE DOSE OF BUSULFAN: TRANSPLANT COMPLICATIONS WORKING GROUP OF THE JSHCT**

**TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA**

**A CD45-TARGETED ANTIBODY DRUG CONJUGATE ENABLES ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS A SINGLE AGENT IN MICE**

**INFLUENCE OF THE CELL SOURCE TYPE AND CONDITIONING TYPE ON HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME**

**PRECONDITIONING INTENSITY IMPACTS ON IMMUNE RECONSTITUTION AND OUTCOMES FOLLOWING CORD BLOOD TRANSPLANTATION**

**FINAL RESULTS OF A PROSPECTIVE, MULTICENTER, NON-INTERVENTIONAL STUDY ON THIOTEPA-BASED AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (ASCT) FOR CNS OR NON-CNS LYMPHOMA**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY), CYCLOSPORIN (CSA) AND MYCOPHENOLATE (MMF) FOR PATIENTS GRAFTED FROM HLA IDENTICAL SIBLINGS OR MATCHED UNRELATED DONORS**

## **Scientific Programme**

**COMPARISON OF FLUDARABINE + BUSULFAN AND FLUDARABINE+BUSUFAN+ LOW-DOSE ATG CONDITIONING REGIMENS IN PATIENTS WITH MYELOID MALIGNANCIES WHO HAD ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE**

**CONDITIONING REGIMEN COMPARISON FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA**

**PK-GUIDED BUSULFAN CONDITIONING REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) WITH PTCY AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES**

**A THIOTEPA BASED INTENSIFIED REDUCED INTENSITY CONDITIONING REGIME IN ADULT CORD BLOOD TRANSPLANT IS A PROMISING ALTERNATIVE IN PATIENTS UNABLE TO RECEIVE MYELOABLATIVE CONDITIONING**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE USING AS CONDITIONING FLUDARABINE MELPHALAN PLUS LOW DOSES OF TOTAL BODY IRRADIATION. LONG TERM FOLLOW-UP OF 60 PATIENTS**

**TREOSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE**

**COMPARISON OF BEAM AND TEAM AS CONDITIONING REGIMEN FOR LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**

**ASSESSMENT OF THE SAFETY AND EFFICACY OF THE CONDITIONING REGIMEN BEEAC BEFORE AUTO-HSCT FOR THE TREATMENT OF PRIMARY-REFRACTORY AND RELAPSED FORMS OF MALIGNANT LYMPHOMAS**

**ALLOGENEIC STEM CELL TRANSPLANTATION AFTER TOTAL-BODY IRRADIATION USING HELICAL TOMOTHERAPY: A SINGLE CENTER EXPERIENCE**

**FEASIBILITY OF CLAMSA-RIC AS AN ALTERNATIVE CONDITIONING REGIMEN COMPARED TO FLAMSA-RIC IN HEAVILY PRETREATED REFRACTORY AML PATIENTS - A RETROSPECTIVE SINGLE CENTER ANALYSIS**

**THIOTEPA, BUSULPHAN AND FLUDARABINE CONDITIONING IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA**

**FLAMSA-BASED HIGH-DOSE SEQUENTIAL CONDITIONING REGIMEN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): IS IT EFFECTIVE IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED ACUTE LEUKEMIA?**

**INCREASING IN SERUM TOTAL AMYLASE LEVELS AFTER TOTAL BODY IRRADIATION CONDITIONING REGIMEN AS A PREDICTIVE MARKER OF TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HEMATOPOIETIC STEM CELL RECIPIENTS**

**EVOLUTION OF DONOR CHIMERISM AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT - CLINICAL CORRELATIONS**

**THIOTEPA-BUSULFAN-FLUDARABINE AS CONDITIONING REGIMEN FOR PATIENTS WITH MYELOFIBROSIS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA-HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE REGIMEN IN CHILDREN**

**ANALYSIS OF DIFFERENCES IN PREVENTIVE MEASURES AFTER HIGH-DOSE CYCLOPHOSPHAMIDE AMONG BELGIAN STEM CELL TRANSPLANT CENTRES**

## Scientific Programme

**IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION**

**LOW GRAFT CD4 CELL DOSE PREDICTS RELAPSE IN THE ATG-BASED MYELOABLATIVE CONDITIONING REGIMEN**

**CLINICAL EFFICACY OF HAPLOID TRANSPLANTATION WITH BU/CY/MEL PRETREATMENT SCHEME TO IMPROVE 68 CASES OF UNICENTRIC REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA**

**REDUCING INTENSITY CONDITIONING (RIC) PROTOCOL HARMONISATION IN THE UK**

**HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN HIGH-RISK HEMATOLOGICAL MALIGNANCIES, ALGERIAN EXPERIENCE**

**INTERRUPTION OF CONDITIONING FOR ALLO-HCT DOES NOT AFFECT CLINICAL OUTCOMES OTHER THAN CHRONIC GVHD**

**THERAPEUTIC DRUG MONITORING OF BUSULFAN IN PEDIATRIC POPULATION**

**REDUCED INTENSITY CONDITIONING FOLLOWED BY HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (RIC-HAPLOHCT) AND POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS, FOR HEMATOLOGICAL DISORDERS: SINGLE CENTRE EXPERIENCE**

**HIGH DOSE TREATMENT WITH LEAM AND AUTOLOGOUS STEM CELL TRANSPLANTATION DURING THE SHORTAGE OF MOSTLY USED AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA**

**REDUCED DOSE ALEMTUZUMAB IN REDUCED INTENSITY CONDITIONING VOLUNTEER DONOR UNRELATED TRANSPLANT FOR MYELOID MALIGNANCIES IS SAFE AND EFFICACIOUS. A SINGLE CENTRE EXPERIENCE**

**DESCRIBE AND EXPLORE A PATIENTS' OUTLOOK ON DENTAL CARE IN THE CONTEXT OF THEIR MEDICAL DIAGNOSIS AND TREATMENT PRIOR TO AND FOLLOWING ALLOGENEIC HSCT**

**SAFETY AND EFFICACY OF LOW-DOSE BENDA-EAM AS COMPARED TO BEAM CONDITIONING FOR AUTOLOGOUS TRANSPLANTATION OF REFRACTORY/RELAPSED LYMPHOMA PATIENTS**

**CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS**

**OUTCOMES OF UNRELATED DONOR STEM CELL TRANSPLANTATION WITH OR WITHOUT ANTI-THYMOCYTE GLOBULIN USED AS GRAFT-VERSUS HOST DISEASE (GVHD) PROPHYLAXIS: A SINGLE CENTER EXPERIENCE**

**BUSULFAN-FLUDARABINE CONDITIONING REGIMEN FOR CORD BLOOD TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE TWO-CENTER STUDY**

**ATG IN CONDITIONING FOR SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE**

e-Posters  
09:30 - 18:00

ePoster Area

## Gene Therapy

## Scientific Programme

**CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT  $\beta$ -THALASSEMIA**

**LENTIVIRAL HEMATOPOIETIC STEM AND PROGENITOR CELL GENE THERAPY (HSPC-GT) FOR METACHROMATIC LEUKODYSTROPHY (MLD): CLINICAL OUTCOMES FROM 33 PATIENTS**

**A SINGLE DOSE OF SHORT HALF-LIFE CD117 ANTIBODY DRUG CONJUGATE ENABLES HEMATOPOIETIC STEM CELL BASED GENE THERAPY IN NONHUMAN PRIMATES**

**LENTI-D HEMATOPOIETIC STEM CELL GENE THERAPY STABILIZES NEUROLOGIC FUNCTION IN BOYS WITH CEREBRAL ADRENOLEUKODYSTROPHY**

**SAFETY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH GENE ADDITION THERAPY FOR TRANSFUSION-DEPENDENT  $\beta$ -THALASSEMIA, SICKLE CELL DISEASE, AND CEREBRAL ADRENOLEUKODYSTROPHY**

**EX-VIVO AUTOLOGOUS HAEMATOPOIETIC STEM CELL GENE THERAPY IN MUCOPOLYSACCHARIDOSIS TYPE IIIA**

e-Posters  
09:30 - 18:00

ePoster Area

### Graft-versus-host disease - clinical

**KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) - LONG-TERM FOLLOW-UP OF A PHASE 2A STUDY (KD025-208)**

**A PHASE 2 STUDY OF F-652, A NOVEL TISSUE-TARGETED RECOMBINANT HUMAN INTERLEUKIN-22 (IL-22) DIMER, FOR TREATMENT OF NEWLY DIAGNOSED ACUTE LOWER GI GVHD**

**THE MAGIC BIOMARKER ALGORITHM PREDICTS OUTCOMES FOR CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE**

**A NOVEL TREATMENT IN CHRONIC OCULAR GRAFT-VS-HOST DISEASE (OGVHD): A PHASE II CLINIC TRIAL WITH TRANSDERMAL PROGESTERONE**

**EARLY CD4+ T-CELL RECONSTITUTION IS AN EXCELLENT PREDICTOR OF OUTCOMES IN PEDIATRIC PATIENTS WHO DEVELOP MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST-DISEASE: A DUAL CENTER VALIDATION**

**EFFECT OF SINGLE OR DOUBLE MISMATCHES AT EACH HLA LOCUS ON THE OUTCOMES AFTER SINGLE CORD BLOOD TRANSPLANTATION: THE JSHCT HLA WG STUDY**

**INTERIM ANALYSIS OF KD025-213: A PHASE 2, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KD025 IN SUBJECTS WITH CGVHD (THE ROCKSTAR STUDY)**

**ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) AND RITUXIMAB FOR IMMUNOMODULATION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT FAILURE IN PATIENTS WITH NON-MALIGNANT DISORDERS: RESULTS OF A MULTICENTRE, RANDOMIZED, OPEN-LABEL STUDY**

**EXPERIENCE USING DUAL T-CELL DEPLETION WITH ATG AND PTCY FOR GVHD PROPHYLAXIS IN RIC ALLOHCT USING IN 10/10 MATCHED RELATED AND UNRELATED DONORS**

**MACHINE LEARNING APPLIED TO THE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE IMPROVES SURVIVAL ESTIMATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

## **Scientific Programme**

**SINGLE-CELL MOLECULAR ANALYSIS DEFINES CHARACTERIZATION OF SPECIFIC T CELL SUBSETS CORRELATE WITH HUMAN CHRONIC GVHD AND BRONCHIOLITIS OBLITERANS**

**A PHASE II TRIAL EVALUATING THE USE OF THE HISTONE DEACETYLASE INHIBITOR PANOBINOSTAT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PREVENTION**

**REDUCED CALCIUM SIGNALING IS ASSOCIATED WITH GVHD: RESULTS FROM PRECLINICAL ALLOSCT MODELS AND FROM A PROSPECTIVE MULTICENTER STUDY**

**IDENTIFICATION OF PREDICTIVE MODELS INCLUDING POLYMORPHISMS IN CYTOKINES GENES ASSOCIATED WITH ACUTE GRAFT VERSUS HOST DISEASE AND OVERALL SURVIVAL AFTER IDENTICAL HLA-ALLOGENEIC STEM-CELL TRANSPLANTATION**

**SEARCH FOR CIRCULATING ENDOTHELIAL CELLS OF DONOR ORIGIN AFTER ALLO-HSCT: POTENTIAL CLINICALLY RELEVANT IMPLICATIONS IN THE CONTEXT OF GRAFT-VERSUS-HOST DISEASE**

**DOUBLE LUNG TRANSPLANTATION IN ADULTS FOR CHRONIC PULMONARY GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**REDUCED INFLAMMATORY TISSUE INFILTRATION DURING INTESTINAL STEROID-REFRACTORY GVHD**

**IMPACT OF ANTITHYMOCYTE GLOBULIN DOSE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN STEM CELL TRANSPLANTATION FROM UNRELATED DONORS**

**DECREASED SOLUBLE HLA-E LEVELS IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH SEVERE ACUTE AND EXTENDED CHRONIC GRAFT-VERSUS-HOST DISEASE AND INFERIOR OVERALL SURVIVAL**

**EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON PRODUCTION OF SERUM SOLUBLE CD163: RELATIONSHIP TO IMMUNOSUPPRESSION AND DISEASE ACTIVITY IN CHRONIC GRAFT VERSUS HOST DISEASE**

**POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE OVERCOMES THE DETRIMENTAL EFFECT OF A SINGLE-LOCUS HLA MISMATCHED IN UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: 'SIR-PTCY' RESULTS IN 249 PATIENTS**

**A NEW HOPE IN THE TREATMENT OF STEROID-REFRACTORY GRAFT VERSUS HOST DISEASE (SR-GVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT): RUXOLITINIB**

**AZACITIDINE IS SAFE AND ACTIVE IN THE TREATMENT OF STEROID REFRACTORY CHRONIC GRAFT-VERSUS-HOST-DISEASE - INTERIM RESULTS OF THE PHASE II AZTEC TRIAL**

**BASILIXIMAB AS TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EFFICACY AND TOLERANCE OF NILOTINIB IN PATIENTS WITH REFRACTORY CHRONIC GVHD WHO ARE REFRACTORY/INTOLERANT TO IMATINIB: A PROSPECTIVE MULTICENTER PHASE II STUDY OF THE SFGM-TC**

**EVALUATION OF THE PROGNOSTIC VALUE OF HISTOLOGIC ASSESSMENT OF ACUTE GRAFT-VERSUS-HOST-DISEASE OF THE UPPER GASTROINTESTINAL TRACT ACCORDING TO LERNER EARLY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

## **Scientific Programme**

**CYCLOSPORINE A ALONE VERSUS MYCOPHENOLATE MOFETIL PLUS CYCLOSPORINE A BASED GVHD PROPHYLAXIS FOR PATIENTS WITH AML UNDERGOING MUD TRANSPLANTATION. A STUDY FROM THE ALWP**

**TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS INDEPENDENTLY ASSOCIATED WITH RUXOLITINIB ADMINISTRATION IN PATIENTS WITH GRAFT-VERSUS-HOST-DISEASE**

**DIAGNOSTIC SIGNIFICANCE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE (GVHD)**

**LONG TERM OUTCOMES OF RUXOLITINIB THERAPY IN STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN AND ADULTS**

**INVESTIGATING ANTIBIOTIC EXPOSURE AND RISK OF SEVERE ACUTE GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**EFFICACY AND TOXICITY OF RUXOLITINIB IN PATIENTS WITH STEROID-RESISTANT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION**

**PATIENT CHARACTERIZATION AND SURVIVAL OUTCOMES IN PAEDIATRIC CHRONIC GRAFT VERSUS HOST DISEASE PATIENTS: A POPULATION-BASED STUDY IN SWEDEN**

**CYTOKINE LEVELS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION: A MATCH-PAIR ANALYSIS OF HOME CARE VERSUS HOSPITAL CARE**

**FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH STEROID-RESISTANT GRAFT VERSUS HOST DISEASE COLONIZED BY ANTIBIOTIC-RESISTANT BACTERIA - SINGLE-CENTER ANALYSIS OF 15 PROCEDURES**

**INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE: RESULTS FROM A PROSPECTIVE MULTICENTRE ANALYSIS OF 2 COHORTS**

**THE CXCL9 POLYMORPHISM RS884304 COUNTERACTS CALCINEURIN-INHIBITOR REPRESSION OF EARLY CXCL9 RECONSTITUTION AND ASSOCIATES WITH SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE**

**EARLY INTRODUCTION OF RUXOLITINIB FOR CHILDREN WITH GRAFT VERSUS HOST DISEASE - A STITCH IN TIME SAVES NINE**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE AS AN EFFECTIVE STRATEGY FOR GVHD PREVENTION IN BOTH HLA-MATCHED AND MISMATCHED ALLOGENEIC TRANSPLANTS**

**SERUM AUTOANTIBODIES IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY**

**OPTIMIZED STARTING DOSE OF CYCLOSPORINE REDUCES RISK OF ACUTE GVHD AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**SUCCESS OF IMMUNOSUPPRESSION IN PATIENTS WITH CHRONIC GVHD: ANALYSIS ON 108 ADULT LONG-TERM SURVIVORS AFTER MATCHED AND HAPLO HSCT**

**INCIDENCE AND OUTCOME OF LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE DURING TAPERING OR AFTER STOPPING CALCINEURIN INHIBITORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING AND MATCHED UNRELATED COMPARED TO HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, A STUDY ON BEHALF OF GETH**

## Scientific Programme

**MESENCHYMAL STROMAL CELLS (MSC) FOR STEROID-REFRACTORY ACUTE GVHD, A SINGLE CENTER PHASE I/II TRIAL**

**T-LYMPHOCYTE TRANSCRIPTIONAL SIGNATURE IN ECP-TREATED PAEDIATRIC PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE**

**EFFICACY OF LOW-DOSE RUXOLITINIB AS SAVAGE THERAPY IN HEAVILY PRETREATED PATIENTS WITH MODERATE/SEVERE STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE**

**RESTRICTIVE USE OF INTRAVENOUS ANTIBIOTICS IN ALLOGENEIC SCT PTS WITH FEVER DUE TO CYTOKINE RELEASE SYNDROME ALLOWS MICROBIOTA PROTECTION WITHOUT INCREASE OF INFECTIONS AND TRM**

**EXTRACORPOREAL PHOTOPHERESIS (ECP) AS FIRST-LINE TREATMENT FOR ACUTE GVHD (AGVHD) IN PEDIATRIC PATIENTS WHO UNDERWENT T-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (APLO-HSCT)**

**EFFICACY OF METHOXSALEN STERILE SOLUTION IN CONJUNCTION WITH THE THERAKOS (R) CELLEX (R) PHOTOPHERESIS SYSTEM IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: INTERIM ANALYSIS**

**MICRO RNA PROFILING OF ACOUSTICALLY-ISOLATED EXTRACELLULAR VESICLES IDENTIFIES POTENTIAL BIOMARKERS FOR POST-ALLO-HSCT COMPLICATIONS**

**COLONIZATION PLAYS AN IMPORTANT ROLE IN THE OUTCOME OF ALLOGENEIC TRANSPLANTATION**

**ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) SCORE AT THE ONSET OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PREDICTING OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION-A RETROSPECTIVE ANALYSIS**

**CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS**

**COMPARISON OF EXCLUSIVE POSTTRANSPLANT CYCLOPHOSPHAMIDE VERSUS A CALCINEURIN INHIBITOR BASED REGIMEN AS GVHD PROPHYLAXIS IN ALLOGENEIC BONE MARROW TRANSPLANTATION FROM HLA IDENTICAL SIBLING**

**SIROLIMUS VERSUS CYCLOSPORINE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND MYCOPHENOLATE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HAPLOIDENTICAL TRANSPLANTS: A RETROSPECTIVE ANALYSIS OF ONE SINGLE INSTITUTION**

Mario Andres Sanchez Salinas, Rafael Hernani Morales, Ana Benzaquen Vallejos, Juan Carlos Hernandez Boluda, Ariadna Perez Martinez, Paula Amat Martinez, Montserrat Gomez Calafat, Rosa Goterris Viciado, Carlos Solano Vercet (Spain)

**TARGETED SEQUENCE CAPTURE METAGENOMICS (VIROCAP) TO DETECT VIRUS IN STOOL SAMPLES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS**

**EXTRACORPOREAL PHOTOPHERESIS AND PRODUCTION OF SERUM IL-34 AND ELAFIN IN CHRONIC GRAFT VERSUS HOST DISEASE**

**IMPACT OF UPPER AND LOWER ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE ON GRADING AND OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS IN 122 CONSECUTIVE PATIENTS**

Monica Poiani, Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Marianna Mariani, Giorgia Micucci, Chiara Montagna, Giuseppina Urbano, Federica Monaco, Giuseppe Tarantino, Irene Federici, Attilio Olivieri (Italy)

**PRELIMINARY EXPERIENCE WITH THE USE OF RUXOLITINIB, IBRUTINIB OR IMATINIB FOR THE TREATMENT OF ACUTE OR CHRONIC GVHD**

## Scientific Programme

**RUXOLITINIB WITH OR WITHOUT IBRUTINIB AS AN ALTERNATIVE FIRST LINE THERAPY FREE OF CORTICOSTEROIDS OR CALCINEURIN INHIBITORS IN TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE**

**CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS**

**IMPACT OF KIR/HLA INCOMPATIBILITIES AFTER POSTTRANSPLANT CYCLOPHOSPHAMIDE BASED T CELL-REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ELEVATED PTH LEVELS AMONG CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS AND OTHER LONG TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CONCURRENCE OF GVHD AND NON-INFECTIOUS NEUROLOGICAL COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION**

**ACUTE GVHD INCIDENCE IN MISMATCHED UNRELATED DONOR HSCT IN PAEDIATRIC ADULT PATIENTS: A STUDY FROM THE TURIN METROPOLITAN TRANSPLANT CENTER**

**PRACTICAL IMPLEMENTATION OF THE NIH DIAGNOSTIC CRITERIA FOR ORAL CHRONIC GVHD IN A MULTIDISCIPLINARY TEAM IN THE LATE FOLLOW UP OF ALLOGENIC HSCT PATIENTS**

**THE IMPACT OF ANTIBIOTIC-MEDIATED MODIFICATION OF THE INTESTINAL MICROBIOME ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SYSTEMATIC REVIEW AND META-ANALYSIS**

**CLINICAL APPLICATION OF MESENCHYMAL STEM CELLS FROM WHARTON'S JELLY IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE**

**PREDICTIVE ROLE OF ENDOSCOPIC/HISTOLOGICAL EXAMINATIONS FOR GASTRO-INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM CELLS TRANSPLANT: 'A POSTERIORI' ANALYSIS IN A SINGLE CENTER**

**THE INCIDENCE, RISK FACTORS, AND OUTCOMES OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**PROGNOSTIC CT FINDINGS AROUND THE ONSET OF ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE**

**THYMOGLOBULIN AND GRAFALON EFFECT ON ALLOGENEIC STEM CELL TRANSPLANT - POOLED DATA FROM WROCLAW MEDICAL UNIVERSITY, POLAND AND UNIVERSITY MEDICAL CENTER LJUBLJANA, SLOVENIA**

**THE ROLE OF LOW-DOSE ANTI-THYMOCYTE GLOBULIN IN MATCHED SIBLING DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES**

**NEPHROTIC SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AS A FORM OF CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE**

**CORRELATION AMONG TOTAL NUCLEATED CELLS (TNC), CD34+, CD3+ CELL CONTENT IN G-CSF-PRIMED BONE MARROW COLLECTIONS AND THEIR RELATIVE INFLUENCE ON DEVELOPMENT OF ACUTE GVHD**

**PREDICTION FOR LETHAL ACUTE GRAFT VERSUS HOST DISEASE AND NON-RELAPSE MORTALITY BY EARLY PLASMA BIOMARKERS: A SINGLE CENTER RETROSPECTIVE STUDY IN JAPAN**

**RUXOLITINIB IN THE TREATMENT OF CORTICOSTEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD): ONE SINGLE CENTER EXPERIENCE**

**OUTCOME OF PATIENTS ALIVE AT 1-YEAR POST ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS FROM A SINGLE INSTITUTION**

## Scientific Programme

**RUXOLITINIB IN STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE:  
EXPERIENCE IN OUR CENTRE**

**LOW-DOSE OF RUXOLITINIB: AN EFFECTIVE THERAPY FOR REFRACTORY BOS PATIENTS**

**SIROLIMUS BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PAEDIATRIC PATIENTS  
UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT FOR BENIGN  
DISEASE**

**DETECTION OF BIOMARKERS PREDICTIVE OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC  
HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PATIENTS: A PILOT STUDY**

**OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)  
AFTER PD-1 BLOCKADE IN RELAPSED/REFRACTORY (R/R) LYMPHOMAS: A SINGLE CENTER  
EXPERIENCE**

**CD3+ DOSE IN PERIPHERAL BLOOD PROGENITOR CELLS PRODUCTS FOR ALLOTRANSPLANT  
FROM MATCHED UNRELATED DONORS FOR AML: IMPACT ON CHRONIC GRAFT VERSUS HOST  
DISEASE AND SURVIVAL**

**CYCLOPHOSPHAMIDE FOR SALVAGE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE: A  
RETROSPECTIVE ANALYSIS**

**A ROLE OF METHOTREXATE IN THE THERAPY OF CHRONIC GRAFT-VERSUS-HOST DISEASE - A  
MULTICENTER OBSERVATIONAL STUDY ON BEHALF OF POLISH ADULT LEUKEMIA GROUP  
(PALG)**

**EVALUATION OF EXTRACORPOREAL PHOTOPHERESIS USED AS SECOND-LINE TREATMENT  
FOR GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HSCT IN A BRAZILIAN CENTER**

**THE OPTIMAL GVHD PROPHYLAXIS IN UNRELATED TRANSPLANTATIONS OF NON-  
MANIPULATED HEMATOPOIETIC STEM CELLS IN CHILDREN**

**ANALYSIS OF HISTOLOGY'S IMPACT IN PATIENTS WITH ACUTE GRAFT VERSUS HOST DISEASE  
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE: SINGLE CENTER EXPERIENCE**

**IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) FOR GRAFT-VERSUS-HOST  
DISEASE (GVHD) PROPHYLAXIS IN ALLOGENIC HEMATOPOIETIC STEM CELL  
TRANSPLANTATION (ALLO-HSCT). UNICENTRIC EXPERIENCE**

**FECAL MICROBIOTA TRANSPLANTATION FOR TREATING STEROID-REFRACTORY ACUTE GRAFT-  
VERSUS-HOST DISEASE OF THE GUT: A PILOT STUDY**

**EARLY RECOVERY OF LYMPHOCYTES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION  
IS RISK FACTOR OF CGVHD**

**FAVORABLE OUTCOME USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) IN  
HAPLOIDENTICAL (HAPLO-SCT) AND MATCHED RELATED DONORS (MRD): SINGLE CENTER  
EXPERIENCE IN CHILE**

**COMBINED THERAPY WITH MSC INFUSIONS TO OVERCOME STEROID-DEPENDENCY IN A CASE  
OF SEVERE PULMONARY CGVHD**

**MULTIPLE STRICTURES OF THE SMALL INTESTINE DEMANDING SURGICAL INTERVENTION AS  
A COMPLICATION OF GRAFT VERSUS HOST DISEASE: A CASE REPORT**

**A REMARKABLY LONG REMISSION ACHIEVED WITH IBRUTINIB MONOTHERAPY IN A PATIENT  
WHO WAS DIAGNOSED WITH STEROID REFRACTORY SCLEROSING CHRONIC GVHD**

**INCREASED RISK OF ACUTE GVHD IN PATIENTS WITH MYELOFIBROSIS AFTER ALLO  
TRANSPLANT IN THE ABSENCE OF JAK-STAT INHIBITION**

## Scientific Programme

**AUTOIMMUNE MYOSITIS AS PARANEOPLASTIC COMPLICATION OF A SQUAMOUS CELL CARCINOMA OF THE TONGUE AFTER SEVERE CHRONIC GRAFT VERSUS HOST DISEASE**

**UNUSUAL CAUSE OF DYSPNEA IN POST-TRANSPLANT PATIENT**

e-Posters  
09:30 - 18:00

ePoster Area

### Graft-versus-host disease - preclinical and animal models

**DIETARY STEARIC ACID LEADS TO A SEVERE AGVHD BY MODULATING THE GUT MICROBIOTA AND GLUCOSE METABOLISM**

**GRANULOCYTE COLONY-STIMULATING FACTOR-PRIMED DONOR T CELLS ATTENUATE MURINE ACUTE GVHD THROUGH REGULATING T CELL DIFFERENTIATION IN TARGET ORGANS**

**MTOR REGULATE GENERATION AND FUNCTION OF PMN-MDSCS AND PLAY PROTECTION ROLE IN ACUTE GRAFT-VERSUS-HOST DISEASE**

**FULL REGULATORY T CELL RECONSTITUTION BEFORE T CELL TRANSFER PREVENTS GRAFT-VERSUS-HOST DISEASE BY SUPPRESSING COSTIMULATION AND T CELL ACTIVATION IN A HAPLOIDENTICAL MODEL**

**TARGETING OF CHEMOKINE RECEPTOR 7 PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE**

**ENHANCING REGULATORY T CELL FUNCTION AND HOMING TO THE GUT TO IMPROVE GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER ADOPTIVE TRANSFER IN ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION**

**LYG1-DEFICIENT DONOR SPLENOCYTES ATTENUATED THE SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE VIA SKEWING CD4+ T CELL POLARIZATION TOWARDS TREG CELLS**

**ATTENUATION OF MURINE CHRONIC GRAFT VERSUS HOST DISEASE BY THE NRF2 ACTIVATOR MANGIFERIN**

**CHEMOTHERAPY AND INFLAMMATION INDUCED DAMAGE OF INTESTINAL EPITHELIUM IS ASSOCIATED WITH INCREASED T CELL CHEMOTAXIS**

**INKT CELLS PROMOTE IMMUNE TOLERANCE BY SELECTIVE DENDRITIC CELL APOPTOSIS**

**ACTIVE PARTICIPATION OF CXCR4+ T LYMPHOCYTES IN ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC TRANSPLANTATION**

**A MURINE MODEL REVEALS A CRITICAL ROLE FOR REACTIVE OXYGEN SPECIES IN HYPERACUTE GRAFT-VERSUS-HOST DISEASE**

**MAPPING THE ROAD OF GVHD AND GVT. A LONGITUDINAL STUDY OF IMMUNE-TRANSCRIPTOME SIGNATURES AS NOVEL APPROACH TO SOLVE POST-ALLOGENEIC TRANSPLANTATION DILEMMAS**

**CELL-FREE DNA LEVELS ARE INCREASED IN ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS AND MICE**

**DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION**

**ENDOTHELIAL MICROPARTICLES DELIVERING LNCRNA NEAT1 ARE INVOLVED IN THE PATHOPHYSIOLOGY OF AGVHD FOLLOWING ALLO-HSCT**

**B-T CELL INTERACTIONS IN GRAFT-VERSUS-HOST DISEASE**

## Scientific Programme

### IDENTIFICATION OF POTENTIAL MICROBIOME MARKERS FOR AGVHD EARLY DIAGNOSIS

e-Posters  
09:30 - 18:00

ePoster Area

## Granulocyte and osteoclast disorders

### HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR OSTEOPETROSIS

e-Posters  
09:30 - 18:00

ePoster Area

## Haemoglobinopathy and inborn errors

### SUCCESSFUL HLA-MISMATCHED HSCT IN PAEDIATRIC PATIENTS WITH HEMOGLOBINOPATHIES USING ATG SEROTHERAPY AND POSTTRANSPLANT CYCLOPHOSPHAMIDE

### OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH CEREBRAL ADRENOLEUKODYSTROPHY VARY BY DONOR CELL SOURCE, CONDITIONING REGIMEN, AND STAGE OF CEREBRAL DISEASE STATUS

### OUTCOME OF NON MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE: A 100 PATIENT EXPERIENCE FROM SAUDI ARABIA

### HIGH DOSE STEM CELL THERAPIES, LIKE MGTA-456, ENABLE COMPLETE NEURAL AND PERIPHERAL DISEASE CROSS-CORRECTION THROUGH RAPID AND ROBUST HEMATOPOIETIC ENGRAFTMENT

### HLA SET-UP IS A MAJOR PREDICTOR OF ENGRAFTMENT IN HAPLO-IDENTICAL TRANSPLANT FOR SEVERE THALASSEMIA (ST) USING POST-CYCLOPHOSPHAMIDE (PTCY)

### CTLA4IG-BASED T CELL COSTIMULATION BLOCKADE IN PTCY BASED HAPLOIDENTICAL HCT FOR THALASSEMIA MAJOR [TM] AND SICKLE CELL DISEASE [SCD] RESULTS IN IMPROVED DISEASE-FREE SURVIVAL WITHOUT GVHD

### LENTIGLOBIN GENE THERAPY TREATMENT OF TWO PATIENTS WITH TRANSFUSION-DEPENDENT $\beta$ -THALASSEMIA

### BONE MARROW TRANSPLANT IN PATIENTS WITH SICKLE CELL ANAEMIA. EXPERIENCE IN ONE CENTRE

Marina García Morín, Laura Escobar Fernández, Eduardo Bardón Cancho, Cristina Beléndez Bieler, Jorge Huerta Aragonés, Carmen Garrido Colino, Cristina Mata Fernández, Elena Cela de Julián (Spain)

### OUTCOMES IN CEREBRAL ADRENOLEUKODYSTROPHY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE

### NEURODEVELOPMENTAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MUCOPOLYSACCHARIDOSIS TYPE II: A PROSPECTIVE, LONGITUDINAL STUDY

### HEMATOPOIETIC RECOVERY AND TRANSFUSION NEED AFTER HAPLOIDENTICAL TRANSPLANTATION IN BETA THALASSEMIA PATIENTS

### PRE- AND POST-TRANSPLANT RITUXIMAB REDUCES THE HIGH INCIDENCE OF PRIMARY GRAFT FAILURE AND IMMUNE-MEDIATED CYTOPENIA FOLLOWING CORD BLOOD TRANSPLANT FOR LYSOSOMAL STORAGE DISEASE IN CHILDREN

## Scientific Programme

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE: THE SPANISH EXPERIENCE**

**LONG-TERM QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR FOLLOWING HEMATOPOETIC STEM CELL TRANSPLANTATION IN CHILDHOOD**

**HIGH INCIDENCE OF AUTOIMMUNE CYTOPENIAS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE: THE IMPACT OF MATCHED UNRELATED DONOR**

**ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI MAY REDUCE RISK OF GRAFT FAILURE IN MATCHED SIBLING DONOR ALLOGENEIC HSCT IN ADULT SICKLE CELL PATIENTS**

**A PHASE II STRATIFIED TRIAL TO ASSESS HAPLOIDENTICAL T-DEPLETED STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE WITH NO AVAILABLE SIBLING DONOR**

**COMBINED UMBILICAL CORD BLOOD AND BONE MARROW FROM HLA-IDENTICAL SIBLING DONORS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA MAJOR**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF METABOLISM USING ALTERNATE DONORS: A PROSPECTIVE SINGLE STUDY**

**UMBILICAL CORD BLOOD TRANSPLANTATION IN CHILDREN WITH LEUKODYSTROPHIES: SINGLE CENTER EXPERIENCE IN CHINA**

**PEARSON SYNDROME IN A PATIENT TRANSPLANTED FOR DIAMOND-BLACKFAN ANEMIA**

**CHALLENGES AND SUCCESSES WITH PRE-TRANSPLANT IMMUNE SUPPRESSION IN ALTERNATIVE DONOR TRANSPLANTS**

**HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR CLASS 3 THALASSEMIA MAJOR USING POST-TRANSPLANT CYCLOPHOSPHAMIDE**

e-Posters  
09:30 - 18:00

ePoster Area

## Multiple myeloma

**DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF HIGH-RISK PATIENTS IN CASSIOPEIA**

**EVALUATION OF PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (PET/CT) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PHASE 3 CASSIOPEIA STUDY PATIENTS: CASSIOPET STUDY RESULTS**

**CONCORDANCE OF POSTCONSOLIDATION MINIMAL RESIDUAL DISEASE RATES BY MULTIPARAMETRIC FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING IN CASSIOPEIA**

**LONG-TERM FOLLOW-UP OF THE RANDOMIZED PHASE 3 PETHEMA/GEM 2005MENOS65 STUDY SUPPORTS THE USE OF VTD (BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE) AS PRETRANSPLANT INDUCTION REGIMEN FOR MULTIPLE MYELOMA (MM)**

**DEPTH OF RESPONSE TO DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IMPROVES OVER TIME IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: GRIFFIN STUDY UPDATE**

## Scientific Programme

**HOW TO ASSESS RISK OF PROGRESSION IN MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE REMISSION AFTER AUTOLOGOUS TRANSPLANT: SUB ANALYSIS FROM THE GEM2012MENOS65 PHASE III CLINICAL TRIAL**

**OUTCOMES OF ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS**

**25 YEARS OF AUTOLOGOUS TRANSPLANTATION FOR MYELOMA IN EBMT CENTRES - CHANGING PRACTICE PATTERNS**

**PROGNOSIS IN DIFFERENT RISK-GROUPS OF MULTIPLE MYELOMA WITH MINIMAL RESIDUAL DISEASE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BORTEZOMIB-INTEGRATED CONDITIONING: A SINGLE-CENTER EXPERIENCE**

**UNINTERRUPTED MOBILIZATION AND TRANSPLANTATION PROCEDURE WITH NON-CRYOPRESERVED YIELD IS FEASIBLE WITHOUT INCREASEMENT OF COMPLICATION RISK IN MULTIPLE MYELOMA PATIENTS**

**CONDITIONING WITH BORTEZOMIB-MEL200 IN COMPARISON TO MEL200 IMPROVES SURVIVAL AMONG MYELOMA PATIENTS IN<sub>≤</sub>PR PRIOR TO AUTO-HCT: A STUDY FROM THE CMWP OF THE EBMT**

**RESULTS OF DEFERRED AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED STAGES OF SYSTEMIC AL AMYLOIDOSIS**

**IN VITRO STIMULATION WITH CD40L/IL-21 CAN RETRIEVE B-CELL DYSFUNCTION IN MULTIPLE MYELOMA PATIENTS SUFFERING FROM SECONDARY IMMUNODEFICIENCY**

**ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA; EXCELLENT OUTCOMES FOR EARLY TRANSPLANTATION**

**SEQUENTIAL HEART TRANSPLANTATION FOLLOWED BY HIGH DOSE CHEMOTHERAPY PLUS AUTOLOGOUS STEM CELL REINFUSION IN CARDIAC AL AMYLOIDOSIS**

**AUTOGRAFT CELLULAR COMPOSITION AND OUTCOME IN MYELOMA PATIENTS: RESULTS OF THE PROSPECTIVE MULTICENTER GOA STUDY**

**RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE**

**PHASE 3, OPEN-LABEL, NONINFERIORITY STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): BODY WEIGHT SUBGROUP ANALYSIS OF COLUMBA**

**ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) IS A RELIABLE PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION**

**ABERRANT PHENOTYPE PLASMA CELL MULTIPARAMETRIC FLOW CYTOMETRY (MFC) DETECTION IN AUTOGRAFT PRODUCTS OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)**

**RETROSPECTIVE MULTI-CENTER STUDY OF ADOLESCENT AND YOUNG ADULT (AYA) MULTIPLE MYELOMA IN KANSAI MYELOMA FORUM REGISTRY**

**MAINTENANCE THERAPY WITH ELOTUZUMAB AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA**

**AUTOLOGOUS STEM CELL TRANSPLANTATION CANDIDACY IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS**

**NOVEL PROTOCOL FOR AUTOLOGOUS HSCT IN MULTIPLE MYELOMA ACHIEVES 'ZERO' CENTRAL LINE ASSOCIATED BLOOD STREAM INFECTIONS (CLABSI)**

## Scientific Programme

**OUTCOMES OF NON-CRYOPRESERVED VERSUS CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA**

**DOWN REGULATION OF AUTOPHAGY ENHANCES BORTEZOMIB-INDUCED APOPTOSIS OF MYELOMA CELL BY UP REGULATION OF MITOCHONDRIAL REACTIVE OXYGEN SPECIES**

**RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE**

**FAVORABLE LONG-TERM OUTCOMES WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HIGH RISK PATIENTS WITH MULTIPLE MYELOMA WHO ARE POSITIVE AT FDG-PET/CT**

**LONG TERM SURVIVAL OF MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELATION TO AVAILABILITY OF NOVEL DRUGS**

**MULTIPLE MYELOMA (MM) IN FIRST RELAPSE PATIENTS. ROLE OF THE SECOND AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT) IN REAL LIFE: EXPERIENCE OF TWO SPANISH CENTERS**

**ROLE OF ANALYSIS OF CHIMERISM IN MULTIPLE MYELOMA PATIENTS UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE**

**USE OF NETUPITRANT/PALONOSETRON IN MULTIPLE MYELOMA PATIENTS RECEIVING HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE**

**THE EFFECT OF UCP-2 AND NR3C1 GENES ON TREATMENT EFFICACY AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA**

**SAFETY AND EFFECTIVENESS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA IN FIRST LINE**

**PLASMAPHERESIS ASSISTED THE TREATMENT OF 1 CASE OF HYPERGLOBULINEMIA AFTER CART THERAPY**

e-Posters  
09:30 - 18:00

ePoster Area

## Myelodysplastic syndromes

**ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OF ADULT PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA: A NORDIC RETROSPECTIVE STUDY**

**DECITABINE MONOTHERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION RESULTED IN SUPERIOR SURVIVAL FOR MYELODYSPLASTIC SYNDROME PATIENTS WITH EXCESS BLASTS**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM: A STUDY FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT**

**IMPACT OF MUTATION PROFILE IN CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**

**NEW INSIGHTS OF MYELODYSPLASTIC SYNDROME (MDS) WITH ERYTHROID PREDOMINANCE BASED ON THE NEXT-GENERATION SEQUENCING AND SINGLE-CELL RNA SEQUENCING**

## Scientific Programme

**IMPACT OF TREATMENT PRIOR TO ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: RESULTS OF THE LATIN AMERICAN BONE MARROW TRANSPLANT REGISTRY**

**RESULTS OF LATIN AMERICAN RECORD OF BONE MARROW TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME**

**OUTCOME AND MUTATIONAL PROFILE IN MDS PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

e-Posters  
09:30 - 18:00

ePoster Area

### Non-infectious late effects, quality of life and fertility

**EASIX-1YEAR- THE FIRST BIOMARKER PREDICTING LATE MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**AN UPDATED REPORT ON SECONDARY SOLID CANCER FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMIA MAJOR**

**ALLOGENEIC STEM-CELL TRANSPLANTATION IN AML AND MDS USING CONDITIONING REGIMENS WITH DIFFERENT DOSE-INTENSITIES; 15 YEARS LATER**

**EMPLOYMENT STATUS AND RETURN TO WORK AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A NATIONWIDE SURVEY**

**FUNCTIONAL OUTCOME MEASURES IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): FOCUS ON THE 2-MINUTE WALK TEST**

**FERTILITY IN ADULT FEMALE ALLOGENEIC STEM CELL RECIPIENTS**

**A RISK SCORE MODEL (HAD-TCG) TO EVALUATE THE RISK OF STROKE IN PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**BRONCHIOLITIS OBLITERANS SYNDROME IN THE CHANGING LANDSCAPE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**CURRENT STATUS AND NEEDS OF LONG-TERM FOLLOW-UP CLINICS FOR HEMATOPOIETIC CELL TRANSPLANT SURVIVORS: RESULTS OF A NATIONWIDE SURVEY IN JAPAN**

**SURVIVORSHIP CARE FOR ALLOGENEIC TRANSPLANT PATIENTS IN THE UK: CURRENT SERVICE PROVISION AND BARRIERS TO IMPLEMENTATION**

**CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN EPSTEIN-BARR VIRUS RELATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (EBV-PTLD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)**

**INCIDENCE, RISK FACTORS AND OUTCOMES OF DIFFUSE ALVEOLAR HEMORRHAGE AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION**

**WHOLE BODY VIBRATION TRAINING DURING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION - THE EFFECTS ON PATIENTS' PHYSICAL CAPACITY, FATIGUE, BODY COMPOSITION AND QUALITY OF LIFE**

**MULTI-MORBIDITY IN ADULT SURVIVORS OF STEM CELL TRANSPLANTATION (SCT)**

**GONADOTOXICITY AFTER TREOSULFAN-BASED MYELOABLATIVE CONDITIONING REGIMEN FOR ALLOGENEIC HSCT IN GIRLS WITH LEUKEMIA**

## Scientific Programme

**REDUCED-INTENSITY TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH HIGH-RISK OR ADVANCED HEMATOLOGICAL MALIGNANCIES IN LAST 10 YEARS - SINGLE CENTRE EXPERIENCE**

**FATHERHOOD AFTER A MYELOABLATIVE TREOSULFAN BASED ALLOGENEIC STEM CELL TRANSPLANTATION: ANALYSIS ON 453 PATIENTS**

**COMPARISON OF CENTRAL NERVOUS SYSTEM RELAPSE OUTCOMES FOLLOWING HAPLOIDENTICAL VS IDENTICAL-SIBLING TRANSPLANT FOR ACUTE LYMPHOBLASTIC LEUKEMIA**

**OLDER AGE AND PERIPHERAL BLOOD AS A STEM CELL SOURCE ARE THE MAJOR NEGATIVE PREDICTORS OF SURVIVAL LONG TERM**

**PREVALENCE OF BRONCHIOLITIS OBLITERANS SYNDROME (BOS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLOHSCT) IN THE US, EUROPE AND JAPAN**

**NETUPITANT-PALONOSETRON (NEPA) TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MULTIPLE MYELOMA (MM) PATIENTS RECEIVING HIGH-DOSE (HD) MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)**

**MOST FREQUENT LATE EFFECTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA DOES NOT SEEM TO WORSEN PERFORMANCE STATUS**

**INVOLVING STEM CELL TRANSPLANT PATIENTS AND THEIR FAMILIES TO IMPROVE THE ANTHONY NOLAN MY TRANSPLANT TRACKER APP**

**EARLY MENOPAUSE AND RISK FACTORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PREMENOPAUSAL ADULT WOMEN**

**MUSCULOSKELETAL COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS**

**CLINICAL CHARACTERISTICS AND MANAGEMENT OF LATE RELAPSE OF ACUTE MYELOID LEUKAEMIA MORE THAN FIVE YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION**

**FOLLOWING UP WITH ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING 5+ YEARS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE**

**LOW BACK PAIN AND LASER ACUPUNCTURE IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELLS TRANSPLANTATION**

**EFFECTS OF CONTROLLED EXERCISE ON PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC TRANSPLANT IN AN ASIAN POPULATION: A SINGLE-CENTER EXPERIENCE**

**DEVELOPMENT OF GUILLAIN-BARRE-LIKE SYNDROME IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELLS TRANSPLANTATION**

e-Posters  
09:30 - 18:00

ePoster Area

## Pharmacology

## Scientific Programme

**ELTROMBOPAG THERAPY IN STEM CELL TRANSPLANT RECIPIENTS SHOWS EFFECTIVE IRON MOBILISATION**

**CLINICAL IMPACT OF MODEL PK GUIDED-CYCLOSPORINE DOSE INDIVIDUALIZATION IN CHILDREN UNDERGOING HSCT**

**INFLUENCE OF CYP2D6 METABOLIZER STATUS ON THE CONTROL OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING BY ONDANSETRON ON PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**ESTIMATION OF GLOMERULAR FILTRATION RATE IN ADULTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CYSTATIN C VERSUS CREATININE**

**USE OF SUBLINGUAL TACROLIMUS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH HISTORY OF ANAPHYLAXIS TO INTRAVENOUS CYCLOSPORINE**

**ORAL CLONAZEPAM FOR SEIZURE PROPHYLAXIS IN ADULT PATIENTS TREATED WITH HIGH DOSE BUSULFAN**

**DISSOLUTION TIME FOR CONVENTIONAL AND LYOPHILIZED CYCLOPHOSPHAMIDE: A SINGLE CENTER STUDY**

**OUTCOMES OF EBV VIREMIA AND PTLN AFTER RITUXIMAB: A PHARMACO-COST ANALYSIS**

**PHARMACOLOGICAL INTERACTIONS IN THE POST-TRANSPLANT PHASE OF HEMATOPOIETIC PROGENITORS TRANSPLANTATION**

**EVALUATION OF SIDE EFFECTS AND EFFICACY OF LOMUSTINE (CCNU) AND BANDAMUSTINE IN PATIENTS WITH LYMPHOMA**

e-Posters  
09:30 - 18:00

ePoster Area

## Psychological issues

**INVESTIGATING THE LONG-TERM OUTCOMES OF ADULT PATIENTS WHO UNDERWENT HAEMATOPOIETIC STEM CELL TRANSPLANT FOR PRIMARY IMMUNODEFICIENCY DURING CHILDHOOD**

**THE IMPACT OF MEDICAL AND SOCIAL REHABILITATION ON THE QUALITY OF LIFE IN CHILDREN WITH ONCOLOGIC AND HEMATOLOGIC DISEASES**

**THE IMPACT OF PRE-TRANSPLANT DEPRESSION AND ANXIETY ON THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION, A STUDY OF THE TCWP OF THE EBMT**

**ASSOCIATIONS BETWEEN FAMILY FUNCTION DOMAINS AND COPING STRATEGIES OF ADOLESCENTS UNDERGOING HSCT**

**HOW PATIENTS' VIEWS ARE HELPING SHAPE PLANS FOR A NEW TRANSPLANT PSYCHOLOGY SERVICE**

**CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: TWO DIFFERENT ANALYTICAL APPROACHES**

**ARC CLINIC: APPLYING PSYCHOLOGICAL INSIGHTS TO PROMOTE EARLY REHABILITATION IN MYELOMA POST-TRANSPLANT**

**FROM HOSPITALIZATION TO RETURN HOME: A TRANSITIONAL ACTION RESEARCH IN THE HEMATOLOGY SECTOR**

## Scientific Programme

**1000 IN 10 . 10 YEARS OF CLINICAL PSYCHOLOGY PRACTICE WITH 1000 PATIENTS IN THE SAME BMT UNIT IN MARSEILLE, FRANCE**

**IMPLEMENTATION OF PSYCHOLOGICAL SUPPORT AND DEVELOPMENT OF EDUCATIONAL PROGRAM FOR CHILDREN AND ADOLESCENTS UNDERGOING HSCT AND THEIR PARENTS IN RUSSIA**

e-Posters  
09:30 - 18:00

ePoster Area

## Quality Management

**COMPARING COMPLIANCE FOR COLLECTION FACILITY JACIE STANDARDS 6.1 AND 7TH EDITIONS**

**INTEGRATION OF THEORY AND PRACTICE: SCENARIO-BASED SKILL TRAINING IN ADMINISTERING CAR-T CELLS**

**"TPFMEA", AN INTERNATIONAL MODEL FOR ASSESSING RISKS IN A STEM CELL TRANSPLANT PROGRAM**

**DEFINING PATIENT-IMPORTANT OUTCOMES AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT**

**IMPLEMENTATION OF JACIE ACCREDITATION AT A NOVEL TRANSPLANT PROGRAM: THE IMPACT ON THE CLINICAL PRACTICE**

**HOW ONE PROCESSING CENTRE PREPARED FOR ITS FIRST JACIE INSPECTION?**

**TIPS FOR GENERATING SUCCESSFUL 'TEAMWORKING' IN OUR HEALTHCARE FACILITIES: THE EXPERIENCE OF A HOSPITAL UNIT IN A FRENCH CANCER CENTER**

**IMPLEMENTATION OF A QUALITY SYSTEM FOR RUNNING A CELL AND GENE THERAPY CLINICAL TRIAL WITHIN A JACIE-ACCREDITED TRANSPLANT PROGRAM**

**NEW ONLINE PLATFORMS IN QUALITY MANAGEMENT: COORDINATION AND MULTIDISCIPLINARY CARE**

**RISK MANAGEMENT ASSESSMENT IN IMPLEMENTING CAR-T CELL THERAPY IN A CLINICAL UNIT**

**FEBRILE REACTION AFTER HSC INFUSION IS MORE FREQUENT IF NO STEROID PREMEDICATION IS GIVEN WHICH RESULTS IN MORE FREQUENT USE OF ANTIBIOTICS EARLY POST-TRANSPLANT**

**SEARCHING FOR OTHER TOPICS OF QUALIFICATION PLANS IN THE TRANSPLANT PROGRAM CLINICAL PART - THE ONE CENTER EXPERIENCE**

**PRACTICE PATTERNS IN CHRONIC GVHD PATIENT MANAGEMENT AND PATIENT REPORTED OUTCOME MEASURES ACROSS THE EBMT ALLOGENEIC TRANSPLANTATION NETWORK**

**MAINTAINING DONOR SAFETY AND WELFARE THROUGHOUT CELLULAR THERAPY PRODUCT DONATION**

**DIGITAL JACIE AT THE CHRISTIE**

**INTEGRATION OF CELLULAR THERAPY IN THE JACIE (JOINT ACCREDITATION COMMITTEE ISCT-EBMT) QUALITY MANAGEMENT PLAN. SINGLE CENTER EXPERIENCE**

## **Scientific Programme**

**AUDIT - A METHOD TO EVALUATE INTERVENTIONS - EXPERIENCES FROM AN ATTEMPT TO IMPROVE NUTRITIONAL STATUS IN PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**QUALITY OF LIFE ASSESSMENT AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**RETROSPECTIVE ANALYSIS OF TIME TO ALTERNATIVE DONOR IDENTIFICATION AND HEMATOPOIETIC STEM CELLS PROCUREMENT IN THE ABSENCE OF MATCHED-SIBLING DONORS IN A SINGLE CENTER IN SPAIN**

**GOVERNANCE, RISKS AND REGULATORY ASPECTS OF UNLICENSED LENTIVIRAL VECTOR-MODIFIED AUTOLOGOUS STEM CELL TREATMENT**

**UNIQUE SUPPORTIVE CARE ALGORITHMS FOR CHILDREN UNDERGOING HAPLOIDENTICAL HSCT FOR BENIGN HAEMATOLOGICAL DISORDERS**

**QUALITY OF LIFE IN PARENTS OF TURKISH AND SYRIAN PEDIATRIC BONE MARROW TRANSPLANT AND ONCOLOGY PATIENTS**

**COLLECTION OF AUTOLOGOUS MONONUCLEAR CELLS IN NON-CYTOKINE STIMULATED DONORS: COMPARING TWO APHERESIS METHODS**

**EFFECTIVE CAR-T CELL DELIVERY: A MULTIDISCIPLINARY APPROACH AT MFT**

**HAEMOPOIETIC PROGENITOR CELL PROFICIENCY TESTING**

**VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ALERT (R) 3D (TM) AND VIRTUO (TM) MICROBIAL BIOBURDEN SYSTEMS FOR HAEMATOPOIETIC PROGENITOR CELLS (HPC)**

**START-UP OF AN ADHERENCE RECEPTION FOR ALLOGENIC STEM CELL TRANSPLANTED PATIENTS AT THE HEMATOLOGICAL DEPARTMENT LINKÖPING, SWEDEN**

**ENUMERATION OF RESIDUAL RED BLOOD CELLS IN MIS-MATCHED ALLOGENEIC PBSC COLLECTIONS - TRADITIONAL HAEMATOLOGY ANALYSER VS FLOW CYTOMETRY**

**INVESTIGATION AND ANALYSIS OF FACTORS AFFECTING GASTROINTESTINAL NUTRITION RECOVERY AFTER MULTIPLE MYELOMA AUTOLOGOUS STEM CELL TRANSPLANTATION AND EFFECTS OF NUTRITIONAL INTERVENTION**

**CHARACTERISTICS OF IRON DEFICIENCY ANEMIA IN PRE-MENOPAUSAL WOMEN IN KOREA  
LEUKEMIA AND ITS TYPES**

e-Posters  
09:30 - 18:00

ePoster Area

## **Solid tumours**

**SUCCESSFUL KIR ALLOREACTIVE HSCT IN A CHILD WITH RESISTANT EWING SARCOMA**

**TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS**

**VOC PATTERN RECOGNITION OF LUNG CANCER: A COMPARATIVE EVALUATION OF DIFFERENT DOG- AND ENOSE-BASED STRATEGIES USING DIFFERENT SAMPLING MATERIALS**

## Scientific Programme

e-Posters  
09:30 - 18:00

ePoster Area

### Stem cell donor

**DONOR-RECIPIENT HLA MATCHING FOR UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION <b>Outcomes: </b> A STUDY FROM THE CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY (CTIWP) OF THE EBMT**

**PRESENCE OF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN DONOR DOES NOT INCREASE THE RISK OF LATE SECONDARY MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**

Kyoung Ha Kim, Tae Hyung Kim, Jae-Sook Ahn, Ivan Pasic, Zeyad Al-Shaibani, Arjun Law, Wilson Lam, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Zhaolei Zhang, Tamir Biezuner, Liran Shlush, Dennis Dong Hwan Kim (Canada)

**SERIOUS EVENTS AND ADVERSE REACTIONS IN RELATION TO BLOOD STEM CELL DONATION REPORTED TO WMDA IN 2018**

**THE IMPROVEMENT IN OVERALL SURVIVAL FROM UNRELATED DONOR TRANSPLANT IN AUSTRALIA AND NEW ZEALAND IS DRIVEN BY A REDUCTION IN TRANSPLANT RELATED MORTALITY**

**POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER MATCHED SIBLING, UNRELATED AND HAPLOIDENTICAL DONOR TRANSPLANTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA, A COMPARATIVE STUDY OF THE ALWP EBMT**

**ALLOREACTIVITY AGAINST HLA-DPB1 IN HOST-VERSUS-GRAFT DIRECTION IS ASSOCIATED WITH INCREASED RISK OF GRAFT FAILURE AFTER MATCHED UNRELATED DONOR TRANSPLANTATION FOR NONMALIGNANT DISEASES**

**IMPACT OF KIR ON PATIENTS WITH LYMPHOID DISEASES AFTER T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION**

**INDICATIONS AND SAFETY OF MULTIPLE BONE MARROW HARVESTS IN PEDIATRIC DONORS FOR MATCHED SIBLING RECIPIENT TRANSPLANTATION**

**HEALTHY VOLUNTARY STEM CELL DONORS: FOLLOW UP AFTER HPC APHERESIS DONATION: THE EXPERIENCE OF ITALIAN BONE MARROW DONOR REGISTRY**

**ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH INHERITED DISORDERS**

**HAPLOIDENTICAL REDUCED-INTENSITY HEMATOPOIETIC CELL TRANSPLANTATION USING BUSULFAN, FLUDARABINE, AND ANTITHYMOCYTE GLOBULIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**

**THE RESULTS OF A TELECONFERENCE ABOUT THE EXPERIENCES AND EXPECTATIONS OF RELATED HEMATOPOIETIC STEM CELL DONORS AFTER DONATION**

**IMPACT OF THE ESTABLISHMENT OF THE TURKISH NATIONAL DONOR REGISTRY (TURKOK) ON A SINGLE CENTER'S TRANSPLANT OUTCOME: INTERNATIONAL STEM CELL DONORS VERSUS NATIONAL**

**YOUNG MALE DONORS MAY RESULT IN BETTER OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA WITH PT-CY**

**DONORS OF PERIPHERAL HEMATOPOIETIC STEM CELLS, OUR EXPERIENCE FOR LAST 10 YEARS**

**ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS OVER 70 YEARS :A MONOCENTRIC EXPERIENCE OF 48 PATIENTS**

## Scientific Programme

**COMPARISON OF TRANSPLANT OUTCOMES AND ECONOMIC COSTS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML AND MDS BETWEEN THE DIFFERENT TYPE OF DONORS**

**HIGH DISEASE-FREE SURVIVAL OF THE SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DONOR CHANGE AND MAINLY REDUCED-INTENSITY CONDITIONING IN RELAPSED HEMATOLOGICAL MALIGNANCIES**

**EPIDEMIOLOGICAL STUDY OF RARE ANTIGENS OF THE MAIN HISTOCOMPATIBILITY COMPLEX AMONG HEMATOPOIETIC STEM CELL DONORS IN BELARUS**

**IMPACT OF DONOR-RECIPIENT SEX MISMATCH IN PATIENTS RECEIVING PARTIAL T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE MONOCENTRIC STUDY**

**HAPLOIDENTICAL DONOR SELECTION AND ITS IMPLICATIONS IN TRANSPLANTATION OUTCOME. OUR EXPERIENCE AT HUDGC DR. NEGRIN**

**OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION ACCORDING TO DONOR AVAILABILITY, DURATION FROM DIAGNOSIS TO TRANSPLANT AND DONOR-SPECIFIC PARAMETERS - A SINGLE CENTER ANALYSIS**

**THE BENEFITS OF HLA-MATCHED RELATED DONORS FOR PATIENTS LACKING HLA-IDENTICAL SIBLING IN THE ABSENCE OF POWERFUL LOCAL UNRELATED REGISTRY IN COUNTRIES WITH PREVALENT COUSIN MARRIAGES**

**DONOR AGE INFLUENCES THE GRAFT-VERSUS-HOST-DISEASE-FREE AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT IN ELDERLY PATIENTS IN LATIN AMERICA**

**A STUDY OF THE UNCERTAINTY, UNCERTAINTY APPRAISAL AND GROWTH AND THE AFFECTED FACTORS ON HEMATOPOIETIC STEM CELL DONORS**

**WITHDRAWAL OF VOLUNTEER DONORS FROM THE INTERNATIONAL REGISTRIES: A SINGLE CENTRE EXPERIENCE**

**OUTCOME OF HAPLOIDENTICAL TRANSPLANTATION FOR AML AND MYELODYSPLASTIC SYNDROME IN ELDERLY WITH REDUCED-INTENSITY CONDITIONING**

**HAPLOIDENTICAL VS UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS WITH HEMATOLOGIC MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS**

**HEPATITIS E VIRUS (HEV) CONTAMINATED HEMATOPOIETIC STEM CELL GRAFT IN A MATCHED UNRELATED DONOR TRANSPLANTATION**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH MATCH RELATED DONORS IN CHILDHOOD: SINGLE CENTER EXPERIENCE**

**FIRST EXPERIENCE WITH UNRELATED STEM CELL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A TRANSPLANT CENTER FROM NORTH MACEDONIA**

e-Posters  
09:30 - 18:00

ePoster Area

## Stem cell source

**OPTIMIZING OUTCOMES OF ACUTE LEUKEMIA AFTER TRANSPLANTS WITH SINGLE UNRELATED CORD BLOOD UNITS SELECTED ACCORDING TO CURRENT INTERNATIONAL RECOMMENDATIONS FOR CELL DOSE AND HLA MATCH**

## Scientific Programme

**IMPACT OF HLA-MISMATCH ON OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS: A RETROSPECTIVE ANALYSIS BY THE JSHCT HLA WORKING GROUP**

**CLINICAL IMPACT OF DONOR EPITOPE-SPECIFIC HLA ANTIBODIES AND THIRD-PARTY HLA ANTIBODIES IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION**

**ADDITION OF TOCILIZUMAB TO CYCLOSPORINE-A AND MYCOPHENOLATE MOFETIL FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS SIGNIFICANTLY ABROGATES SEVERE ACUTE GVHD AFTER DOUBLE-UNIT CORD BLOOD TRANSPLANTATION IN ADULTS**

**THE USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION**

**COMPARATIVE STUDY OF HAPLOIDENTICAL TRANSPLANT FOLLOWED BY POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SELECTIVE EX VIVO T-CELL DEPLETION VS UNRELATED CORD BLOOD TRANSPLANT FOR ADULTS WITH HAEMATOLOGICAL MALIGNANCIES**

**USE OF G-CSF MOBILIZED BONE MARROW GRAFTS IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION (BMT) WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (PT-CY) DECREASES RISK OF SEVERE ACUTE GVHD**

**CMV-SPECIFIC FUNCTIONAL IMMUNE RECONSTITUTION IS SLOWER AFTER UMBILICAL CORD BLOOD COMPARED WITH MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION**

**REDUCED INTENSITY (RIC) VS MYELOABLATIVE CONDITIONING (MAC) IN CORD BLOOD TRANSPLANTATION FOR AML (40-60 YEARS) ACROSS MISMATCHED HLA BARRIERS - ANALYSIS BY CTIWP/EUROCORD OF EBMT**

**COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE REAL WORLD: AN ANALYSIS USING THE JAPANESE NATIONAL DATABASE**

**ASSOCIATION BETWEEN THE DOSE OF CD3+ AND CD34+ CELLS IN THE GRAFT AND POST-TRANSPLANT OUTCOMES**

**HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A RELATED DONOR WITH HLA-1 ANTIGEN MISMATCH IN THE GRAFT-VERSUS-HOST DIRECTION USING LOW-DOSE ANTI-THYMOCYTE GLOBULIN: MULTICENTER PHASE II TRIAL**

**INTRA-BONE CORD-BLOOD TRANSPLANT OF UNWASHED UNITS WITH ATG-FREE AND SIROLIMUS-BASED GVHD PROPHYLAXIS: FAST IMMUNE-RECONSTITUTION AND LONG-TERM DISEASE CONTROL IN 22 PATIENTS WITH HIGH-RISK DISEASES**

**ANTI-HLA DONOR SPECIFIC ANTIBODIES (DSA) DOES NOT AFFECT GRAFT AND SURVIVAL IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) WITH ORIGINAL POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) SCHEDULE**

**MESENCHYMAL STEM/STROMAL CELL PRODUCTION COMPLIANT WITH GOOD MANUFACTURING PRACTICE: COMPARISON BETWEEN BONE MARROW AND WHARTON'S JELLY**

**EFFICIENT DMSO REMOVAL AND HIGH CELL RECOVERY WITH LOVO CELL PROCESSING SYSTEM IN HPC-A CONCENTRATES: A SINGLE CENTRE EXPERIENCE**

Social Events  
10:35 - 11:57

Auditorium 1

**Meditation session**

## Scientific Programme

Educational  
11:00 - 12:00

Auditorium 1

### **E11, Immune therapy beyond CAR T-cells**

**Chairs:**

Antonio Pérez-Martínez (Spain)

<b>Gamma-Delta T-cell Therapy</b>	<b>11:00 - 11:12</b>
Jürgen Kuball (Netherlands)	
<b>Stem cell derived NK cell Therapy</b>	<b>11:12 - 11:24</b>
Harry Dolstra (Netherlands)	
<b>MSC and extracellular vesicles in stem cell transplantation</b>	<b>11:24 - 11:36</b>
Fermín Sánchez-Guijo (Spain)	
<b>HLA-mismatched microtransplantation</b>	<b>11:36 - 11:48</b>
Huisheng Ai (China)	
<b>Q&amp;A</b>	<b>11:48 - 12:00</b>

Joint Session  
11:00 - 12:00

Auditorium 2

### **JS4, Joint session KSBMT: Status of Next Generation Sequencing for indication and monitoring in stem cell transplantation 2020**

**Chairs:**

Nicolaus Kröger (Germany)

Hoon Kook (Korea, Republic of)

<b>NGS for indication in myeloid malignancies</b>	<b>11:00 - 11:25</b>
Jae-Sook Ahn (Korea, Republic of)	
<b>Disease monitoring post transplant with NGS</b>	<b>11:25 - 11:38</b>
Maximilian Christopeit (Germany)	
<b>Discussion</b>	<b>11:38 - 12:00</b>

How do I ... ?  
11:00 - 12:00

Auditorium 3

### **HDI5, How Do I... consider patients' needs in induction and front line therapy for transplant (eligible patients with Multiple Myeloma) - Nurses' Session - Supported through an unrestricted educational grant by Janssen**

**Chairs:**

Isabel Salcedo (Spain)

<b>Treatment approaches for transplant eligible patients in front line Multiple Myeloma</b>	<b>11:00 - 11:15</b>
Laure Vincent (France)	

## Scientific Programme

<b>How do new therapy combinations offer newly diagnosed Multiple Myeloma patients' benefits, case studies</b>	<b>11:15 - 11:30</b>
Sarah Henshaw (United Kingdom)	
<b>How do I.....consider patients' needs from a psycho-social perspective?</b>	<b>11:30 - 11:45</b>
Surabhi Chaturvedi (United Kingdom)	
<b>Q&amp;A</b>	<b>11:45 - 12:00</b>

Paediatric Day  
11:00 - 12:00

Auditorium 4

### Paediatrics2, Inborn Errors Working Party Session

#### Chairs:

Arjan Lankester (Netherlands)  
Michael Albert (Germany)

<b>Landscape of GT and allogeneic therapy in IEM: The next years</b>	<b>11:00 - 11:12</b>
Robert Wynn (United Kingdom)	
<b>Therapeutic standards for patients with SCID - Still a matter of discussion</b>	<b>11:12 - 11:24</b>
Manfred Hoenig (Germany)	
<b>Induction therapy in Inborn Errors of Immunity before HSCT</b>	<b>11:24 - 11:36</b>
Victoria Tesch (Austria)	
<b>Inflammation and autoimmunity in PID: Does it matter for HSCT?</b>	<b>11:36 - 11:48</b>
Bénédicte Neven (France)	
<b>Q&amp;A</b>	<b>11:48 - 12:00</b>

Data Management  
11:00 - 12:00

Auditorium 5

### DM1, Education session 1

#### Chairs:

Helen Baldomero (Switzerland)

<b>Reporting on CAR-T Cell outcomes and LTFU: Role of the EBMT registry</b>	<b>11:00 - 11:20</b>
Christian Chabannon (France)	
<b>Registry upgrade and other data collection news in the EBMT</b>	<b>11:20 - 11:35</b>
Per Ljungman (Sweden)	
<b>Text chat Q&amp;A</b>	<b>11:35 - 12:00</b>

## Scientific Programme

Quality Management  
11:00 - 12:00

Auditorium 6

### QM1, Highlights of the Draft 8th Edition of the STD

#### Chairs:

Eugenia Trigos Arjona (Spain)

<b>Clinical standards</b>	<b>11:00 - 11:10</b>
Kim Orchard (United Kingdom)	
<b>Collections standards</b>	<b>11:10 - 11:20</b>
Nina Worel (Austria)	
<b>Processing standards</b>	<b>11:20 - 11:30</b>
Ivan van Riet (Belgium)	
<b>Quality Management standards</b>	<b>11:30 - 11:40</b>
Simon Hack (United Kingdom)	
<b>Immune effector cells standards</b>	<b>11:40 - 11:50</b>
Riccardo Saccardi (Italy)	
<b>Text chat Q&amp;A</b>	<b>11:50 - 12:00</b>

Industry Symposium  
13:00 - 14:15

Auditorium 1

### IS29, An update on induction and front-line therapy for transplantation-eligible patients with MM - Janssen Industry Symposium

#### Chairs:

María-Victoria Mateos (Spain)  
Mohamad Mohty (France)

<b>Introduction</b>	<b>13:00 - 13:05</b>
María-Victoria Mateos (Spain)	
<b>Latest data on treatment approaches for transplant eligible patients in frontline MM</b>	<b>13:05 - 13:30</b>
Mohamad Mohty (France)	
<b>How will recent data change your clinical practice? - A case study discussion</b>	<b>13:30 - 14:00</b>
María-Victoria Mateos (Spain) Niels van de Donk (Netherlands)	
<b>Panel discussion</b>	<b>14:00 - 14:15</b>
María-Victoria Mateos (Spain) Mohamad Mohty (France) Niels van de Donk (Netherlands)	

## Scientific Programme

Industry Symposium  
13:00 - 14:15

Auditorium 2

### **IS30, Antineoplastic treatments and Invasive Mould Disease - Should we be worried and what can we do? - Pfizer Industry Symposium**

**Chairs:**

Samir Agrawal (United Kingdom)

<b>Introduction</b>	<b>13:00 - 13:05</b>
Samir Agrawal (United Kingdom)	
<b>An introduction to IMD in the haematology unit and epidemiology</b>	<b>13:05 - 13:20</b>
Rafael de la Cámara (Spain)	
<b>Novel therapies in haematology-oncology and the changing face of fungal disease</b>	<b>13:20 - 13:35</b>
Samir Agrawal (United Kingdom)	
<b>PK/PD principles for choosing an invasive mould disease treatment in a complex environment</b>	<b>13:35 - 13:50</b>
Federico Pea (Italy)	
<b>Real-life decision-making pathways when treating invasive mould disease in the haematology unit: case study</b>	<b>13:50 - 14:05</b>
Amit Patel (United Kingdom)	
<b>Discussion and close</b>	<b>14:05 - 14:15</b>

Special Session  
13:00 - 14:00

Auditorium 3

### **SS4, Gender Equality forum**

**Chairs:**

Anna Sureda (Spain)

John Murray (United Kingdom)

<b>Physician's (female) perspective</b>	<b>13:00 - 13:12</b>
Silvia Montoto (United Kingdom)	
<b>Physician's (male) perspective</b>	<b>13:12 - 13:24</b>
John Snowden (United Kingdom)	
<b>Nurse's perspective</b>	<b>13:24 - 13:36</b>
John Murray (United Kingdom)	
<b>The role of gender in doctor-patient interaction and outcomes</b>	<b>13:36 - 13:48</b>
Natacha Bolaños (Spain)	
<b>Q&amp;A</b>	<b>13:48 - 14:00</b>

## Scientific Programme

Data Management  
13:00 - 14:00

Auditorium 5

### DM2, Education session 2

#### Chairs:

Jorinde Hoogenboom (Netherlands)

#### **CAR T-cells - Moving into the mainstream**

**13:00 - 13:45**

Reuben Benjamin (United Kingdom)

#### **Text chat Q&A**

**13:45 - 14:00**

Quality Management  
13:00 - 14:00

Auditorium 6

### QM2, Role of Quality Management Professionals in Stem Cell Transplant Programs

#### Chairs:

Julia Ruiz Pato (Spain)

#### **Results of the survey QM role**

**13:00 - 13:20**

Renza Monteleone (Italy)

#### **COVID-19 & QM experience in Italy**

**13:20 - 13:30**

Mara Magri (Italy)

#### **COVID-19 & QM experience in UK**

**13:30 - 13:40**

Sarah Holtby (United Kingdom)

#### **COVID-19 & QM experience in Spain**

**13:40 - 13:50**

Christelle Ferrà (Spain)

#### **Text chat Q&A**

**13:50 - 14:00**

Industry Symposium  
13:00 - 14:00

Meet the Expert Rooms

### IS31, Therakos Industry Meet the Expert Lunch - Room MTE1

Pre-registration required via the general registration form (free of charge). <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>  
If you have already registered, you can modify your bookings on the official registration form: <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>

#### **Calibrating the intensity of GVHD therapy to allow clinical tolerance - A role for ECP?**

**13:00 - 14:00**

Daniel Wolff (Germany)

## Scientific Programme

Industry Symposium  
13:00 - 14:00

Meet the Expert Rooms

### IS32, Medac Industry Meet the Expert Lunch - Room MTE2

Pre-registration required via the general registration form (free of charge). <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>  
If you have already registered, you can modify your bookings on the official registration form: <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>

**Extending transplant indication for elderly patients by novel conditioning approaches** **13:00 - 14:00**

Matthias Stelljes (Germany)

Industry Symposium  
13:00 - 14:00

Meet the Expert Rooms

### IS33, MSD Industry Meet the Expert Lunch 2 - Room MTE3

Pre-registration required via the general registration form (free of charge). <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>  
If you have already registered, you can modify your bookings on the official registration form: <https://www.ebmt.org/annual-meeting/ebmt-annual-meeting-registration>

**Roundtable Discussion: CMV Management** **13:00 - 14:00**

Miguel-Angel Perales (United States)

Educational  
14:30 - 15:30

Auditorium 1

### E12, New developments in the field of CAR T-cell therapy

#### Chairs:

Christian Chabannon (France)  
Álvaro Urbano-Ispizua (Spain)

**An independent evaluation of the economic value of the two approved CAR T-cells** **14:30 - 14:42**

John K. Lin (United States)

**Safe and potent anti-CD19 CAR T-cell therapy - An experience from China** **14:42 - 14:54**

Zhitao Ying (China)

**CAR T-cell technology and strategy for solid tumors** **14:54 - 15:06**

Hinrich Abken (Germany)

**Future of CAR T-cell therapies** **15:06 - 15:18**

Stéphane Depil (France)

**Q&A** **15:18 - 15:30**

## Scientific Programme

Educational  
14:30 - 15:30

Auditorium 2

### E13, Unusual GVHD manifestations

#### Chairs:

Zinaida Peric (Croatia)  
Olaf Penack (Germany)

<b>Neurologic aspects of cGVHD</b>	<b>14:30 - 14:45</b>
Ervina Bilic (Croatia)	
<b>The kidney and GVHD - Is the kidney a target organ?</b>	<b>14:45 - 15:00</b>
Sangeeta Hingorani (United States)	
<b>Late acute GVHD and steroid refractory GVHD</b>	<b>15:00 - 15:15</b>
Robert Zeiser (Germany)	
<b>Q&amp;A</b>	<b>15:15 - 15:30</b>

Nurses Group  
14:30 - 15:30

Auditorium 3

### NG08, How do I become an expert?

#### Chairs:

Marijke Quaghebeur (Belgium)

<b>Sexual function assessment in care</b>	<b>14:30 - 14:45</b>
Corien Eeltink (Netherlands)	
<b>Late effects: Implementation of guidelines</b>	<b>14:45 - 15:00</b>
Michelle Kenyon (United Kingdom)	
<b>How I teach people to become an expert in CAR-T</b>	<b>15:00 - 15:15</b>
Ruth Clout (United Kingdom)	
<b>Q&amp;A</b>	<b>15:15 - 15:30</b>

Paediatric Day  
14:30 - 15:30

Auditorium 4

### Paediatrics3, Paediatrics Diseases Oral Session

<b>TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: ASSESSING, CONTAINING, AND EXTINGUISHING THE FIRESTORM</b>	<b>14:30 - 14:37</b>
<u>Sonata Jodele</u> , Christopher E Dandoy, Adam Lane, Ashley Teusink-Cross, Kasiani C Myers, Gregory Wallace, Adam Nelson, Nicholas J Gloude, Stella M Davies (United States)	
<b>ELEVATED MACROPHAGE ACTIVATION MARKERS SCD163 AND MANNOSE RECEPTOR ARE ASSOCIATED WITH OCCURRENCE OF AGVHD AND SOS AFTER PEDIATRIC ALLOGENEIC HSCT</b>	<b>14:37 - 14:44</b>
<u>Laura Louise Fosgrau Hergel</u> , Katrine Kielsen, Sarah Wegener Weischendorff, Marianne Segelcke Rosenkrantz Ifversen, Claus Nielsen, Henning Grønbaek, Klaus Gottlob Müller (Denmark)	

## Scientific Programme

**SURVEY OF TRANSPLANT ASSOCIATED MACROPHAGE ACTIVATION SYNDROME (TAMAS) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND YOUNG ADULTS** **14:44 - 14:51**

Petr Sedlacek, Cristina Diaz de Heredia, Akif Yesilipek, Pietro Merli, Priya Marwah, Stalin Ramprakash, Giorgio Ottaviano, Selim Corbacioglu (Czech Republic)

**THE EFFICACY AND TOXICITY OF UNMANIPULATED DLI AFTER HAPLOIDENTICAL EX-VIVO T-CELL DEPLETED STEM CELL TRANSPLANTATION IN CHILDREN - A RETROSPECTIVE COHORT STUDY** **14:51 - 14:58**

Sundén Gustav, Jacek Toporski, Ladislav Krol, Josefina Dykes, Albert N Békássy, Cornelis Jan Pronk, Dominik Turkiewicz (Sweden)

**IMPACT OF ABO INCOMPATIBILITY, AGE AND STEM CELL SOURCE ON OUTCOME PARAMETERS IN MSD HSCT FOR HEMOGLOBINOPATHIES: A RETROSPECTIVE STUDY ON BEHALF OF THE PDWP** **14:58 - 15:05**

Katharina Kleinschmidt, Josu de la Fuente, Jacques-Emmanuel Galimard, Arnaud Dalissier, Giorgio La Nasa, Jean-Hugues Dalle, Abdelghani Tbakhi, Yves Bertrand, Xavier Poiré, Gulsun Karasu, Gérard Michel, Despina Moshous, Hakan Ozdogu, Emel Ünal, Catherine Paillard, Akif Yesilipek, Selim Corbacioglu (Germany)

**THE ROLE OF HLA MATCHING IN UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE IN EUROPE** **15:05 - 15:12**

Eliane Gluckman, Josu De la Fuente, Barbara Cappelli, Graziana M. Scigliuolo, Fernanda Volt, Karina Tozatto Maio, Vanderson Rocha, Tommaso Mina, Farah O'Boyle, Frans Smiers, Claudia Bettoni Da Cunha-Riehm, Elisabetta Calore, Sonia Bonanomi, Stelios Graphakos, Anna Paisiou, Michael H. Albert, Annalisa Ruggeri, Marco Zecca, Arjan C. Lankester, Selim Corbacioglu (Monaco)

**HAPLOIDENTICAL T-CELL DEPLETED HSCT REPRESENTS A SAFE THERAPEUTIC ALTERNATIVE TO MSD TRANSPLANTATION IN PATIENTS WITH TRANSFUSION-DEPENDENT  $\beta$ -THALASSEMIA MAJOR** **15:12 - 15:19**

Katharina Kleinschmidt, Juergen Foell, Beatrix Pfirstinger, Anja Troeger, Agnes Mayr, Pauline Dibbern, Andreas Brosig, Norbert Ahrens, Selim Corbacioglu (Germany)

**ALPHABETA T AND B-CELL DEPLETED HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (TBDEPL-HAPLOHSCT) IN CHILDREN WITH NON-MALIGNANT DISORDERS** **15:19 - 15:26**

Pietro Merli, Federica Galaverna, Mattia Algeri, Daria Pagliara, Stefania Gaspari, Roberto Carta, Marco Becilli, Michele Massa, Emilia Bocchieri, Rita Maria Pinto, Giulia Bozza, Luciana Vinti, Luisa Strocchio, Giovanna Leone, Giovanna Del Principe, Giuseppina Li Pira, Annalisa Ruggeri, Franco Locatelli (Italy)

Data Management  
14:30 - 15:30

Auditorium 5

### DM3, Education session 3

#### Chairs:

Julia Lee (United Kingdom)

**Molecular diagnostic markers: Interpreting the results of molecular diagnostics for Med-A/B forms** **14:30 - 15:15**

April Sellors (United Kingdom)

**Text chat Q&A** **15:15 - 15:30**

## Scientific Programme

Quality Management  
14:30 - 15:30

Auditorium 6

### QM3, QM and future development in HSCT

#### Chairs:

Almudena de Laiglesia (Spain)

#### **TRANSPOSE EU Project - WP6**

**14:30 - 14:45**

Suzanna M. van Walraven (Netherlands)

#### **EuroGTPII: An interactive assessment tool for risk assessment of new processes**

**14:45 - 15:00**

Aurora Vassanelli (Italy)

#### **CAR T accreditation: What can you expect?**

**15:00 - 15:15**

Mara Magri (Italy)

#### **Text chat Q&A**

**15:15 - 15:30**

Special Session  
16:00 - 17:00

Auditorium 1

### SS5, Hematological therapies at the crossroad of the COVID-19 pandemic

#### Chairs:

Rafael de la Cámara (Spain)

Mohamad Mohty (France)

#### **Endothelial dysfunction in COVID-19 and its management**

**16:00 - 16:12**

José María Moraleda (Spain)

#### **Mesenchymal stromal cells**

**16:12 - 16:24**

Felipe Prósper (Spain)

#### **Convalescent donor plasma**

**16:24 - 16:36**

Rafael Duarte (Spain)

#### **Monoclonal antibodies and other forms of immunotherapy**

**16:36 - 16:52**

Christian Chabannon (France)

#### **Q&A**

**16:52 - 17:00**

Joint Session  
16:00 - 17:00

Auditorium 2

### JS5, Joint session ASTCT/CIBMTR: Bridging the gap in BMT and cellular therapy between North America and Europe

#### Chairs:

Navneet Majhail (United States)

Robert Soiffer (United States)

Nicolaus Kröger (Germany)

## Scientific Programme

<b>A tale of two continents: Differences and similarities in BMT practices in North America and Europe</b>	<b>16:00 - 16:15</b>
Robert Soiffer (United States)	
<b>Landscape of CAR T-cell therapy in North America and Europe: Lessons learned and future directions</b>	<b>16:15 - 16:30</b>
Miguel-Angel Perales (United States)	
<b>Looking back and moving forward: Blueprint for collaborative international studies in BMT and Cellular therapy</b>	<b>16:30 - 16:45</b>
Anna Sureda (Spain)	
<b>Q&amp;A</b>	<b>16:45 - 17:00</b>

Nurses Group  
16:00 - 17:00

Auditorium 3

### NG09, Paediatric Session

#### Chairs:

Teija Schröder (Finland)  
Hilda Mekelenkamp (Netherlands)

<b>Impact of a health information technology tool addressing information needs of caregivers of adult and paediatric haematopoietic stem cell transplantation patients</b>	<b>16:00 - 16:25</b>
Sung Won Choi (United States)	
<b>Music therapy supported quality of life and coping strategies for children during and after haematopoietic stem cell transplant</b>	<b>16:25 - 16:50</b>
Lena Uggla (Sweden)	
<b>Q&amp;A</b>	<b>16:50 - 17:00</b>

Paediatric Day  
16:00 - 17:00

Auditorium 4

### Paediatrics4, Inborn Errors Oral Session

<b>HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH TCRαβ/CD19 GRAFT DEPLETION AMONG CHILDREN WITH PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: HIGH SURVIVAL WITH LOW RATE OF GVHD</b>	<b>16:00 - 16:07</b>
<u>Aishat Kantulaeva</u> , Elena Gutovskaya, Alexandra Laberko, Yulia Skvortsova, Larisa Shelikhova, Julia Starichkova, Dmitry Pershin, Elena Kurnikova, Yakov Muzalevskii, Aleksey Kazachenok, Galina Novichkova, Aleksey Maschan, Dmitry Balashov, Michael Maschan (Russian Federation)	
<b>NATIONAL HEALTH SERVICE ENGLAND (NHSE) PROGRAM FOR SELECTION OF ADULT PRIMARY IMMUNODEFICIENCY PATIENTS FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	<b>16:07 - 16:14</b>
<u>Emma Morris</u> , Venetia Bigley, Siobhan O Burns, Smita Patel, David Lowe, Arian Laurence, Suzanne Elcombe, Helen Baxendale, Benjamin Uttenthal, Aarnoud Huissoon, Ravishankar Sargur, Patrick Yong, Sarah Grace, Mari Campbell, Benjamin Carpenter, Rachael Hough, John Snowden, Matthew Collin, Ronjon Chakraverty (United Kingdom)	

## Scientific Programme

<b>OUTCOME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION IN ADOLESCENTS AND YOUNG ADULTS WITH PRIMARY IMMUNODEFICIENCY</b>	<b>16:14 - 16:21</b>
Su Han Lum, Venetia Bigley, Daniel Drozdov, Zohreh Nademi, Terry Flood, Mario Abinun, Andrew Cant, Sophie Hambleton, Mary Slatter, Andrew Gennery (United Kingdom)	
<b>DONOR CHARACTERISTICS PREDICT THE SUCCESS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSAEMIA MAJOR: A SINGLE CENTRE ANALYSIS OF 250 PATIENTS</b>	<b>16:21 - 16:28</b>
Revathi Raj, Ramya Uppuluri, Venkateswaran Vellaichamy, Nikila Ravichandran, Kesavan Iyer, David Dennison, Abdulhakim Alrawas (India)	
<b>LONG-TERM NEURODEVELOPMENTAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR LATE-INFANTILE KRABBE DISEASE</b>	<b>16:28 - 16:35</b>
Maria Escolar, Isabel Yoon, Nicholas Bascou, Michele Poe (United States)	
<b>LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD) GENE THERAPY (GT): UPDATED RESULTS IN GROUP C PATIENTS FROM THE PHASE 1/2 HGB-206 STUDY</b>	<b>16:35 - 16:42</b>
Markus Y. Mapara, John F. Tisdale, Julie Kanter, Janet L. Kwiatkowski, Lakshmanan Krishnamurti, Manfred Schmidt, Alexandra L. Miller, Francis J. Pierciey Jr., Melissa Bonner, Wenmei Huang, Jean-Antoine Ribeil, Alexis A. Thompson, Mark C Walters (United States)	
<b>VERY LONG-TERM FOLLOW UP OF 83 ADULTS WHO UNDERWENT ALLOGENEIC HSCT IN CHILDHOOD FOR PRIMARY IMMUNODEFICIENCY (PID): A SINGLE CENTRE EXPERIENCE</b>	<b>16:42 - 16:49</b>
James Day, Rupert Goodman, Bethany Nicholson, Austen Worth, Paul Veys, Ronjon Chakraverty, Benjamin Carpenter, Rachael Hough, Mari Campbell, Penny Titman, Deborah Ridout, Kit Sandford, Siobhan O Burns, Emma Morris (United Kingdom)	
<b>LENTIVIRAL HAEMATOPOIETIC STEM CELL THERAPY IN PATIENTS WITH WISKOTT ALDRICH SYNDROME (WAS): LONDON EXPERIENCE</b>	<b>16:49 - 16:56</b>
Reem Elfeky, Christine Rivat, Katie Snell, Jinhua Xu-Bayford, Kimberly Gilmour, Stuart Adams, Emma Morris, Gerialdine Honnet, Anne Galy, Claire Booth, Adrian J Thrasher (United Kingdom)	

Data Management  
16:00 - 17:00

Auditorium 5

### DM4, Education session 4

#### Chairs:

Emmanuelle Polge (France)

<b>Treatment of relapse after transplant (DLI, CAR T, second allograft)</b>	<b>16:00 - 16:45</b>
Christoph Schmid (Germany)	
<b>Text chat Q&amp;A</b>	<b>16:45 - 17:00</b>

## Scientific Programme

Quality Management  
16:00 - 17:00

Auditorium 6

### QM4, Auditing more than JACIE

#### Chairs:

Sarah Holtby (United Kingdom)

#### Introduction

Olga López Villar (Spain)

**16:00 - 16:05**

#### Spain / UK

Olga López Villar (Spain)

Anne Emmett (United Kingdom)

**16:05 - 16:20**

#### The Netherlands / Turkey

Nick van Sinderen (Netherlands)

Ilknur Kozanoglu (Turkey)

**16:20 - 16:35**

#### Italy / Belgium

Renza Monteleone (Italy)

Phuong Huynh (Belgium)

**16:35 - 16:50**

#### Text chat Q&A

**16:50 - 17:00**

General  
17:00 - 17:35

Auditorium 1

### GS3, General Assembly

#### Chairs:

Nicolaus Kröger (Germany)

#### President's Report

Nicolaus Kröger (Germany)

**17:00 - 17:16**

#### Treasurer's Financial Report

Harry Dolstra (Netherlands)

**17:16 - 17:23**

#### Secretary's Report

John Snowden (United Kingdom)

**17:23 - 17:28**

#### EBMT Brand: Mission and vision project

John Snowden (United Kingdom)

**17:28 - 17:30**

#### Text chat Q&A

**17:30 - 17:35**

Nurses Group  
17:00 - 17:30

Auditorium 3

### NG10, Nurses Group Closing Session

#### Chairs:

John Murray (United Kingdom)

## Scientific Programme

<b>Highlights from physicians' sessions</b> Izaskun Zeberio (Spain)	<b>17:00 - 17:20</b>
<b>Best of the Best: Presentation of NG Abstract prizes</b> John Murray (United Kingdom)	<b>17:20 - 17:26</b>
<b>Presentation of Madrid 2021</b> Julia Ruiz Pato (Spain) Isabel Salcedo (Spain)	<b>17:26 - 17:30</b>

General  
17:40 - 18:10

Auditorium 1

### GS4, Closing Ceremony

#### Chairs:

Nicolaus Kröger (Germany)

<b>Presentation of the Springer Nature Poster Awards</b> Nicolaus Kröger (Germany)	<b>17:40 - 17:45</b>
<b>Presentation of the results of the EBMT Fellowship grant 2019: Cord versus marrow: Are young stem cells superior for transplantation?</b> Flavia Peci (Netherlands)	<b>17:45 - 17:55</b>
<b>Local President for EBMT 2021 Madrid: Welcome</b> Rafael Duarte (Spain)	<b>17:55 - 18:00</b>
<b>EBMT President closing remarks</b> Nicolaus Kröger (Germany)	<b>18:00 - 18:10</b>